FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Reinke, LF Griffith, RG Wolpin, S Donesky-Cuenco, D Carrieri-Kohlman, V Nguyen, HQ AF Reinke, L. F. Griffith, R. G. Wolpin, S. Donesky-Cuenco, D. Carrieri-Kohlman, V. Nguyen, H. Q. TI Feasibility Of A Webinar For Coaching Patients With Chronic Obstructive Pulmonary Disease On End-of-Life Communication SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Reinke, L. F.] VA Puget Sound, Seattle, WA USA. [Griffith, R. G.; Wolpin, S.; Nguyen, H. Q.] Univ Washington, Seattle, WA 98195 USA. [Donesky-Cuenco, D.; Carrieri-Kohlman, V.] Univ Calif San Francisco, San Francisco, CA 94143 USA. EM pac6@cornell.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2010 VL 181 MA A6766 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29TP UT WOS:000208771005385 ER PT J AU Swenson, ER Lamm, WJE Tsang, JYC AF Swenson, E. R. Lamm, W. J. E. Tsang, J. Y. C. TI Regional Carbon Dioxide Tension Mediates Homeostatic Redistribution Of Ventilation In Pulmonary Thromboembolism SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Swenson, E. R.; Lamm, W. J. E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Tsang, J. Y. C.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2010 VL 181 MA A1925 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29TP UT WOS:000208771001133 ER PT J AU van den Berg, E van Woensel, JBM Bos, AP Bem, RA Altemeier, WA Martin, TR Matute-Bello, G AF van den Berg, E. van Woensel, J. B. M. Bos, A. P. Bem, R. A. Altemeier, W. A. Martin, T. R. Matute-Bello, G. TI Role Of The Fas/FasL System In A Murine Model Of RSV Infection In Mechanically Ventilated Mice SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [van den Berg, E.] Univ Washington, Ctr Lung Biol, Seattle, WA 98195 USA. [van Woensel, J. B. M.; Bos, A. P.; Bem, R. A.] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, NL-1105 AZ Amsterdam, Netherlands. [Altemeier, W. A.] Univ Washington, Med Ctr, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [Martin, T. R.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Matute-Bello, G.] Univ Washington, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2010 VL 181 MA A2778 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29TP UT WOS:000208771001691 ER PT J AU Winthrop, KL Baxter, R Liu, L McFarland, B Austin, D Varley, C Radcliffe, L Suhler, E Choi, D Rosenbaum, J Herrinton, L AF Winthrop, K. L. Baxter, R. Liu, L. McFarland, B. Austin, D. Varley, C. Radcliffe, L. Suhler, E. Choi, D. Rosenbaum, J. Herrinton, L. TI Mycobacterial Disease In Rheumatoid Arthritis Patients Who Use Anti-tumor Necrosis Therapy SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Winthrop, K. L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Baxter, R.; Liu, L.; Herrinton, L.] Kasier Permanente Northern Calif, Oakland, CA USA. [McFarland, B.; Varley, C.; Choi, D.; Rosenbaum, J.] Oregon Hlth & Sci Univ, Mailcode CLEI, Portland, OR 97201 USA. [Austin, D.; Suhler, E.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. [Radcliffe, L.] Portland VA Med Ctr, Portland, OR USA. EM varleyc@ohsu.edu NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2010 VL 181 MA A2603 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29TP UT WOS:000208771001516 ER PT J AU Zarndt, R Pickerodt, PA Emery, MJ Swenson, ER AF Zarndt, R. Pickerodt, P. A. Emery, M. J. Swenson, E. R. TI SODIUM NITRITE IS PROTECTIVE IN A RAT MODEL OF VENTILATOR-INDUCED LUNG INJURY SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Zarndt, R.; Pickerodt, P. A.; Emery, M. J.; Swenson, E. R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2010 VL 181 MA A1685 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29TP UT WOS:000208771000685 ER PT J AU Woodworth, BA Zhang, SY Tamashiro, E Bhargave, G Palmer, JN Cohen, NA AF Woodworth, Bradford A. Zhang, Shaoyan Tamashiro, Edwin Bhargave, Geeta Palmer, James N. Cohen, Noam A. TI Zinc increases ciliary beat frequency in a calcium-dependent manner SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Article; Proceedings Paper CT 53rd Annual Meeting of the American-Rhinologic-Society CY SEP 15, 2007 CL Washington, DC SP Amer Rhinol Soc DE Alternative treatments; calcium; cilia physiology; ciliary beat frequency; mucociliary clearance; nutritional supplements; P2X receptor; SAVA system; zinc ID AIRWAY EPITHELIAL-CELLS; CA2+-SENSING RECEPTORS; NUCLEOTIDE RECEPTOR; INTRACELLULAR CA2+; SENSING RECEPTOR; CYSTIC-FIBROSIS; ATP; MECHANOSENSITIVITY; DESENSITIZATION; MUCOCILIARY AB Background: Dynamic regulation of respiratory ciliary beat frequency (CBF) is regulated by fluxes in intracellular calcium (Ca(2+)). P2X receptors (P2XR) are extracellular ATP-gated, Ca(2+)-permeable, nonselective cation channels. Zinc increases intracellular Ca(2+) in a sodium (Na(+))-free environment through activation of P2XR channels. We hypothesize that topical zinc increases CBF in a Ca(2+)-dependent fashion as a result of this mechanism. Methods: The apical surface of mouse sinonasal air-liquid interface cultures were bathed in zinc in a Na(+)-free solution with or without Ca(2+). High-speed digital video imaging captured and analyzed CBF at a sampling rate of 100 frames/s. Results: CBF significantly increased fourfold over baseline from 5.99 +/- 3.16 Hz to 22.4 +/- 4.33 Hz in the presence of zinc chloride (50 micromoles) and calcium chloride (3 mM). This effect is abolished in the presence of extracellular Na(+) and was pH dependent. Conclusion: Zinc stimulates CBF in the presence of Ca(2+) likely through activation of P2X receptors. Thus, zinc represents a promising agent for stimulation of mucociliary clearance. (Am J Rhinol Allergy 24, 6-10, 2010; doi: 10.2500/ajra.2010.24.3379) C1 [Woodworth, Bradford A.; Zhang, Shaoyan] Univ Alabama, Dept Surg, Div Otolaryngol, Birmingham, AL 35294 USA. [Woodworth, Bradford A.; Zhang, Shaoyan] Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL USA. [Tamashiro, Edwin; Bhargave, Geeta; Palmer, James N.; Cohen, Noam A.] Univ Penn Hlth Syst, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA USA. [Tamashiro, Edwin; Bhargave, Geeta; Palmer, James N.; Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Div Otolaryngol Head & Neck Surg, Philadelphia, PA USA. RP Woodworth, BA (reprint author), Univ Alabama, Dept Surg, Div Otolaryngol, BDB 563,1530 3rd Ave S, Birmingham, AL 35294 USA. EM bwoodwo@hotmail.com RI Tamashiro, Edwin/C-5062-2012 OI Tamashiro, Edwin/0000-0002-3153-6292; Cohen, Noam/0000-0002-9462-3932 NR 33 TC 9 Z9 9 U1 0 U2 1 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 J9 AMJ RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD JAN-FEB PY 2010 VL 24 IS 1 BP 6 EP 10 DI 10.2500/ajra.2010.24.3379 PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA 556DW UT WOS:000274570000002 PM 20109308 ER PT J AU Poon, I Lal, LS Ford, ME Braun, UK AF Poon, Ivy Lal, Lincy S. Ford, Marvella E. Braun, Ursula K. TI Racial/Ethnic Differences in Blood Pressure Control and Medication Utilization in a Cohort of Older Veterans with Dementia SO AMERICAN JOURNAL OF THERAPEUTICS LA English DT Article DE ethnic groups; race; dementia; hypertension; drug utilization; aged ID ANTIHYPERTENSIVE TREATMENT; AFRICAN-AMERICANS; ALZHEIMER-DISEASE; HYPERTENSION; PREVENTION; AFFAIRS; PREVALENCE; ADHERENCE; COMMUNITY; COMMITTEE AB Hypertension and dementia are common illnesses in geriatric patients, resulting in significant morbidity and mortality. The objective of this study was to investigate racial and ethnic differences in blood pressure control and medication utilization in veterans aged 65 years or older with a diagnosis of both hypertension and dementia. We conducted a retrospective chart review for such veterans who attended the Michael E. DeBakey VA Medical Center outpatient clinics in Houston, Texas, during the period of October 1, 2003, to September 30, 2004. A total of 304 patients (190 Caucasians and 114 African-Americans) were included in the study. The mean number of concurrent antihypertensive medications for African-Americans was higher than for Caucasians (3.2 and 2.8, respectively; P = 0.02). African-American ethnicity was associated with higher use of thiazide diuretics (P = 0.02), dihydropyridine calcium channel blockers (P = 0.04), and clonidine (P = 0.01) than was Caucasian ethnicity. Forty-eight percent of African-Americans achieved adequate blood pressure control, compared with 59% of Caucasians. Mini-mental state exam scores were lower for African-Americans than for Caucasians (17.8 and 21.6, respectively; P = 0.01). The utilization of dementia medications was not found to be different between African-Americans and Caucasians. Veterans in this cohort achieved better blood pressure control than previously reported in other studies consisting of older patients. Physicians might have considered patients' race when prescribing antihypertensive medications reflected by the higher use of thiazide diuretics and calcium channel blockers for African-Americans. C1 [Poon, Ivy] Texas So Univ, Coll Pharm & Hlth Sci, Dept Pharm Practice, Houston, TX 77004 USA. [Poon, Ivy] Michael E DeBakey VA Med Ctr, Dept Pharm, Houston, TX USA. [Lal, Lincy S.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Ford, Marvella E.] Med Univ S Carolina, Dept Biostat, Charleston, SC 29425 USA. [Ford, Marvella E.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Braun, Ursula K.] Michael E De Bakey VA Med Ctr, Houston VA HSR&D Ctr Excellence, Sect Geriatr, Houston, TX USA. [Braun, Ursula K.] Michael E De Bakey VA Med Ctr, Houston VA HSR&D Ctr Excellence, Sect Hlth Serv Res, Houston, TX USA. [Braun, Ursula K.] Baylor Coll Med, Houston, TX 77030 USA. RP Poon, I (reprint author), Texas So Univ, Coll Pharm & Hlth Sci, Dept Pharm Practice, 3100 Cleburne St, Houston, TX 77004 USA. EM chui_io@tsu.edu FU NIH Center of Excellence in Health Disparity Research (CEDHR); Houston VA HSR&D Center of Excellence [HFP90-020] FX This project was funded by an NIH Center of Excellence in Health Disparity Research (CEDHR) faculty fellowship award at Texas Southern University College of Pharmacy and Health Sciences. This work was supported in part by the Houston VA HSR&D Center of Excellence (HFP90-020). NR 34 TC 3 Z9 3 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1075-2765 J9 AM J THER JI Am. J. Ther. PD JAN-FEB PY 2010 VL 17 IS 1 BP 34 EP 41 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 546XR UT WOS:000273849000007 PM 19535967 ER PT J AU Baratelli, F Lee, JM Hazra, S Lin, Y Walser, TC Schaue, D Pak, PS Elashoff, D Reckamp, K Zhang, L Fishbein, MC Sharma, S Dubinett, SM AF Baratelli, Felicita Lee, Jay M. Hazra, Saswati Lin, Ying Walser, Tonya C. Schaue, Dorthe Pak, Peter S. Elashoff, David Reckamp, Karen Zhang, Ling Fishbein, Michael C. Sharma, Sherven Dubinett, Steven M. TI PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH LA English DT Article DE T regulatory cells; PGE(2); TGF-beta; non-small cell lung cancer; CD4(+) T cells AB CD4(+)CD25(bright) regulatory T cells (T-reg) play an important role in cancer-mediated immunosuppression. We and others have previously shown that prostaglandin E2 (PGE(2)) and transforming growth factor beta (TGF-beta) induce CD4(+)CD25(bright) FOXP3(+)T(reg). Based on these studies, we investigated the requirement for PGE(2) in T-reg induction by TGF-beta. TGF-beta stimulation of human CD4(+) T cells induced COX-2-dependent production of PGE(2). PGE(2)-neutralizing antibody treatment significantly reduced the suppressive function of TGF-beta-induced T-reg (TGF-beta-T-reg) in vitro. TGF-beta concentration measured in the plasma of non-small cell lung cancer (NSCLC) patients directly correlated with the frequency of circulating CD4(+)CD25(bright)FOXP3(+) T cells. Flow cytometry analysis showed increased FOXP3 expression in circulating CD4(+)CD25(+)HLA-DR- cells of lung cancer patients compared to control subjects. Immunohistochemical analysis revealed co-expression of TGF-beta, COX-2, and FOXP3 in serial sections from resected lung tumor tissues. All together these observations suggest interplay between TGF-beta and COX-2 in the induction of T-reg activities. Interrupting TGF-beta and PGE(2) signaling may be important in therapeutic interventions that aim to limit T-reg function in lung cancer. C1 [Baratelli, Felicita; Lee, Jay M.; Hazra, Saswati; Lin, Ying; Walser, Tonya C.; Schaue, Dorthe; Pak, Peter S.; Elashoff, David; Zhang, Ling; Sharma, Sherven; Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, UCLA Lung Canc Res Program, Los Angeles, CA 90095 USA. [Baratelli, Felicita; Hazra, Saswati; Lin, Ying; Walser, Tonya C.; Pak, Peter S.; Sharma, Sherven; Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. [Lee, Jay M.; Pak, Peter S.; Zhang, Ling] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Cardiothorac Surg, Los Angeles, CA 90095 USA. [Schaue, Dorthe] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA 90095 USA. [Elashoff, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biostat, Los Angeles, CA 90095 USA. [Fishbein, Michael C.; Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Reckamp, Karen] City Hope Natl Med Ctr, Dept Hematol, Duarte, CA USA. [Reckamp, Karen] City Hope Natl Med Ctr, Dept Med Oncol, Duarte, CA USA. [Sharma, Sherven; Dubinett, Steven M.] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Med Lab, Los Angeles, CA USA. RP Lee, JM (reprint author), Ronald Reagan UCLA Med Ctr, Sect Thorac Surg, Div Cardiothorac Surg, CHS, Box 957313,Room 64-128,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM jay-moonlee@mednet.ucla.edu FU National Institutes of Health [CA-16042, AI-28697, R01 CA111851]; Jonsson Comprehensive Cancer Center; UCLA AIDS Institute; David Geffen School of Medicine at UCLA; UCLA Lung Cancer SPORE [P50 CA90388, 5K12CA076095, 1K23CA131577]; UC Tobacco Related Research Program; Department of Veteran Affairs; Ronald Binder Memorial Fund for Lung Cancer Research; STOP Cancer; Jonsson Cancer Foundation FX Flow cytometry was performed at the UCLA Jonsson Comprehensive Cancer for AIDS Research Flow Cytometry Core Facility that is supported by the National Institutes of Health awards CA-16042 and AI-28697, Jonsson Comprehensive Cancer Center, UCLA AIDS Institute, and David Geffen School of Medicine at UCLA.; This study was supported by the National Institutes of Health Grants R01 CA111851, UCLA Lung Cancer SPORE P50 CA90388, 5K12CA076095, and 1K23CA131577; UC Tobacco Related Research Program; Merit Review Research Funds from the Department of Veteran Affairs; Ronald Binder Memorial Fund for Lung Cancer Research; STOP Cancer; and Jonsson Cancer Foundation. NR 46 TC 30 Z9 32 U1 0 U2 1 PU E-CENTURY PUBLISHING CORP PI MADISON PA 40 WHITE OAKS LN, MADISON, WI 53711 USA SN 1943-8141 J9 AM J TRANSL RES JI Am. J. Transl. Res. PY 2010 VL 2 IS 4 BP 356 EP 367 PG 12 WC Oncology; Medicine, Research & Experimental SC Oncology; Research & Experimental Medicine GA V28QD UT WOS:000208694400002 PM 20733946 ER PT J AU McFarland, LV AF McFarland, Lynne V. TI Probiotics and Diarrhea SO ANNALS OF NUTRITION AND METABOLISM LA English DT Article; Proceedings Paper CT Scientific Symposium on Probiotics in Health and Disease - What Is the Scientific Evidence CY DEC 11, 2009 CL Frankfurt, GERMANY C1 [McFarland, Lynne V.] VA Puget Sound Hlth Care Syst, Dept Hlth Serv Res & Dev, Seattle, WA 98101 USA. [McFarland, Lynne V.] Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA 98195 USA. RP McFarland, LV (reprint author), VA Puget Sound Hlth Care Syst, Dept Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM lynne.mcfarland@va.gov NR 5 TC 3 Z9 3 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-6807 J9 ANN NUTR METAB JI Ann. Nutr. Metab. PY 2010 VL 57 SU 1 BP 10 EP 11 DI 10.1159/000309016 PG 2 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 648BH UT WOS:000281664900003 PM 20829585 ER PT J AU Wang, LM Wong, M Lightwood, JM Cheng, CM AF Wang, Lorraine M. Wong, Maple Lightwood, James M. Cheng, Christine M. TI Black Box Warning Contraindicated Comedications: Concordance Among Three Major Drug Interaction Screening Programs SO ANNALS OF PHARMACOTHERAPY LA English DT Article DE black box warning; drug interaction; drug interaction screening program ID PERSONAL DIGITAL ASSISTANT; MEDICATIONS; SUICIDALITY; DEPRESSION; DATABASES; COMPENDIA; SOFTWARE; SSRIS; ALPHA; RISK AB BACKGROUND: Black box warnings represent the strongest safety warning that the Food and Drug Administration can issue for a marketed prescription drug. Some black box warnings recommend against coadministration of specific medications due to an increased risk for serious, perhaps life-threatening, effects. OBJECTIVE: To determine the level of agreement in presence, clinical severity scores level of documentation ratings, and alert content among 3 leading drug interaction screening programs with regard to contraindicated comedications that are mentioned in black box warnings. METHODS: We reviewed the prescribing information for currently marketed prescription drugs with a black box warning that mentioned a contraindicated drug combination. We selected the drug interaction databases Facts & Comparisons 4.0, MICROMEDEX DRUG-REAX, and Lexi-Comp Lexi-Interact to evaluate the interactions. Discrepancies in the inclusion of interactions and level of agreement in clinical severity scores and level of documentation ratings for each interaction were assessed, using descriptive statistics, Spearman's correlation coefficient, Kendall-Stuart tau-c, and Cronbach's alpha. RESULTS: We identified 11 drugs with black box warnings that contained information on 59 unique contraindicated drug combinations, only 68% of which were covered by any source. Lexi-Comp detected the most interactions (n = 29) and DRUG-REAX the least (n = 18). Only 3 drug combinations were detected and rated as contraindicated or potentially life-threatening in all 3 databases. The severity scores and level of documentation ratings varied widely. CONCLUSIONS: There are discrepancies among major drug interaction screening programs in the inclusion, severity, and level of documentation of contraindicated drug combinations mentioned in black box warnings. Further studies could explore the implications of these inconsistencies, particularly with regard to the integration of black box warning information in clinical practice. Clinicians should consult multiple drug resources to maximize the potential for detecting a potentially severe drug interaction. C1 [Wang, Lorraine M.] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. [Wong, Maple] Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA. [Cheng, Christine M.] Univ Calif San Francisco, Dept Clin Pharm, Medicat Outcomes Ctr, San Francisco, CA 94143 USA. RP Cheng, CM (reprint author), 521 Parnassus Ave,C-152,Box 0622, San Francisco, CA 94143 USA. EM Chengc@pharmacy.ucsf.edu NR 26 TC 37 Z9 37 U1 1 U2 10 PU HARVEY WHITNEY BOOKS CO PI CINCINNATI PA PO BOX 42696, CINCINNATI, OH 45242 USA SN 1060-0280 J9 ANN PHARMACOTHER JI Ann. Pharmacother. PD JAN PY 2010 VL 44 IS 1 BP 28 EP 34 DI 10.1345/aph.1M475 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 543ZO UT WOS:000273620900003 PM 20040698 ER PT J AU Jhun, CS Wenk, JF Zhang, ZH Wall, ST Sun, K Sabbah, HN Ratcliffe, MB Guccione, JM AF Jhun, Choon-Sik Wenk, Jonathan F. Zhang, Zhihong Wall, Samuel T. Sun, Kay Sabbah, Hani N. Ratcliffe, Mark B. Guccione, Julius M. TI Effect of Adjustable Passive Constraint on the Failing Left Ventricle: A Finite-Element Model Study SO ANNALS OF THORACIC SURGERY LA English DT Article ID CARDIAC SUPPORT DEVICE; CHRONIC HEART-FAILURE; MYOCARDIAL-INFARCTION; MECHANICS; STRESS; HYPERTROPHY; DYSFUNCTION; VARIABLES; PATTERNS; REVERSAL AB Background. Passive constraint is used to prevent left ventricular dilation and subsequent remodeling. However, there has been concern about the effect of passive constraint on diastolic left ventricular chamber stiffness and pump function. This study determined the relationship between constraint, diastolic wall stress, chamber stiffness, and pump function. We tested the hypothesis that passive constraint at 3 mm Hg reduces wall stress with minimal change in pump function. Methods. A three-dimensional finite-element model of the globally dilated left ventricle based on left ventricular dimensions obtained in dogs that had undergone serial intracoronary microsphere injection was created. The model was adjusted to match experimentally observed end-diastolic left ventricular volume and midventricular wall thickness. The experimental results used to create the model were previously reported. A pressure of 3, 5, 7, and 9 mm Hg was applied to the epicardium. Fiber stress, end-diastolic pressure-volume relationship, end-systolic pressure-volume relationship, and the stroke volume-end-diastolic pressure (Starling) relationship were calculated. Results. As epicardial constraint pressure increased, fiber stress decreased, the end-diastolic pressure-volume relationship shifted to the left, and the Starling relationship shifted down and to the right. The end-systolic pressure-volume relationship did not change. A constraining pressure of 2.3 mm Hg was associated with a 10% reduction in stroke volume, and mean end-diastolic fiber stress was reduced by 18.3% (inner wall), 15.3% (mid wall), and 14.2% (outer wall). Conclusions. Both stress and cardiac output decrease in a linear fashion as the amount of passive constraint is increased. If the reduction in cardiac output is to be less than 10%, passive constraint should not exceed 2.3 mm Hg. On the other hand, this amount of constraint may be sufficient to reverse eccentric hypertrophy after myocardial infarction. (Ann Thorac Surg 2010; 89: 132- 8) (C) 2010 by The Society of Thoracic Surgeons C1 Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Bioengn, San Francisco, CA 94143 USA. Dept Vet Affairs Med Ctr, San Francisco, CA USA. Henry Ford Hosp, Detroit, MI 48202 USA. RP Ratcliffe, MB (reprint author), San Francisco VA Med Ctr, Surg Serv 112, 4150 Clement St, San Francisco, CA 94121 USA. EM mark.ratcliffe@va.gov FU National Institutes of Health [5R01 HL077921, 5R01 HL063348, P41 RR08605] FX This work was supported by grants 5R01 HL077921 (J.M.G.), 5R01 HL063348 (Mark B. Ratcliffe), and P41 RR08605 from the National Institutes of Health. NR 34 TC 16 Z9 16 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD JAN PY 2010 VL 89 IS 1 BP 132 EP + DI 10.1016/j.athoracsur.2009.08.075 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 535AU UT WOS:000272939700020 PM 20103222 ER PT J AU Mauldin, PD Salgado, CD Hansen, IS Durup, DT Bosso, JA AF Mauldin, Patrick D. Salgado, Cassandra D. Hansen, Ida Solhoj Durup, Darshana T. Bosso, John A. TI Attributable Hospital Cost and Length of Stay Associated with Health Care-Associated Infections Caused by Antibiotic-Resistant Gram-Negative Bacteria SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID FOR-DISEASE-CONTROL; ANTIMICROBIAL RESISTANCE; ECONOMIC OUTCOMES; NOSOCOMIAL INFECTIONS; STAPHYLOCOCCUS-AUREUS; ACINETOBACTER-BAUMANNII; PSEUDOMONAS-AERUGINOSA; METHICILLIN-RESISTANCE; KLEBSIELLA-PNEUMONIAE; ESCHERICHIA-COLI AB Determination of the attributable hospital cost and length of stay (LOS) are of critical importance for patients, providers, and payers who must make rational and informed decisions about patient care and the allocation of resources. The objective of the present study was to determine the additional total hospital cost and LOS attributable to health care-associated infections (HAIs) caused by antibiotic-resistant, gram-negative (GN) pathogens. A single-center, retrospective, observational comparative cohort study was performed. The study involved 662 patients admitted from 2000 to 2008 who developed HAIs caused by one of following pathogens: Acinetobacter spp., Enterobacter spp., Escherichia coli, Klebsiella spp., or Pseudomonas spp. The attributable total hospital cost and LOS for HAIs caused by antibiotic-resistant GN pathogens were determined by comparison with the hospital costs and LOS for a control group with HAIs due to antibiotic-susceptible GN pathogens. Statistical analyses were conducted by using univariate and multivariate analyses. Twenty-nine percent of the HAIs were caused by resistant GN pathogens, and almost 16% involved a multidrug-resistant GN pathogen. The additional total hospital cost and LOS attributable to antibiotic-resistant HAIs caused by GN pathogens were 29.3% (P < 0.0001; 95% confidence interval, 16.23 to 42.35) and 23.8% (P = 0.0003; 95% confidence interval, 11.01 to 36.56) higher than those attributable to HAIs caused by antibiotic-susceptible GN pathogens, respectively. Significant covariates in the multivariate analysis were age >= 12 years, pneumonia, intensive care unit stay, and neutropenia. HAIs caused by antibiotic-resistant GN pathogens were associated with significantly higher total hospital costs and increased LOSs compared to those caused by their susceptible counterparts. This information should be used to assess the potential cost-efficacy of interventions aimed at the prevention of such infections. C1 [Mauldin, Patrick D.; Hansen, Ida Solhoj; Durup, Darshana T.; Bosso, John A.] S Carolina Coll Pharm, Dept Clin Pharm & Outcome Sci, Charleston, SC 29425 USA. [Mauldin, Patrick D.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Salgado, Cassandra D.; Bosso, John A.] Med Univ S Carolina, Coll Med, Div Infect Dis, Charleston, SC 29425 USA. RP Bosso, JA (reprint author), S Carolina Coll Pharm, Dept Clin Pharm & Outcome Sci, MUSC Campus,280 Calhoun St,MSC 140, Charleston, SC 29425 USA. EM bossoja@musc.edu FU AstraZeneca Pharmaceuticals LP, Wilmington, DE FX This work was funded, in part, by an investigator-initiated research grant from AstraZeneca Pharmaceuticals LP, Wilmington, DE. NR 43 TC 91 Z9 95 U1 2 U2 13 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JAN PY 2010 VL 54 IS 1 BP 109 EP 115 DI 10.1128/AAC.01041-09 PG 7 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 534XQ UT WOS:000272931200013 PM 19841152 ER PT B AU Kim, MS Page, RL Casserly, IP AF Kim, Michael S. Page, Robert L. Casserly, Ivan P. BE Askari, AT Lincoff, AM TI Synthetic Factor Xa Inhibition in Acute Coronary Syndromes SO ANTITHROMBOTIC DRUG THERAPY IN CARDIOVASCULAR DISEASE LA English DT Article; Book Chapter DE Fondaparinux; Acute coronary syndrome; Anticoagulant ID ACUTE MYOCARDIAL-INFARCTION; ST-SEGMENT ELEVATION; RANDOMIZED-TRIALS; FONDAPARINUX SODIUM; ANTITHROMBIN-III; COLLABORATIVE METAANALYSIS; UNFRACTIONATED HEPARIN; VENOUS THROMBOEMBOLISM; COST-EFFECTIVENESS; HIGH-AFFINITY AB Over the last decade, several advances in the management of patients with acute coronary syndrome have been made. Despite these therapeutic advances, the risk of major adverse cardiovascular events related to acute coronary syndrome remains significant. These findings have led to continued efforts to find more efficacious antiplatelet agents and anticoagulants to help reduce the risk of recurrent ischemic events. This chapter reviews the clinical data pertaining to the novel anticoagulant fondaparinux for the treatment of acute coronary syndrome. C1 [Kim, Michael S.; Casserly, Ivan P.] Univ Colorado Denver, Sect Intervent Cardiol, Aurora, CO USA. [Kim, Michael S.; Page, Robert L.; Casserly, Ivan P.] Hlth Sci Ctr, Aurora, CO USA. [Casserly, Ivan P.] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA. RP Kim, MS (reprint author), Univ Colorado Denver, Sect Intervent Cardiol, Aurora, CO USA. NR 40 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60327-234-6 PY 2010 BP 203 EP 215 DI 10.1007/978-1-60327-235-3_10 D2 10.1007/978-1-60327-235-3 PG 13 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA BMP79 UT WOS:000273299400010 ER PT J AU Amorosa, VK Slim, J Mounzer, K Bruno, C Hoffman-Terry, M Dorey-Stein, Z Ferrara, T Kostman, JR Lo Re, V AF Amorosa, Valerianna K. Slim, Jihad Mounzer, Karam Bruno, Christopher Hoffman-Terry, Margaret Dorey-Stein, Zachariah Ferrara, Thomas Kostman, Jay R. Lo Re, Vincent, III TI The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients SO ANTIVIRAL THERAPY LA English DT Article; Proceedings Paper CT 16th Conference on Retroviruses and Opportunistic Infections CY FEB 08-11, 2009 CL Montreal, CANADA ID CHRONIC HEPATITIS-C; INTERFERON PLUS RIBAVIRIN; HUMAN-IMMUNODEFICIENCY-VIRUS; PEGYLATED INTERFERON; COINFECTED PATIENTS; RECOMMENDATIONS; PROGRESSION; MANAGEMENT; DIAGNOSIS; PANEL AB Background: It remains unclear if certain antiretroviral medications, particularly abacavir, compromise response to HCV therapy. Such data could inform the selection of appropriate antiretrovirals in HIV/HCV-coinfected patients. The aim of this study was to determine if use of abacavir, as well as other antiretrovirals, was associated with reduced response to pegylated interferon (PEG-IFN) plus ribavirin. Methods: A cohort study was performed among antiretroviral-treated HIV/HCV-coinfected patients initiating PEG-IFN plus ribavirin between January 2001 and June 2007 at six sites in the United States. Abacavir and other antiretrovirals represented exposures of interest. Study outcomes included an early virological response (>= 2 log IU/ml decrease in HCV viral load at 12 weeks) and sustained virological response (undetectable HCV viral load 24 weeks after treatment discontinuation). Results: Among 212 patients, 74 (35%) received abacavir. For patients infected with HCV genotype 1 or 4, no differences were observed between abacavir users and non-users in early virological response (26 [40%] versus 53 [44%]; adjusted odds ratio [OR] 1.00; 95% confidence interval [CI] 0.50-2.00) or sustained virological response (8 [13%] versus 13 [12%]; adjusted OR 1.34; 95% CI 0.50-3.62). Among genotype 2 and 3 patients, rates of early virological response (7 [78%] versus 16 [89%]; OR 0.44; 95% CI 0.05-3.76) and sustained virological response (3 [33%] versus 8 [44%]; OR 0.63; 95% CI 0.12-3.32) were also similar between abacavir users and non-users. No association was found between other antiretrovirals and a lack of early or sustained response. Conclusions: Use of abacavir or other antiretroviral medications was not associated with reduced early or sustained virological response rates. C1 [Amorosa, Valerianna K.; Dorey-Stein, Zachariah; Kostman, Jay R.; Lo Re, Vincent, III] Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Amorosa, Valerianna K.; Ferrara, Thomas; Lo Re, Vincent, III] Philadelphia Vet Affairs Med Ctr, Infect Dis Sect, Philadelphia, PA USA. [Slim, Jihad] St Michaels Hosp, Div Infect Dis, Newark, NJ 07102 USA. [Mounzer, Karam] Jonathan Lax Treatment Ctr, Philadelphia, PA USA. [Bruno, Christopher] Drexel Univ, Div Infect Dis, Sch Med, Philadelphia, PA 19104 USA. [Hoffman-Terry, Margaret] Lehigh Valley Hosp, Div Infect Dis, Allentown, PA USA. [Lo Re, Vincent, III] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Lo Re, Vincent, III] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Lo Re, Vincent, III] Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA. RP Lo Re, V (reprint author), Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA. EM vincenti@mail.med.upenn.edu RI Lo Re, Vincent/N-7817-2015 FU AHRQ HHS [U18 HS010399, HS10399]; NIAID NIH HHS [K01-AI070001, K01 AI070001, K01 AI070001-01A1] NR 25 TC 19 Z9 20 U1 0 U2 0 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2010 VL 15 IS 1 BP 91 EP 99 DI 10.3851/IMP1492 PG 9 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 581MX UT WOS:000276528900010 PM 20167995 ER PT J AU Huckans, M Mitchell, A Pavawalla, S Morasco, BJ Ruimy, S Loftis, JM Rifai, MA Hauser, P AF Huckans, Marilyn Mitchell, Alex Pavawalla, Shital Morasco, Benjamin J. Ruimy, Samantha Loftis, Jennifer M. Rifai, Muhamad A. Hauser, Peter TI The influence of antiviral therapy on psychiatric symptoms among patients with hepatitis C and schizophrenia SO ANTIVIRAL THERAPY LA English DT Article ID SUBSTANCE USE DISORDERS; SEVERE MENTAL-ILLNESS; PREVALENCE; MANAGEMENT; VETERANS; PEOPLE AB Background: Antiviral therapy for chronic infection with HCV is associated with significant neuropsychiatric side effects. Research indicates that patients with mental illness are less likely to receive antiviral therapy, despite limited data regarding the influence of antiviral therapy on psychiatric symptoms in patients with specific psychiatric disorders. The aim of this study was to determine whether antiviral therapy is associated with higher rates of psychiatric symptoms in patients with schizophrenia (SCHZ). Methods: A regional Veterans Healthcare Administration database was used to identify veterans meeting criteria for this retrospective chart review. Patients confirmed to have SCHZ and to have received antiviral therapy for HCV between 1998 and 2006 (n=30) were compared with a control group of demographically matched (age, race and gender) patients with SCHZ who did not receive antiviral therapy (n=30). Clinicians blinded to antiviral therapy status used chart notes to evaluate whether patients exhibited prominent symptoms of SCHZ, depression or mania during a 6 month pre-treatment period, the treatment period and a 6 month post-treatment period (or during equivalent periods for the control group). Results: Groups did not significantly differ in rates of symptoms of SCHZ, depression or mania during any study period. During the treatment period, groups did not significantly differ in rates of emergency room visits or inpatient hospitalizations. Conclusions: Our retrospective chart review suggests that patients with SCHZ experience similar rates of psychiatric symptoms on and off antiviral therapy. Despite limitations and constraints of the methods, our data suggest that SCHZ is not a contraindication to antiviral therapy for HCV. C1 [Huckans, Marilyn; Mitchell, Alex; Morasco, Benjamin J.; Ruimy, Samantha; Loftis, Jennifer M.; Hauser, Peter] Portland VA Med Ctr, NW Hepatitis Resource Ctr C, Portland, OR USA. [Huckans, Marilyn; Mitchell, Alex; Pavawalla, Shital; Morasco, Benjamin J.; Ruimy, Samantha; Hauser, Peter] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR USA. [Huckans, Marilyn; Loftis, Jennifer M.; Hauser, Peter] Portland VA Med Ctr, Div Res, Portland, OR USA. [Huckans, Marilyn; Morasco, Benjamin J.; Loftis, Jennifer M.; Hauser, Peter] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Loftis, Jennifer M.; Hauser, Peter] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Rifai, Muhamad A.] Lehigh Valley Hosp, Dept Psychiat, Allentown, PA USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97201 USA. RP Huckans, M (reprint author), Portland VA Med Ctr, NW Hepatitis Resource Ctr C, Portland, OR USA. EM marilyn.huckans@va.gov FU NIDA NIH HHS [K23 DA023467, K23 DA023467-01A1] NR 16 TC 10 Z9 11 U1 0 U2 2 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2010 VL 15 IS 1 BP 111 EP 119 DI 10.3851/IMP1493 PG 9 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 581MX UT WOS:000276528900012 PM 20167997 ER PT J AU Glesby, MJ Hoover, DR Shi, QH Danoff, A Howard, A Tien, P Merenstein, D Cohen, M Golub, E DeHovitz, J Nowicki, M Anastos, K AF Glesby, Marshall J. Hoover, Donald R. Shi, Qiuhu Danoff, Ann Howard, Andrea Tien, Phyllis Merenstein, Dan Cohen, Mardge Golub, Elizabeth DeHovitz, Jack Nowicki, Marek Anastos, Kathryn TI Glycated haemoglobin in diabetic women with and without HIV infection: data from the Women's Interagency HIV Study SO ANTIVIRAL THERAPY LA English DT Article ID ANTIRETROVIRAL THERAPY; MELLITUS; GLUCOSE; GLYCEMIA; PREVALENCE; DIAGNOSIS; COHORT AB Background: Limited data suggest that glycated haemoglobin (haemoglobin A1c; A1C) values might not reflect glycaemic control accurately in HIV-infected individuals with diabetes. Methods: We evaluated repeated measures of paired fasting glucose and A1C values in 315 HIV-infected and 109 HIV-uninfected diabetic participants in the Women's Interagency HIV Study. Generalized estimating equations used log A1C as the outcome variable, with adjustment for log fasting glucose concentration in all models. Results: An HIV-infected woman on average had 0.9868 times as much A1C (that is, 1.32% lower; 95% confidence interval 0.9734-0.9904) as an HIV-uninfected woman with the same log fasting glucose concentration. In multivariate analyses, HIV serostatus was not associated, but White, other non-Black race, and higher red blood cell mean corpuscular volume (MCV) were statistically associated with lower A1C values. Use of diabetic medication was associated with higher A1C values. In multivariate analyses restricted to HIV-infected women, White and other race, higher MCV, and HCV viraemia were associated with lower A1C values, whereas older age, use of diabetic medications and higher CD4(+) T-cell count were associated with higher A1C values. Use of combination antiretroviral therapy, protease inhibitors, zidovudine, stavudine or abacavir was not associated with A1C values. Conclusions: A1C values were modestly lower in HIV-infected diabetic women relative to HIV-uninfected diabetic women after adjustment for fasting glucose concentration. The difference was abrogated by adjustment for MCV, race and diabetic medication use. Our data suggest that in clinical practice A1C gives a reasonably accurate refection of glycaemic control in HIV-infected diabetic women. C1 [Glesby, Marshall J.] Weill Cornell Med Coll, Dept Med, Div Infect Dis, New York, NY USA. [Hoover, Donald R.] Rutgers State Univ, Dept Stat & Biostat, Piscataway, NJ USA. [Shi, Qiuhu] New York Med Coll, Sch Hlth Sci & Practice, Valhalla, NY 10595 USA. [Danoff, Ann] NYU, Sch Med, Dept Med, New York, NY USA. [Howard, Andrea] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA. [Tien, Phyllis] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Tien, Phyllis] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Merenstein, Dan] Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA. [Cohen, Mardge] Stroger Cook Cty Hosp, Dept Med, Chicago, IL USA. [Cohen, Mardge] Rush Med Coll, Dept Med, Chicago, IL 60612 USA. [Golub, Elizabeth] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [DeHovitz, Jack] SUNY Hlth Sci Ctr, Brooklyn, NY 11203 USA. [Nowicki, Marek] Univ So Calif, Dept Med, Los Angeles, CA USA. [Anastos, Kathryn] Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA. [Anastos, Kathryn] Albert Einstein Coll Med, Bronx, NY 10467 USA. RP Glesby, MJ (reprint author), Weill Cornell Med Coll, Dept Med, Div Infect Dis, New York, NY USA. FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1 AI-31834, UO1-AI-314994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590, K24 AI 78884]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources [UL1 RR024131] FX The WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1 AI-31834, UO1-AI-314994, UO1-AI-34989, UO1-AI-34993 and UO1-AI-42590) and by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (UO1-HD-32632). The study is cofunded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders Funding is also provided by the National Center for Research Resources (UCSF-CTSI grant number UL1 RR024131). Additional support for this project was provided by the National Institute of Allergy and Infectious Diseases (K24 AI 78884). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. NR 17 TC 15 Z9 15 U1 0 U2 2 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2010 VL 15 IS 4 BP 571 EP 577 DI 10.3851/IMP1557 PG 7 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 629QW UT WOS:000280215800004 PM 20587850 ER PT J AU Stawiski, E Huang, W Tomo, J Frantzell, A Haddad, M Lie, Y Napolitano, L Whitcomb, J Leduc, R Brumme, Z Skowron, G Goetz, M Coakley, E AF Stawiski, E. Huang, W. Tomo, J. Frantzell, A. Haddad, M. Lie, Y. Napolitano, L. Whitcomb, J. Leduc, R. Brumme, Z. Skowron, G. Goetz, M. Coakley, E. TI HIV-1 disease stage significantly correlates with sensitivity of V3 sequence-based predictions of CXCR4 use SO ANTIVIRAL THERAPY LA English DT Meeting Abstract CT Workshop on International HIV and Hepatitis Virus Drug Resistance and Curative Strategies CY JUL 08-12, 2010 CL Dubrovnik, CROATIA SP Univ California, Sch Med C1 [Stawiski, E.; Huang, W.; Tomo, J.; Frantzell, A.; Haddad, M.; Lie, Y.; Napolitano, L.; Whitcomb, J.; Coakley, E.] Monogram Biosci, San Francisco, CA USA. [Leduc, R.] Univ Minnesota, Minneapolis, MN USA. [Brumme, Z.] Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada. [Brumme, Z.] BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada. [Skowron, G.] Roger Williams Med Ctr, Providence, RI USA. [Skowron, G.] Boston Univ Sch Med, Boston, MA USA. [Goetz, M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Goetz, M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2010 VL 15 SU 2 BP A131 EP A131 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 722KO UT WOS:000287431300109 ER PT J AU Stawiski, E Huang, W Toma, J Frantzell, A Haddad, M Lie, Y Napolitano, L Whitcomb, J Leduc, R Brumme, Z Skowron, G Goetz, M Coakley, E AF Stawiski, E. Huang, W. Toma, J. Frantzell, A. Haddad, M. Lie, Y. Napolitano, L. Whitcomb, J. Leduc, R. Brumme, Z. Skowron, G. Goetz, M. Coakley, E. TI HIV-1 disease stage significantly correlates with sensitivity of V3 sequence-based predictions of CXCR4 use SO ANTIVIRAL THERAPY LA English DT Meeting Abstract CT International HIV and Hepatitis Virus Drug Resistance and Curative Strategies Workshop CY JUN 08-12, 2010 CL Dubrovnik, CROATIA C1 [Stawiski, E.; Huang, W.; Toma, J.; Frantzell, A.; Haddad, M.; Lie, Y.; Napolitano, L.; Whitcomb, J.; Coakley, E.] Monogram Biosci, San Francisco, CA USA. [Leduc, R.] Univ Minnesota, Minneapolis, MN USA. [Brumme, Z.] Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada. [Brumme, Z.] BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada. [Skowron, G.] Roger Williams Med Ctr, Providence, RI USA. [Skowron, G.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Goetz, M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Goetz, M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2010 VL 15 IS 4 MA 105 BP A131 EP A131 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 629QW UT WOS:000280215800124 ER PT J AU Dickey, MW Yoo, H AF Dickey, Michael Walsh Yoo, Hyunsoo TI Predicting outcomes for linguistically specific sentence treatment protocols SO APHASIOLOGY LA English DT Article; Proceedings Paper CT 39th Annual Clinical Aphasiology Conference CY MAY 26-30, 2009 CL Keystone, CO DE Aphasia; Treatment; Sentence production; Syntax; Outcomes ID AGRAMMATIC APHASIA; SYNTACTIC COMPLEXITY; MOVEMENT STRUCTURES; UNDERLYING FORMS; BROCAS APHASIA; WH-MOVEMENT; COMPREHENSION; DEFICITS; STROKE AB Background: Linguistically motivated treatment protocols like the Treatment of Underlying Forms (TUF: Thompson Shapiro, 2005) have shown significant success in remediating aphasic individuals' sentence production deficits. However, adults with aphasia are not uniform in their response to TUF: not all individuals trained with TUF successfully acquire the sentence types they are trained on or generalise to untrained sentence types. More research is therefore needed to determine which individuals are most likely to benefit from TUF treatment. Aims: The current study analysed existing TUF treatment studies in an effort to determine what measures may be predictive of TUF outcomes for different aphasic individuals. Three different measures were tested: aphasia severity, auditory comprehension ability, and complex sentence comprehension ability. Methods Procedures: A meta-analysis was conducted based on existing TUF treatment studies drawn from the aphasiological literature. These studies included individual demographic, language-testing, and treatment data from 30 aphasic individuals. Regression analyses were conducted comparing these individuals' improvements on production of treated and untreated sentence types (treatment and generalisation effects) with the three predictor measures (severity, auditory comprehension, and complex sentence comprehension scores). Outcomes Results: Only one of the measures tested, general auditory comprehension, was predictive of the size of individuals' gains on treated sentence types. None of the measures tested was predictive of these individuals' generalisation to untrained structures. Conclusions: The current results suggest that general auditory comprehension appears to be related to improved sentence production following TUF treatment. In contrast, neither overall aphasia severity nor performance with complex sentence stimuli is a strong predictor of TUF treatment outcomes. Interestingly, there were no strong relationships between any of the measures and the generalisation effect scores. These findings suggest that clinicians should consider a patient's general auditory comprehension when deciding whether TUF would be appropriate. They also suggest that partially different cognitive mechanisms may underlie treatment and generalisation effects following treatment, at least for TUF protocols. C1 [Dickey, Michael Walsh] Univ Pittsburgh, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Dickey, MW (reprint author), Univ Pittsburgh, 4033 Forbes Tower, Pittsburgh, PA 15260 USA. EM mdickey@pitt.edu OI Dickey, Michael Walsh/0000-0002-9068-3313 NR 38 TC 6 Z9 6 U1 0 U2 3 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0268-7038 J9 APHASIOLOGY JI Aphasiology PY 2010 VL 24 IS 6-8 BP 787 EP 801 AR PII 922040489 DI 10.1080/02687030903515354 PG 15 WC Clinical Neurology SC Neurosciences & Neurology GA 628WL UT WOS:000280154900011 ER PT J AU True, G Bartlett, MR Fink, RB Linebarger, MC Schwartz, M AF True, Gala Bartlett, Megan R. Fink, Ruth B. Linebarger, Marcia C. Schwartz, Myrna TI Perspectives of persons with aphasia towards SentenceShaper To Go: A qualitative study SO APHASIOLOGY LA English DT Article DE Augmentative and alternative communication; Persons with aphasia; Qualitative research methods; Supportive interviewing techniques; Attitudes and preferences ID PROCESSING PROSTHESIS; LANGUAGE PRODUCTION; ALTERNATIVE COMMUNICATION; AAC; SUPPORT; ADULTS; INFORMATIVENESS; DISORDERS; PARTNERS; RATINGS C1 [True, Gala] Ctr Hlth Equ & Res Promot, VA Med Ctr, Philadelphia, PA 19104 USA. [Bartlett, Megan R.; Fink, Ruth B.; Schwartz, Myrna] Moss Rehabil Res Inst, Philadelphia, PA USA. [Linebarger, Marcia C.] Psycholinguist Technol Inc, Jenkintown, PA USA. RP True, G (reprint author), Ctr Hlth Equ & Res Promot, VA Med Ctr, 9th Floor E,3900 Woodland Ave, Philadelphia, PA 19104 USA. EM galatrue@verizon.net FU NIH [1 R01 HD043991] FX The authors wish to thank Jennifer S. Lowery MA CCC/SLP, Michelene Kalinyak-Fliszar MA CCC/SLP, and Roberta Brooks MA CCC/SLP for their assistance with the CIU scoring procedures and modifications. We gratefully acknowledge Paula Sobel MA CCC/SLP for her assistance with the interview validation procedures and Laura MacMullen BA for her help with the literature review and construction of earlier drafts. We also wish to thank the anonymous reviewers for their insightful comments. Support for this study was provided by a grant from the NIH (#1 R01 HD043991; P.I., M. Schwartz). NR 42 TC 3 Z9 3 U1 2 U2 15 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0268-7038 J9 APHASIOLOGY JI Aphasiology PY 2010 VL 24 IS 9 BP 1032 EP 1050 AR PII 917993626 DI 10.1080/02687030903249350 PG 19 WC Clinical Neurology SC Neurosciences & Neurology GA 628WM UT WOS:000280155000004 ER PT J AU Hula, W Donovan, NJ Kendall, DL Gonzalez-Rothi, LJ AF Hula, William Donovan, Neila J. Kendall, Diane L. Gonzalez-Rothi, Leslie J. TI Item response theory analysis of the Western Aphasia Battery SO APHASIOLOGY LA English DT Article DE Aphasia; Item response theory; Rasch analysis; Assessment; Psychometrics ID VALIDITY; STATISTICS; EFFICACY; ADULTS AB Background: The Western Aphasia Battery (WAB) (Kertesz, 1982) is one of the most frequently used tests of general language performance in aphasia, despite significant psychometric limitations. Item response theory (IRT) provides measurement models that may address some of these limitations. Aims: The purposes of this investigation were to evaluate whether the WAB can be productively fit to an IRT model, and to evaluate whether IRT modelling confers psychometric benefits. Methods Procedures: An analysis of WAB data collected from a convenience sample of 101 individuals with chronic aphasia was undertaken. Exploratory factor analysis was conducted to evaluate the dimensionality of the WAB, and a Rasch Partial Credit Model was fit to the data. Item fit statistics and residual correlations were used to test key model assumptions. The distribution of traditional and Rasch-based person scores, and the relationship between ability level and test reliability were also examined. Outcomes Results: Despite reasonable overall fit to the model, a small number of WAB items demonstrated significant misfit, suggesting that they do not productively contribute to the measurement of aphasia severity. A small but substantial minority of individuals also demonstrated inadequate fit to the measurement model. Rasch-based scores were more normally distributed than traditional scores, and score reliability varied substantially across the ability range. Conclusions: These results suggest that the WAB may be productively fit to an IRT-based measurement model, and that such models may be used to improve the psychometric properties of aphasia tests. Benefits include indices of severity and score reliability that are more valid than those currently in use, and the potential for improved efficiency of testing through adaptive administration. C1 [Hula, William] VA Pittsburgh Healthcare Syst, CCC SLP, Pittsburgh, PA 15206 USA. [Hula, William] Univ Pittsburgh, Pittsburgh, PA USA. [Donovan, Neila J.] Louisiana State Univ, Baton Rouge, LA 70803 USA. [Kendall, Diane L.] Univ Washington, Seattle, WA 98195 USA. [Gonzalez-Rothi, Leslie J.] Malcolm Randall VA Med Ctr, Gainesville, FL USA. [Gonzalez-Rothi, Leslie J.] Univ Florida, Gainesville, FL USA. RP Hula, W (reprint author), VA Pittsburgh Healthcare Syst, CCC SLP, 7180 Highland Dr 132A-H, Pittsburgh, PA 15206 USA. EM William.Hula@VA.gov FU VA [C6210M]; VA Pittsburgh Healthcare System Geriatric Research Education and Clinical Center; VA RR&D Brain Rehabilitation Research Center of Excellence [B6793C] FX Dr Hula's work was supported by VA RR&D Career Development Award # C6210M and the VA Pittsburgh Healthcare System Geriatric Research Education and Clinical Center. Dr Gonzalez-Rothi's work was supported by the VA RR&D Brain Rehabilitation Research Center of Excellence Award # B6793C. The authors thank Sally Ouimet-Waters, Katherine Malek, Matthew Comer, and Lauren Bislick for their work on data coding, data entry, and data management. An earlier draft of this work was presented to the 2009 Clinical Aphasiology Conference in Keystone, CO. The authors have no conflicts of interest to report. NR 55 TC 5 Z9 5 U1 1 U2 4 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0268-7038 J9 APHASIOLOGY JI Aphasiology PY 2010 VL 24 IS 11 BP 1326 EP 1341 AR PII 920190140 DI 10.1080/02687030903422502 PG 16 WC Clinical Neurology SC Neurosciences & Neurology GA 659QB UT WOS:000282580900002 ER PT J AU Schreer, JF Lapierre, JL Hammill, MO AF Schreer, Jason F. Lapierre, Jennifer L. Hammill, Michael O. TI Stomach Temperature Telemetry Reveals that Harbor Seal (Phoca vitulina) Pups Primarily Nurse in the Water SO AQUATIC MAMMALS LA English DT Article DE telemetry; stomach temperature; harbor seal; Phoca vitulina; nursing; pups ID FORAGING SUCCESS; LACTATION; CONSUMPTION; WASHINGTON; INGESTION; SEABIRDS; PATTERNS; CONCOLOR; BEHAVIOR; QUANTIFY AB Research on a captive harbor seal (Phoca vitulina) mother-pup pair showed that ingestion of milk caused a decrease in stomach temperature (Hedd et al., 1995). Herein the feasibility of stomach temperature telemetry for measuring nursing behavior was tested in wild harbor seal pups from the St. Lawrence River Estuary. Fifteen pups were outfitted with time-depth recorders, stomach temperature transmitters (STT), and stomach temperature recorders in 2002 and 2003. Twelve pups were recaptured, and seven yielded usable stomach temperature data. Excluding a mortality that lost its transmitter the day of release, transmitter retention time ranged from at least 7 to 22 d (12.5 +/- 1.45 d) based on a STT signal at recapture. Pups that gained more weight had a higher frequency of decreases in stomach temperature (DST) (R(2) = 0.954, p < 0.001). Depth and external temperature data showed that most DST occurred while pups were "in the water" (57%) followed by "just before or after hauling out" (19%), "just before or after entering the water" (15%), and "hauled out" (9%) (chi(2) = 56.376, p < 0.001). The frequency DST did not change with age, and there was no diel pattern of DST, which also did not change with age. These findings indicate that transmitter retention times are sufficient to monitor most of the nursing period for harbor seals, that stomach temperature can be used to quantify nursing characteristics in the field, and that a telemetric technique is needed for harbor seals as most nursing events occur in the water. C1 [Schreer, Jason F.] SUNY Coll Potsdam, Dept Biol, Potsdam, NY 13676 USA. [Lapierre, Jennifer L.] Vet Affairs Greater Los Angeles Hlth Care Syst, Neurobiol Res 151 A3, North Hills, CA 91343 USA. [Lapierre, Jennifer L.] Univ Calif Berkeley, Ctr Sleep Res, Semel Inst Neurosci & Human Behav, Berkeley, CA 94720 USA. [Hammill, Michael O.] Inst Maurice Lamontagne, Dept Fisheries & Oceans, Mont Joli, PQ G5H 3Z4, Canada. RP Schreer, JF (reprint author), SUNY Coll Potsdam, Dept Biol, Potsdam, NY 13676 USA. EM schreejf@potsdam.edu FU SUNY Potsdam; University of Waterloo; Department of Fisheries and Oceans; Natural Sciences and Engineering Research Council of Canada FX All procedures were conducted in accordance with the guidelines set out by the Canadian Council on Animal Care as implemented by the University of Waterloo, Waterloo, Ontario, Canada. We thank Pierre Carter, Erin Copeland, Jean-Francois Gosselin, James Greig, and Geoff Yunker for help in the field and Meghan Ellis for compiling the graphical output. We also thank several reviewers and editors for providing comments to improve this manuscript. This work was supported by SUNY Potsdam, the University of Waterloo, the Department of Fisheries and Oceans, and the Natural Sciences and Engineering Research Council of Canada. JFS thanks XOQ. NR 26 TC 3 Z9 3 U1 2 U2 13 PU EUROPEAN ASSOC AQUATIC MAMMALS PI MOLINE PA C/O DR JEANETTE THOMAS, BIOLOGICAL SCIENCES, WESTERN ILLIONIS UNIV-QUAD CITIES, 3561 60TH STREET, MOLINE, IL 61265 USA SN 0167-5427 J9 AQUAT MAMM JI Aquat. Mamm. PY 2010 VL 36 IS 3 BP 270 EP 277 DI 10.1578/AM.36.3.2010.270 PG 8 WC Marine & Freshwater Biology; Zoology SC Marine & Freshwater Biology; Zoology GA 670UJ UT WOS:000283452500006 ER PT J AU Baker, LD Frank, LL Foster-Schubert, K Green, PS Wilkinson, CW McTiernan, A Plymate, SR Fishel, MA Watson, GS Cholerton, BA Duncan, GE Mehta, PD Craft, S AF Baker, Laura D. Frank, Laura L. Foster-Schubert, Karen Green, Pattie S. Wilkinson, Charles W. McTiernan, Anne Plymate, Stephen R. Fishel, Mark A. Watson, G. Stennis Cholerton, Brenna A. Duncan, Glen E. Mehta, Pankaj D. Craft, Suzanne TI Effects of Aerobic Exercise on Mild Cognitive Impairment A Controlled Trial SO ARCHIVES OF NEUROLOGY LA English DT Article ID VERBAL FLUENCY PERFORMANCE; HIGH-INTENSITY EXERCISE; ADRENAL AXIS RESPONSE; ALZHEIMERS-DISEASE; OLDER-ADULTS; NEUROTROPHIC FACTOR; PHYSICAL-ACTIVITY; INSULIN-RESISTANCE; SYNAPTIC PLASTICITY; GENDER-DIFFERENCES AB Objectives: To examine the effects of aerobic exercise on cognition and other biomarkers associated with Alzheimer disease pathology for older adults with mild cognitive impairment, and assess the role of sex as a predictor of response. Design: Six-month, randomized, controlled, clinical trial. Setting: Veterans Affairs Puget Sound Health Care System clinical research unit. Participants: Thirty-three adults (17 women) with amnestic mild cognitive impairment ranging in age from 55 to 85 years (mean age, 70 years). Intervention: Participants were randomized either to a high-intensity aerobic exercise or stretching control group. The aerobic group exercised under the supervision of a fitness trainer at 75% to 85% of heart rate reserve for 45 to 60 min/d, 4 d/wk for 6 months. The control group carried out supervised stretching activities according to the same schedule but maintained their heart rate at or below 50% of their heart rate reserve. Before and after the study, glucometabolic and treadmill tests were performed and fat distribution was assessed using dual-energy x-ray absorptiometry. At baseline, month 3, and month 6, blood was collected for assay and cognitive tests were administered. Main Outcome Measures: Performance measures on Symbol-Digit Modalities, Verbal Fluency, Stroop, Trails B, Task Switching, Story Recall, and List Learning. Fasting plasma levels of insulin, cortisol, brain-derived neurotrophic factor, insulinlike growth factor-I, and beta-amyloids 40 and 42. Results: Six months of high-intensity aerobic exercise had sex-specific effects on cognition, glucose metabolism, and hypothalamic-pituitary-adrenal axis and trophic activity despite comparable gains in cardiorespiratory fitness and body fat reduction. For women, aerobic exercise improved performance on multiple tests of executive function, increased glucose disposal during the metabolic clamp, and reduced fasting plasma levels of insulin, cortisol, and brain-derived neurotrophic factor. For men, aerobic exercise increased plasma levels of insulinlike growth factor I and had a favorable effect only on Trails B performance. Conclusions: This study provides support, using rigorous controlled methodology, for a potent nonpharmacologic intervention that improves executive control processes for older women at high risk of cognitive decline. Moreover, our results suggest that a sex bias in cognitive response may relate to sex-based differences in glucometabolic and hypothalamic-pituitary-adrenal axis responses to aerobic exercise. C1 [Baker, Laura D.; Frank, Laura L.; Wilkinson, Charles W.; Watson, G. Stennis; Cholerton, Brenna A.; Craft, Suzanne] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Foster-Schubert, Karen; Green, Pattie S.; McTiernan, Anne; Plymate, Stephen R.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Fishel, Mark A.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Duncan, Glen E.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Nutr Sci Program, Seattle, WA 98195 USA. [Baker, Laura D.; Wilkinson, Charles W.; Plymate, Stephen R.; Fishel, Mark A.; Watson, G. Stennis; Cholerton, Brenna A.; Craft, Suzanne] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Green, Pattie S.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA 98108 USA. [Foster-Schubert, Karen; McTiernan, Anne] Fred Hutchinson Canc Res Ctr, Canc Prevent Res Program, Seattle, WA 98104 USA. [Frank, Laura L.] Washington State Univ, Dept Nutr & Exercise Metab, Spokane, WA USA. [Fishel, Mark A.] Landstuhl Reg Med Ctr, Dept Med, Landstuhl, Germany. [Mehta, Pankaj D.] New York State Inst Basic Res Dev Disabil, Dept Immunol, New York, NY USA. RP Baker, LD (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr S182, 1660 S Columbian Way, Seattle, WA 98108 USA. EM ldbaker@uw.edu RI Duncan, Glen/A-3771-2008 OI Duncan, Glen/0000-0001-6909-1869 FU Department of Veterans Affairs; Alzheimer's Association [NIRG-04-1010] FX This study was supported by the Department of Veterans Affairs and Alzheimer's Association grant NIRG-04-1010. NR 83 TC 340 Z9 354 U1 9 U2 104 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD JAN PY 2010 VL 67 IS 1 BP 71 EP 79 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 542YQ UT WOS:000273535700010 PM 20065132 ER PT J AU Sepulveda, JL Tanhehco, YC Frey, M Guo, LD Cropcho, LJ Gibson, KM Blair, HC AF Sepulveda, Jorge L. Tanhehco, Yvette C. Frey, Monica Guo, Lida Cropcho, Lorna J. Gibson, K. Michael Blair, Harry C. TI Variation in Human Erythrocyte Membrane Unsaturated Fatty Acids Correlation With Cardiovascular Disease SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-HEART-DISEASE; SUDDEN CARDIAC DEATH; ADIPOSE-TISSUE; LINOLEIC-ACID; BLOOD; PLASMA; RISK; SERUM; BIOMARKERS AB Context.-Whether cell membrane fatty acid (FA) composition is a useful indicator of vascular disease is unclear. Objective.-To study variation of erythrocyte (RBC) membrane FA in samples from healthy volunteers, hospitalized patients, and cardiac troponin I-elevated patients with myocardial damage without a priori assumptions as to FA composition. Design.-We separated FAs extracted from RBCs by gas chromatography and identified them by mass spectrometry. Fatty acids with abundance greater than 1% of total were quantified and compared: hexadecanoic (C16:0), octadecadienoic (C18:2), cis- and trans-octadecenoic (C18: 1), and eicosatetraenoic (C20:4) acids. Deuterated standards established proportionality of FA recovery. The cis-and trans-C18:1 identification was verified by comparison with standards. Results.-In troponin-positive samples, C18: 2 to C18: 1 ratios were increased 30% compared with healthy controls or with random patient samples. Erythrocyte trans-C18: 1 had a wide variation, similar to 10-fold, in all groups but without differences between groups. Replicates showed that the wide range of RBC trans-FA load is not due to analytic variation. In healthy subjects, the RBC content of lower molecular weight FAs (C16-C18) correlated with serum low-density lipoprotein cholesterol, but despite the established relationship between dietary trans-FA and increased low-density lipoprotein cholesterol, lipid profiles had no correlation with RBC trans-FA content. Conclusions.-Erythrocyte accumulation of unsaturated FA may be a useful indicator of vascular disease, whereas the wide range in trans-FAs suggests that both diet and genetic variation affect RBC trans-FA accumulation. Unsaturated FAs increase membrane fluidity and may reflect a natural response to subclinical vascular changes, which may in turn reflect increased risk of clinical disease. (Arch Pathol Lab Med. 2010; 134: 73-80) C1 [Frey, Monica; Guo, Lida; Cropcho, Lorna J.; Gibson, K. Michael; Blair, Harry C.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA. [Sepulveda, Jorge L.; Tanhehco, Yvette C.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Sepulveda, Jorge L.] Vet Affairs Med Ctr, Philadelphia, PA USA. [Cropcho, Lorna J.; Gibson, K. Michael] Childrens Hosp, Pittsburgh, PA 15213 USA. [Blair, Harry C.] Vet Affairs Med Ctr, Pittsburgh, PA USA. RP Blair, HC (reprint author), Univ Pittsburgh, Dept Pathol, 705 Scaife Hall, Pittsburgh, PA 15261 USA. EM hcblair@imap.pitt.edu FU US Department of Veterans Affairs; National Institutes of Health FX This study was supported in part by the US Department of Veterans Affairs and by the National Institutes of Health. NR 37 TC 13 Z9 13 U1 0 U2 3 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD JAN PY 2010 VL 134 IS 1 BP 73 EP 80 PG 8 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 542ZV UT WOS:000273539400014 PM 20073608 ER PT J AU Merrill, JT Neuwelt, CM Wallace, DJ Shanahan, JC Latinis, KM Oates, JC Utset, TO Gordon, C Isenberg, DA Hsieh, HJ Zhang, D Brunetta, PG AF Merrill, Joan T. Neuwelt, C. Michael Wallace, Daniel J. Shanahan, Joseph C. Latinis, Kevin M. Oates, James C. Utset, Tammy O. Gordon, Caroline Isenberg, David A. Hsieh, Hsin-Ju Zhang, David Brunetta, Paul G. TI Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial SO ARTHRITIS AND RHEUMATISM LA English DT Article ID B-CELL DEPLETION; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; PLUS CYCLOPHOSPHAMIDE; LONGITUDINAL ANALYSIS; DISEASE-ACTIVITY; RESISTANT SLE; BILAG INDEX; THERAPY; ANTI-CD20 AB Objective. B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in patients with moderately-to-severely active extrarenal SLE. Methods. Patients entered with >= 1 British Isles Lupus Assessment Group (BILAG) A score or >= 2 BILAG B scores despite background immunosuppressant therapy, which was continued during the trial. Prednisone was added and subsequently tapered. Patients were randomized at a ratio of 2:1 to receive rituximab (1,000 mg) or placebo on days 1, 15, 168, and 182. Results. In the intent-to-treat analysis of 257 patients, background treatment was evenly distributed among azathioprine, mycophenolate mofetil, and methotrexate. Fifty-three percent of the patients had >= 1 BILAG A score at entry, and 57% of the patients were categorized as being steroid dependent. No differences were observed between placebo and rituximab in the primary and secondary efficacy end points, including the BILAG-defined response, in terms of both area under the curve and landmark analyses. A beneficial effect of rituximab on the primary end point was observed in the African American and Hispanic subgroups. Safety and tolerability were similar in patients receiving placebo and those receiving rituximab. Conclusion. The EXPLORER trial enrolled patients with moderately-to-severely active SLE and used aggressive background treatment and sensitive cutoffs for nonresponse. No differences were noted between placebo and rituximab in the primary and secondary end points. Further evaluation of patient subsets, biomarkers, and exploratory outcome models may improve the design of future SLE clinical trials. C1 [Merrill, Joan T.] Oklahoma Med Res Fdn, Clin Pharmacol Res Program, Oklahoma City, OK 73104 USA. [Neuwelt, C. Michael] Alameda Cty Med Ctr, Oakland, CA USA. [Wallace, Daniel J.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Wallace, Daniel J.] Univ Calif Los Angeles, Los Angeles, CA USA. [Shanahan, Joseph C.] Duke Univ, Durham, NC USA. [Latinis, Kevin M.] Univ Kansas, Med Ctr, Kansas City, MO USA. [Oates, James C.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Oates, James C.] Med Univ S Carolina, Charleston, SC 29425 USA. [Utset, Tammy O.] Univ Chicago, Chicago, IL 60637 USA. [Gordon, Caroline] Univ Birmingham, Birmingham, W Midlands, England. [Isenberg, David A.] UCL, London, England. [Hsieh, Hsin-Ju; Zhang, David; Brunetta, Paul G.] Genentech Inc, San Francisco, CA 94080 USA. RP Merrill, JT (reprint author), Oklahoma Med Res Fdn, Clin Pharmacol Res Program, MS 22,825 NE 13th St, Oklahoma City, OK 73104 USA. EM JTMmail@aol.com OI Isenberg, David/0000-0001-9514-2455 FU Genentech FX Supported by Genentech. NR 48 TC 430 Z9 456 U1 2 U2 26 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD JAN PY 2010 VL 62 IS 1 BP 222 EP 233 DI 10.1002/art.27233 PG 12 WC Rheumatology SC Rheumatology GA 617JA UT WOS:000279275700024 PM 20039413 ER PT J AU Mikuls, TR Gould, KA Bynote, KK Yu, F LeVan, TD Thiele, GM Michaud, KD O'Dell, JR Reimold, AM Hooker, R Caplan, L Johnson, DS Kerr, G Richards, JS Cannon, GW Criswell, LA Noble, JA Bridges, SL Hughes, L Gregersen, PK AF Mikuls, Ted R. Gould, Karen A. Bynote, Kimberly K. Yu, Fang LeVan, Tricia D. Thiele, Geoffrey M. Michaud, Kaleb D. O'Dell, James R. Reimold, Andreas M. Hooker, Roderick Caplan, Liron Johnson, Dannette S. Kerr, Gail Richards, J. Steuart Cannon, Grant W. Criswell, Lindsey A. Noble, Janelle A. Bridges, S. Louis, Jr. Hughes, Laura Gregersen, Peter K. TI Anticitrullinated protein antibody (ACPA) in rheumatoid arthritis: influence of an interaction between HLA-DRB1 shared epitope and a deletion polymorphism in glutathione s-transferase in a cross-sectional study SO ARTHRITIS RESEARCH & THERAPY LA English DT Article ID CYCLIC CITRULLINATED PEPTIDE; GENE-ENVIRONMENT INTERACTION; SHARED EPITOPE; INFLAMMATORY POLYARTHRITIS; CANCER SUSCEPTIBILITY; DISEASE SEVERITY; NULL GENOTYPE; SMOKING; RISK; ASSOCIATION AB Introduction: A deletion polymorphism in glutathione S-transferase Mu-1 (GSTM1-null) has previously been implicated to play a role in rheumatoid arthritis (RA) risk and progression, although no prior investigations have examined its associations with anticitrullinated protein antibody (ACPA) positivity. The purpose of this study was to examine the associations of GSTM1-null with ACPA positivity in RA and to assess for evidence of interaction between GSTM1 and HLA-DRB1 shared epitope (SE). Methods: Associations of GSTM1-null with ACPA positivity were examined separately in two RA cohorts, the Veterans Affairs Rheumatoid Arthritis (VARA) registry (n = 703) and the Study of New-Onset RA (SONORA; n = 610). Interactions were examined by calculating an attributable proportion (AP) due to interaction. Results: A majority of patients in the VARA registry (76%) and SONORA (69%) were positive for ACPA with a similar frequency of GSTM1-null (53% and 52%, respectively) and HLA-DRB1 SE positivity (76% and 71%, respectively). The parameter of patients who had ever smoked was more common in the VARA registry (80%) than in SONORA (65%). GSTM1-null was significantly associated with ACPA positivity in the VARA registry (odds ratio (OR), 1.45; 95% confidence interval (CI), 1.02 to 2.05), but not in SONORA (OR, 1.00; 95% CI, 0.71 to 1.42). There were significant additive interactions between GSTM1 and HLA-DRB1 SE in the VARA registry (AP, 0.49; 95% CI, 0.21 to 0.77; P < 0.001) in ACPA positivity, an interaction replicated in SONORA (AP, 0.38; 95% CI, 0.00 to 0.76; P = 0.050). Conclusions: This study is the first to show that the GSTM1-null genotype, a common genetic variant, exerts significant additive interaction with HLA-DRB1 SE on the risk of ACPA positivity in RA. Since GSTM1 has known antioxidant functions, these data suggest that oxidative stress may be important in the development of RA-specific autoimmunity in genetically susceptible individuals. C1 [Mikuls, Ted R.; Thiele, Geoffrey M.; Michaud, Kaleb D.; O'Dell, James R.] Univ Nebraska Med Ctr, Omaha Vet Affairs Med Ctr, Omaha, NE 68198 USA. [Mikuls, Ted R.; Thiele, Geoffrey M.; Michaud, Kaleb D.; O'Dell, James R.] Univ Nebraska Med Ctr, Nebraska Arthrit Outcomes Res Ctr, Omaha, NE 68198 USA. [Gould, Karen A.; Bynote, Kimberly K.] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA. [Yu, Fang] Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE 68198 USA. [LeVan, Tricia D.] Univ Nebraska Med Ctr, Dept Med & Epidemiol, Omaha, NE 68198 USA. [Reimold, Andreas M.; Hooker, Roderick] Dallas Vet Affairs Med Ctr, Dept Med, Dallas, TX 75216 USA. [Caplan, Liron] Denver Vet Affairs Med Ctr, Aurora, CO 80045 USA. [Caplan, Liron] Univ Colorado Denver, Aurora, CO 80045 USA. [Johnson, Dannette S.] Jackson Vet Affairs Med Ctr, Dept Med, Jackson, MS 39216 USA. [Johnson, Dannette S.] Univ Mississippi, Jackson, MS 39216 USA. [Kerr, Gail; Richards, J. Steuart] Vet Affairs Med Ctr, Dept Med, Washington, DC 20422 USA. [Kerr, Gail; Richards, J. Steuart] Georgetown Univ, Washington, DC 20422 USA. [Cannon, Grant W.] Salt Lake City Vet Affairs Med Ctr, Dept Med, Salt Lake City, UT 84132 USA. [Cannon, Grant W.] Univ Utah, Salt Lake City, UT 84132 USA. [Criswell, Lindsey A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Noble, Janelle A.] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA. [Bridges, S. Louis, Jr.; Hughes, Laura] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Gregersen, Peter K.] Feinstein Inst Med Res, Manhasset, NY 11030 USA. RP Mikuls, TR (reprint author), Univ Nebraska Med Ctr, Omaha Vet Affairs Med Ctr, 986270 Nebraska Med Ctr, Omaha, NE 68198 USA. EM tmikuls@unmc.edu RI Yu, Fang/B-9874-2013 OI Thiele, Geoffrey/0000-0001-5688-8596 FU National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases [R03 AR054539]; Veterans Health Administration (VHA); Abbott Laboratories; Bristol-Myers Squibb; American College of Rheumatology Research and Education Foundation FX This work was funded by a grant from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant R03 AR054539). The VARA Registry has received research support from the Health Services Research & Development (HSR&D) Program of the Veterans Health Administration (VHA) in addition to unrestricted research funds from Abbott Laboratories and Bristol-Myers Squibb. Dr Mikuls receives research support from the VHA (VA Merit) and the American College of Rheumatology Research and Education Foundation. The authors thank Debra Bergman and Bart Hamilton for their assistance in this work and the many U. S. veterans who have generously participated in this research. NR 50 TC 23 Z9 23 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PY 2010 VL 12 IS 6 AR R213 DI 10.1186/ar3190 PG 10 WC Rheumatology SC Rheumatology GA 723OQ UT WOS:000287517000023 PM 21087494 ER PT J AU Ramiro, S Machado, P Singh, JA Landewe, RB da Silva, JAP AF Ramiro, Sofia Machado, Pedro Singh, Jasvinder A. Landewe, Robert B. da Silva, Jose Antonio P. TI Applying science in practice: the optimization of biological therapy in rheumatoid arthritis SO ARTHRITIS RESEARCH & THERAPY LA English DT Review ID PRELIMINARY REMISSION CRITERIA; MINIMAL DISEASE-ACTIVITY; DOUBLE-BLIND; METHOTREXATE MONOTHERAPY; EULAR RECOMMENDATIONS; RECEPTOR INHIBITION; CLINICAL REMISSION; RANDOMIZED-TRIAL; ACTIVITY STATES; ACTIVITY SCORE AB Most authorities recommend starting biological agents upon failure of at least one disease-modifying agent in patients with rheumatoid arthritis. However, owing to the absence of head-to-head studies, there is little guidance about which biological to select. Still, the practicing clinician has to decide. This review explores the application of published evidence to practice, discussing the goals of treatment, the (in) ability to predict individual responses to therapy, and the potential value of indirect comparisons. We suggest that cycling of biological agents, until remission is achieved or until the most effective agent for that individual patient is determined, deserves consideration in the current stage of knowledge. C1 [Machado, Pedro; da Silva, Jose Antonio P.] Hosp Univ Coimbra, Dept Rheumatol, P-3000076 Coimbra, Portugal. [Ramiro, Sofia; Landewe, Robert B.] Maastricht Univ Med Ctr, NL-6202 AZ Maastricht, Netherlands. [Ramiro, Sofia; Landewe, Robert B.] Sch Publ Hlth & Primary Care CAPHRI, NL-6200 MD Maastricht, Netherlands. [Ramiro, Sofia] Hosp Garcia Orta, Dept Rheumatol, P-2801951 Almada, Portugal. [Machado, Pedro] Leiden Univ Med Ctr, Dept Rheumatol, NL-2300 RC Leiden, Netherlands. [Singh, Jasvinder A.] Univ Alabama, Div Rheumatol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP da Silva, JAP (reprint author), Hosp Univ Coimbra, Dept Rheumatol, P-3000076 Coimbra, Portugal. EM jdasilva@huc.min-saude.pt RI Machado, Pedro/C-8621-2013 OI Machado, Pedro/0000-0002-8411-7972; singh, jasvinder/0000-0003-3485-0006; Da Silva, Jose/0000-0002-2782-6780 NR 54 TC 6 Z9 6 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PY 2010 VL 12 IS 6 AR 220 DI 10.1186/ar3149 PG 8 WC Rheumatology SC Rheumatology GA 723OQ UT WOS:000287517000004 PM 21067530 ER PT J AU Singh, JA AF Singh, Jasvinder A. TI Advances in gout: some answers, more questions SO ARTHRITIS RESEARCH & THERAPY LA English DT Editorial Material ID MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; SERUM URATE; FEBUXOSTAT; ALLOPURINOL; HYPERURICEMIA; EFFICACY; SAFETY; RISK AB In a previous issue of the journal, Becker and colleagues present efficacy and safety data from a large study comparing febuxostat to allopurinol. The study showed non-inferiority of febuxostat 40 mg/day in lowering serum urate compared to allopurinol 200 to 300 mg/day. More importantly, the study showed a similar frequency of important cardiovascular adverse events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) for febuxostat 40 mg/day (0%), febuxostat 80 mg/day (0.4%) and allopurinol groups (0.4%). Other cardiac adverse event rates (unstable angina, coronary revascularization, cerebral revascularization, transient ischemic attack, venous and peripheral arterial vascular thrombotic event, congestive heart failure, and arrhythmia) were also similar for febuxostat 40 mg/day (1.3%), febuxostat 80 mg/day (1.2%) and allopurinol groups (0.9%). A meta-analysis of safety data from published studies is presented. C1 [Singh, Jasvinder A.] Univ Alabama, Med Serv, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL 35205 USA. [Singh, Jasvinder A.] Univ Alabama, Div Epidemiol, Sch Publ Hlth, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Hlth Sci Res, Rochester, MN 55905 USA. [Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Orthoped, Rochester, MN 55905 USA. RP Singh, JA (reprint author), Univ Alabama, Med Serv, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com OI singh, jasvinder/0000-0003-3485-0006 NR 15 TC 5 Z9 7 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PY 2010 VL 12 IS 5 AR 136 DI 10.1186/ar3110 PG 3 WC Rheumatology SC Rheumatology GA 685JV UT WOS:000284625900001 PM 20959031 ER PT S AU Kalkstein, S Hurford, I Gur, RC AF Kalkstein, Solomon Hurford, Irene Gur, Ruben C. BE Swerdlow, NR TI Neurocognition in Schizophrenia SO BEHAVIORAL NEUROBIOLOGY OF SCHIZOPHRENIA AND ITS TREATMENT SE Current Topics in Behavioral Neurosciences LA English DT Article; Book Chapter DE Cognition; Endophenotypes; Memory; Neuropsychology; Schizophrenia ID COGNITIVE DEFICITS; SOCIAL COGNITION; HIGH-RISK; 1ST-EPISODE SCHIZOPHRENIA; NEURODEVELOPMENTAL MODEL; EMOTION RECOGNITION; MEMORY IMPAIRMENT; HEALTHY CONTROLS; METAANALYSIS; ENDOPHENOTYPES AB Neuropsychological deficits among schizophrenia patients have been consistently documented in research over the past 20 years and are reviewed in this chapter. Discussion of general abilities is presented as a background and is followed by analysis of functioning in specific cognitive domains. Overall intellectual deficits are indicated by results from both general intelligence tests and composite test battery scores. Within specific cognitive domains, effect size differences are noted in numerous areas, including attention, with indications that working memory is affected more severely than simple attention, likely due to inclusion of an executive component in such tasks. There is also evidence of slowed processing speed among schizophrenia patients, likely contributing to deficits in other domains which rely on rapid and efficient assimilation of information. Executive impairments have been found on tests assessing set-shifting abilities, selective attention, and inhibition of inappropriate responses. Learning and memory deficits have been demonstrated extensively, with some evidence that recall of verbal material is more affected than recall of visual information, and that recognition abilities are comparatively less impaired than recall for both modalities. Receptive and expressive language abilities are compromised in schizophrenia patients, as well as visual perceptual, constructional, and fine motor skills. Social cognition is an area of particular importance due to its relevance to functional outcome. Deficits in expression and recognition of facial and prosodic affect have been demonstrated, although subjective experience of emotion appears to be relatively well preserved. Neuropsychological deficits described in this review appear to generally remain stable throughout adulthood, supporting neurodevelopmental, rather than neurodegenerative, models of the illness. Finally, cognitive deficits are increasingly used as endophenotypes, which is likely an important direction of future research. C1 [Kalkstein, Solomon; Hurford, Irene; Gur, Ruben C.] Univ Penn, Sch Med, Dept Psychiat, Schizophrenia Res Ctr,Neuropsychiat Sect, Philadelphia, PA 19104 USA. [Kalkstein, Solomon; Hurford, Irene] Univ Penn, Sch Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Kalkstein, S (reprint author), Univ Penn, Sch Med, Dept Psychiat, Schizophrenia Res Ctr,Neuropsychiat Sect, 10th Floor,Gates Bldg,3400 Spruce St, Philadelphia, PA 19104 USA. EM solomon.kalkstein@va.gov; ihurford@upenn.edu; gur@bblmail.psycha.upenn.edu NR 95 TC 77 Z9 78 U1 2 U2 14 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 1866-3370 BN 978-3-642-13716-7 J9 CURR TOP BEHAV NEURO JI Cur. Top. Behav. Neurosci. PY 2010 VL 4 BP 373 EP 390 DI 10.1007/7854_2010_42 D2 10.1007/978-3-642-13717-4 PG 18 WC Neurosciences SC Neurosciences & Neurology GA BQY42 UT WOS:000282104600013 PM 21312407 ER PT J AU Santucci, AK Gold, MA Akers, AY Borrero, S Schwarz, EB AF Santucci, Aimee K. Gold, Melanie A. Akers, Aletha Y. Borrero, Sonya Schwarz, Eleanor Bimla TI Women's Perspectives on Counseling about Risks for Medication-Induced Birth Defects SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article; Proceedings Paper CT 21st International Conference of the Organization-of-Teratology-Information-Specialists CY JUN 28-JUL 01, 2008 CL Monterey, CA SP Org Teratol Soc Informat Specialists DE birth defects; counseling; contraception; medications; teratogens; qualitative ID PREGNANCY AB PURPOSE: This qualitative study explored women's experiences with counseling about medication-induced birth defects, as well as how and when they would like to receive information on medication-induced birth defects from their health care providers (HCPs). METHODS: We conducted four focus groups with 36 women of reproductive age (18-45 years old) in Pittsburgh, Pennsylvania. Twenty-one women were using medications to treat a chronic health condition, and two were pregnant. Content analysis was performed by three independent coders using a grounded theory approach. Discrepancies were resolved by consensus. RESULTS: Women reported depending on their HCPs for information about the risks of teratogenic effects of medications on a pregnancy, but felt the information they had been provided was not always comprehensive. Women want HCPs to initiate discussions about potentially teratogenic medications at the time the medications are prescribed, regardless of whether the woman is sexually active or planning a pregnancy. Women want clear information about all potential outcomes for a fetus. Factors women reported as being critical to effective teratogenic risk counseling included privacy, sufficient time to discuss the topic, and a trusting relationship with their HCP. CONCLUSIONS: Women of reproductive age think that providing information about the possible teratogenic effects of medications could be improved by routine discussions of teratogenic risks at the time medications are prescribed. Birth Defects Research (Part A) 88:64-69, 2010. (C) 2009 Wiley-Liss, Inc. C1 [Santucci, Aimee K.; Borrero, Sonya; Schwarz, Eleanor Bimla] Univ Pittsburgh, Dept Med, Ctr Res Hlth Care, Pittsburgh, PA USA. [Gold, Melanie A.] Univ Pittsburgh, Sch Med, Dept Pediat, Div Adolescent Med, Pittsburgh, PA 15261 USA. [Akers, Aletha Y.; Schwarz, Eleanor Bimla] Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA. [Borrero, Sonya; Schwarz, Eleanor Bimla] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Borrero, Sonya] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Schwarz, EB (reprint author), 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM schwarzeb@upmc.edu OI Schwarz, Eleanor Bimla/0000-0002-9912-8236 FU AHRQ HHS [R18 HS017093, R18 HS017093-01]; NICHD NIH HHS [K23 HD051585, K23 HD051585-04] NR 11 TC 12 Z9 13 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD JAN PY 2010 VL 88 IS 1 BP 64 EP 69 DI 10.1002/bdra.20618 PG 6 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 548FG UT WOS:000273944500009 PM 19637252 ER PT J AU Hung, WW Liu, S Boockvar, KS AF Hung, William W. Liu, Sophia Boockvar, Kenneth S. TI A prospective study of symptoms, function, and medication use during acute illness in nursing home residents: design, rationale and cohort description SO BMC GERIATRICS LA English DT Article AB Background: Nursing home residents are at high risk for developing acute illnesses. Compared with community dwelling adults, nursing home residents are often more frail, prone to multiple medical problems and symptoms, and are at higher risk for adverse outcomes from acute illnesses. In addition, because of polypharmacy and the high burden of chronic disease, nursing home residents are particularly vulnerable to disruptions in transitions of care such as medication interruptions in the setting of acute illness. In order to better estimate the effect of acute illness on nursing home residents, we have initiated a prospective cohort which will allow us to observe patterns of acute illnesses and the consequence of acute illnesses, including symptoms and function, among nursing home residents. We also aim to examine the patterns of medication interruption, and identify patient, provider and environmental factors that influence continuity of medication prescribing at different points of care transition. Methods: This is a prospective cohort of nursing home residents residing in two nursing homes in a metropolitan area. Baseline characteristics including age, gender, race, and comorbid conditions are recorded. Participants are followed longitudinally for a planned period of 3 years. We record acute illness incidence and characteristics, and measure symptoms including depression, pain, withdrawal symptoms, and function using standardized scales. Results: 76 nursing home residents have been followed for a median of 666 days to date. At baseline, mean age of residents was 74.4 (+/- 11.9); 32% were female; 59% were white. The most common chronic conditions were dementia (41%), depression (38%), congestive heart failure (25%) and chronic obstructive lung disease (27%). Mean pain score was 4.7 (+/- 3.6) on a scale of 0 to 10; Geriatric Depression Scale (GDS-15) score was 5.2 (+/- 4.4). During follow up, 138 acute illness episodes were identified, for an incidence of 1.5 (SD 2.0) episodes per resident per year; 74% were managed in the nursing home and 26% managed in the acute care setting. Conclusion: In this report, we describe the conceptual model and methods of designing a longitudinal cohort to measure acute illness patterns and symptoms among nursing home residents, and describe the characteristics of our cohort at baseline. In our planned analysis, we will further estimate the effect of the use and interruption of medications on withdrawal and relapse symptoms and illness outcomes. C1 [Hung, William W.; Boockvar, Kenneth S.] James J Peters VA Med Ctr, Ctr Study Hlth Care Syst & Sites Care, Dept Veteran Affairs HSR&D Serv, Bronx, NY 10468 USA. [Hung, William W.; Boockvar, Kenneth S.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Liu, Sophia] New York Presbyterian Columbia Univ Med Ctr, Dept Anesthesiol, New York, NY 10032 USA. [Boockvar, Kenneth S.] Jewish Home Lifecare, Res Inst Aging, New York, NY 10025 USA. RP Hung, WW (reprint author), James J Peters VA Med Ctr, Ctr Study Hlth Care Syst & Sites Care, Dept Veteran Affairs HSR&D Serv, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM william.hung@mssm.edu OI Boockvar, Kenneth/0000-0003-1165-5558 NR 32 TC 7 Z9 8 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2318 J9 BMC GERIATR JI BMC Geriatr. PY 2010 VL 10 AR 47 DI 10.1186/1471-2318-10-47 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA V29EL UT WOS:000208731600047 PM 20630095 ER PT J AU Tranah, GJ Parimi, N Blackwell, T Ancoli-Israel, S Ensrud, KE Cauley, JA Redline, S Lane, N Paudel, ML Hillier, TA Yaffe, K Cummings, SR Stone, KL AF Tranah, Gregory J. Parimi, Neeta Blackwell, Terri Ancoli-Israel, Sonia Ensrud, Kristine E. Cauley, Jane A. Redline, Susan Lane, Nancy Paudel, Misti L. Hillier, Teresa A. Yaffe, Kristine Cummings, Steven R. Stone, Katie L. TI Postmenopausal hormones and sleep quality in the elderly: a population based study SO BMC WOMENS HEALTH LA English DT Article AB Background: Sleep disturbance and insomnia are commonly reported by postmenopausal women. However, the relationship between hormone therapy (HT) and sleep disturbances in postmenopausal community-dwelling adults is understudied. Using data from the multicenter Study of Osteoporotic Fractures (SOF), we tested the relationship between HT and sleep-wake estimated from actigraphy. Methods: Sleep-wake was ascertained by wrist actigraphy in 3,123 women aged 84 +/- 4 years (range 77-99) from the Study of Osteoporotic Fractures (SOF). This sample represents 30% of the original SOF study and 64% of participants seen at this visit. Data were collected for a mean of 4 consecutive 24-hour periods. Sleep parameters measured objectively included total sleep time, sleep efficiency (SE), sleep latency, wake after sleep onset (WASO), and nap time. All analyses were adjusted for potential confounders (age, clinic site, race, BMI, cognitive function, physical activity, depression, anxiety, education, marital status, age at menopause, alcohol use, prior hysterectomy, and medical conditions). Results: Actigraphy measurements were available for 424 current, 1,289 past, and 1,410 never users of HT. Women currently using HT had a shorter WASO time (76 vs. 82 minutes, P = 0.03) and fewer long-wake (>= 5 minutes) episodes (6.5 vs. 7.1, P = 0.004) than never users. Past HT users had longer total sleep time than never users (413 vs. 403 minutes, P = 0.002). Women who never used HT had elevated odds of SE <70% (OR, 1.37; 95%CI, 0.98-1.92) and significantly higher odds of WASO >= 90 minutes (OR, 1.37; 95%CI, 1.02-1.83) and >= 8 long-wake episodes (OR, 1.58; 95%CI, 1.18-2.12) when compared to current HT users. Conclusions: Postmenopausal women currently using HT had improved sleep quality for two out of five objective measures: shorter WASO and fewer long-wake episodes. The mechanism behind these associations is not clear. For postmenopausal women, starting HT use should be considered carefully in balance with other risks since the vascular side-effects of hormone replacement may exceed its beneficial effects on sleep. C1 [Tranah, Gregory J.; Parimi, Neeta; Blackwell, Terri; Cummings, Steven R.; Stone, Katie L.] CPMC Res Inst, San Francisco, CA 94120 USA. [Ancoli-Israel, Sonia] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Ensrud, Kristine E.; Paudel, Misti L.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Ensrud, Kristine E.] Minneapolis VA Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Ensrud, Kristine E.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA. [Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Redline, Susan] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA. [Redline, Susan] Case Western Reserve Univ, Ctr Clin Invest, Cleveland, OH 44106 USA. [Lane, Nancy] Univ Calif Davis, Sch Med, Dept Med, Sacramento, CA 95817 USA. [Hillier, Teresa A.] Kaiser Permanente Ctr Hlth Res NW Hawaii, Portland, OR USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Tranah, GJ (reprint author), CPMC Res Inst, San Francisco, CA 94120 USA. EM gtranah@sfcc-cpmc.net OI Cauley, Jane A/0000-0003-0752-4408 FU NIH [AG05407, AR35582, AG05394, AR35584, AR35583, AR46238, AG005407, AG08415, AG027576-22, AG005394-22A1, AG027574-22A1] FX This work was supported by grants from the NIH: AG05407, AR35582, AG05394, AR35584, AR35583, AR46238, AG005407, AG08415, AG027576-22, AG005394-22A1, AG027574-22A1. NR 48 TC 11 Z9 11 U1 0 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6874 J9 BMC WOMENS HEALTH JI BMC Womens Health PY 2010 VL 10 AR 15 DI 10.1186/1472-6874-10-15 PG 8 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology SC Public, Environmental & Occupational Health; Obstetrics & Gynecology GA V27IS UT WOS:000208607500015 PM 20441593 ER PT J AU Warden, SJ Robling, AG Haney, EM Turner, CH Bliziotes, MM AF Warden, Stuart J. Robling, Alexander G. Haney, Elizabeth M. Turner, Charles H. Bliziotes, Michael M. TI The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5) SO BONE LA English DT Review DE Antidepressants; Enterochromaffin cells; Hormones; Osteoporosis; Serotonin ID BONE-MINERAL DENSITY; TRYPTOPHAN-HYDROXYLASE INHIBITORS; REUPTAKE INHIBITORS; TRICYCLIC ANTIDEPRESSANTS; GASTROINTESTINAL-TRACT; ESTROGEN-DEFICIENCY; 5-HT TRANSPORTER; WNT CORECEPTOR; GROWING RATS; MICE AB Novel molecular pathways obligatory for bone health are being rapidly identified. One pathway recently revealed involves gut-derived 5-hydroxytryptamine (5-HT) mediation of the complete skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5). Mounting evidence supports 5-HT as an important regulatory compound in bone with previous evidence demonstrating that bone cells possess functional pathways for responding to 5-HT. In addition, there is growing evidence that potentiation of 5-HT signaling via inhibition of the 5-HT transporter (5-HTT) has significant skeletal effects. The later is clinically significant as the 5-HTT is a popular target of pharmaceutical agents, such as selective serotonin reuptake inhibitors (SSRIs), used for the management of major depressive disorder and other affective conditions. The observation that 5-HT mediates the complete skeletal effects of LRP5 represents a significant paradigm shift from the traditional view that LRP5 located on the cell surface membrane of osteoblasts exerts direct skeletal effects via Wnt/beta-catenin signaling. This paper discusses the mounting evidence for skeletal effects of 5-HT and the ability of gut-derived 5-HT to satisfactorily explain the skeletal effects of LRP5. (C) 2009 Elsevier Inc. All rights reserved. C1 [Warden, Stuart J.] Indiana Univ, Sch Hlth & Rehabil Sci, Dept Phys Therapy, Indianapolis, IN 46202 USA. [Bliziotes, Michael M.] Portland VA Med Ctr, Portland, OR 97239 USA. [Haney, Elizabeth M.; Bliziotes, Michael M.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA. [Warden, Stuart J.; Robling, Alexander G.] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA. [Turner, Charles H.] Indiana Univ Purdue Univ, Dept Biomed Engn, Purdue Sch Engn & Technol, Indianapolis, IN 46202 USA. RP Warden, SJ (reprint author), Indiana Univ, Sch Hlth & Rehabil Sci, Dept Phys Therapy, Indianapolis, IN 46202 USA. EM stwarden@iupui.edu RI Warden, Stuart/C-5287-2012 OI Warden, Stuart/0000-0002-6415-4936 FU National Institutes of Health [AR-052018, AR-051926, AR-53237] FX Completion of this review was enabled by support from National Institutes of Health grants AR-052018 (to M.M.B.), AR-051926 (to E.M.H.) and AR-53237 (to A.G.R.). NR 58 TC 38 Z9 42 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 J9 BONE JI Bone PD JAN PY 2010 VL 46 IS 1 BP 4 EP 12 DI 10.1016/j.bone.2009.06.029 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 550LN UT WOS:000274129400001 PM 19591966 ER PT J AU Haney, EM Warden, SJ Bliziotes, MM AF Haney, Elizabeth M. Warden, Stuart J. Bliziotes, M. Michael TI Effects of selective serotonin reuptake inhibitors on bone health in adults: Time for recommendations about screening, prevention and management? SO BONE LA English DT Review DE Bone; Depression; Serotonin; Selective serotonin reuptake inhibitor; Screening; Epidemiology; Neurotransmitter ID GLUCOCORTICOID-INDUCED OSTEOPOROSIS; SYSTEM-ACTIVE MEDICATIONS; NURSING-HOME RESIDENTS; PROTON PUMP INHIBITORS; MINERAL DENSITY; OLDER WOMEN; DEPRESSIVE SYMPTOMS; HIP FRACTURE; POSTMENOPAUSAL WOMEN; RISK-FACTOR AB Evidence regarding a functional serotonin (5-hydroxytryptamine) signaling system in bone has generated considerable recent interest. The specific biochemical nature of serotoninergic pathways and their direct and/or indirect effects on bone metabolism are still unclear. Clinical evidence supports an effect of serotonin and altered serotonin signaling on bone metabolism. Serotonin is involved in the pathophysiology of depression, and therefore studies of depression and antidepressant treatments (as modulators of the serotonin system) are relevant with regard to bone outcomes. Studies on the effect of depression on bone mineral density (BMD) and fractures have been mixed. Studies on the associations between antidepressant use and BMD and/or fractures are more consistent. SSRIs have been associated with lower BMD and increased rates of bone loss, as well as increased rates of fracture after accounting for falls. These studies are limited by confounding because depression is potentially associated with both the outcome of interest (BMD and fracture) and the exposure (SSRIs). With Mounting evidence for an effect on bone, this review considers the question of causality and whether selective serotonin reuptake inhibitors should be considered among those medications that contribute to bone loss, and therefore prompt clinicians to evaluate BMD proactively. Future research will be required to confirm the serotoninergic effects on bone and the biochemical pathways involved, and to identify clinical implications for treatment based on this novel pathway. (C) 2009 Published by Elsevier Inc. C1 [Bliziotes, M. Michael] Portland VA Med Ctr, Portland, OR 97239 USA. [Warden, Stuart J.] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA. [Warden, Stuart J.] Indiana Univ, Sch Hlth & Rehabil Sci, Dept Phys Therapy, Indianapolis, IN 46202 USA. [Haney, Elizabeth M.; Bliziotes, M. Michael] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA. RP Haney, EM (reprint author), Oregon Hlth & Sci Univ, Dept Med, L-475,SW Sam Jackson Pk Rd, Portland, OR 97219 USA. EM haneye@ohsu.edu RI Warden, Stuart/C-5287-2012 OI Warden, Stuart/0000-0002-6415-4936 FU National Institute of Arthritis and Musculoskeletal and Skin Diseases [051926] FX Dr. Haney is supported by a K23 award (051926) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. NR 67 TC 45 Z9 48 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 J9 BONE JI Bone PD JAN PY 2010 VL 46 IS 1 BP 13 EP 17 DI 10.1016/j.bone.2009.07.083 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 550LN UT WOS:000274129400002 PM 19664737 ER PT J AU Kiank, C Tache, Y Larauche, M AF Kiank, Cornelia Tache, Yvette Larauche, Muriel TI Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: Role of corticotropin-releasing factor receptors SO BRAIN BEHAVIOR AND IMMUNITY LA English DT Review DE Corticotropin-releasing factor; Inflammatory bowel disease; Irritable bowel syndrome; Inflammation; Stress ID FACTOR SIGNALING PATHWAYS; ENTERIC NERVOUS-SYSTEM; MAST-CELLS; INTESTINAL INFLAMMATION; DENDRITIC CELL; COLONIC-MUCOSA; MATERNAL-DEPRIVATION; FACTOR CRF; IN-VITRO; HORMONE AB The interaction between gut inflammatory processes and stress is gaining increasing recognition. Corticotropin-releasing factor (CRF)-receptor activation in the brain is well established as a key signaling pathway initiating the various components of the stress response including in the viscera. In addition, a local CRF signaling system has been recently established in the gut. This review summarize the present knowledge on mechanisms through which both brain and gut CRF receptors modulate intestinal inflammatory processes and its relevance towards increased inflammatory bowel disease (IBD) activity and post-infectious irritable bowel syndrome (IBS) susceptibility induced by stress. (C) 2009 Elsevier Inc. All rights reserved. C1 [Kiank, Cornelia; Tache, Yvette; Larauche, Muriel] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr Anim Core, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Kiank, C (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr Anim Core, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,CURE Bldg 115,Room 111, Los Angeles, CA 90073 USA. EM ckiank@mednet.ucla.edu OI Vacca, Giovanni/0000-0002-0864-1887; Larauche, Muriel/0000-0003-3320-3675 FU German Research Foundation [KI 1389/2-1]; Veteran Administration Research Career Scientist Award; NIHDDK [R01 DK33061, R01 DK57238, R01 DK33506] FX The authors thank Miss Eugenia Hu for reviewing the manuscript. Dr. C. Kiank is supported by the German Research Foundation Grant KI 1389/2-1 and Dr. Y. Tache is in receipt of Veteran Administration Research Career Scientist Award and NIHDDK R01 Grants DK33061, DK57238 and DK33506. NR 93 TC 38 Z9 41 U1 2 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0889-1591 J9 BRAIN BEHAV IMMUN JI Brain Behav. Immun. PD JAN PY 2010 VL 24 IS 1 BP 41 EP 48 DI 10.1016/j.bbi.2009.08.006 PG 8 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 531OE UT WOS:000272676400006 PM 19698778 ER PT J AU Goldstein, G Allen, DN Caponigro, JM AF Goldstein, Gerald Allen, Daniel N. Caponigro, Janelle M. TI A retrospective study of heterogeneity in neurocognitive profiles associated with traumatic brain injury SO BRAIN INJURY LA English DT Article DE Brain injury; assessment; cluster analysis; intelligence ID VERBAL-LEARNING TEST; PATTERNS; SUBTYPES; PERFORMANCE AB Research design: The study was retrospective, applying cluster analyses and associated statistical tests to an established database. Methods and procedures: Neuropsychological data from veterans with brain trauma were cluster analysed using the WAIS-R and Halstead-Reitan Battery (HRB). External validity of the cluster solutions was evaluated. Experimental interventions: The study was based upon use of an established database that contained cognitive test data and information regarding diagnosis and clinical history. Main outcomes and results: The WAIS-R clusters described sub-groups with near normal function, preserved verbal but impaired problem-solving abilities or global impairment. The HRB clusters differed in level of performance with Near Normal, Moderately Impaired and Globally Impaired clusters. Cluster membership was associated with age and employment status, but not with neurological findings. Conclusion: The outcome of traumatic brain injury is heterogeneous and mainly associated with demographic considerations. C1 [Goldstein, Gerald; Caponigro, Janelle M.] VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA 15206 USA. [Allen, Daniel N.] Univ Nevada Las Vegas, Dept Psychol, Las Vegas, NV USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, MIRECC, 7180 Highland Dr 151R, Pittsburgh, PA 15206 USA. EM ggold@nb.net FU DVA VISN IV Mental Illness Research, Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, PA; Medical Research Service, Department of Veterans Affairs FX This research was supported by the DVA VISN IV Mental Illness Research, Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, PA and the Medical Research Service, Department of Veterans Affairs. NR 23 TC 6 Z9 6 U1 0 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0269-9052 J9 BRAIN INJURY JI Brain Inj. PY 2010 VL 24 IS 4 BP 625 EP 635 DI 10.3109/02699051003670882 PG 11 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 570ML UT WOS:000275682300007 PM 20235765 ER PT J AU Ramsey, SD Zeliadt, SB Richardson, LC Pollack, LA Linden, H Blough, DK Cheteri, MK Tock, L Nagy, K Anderson, N AF Ramsey, Scott D. Zeliadt, Steven B. Richardson, Lisa C. Pollack, Lori A. Linden, Hannah Blough, David K. Cheteri, Mahesh Keitheri Tock, Lauri Nagy, Krisztina Anderson, Nancy TI Discontinuation of Radiation Treatment among Medicaid-Enrolled Women with Local and Regional Stage Breast Cancer SO BREAST JOURNAL LA English DT Article DE breast cancer; medicaid; radiation treatment discontinuation ID CARCINOMA-IN-SITU; SURGICAL ADJUVANT BREAST; CONSERVING TREATMENT; COLORECTAL-CANCER; THERAPY; CHEMOTHERAPY; RADIOTHERAPY; INSURANCE; SURVIVAL; RACE AB For women with nonmetastatic breast cancer, radiation therapy is recommended as a necessary component of the breast conserving surgery (BCS) treatment option. The degree to which Medicaid-enrolled women complete recommended radiation therapy protocols is not known. We evaluate radiation treatment completion rates for Medicaid enrollees aged 18-64 diagnosed with breast cancer. We determine clinical and socio-demographic factors associated with not starting treatment, and with interruptions or not completing radiation treatment. Using data from the Washington State Cancer Registry linked to Medicaid enrollment and claims records, we identified Medicaid enrollees diagnosed with breast cancer from 1997 to 2003 who received BCS. Among the 402 women who met inclusion criteria, 105 (26%) did not receive any radiation. Factors significantly associated with not receiving radiation included in situ disease and non-English as a primary language. Among those who received at least one radiation treatment, 65 (22%) failed to complete therapy and 71 (24%) patients had at least one 5 to 30 day gap in treatment. We found no significant predictors of interruptions in treatment or early discontinuation. A substantial proportion of Medicaid-insured women who are eligible for radiation therapy following BCS either fail to receive any treatment, experience significant interruptions during therapy, or do not complete a minimum course of treatment. More effort is needed to ensure this vulnerable population receives adequate radiation following BCS. C1 [Ramsey, Scott D.; Zeliadt, Steven B.; Tock, Lauri] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Zeliadt, Steven B.] Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. [Zeliadt, Steven B.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Richardson, Lisa C.; Pollack, Lori A.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Linden, Hannah] Univ Washington, Div Oncol, Seattle, WA 98195 USA. [Blough, David K.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA. [Cheteri, Mahesh Keitheri] Washington State Canc Registry, Washington State Dept Hlth, Olympia, WA USA. [Nagy, Krisztina] Univ Washington, Dept Econ, Seattle, WA 98195 USA. [Anderson, Nancy] Dept Social & Hlth Serv, Olympia, WA USA. RP Ramsey, SD (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,M3-B232, Seattle, WA 98109 USA. EM sramsey@fhcrc.org FU Centers for Disease Control and Prevention, Prevention Research Centers Program, through the University of Washington Health Promotion Research Center [1-U48-DP-000050 SIP 7-05] FX This publication was supported by Cooperative Agreement Number 1-U48-DP-000050 SIP 7-05 from the Centers for Disease Control and Prevention, Prevention Research Centers Program, through the University of Washington Health Promotion Research Center. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 35 TC 9 Z9 9 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1075-122X J9 BREAST J JI Breast J. PD JAN-FEB PY 2010 VL 16 IS 1 BP 20 EP 27 DI 10.1111/j.1524-4741.2009.00865.x PG 8 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 542FL UT WOS:000273478300005 PM 19929888 ER PT J AU Chauncey, TR Gundacker, H Shadman, M List, AF Dakhil, SR Erba, HP Slovak, ML Chen, IM Willman, CL Kopecky, KJ Appelbaum, FR AF Chauncey, Thomas R. Gundacker, Holly Shadman, Mazyar List, Alan F. Dakhil, Shaker R. Erba, Harry P. Slovak, Marilyn L. Chen, I-Ming Willman, Cheryl L. Kopecky, Kenneth J. Appelbaum, Frederick R. TI Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Article DE acute myeloid leukaemia; P-glycoprotein; multi-drug resistance; ciclosporin; chemoresistance ID MULTIDRUG-RESISTANCE INHIBITOR; RISK MYELODYSPLASTIC SYNDROME; GROUP-B; P-GLYCOPROTEIN; INDUCTION CHEMOTHERAPY; TREATMENT OUTCOMES; MODULATOR PSC-833; ELDERLY-PATIENTS; DOSE-ESCALATION; AML AB P>Attempts to overcome multi-drug resistance in acute myeloid leukaemia (AML) have been limited by toxicities. To investigate the effect of reducing peak drug levels, we performed sequential phase II studies using continuous infusion daunorubicin and cytarabine without (AD) and then with ciclosporin (ADC) in older patients with AML. Untreated patients (age 56+ years) received daunorubicin (45 mg/m2 per day for 3 d) and cytarabine (200 mg/m2 per day for 7 d), both by continuous infusion, without (S0112, 60 patients) and then with (S0301, 50 patients) the addition of ciclosporin. Complete response (CR) rates were 38% on S0112 and 44% on S0301. Fatal induction toxicities occurred in 17% and 12% respectively, arising primarily from infection and haemorrhage. Median overall and relapse-free survival was 7 and 8 months for AD respectively, and 6 and 14 months for ADC. Patients with phenotypic or functional P-glycoprotein had somewhat higher CR rates with ADC than AD, although confidence intervals overlapped. In these sequential trials, continuous infusion AD produced CR rates comparable to those with bolus daunorubicin. The addition of ciclosporin did not cause undue toxicities, produced a similar CR rate, and possibly improved relapse-free survival. Further correlate analyses did not identify a subpopulation specifically benefitting from the addition of ciclosporin. C1 [Chauncey, Thomas R.] Univ Washington, VA Puget Sound Hlth Care Syst 111, Seattle, WA 98108 USA. [Chauncey, Thomas R.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Chauncey, Thomas R.; Appelbaum, Frederick R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Gundacker, Holly; Shadman, Mazyar; Kopecky, Kenneth J.] SW Oncol Grp, Ctr Stat, Seattle, WA USA. [List, Alan F.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Dakhil, Shaker R.] Wichita CCOP, Wichita, KS USA. [Erba, Harry P.] Univ Michigan, Ann Arbor, MI 48109 USA. [Slovak, Marilyn L.] City Hope Natl Med Ctr, Duarte, CA 91010 USA. [Chen, I-Ming; Willman, Cheryl L.] Univ New Mexico, Albuquerque, NM 87131 USA. RP Chauncey, TR (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst 111, 1660 S Columbian Way, Seattle, WA 98108 USA. EM tchaunce@u.washington.edu FU National Cancer Institute, DHHS [CA32102, CA38926, CA04919, CA11083, CA12644, CA13612, CA20319, CA27057, CA35090, CA35119, CA35128, CA35176, CA35178, CA35261, CA35431, CA37981, CA45807, CA45808, CA46113, CA46282, CA46441, CA58416, CA58658, CA58861, CA63845, CA67575, CA74647, CA76462] FX This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA32102, CA38926, CA04919, CA11083, CA12644, CA13612, CA20319, CA27057, CA35090, CA35119, CA35128, CA35176, CA35178, CA35261, CA35431, CA37981, CA45807, CA45808, CA46113, CA46282, CA46441, CA58416, CA58658, CA58861, CA63845, CA67575, CA74647 and CA76462. NR 40 TC 15 Z9 16 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0007-1048 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD JAN PY 2010 VL 148 IS 1 BP 48 EP 58 DI 10.1111/j.1365-2141.2009.07919.x PG 11 WC Hematology SC Hematology GA 533ZB UT WOS:000272864000005 PM 19821823 ER PT J AU Milo-Cotter, O Teerlink, JR Metra, M Felker, GM Ponikowski, P Voors, AA Edwards, C Weatherley, BD Greenberg, B Filippatos, G Unemori, E Teichman, SL Cotter, G AF Milo-Cotter, Olga Teerlink, John R. Metra, Marco Felker, G. Michael Ponikowski, Piotr Voors, Adriaan A. Edwards, Christopher Weatherley, Beth Davison Greenberg, Barry Filippatos, Gerassimos Unemori, Elaine Teichman, Sam L. Cotter, Gad TI Low Lymphocyte Ratio as a Novel Prognostic Factor in Acute Heart Failure: Results from the Pre-RELAX-AHF Study SO CARDIOLOGY LA English DT Article DE White blood cells; Lymphocytes; Heart failure ID COUNT; MORTALITY; TRANSPLANT; APOPTOSIS; SURVIVAL; DEATH; RISK AB Background: Previous studies have suggested that a lower lymphocyte ratio (Ly%) in the white blood cell (WBC) differential count is related to worse outcomes in patients with acute heart failure (AHF) and other cardiovascular disorders. Methods: In the Pre-RELAX-AHF study, 234 patients with AHF, systolic blood pressure >125 mm Hg and brain natriuretic peptide >= 350 pg/ml or equivalent were randomized to 1 of 4 intravenous doses of relaxin or placebo and followed up for 6 months following randomization. Complete blood count and differential were performed by a central laboratory at baseline and then daily to day 5 and on day 14. Results: The WBC count by itself was not associated with measures of disease severity or outcome, and patients with Ly% <13% had similar baseline characteristics to patients with Ly% >13%, except for a higher baseline WBC count, elevated baseline glucose, older age and higher rates of peripheral vascular disease. However, patients with Ly% <13% had less improvement of dyspnea, greater worsening of heart failure, longer length of initial hospital stay and fewer days alive and out of hospital. Statistical significance was reached for all-cause death by days 60 and 180 (hazard ratio = 1.11 per percent decrease, 95% confidence interval 1.03-1.19; p = 0.0048). Conclusions: Despite no association with any baseline characteristic known to strongly predict outcome in AHF, low Ly% is associated with less symptom relief and worse in-hospital and postdischarge clinical outcomes. Copyright (C) 2010 S. Karger AG, Basel C1 [Milo-Cotter, Olga; Edwards, Christopher; Weatherley, Beth Davison; Cotter, Gad] Momentum Res, Durham, NC 27707 USA. [Felker, G. Michael] Duke Univ, Duke Clin Res Inst, Durham, NC USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Cardiol Sect, San Francisco, CA 94143 USA. [Greenberg, Barry] Univ Calif San Diego, MD Adv Heart Failure Treatment Program, San Diego, CA 92103 USA. [Unemori, Elaine; Teichman, Sam L.] Corthera, San Mateo, CA USA. [Metra, Marco] Univ Brescia, Dept Expt & Appl Sci, Sect Cardiovasc Dis, Brescia, Italy. [Ponikowski, Piotr] Med Univ, Dept Hlth Sci, Mil Hosp, Dept Cardiol, Wroclaw, Poland. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9713 AV Groningen, Netherlands. [Filippatos, Gerassimos] Athens Univ Hosp Attikon, Athens, Greece. RP Milo-Cotter, O (reprint author), Momentum Res, 3100 Tower Blvd,Suite 802, Durham, NC 27707 USA. EM olgacotter@momentum-research.com RI Teerlink, John/D-2986-2012; Lainscak, Mitja/F-3237-2015; Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Metra, Marco/0000-0001-6691-8568 NR 18 TC 5 Z9 5 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 J9 CARDIOLOGY JI Cardiology PY 2010 VL 117 IS 3 BP 190 EP 196 DI 10.1159/000321416 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 714JI UT WOS:000286805500007 PM 21088400 ER PT J AU La Fountaine, MF Wecht, JM Rosado-Rivera, D Cirnigliaro, CM Spungen, AM Bauman, WA AF La Fountaine, Michael F. Wecht, Jill M. Rosado-Rivera, Dwindally Cirnigliaro, Christopher M. Spungen, Ann M. Bauman, William A. TI The QT Variability Index and Cardiac Autonomic Modulation: Perspectives from Apparently Healthy Men with Spinal Cord Injury SO CARDIOLOGY LA English DT Article DE Spinal cord injury; QT interval; Autonomic nervous system; QT variability ID HEART-RATE-VARIABILITY; NERVOUS-SYSTEM ACTIVITY; INTERVAL VARIABILITY; REPOLARIZATION LABILITY; ELECTROCARDIOGRAPHIC FINDINGS; VENTRICULAR REPOLARIZATION; SPECTRAL-ANALYSIS; DEATH; RISK; CARDIOMYOPATHY AB Objective: To describe the effect of spinal cord injury (SCI) on the QT variability index (QTVI). Methods: Digital electrocardiograms from 113 age-matched men (40 with tetraplegia, 26 with high paraplegia, 17 low paraplegia and 31 controls) were analyzed. RR interval, heart rate (HR) variability [total power (TP(RR)), low frequency (LF(RR)) and high frequency (HF(RR))], QT interval duration, Bazett HR-corrected QT (QTc), QT interval variance (QTVN) and QTVI were compared. Results: Significant group main effects were present for RR, QTc, TP(RR) and LF(RR), but not QT duration, QTVN or HF(RR). Post hoc comparisons revealed the following: (1) longer RR in controls versus subjects with high paraplegia and low paraplegia, and in subjects with tetraplegia versus high paraplegia and low paraplegia; (2) QTc was longer in subjects with low paraplegia versus controls and shorter in subjects with tetraplegia versus high paraplegia, and (3) TP(RR) and LF(RR) were different in controls and subjects with high paraplegia compared to those with low paraplegia. QTVI was significantly elevated in all SCI groups compared to controls. Significant negative correlations between QTVI and HF(RR) were observed in all SCI groups, and TP(RR) and LF(RR) in subjects with tetraplegia and high paraplegia only. Age was negatively correlated in controls. Conclusions: QTVI is negatively affected in otherwise healthy SCI men compared to age-matched controls. This observation appears to reflect the attenuation of vagal modulation, sympathetic impairment above the sixth thoracic vertebra and/or a heightened degree of cardiovascular disease risk. Copyright (C) 2011 S. Karger AG, Basel C1 [La Fountaine, Michael F.] Mt Sinai Sch Med, Ctr Excellence Med Consequences Spinal Cord Injur, James J Peters VA Med Ctr, Bronx, NY 10468 USA. [La Fountaine, Michael F.] Mt Sinai Sch Med, Dept Med, Bronx, NY 10468 USA. [Wecht, Jill M.; Spungen, Ann M.; Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, Bronx, NY 10468 USA. RP La Fountaine, MF (reprint author), Mt Sinai Sch Med, Ctr Excellence Med Consequences Spinal Cord Injur, James J Peters VA Med Ctr, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM michael.lafountaine@va.gov FU Veteran Affairs Rehabilitation Research and Development Service [B4162C, B3600R]; James J. Peters VA Medical Center FX This research was supported by the Veteran Affairs Rehabilitation Research and Development Service (No. B4162C, No. B3600R) and the James J. Peters VA Medical Center. NR 28 TC 6 Z9 6 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 J9 CARDIOLOGY JI Cardiology PY 2010 VL 117 IS 4 BP 253 EP 259 DI 10.1159/000323337 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 741PP UT WOS:000288876300003 PM 21252534 ER PT S AU Bellomo, R Palevsky, PM Bagshaw, SM Gibney, N McAlister, FA Honore, PM Joannes-Boyau, O Prowle, J Haase, M Cruz, DN Ronco, C AF Bellomo, Rinaldo Palevsky, Paul M. Bagshaw, Sean M. Gibney, Noel McAlister, Finlay A. Honore, Patrick M. Joannes-Boyau, Olivier Prowle, John Haase, Michael Cruz, Dinna N. Ronco, Claudio BE Ronco, C Bellomo, R McCullough, PA TI Recent Trials in Critical Care Nephrology SO CARDIORENAL SYNDROMES IN CRITICAL CARE SE Contributions to Nephrology LA English DT Article; Proceedings Paper CT 19th International Vicenza Course on Critical Care Nephrology CY JUN 08-11, 2010 CL Vicenza, ITALY SP Congress Ctr Ente Fiera ID RANDOMIZED CONTROLLED-TRIAL; ILL PATIENTS; HEMOFILTRATION; INTENSITY; THERAPY; FAILURE; SEPSIS AB Several large observational studies or randomized controlled trials in the field of critical care nephrology have been completed and reported, or recently completed or have recently begun recruitment. These studies provide important information to guide our appreciation of current practice and consider new potentially effective intervention for the prevention or attenuation of acute kidney injury or suggest new avenues for the use of renal replacement therapy (RRT) in the treatment of sepsis. In particular, two studies, the ATN study and the RENAL study (both multicenter randomized controlled trials of >1,000 patients) provide, for the first time, level I evidence to guide the practice of RRT in critically ill patients and to better define the optimal intensity of such RAT in this setting. Clinicians practicing in the field of critical care nephrology need to be aware of these trials, their details, their findings or design or current recruitment rate and likely time of completion to continue to offer their patients the highest level of evidence-based medical care. Copyright (C) 2010 S. Karger AG, Basel C1 [Bellomo, Rinaldo; Prowle, John] Austin Hosp, Dept Intens Care, Melbourne, Vic 3084, Australia. [Palevsky, Paul M.] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Bagshaw, Sean M.; Gibney, Noel] Univ Alberta, Fac Med & Dent, Div Crit Care Med, Edmonton, AB, Canada. [McAlister, Finlay A.] Univ Alberta, Dept Med, Fac Med & Dent, Edmonton, AB, Canada. [Honore, Patrick M.] Queen Astrid Mil Hosp, Burns Ctr, Brussels, Belgium. [Joannes-Boyau, Olivier] Univ Bordeaux 2, Haut Leveque Univ Hosp Bordeaux, Pessac, France. [Haase, Michael] Charite Hosp, Dept Intens Care & Nephrol, Berlin, Germany. [Cruz, Dinna N.; Ronco, Claudio] San Bortolo Hosp, Int Renal Res Inst, Dept Nephrol Dialysis &Transplantat, Vicenza, Italy. RP Bellomo, R (reprint author), Monash Univ, Sch Publ Hlth & Prevent Med, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic 3004, Australia. EM rinaldo.bellomo@med.monash.edu.au; rinaldo.bellomo@med.monash.edu.au RI McAlister, Finlay/C-4151-2013; Prowle, John/D-5014-2009 OI Prowle, John/0000-0002-5002-2721; Palevsky, Paul/0000-0002-7334-5400; GIBNEY, NOEL/0000-0003-3376-0535 NR 12 TC 10 Z9 10 U1 0 U2 1 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0302-5144 BN 978-3-8055-9472-1 J9 CONTRIB NEPHROL JI Contrib.Nephrol. PY 2010 VL 165 BP 299 EP 309 DI 10.1159/000313770 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA BQO22 UT WOS:000281438400033 PM 20427981 ER PT J AU Ogale, SS Lee, TA Au, DH Boudreau, DM Sullivan, SD AF Ogale, Sarika S. Lee, Todd A. Au, David H. Boudreau, Denise M. Sullivan, Sean D. TI Cardiovascular Events Associated With Ipratropium Bromide in COPD SO CHEST LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; RISK; ANTICHOLINERGICS; MORTALITY; DEATH; EXACERBATIONS; METAANALYSIS; HEALTH; ASTHMA AB Background: Studies have suggested an increased risk of cardiovascular morbidity and mortality associated with the use of ipratropium bromide. We sought to examine the association between ipratropium bromide use and the risk of cardiovascular events (CVEs). Methods: We performed a cohort study of 82,717 US veterans with a new diagnosis of COPD between 1999 and 2002. Subjects were followed until they had their first hospitalization for a CVE (acute coronary syndrome, heart failure, or cardiac dysrhythmia), they died, or the end of the Study period (September 30,2004). Cumulative anticholinergic exposure was calculated as the number 4 30-day equivalents (ipratropium bromide) within the past year. We used Cox regression models with time-dependent covariates to estimate the risk of CAT associated with anticholinergic exposure and to adjust for potential confounders, including markers of COPD severity and cardiovascular risk. Results: We identified 6,234 CVEs (44% heart failure, 28% acute coronary syndrome, 28% dysrhythmia). Compared with subjects not exposed to anticholinergics within the past year, any exposure to anticholinergics within the past 6 months was associated with an increased risk of CVE (hazard ratio [95% CI] for <= four and > four 30-day equivalents: 1.40 [1.30-1.51] and 1.23 [1.13-1.36], respectively). Among subjects who received anticholinergics more than 6 months prior, there did not appear to be elevated risk of a CVE. Conclusions: We found an increased risk of CVEs associated with the use of ipratropium bromide within the past 6 months. These findings are consistent with previous concerns raised about the cardiovascular safety of ipratropium bromide. CHEST 2010; 137(1):13-19 C1 [Lee, Todd A.] Hines VA Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA. [Ogale, Sarika S.; Boudreau, Denise M.; Sullivan, Sean D.] Univ Washington, Pharmaceut Outcomes Res & Policy Program, Dept Pharm, Seattle, WA 98195 USA. [Lee, Todd A.] Univ Illinois, Ctr Pharmacoecon Res, Chicago, IL USA. [Lee, Todd A.] Univ Illinois, Dept Pharm Practice, Chicago, IL USA. [Au, David H.] Univ Washington, Hlth Serv Res & Dev, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Au, David H.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Boudreau, Denise M.] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA USA. RP Lee, TA (reprint author), Hines VA Hosp, Ctr Management Complex Chron Care, 5000 S 5th Ave 151-H, Hines, IL 60141 USA. EM todd.lee@va.gov FU US Department of Veterans Affairs Health Services Research and Development [IIR 03-307] FX This research was funded by the US Department of Veterans Affairs Health Services Research and Development (IIR 03-307) NR 14 TC 44 Z9 46 U1 0 U2 2 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD JAN PY 2010 VL 137 IS 1 BP 13 EP 19 DI 10.1378/chest.08-2367 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 542DK UT WOS:000273471500007 PM 19363211 ER PT J AU Platt, AB Kuna, ST Field, SH Chen, Z Gupta, R Roche, DE Christie, JD Asch, DA AF Platt, Alec B. Kuna, Samuel T. Field, Samuel H. Chen, Zhen Gupta, Rajesh Roche, Dominic E. Christie, Jason D. Asch, David A. TI Adherence to Sleep Apnea Therapy and Use of Lipid-Lowering Drugs A Study of the Healthy-User Effect SO CHEST LA English DT Article ID POSITIVE AIRWAY PRESSURE; PLACEBO-CONTROLLED TRIAL; INDEPENDENT RISK-FACTOR; BLOOD-PRESSURE; CARDIOVASCULAR OUTCOMES; MEDICATION ADHERENCE; PRACTICE PARAMETERS; DAYTIME SLEEPINESS; FOLLOW-UP; CPAP USE AB Background: Evidence that continuous positive airway pressure (CPAP) reduces cardiovascular morbidity comes largely from observational studies. This association may be confounded if CPAP adherents are healthier in ways not measured by investigators. We assessed whether patients adhering to lipid-lowering medications were more adherent to CPAP. Methods: This was a retrospective cohort study undertaken at the Philadelphia Veterans Affairs (VA) Medical Center (2005-2006) of consecutive patients on lipid-lowering therapy newly initiating CPAP for obstructive sleep apnea. Adherence to medications dispensed via the VA closed-pharmacy system was measured as the proportion of days covered (>= 80% vs <80%) in the year prior to CPAP initiation. CPAP adherence was defined as >= 4 h/d of "mask-on" time, measured electronically daily during the first week of CPAP, We examined the association between medication adherence and CPAP adherence using multivariable logistic regression. Results: Complete data were available for 117 of 142 (81.5%) subjects. After adjustment for age, race, medical comorbidity, and sleep apnea-related clinical factors, subjects with low medication adherence demonstrated a 40.1% (95% CI, 30.0-51.0) probability of using CPAP >= 4 h/d compared with 55.2% (95% CI, 46.9-63.1) for subjects with adequate (>= 80%) medication adherence (adjusted for comparison, odds ratio (OR) = 1.8 [95% CI, 1.0-3.3], P = .04). Married patients were more adherent to medications and CPAP; inclusion of this factor reduced to nonsignificance the association of medication and CPAP adherence (OR = 1.6 [95% CI, 0.9-2.8], P = .12). Conclusion: Patients consistently refilling lipid-lowering medications were more adherent to CPAP, suggesting that differences in medication adherence or other health-promoting behaviors should be investigated in future nonrandomized, observational studies linking CPAP adherence and cardiovascular outcomes. CHEST 2010; 137(1).102-108 C1 [Platt, Alec B.; Kuna, Samuel T.; Field, Samuel H.; Roche, Dominic E.; Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Gupta, Rajesh] Philadelphia Vet Affairs Med Ctr, Pulm Crit Care & Sleep Sect, Philadelphia, PA USA. [Kuna, Samuel T.; Christie, Jason D.; Asch, David A.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Christie, Jason D.; Asch, David A.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Platt, Alec B.] Reading Hosp Med Ctr, Reading, PA USA. [Field, Samuel H.] Univ N Carolina, FPG Child Dev Inst, Chapel Hill, NC USA. [Chen, Zhen] NICHD, Div Epidemiol Stat & Prevent Res, Rockville, MD USA. RP Platt, AB (reprint author), 2608 Keiser Blvd, Wyomissing, PA 19610 USA. EM alecplatt@gmail.com OI Asch, David/0000-0002-7970-286X FU Center for Health Equity Research and Promotion; Philadelphia VA Medical Center, Philadelphia, PA; National Institutes of Health [T-32 HL07713-14] FX This study was supported by grant funding to Dr Platt from Center for Health Equity Research and Promotion, Philadelphia VA Medical Center, Philadelphia, PA. Dr Platt was supported by a training grant from National Institutes of Health [Grant T-32 HL07713-14]. NR 51 TC 23 Z9 25 U1 0 U2 2 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD JAN PY 2010 VL 137 IS 1 BP 102 EP 108 DI 10.1378/chest.09-0842 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 542DK UT WOS:000273471500019 PM 19820075 ER PT J AU Peterson, PN Rumsfeld, JS Liang, L Albert, NM Hernandez, AF Peterson, ED Fonarow, GC Masoudi, FA AF Peterson, Pamela N. Rumsfeld, John S. Liang, Li Albert, Nancy M. Hernandez, Adrian F. Peterson, Eric D. Fonarow, Gregg C. Masoudi, Frederick A. CA Amer Heart Assoc Get Guidelines TI A Validated Risk Score for In-Hospital Mortality in Patients With Heart Failure From the American Heart Association Get With the Guidelines Program SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE epidemiology; heart failure; mortality; registries; risk factors ID PREDICTING MORTALITY; MODEL; STRATIFICATION; SURVIVAL AB Background-Effective risk stratification can inform clinical decision-making. Our objective was to derive and validate a risk score for in-hospital mortality in patients hospitalized with heart failure using American Heart Association Get With the Guidelines-Heart Failure (GWTG-HF) program data. Methods and Results-A cohort of 39 783 patients admitted January 1, 2005, to June 26, 2007, to 198 hospitals participating in GWTG-HF was divided into derivation (70%, n = 27 850) and validation (30%, n = 11 933) samples. Multivariable logistic regression identified predictors of in-hospital mortality in the derivation sample from candidate demographic, medical history, and laboratory variables collected at admission. In-hospital mortality rate was 2.86% (n = 1139). Age, systolic blood pressure, blood urea nitrogen, heart rate, sodium, chronic obstructive pulmonary disease, and nonblack race were predictive of in-hospital mortality. The model had good discrimination in the derivation and validation datasets (c-index, 0.75 in each). Effect estimates from the entire sample were used to generate a mortality risk score. The predicted probability of in-hospital mortality varied more than 24-fold across deciles (range, 0.4% to 9.7%) and corresponded with observed mortality rates. The model had the same operating characteristics among those with preserved and impaired left ventricular systolic function. The morality risk score can be calculated on the Web-based calculator available with the GWTG-HF data entry tool. Conclusions-The GWTG-HF risk score uses commonly available clinical variables to predict in-hospital mortality and provides clinicians with a validated tool for risk stratification that is applicable to a broad spectrum of patients with heart failure, including those with preserved left ventricular systolic function. (Circ Cardiovasc Qual Outcomes. 2010; 3: 25-32.) C1 [Peterson, Pamela N.; Masoudi, Frederick A.] Denver Hlth Med Ctr, Denver, CO USA. [Peterson, Pamela N.; Rumsfeld, John S.; Masoudi, Frederick A.] Univ Colorado Denver, Denver, CO USA. [Peterson, Pamela N.; Rumsfeld, John S.; Masoudi, Frederick A.] Kaiser Permanente, Inst Hlth Res, Denver, CO USA. [Liang, Li; Hernandez, Adrian F.; Peterson, Eric D.] Duke Clin Res Inst, Durham, NC USA. [Albert, Nancy M.] Cleveland Clin, Cleveland, OH 44106 USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles, CA USA. RP Masoudi, FA (reprint author), Div Cardiol, Mail Code 0960,777 Bannock St, Denver, CO 80204 USA. EM fred.masoudi@ucdenver.edu RI Hernandez, Adrian F./A-7818-2016 OI Hernandez, Adrian F./0000-0003-3387-9616 FU GlaxoSmithKline; American Heart Association Pharmaceutical Roundtable [067001N]; American Heart Association [0675060N]; Johnson Johnson/Scios; Medtronic; Merck; Novartis; AstraZeneca; Amgen; National Heart, Lung, and Blood Institute; Agency for Healthcare Research and Quality; American College of Cardiology; Oklahoma Foundation for Medical Quality FX GWTG-HF was supported in part by an unrestricted educational grant from GlaxoSmithKline. Dr Peterson is supported by an American Heart Association Pharmaceutical Roundtable Grant (067001N) and an American Heart Association Young Investigator Database Research Seed Grant. Dr Hernandez is supported by an American Heart Association Pharmaceutical Roundtable grant (0675060N).; Dr Hernandez has received research funding from Johnson & Johnson/Scios, Medtronic, and Merck and honoraria from Medtronic, Novartis, and AstraZeneca. Dr Fonarow has received research funding from the National Heart, Lung, and Blood Institute, honoraria from GlaxoSmithKline, Medtronic, and Novartis, and serves as a consultant for GlaxoSmithKline, Medtronic, and Novartis. Dr Masoudi has received research funding from Amgen, the National Heart, Lung, and Blood Institute, and the Agency for Healthcare Research and Quality; has served on advisory boards for Amgen and United Healthcare; and has contracts with the American College of Cardiology and the Oklahoma Foundation for Medical Quality. NR 18 TC 84 Z9 91 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD JAN PY 2010 VL 3 IS 1 BP 25 EP 32 DI 10.1161/CIRCOUTCOMES.109.854877 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 575PR UT WOS:000276080000007 PM 20123668 ER PT J AU Ko, DT Ross, JS Wang, YF Krumholz, HM AF Ko, Dennis T. Ross, Joseph S. Wang, Yongfei Krumholz, Harlan M. TI Determinants of Cardiac Catheterization Use in Older Medicare Patients With Acute Myocardial Infarction SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE cardiac catheterization; acute myocardial infarction; determinants of use; Medicare beneficiaries ID ACUTE CORONARY SYNDROMES; ASSOCIATION TASK-FORCE; TREATMENT-RISK PARADOX; BASE-LINE RISK; GLOBAL REGISTRY; PRACTICE GUIDELINES; ACC/AHA GUIDELINES; REGIONAL-VARIATION; RACIAL-DIFFERENCES; AMERICAN-COLLEGE AB Background-Cardiac catheterization is substantially underused among higher-risk patients with acute myocardial infarction (AMI) with appropriate indications but overused among patients with inappropriate indications. We sought to determine the importance of anticipated benefit and anticipated harm on the use of cardiac catheterization among older patients with AMI. Methods and Results-We performed an analysis of Medicare fee-for-service beneficiaries hospitalized with an AMI between 1998 and 2001. Multivariate models were developed to determine relative importance of anticipated benefit (baseline cardiovascular risk), anticipated harm (bleeding risk, comorbidities), and demographic factors (age, sex, race, regional invasive intensity) in predicting cardiac catheterization use within 60 days of AMI admission. Analyses were stratified by American College of Cardiology/American Heart Association class I or II as appropriate, and class III as inappropriate. Determinants of reduced likelihood of cardiac catheterization among 42 241 AMI patients with appropriate indications included (in order of importance) older age (likelihood chi(2) = 1309.5), higher bleeding risk score (likelihood chi(2) = 471.2), more comorbidities (likelihood chi(2) = 276.6), female sex (likelihood chi(2) = 162.9), hospitalization in low (likelihood chi(2) = 67.9) or intermediate intensity invasive regions (likelihood chi(2) = 22.4) (all P < 0.001), and baseline cardiovascular risk (likelihood chi(2) = 6.4, P = 0.01). Among 2398 AMI patients with inappropriate indications, significant determinants of greater procedure likelihood included younger age, male sex, lower bleeding risk score, and fewer comorbidities. Conclusions-Regardless of the procedure indication, the decision to perform cardiac catheterization in this population appears largely driven by demographic factors and potential harm rather than potential benefit of the procedure. (Circ Cardiovasc Qual Outcomes. 2010; 3: 54-62.) C1 [Wang, Yongfei; Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT 06510 USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Sch Publ Hlth, Robert Wood Johnson Clin Scholars Program,Sect Hl, New Haven, CT 06510 USA. Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. James J Peters Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. HSR&D Targeted Res Enhancement Program, Bronx, NY USA. [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. [Ross, Joseph S.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Ko, Dennis T.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Schulich Heart Ctr, Div Cardiol, Toronto, ON, Canada. Inst Clin Evaluat Sci, Toronto, ON, Canada. RP Krumholz, HM (reprint author), Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, 1 Church St,Suite 200, New Haven, CT 06510 USA. EM harlan.krumholz@yale.edu OI Ko, Dennis/0000-0001-6840-8051 FU Canadian Institutes of Health Research; Heart and Stroke Foundation of Ontario; Department of Veterans Affairs Health Services Research and Development Service [TRP-02-149]; US Department of Health and Human Services [HHSM-500-2005-CO001C] FX Dr Ko is supported by a New Investigator Award from the Canadian Institutes of Health Research and a Clinician Scientist Award from the Heart and Stroke Foundation of Ontario. Dr Ross is currently supported by Department of Veterans Affairs Health Services Research and Development Service project TRP-02-149.; The analyses on which this publication is based were performed under contract HHSM-500-2005-CO001C, entitled "Utilization and Quality Control Quality Improvement Organization for the State (commonwealth) of Colorado," sponsored by the Centers for Medicare and Medicaid Services, an agency of the US Department of Health and Human Services. The content of the publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. The authors assume full responsibility for the accuracy and completeness of the ideas presented. The Centers for Medicare & Medicaid Services did not play a role in the design and conduct of the study or in the analysis and interpretation of the data. NR 35 TC 8 Z9 8 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD JAN PY 2010 VL 3 IS 1 BP 54 EP U90 DI 10.1161/CIRCOUTCOMES.109.858456 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 575PR UT WOS:000276080000011 PM 20123672 ER PT J AU Ross, JS Chen, J Lin, Z Bueno, H Curtis, JP Keenan, PS Normand, SLT Schreiner, G Spertus, JA Vidan, MT Wang, YF Wang, Y Krumholz, HM AF Ross, Joseph S. Chen, Jersey Lin, Zhenqiu Bueno, Hector Curtis, Jeptha P. Keenan, Patricia S. Normand, Sharon-Lise T. Schreiner, Geoffrey Spertus, John A. Vidan, Maria T. Wang, Yongfei Wang, Yun Krumholz, Harlan M. TI Recent National Trends in Readmission Rates After Heart Failure Hospitalization SO CIRCULATION-HEART FAILURE LA English DT Article DE heart failure; health policy; hospitalizations/rehospitalizations; epidemiology; congestive; Centers for Medicare and Medicaid Services (US); patient readmission; United States/epidemiology ID DISEASE MANAGEMENT PROGRAMS; OF-CARDIOLOGY FOUNDATION; SCIENTIFIC STATEMENT; CLINICAL-OUTCOMES; OLDER PATIENTS; HEALTH-CARE; QUALITY; METAANALYSIS; INTERVENTION; ASSOCIATION AB Background-In July 2009, Medicare began publicly reporting hospitals' risk-standardized 30-day all-cause readmission rates (RSRRs) among fee-for-service beneficiaries discharged after hospitalization for heart failure from all the US acute care nonfederal hospitals. No recent national trends in RSRRs have been reported, and it is not known whether hospital-specific performance is improving or variation in performance is decreasing. Methods and Results-We used 2004-2006 Medicare administrative data to identify all fee-for-service beneficiaries admitted to a US acute care hospital for heart failure and discharged alive. We estimated mean annual RSRRs, a National Quality Forum-endorsed metric for quality, using 2-level hierarchical models that accounted for age, sex, and multiple comorbidities; variation in quality was estimated by the SD of the RSRRs. There were 570 996 distinct hospitalizations for heart failure in which the patient was discharged alive in 4728 hospitals in 2004, 544 550 in 4694 hospitals in 2005, and 501 234 in 4674 hospitals in 2006. Unadjusted 30-day all-cause readmission rates were virtually identical over this period: 23.0% in 2004, 23.3% in 2005, and 22.9% in 2006. The mean and SD of RSRRs were also similar: mean (SD) of 23.7% (1.3) in 2004, 23.9% (1.4) in 2005, and 23.8% (1.4) in 2006, suggesting similar hospital variation throughout the study period. Conclusions-National mean and RSRR distributions among Medicare beneficiaries discharged after hospitalization for heart failure have not changed in recent years, indicating that there was neither improvement in hospital readmission rates nor in hospital variations in rates over this time period. (Circ Heart Fail. 2010; 3: 97-103.) C1 [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr, New York, NY 10029 USA. [Ross, Joseph S.] Mt Sinai Sch Med, Dept Palliat Med, New York, NY 10029 USA. [Ross, Joseph S.] James J Peters Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. [Ross, Joseph S.] James J Peters Vet Adm Med Ctr, HSR&D Res Enhancement Award Program, Bronx, NY USA. [Chen, Jersey; Curtis, Jeptha P.; Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT 06510 USA. [Chen, Jersey; Lin, Zhenqiu; Curtis, Jeptha P.; Schreiner, Geoffrey; Wang, Yongfei; Wang, Yun; Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. [Bueno, Hector] Hosp Gen Univ Gregorio Maranon, Dept Cardiol, Madrid, Spain. [Keenan, Patricia S.; Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA. [Normand, Sharon-Lise T.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Sch Publ Hlth, Boston, MA 02115 USA. [Normand, Sharon-Lise T.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Spertus, John A.] Univ Missouri, Sch Med, Dept Med, Cardiol Sect, Kansas City, MO 64108 USA. [Spertus, John A.] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. [Vidan, Maria T.] Hosp Gen Univ Gregorio Maranon, Dept Geriatr Med, Madrid, Spain. [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA. RP Ross, JS (reprint author), Mt Sinai Sch Med, Dept Geriatr, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. EM joseph.ross@mssm.edu RI BUENO, HECTOR/I-3910-2015 OI BUENO, HECTOR/0000-0003-0277-7596 FU Centers for Medicare & Medicaid Services [HHSM-500-2005-CO001C]; agency of the US Department of Health and Human Services; National Institute on Aging [K08 AG032886]; Beeson; Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Madrid, Spain [BA08/90010, BA08/90012] FX The analyses upon which this publication is based were performed under contract HHSM-500-2005-CO001C, entitled "Utilization and Quality Control Quality Improvement Organization for the State (Commonwealth) of Colorado," funded by the Centers for Medicare & Medicaid Services, an agency of the US Department of Health and Human Services. Dr Ross is currently supported by the National Institute on Aging (K08 AG032886) and by the American Federation of Aging Research through the Paul B. Beeson Career Development Award Program. Dr Bueno was supported by grant BA08/90010 from the Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Madrid, Spain. Dr Vidan was supported by grant BA08/90012 from the Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Madrid, Spain. NR 28 TC 187 Z9 191 U1 1 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD JAN PY 2010 VL 3 IS 1 BP 97 EP 103 DI 10.1161/CIRCHEARTFAILURE.109.885210 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 545MA UT WOS:000273735100015 PM 19903931 ER PT J AU Anderson, S Chapman, JG Oyama, TT Komers, R AF Anderson, Sharon Chapman, Justin G. Oyama, Terry T. Komers, Radko TI Effect of orchiectomy on renal function in control and diabetic rats with chronic inhibition of nitric oxide SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY LA English DT Article DE diabetic nephropathy; glomerular filtration rate; nitric oxide inhibition; orchiectomy; proteinuria; renal plasma flow ID SPONTANEOUSLY HYPERTENSIVE-RATS; ENDOTHELIAL DYSFUNCTION; VASCULAR REACTIVITY; GENDER-DIFFERENCES; OXIDATIVE STRESS; URINARY ALBUMIN; TESTOSTERONE; DISEASE; PROGRESSION; MEN AB P>Male gender is associated with higher blood pressure (BP) and more rapid loss of renal function in a spectrum of clinical and experimental renal diseases, including diabetic nephropathy. Consequently, modulation of testosterone levels could exert beneficial effects in the diabetic kidney. The aim of the present study was to determine whether testosterone deficiency (orchiectomy) could influence BP and renal function in streptozotocin-diabetic rats, with or without accelerated endothelial dysfunction achieved by chronic inhibition of nitric oxide (NO) synthesis using NG-nitro-l-arginine methyl ester (l-NAME; 40-100 mg/L in the drinking water for 2 weeks), as well as in age-matched non-diabetic rats subjected to the same interventions. Orchiectomy did not affect l-NAME-induced increases in BP in non-diabetic or diabetic rats. In non-diabetic rats, orchiectomy prevented l-NAME-induced increases in proteinuria. These effects on proteinuria were not observed in diabetic rats. In non-diabetic rats, orchiectomy had no effect on renal haemodynamics in animals receiving vehicle and did not affect l-NAME-induced changes in renal haemodynamics, characterized by reductions in renal plasma flow (RPF) and higher filtration fractions (FF). In intact diabetic rats, l-NAME treatment resulted in lower RPF. This difference was not observed in diabetic rats subjected to orchiectomy, although l-NAME-treated diabetic orchiectomized rats had lower RPF and higher FF compared with vehicle-treated intact diabetic rats. In conclusion, we report modest beneficial effects of orchiectomy on proteinuria in normal, but not in diabetic, rats with inhibition of NO production. This suggests that testosterone reduction does not attenuate the deleterious impact of the diabetic metabolic milieu in the kidney. C1 [Anderson, Sharon; Chapman, Justin G.; Oyama, Terry T.; Komers, Radko] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA. [Anderson, Sharon] Portland VA Med Ctr, Portland, OR USA. RP Komers, R (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, PP262,3314 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM komersr@ohsu.edu FU National Institutes of Health [DK 63 231]; VA Merit Review FX These studies were supported by a National Institutes of Health grant (DK 63 231) and by VA Merit Review grant (to SA). NR 23 TC 3 Z9 3 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0305-1870 J9 CLIN EXP PHARMACOL P JI Clin. Exp. Pharmacol. Physiol. PD JAN PY 2010 VL 37 IS 1 BP 19 EP 23 DI 10.1111/j.1440-1681.2009.05206.x PG 5 WC Pharmacology & Pharmacy; Physiology SC Pharmacology & Pharmacy; Physiology GA 533PD UT WOS:000272835800007 PM 19473197 ER PT J AU Bryan, CL Beard, KS Pott, GB Rahkola, J Gardner, EM Janoff, EN Shapiro, L AF Bryan, Courtney L. Beard, K. Scott Pott, Gregory B. Rahkola, Jeremy Gardner, Edward M. Janoff, Edward N. Shapiro, Leland TI HIV infection is associated with reduced serum alpha-1-antitrypsin concentrations SO CLINICAL AND INVESTIGATIVE MEDICINE LA English DT Article ID IN-VITRO; DEFICIENCY; ALPHA(1)-ANTITRYPSIN; DISEASE; MECHANISMS; INHIBITOR; PROTEASE AB Purpose: Several observations suggest the presence of HIV-suppressive factors in the fluid phase of blood. Alpha-1-antitrypsin (AAT), the most abundant serine protease inhibitor in the circulation, has potent anti-HIV activity in vitro, and may function as an endogenous HIV suppressor. Therefore, we assessed serum AAT concentrations for association with HIV infection. Methods: In this cross-sectional study, serum AAT concentrations were measured in 66 persons with HIV infection and in 45 healthy persons (Controls). In the HIV-infected group, antiretroviral therapy (ART) use was assessed and CD4(+) T cell levels and plasma HIV RNA were quantified. Results: Median AAT concentration was significantly lower in the HIV-infected group (1.64 mg/mL) in comparison with Controls (1.94 mg/mL; p=0.001). AAT reduction was most pronounced in the HIV-infected subgroup with CD4+ T cell levels >200 cells/mu L in comparison with Controls (p<0.01). Serum AAT concentrations <1.0 % mg/mL are clinically significant, and concentrations below this level were identified in 4.5% of the HIV-infected group and in no Control subjects. No association between AAT levels and viral load or use of ART was observed in HIV-infected subjects. Conclusion: The association between reduced serum AAT concentration and HIV infection is consistent with a role for AAT as an endogenous HIV suppressor. C1 [Bryan, Courtney L.; Beard, K. Scott; Pott, Gregory B.; Rahkola, Jeremy; Janoff, Edward N.; Shapiro, Leland] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO 80220 USA. [Bryan, Courtney L.; Beard, K. Scott; Pott, Gregory B.; Rahkola, Jeremy; Gardner, Edward M.; Janoff, Edward N.; Shapiro, Leland] Univ Colorado Denver, Dept Med, Aurora, CO USA. [Gardner, Edward M.] Denver Publ Hlth, Dept Publ Hlth, Denver, CO USA. [Rahkola, Jeremy; Janoff, Edward N.] Mucosal & Vaccine Res Program Colorado MAVRC, Dept Med, Denver, CO USA. RP Shapiro, L (reprint author), Denver Vet Affairs Med Ctr, Dept Med, 1055 Clermont St,Box 111L, Denver, CO 80220 USA. EM leland.shapiro@ucdenver.edu FU Campbell Foundation; Veterans Affairs Research Service; Mucosal and Vaccine Research Program Colorado (MAVRC); Baxter Catalyst FX Campbell Foundation and Baxter Catalyst awards to Leland Shapiro, MD, and Veterans Affairs Research Service and Mucosal and Vaccine Research Program Colorado (MAVRC) to Edward N. Janoff, MD NR 21 TC 11 Z9 12 U1 2 U2 2 PU CANADIAN SOC CLINICAL INVESTIGATION PI OTTAWA PA CSCI HEAD OFFICE, 774 ECHO DRIVE, OTTAWA, ON K1S 5N8, CANADA SN 0147-958X J9 CLIN INVEST MED JI Clin. Invest. Med. PY 2010 VL 33 IS 6 BP E384 EP E389 PG 6 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 699FV UT WOS:000285650200006 PM 21134340 ER PT J AU Nabatian, A Bashir, M Werth, V AF Nabatian, Adam Bashir, Muhammad Werth, Victoria TI Immunologic Actions of Glycosaminoglycans in Cutaneous Lupus Erythematosus Et Dermatomyositis SO CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 10th Annual Meeting of the Federation-of-Clinical-Immunology-Societies CY JUN 24-27, 2010 CL Boston, MA SP Federat Clin Immunol Soc C1 [Nabatian, Adam; Bashir, Muhammad; Werth, Victoria] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 J9 CLIN IMMUNOL JI Clin. Immunol. PY 2010 VL 135 SU S BP S85 EP S85 DI 10.1016/j.clim.2010.03.256 PG 1 WC Immunology SC Immunology GA 599ZS UT WOS:000277953700240 ER PT J AU Lehman, D Tseng, CW Eells, S Miller, LG Fan, XM Beenhouwer, DO Liu, GY AF Lehman, Deborah Tseng, Ching Wen Eells, Samantha Miller, Loren G. Fan, Xuemo Beenhouwer, David O. Liu, George Y. TI Staphylococcus aureus Panton-Valentine Leukocidin Targets Muscle Tissues in a Child with Myositis and Necrotizing Fasciitis SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID VIRULENCE DETERMINANT; SKIN INFECTIONS; GENES; PNEUMONIA; DISEASE; PYOMYOSITIS; USA300; CLONE; LUNG AB The incidence of myositis has been increasing since the advent of the epidemic of community-associated methicillin-resistant Staphylococcus aureus infection, and Panton-Valentine leukocidin has been implicated as a factor contributing to more-severe muscle injury. We report a case of severe myositis accompanying septic osteomyelitis and necrotizing fasciitis caused by a Panton-Valentine leukocidin-positive S. aureus strain. Immunostaining showed strong binding of the Panton-Valentine leukocidin toxin to necrotic muscle tissues. C1 [Lehman, Deborah; Tseng, Ching Wen; Liu, George Y.] Cedars Sinai Med Ctr, Div Pediat Infect Dis, Los Angeles, CA 90048 USA. [Tseng, Ching Wen; Liu, George Y.] Cedars Sinai Med Ctr, Immunobiol Res Inst, Los Angeles, CA 90048 USA. [Fan, Xuemo] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA. [Lehman, Deborah; Tseng, Ching Wen; Liu, George Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Beenhouwer, David O.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Beenhouwer, David O.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. [Eells, Samantha; Miller, Loren G.] Univ Calif Los Angeles, Los Angeles BioMed Res Inst Harbor, Torrance, CA USA. [Eells, Samantha; Miller, Loren G.] Univ Calif Los Angeles, Div Infect Dis, Torrance, CA USA. RP Liu, GY (reprint author), Cedars Sinai Med Ctr, Div Pediat Infect Dis, NT4221, Los Angeles, CA 90048 USA. EM george.liu@cshs.org FU Burroughs-Wellcome Career; National Institutes of Health [AI074832] FX Financial support. Burroughs-Wellcome Career Award and National Institutes of Health (AI074832 to G. Y. L.). NR 22 TC 7 Z9 7 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2010 VL 50 IS 1 BP 69 EP 72 DI 10.1086/649217 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 539YO UT WOS:000273296500011 PM 19995216 ER PT J AU Forrest, GN Tamura, K AF Forrest, Graeme N. Tamura, Kimberly TI Rifampin Combination Therapy for Nonmycobacterial Infections SO CLINICAL MICROBIOLOGY REVIEWS LA English DT Review ID RESISTANT STAPHYLOCOCCUS-AUREUS; PROSTHETIC VALVE ENDOCARDITIS; IN-VITRO ACTIVITY; VANCOMYCIN PLUS RIFAMPIN; ACINETOBACTER-BAUMANNII INFECTIONS; LEGIONELLA-PNEUMOPHILA PNEUMONIA; COAGULASE-NEGATIVE STAPHYLOCOCCI; RIFABUTIN DRUG-INTERACTIONS; SERUM BACTERICIDAL ACTIVITY; CENTRAL VENOUS CATHETERS AB The increasing emergence of antimicrobial-resistant organisms, especially methicillin-resistant Staphylococcus aureus (MRSA), has resulted in the increased use of rifampin combination therapy. The data supporting rifampin combination therapy in nonmycobacterial infections are limited by a lack of significantly controlled clinical studies. Therefore, its current use is based upon in vitro or in vivo data or retrospective case series, all with major limitations. A prominent observation from this review is that rifampin combination therapy appears to have improved treatment outcomes in cases in which there is a low organism burden, such as biofilm infections, but is less effective when effective surgery to obtain source control is not performed. The clinical data support rifampin combination therapy for the treatment of prosthetic joint infections due to methicillin-sensitive S. aureus (MSSA) after extensive debridement and for the treatment of prosthetic heart valve infections due to coagulase-negative staphylococci. Importantly, rifampin-vancomycin combination therapy has not shown any benefit over vancomycin monotherapy against MRSA infections either clinically or experimentally. Rifampin combination therapy with daptomycin, fusidic acid, and linezolid needs further exploration for these severe MRSA infections. Lastly, an assessment of the risk-benefits is needed before the addition of rifampin to other antimicrobials is considered to avoid drug interactions or other drug toxicities. C1 [Forrest, Graeme N.; Tamura, Kimberly] Portland VA Med Ctr, Portland, OR 97239 USA. [Forrest, Graeme N.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Forrest, GN (reprint author), Portland VA Med Ctr, 3701 SW US Vet Hosp Rd,Mail Code P3-ID, Portland, OR 97239 USA. EM forrestg@ohsu.edu NR 279 TC 76 Z9 79 U1 1 U2 11 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0893-8512 J9 CLIN MICROBIOL REV JI Clin. Microbiol. Rev. PD JAN PY 2010 VL 23 IS 1 BP 14 EP 34 DI 10.1128/CMR.00034-09 PG 21 WC Microbiology SC Microbiology GA 542QW UT WOS:000273511000001 PM 20065324 ER PT J AU Johnson, AL Storzbach, D Binder, LM Barkhuizen, A Anger, WK Salinsky, MC Tun, SM Rohlman, DS AF Johnson, Amy L. Storzbach, Daniel Binder, Laurence M. Barkhuizen, Andre Anger, W. Kent Salinsky, Martin C. Tun, Saw-Myo Rohlman, Diane S. TI MMPI-2 PROFILES: FIBROMYALGIA PATIENTS COMPARED TO EPILEPTIC AND NON-EPILEPTIC SEIZURE PATIENTS SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Fibromyalgia; Veterans; MMPI-2 ID FAKE BAD SCALE; CEREBRAL BLOOD-FLOW; RHEUMATOID-ARTHRITIS; UNEXPLAINED SYMPTOMS; PSYCHOSOCIAL FACTORS; CHRONIC PAIN; DEPRESSION; HEALTH; WOMEN; VETERANS AB We compared MMPI-2 profiles of Gulf War veterans with fibromyalgia (FM) to epileptic seizure (ES) patients, psychogenic non-epileptic seizure (PNES) patients, and Gulf War veteran healthy controls. Both PNES and FM are medically unexplained conditions. In previous MMPI-2 research PNES patients were shown to have significantly higher Hs and Hy clinical scales than ES patients. In the present research the FM group had significantly higher Hs and Hy scale scores than both the ES group and the healthy control group. There was no significant difference between the FM and PNES Hs scale scores; however, the FM Hy scale score was significantly lower than the PNES Hy scale score. Present findings indicate a high level of psychological distress in the FM group. C1 [Johnson, Amy L.; Storzbach, Daniel; Tun, Saw-Myo] Portland VA Med Ctr, Portland, OR 97239 USA. [Storzbach, Daniel; Binder, Laurence M.; Barkhuizen, Andre; Anger, W. Kent; Salinsky, Martin C.; Rohlman, Diane S.] Oregon Hlth & Sci Univ, Beaverton, OR USA. RP Johnson, AL (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM amy.johnson2@va.gov NR 64 TC 8 Z9 10 U1 1 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1385-4046 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2010 VL 24 IS 2 BP 220 EP 234 DI 10.1080/13854040903266902 PG 15 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 566HR UT WOS:000275361200003 PM 19859855 ER PT J AU Foley, J Ettenhofer, M Wright, MJ Siddiqi, I Choi, M Thames, AD Mason, K Castellon, S Hinkin, CH AF Foley, Jessica Ettenhofer, Mark Wright, Matthew J. Siddiqi, Iraj Choi, Melissa Thames, April D. Mason, Karen Castellon, Steven Hinkin, Charles H. TI NEUROCOGNITIVE FUNCTIONING IN HIV-1 INFECTION: EFFECTS OF CEREBROVASCULAR RISK FACTORS AND AGE SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Cerebrovascular; HIV/AIDS; Neurocognitive; Aging ID IMMUNODEFICIENCY-VIRUS-INFECTION; INTIMA-MEDIA THICKNESS; AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY; MYOCARDIAL-INFARCTION; COGNITIVE FUNCTION; MEDICATION ADHERENCE; KUNGSHOLMEN PROJECT; CARDIOVASCULAR RISK; DIABETES-MELLITUS AB This study examined the interactive effects of cerebrovascular risks, advancing age, and HIV infection on neurocognition, and explored whether pharmacological treatment of cerebrovascular risk factors attenuated neurocognitive dysfunction. Participants included 98 HIV-seropositive adults (cerebrovascular risk: 23.5%; age > 50: 27.6%). Cerebrovascular risk was associated with slower processing speed even after controlling for age effects (b = -2.071; p = .04), and the interaction of age and cerebrovascular risk was associated with poorer verbal fluency (b = 1.276, p = .002). Participants with pharmacologically untreated cerebrovascular risk demonstrated reduced processing speed, learning/memory, and executive functioning relative to those on medication. Poor cerebrovascular health confers significant risk for HIV+ individuals, and this effect may be of greater consequence than advancing age. The cognitive impact of risk appears to be more pronounced in the absence of adequate pharmacological treatment. C1 [Foley, Jessica; Ettenhofer, Mark; Castellon, Steven; Hinkin, Charles H.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Siddiqi, Iraj] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Wright, Matthew J.] Harbor UCLA Med Ctr, Los Angeles, CA USA. [Choi, Melissa; Thames, April D.; Castellon, Steven; Hinkin, Charles H.] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. [Mason, Karen] Calif State Univ Dominguez Hills, Los Angeles, CA USA. RP Foley, J (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,C8-746, Los Angeles, CA 90095 USA. EM jmfoley@ucla.edu RI Thames, April/K-1964-2014 OI Thames, April/0000-0001-8414-7189 FU NIMH [R01 MH58522]; [5 T32 MH19535] FX Funding was as follows: (1) NIMH R01 MH58522: Cognitive deficits and medication adherence in HIV/AIDS to CHH; (2) 5 T32 MH19535: Neuropsychology of HIV/AIDS to CHH. NR 89 TC 34 Z9 34 U1 3 U2 8 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1385-4046 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2010 VL 24 IS 2 BP 265 EP 285 DI 10.1080/13854040903482830 PG 21 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 566HR UT WOS:000275361200006 PM 20162495 ER PT J AU Goldstein, G AF Goldstein, Gerald TI ADVOCACY FOR NEUROPSYCHOLOGY IN THE PUBLIC SECTOR: THE VA EXPERIENCE SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Veterans; Advocacy; Neuropsychology; Geropsychology ID ACADEMY AB In this paper important advocacy areas for the VA are described with implications for other psychologists working in institutional settings in the public sector, and some advice is provided concerning how best to advocate in the VA. Distinctions among advocacy issues that are of concern to the general public, those that are of concern to all psychologists involved in healthcare, and those specifically related to clinical neuropsychology are made. C1 [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst 151R, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM ggold@nb.net FU Medical Research Service, Department of Veterans Affairs FX This work was supported by the Medical Research Service, Department of Veterans Affairs. NR 11 TC 4 Z9 4 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1385-4046 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2010 VL 24 IS 3 SI SI BP 401 EP 416 DI 10.1080/13854040903313597 PG 16 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 589ZL UT WOS:000277192600003 PM 20373221 ER PT J AU Hilsabeck, RC Martin, EM AF Hilsabeck, Robin C. Martin, Eileen M. TI WOMEN AND ADVANCEMENT IN NEUROPSYCHOLOGY: REAL-LIFE LESSONS LEARNED SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Leadership; Advancement; Advocacy; Women; Neuropsychology ID ASSOCIATION PRACTICE SURVEY; CLINICAL NEUROPSYCHOLOGY; ACADEMIC MEDICINE; UNITED-STATES; LEADERSHIP; NATIONAL-ACADEMY-OF-NEUROPSYCHOLOGY/DIVISION-40; FACULTY; GENDER AB The number of women in neuropsychology has been increasing over the past 20 years while the number of women in senior and leadership positions within neuropsychology has not. The field of neuropsychology has much to gain by facilitating the advancement of women into leadership roles, including access to some of the brightest and creative minds in the field. The purpose of this article is to offer practical advice about how to overcome barriers and advance within neuropsychology. Suggestions for professional organizations, women, and mentors of women are provided that will likely benefit trainees and junior colleagues regardless of their gender. C1 [Hilsabeck, Robin C.] Univ Texas Hlth Sci Ctr San Antonio, Psychol Serv 116B, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Martin, Eileen M.] Univ Illinois, Chicago, IL USA. RP Hilsabeck, RC (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Psychol Serv 116B, S Texas Vet Hlth Care Syst, 7400 Merton Winter Blvd, San Antonio, TX 78229 USA. EM Hilsabeck@uthscsa.edu FU NIDA NIH HHS [R01 DA012828, R01 DA12828]; NINDS NIH HHS [K23 NS051244] NR 15 TC 3 Z9 3 U1 1 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1385-4046 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2010 VL 24 IS 3 SI SI BP 481 EP 492 DI 10.1080/13854040802360566 PG 12 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 589ZL UT WOS:000277192600008 PM 18841516 ER PT J AU Barker, MD Horner, MD Bachman, DL AF Barker, Marie D. Horner, Michael David Bachman, David L. TI Embedded Indices of Effort In The Repeatable Battery For The Assessment of Neuropsychological Status (Rbans) In A Geriatric Sample SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Effort; Motivation; Repeatable Battery for the Assessment of Neuropsychological Status; RBANS; Geriatric ID MEMORY MALINGERING TOMM; ALZHEIMERS-DISEASE; COGNITIVELY INTACT; NORMATIVE DATA; VALIDITY; SPECIFICITY; SENSITIVITY; DEPRESSION; SYMPTOMS; DEMENTIA AB The clinical utility of embedded indices of effort in the RBANS was examined in a geriatric sample. Patients were classified as providing suspect effort (n = 45) or probable good effort (n = 258) using the TOMM and clinical consensus. Following the methodology of Silverberg and colleagues (2007), selected individual subtests and a summary Effort Index were evaluated. Setting specificity at approximately 85% yielded cut-offs of 15 on List Recognition, 8 on Digit Span, and 3 on the Effort Index. The modest sensitivity (51.1-64.4%) suggests that the indices should be used in conjunction with additional effort measures. In addition, the RBANS Picture Naming subtest was examined and showed modest sensitivity to detect suboptimal effort, but did not show notable incremental validity for detecting suboptimal effort beyond the Effort Index. C1 [Barker, Marie D.; Horner, Michael David; Bachman, David L.] Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv 116, Charleston, SC 29407 USA. [Barker, Marie D.; Horner, Michael David; Bachman, David L.] Med Univ S Carolina, Charleston, SC 29425 USA. [Barker, Marie D.] Univ Florida, Gainesville, FL USA. RP Barker, MD (reprint author), Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29407 USA. EM barker.marie@gmail.com NR 32 TC 18 Z9 18 U1 1 U2 7 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1385-4046 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2010 VL 24 IS 6 BP 1064 EP 1077 AR PII 922905051 DI 10.1080/13854046.2010.486009 PG 14 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 636WE UT WOS:000280773600007 PM 20544558 ER PT J AU Solomon, RE Boone, KB Miora, D Skidmore, S Cottingham, M Victor, T Ziegler, E Zeller, M AF Solomon, Ryan E. Boone, Kyle Brauer Miora, Deborah Skidmore, Sherry Cottingham, Maria Victor, Tara Ziegler, Elizabeth Zeller, Michelle TI Use of the WAIS-III Picture Completion Subtest as an Embedded Measure of Response Bias SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Response bias; Picture completion; Malingering ID SUSPECT EFFORT; RECOGNITION TRIAL; SENSITIVITY; PERFORMANCE; DEFICITS; SCORES; SPECIFICITY AB In the present study a large sample of credible patients (n = 172) scored significantly higher than a large sample of noncredible participants (n = 195) on several WAIS-III Picture Completion variables: Age Adjusted Scaled Score, raw score, a oRarely Missedo index (the nine items least often missed by credible participants), a oRarely Correcto index (nine items correct 26% of the time in noncredible participants and with at least a 25 percentage-point lower endorsement rate as compared to credible participants), and a oMost Discrepanto index (the six items that were the most discrepant in correct endorsement between groupsat least a 40 percentage point difference). Comparison of the various scores showed that the oMost Discrepanto index outperformed all the others in identifying response bias (nearly 65% sensitivity at 92.8% specificity as compared to at most 59% sensitivity for the other scores). While no differences in Picture Completion scores were observed between less-educated (12 years) and better-educated (epsilon 12 years) credible participants, noncredible participants with 12 years of education scored significantly poorer than noncredible participants with 12 or more years of education. On the oMost Discrepanto index, 76.7% of less-educated noncredible participants were detected as compared to 58.3% of better-educated noncredible participants. Results of the current study suggest that the Picture Completion subtest of the WAIS-III is an effective measure of response bias, and that it may have a unique role in identifying suboptimal effort in less-educated test takers. C1 [Solomon, Ryan E.; Boone, Kyle Brauer; Miora, Deborah; Skidmore, Sherry] Alliant Int Univ, Calif Sch Forens Studies, Los Angeles, CA USA. [Cottingham, Maria] Harbor UCLA Med Ctr, Dept Psychiat, Torrance, CA 90509 USA. [Victor, Tara] Calif State Univ Dominguez Hills, Carson, CA 90747 USA. [Ziegler, Elizabeth] VA Med Ctr Spokane, Washington, DC USA. [Zeller, Michelle] W Los Angeles VA, Los Angeles, CA USA. RP Solomon, RE (reprint author), Alliant Int Univ, Calif Sch Forens Studies, Los Angeles, CA USA. EM rsolomon@alliant.edu NR 27 TC 9 Z9 9 U1 1 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1385-4046 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2010 VL 24 IS 7 BP 1243 EP 1256 AR PII 927591054 DI 10.1080/13854046.2010.514864 PG 14 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA 659UM UT WOS:000282592400010 PM 20924983 ER PT J AU Anderson, A Singh, JA AF Anderson, Amy Singh, Jasvinder A. TI Pegloticase for chronic gout SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID TREATMENT-FAILURE GOUT; URATE OXIDASE; RHEUMATOID-ARTHRITIS; REFRACTORY GOUT; HYPERURICEMIA; URICASE; EPIDEMIOLOGY; RASBURICASE; QUALITY; LIFE AB Background Pegloticase is a potential new treatment option for patients with chronic gout intolerant to other urate-lowering therapies. Objectives To assess safety (adverse events, death) and efficacy (pain, function, frequency of flares, quality of life, uric acid level, radiographic damage) of pegloticase in various doses or as compared to placebo or other interventions for treatment of hyperuricemia in patients with chronic gout. Search strategy We searched six databases: The Cochrane Central Register of Controlled Trials (CENTRAL), via The Cochrane Library, OVID MEDLINE, CINAHL (via EBSCOHost), OVID SPORTdiscus, EMBASE and the Science Citation Index (Web of Science). Selection criteria All published randomized controlled trials (RCTs) or controlled clinical trials that compared various doses of pegloticase alone or pegloticase alone or in combination with other urate-lowering or anti-inflammatory medications to placebo alone or placebo in combination with these medications, in patients with gout. Data collection and analysis Two review authors (AA, JS) independently extracted data from the included trials, including trial and population characteristics, primary and secondary outcomes. For dichotomous and continuous outcomes, we calculated the risk ratio and mean difference, respectively with 95% confidence interval. Major outcomes were: (a) Efficacy: frequency of gout flares and change in serum uric acid; and (b) safety: adverse events, serious adverse events, withdrawals and death. Minor/secondary outcomes were pain, patient/physician global assessment, tophus burden, health related quality of life, function and radiographic progression. Main results Only one open-label, phase-II RCT (n = 41) met the selection criteria that compared various doses of pegloticase without comparison to placebo or another treatment. Patients were randomized to one of the four doses of pegloticase for 12 to 14 weeks -4mg every 2 weeks, 8mg every 2 weeks, 8mg every 4 weeks and 12mg every 4 weeks. Percent responders (uric acid below 6 mg/dl 80% or more time) in the four dose groups were 56%, 88%, 52% and 62%. Percent time without hyperuricemia (uric acid below 6 mg/dl) was 78%, 92%, 76% and 76% respectively. No between dose differences were noted. Most common adverse events (10% or more patients) included nephrolithiasis, arthralgia, anemia, dyspnea, headache, muscle spasms, nausea and pyrexia. 89% reported one or more gout flares during the study. Pain, patient/physician global, function, quality of life, tophus size/regression and radiographic progression were not reported in this study. Authors' conclusions There are no published double-blind, placebo-controlled RCTs of pegloticase. More evidence is needed to assess risks/benefits of pegloticase in patients with chronic gout. C1 [Anderson, Amy] Univ Alabama, Dept Med, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Anderson, Amy] Minneapolis VA Med Ctr, Minneapolis, MN USA. [Anderson, Amy] Univ Minnesota, Minneapolis, MN USA. RP Singh, JA (reprint author), Univ Alabama, Dept Med, Birmingham VA Med Ctr, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com FU Takeda; Savient; AMGEN pharmaceuticals; National Institues of Health; Department of Veterans Affairs; Arthritis Foundation; University of Minnesota; Minnesota Medical Foundation; Cochrane Collaboration; Minneapolis VA Medical Center, Minneapolis, USA; NIH CTSA, (Mayo Clinic Center for Clinical and Translational Research), USA [1 KL2 RR024151-01] FX JS - Research grants from Takeda, Savient and AMGEN pharmaceuticals; Consultant/honraria-Savient, Abbott and URL pharmaceuticals; Research grants from National Institues of Health, Department of Veterans Affairs, Arthritis Foundation, University of Minnesota, Minnesota Medical Foundation and Cochrane Collaboration. AA-None; Internal sources; Minneapolis VA Medical Center, Minneapolis, MN 55417, USA.; External sources; NIH CTSA Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research), USA. 75% time-protection for research NR 64 TC 7 Z9 7 U1 1 U2 3 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2010 IS 3 AR CD008335 DI 10.1002/14651858.CD008335.pub2 PG 27 WC Medicine, General & Internal SC General & Internal Medicine GA 570ZP UT WOS:000275717700003 PM 20238366 ER PT J AU Singh, JA Sperling, J Buchbinder, R McMaken, K AF Singh, Jasvinder A. Sperling, John Buchbinder, Rachelle McMaken, Kelly TI Surgery for shoulder osteoarthritis SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID KEELED GLENOID COMPONENTS; RANDOMIZED-TRIAL; PRIMARY-CARE; ARTHROPLASTY; PAIN; HEMIARTHROPLASTY; LIFE; INSTABILITY; PREVALENCE; DISABILITY AB Background Surgical treatment including shoulder arthroplasty is a treatment option for patients with advanced osteoarthritis of the shoulder who have failed conservative treatment. Objectives To determine the benefit and harm of surgery in patients with osteoarthritis of the shoulder confirmed on X-ray who do not respond to analgesics and NSAIDs. Search strategy We searched: The Cochrane Central Register of Controlled Trials (CENTRAL), via The Cochrane Library; OVIDMEDLINE; CINAHL (via EBSCOHost); OVID SPORTdiscus; EMBASE; and Science Citation Index (Web of Science). Selection criteria All randomized clinical trials (RCTs) or quasi-randomized trials including adults with osteoarthritis of the shoulder joint (PICO-patients) comparing surgical techniques (total shoulder arthroplasty, hemiarthroplasty, implant types and fixation-intervention) versus placebo or sham surgery, non-surgical modalities, no treatment, or comparison of one type of surgical technique to another (comparison) with patient-reported outcomes (pain, function, quality of life etc.) or revision rates (outcomes). Data collection and analysis We reviewed titles and abstracts for inclusion, extracted study and outcomes data and assessed the risk of bias of included studies. For categorical outcomes, we calculated the risk ratio (with 95% confidence interval (CI)) and for continuous outcomes, the mean difference (95% CI). Main results Seven studies (238 patients) were included for analyses. None of the studies compared shoulder surgery to sham surgery, non-surgical modalities or placebo. Two studies compared hemiarthroplasty to total shoulder arthroplasty; three compared keeled and pegged humeral components; and one each compared navigation surgery to conventional and all-polyethylene to metal-backed implant. Two studies (88 patients) compared hemiarthroplasty to total shoulder arthroplasty. Patients who underwent hemiarthroplasty had statistically significantly worse functional scores on American Shoulder and Elbow Surgeons Shoulder Scale (100 point scale; higher = better) at 24 to 34 month follow-up compared to those who underwent total shoulder arthroplasty (mean difference, -10.05; 95% CI, -18.97 to -1.13; 2 studies, 88 patients), but no statistically significant differences between hemiarthroplasty and TSA were noted for pain scores (mean difference, 7.8; 95% CI, -5.33 to 20.93; 1 study, 41 patients), quality of life on short-form 36 physical component summary (mean difference, 0.80; 95% CI, -6.63 to 8.23; 1 study, 41 patients) and adverse events (Risk ratio, 1.19; 95% CI, 0.37 to 3.81; 1 study, 41 patients), respectively. A non-statistically significant trend towards higher revision rate in hemiarthroplasty compared to total shoulder arthroplasty was noted (Risk ratio, 6.18; 95% CI, 0.77 to 49.52; 2 studies, 88 patients; P = 0.09). Authors' conclusions Total shoulder arthroplasty seems to offer an advantage in terms of shoulder function, with no other clinical benefits over hemiarthroplasty. More studies are needed to compare clinical outcomes of surgery using different components and techniques in patients with osteoarthritis of the shoulder. There is a need for studies comparing shoulder surgery to sham, placebo and other non-surgical treatment options. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL 35294 USA. [Sperling, John] Mayo Clin, Sch Med, Rochester, MN USA. [Buchbinder, Rachelle] Monash Univ, Dept Epidemiol & Prevent Med, Cabrini Hosp, Monash Dept Clin Epidemiol, Malvern, Australia. [McMaken, Kelly] Univ Minnesota, Minneapolis, MN USA. [McMaken, Kelly] Minneapolis VA Med Ctr, Minneapolis, MN USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com RI Buchbinder, Rachelle/G-2952-2011 FU Takeda; Savient; Wyeth; Amgen; URL pharmaceuticals; Bristol-Myers Squibb; Abbott; Parker Institute: Musculoskeletal Statistics Unit; Oak Foundation; Minneapolis and Birmingham VA Medical Centers; University of Alabama at Birmingham, AL, USA FX JAS - speaker honoraria from Abbott; research and travel grants from Takeda, Savient, Wyeth and Amgen; and consultant fees from Savient and URL pharmaceuticals.; RB - research grant and consultant fee from Bristol-Myers Squibb and Abbott. The Parker Institute: Musculoskeletal Statistics Unit is sponsored, and acknowledges The Oak Foundation.; Internal sources; Minneapolis and Birmingham VA Medical Centers and University of Alabama at Birmingham, AL, USA. NR 53 TC 10 Z9 10 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2010 IS 10 AR CD008089 DI 10.1002/14651858.CD008089.pub2 PG 46 WC Medicine, General & Internal SC General & Internal Medicine GA 659TS UT WOS:000282590400009 PM 20927773 ER PT J AU Singh, JA Fitzgerald, PM AF Singh, Jasvinder A. Fitzgerald, Patrick M. TI Botulinum toxin for shoulder pain SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID CHRONIC MYOFASCIAL PAIN; MODIFIED RANKIN SCALE; DOUBLE-BLIND; PRIMARY-CARE; RHEUMATOID-ARTHRITIS; SUBSCAPULAR MUSCLE; SPASTIC HEMIPLEGIA; CONTROLLED-TRIAL; BARTHEL INDEX; TENNIS ELBOW AB Background Recent evidence suggests an anti-nociceptive effect of botulinum toxin. Objectives To compare the efficacy and safety of botulinum toxin in comparison to placebo or other treatment options for shoulder pain. Search strategy We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (T h e Cochrane Library), Ovid MEDLINE, CINAHL (via EBSCOhost), Ovid SPORTDiscus, EMBASE and Science Citation Index. Selection criteria Randomized controlled trials (RCTs) comparing botulinum toxin with placebo or active treatment in people with shoulder pain were included. Data collection and analysis For continuous measures we calculated mean difference (MD), and for categorical measures risk ratio (RR) (with 95% confidence interval (CI)). Main results Six RCTs with 164 patients were included. Five RCTs in participants with post-stroke shoulder pain indicated that compared with placebo, a single intramuscular injection of botulinum toxin A significantly reduced pain at three to six months post-injection (MD -1.2 points, 95% CI -2.4 to -0.07; 0 to 10 point scale) but not at one month (MD -1.1 points, 95% CI -2.9 to 0.7). Shoulder external rotation was increased at one month (MD 9.8, 95% CI 0.2 to 19.4) but not at three to six months. Shoulder abduction, external rotation or spasticity did not differ between groups, nor did the number of adverse events (RR 1.46, 95% CI 0.6 to 24.3). One RCT in arthritis-related shoulder pain indicated that botulinum toxin reduced pain severity (MD -2.0, 95% CI -3.7 to -0.3; 10 point scale) and shoulder disability with a reduction in Shoulder Pain and Disability Index score (MD -13.4, 95% CI -24.9 to -1.9; 100 point scale) when compared with placebo. Shoulder abduction was improved (MD 13.8 degrees, 95% CI 3.2 to 44.0). Serious adverse events did not differ between groups (RR 0.35, 95% CI: 0.11, 1.12). Authors' conclusions The results should be interpreted with caution due to few studies with small sample sizes and high risk of bias. Botulinum toxin A injections seem to reduce pain severity and improve shoulder function and range of motion when compared with placebo in patients with shoulder pain due to spastic hemiplegia or arthritis. It is unclear if the benefit of pain relief in post-stroke shoulder pain at three to six months but not at one month is due to limitations of the evidence, which includes small sample sizes with imprecise estimates, or a delayed onset of action. More studies with safety data are needed. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL 35294 USA. [Fitzgerald, Patrick M.] Minneapolis VA Med Ctr, Minneapolis, MN USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com FU Birmingham VA Medical Center, Minneapolis, USA, USA; NIH, USA; Amgen; Allergan; Takeda; Savient pharmaceuticals; URL pharmaceuticals; Wyeth pharmaceuticals FX JS: speaker honoraria from Abbott pharmaceuticals; research grants from Amgen, Allergan, Takeda and Savient pharmaceuticals; consultant fee from Savient and URL pharmaceuticals; travel grants from Allergan and Wyeth pharmaceuticals.; SOURCES OF SUPPORT; Internal sources; Birmingham VA Medical Center, Minneapolis, USA, USA.; Research time protection; External sources; NIH CTSA KL2 Award (Mayo Clinic), USA, Not specified.; 75% time protection for research NR 71 TC 9 Z9 10 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2010 IS 9 AR CD008271 DI 10.1002/14651858.CD008271.pub2 PG 48 WC Medicine, General & Internal SC General & Internal Medicine GA 647PC UT WOS:000281629700033 PM 20824874 ER PT J AU Singh, JA Beg, S Lopez-Olivo, MA AF Singh, Jasvinder A. Beg, Saba Lopez-Olivo, Maria Angeles TI Tocilizumab for rheumatoid arthritis SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY; PLACEBO-CONTROLLED TRIAL; DISEASE-ACTIVITY SCORE; DOUBLE-BLIND; IL-6 RECEPTOR; PRELIMINARY DEFINITION; INADEQUATE RESPONSE; INHIBITION; CRITERIA; THERAPY AB Background Tocilizumab, a new biologic that inhibits interleukin-6, is approved for treatment of rheumatoid arthritis (RA) in Europe, Japan and the US. Objectives To assess the efficacy and safety of tocilizumab in patients with RA using the data from published randomized or quasi-randomized controlled trials (RCTs). Search strategy We performed a search of the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL) up to issue 3, 2009; OVID MEDLINE(1966 to 1 October 2009); CINAHL(1982 to 2009); EMBASE (1980 to week 39, 2009); Science Citation Index (Web of Science) (1945 to 2009) and Current Controlled Trials. Selection criteria Tocilizumab alone or in combination with disease-modifying anti-rheumatic drugs (DMARDs) or biologics compared to placebo or other DMARDs or biologics. Data collection and analysis Two review authors independently extracted all data including major (ACR50, adverse events, serious adverse events, withdrawals, specific adverse events) and secondary outcomes. We calculated the risk ratio for dichotomous outcomes and mean difference for continuous outcomes. Main results Eight RCTs were included in this systematic review with 3334 participants; 2233 treated with tocilizumab and 1101 controls. Of the 2233, 1561 were treated with tocilizumab 8 mg/kg every four weeks, which is the approved dose. In patients taking concomitant methotrexate, compared to placebo, tocilizumab-treated patients were four times more likely to achieve ACR50 (absolute %, 38.8% versus 9.6%), 11 times more likely to achieve Disease Activity Score (DAS) remission (absolute %, 30.5% versus 2.7%), 1.8 times more likely to achieve clinically meaningful decrease in Health Assessment Questionnaire (HAQ/mHAQ) scores (absolute %, 60.5% versus 34%), 1.2 times more likely to have any adverse event (absolute %, 74% versus 65%) and 0.6 times less likely to withdraw from therapy for any reason (absolute %, 8.1% versus 14.9%). With the limitation that none of the studies were powered for safety as primary outcome, there were no statistically significant differences in serious adverse effects, or withdrawals due to adverse events. A significant increase in total, HDL and LDL cholesterol and triglyceride level was seen in the tocilizumab treated patients. Authors' conclusions Tocilizumab is beneficial in decreasingRA disease activity and improving function. Tocilizumab treatment was associated with significant increase in cholesterol levels and in total adverse events. Larger safety studies are needed to address these safety concerns. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Dept Med, Birmingham, AL 35294 USA. [Beg, Saba] Univ Minnesota, Minneapolis, MN USA. [Beg, Saba] Minneapolis VA Med Ctr, Minneapolis, MN USA. [Lopez-Olivo, Maria Angeles] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com NR 57 TC 26 Z9 26 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2010 IS 7 AR CD008331 DI 10.1002/14651858.CD008331.pub2 PG 307 WC Medicine, General & Internal SC General & Internal Medicine GA 622AR UT WOS:000279630900028 PM 20614469 ER PT J AU Sox, HC Helfand, M Grimshaw, J Dickersin, K Tovey, D Knottnerus, JA Tugwell, P AF Sox, Harold C. Helfand, Mark Grimshaw, Jeremy Dickersin, Kay Tovey, David Knottnerus, J. Andre Tugwell, Peter TI Comparative Effectiveness Research: Challenges for Medical Journals SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Editorial Material DE Evidence synthesis; Study methodology C1 [Sox, Harold C.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dartmouth Inst, Hanover, NH 03756 USA. [Helfand, Mark] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. [Helfand, Mark] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Grimshaw, Jeremy] Ottawa Hosp, Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada. [Dickersin, Kay] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Tovey, David] Cochrane Lib, London, England. [Knottnerus, J. Andre] Univ Maastricht, Dept Gen Practice, Maastricht, Netherlands. [Tugwell, Peter] Univ Ottawa, Dept Med, Ottawa, ON, Canada. [Tugwell, Peter] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada. RP Sox, HC (reprint author), Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dartmouth Inst, Hanover, NH 03756 USA. EM helfand@ohsu.edu RI Knottnerus, Johannes/A-3829-2009 FU Public Library of Science FX The PLoS Medicine Editors are each paid a salary by the Public Library of Science, and they contributed to this editorial during their salaried time. The other authors received no specific funding for this article. NR 7 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2010 IS 4 AR ED000003 DI 10.1002/14651858.ED00003 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA V34NI UT WOS:000209092700002 ER PT J AU Tovey, D Dellavalle, R AF Tovey, David Dellavalle, Robert TI Cochrane in the United States of America SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Editorial Material DE The Cochrane Library C1 [Tovey, David] Cochrane Editorial Unit, London SE1 2LP, England. [Dellavalle, Robert] Univ Colorado, Dept Dermatol, Sch Med, Denver VA Med Ctr, Denver, CO 80220 USA. RP Tovey, D (reprint author), Cochrane Editorial Unit, 29 Queen Elizabeth St, London SE1 2LP, England. EM dtovey@cochrane.org; robert.dellavalle@ucdenver.edu RI Dellavalle, Robert/L-2020-2013 OI Dellavalle, Robert/0000-0001-8132-088X NR 4 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2010 IS 9 AR ED000010 DI 10.1002/14651858.ED000010 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA V34NN UT WOS:000209093200001 ER PT B AU Shi, Y Buffenstein, R Van Remmen, H AF Shi, Yun Buffenstein, Rochelle Van Remmen, Holly BE Wolf, NS TI Mitochondria, Oxidative Damage and Longevity: What Can Comparative Biology Teach Us? SO COMPARATIVE BIOLOGY OF AGING LA English DT Article; Book Chapter DE Mitochondria; Aging; Oxidative damage; Reactive oxygen species; Metabolic rate ID FREE-RADICAL PRODUCTION; MAXIMUM LIFE-SPAN; NAKED MOLE-RAT; HYDROGEN-PEROXIDE PRODUCTION; LONGEST-LIVING RODENT; AGE-RELATED-CHANGES; BUTYL-ALPHA-PHENYLNITRONE; ELECTRON-TRANSPORT CHAIN; SHORT-LIVED RAT; PROTEIN OXIDATION AB The most studied theory of aging is the oxidative stress theory of aging, and evidence supporting or disputing the theory has come primarily from investigations using common model organisms such as C elegans, Drosophila, and laboratory rodent models. However, studies using more non-traditional animal models offer an excellent opportunity to critically evaluate different aging hypotheses. The advantage of studying a broader spectrum of species is that one can significantly expand the amount of information obtained on a wide range of biological phenotypes/traits such as life span, body weight, and metabolic rate. In addition, the ultimate validity of a hypothesis/theory can be more critically tested using as many samples, in this case, species as possible. In this chapter we present evidence regarding different aspects of oxidative stress theory of aging with special emphasis on metabolic rate, reactive oxygen species generation, and oxidative damage to macromolecules. The purpose of the chapter is to initiate the integration of current knowledge and also to inspire readers to consider the advantages and power of using a comparative biology approach to study aging. C1 [Buffenstein, Rochelle; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Dept Physiol Cellular & Struct Biol, San Antonio, TX 78229 USA. [Van Remmen, Holly] S Texas Vet Hlth Care Syst, Audie Murphy Div, San Antonio, TX USA. [Shi, Yun] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Dept Physiol, San Antonio, TX 78229 USA. RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Dept Physiol Cellular & Struct Biol, San Antonio, TX 78229 USA. EM vanremmen@uthscsa.edu NR 96 TC 1 Z9 1 U1 1 U2 4 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-90-481-3464-9 PY 2010 BP 163 EP 190 DI 10.1007/978-90-481-3465-6_8 D2 10.1007/978-90-481-3465-6 PG 28 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA BNP40 UT WOS:000275173300008 ER PT B AU Wenk, JF Jhun, CS Zhang, ZH Sun, K Burger, M Einstein, D Ratcliffe, M Guccione, JM AF Wenk, Jonathan F. Jhun, Choon-Sik Zhang, Zhihong Sun, Kay Burger, Mike Einstein, Dan Ratcliffe, Mark Guccione, Julius M. BE Guccione, JM Kassab, GS Ratcliffe, MB TI In Vivo Left Ventricular Geometry and Boundary Conditions SO COMPUTATIONAL CARDIOVASCULAR MECHANICS: MODELING AND APPLICATIONS IN HEART FAILURE LA English DT Article; Book Chapter ID ENGINEERING MECHANICS; SUCCESSIVE STATES; IMAGING DATA; FINITE; FORMULATION; MYOCARDIUM; ELEMENTS; STRAIN AB The first basic biomechanics modeling step outlined in the introductory chapter is to define the geometric configuration. In Chapters 12 and 14 we demonstrate the application of either simple (i.e., axisymmetric truncated ellipsoid) or complex (i.e., fully 3-D) left ventricular (LV) geometric models or finite element (FE) meshes. This chapter is primarily concerned with an instructive review of the methodology we have used to create both types of FE meshes, which relies on the "parametric" meshing software TrueGrid (R). Since TrueGrid is rather expensive. Section 1.6 describes the use of free software executables available from the Pacific Northwest National Laboratory. The second basic biomechanics modeling step (determine mechanical properties) is addressed in the next three chapters. The third and fourth basic biomechanics modeling steps (governing equations and boundary conditions) are discussed briefly at the end of this chapter. C1 [Wenk, Jonathan F.; Jhun, Choon-Sik; Zhang, Zhihong; Sun, Kay; Ratcliffe, Mark; Guccione, Julius M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Wenk, Jonathan F.; Jhun, Choon-Sik; Zhang, Zhihong; Sun, Kay; Ratcliffe, Mark; Guccione, Julius M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Burger, Mike] XYZ Sci Applicat Inc, Livermore, CA USA. [Einstein, Dan] Pacific NW Natl Lab, Olympia, WA USA. RP Guccione, JM (reprint author), Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. EM jwenk1@gmail.com; csjhun@gmail.com; guccionej@surgery.ucsf.edu; guccionej@surgery.ucsf.edu NR 11 TC 1 Z9 1 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-0729-5 PY 2010 BP 3 EP 21 DI 10.1007/978-1-4419-0730-1_l D2 10.1007/978-1-4419-0730-1 PG 19 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical; Surgery SC Cardiovascular System & Cardiology; Engineering; Surgery GA BNM97 UT WOS:000275006800001 ER PT B AU Jhun, CS Wenk, JF Sun, K Guccione, JM AF Jhun, Choon-Sik Wenk, Jonathan F. Sun, Kay Guccione, Julius M. BE Guccione, JM Kassab, GS Ratcliffe, MB TI Constitutive Equations and Model Validation SO COMPUTATIONAL CARDIOVASCULAR MECHANICS: MODELING AND APPLICATIONS IN HEART FAILURE LA English DT Article; Book Chapter ID CANINE LEFT-VENTRICLE; CARDIAC-MUSCLE; ACTIVE CONTRACTION; FIBER STRESS; DEFORMATION; MYOCARDIUM; MECHANICS; DEACTIVATION; ACTIVATION; KINETICS AB Of the Four basic biomechanics modeling steps outlined in the Introduction. determining the constitutive equations for cardiovascular tissue is often the most difficult step, especially when the tissue properties vary with time and sarcomere length history, its is the case with contracting myocardium. Using a cylindrical model to study transmural variations in stress and strain rather than a finite element model of the entire left ventricle allows for the implementation of a time- and sarcomere length history-dependent constitutive equation. The cylindrical model simulations can then be repeated with progressively simpler constitutive equations and the resulting transmural stress and strain distributions compared to determine under what conditions the moll computationally efficient constitutive equations are valid. This chapter is primarily concerned with an instructive review of the constitutive equations we have implemented in cylindrical and finite element models of the passive and beating left ventricle, including that of diseased and surgically treated hearts. The last section of this chapter is concerned with experimental measurements that we have used to validate these models. C1 [Jhun, Choon-Sik; Wenk, Jonathan F.; Sun, Kay; Guccione, Julius M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Jhun, Choon-Sik; Wenk, Jonathan F.; Sun, Kay; Guccione, Julius M.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Guccione, JM (reprint author), Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. EM guccionej@surgery.ucsf.edu; guccionej@surgery.ucsf.edu NR 23 TC 1 Z9 1 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-0729-5 PY 2010 BP 41 EP 54 DI 10.1007/978-1-4419-0730-1_3 D2 10.1007/978-1-4419-0730-1 PG 14 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical; Surgery SC Cardiovascular System & Cardiology; Engineering; Surgery GA BNM97 UT WOS:000275006800003 ER PT B AU Wenk, JF Jhun, CS Sun, K Stander, N Guccione, JM AF Wenk, Jonathan F. Jhun, Choon-Sik Sun, Kay Stander, Nielen Guccione, Julius M. BE Guccione, JM Kassab, GS Ratcliffe, MB TI Determination of Myocardial Material Properties by Optimization SO COMPUTATIONAL CARDIOVASCULAR MECHANICS: MODELING AND APPLICATIONS IN HEART FAILURE LA English DT Article; Book Chapter ID LEFT-VENTRICULAR ANEURYSM; LARGE ELASTIC DEFORMATIONS; CANINE LEFT-VENTRICLE; FINITE-ELEMENT-METHOD; MECHANICAL DYSFUNCTION; 3-DIMENSIONAL STRAIN; BORDER ZONE; MR-IMAGES; MODEL; STRESS AB The previous chapter includes a computationally efficient strain energy function for describing the three-dimensional relationship between stress and strain in passive myocardial material properties, the material parameters of which were formally optimized using left ventricular pressure and epicardial strain measurements in a cylindrical model. Results from such a model are confined at best to the equatorial region of the left ventricle. A finite element model of the entire left ventricle is required to determine regional variations in myocardial material properties. The most important or at least interesting finding from such a study is that myocardial contractility in the (border zone) region adjacent to a myocardial infarction is much less than (typically only hall) that in regions remote from the myocardial infarction. This finding has been confirmed with active stress measurements in skinned muscle fibers dissected from these regions. This chapter is concerned with brief descriptions of the studies from our laboratory that have led up to our current knowledge concerning regional variations of myocardial contractility in infarcted left ventricles. C1 [Wenk, Jonathan F.; Jhun, Choon-Sik; Sun, Kay; Guccione, Julius M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Wenk, Jonathan F.; Jhun, Choon-Sik; Sun, Kay; Guccione, Julius M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Stander, Nielen] Livermore Software Technol Corp, Livermore, CA USA. RP Guccione, JM (reprint author), Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. EM guccionej@surgery.ucsf.edu; guccionej@surgery.ucsf.edu NR 28 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-0729-5 PY 2010 BP 55 EP 72 DI 10.1007/978-1-4419-0730-1_4 D2 10.1007/978-1-4419-0730-1 PG 18 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical; Surgery SC Cardiovascular System & Cardiology; Engineering; Surgery GA BNM97 UT WOS:000275006800004 ER PT B AU Ge, L Kassab, GS AF Ge, Liang Kassab, G. S. BE Guccione, JM Kassab, GS Ratcliffe, MB TI Turbulence in the Cardiovascular System: Aortic Aneurysm as an Illustrative Example SO COMPUTATIONAL CARDIOVASCULAR MECHANICS: MODELING AND APPLICATIONS IN HEART FAILURE LA English DT Article; Book Chapter ID SHEAR-STRESS; CAROTID BIFURCATION; ENDOTHELIAL-CELLS; PULSATILE FLOW; ENLARGEMENT AB Turbulence is a fluid regime characterized by chaotic and stochastic changes of flow. The onset of turbulence can occur under disease conditions and is known to have adverse effects on the function of the cardiovascular (CV) system. This chapter outlines the basic features of turbulence in the CV system. As a specific example. simulation of turbulent flow in an abdominal aortic aneurysm (AAA) is presented. The simulated results show that transition to turbulence occurs in large aneurysms with high Reynolds number. Onset of turbulence is seen to drastically change the distribution of wall shear stress and fluid pressure. The general implications are enumerated. C1 [Ge, Liang] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Ge, Liang] San Francisco VA Med Ctr, San Francisco, CA USA. [Kassab, G. S.] IUPUI, Dept Biomed Engn, Dept Cellular & Integrat Physiol, Dept Surg,Indiana Ctr Vasc Biol & Med, Indianapolis, IN 46202 USA. [Kassab, G. S.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA. RP Ge, L (reprint author), Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. EM gkassab@iupui.edu; gkassab@iupui.edu NR 24 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-0729-5 PY 2010 BP 159 EP 176 DI 10.1007/978-1-4419-0710-1_10 D2 10.1007/978-1-4419-0730-1 PG 18 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical; Surgery SC Cardiovascular System & Cardiology; Engineering; Surgery GA BNM97 UT WOS:000275006800010 ER PT B AU Wenk, JF Jhun, CS Sun, K Ratcliffe, MB Guccione, JM AF Wenk, Jonathan F. Jhun, Choon-Sik Sun, Kay Ratcliffe, Mark B. Guccione, Julius M. BE Guccione, JM Kassab, GS Ratcliffe, MB TI Surgical Left Ventricular Remodeling Procedures SO COMPUTATIONAL CARDIOVASCULAR MECHANICS: MODELING AND APPLICATIONS IN HEART FAILURE LA English DT Article; Book Chapter ID FINITE-ELEMENT MODEL; VOLUME REDUCTION SURGERY; CANINE LEFT-VENTRICLE; MYOCARDIAL-INFARCTION; 3-DIMENSIONAL STRAIN; STRESS-ANALYSIS; ANEURYSM; RESTORATION; MECHANICS; REPAIR AB Perhaps the most straightforward clinical application of validated regional ventricular mechanics models for diseased hearts is the simulation of a novel surgical procedure or medical device for treating heart failure or ischemic cardiomyopathy. In each study our cardiac biomechanics laboratory uses one of two different approaches: (I) an axisymmetric truncated ellipsoidal model with left ventricular (LV) cavity and wall volumes typical of the failing human heart or animal model of heart failure to determine efficacy of the surgical procedure or device; or (2) an animal- or patient-specific fully 3-D model of the infarcted IN created using echocardiography or MRI to optimize the design of the surgical procedure or device. This chapter is concerned with brief descriptions of the studies From our laboratory that provide the best examples of these two approaches. C1 [Wenk, Jonathan F.; Jhun, Choon-Sik; Sun, Kay; Ratcliffe, Mark B.; Guccione, Julius M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Wenk, Jonathan F.; Jhun, Choon-Sik; Sun, Kay; Ratcliffe, Mark B.; Guccione, Julius M.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Guccione, JM (reprint author), Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. EM jwenk1@gmail.com; csjhun@gmail.com; guccionej@surgery.ucsf.edu; guccionej@surgery.ucsf.edu NR 24 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-0729-5 PY 2010 BP 197 EP 210 DI 10.1007/978-1-4419-0730-1_12 D2 10.1007/978-1-4419-0730-1 PG 14 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical; Surgery SC Cardiovascular System & Cardiology; Engineering; Surgery GA BNM97 UT WOS:000275006800012 ER PT B AU Jhun, CS Gundiah, N Sun, K Sabbah, HN Tseng, EE Ratcliffe, MB Guccione, JM AF Jhun, Choon-Sik Gundiah, Namrata Sun, Kay Sabbah, Hani N. Tseng, E. Elaine Ratcliffe, Mark B. Guccione, Julius M. BE Guccione, JM Kassab, GS Ratcliffe, MB TI Passive Left Ventricular Constraint Devices SO COMPUTATIONAL CARDIOVASCULAR MECHANICS: MODELING AND APPLICATIONS IN HEART FAILURE LA English DT Article; Book Chapter ID CARDIAC SUPPORT DEVICE; ACUTE MYOCARDIAL-INFARCTION; DILATED CARDIOMYOPATHY; HEART-FAILURE; WALL STRESS; SURVIVAL; MECHANICS; VOLUME; MODEL; SHAPE AB Both myocardial infarction and volume overloading associated with regurgitant valve lesions lead to eccentric left. ventricular (LV) hypertrophy. The mechanism is presumed to be positive feedback between diastolic LV wall stress and eccentric LV hypertrophy. Further, in each case, an increase in LV sire is an important adverse prognostic finding. The experience with skeletal muscle cardiomyoplasty led to the hypothesis that passive constraint of LV enlargement would interrupt the diastolic stress and eccentric hypertrophy cycle, in addition to halting and possibly reversing the adverse LV remodeling. A number of passive constraint devices such as the Acorn CorCap (TM) Cardiac Support Device (CSD), Paracor Medical HeartNet (TM) Ventricular Support System (VSS), and Myocor (TM) Myosplint (R) have been used. Most recently, an Adjustable Fluid Filled Balloon CSD was proposed by Ghanta and colleagues. In this chapter we model the effect of passive constraint devices, with the exception of the Paracor Medical HeartNet (TM) VSS. on the LV stroke volume/end-diastolic pressure (Starling) relationship and regional distributions of stress in the local muscle fiber direction. C1 [Jhun, Choon-Sik; Sun, Kay; Tseng, E. Elaine; Ratcliffe, Mark B.; Guccione, Julius M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Jhun, Choon-Sik; Sun, Kay; Tseng, E. Elaine; Ratcliffe, Mark B.; Guccione, Julius M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Sabbah, Hani N.] Henry Ford Hosp, Detroit, MI 48202 USA. [Gundiah, Namrata] Indian Inst Sci, Dept Mech Engn, Bangalore 560012, Karnataka, India. RP Guccione, JM (reprint author), Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. EM csjhun@gmail.com; guccionej@surgery.ucsf.edu; guccionej@surgery.ucsf.edu NR 27 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-0729-5 PY 2010 BP 211 EP 226 DI 10.1007/978-1-4419-0730-1_13 D2 10.1007/978-1-4419-0730-1 PG 16 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical; Surgery SC Cardiovascular System & Cardiology; Engineering; Surgery GA BNM97 UT WOS:000275006800013 ER PT B AU Wall, ST Wenk, JF Jhun, CS Guccione, JM AF Wall, Samuel T. Wenk, Jonathan F. Jhun, Choon-Sik Guccione, Julius M. BE Guccione, JM Kassab, GS Ratcliffe, MB TI Left Ventricular Implantation of Biomaterials SO COMPUTATIONAL CARDIOVASCULAR MECHANICS: MODELING AND APPLICATIONS IN HEART FAILURE LA English DT Article; Book Chapter ID FINITE-ELEMENT MODEL; CARDIOMYOPATHY AB In recent years, there has been a significant effort to restore heart function by the addition of stem cells directly into the myocardium. These cells are normally carried in a synthetic extracellular matrix and implanted into the injured heart. While there has been little demonstration of actual tissue regeneration using such methods, there has been long-term improvement from these techniques, and surprisingly, from the implantation of biomaterials alone, without any included cells. This has in fact led to therapies that directly add passive materials into the ventricle to help prevent heart failure. Therefore, theoretically evaluating the addition of passive material volumes into the myocardium is of clinical importance to understand the mechanisms for the improvement of ventricular mechanics and for optimizing such treatments. In this chapter we discuss the role of finite element studies in investigating the direct addition of non-contractile materials into the myocardium. C1 [Wall, Samuel T.; Wenk, Jonathan F.; Jhun, Choon-Sik; Guccione, Julius M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Wall, Samuel T.; Wenk, Jonathan F.; Jhun, Choon-Sik; Guccione, Julius M.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Guccione, JM (reprint author), Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. EM jwenk1@gmail.com; csjhun@gmail.com; guccionej@surgery.ucsf.edu; guccionej@surgery.ucsf.edu NR 12 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-0729-5 PY 2010 BP 227 EP 238 DI 10.1007/978-1-4419-0730-1_14 D2 10.1007/978-1-4419-0730-1 PG 12 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical; Surgery SC Cardiovascular System & Cardiology; Engineering; Surgery GA BNM97 UT WOS:000275006800014 ER PT B AU Hollander, DA AF Hollander, David A. BA Trattler, WB Majmudar, PA Luchs, JI Swartz, TS BF Trattler, WB Majmudar, PA Luchs, JI Swartz, TS TI ANTERIOR SEGMENT NEOPLASIA SO CORNEA HANDBOOK LA English DT Article; Book Chapter ID SQUAMOUS-CELL CARCINOMA; PRIMARY ACQUIRED MELANOSIS; TOPICAL MITOMYCIN-C; CONJUNCTIVAL INTRAEPITHELIAL NEOPLASIA; SEBACEOUS GLAND CARCINOMA; LYMPHOID-TISSUE LYMPHOMA; IMMUNODEFICIENCY-VIRUS-INFECTION; MALIGNANT FIBROUS HISTIOCYTOMA; HUMAN-PAPILLOMAVIRUS DNA; OCULAR ADNEXAL LYMPHOMA C1 Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Greater Los Angeles VA Med Ctr, Los Angeles, CA 90095 USA. RP Hollander, DA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Greater Los Angeles VA Med Ctr, Los Angeles, CA 90095 USA. NR 238 TC 0 Z9 0 U1 0 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE ROAD, THOROFARE, NJ 08086-9447 USA BN 978-1-55642-842-5 PY 2010 BP 163 EP 189 PG 27 WC Ophthalmology SC Ophthalmology GA BNG60 UT WOS:000274515200010 ER PT J AU Mailloux, AW Young, MRI AF Mailloux, Adam W. Young, M. Rita I. TI Regulatory T-cell Trafficking: From Thymic Development to Tumor-Induced Immune Suppression SO CRITICAL REVIEWS IN IMMUNOLOGY LA English DT Article DE regulatory T cell; Treg; migration; trafficking; localization; chemokine; inflammation; cancer; immune suppression ID TRANSCRIPTION FACTOR FOXP3; DRAINING LYMPH-NODES; BONE-MARROW; DENDRITIC CELLS; CHEMOKINE RECEPTOR; HEPATOCELLULAR-CARCINOMA; PERIPHERAL-BLOOD; EPITHELIAL-CELLS; HUMAN THYMOCYTES; OVARIAN-CANCER AB Regulatory T cells (Tregs) have become a priority for many investigators in immunology due to their potent immunosuppressive and tolerogenic effects. While Treg activity is required for normal immune homeostasis, dysregulation of their numbers can induce autoimmunity or aid in the pathogenesis of disease. Therefore, great effort has been made to understand the mechanisms by which Tregs accumulate in different areas of the body. Like other lymphocytes, Tregs migrate in response to a network of chemotactic stimuli involving chemokines, chemokine receptors, integrins, and their corresponding ligands. However, many of these stimuli are exclusive to Tregs, inducing their migration while leaving conventional populations unaffected. It is these selective stimuli that result in increased ratios of Tregs among conventional effector populations, leading to changes in immune suppression and homeostasis. This review explores selective Treg trafficking during thymic Treg development, migration to secondary lymphoid tissues and emigration into the periphery during homeostatic conditions, inflammation, and the tumor microenvironment, placing emphasis on stimuli :hat selectively recruits Tregs to target locations. C1 [Young, M. Rita I.] Ralph H Johnson VA Med Ctr, Res Serv 151, Charleston, SC 29401 USA. [Mailloux, Adam W.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA. [Young, M. Rita I.] Med Univ S Carolina, Dept Otolaryngol, Charleston, SC 29425 USA. [Young, M. Rita I.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, Res Serv 151, 109 Bee St, Charleston, SC 29401 USA. EM adam.mailloux@moffitt.org; rita.young@va.gov FU National Cancer Institute (NCI) [T32 CA115308] FX We would like to acknowledge the financial assistance and research resources of the T32 Tumor Immunology Training Grant; T32 CA115308, Program Leader, Julie Y. Djeu, Ph.D. (2007 -2012), provided by the National Cancer Institute (NCI). NR 125 TC 25 Z9 28 U1 0 U2 7 PU BEGELL HOUSE INC PI REDDING PA 50 CROSS HIGHWAY, REDDING, CT 06896 USA SN 1040-8401 J9 CRIT REV IMMUNOL JI Crit. Rev. Immunol. PY 2010 VL 30 IS 5 BP 435 EP 447 PG 13 WC Immunology SC Immunology GA 683VL UT WOS:000284505500003 PM 21083525 ER PT J AU Rohatgi, R Flores, D AF Rohatgi, Rajeev Flores, Daniel TI Intratubular hydrodynamic forces influence tubulointerstitial fibrosis in the kidney SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION LA English DT Review DE fibrosis; hydrodynamic forces; inflammation; signaling; tubule ID CORTICAL COLLECTING DUCT; RENAL EPITHELIAL-CELLS; THICK ASCENDING LIMB; FLUID SHEAR-STRESS; PROTEIN-1 GENE-EXPRESSION; PROXIMAL TUBULE CELLS; ENDOTHELIAL-CELLS; NITRIC-OXIDE; URETERAL OBSTRUCTION; PRIMARY CILIUM AB Purpose of review Renal epithelial cells respond to mechanical stimuli with immediate transduction events (e.g. activation of ion channels), intermediate biological responses (e.g. changes in gene expression), and long-term cellular adaptation (e.g. protein expression). Progressive renal disease is characterized by disturbed glomerular hydrodynamics that contributes to glomerulosclerosis but how intratubular biomechanical forces contribute to tubulointerstital inflammation and fibrosis is poorly understood. Recent findings In-vivo and in-vitro models of obstructive uropathy demonstrate that tubular stretch induces robust expression of transforming growth factor beta-1, activation of tubular apoptosis, and induction of nuclear factor-kappa B signaling, which contribute to the inflammatory and fibrotic milieu. Nonobstructive structural kidney diseases associated with nephron loss follow a course characterized by compensatory increases of single nephron glomerular filtration rate and tubular flow rate. Resulting increases in tubular fluid shear stress reduce tissue-plasminogen activator and urokinase enzymatic activity, which diminishes breakdown of extracellular matrix. In models of high dietary Na intake, which increases tubular flow, urinary transforming growth factor beta-1 concentrations and renal mitogen-activated protein kinase activity are increased. Summary In conclusion, intratubular biomechanical forces, stretch, and fluid shear stress generate changes in intracellular signaling and gene expression that contribute to the pathobiology of obstructive and nonobstructive kidney disease. C1 [Rohatgi, Rajeev; Flores, Daniel] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Rohatgi, Rajeev] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA. [Rohatgi, Rajeev] James J Peters VA Med Ctr, Bronx, NY USA. RP Rohatgi, R (reprint author), Mt Sinai Sch Med, Dept Med, Box 1243,1 Gustave L Levy Pl, New York, NY 10029 USA. EM Rajeev.Rohatgi@mssm.edu FU National Institutes of Health [K08 DK062172]; PKD Foundation; Norman S. Coplon Extramural FX The present work was supported by grants from the National Institutes of Health K08 DK062172 (RR), PKD Foundation Standard Grant (RR) and The Norman S. Coplon Extramural Grant Program (RR). We would like to thank Dr Lisa M. Satlin for the constructive criticism during the preparation of the manuscript. NR 55 TC 28 Z9 34 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1062-4821 J9 CURR OPIN NEPHROL HY JI Curr. Opin. Nephrol. Hypertens. PD JAN PY 2010 VL 19 IS 1 BP 65 EP 71 DI 10.1097/MNH.0b013e32833327f3 PG 7 WC Urology & Nephrology; Peripheral Vascular Disease SC Urology & Nephrology; Cardiovascular System & Cardiology GA 537LR UT WOS:000273114900011 PM 19851105 ER PT J AU Nagami, GT Kraut, JA AF Nagami, Glenn T. Kraut, Jeffrey A. TI Acid-base regulation of angiotensin receptors in the kidney SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION LA English DT Review DE acidosis; ammonia excretion; nephron; type 1 Ang II receptor; urinary acidification ID THICK ASCENDING LIMB; CHRONIC METABOLIC-ACIDOSIS; MEDULLARY COLLECTING DUCT; II-BINDING-SITES; PROXIMAL BICARBONATE ABSORPTION; LATE DISTAL TUBULE; PERFUSED IN-VITRO; H+-K+-ATPASE; AMMONIA PRODUCTION; INTERCALATED CELLS AB Purpose of review Angiotensin II (Ang II) is a major systemic regulator of blood pressure, blood volume, and acid-base homeostasis. However, the effects of local Ang II signaling in the kidney are less well known. Here we review the impact of Ang II on acid-base transport in specific nephron segments and discuss the recently described role of acid loading in sensitizing the proximal tubule to Ang II. Recent findings Recent studies suggest that Ang II signaling is necessary for a normal kidney response to acid loads. Under acidic conditions, tubule cells upregulate type 1 Ang II receptors, amplifying the effects of Ang II. Site of action may also affect Ang II activity, as Ang II can produce divergent effects when acting on the luminal versus basolateral aspects of tubule cells. High luminal concentrations of Ang II and its precursors may facilitate coordinated acid-base transport and metabolic activity throughout the nephron. Summary Local Ang II signaling in the kidney directly modulates acid-base transport and metabolism, providing an additional mechanism by which the renin-angiotensin-aldosterone system regulates acid-base balance. The segment-specific and acid-stimulated responses of the tubule to Ang II are diverse and merit further exploration for their adaptive and potentially maladaptive roles. C1 [Nagami, Glenn T.; Kraut, Jeffrey A.] VA Greater Los Angeles Healthcare Syst, Nephrol Sect, Los Angeles, CA 90073 USA. [Nagami, Glenn T.; Kraut, Jeffrey A.] VA Greater Los Angeles Healthcare Syst, Nephrol Res Lab, Dept Med, Los Angeles, CA 90073 USA. [Nagami, Glenn T.; Kraut, Jeffrey A.] VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. [Nagami, Glenn T.; Kraut, Jeffrey A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Kraut, Jeffrey A.] Univ Calif Los Angeles, David Geffen Sch Med, Membrane Biol Lab, Los Angeles, CA 90095 USA. RP Nagami, GT (reprint author), VA Greater Los Angeles Healthcare Syst, Nephrol Sect 111L, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM glenn.nagami@va.gov FU Department of Veterans Affairs FX The present work was supported, in part, by medical research funds from the Department of Veterans Affairs. NR 68 TC 1 Z9 1 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1062-4821 J9 CURR OPIN NEPHROL HY JI Curr. Opin. Nephrol. Hypertens. PD JAN PY 2010 VL 19 IS 1 BP 91 EP 97 DI 10.1097/MNH.0b013e32833289fd PG 7 WC Urology & Nephrology; Peripheral Vascular Disease SC Urology & Nephrology; Cardiovascular System & Cardiology GA 537LR UT WOS:000273114900015 PM 19816174 ER PT J AU Naseri, A McLeod, SD AF Naseri, Ayman McLeod, Stephen D. TI Cataract surgery after refractive surgery SO CURRENT OPINION IN OPHTHALMOLOGY LA English DT Article DE cataract; laser in-situ keratomileusis; postlaser in-situ keratomileusis; power calculation; refractive surgery ID INTRAOCULAR-LENS POWER; IN-SITU KERATOMILEUSIS; MYOPIC PHOTOREFRACTIVE KERATECTOMY; CORNEAL POWER; EYES; LASIK; FORMULA; ADJUSTMENT; KERATOMETRY; KERATOTOMY AB Purpose of review To review recent contributions addressing the challenge of intraocular lens (IOL) calculation in patients undergoing cataract extraction following corneal refractive surgery. Recent findings Although several articles have provided excellent summaries of IOL selection in patients wherein prerefractive surgery data are available, numerous authors have recently described approaches to attempt more accurate IOL power calculations for patients who present with no reliable clinical information regarding their refractive history. Additionally, results have been reported using the Scheimpflug camera system to measure corneal power in an attempt to resolve the most important potential source of error for IOL determination in these patients. Summary IOL selection in patients undergoing cataract surgery after corneal refractive surgery continues to be a challenging and complex issue despite numerous strategies and formulas described in the literature. Current focus seems to be directed toward approaches that do not require preoperative refractive surgery information. Due to the relative dearth of comparative clinical outcomes data, the optimal solution to this ongoing clinical problem has yet to be determined. Until such data are available, many cataract surgeons compare the results of multiple formulas to assist them in IOL selection for these patients. C1 [Naseri, Ayman; McLeod, Stephen D.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA. [Naseri, Ayman; McLeod, Stephen D.] Francis I Proctor Fdn Res Ophthalmol, San Francisco, CA USA. [Naseri, Ayman] San Francisco VA Med Ctr, Dept Ophthalmol, San Francisco, CA USA. RP McLeod, SD (reprint author), Univ Calif San Francisco, Dept Ophthalmol, 10 Koret Way, San Francisco, CA 94143 USA. EM McLeodS@vision.ucsf.edu FU Man May See, San Francisco, California, USA; Prevent Blindness, New York, New York, USA. FX The present study is supported in part by an unrestricted grant from That Man May See, San Francisco, California, USA and an unrestricted grant from Research to Prevent Blindness, New York, New York, USA. NR 39 TC 10 Z9 10 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-8738 J9 CURR OPIN OPHTHALMOL JI Curr. Opin. Ophthalmol. PD JAN PY 2010 VL 21 IS 1 BP 35 EP 38 DI 10.1097/ICU.0b013e328333e9ab PG 4 WC Ophthalmology SC Ophthalmology GA 537LT UT WOS:000273115100007 PM 19996749 ER PT J AU Clarke, JT Werth, VP AF Clarke, Jennie T. Werth, Victoria P. TI Rheumatic manifestations of skin disease SO CURRENT OPINION IN RHEUMATOLOGY LA English DT Review DE cutaneous lupus erythematosus; dermatomyositis; rheumatoid arthritis; scleroderma ID CUTANEOUS LUPUS-ERYTHEMATOSUS; INTERSTITIAL GRANULOMATOUS DERMATITIS; SYSTEMIC-SCLEROSIS PATIENTS; SEVERITY INDEX; IMATINIB MESYLATE; ALPHA INHIBITORS; D-PENICILLAMINE; DOUBLE-BLIND; THERAPY; DERMATOMYOSITIS AB Purpose of review There is an increasing interest in improving the understanding of pathophysiology, outcome measures, and therapies of rheumatic skin disease. Increasingly, studies are using the skin as a primary endpoint for evaluating therapies. This will review the current state of the art for the most common rheumatic skin diseases. Recent findings A number of medications, including biologics such as tumor necrosis factor a and interferon, have been associated with onset of cutaneous lupus. The cutaneous lupus erythematosus area and severity index has been further validated and utilized in a number of studies. Smoking continues to be associated both with presence and refractoriness of cutaneous lupus erythematosus to therapy. There are several tools now available for evaluating the skin disease of dermatomyositis, but there is a need for new effective therapies. Measurement of skin disease in scleroderma continues to be a challenge, and there is a need for more effective therapies. Several studies show efficacy of intravenous iloprost for severe Raynaud's and skin ulcers, and of bosentan for digital ulcers. Summary The present review covers new outcome measures, treatments, and unusual manifestations of cutaneous lupus, dermatomyositis, scleroderma, and rheumatoid arthritis. There have been a number of new studies related to validation of disease activity measures, as well as their use in evaluation of new therapies for these conditions. Validated outcome measures are required to perform meaningful studies, and will facilitate organized epidemiologic, quality of life, and therapeutic studies. C1 [Clarke, Jennie T.] Penn State Hershey Med Ctr, Dept Dermatol, Hershey, PA USA. [Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Werth, Victoria P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Hosp Univ Penn, Dept Dermatol, 3600 Spruce St,2 Rhoads Pavil, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU NIH [K24-AR 02207]; V.A. Merit Review Grant FX The present study was supported by NIH K24-AR 02207 and a V.A. Merit Review Grant. NR 74 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-8711 J9 CURR OPIN RHEUMATOL JI Curr. Opin. Rheumatol. PD JAN PY 2010 VL 22 IS 1 BP 78 EP 84 DI 10.1097/BOR.0b013e328333b9e2 PG 7 WC Rheumatology SC Rheumatology GA 534JI UT WOS:000272892000013 PM 19851110 ER PT J AU Lin, F Wharton, W Dowling, NM Ries, ML Johnson, SC Carlsson, CM Asthana, S Gleason, CE AF Lin, Feng Wharton, Whitney Dowling, N. Maritza Ries, Michele L. Johnson, Sterling C. Carlsson, Cynthia M. Asthana, Sanjay Gleason, Carey E. TI Awareness of Memory Abilities in Community-Dwelling Older Adults with Suspected Dementia and Mild Cognitive Impairment SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE Anosognosia; Dementia; Mild cognitive impairment; Memory; Neuropsychology; Community-dwelling ID ALZHEIMERS-DISEASE; SELF-APPRAISAL; ANOSOGNOSIA; DEFICITS; QUESTIONNAIRE; UNAWARENESS; CONSORTIUM; COMPLAINT; ESTABLISH; REGISTRY AB Aims: To examine awareness of memory abilities by groups (healthy control, suspected dementia/mild cognitive impairment, MCI, and diagnosed dementia/MCI), and to describe group differences in the relationship between awareness and cognitive performance in a community sample. Methods: In a cross-sectional design, 183 subjects were evaluated in a community setting and categorized into 3 groups based on their cognitive performance and reported medical history. Awareness of memory abilities was quantified using a published anosognosia ratio (AR) comparing the estimated to the objective memory performance by subjects. Each group was further categorized into 'overestimators', 'accurate estimators', and 'underestimators' based on their AR scores. Results: The suspected and diagnosed dementia/MCI groups had significantly higher AR scores than the controls. The suspected group also had a significantly larger proportion (96.2%) of overestimators than the diagnosed (73.3%) and control groups (26.1%). Impaired awareness in overestimators of the suspected and diagnosed groups was correlated with deficits in executive function, language or global cognition. Conclusion: Impaired awareness of memory abilities was prevalent in community-dwelling older adults with suspected and diagnosed dementia or MCI. Those with suspected dementia or MCI were more likely to overestimate their memory abilities than their diagnosed counterparts, suggesting that limited awareness of deficits may hinder utilization of dementia diagnostic services. Copyright (C) 2010 S. Karger AG, Basel C1 [Lin, Feng] Univ Wisconsin, Sch Nursing, Madison, WI USA. [Wharton, Whitney; Ries, Michele L.; Johnson, Sterling C.; Carlsson, Cynthia M.; Asthana, Sanjay; Gleason, Carey E.] Univ Wisconsin, Dept Med, Sect Geriatr & Gerontol, Sch Med & Publ Hlth, Madison, WI USA. [Dowling, N. Maritza] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI USA. [Wharton, Whitney; Dowling, N. Maritza; Ries, Michele L.; Johnson, Sterling C.; Carlsson, Cynthia M.; Asthana, Sanjay; Gleason, Carey E.] William S Middleton Mem Vet Adm Med Ctr, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Lin, Feng; Johnson, Sterling C.; Carlsson, Cynthia M.; Asthana, Sanjay; Gleason, Carey E.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. RP Gleason, CE (reprint author), Madison VA GRECC D4211 2500 Overlook Terrace, Madison, WI 53705 USA. EM ceg@medicine.wisc.edu FU NIH-National Institute on Aging [K23 AG024302] FX This research was supported by NIH-National Institute on Aging grants K23 AG024302 (PI CEG) and P50 AG033514, and by the Extendicare Foundation Inc. The Biostatistics and Data Management Core of the Wisconsin ADRC provided statistical consultation and assistance with analyses. NR 41 TC 9 Z9 9 U1 2 U2 6 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2010 VL 30 IS 1 BP 83 EP 92 DI 10.1159/000318752 PG 10 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 638YP UT WOS:000280936900014 PM 20714155 ER PT J AU Gold, M Alderton, C Zvartau-Hind, M Egginton, S Saunders, AM Irizarry, M Craft, S Landreth, G Linnamagi, U Sawchak, S AF Gold, Michael Alderton, Claire Zvartau-Hind, Marina Egginton, Sally Saunders, Ann M. Irizarry, Michael Craft, Suzanne Landreth, Gary Linnamaegi, Uella Sawchak, Sharon TI Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer's Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE Rosiglitazone; extended release; Monotherapy; Alzheimer's disease; Peroxisome proliferator-activated receptor-gamma; Cognition; Apolipoprotein E allele epsilon 4; Health outcomes; Donepezil ID CLINICAL-TRIALS; INSULIN-RESISTANCE; VASCULAR DEMENTIA; COGNITIVE IMPAIRMENT; DIABETES-MELLITUS; APOLIPOPROTEIN-E; MEMORY; RIVASTIGMINE; EFFICACY; DECLINE AB Background/Aims: A phase II study of the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer's disease (AD) detected a treatment benefit to cognition in apolipoprotein E (APOE)-epsilon 4-negative subjects. The current phase III study with prospective stratification by APOE genotype was conducted to confirm the efficacy and safety of RSG XR in mild-to-moderate AD. An open-label extension study assessed the long-term safety and tolerability of 8 mg RSG XR. Methods: This double-blind, randomized, placebo-controlled study enrolled 693 subjects. Within 2 APOE allelic strata (epsilon 4-positive, epsilon 4-negative), subjects were randomized (2: 2: 2: 1) to once-daily placebo, 2 mg RSG XR, 8 mg RSG XR or 10 mg donepezil (control). Coprimary endpoints were change from baseline to week 24 in the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) score, and week 24 Clinician's Interview-Based Impression of Change plus caregiver input (CIBIC+). Results: At week 24, no significant differences from placebo in change from baseline in coprimary endpoints were detected with either the RSG XR dose in A POE-epsilon 4-negative subjects or overall. For donepezil, no significant treatment difference was detected in ADAS-Cog; however, a significant difference was detected (p = 0.009) on the CIBIC+. Peripheral edema was the most common adverse event for 8 mg RSG XR (15%) and placebo (5%), and nasopharyngitis for 2 mg RSG XR (7%). Conclusion: No evidence of efficacy of 2 mg or 8 mg RSG XR monotherapy in cognition or global function was detected in the APOE-epsilon 4-negative or other analysis populations. The safety and tolerability of RSG XR was consistent with its known pharmacology. Copyright (C) 2010 S. Karger AG, Basel C1 [Gold, Michael; Irizarry, Michael; Sawchak, Sharon] GlaxoSmithKline Inc, Neurosci Med Dev Ctr, Res Triangle Pk, NC 27709 USA. [Alderton, Claire; Zvartau-Hind, Marina] GlaxoSmithKline Inc, Neurosci Med Dev Ctr, Stockley Pk, England. [Egginton, Sally] GlaxoSmithKline Inc, Neurosci Med Dev Ctr, Harlow, Essex, England. [Saunders, Ann M.] Duke Univ, Med Ctr, Div Neurol, Deane Drug Discovery Inst, Durham, NC 27710 USA. [Craft, Suzanne] Univ Washington, Sch Med, Ctr Geriatr Res Educ & Clin, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Craft, Suzanne] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Landreth, Gary] Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA. [Linnamaegi, Uella] Univ Tartu, Dept Neurol & Neurosurg, EE-50090 Tartu, Estonia. RP Gold, M (reprint author), GlaxoSmithKline Inc, Neurosci Med Dev Ctr, Res Triangle Pk, NC 27709 USA. EM michael.2.gold@gsk.com FU GlaxoSmithKline [NCT00428090, NCT00550420] FX Funding for these studies was provided by GlaxoSmithKline (NCT00428090 and NCT00550420). The authors wish to acknowledge the following: the participating subjects and their caregivers and the REFLECT-1 and REFLECT-5 study investigators; David Hosford, Marc Risner, CarlChiang, Conn Harrington, Carly Donovan and Barbara Jeter of GlaxoSmithKline for their contributions during the study and the study analysis, and Mary Richardson of GlaxoSmithKline for critical review during the development of the manuscript. Editorial support in the form of editorial suggestions on draft versions of this paper, assembling tables and figures, collating author comments and copyediting was provided by Ann Garvey, PhD, at UBC Evidence Solutions and was funded by GlaxoSmithKline. NR 61 TC 131 Z9 135 U1 3 U2 18 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2010 VL 30 IS 2 BP 131 EP 146 DI 10.1159/000318845 PG 16 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 651YR UT WOS:000281965700005 PM 20733306 ER PT J AU Teng, E Becker, BW Woo, E Cummings, JL Lu, PH AF Teng, Edmond Becker, Brian W. Woo, Ellen Cummings, Jeffrey L. Lu, Po H. TI Subtle Deficits in Instrumental Activities of Daily Living in Subtypes of Mild Cognitive Impairment SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE Mild cognitive impairment; Functional impairment; Activities of daily living; Memory performance; Executive function ID VASCULAR RISK-FACTORS; DATA SET UDS; ALZHEIMERS-DISEASE; OLDER-ADULTS; CLINICAL SUBTYPES; EVERYDAY FUNCTION; DEMENTIA; MCI; MEMORY; INDIVIDUALS AB Background/Aims: Greater cognitive and functional deficits in mild cognitive impairment (MCI) are associated with higher rates of dementia. We explored the relationship between these factors by comparing instrumental activities of daily living (IADLs) among cognitive subtypes of MCI and examining associations between IADL and neuropsychological indices. Methods: We analyzed data from 1,108 MCI and 3,036 normal control subjects included in the National Alzheimer's Coordinating Center Uniform Data Set who were assessed with the Functional Activities Questionnaire (FAQ). Results: IADL deficits were greater in amnestic than nonamnestic MCI, but within these subgroups, did not differ between those with single or multiple domains of cognitive impairment. FAQ indices correlated significantly with memory and processing speed/executive function. Conclusions: IADL deficits are present in both amnestic MCI and nonamnestic MCI but are not related to the number of impaired cognitive domains. These cross-sectional findings support previous longitudinal reports suggesting that cognitive and functional impairments in MCI may be independently associated with dementia risk. Copyright (C) 2010 S. Karger AG, Basel C1 [Teng, Edmond] Univ Calif Los Angeles, David Geffen Sch Med, Neurobehav Unit, Los Angeles, CA 90095 USA. [Teng, Edmond; Becker, Brian W.] Univ Calif Los Angeles, David Geffen Sch Med, Geriatr Res Educ & Clin Ctr, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Teng, Edmond; Woo, Ellen; Cummings, Jeffrey L.; Lu, Po H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Cummings, Jeffrey L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Teng, E (reprint author), W Los Angeles VA Healthcare Ctr, Neurobehav Unit 116AF, Bldg 500,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM eteng@ucla.edu FU National Institute on Aging [U01 AG016976, P50 AG16570]; Alzheimer's Disease Research Centers of California; Sidell-Kagan Foundation FX This research was supported by grants from the National Institute on Aging (U01 AG016976 to the National Alzheimer's Coordinating Center and P50 AG16570 to the Mary S. Easton Center for Alzheimer's Disease Research at UCLA), the Alzheimer's Disease Research Centers of California, and the Sidell-Kagan Foundation. We would like to thank Nathaniel Mercaldo for his assistance with data management. NR 55 TC 39 Z9 41 U1 2 U2 8 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 EI 1421-9824 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2010 VL 30 IS 3 BP 189 EP 197 DI 10.1159/000313540 PG 9 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 651YS UT WOS:000281965800001 PM 20798539 ER PT J AU Devier, DJ Villemarette-Pittman, N Brown, P Pelton, G Stern, Y Sano, M Devanand, DP AF Devier, Deidre J. Villemarette-Pittman, Nicole Brown, Patrick Pelton, Gregory Stern, Yaakov Sano, Mary Devanand, D. P. TI Predictive Utility of Type and Duration of Symptoms at Initial Presentation in Patients with Mild Cognitive Impairment SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE Age at onset; Alzheimer's disease; Behavioral symptoms; Mild cognitive impairment; Neuropsychological assessment ID ALZHEIMERS-DISEASE; MEMORY COMPLAINTS; OBJECTIVE MEMORY; DEMENTIA; ONSET; CONVERSION; DIAGNOSIS; AGE; COMMUNITY; ANOSOGNOSIA AB Background/Aims: To assess (1) the duration and symptoms present in participants with mild cognitive impairment (MCI) and (2) the impact of these variables on predicting conversion to Alzheimer's disease (AD). Methods: Participants with MCI (n = 148) were assessed and followed systematically. Results: Decline in memory was reported as the first symptom in 118 of the cases. Converters had more symptoms (e. g. language decline, depression), and the combination of decline in memory and in performance of high-order social/cognitive activities as well as disorientation more often than non-converters (p = 0.036). In an age-stratified Cox model, predictors of conversion to AD were shorter time since onset of memory decline and lower baseline MMSE score. Conclusions: Recent onset of memory decline with older age, decreased MMSE score, change in performance and disorientation indicate a greater likelihood of short-term conversion to AD. Copyright (C) 2010 S. Karger AG, Basel C1 [Devier, Deidre J.; Villemarette-Pittman, Nicole] Louisiana State Univ, Hlth Sci Ctr, Dept Neurol, New Orleans, LA 70112 USA. [Brown, Patrick; Pelton, Gregory; Stern, Yaakov; Devanand, D. P.] Columbia Univ Coll Phys & Surg, Div Geriatr Psychiat, New York, NY 10032 USA. [Brown, Patrick; Pelton, Gregory; Stern, Yaakov; Devanand, D. P.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. [Brown, Patrick; Pelton, Gregory; Stern, Yaakov; Devanand, D. P.] Taub Inst Res Alzheimers Dis & Aging Brain, Sergievsky Ctr, Dept Neurol, New York, NY USA. [Sano, Mary] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Sano, Mary] Mt Sinai Sch Med, Alzheimers Dis Res Ctr, New York, NY USA. [Sano, Mary] James J Peters VA Med Ctr, Dept Neurol, Bronx, NY USA. RP Devier, DJ (reprint author), Louisiana State Univ, Hlth Sci Ctr, Dept Neurol, 1542 Tulane Ave,Floor 7, New Orleans, LA 70112 USA. EM ddevie@lsuhsc.edu FU National Institute on Aging [R01AG17761] FX This study was supported in part by grant No. R01AG17761 from the National Institute on Aging. NR 40 TC 9 Z9 11 U1 2 U2 5 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 EI 1421-9824 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2010 VL 30 IS 3 BP 238 EP 244 DI 10.1159/000320137 PG 7 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 651YS UT WOS:000281965800007 PM 20847554 ER PT J AU Chuang, YF Hayden, KM Norton, MC Tschanz, J Breitner, JCS Welsh-Bohmer, KA Zandi, PP AF Chuang, Yi-Fang Hayden, Kathleen M. Norton, Maria C. Tschanz, Joann Breitner, John C. S. Welsh-Bohmer, Kathleen A. Zandi, Peter P. CA Cache County Investigators TI Association between APOE epsilon 4 Allele and Vascular Dementia: The Cache County Study SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS LA English DT Article DE APOE; Vascular dementia ID APOLIPOPROTEIN-E POLYMORPHISM; ALZHEIMERS-DISEASE; POPULATION; CHOLESTEROL; FREQUENCY; QUESTIONNAIRE; RELIABILITY; PREVALENCE; GENOTYPE; VALIDITY AB Background: The APOE epsilon 4 allele is an established risk factor for Alzheimer's disease, but reports of its association with vascular dementia (VaD) have been inconsistent. We examined the relationship between APOE epsilon 4 allele and the risk of incident VaD in a large, population-based cohort of elderly adults with up to 10 years of follow-up between 1995 and 2005. Methods: A total of 3,424 elderly men and women free of dementia were genotyped at the baseline assessment. Incident VaD was identified through standardized procedures administered at 3 follow-up assessments. Cox proportional hazards models were used to evaluate the risk of VaD associated with APOE epsilon 4. Results: The adjusted hazard ratio was 1.6 for the participants with 1 APOE epsilon 4 allele (95% CI: 0.9-2.7; p = 0.083) and 4.4 for those with 2 APOE epsilon 4 alleles ( 95% CI: 1.6-12.5; p = 0.005). The increased risk did not appear to be mediated by vascular risk factors. Conclusions: The APOE epsilon 4 allele is associated with an increased risk of VaD in a dose-dependent fashion and accounts for almost 20% of VaD in the population. Copyright (C) 2010 S. Karger AG, Basel C1 [Chuang, Yi-Fang; Zandi, Peter P.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Hayden, Kathleen M.; Welsh-Bohmer, Kathleen A.] Duke Univ, Med Ctr, Durham, NC USA. [Breitner, John C. S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Breitner, John C. S.] Univ Washington, Seattle, WA 98195 USA. [Norton, Maria C.; Tschanz, Joann] Utah State Univ, Logan, UT 84322 USA. RP Zandi, PP (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Hampton House,Room 857,624 N Broadway, Baltimore, MD 21205 USA. EM pzandi@jhsph.edu RI Tschanz, JoAnn/E-5986-2010; Norton, Maria/E-6994-2013 FU National Institute of Aging [R01 AG11380] FX We would like to thank all of the study participants for their contributions to this work. We are grateful to the neurogenetics laboratory of the Bryan Alzheimer's Disease Research Center at Duke University for APOE genotyping. We would also like to thank study coordinators Nancy Sassano ( Utah State University) and Michelle McCart ( Duke University); and Cara Brewer, Tony Calvert, Tiffany Newman, Roxane Pfister, Sarah Schwartz, and Joslin Werstak, of Utah State University for their expert technical assistance in data collection and entry. The work on this study was support by a grant from the National Institute of Aging (R01 AG11380) NR 40 TC 27 Z9 28 U1 2 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1420-8008 J9 DEMENT GERIATR COGN JI Dement. Geriatr. Cogn. Disord. PY 2010 VL 29 IS 3 BP 248 EP 253 DI 10.1159/000285166 PG 6 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 584WA UT WOS:000276783100008 PM 20375505 ER PT J AU Bendlin, BB Fitzgerald, ME Ries, ML Xu, GF Kastman, EK Thiel, BW Rowley, HA Lazar, M Alexander, AL Johnson, SC AF Bendlin, Barbara B. Fitzgerald, Michele E. Ries, Michele L. Xu, Guofan Kastman, Erik K. Thiel, Brent W. Rowley, Howard A. Lazar, Mariana Alexander, Andrew L. Johnson, Sterling C. TI White Matter in Aging and Cognition: A Cross-Sectional Study of Microstructure in Adults Aged Eighteen to Eighty-Three SO DEVELOPMENTAL NEUROPSYCHOLOGY LA English DT Article ID ANTERIOR THALAMIC NUCLEI; HUMAN CEREBRAL-CORTEX; DIFFUSION-TENSOR MRI; OLDER-ADULTS; ALZHEIMERS-DISEASE; WORKING-MEMORY; TEMPORAL-LOBE; NEUROPSYCHOLOGICAL PERFORMANCE; FRACTIONAL ANISOTROPY; LONGITUDINAL CHANGES AB Structural brain change and concomitant cognitive decline are the seemingly unavoidable escorts of aging. Despite accumulating studies detailing the effects of age on the brain and cognition, the relationship between white matter features and cognitive function in aging have only recently received attention and remain incompletely understood. White matter microstructure can be measured with diffusion tensor imaging (DTI), but whether DTI can provide unique information on brain aging that is not explained by white matter volume is not known. In the current study, the relationship between white matter microstructure, age, and neuropsychological function was assessed using DTI in a statistical framework that employed white matter volume as a voxel-wise covariate in a sample of 120 healthy adults across a broad age range (18-83). Memory function and executive function were modestly correlated with the DTI measures while processing speed showed the greatest extent of correlation. The results suggest that age-related white matter alterations underlie age-related declines in cognitive function. Mean diffusivity and fractional anisotropy in several white matter brain regions exhibited a nonlinear relationship with age, while white matter volume showed a primarily linear relationship with age. The complex relationships between cognition, white matter microstructure, and white matter volume still require further investigation. C1 [Bendlin, Barbara B.; Fitzgerald, Michele E.; Ries, Michele L.; Xu, Guofan; Kastman, Erik K.; Thiel, Brent W.; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Bendlin, Barbara B.; Fitzgerald, Michele E.; Ries, Michele L.; Xu, Guofan; Kastman, Erik K.; Thiel, Brent W.; Johnson, Sterling C.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI USA. [Rowley, Howard A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Radiol, Madison, WI USA. [Lazar, Mariana] NYU, Sch Med, Dept Radiol, New York, NY USA. [Alexander, Andrew L.] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Alexander, Andrew L.] Univ Wisconsin, Dept Psychiat, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Alexander, Andrew L.] Waisman Lab Brain Imaging & Behav, Madison, WI USA. RP Johnson, SC (reprint author), William S Middleton Mem VA Hosp, GRECC, 2500 Overlook Terrace 11G, Madison, WI 53705 USA. EM scj@medicine.wisc.edu RI Kastman, Erik/N-6645-2016 OI Kastman, Erik/0000-0001-7221-9042; Lazar, Mariana/0000-0001-9285-8124; Bendlin, Barbara/0000-0002-0580-9875; Johnson, Sterling/0000-0002-8501-545X FU Department of Veterans Affairs [R01 MH 65723, ROI AG021155-01] FX This study was supported by a Merit Review Grant from the Department of Veterans Affairs, R01 MH 65723, ROI AG021155-01 (SCJ), and by the facilities and resources at the William S. Middleton Memorial Veterans Hospital; GRECC manuscript number 2009-15. NR 82 TC 58 Z9 62 U1 2 U2 9 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 8756-5641 J9 DEV NEUROPSYCHOL JI Dev. Neuropsychol. PY 2010 VL 35 IS 3 BP 257 EP 277 AR PII 921878108 DI 10.1080/87565641003696775 PG 21 WC Psychology, Developmental; Psychology; Psychology, Experimental SC Psychology GA 594EX UT WOS:000277518100003 PM 20446132 ER PT J AU Kahn, SE Haffner, SM Viberti, G Herman, WH Lachin, JM Kravitz, BG Yu, DH Paul, G Holman, RR Zinman, B AF Kahn, Steven E. Haffner, Steven M. Viberti, Giancarlo Herman, William H. Lachin, John M. Kravitz, Barbara G. Yu, Dahong Paul, Gitanjali Holman, Rury R. Zinman, Bernard CA Diabet Outcome Progression Trial A TI Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain: Observations from A Diabetes Outcome Progression Trial (ADOPT) SO DIABETES CARE LA English DT Article ID INSULIN-RESISTANCE ATHEROSCLEROSIS; INTIMA-MEDIA THICKNESS; CORONARY-HEART-DISEASE; ENDOTHELIAL DYSFUNCTION; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; GAMMA-AGONIST; PIOGLITAZONE; INFLAMMATION; RISK AB OBJECTIVE - C-reactive protein (CRP) is closely associated with obesity and cardiovascular disease in both diabetic and nondiabetic populations. In the short term, commonly prescribed antidiabetic agents have different effects on CRP; however, the long-term effects of those agents are unknown. RESEARCH DESIGN AND METHODS - In A Diabetes Outcome Progression Trial (ADOPT), we examined the long-term effects of rosiglitazone, glyburide, and metformin on CRP and the relationship among CRP, weight, and glycemic variables in 904 subjects over 4 years. RESULTS - Baseline CRP was significantly correlated with homeostasis model assessment of insulin resistance (HOMA-IR), A1C, BMI, waist circumference, and waist-to-hip ratio. p reduction was greater in the rosiglitazone group by -47.6% relative to glyburide and by -30.5% relative to metformin at 48 months. Mean weight gain from baseline (at 48 months) was 5.6 g with rosiglitazone, 1.8 kg with glyburide, and -2.8 kg with metformin. The change in CRP from baseline to 12 months was correlated positively with change in BMI in glyburide (r = 0.18) and metformin(r = 0.20) groups but not in the rosiglitazone(r = -0.05, NS) group. However, there was no longer a significant correlation between change in CRP and change in HOMA-IR, A1C, or waist-to-hip ratio in any Of the three treatment groups. CONCLUSIONS - Rosiglitazone treatment was associated with durable reductions in CRP independent of changes in insulin sensitivity, A1C, and weight gain. CRP in the glyburide and metformin groups was positively associated with changes in weight, but this was not the case with rosiglitazone. C1 [Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Haffner, Steven M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Viberti, Giancarlo] Kings Coll London, Sch Med, London WC2R 2LS, England. [Herman, William H.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Herman, William H.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Lachin, John M.] George Washington Univ, Ctr Biostat, Rockville, MD USA. [Kravitz, Barbara G.; Yu, Dahong; Paul, Gitanjali] GlaxoSmithKline Inc, King Of Prussia, PA USA. [Holman, Rury R.] Oxford Ctr Diabet Endocrinol & Metab, Diabet Trials Unit, Oxford, England. [Zinman, Bernard] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON, Canada. [Zinman, Bernard] Univ Toronto, Toronto, ON M5S 1A1, Canada. RP Kahn, SE (reprint author), VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA USA. EM skahn@u.washington.edu RI Zinman, Bernard/E-7266-2013 OI Lachin, John/0000-0001-9838-2841; Kahn, Steven/0000-0001-7307-9002 FU GlaxoSmithKline (GSK); GSK FX ADOPT was overseen by a steering committee comprised of Steven Kahn, Giancarlo Viberti (cochairs), Steven Haffner, William Herman, Rury Holman, Nigel Jones, John Lachin, Colleen O'Neill, and Bernard Zinman, The study was supported by funds from GlaxoSmithKline (GSK). S.E.K., S.M.H., G.V., W.H.H., J.M.L., R.R.H,, and B.Z. received honoraria, consulting fees, and/or grant/research support from GSK. B.G.K., DY, and G.P. are employees of GSK. No other potential conflicts of interest relevant to this article were reported. NR 36 TC 22 Z9 22 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 2010 VL 33 IS 1 BP 177 EP 183 DI 10.2337/dc09-1661 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 544AA UT WOS:000273622200036 PM 19808911 ER PT J AU Pandol, SJ Gorelick, FS Gerloff, A Lugea, A AF Pandol, Stephen J. Gorelick, Fred S. Gerloff, Andreas Lugea, Aurelia TI Alcohol Abuse, Endoplasmic Reticulum Stress and Pancreatitis SO DIGESTIVE DISEASES LA English DT Article DE Pancreas; Pancreatitis; Unfolded protein response; Alcohol; Smoking ID INFLAMMATORY-BOWEL-DISEASE; C-ALPHA PHOSPHORYLATION; STELLATE CELLS; BASOLATERAL EXOCYTOSIS; CIGARETTE-SMOKING; ACINAR-CELLS; ZYMOGEN ACTIVATION; ETHANOL DIET; RISK-FACTOR; ER STRESS AB Alcohol abuse is a common cause of both acute and chronic pancreatitis. There is a wide spectrum of pancreatic manifestations in heavy drinkers from no apparent disease in most individuals to acute inflammatory and necrotizing pancreatitis in a minority of individuals with some progressing to chronic pancreatitis characterized by replacement of the gland by fibrosis and chronic inflammation. Both smoking and African-American ethnicity are associated with increased risk of alcoholic pancreatitis. In this review we describe how our recent studies demonstrate that ethanol feeding in rodents causes oxidative stress in the endoplasmic reticulum (ER) of the digestive enzyme synthesizing acinar cell of the exocrine pancreas. This ER stress is attenuated by a robust unfolded protein response (UPR) involving X-box binding protein-1 (XBP1) in the acinar cell. When the UPR activation is prevented by genetic reduction in XBP1, ethanol feeding causes significant pathological responses in the pancreas. These results suggest that the reason most individuals who drink alcohol heavily do not get significant pancreatic disease is because the pancreas mounts an adaptive UPR to attenuate the ER stress that ethanol causes. We hypothesize that disease in the pancreas results when the UPR is insufficiently robust to alleviate the ER stress caused by alcohol abuse. Copyright (C) 2011 S. Karger AG, Basel C1 [Pandol, Stephen J.] Univ Calif Los Angeles, Dept Vet Affairs, UCLA Ctr Excellence Pancreat Dis, So Calif Res Ctr Alcohol Liver Pancreat Dis & Cir, Los Angeles, CA 90073 USA. [Pandol, Stephen J.; Gerloff, Andreas; Lugea, Aurelia] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Gorelick, Fred S.] Yale Univ, Dept Med, West Haven, CT USA. [Gorelick, Fred S.] Yale Univ, Dept Cell Biol, West Haven, CT USA. [Gorelick, Fred S.] New England VA Hlth Care Syst, West Haven, CT USA. RP Pandol, SJ (reprint author), Univ Calif Los Angeles, Dept Vet Affairs, UCLA Ctr Excellence Pancreat Dis, So Calif Res Ctr Alcohol Liver Pancreat Dis & Cir, Bldg 258,Rm 340,11310 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Stephen.pandol@va.gov FU Department of Veterans Affairs; Greater Los Angeles Healthcare System; USC-UCLA Southern California Research Center for ALPD and Cirrhosis [P60 AA11999]; UCLA Center for Excellence in Pancreatic Diseases [P01AT003960]; National Institute of Health, NIDDK [1R21 AA016010-01] FX The authors acknowledge support from the Department of Veterans Affairs, Greater Los Angeles Healthcare System, USC-UCLA Southern California Research Center for ALPD and Cirrhosis (P60 AA11999), UCLA Center for Excellence in Pancreatic Diseases (P01AT003960), and National Institute of Health, NIDDK (1R21 AA016010-01). NR 72 TC 26 Z9 26 U1 0 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0257-2753 J9 DIGEST DIS JI Dig. Dis. PY 2010 VL 28 IS 6 BP 776 EP 782 DI 10.1159/000327212 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 757ND UT WOS:000290093200011 PM 21525762 ER PT J AU Gerloff, A Feick, P Singer, MV AF Gerloff, Andreas Feick, Peter Singer, Manfred V. TI Pancreas - Non-Alcoholic Constituents and Their Effects SO DIGESTIVE DISEASES LA English DT Article DE Non-alcoholic constituents of alcoholic beverages; Alcoholic beverages and pancreatitis; Beer and pancreatic secretion ID ALCOHOLIC PANCREATITIS; ENZYME SECRETION; ACINAR-CELLS; IN-VITRO; EXOCRINE PANCREAS; DRINKING HABITS; RISK-FACTORS; BEER; BEVERAGES; ETHANOL AB Alcoholic beverages contain numerous non-alcoholic compounds that could have beneficial or pathological effects. For example, up to now in beer more than 2,000 and in wine more than 1,000 organic and inorganic constituents have been identified. Whereas the role of alcohol (ethanol) in the development of pancreatic diseases-in particular acute and chronic pancreatitis-has been intensively investigated, only little is known about the effects of non-alcoholic compounds in this context. Some of the non-alcoholic constituents have been shown to be biologically active, although discussions of the results in appropriate publications were often not performed with regard to their consumption as a mixture in alcoholic beverages. In this article we provide an overview about the newest data concerning the effect of non-alcoholic constituents of alcoholic beverages, especially of beer, on pancreatic secretion and their possible role in alcoholic pancreatitis. The data indicate that non-alcoholic constituents of beer stimulate pancreatic enzyme secretion in humans and rats, at least in part, by direct action on pancreatic acinar cells. However, there is accumulating evidence that non-alcoholic compounds of alcoholic beverages exert different effects on the pancreas. The effects and mechanisms of most single compounds and their combinations are still unknown and thus caution is required in attempting to draw firm conclusions on the effect of non-alcoholic compounds of alcoholic beverages on defining alcoholic etiology of pancreatitis. Copyright (C) 2011 S. Karger AG, Basel C1 [Gerloff, Andreas; Feick, Peter; Singer, Manfred V.] Univ Heidelberg Hosp, Dept Med 2, D-68135 Mannheim, Germany. [Gerloff, Andreas] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Gerloff, Andreas] Univ Calif Los Angeles, Los Angeles, CA USA. RP Gerloff, A (reprint author), LA Healthcare Syst, UCLA Med VA Greater, Bldg 258,Room 340,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM andreas_gerloff@web.de NR 28 TC 0 Z9 0 U1 1 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0257-2753 J9 DIGEST DIS JI Dig. Dis. PY 2010 VL 28 IS 6 BP 812 EP 819 DI 10.1159/000324290 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 757ND UT WOS:000290093200016 PM 21525767 ER PT J AU Henderson, LM Patel, S Giordano, TP Green, L El-Serag, HB AF Henderson, Louise M. Patel, Shital Giordano, Thomas P. Green, Linda El-Serag, Hashem B. TI Statin Therapy and Serum Transaminases Among a Cohort of HCV-Infected Veterans SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Hepatitis C virus; Statins; Transaminases; Veterans ID VIRUS-RNA REPLICATION; HEPATITIS-C VIRUS; LIVER-DISEASE; SAFETY; HEPATOTOXICITY; GERANYLGERANYLATION; REDUCTASE; TRIAL; CELLS AB Background We sought to determine the effect of statin therapy on serum AST and ALT levels in a cohort of HCV-infected veterans with well-characterized liver disease. Study We examined liver biopsy records of consecutive HCV-infected patients and identified 20 patients who were prescribed statins. We matched them on age, stage of fibrosis, and time between HCV diagnosis and statin start dates with up to four HCV-infected patients who did not use statins. ALT and AST values from up to four time points within 1 year of follow-up were abstracted from the medical record. We compared median ALT and AST levels using Wilcoxon-Mann-Whitney tests and assessed changes in ALT and AST over time between the statin and non-statin groups using a non-parametric repeated measures ANOVA model, adjusting for the matching factors, receipt of HCV treatment, BMI, and diabetes. Results Patients prescribed statins had higher median BMIs, were more likely to have diabetes, and had higher total cholesterol levels. Median baseline ALT levels were higher among those prescribed statins (P = 0.04) while median baseline AST levels were lower among statin users (P = 0.03). From baseline to follow-up, the median decreases in both ALT (-13.5 vs. -4.0) and AST (-4.5 vs. -0.5) were significantly larger among statin users compared to non-statin users ( P = 0.03 and P = 0.0007, respectively) even after adjustment. Conclusions Among HCV-infected patients AST and ALT levels for those prescribed statins decreased over a 6 to 12-month follow-up period compared to patients not taking statins. C1 [Henderson, Louise M.; Giordano, Thomas P.; El-Serag, Hashem B.] Dept Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX 77030 USA. [Henderson, Louise M.; Patel, Shital; Giordano, Thomas P.; El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Green, Linda] Michael E DeBakey VA Med Ctr, Dept Pathol, Houston, TX USA. RP El-Serag, HB (reprint author), Dept Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston Vet Affairs Med Ctr 152,2002 Holcombe Blv, Houston, TX 77030 USA. EM hasheme@bcm.edu FU NIH [K24DK078154-03, DK56338]; Texas Medical Center Digestive Disease Center FX The work was partly supported by NIH K24DK078154-03 for Dr. El-Serag, and Public Health Service Grant DK56338, which funds the Texas Medical Center Digestive Disease Center. NR 25 TC 24 Z9 24 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD JAN PY 2010 VL 55 IS 1 BP 190 EP 195 DI 10.1007/s10620-009-0959-1 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 542TZ UT WOS:000273520500031 PM 19731022 ER PT J AU Fintelmann, RE Naseri, A AF Fintelmann, Robert E. Naseri, Ayman TI Prophylaxis of Postoperative Endophthalmitis Following Cataract Surgery Current Status and Future Directions SO DRUGS LA English DT Review ID VIGAMOX(R) MOXIFLOXACIN 0.5-PERCENT; ACUTE-ONSET ENDOPHTHALMITIS; NATIONAL PROSPECTIVE SURVEY; OCULAR SURFACE FLUID; HUMAN AQUEOUS-HUMOR; PREVENTING ENDOPHTHALMITIS; RISK-FACTORS; INTRACAMERAL MOXIFLOXACIN; POVIDONE-IODINE; VISUAL OUTCOMES AB Endophthalmitis is an uncommon but potentially devastating intraocular infection that can occur after routine cataract surgery. Although a broad spectrum of organisms have been shown to cause acute postoperative endophthalmitis, most cases are caused by Gram-positive bacteria, which may be introduced at the time of surgery from colonization of adjacent conjunctiva or eyelid skin. Risk factors for the development of endophthalmitis following cataract surgery include patient age, intraoperative surgical complications and poor wound construction. There are several antibacterial strategies employed to prevent postoperative endophthalmitis, with topical, intracameral and subconjunctival delivery being the most common. Worldwide, there seems to be significant regional variance in the type and method of prophylactic antibacterial regimens; for example, topical fluoroquinolones are commonly used in the US, while intracameral cephalosporins are employed widely in Europe. The optimal antibacterial strategy for the prevention of endophthalmitis should be safe, inexpensive and broad in microbiological activity spectrum, while not requiring patient compliance for its effectiveness. C1 [Naseri, Ayman] San Francisco Vet Adm Med Ctr, Dept Ophthalmol, San Francisco, CA 94121 USA. [Fintelmann, Robert E.; Naseri, Ayman] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA. [Fintelmann, Robert E.; Naseri, Ayman] Univ Calif San Francisco, Francis I Proctor Fdn Res Ophthalmol, San Francisco, CA 94143 USA. RP Naseri, A (reprint author), San Francisco Vet Adm Med Ctr, Dept Ophthalmol, 4150 Clement St, San Francisco, CA 94121 USA. EM ayman.naseri@va.gov NR 78 TC 14 Z9 18 U1 0 U2 5 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 0012-6667 J9 DRUGS JI Drugs PY 2010 VL 70 IS 11 BP 1395 EP 1409 PG 15 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 640RC UT WOS:000281068600005 PM 20614947 ER PT J AU Albert, SM Colombi, A Hanlon, J AF Albert, Steven M. Colombi, Alberto Hanlon, Joseph TI Potentially Inappropriate Medications and Risk of Hospitalization in Retirees Analysis of a US Retiree Health Claims Database SO DRUGS & AGING LA English DT Article ID OLDER-PEOPLE; EXPLICIT CRITERIA; CONSENSUS PANEL; BEERS CRITERIA; ELDERLY-PEOPLE; QUALITY; DRUGS AB Background and Objective: One important health outcome of inappropriate medication use in the elderly is risk of hospitalization. We examined this relationship over 3 years in a retiree health claims database to determine the strength of this association using alternative definitions of potentially inappropriate medications. Methods: Prescription and hospitalization claims for US retirees from a single large corporation were examined over the 3-year period, 2003-5. Purging the database of non-employees (dependents, spouses), employees aged <65 years (who were not Medicare-eligible) and retirees not covered for the full 3-year period left a sample of 7459 retirees. Respondents' medications were categorized according to two lists of 'drugs to avoid': Beers (2003 update) and the National Committee for Quality Assurance (NCQA). Logistic regression models were developed to examine risk of hospitalization in 2005 relative to use of potentially inappropriate medications across different periods of follow-up. Results: Retirees taking one or more of the potentially inappropriate medications on the Beers or NCQA lists were 1.8-1.9 times more likely to have a hospital admission in models that adjusted for age, gender, number of prescriptions overall and aggregate disease severity. Risk of hospitalization increased in a dose-response relationship according to number of potentially inappropriate medications. Conclusion: Consistency in the strength of the association between 'drugs to avoid' and hospital admission across different definitions of inappropriate medication use suggests the finding is robust. Findings from the retiree cohort provide further evidence for the inappropriateness of these medications among the elderly. C1 [Albert, Steven M.] Univ Pittsburgh, Dept Behav & Community Hlth Sci, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA. [Colombi, Alberto] PPG Ind Inc, Pittsburgh, PA USA. [Hanlon, Joseph] Univ Pittsburgh, Dept Geriatr Med, Sch Med, Pittsburgh, PA 15261 USA. [Hanlon, Joseph] Univ Pittsburgh, Dept Pharm & Therapeut, Sch Pharm, Pittsburgh, PA 15261 USA. [Hanlon, Joseph] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Geriatr Res Educ, Pittsburgh, PA USA. [Hanlon, Joseph] Vet Affairs Pittsburgh Healthcare Syst, Ctr Clin, Pittsburgh, PA USA. RP Albert, SM (reprint author), Univ Pittsburgh, Dept Behav & Community Hlth Sci, Grad Sch Publ Hlth, A211 Crabtree Hall,120 DeSoto Ave, Pittsburgh, PA 15261 USA. EM smalbert@pitt.edu OI Albert, Steven/0000-0001-6786-9956 FU National Institute of Aging [R01 AG027017, P30 AG024827]; VA Health Services Research [IIR-06-062] FX Chongji Wei assisted with data pre-processing. PPG Industries, Inc., provided retiree data through Healthcare Business of Thomson Reuters.; This study was supported in part by National Institute of Aging grants R01 AG027017 and P30 AG024827 and VA Health Services Research grant IIR-06-062.; The authors have no conflicts of interest that are directly relevant to the content of this study. NR 23 TC 42 Z9 42 U1 0 U2 5 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1170-229X EI 1179-1969 J9 DRUG AGING JI Drugs Aging PY 2010 VL 27 IS 5 BP 407 EP 415 PG 9 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 605NX UT WOS:000278355400005 PM 20450238 ER PT J AU Richardson, DM Bain, KT Diamond, JJ Novielli, KD Lee, SP Goldfarb, NI AF Richardson, Diane M. Bain, Kevin T. Diamond, James J. Novielli, Karen D. Lee, Seina P. Goldfarb, Neil I. TI Effectiveness of Guideline-Recommended Cardiac Drugs for Reducing Mortality in the Elderly Medicare Heart Failure Population A Retrospective, Survey-Weighted, Cohort Analysis SO DRUGS & AGING LA English DT Article ID VENTRICULAR EJECTION FRACTIONS; OBSTRUCTIVE PULMONARY-DISEASE; CONVERTING ENZYME-INHIBITORS; MYOCARDIAL-INFARCTION; RANDOMIZED-TRIAL; ACE-INHIBITORS; OLDER PATIENTS; CO-MORBIDITY; SURVIVAL; ENALAPRIL AB Background: Heart failure (HF) management guidelines recommend that most patients with HF receive an ACE inhibitor or an angiotensin II type 1 receptor antagonist (angiotensin receptor blocker [ARB]) and a beta-blocker (beta-adrenoceptor antagonist), collectively referred to as 'cardiac drugs', based on results from randomized controlled trials showing that these drugs reduce mortality. However, the results of randomized controlled trials may not be generalizable to the population most likely (i.e. the elderly) to receive these drugs in clinical practice. Objective: To determine the effectiveness of cardiac drugs for reducing mortality in the elderly Medicare HF population. Study Design: Retrospective, survey-weighted, cohort analysis of the 2002 Medicare Current Beneficiary Survey Cost and Use files. Participants: 12 697 beneficiaries, of whom 1062 had a diagnosis of HF and 577 were eligible to receive cardiac drugs. Measurements: Association between mortality and cardiac drugs, adjusted for sociodemographics, co-morbidity and propensity to receive cardiac drugs. Results: The mortality rate among the 577 eligible beneficiaries with HF was 9.7%. The mortality rate for those receiving an ACE inhibitor or ARB alone, a beta-blocker alone, or both an ACE inhibitor or ARB and a beta-blocker, was 6.1%, 5.9% and 5.3%, respectively; in the absence of any of the three cardiac drugs, the mortality rate was 20.0% (p < 0.0001). In multivariable analyses, ARB mortality rates remained significantly lower for beneficiaries receiving an ACE inhibitor or ARB alone (odds ratio [OR] 0.24; 95% CI 0.11, 0.50), a beta-blocker alone (OR 0.17; 95% CI 0.07, 0.41), or both an ACE inhibitor or ARB and a beta-blocker (OR 0.24; 95% CI 0.10, 0.55) compared with patients who did not receive any of the three cardiac drugs. Conclusions: Use of guideline-recommended cardiac drugs is associated with reduced mortality in the elderly Medicare HF population. Providing evidence of the benefit of cardiac drugs among the elderly with HF will become increasingly important as the size of the Medicare population grows. C1 [Goldfarb, Neil I.] Thomas Jefferson Univ, Sch Populat Hlth, Philadelphia, PA 19107 USA. [Richardson, Diane M.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Bain, Kevin T.] excelleRx Inc, Philadelphia, PA USA. [Diamond, James J.; Novielli, Karen D.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Family & Community Med, Philadelphia, PA 19107 USA. [Lee, Seina P.] Johnson & Johnson Pharmaceut Serv, Horsham, PA USA. RP Goldfarb, NI (reprint author), Thomas Jefferson Univ, Sch Populat Hlth, 1015 Walnut St,Suite 115, Philadelphia, PA 19107 USA. EM neil.goldfarb@jefferson.edu FU excelleRx Inc. FX This research was supported by a grant from excelleRx Inc., an Omnicare company. Kevin T. Bain is an employee of excelleRx Inc. and has received honoraria from Eisai for consultancy services. Seina P. Lee is an employee of Johnson & Johnson Pharmaceutical Services. Some of these findings were presented at the International Society for Pharmacoeconomics and Outcomes Research 13th Annual International Meeting, Toronto, Ontario, Canada, 3-7 May 2008. NR 41 TC 6 Z9 6 U1 0 U2 1 PU S INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1170-229X J9 DRUG AGING JI Drugs Aging PY 2010 VL 27 IS 10 BP 845 EP 854 PG 10 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 672VA UT WOS:000283613800007 PM 20883064 ER PT B AU Handforth, A AF Handforth, Adrian BE Kompoliti, K Metman, LV TI Harmaline Tremor Model SO ENCYCLOPEDIA OF MOVEMENT DISORDERS, VOL 2: H-P LA English DT Article; Book Chapter ID INFERIOR OLIVARY NEURONS; SYSTEM; RATS C1 Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Handforth, A (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. NR 15 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-12-374105-9; 978-0-12-374101-1 PY 2010 BP 9 EP 12 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA BA3XC UT WOS:000335076600005 ER PT B AU Hu, SC Kim, HM Samii, A AF Hu, S. C. Kim, H. M. Samii, A. BE Kompoliti, K Metman, LV TI Manganese SO ENCYCLOPEDIA OF MOVEMENT DISORDERS, VOL 2: H-P LA English DT Article; Book Chapter ID INDUCED PARKINSONISM; NEUROTOXICITY; SCIENCE C1 [Hu, S. C.; Kim, H. M.; Samii, A.] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Kim, H. M.; Samii, A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Hu, SC (reprint author), Univ Washington, Sch Med, Seattle, WA 98195 USA. NR 12 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-12-374105-9; 978-0-12-374101-1 PY 2010 BP 155 EP 159 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA BA3XC UT WOS:000335076600050 ER PT B AU Walker, RH AF Walker, R. H. BE Kompoliti, K Metman, LV TI McLeod Syndrome SO ENCYCLOPEDIA OF MOVEMENT DISORDERS, VOL 2: H-P LA English DT Article; Book Chapter ID NEUROACANTHOCYTOSIS C1 [Walker, R. H.] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Walker, R. H.] Mt Sinai Sch Med, New York, NY USA. RP Walker, RH (reprint author), James J Peters VA Med Ctr, Bronx, NY 10468 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-12-374105-9; 978-0-12-374101-1 PY 2010 BP 162 EP 164 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA BA3XC UT WOS:000335076600052 ER PT B AU Walker, RH AF Walker, R. H. BE Kompoliti, K Metman, LV TI Neuroacanthocytosis Syndromes SO ENCYCLOPEDIA OF MOVEMENT DISORDERS, VOL 2: H-P LA English DT Article; Book Chapter C1 [Walker, R. H.] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Walker, R. H.] Mt Sinai Sch Med, Nyc, NY USA. RP Walker, RH (reprint author), James J Peters VA Med Ctr, Bronx, NY 10468 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-12-374105-9; 978-0-12-374101-1 PY 2010 BP 259 EP 261 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA BA3XC UT WOS:000335076600083 ER PT B AU Walker, RH AF Walker, R. H. BE Kompoliti, K Metman, LV TI Torsin A SO ENCYCLOPEDIA OF MOVEMENT DISORDERS, VOL 3: Q-Z LA English DT Article; Book Chapter ID DYSTONIA C1 [Walker, R. H.] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Walker, R. H.] Mt Sinai Sch Med, New York, NY USA. RP Walker, RH (reprint author), James J Peters VA Med Ctr, Bronx, NY 10468 USA. NR 6 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-12-374105-9; 978-0-12-374101-1 PY 2010 BP 243 EP 247 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA BA3XF UT WOS:000335076900077 ER PT J AU Ribeiro, MO Bianco, SDC Kaneshige, M Schultz, JJ Cheng, SY Bianco, AC Brent, GA AF Ribeiro, Miriam O. Bianco, Suzy D. C. Kaneshige, Masahiro Schultz, James J. Cheng, Sheue-yann Bianco, Antonio C. Brent, Gregory A. TI Expression of Uncoupling Protein 1 in Mouse Brown Adipose Tissue Is Thyroid Hormone Receptor-beta Isoform Specific and Required for Adaptive Thermogenesis SO ENDOCRINOLOGY LA English DT Article ID DIET-INDUCED THERMOGENESIS; IODOTHYRONINE DEIODINASES; BODY-TEMPERATURE; RESPONSE ELEMENT; GENE-EXPRESSION; MICE; TRIIODOTHYRONINE; MUTANT; CHOLESTEROL; ACTIVATION AB Cold-induced adaptive (or nonshivering) thermogenesis in small mammals is produced primarily in brown adipose tissue (BAT). BAT has been identified in humans and becomes more active after cold exposure. Heat production from BAT requires sympathetic nervous system stimulation, T-3, and uncoupling protein 1 (UCP1) expression. Our previous studies with a thyroid hormone receptor-beta (TR beta) isoform-selective agonist demonstrated that after TR-beta stimulation alone, adaptive thermogenesis was markedly impaired, although UCP-1 expression in BAT was normal. We used mice with a dominant-negative TR beta PV mutation (frameshift mutation in resistance to thyroid hormone patient PV) to determine the role of TR beta in adaptive thermogenesis and UCP1 expression. Wild-type and PV mutant mice were made hypothyroid and replaced with T3 (7ng/g.d) for 10 d to produce similar serum thyroid hormone concentration in the wild-type and mutant mice. The thermogenic response of interscapular BAT, as determined by heat production during iv infusions of norepinephrine, was reduced in PV beta heterozygous and homozygous mutant mice. The level of UCP1, the key thermogenic protein in BAT, was progressively reduced in PV beta(-/-) and PV beta(-/-) mutant mice. Brown adipocytes isolated from PV mutant mice had some reduction in cAMP and glycerol production in response to adrenergic stimulation. Defective adaptive thermogenesis in TR beta PV mutant mice is due to reduced UCP1 expression and reduced adrenergic responsiveness. TR beta mediates T-3 regulation of UCP1 in BAT and is required for adaptive thermogenesis. (Endocrinology 151: 432-440, 2010) C1 [Brent, Gregory A.] Univ Calif Los Angeles, Mol Endocrinol Lab, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Physiol, David Geffen Sch Med, Los Angeles, CA 90073 USA. [Ribeiro, Miriam O.] Univ Presbiteriana Mackenzie, Curso Ciencias Biol, Curso Ciencias Biol & Saude, BR-01301903 Sao Paulo, Brazil. [Bianco, Antonio C.] Univ Miami, Miller Sch Med, Div Endocrinol Diabet & Metab, Miami, FL 33136 USA. [Bianco, Suzy D. C.] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA. [Kaneshige, Masahiro; Cheng, Sheue-yann] NCI, Gene Regulat Sect, Mol Biol Lab, NIH, Bethesda, MD 20892 USA. RP Brent, GA (reprint author), Univ Calif Los Angeles, Mol Endocrinol Lab, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Bldg 114,Room 230,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM gbrent@ucla.edu RI Bianco, Suzy/E-8892-2010; Bianco, Antonio/A-4965-2008; Ribeiro, Miriam/A-9367-2013; Ribeiro, Miriam/B-6085-2015; Ribeiro, Miriam/C-6364-2016 OI Bianco, Suzy/0000-0003-3794-9853; Bianco, Antonio/0000-0001-7737-6813; Ribeiro, Miriam/0000-0002-7870-9701; FU NIH [RO1 DK43714, RO1 DK65055]; Coordenacao de Aperfeioamento de Pessoal de Nivel Superior (CAPES) in Brazil; Veterans Affairs Medical Research Funds FX This work was supported by NIH RO1 DK43714 (G.A.B.), a fellowship from the Coordenacao de Aperfeioamento de Pessoal de Nivel Superior (CAPES) in Brazil (M.O.R.), Veterans Affairs Medical Research Funds (G.A.B.), and NIH RO1 DK65055 (A.C.B.). NR 51 TC 48 Z9 51 U1 0 U2 4 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD JAN PY 2010 VL 151 IS 1 BP 432 EP 440 DI 10.1210/en.2009-0667 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 535NT UT WOS:000272977700047 PM 19906816 ER PT S AU Perlin, JB Baggett, KA AF Perlin, Jonathan B. Baggett, Kelvin A. BE Rouse, WB Cortese, DA TI Government, health and system transformation SO ENGINEERING THE SYSTEM OF HEALTHCARE DELIVERY SE Studies in Health Technology and Informatics LA English DT Article; Book Chapter ID UNITED-STATES; PART-D; CARE; QUALITY; OUTCOMES; DEMAND; ADULTS AB All levels of government have an economic and social interest in health. In the United States, Federal, state and local government are involved in the development of health policy, funding health care, and maintaining or improving public health. Federal, State and most municipalities also engage in delivery of health services. As with the private sector, government is grappling with accelerating health care costs, increasing service demands generated by an aging and more chronically ill society, and accumulating evidence that American health outcomes are not commensurate with the resources invested. Unlike the private sector, attempts to improve value in health care - whether through legislation in Congress or regulation or program design in the Executive branch - are subject to the full intensity of the partisan political process. In order to engage effectively with government in health system transformation, an understanding of both the civic processes and the political dynamics is necessary. This chapter provides an overview of the major governmental roles in health care as formally structured and identifies points of influence in the political process. C1 [Perlin, Jonathan B.] HCA, Clin Serv, Nashville, TN 37203 USA. [Perlin, Jonathan B.] HCA, Nashville, TN USA. [Perlin, Jonathan B.] US Dept Vet Affairs, Hlth, Washington, DC USA. [Perlin, Jonathan B.] Vet Hlth Adm, Washington, DC USA. [Perlin, Jonathan B.] Natl Qual Forum, Washington, DC USA. [Perlin, Jonathan B.] Meharry Med Coll, Joint Commiss, Nashville, TN USA. [Perlin, Jonathan B.] Natl eHlth Collaborat, Washington, DC USA. [Perlin, Jonathan B.] HHS Hlth IT Stand Comm, Washington, DC USA. [Perlin, Jonathan B.] Amer Coll Physicians, College Pk, MD USA. [Perlin, Jonathan B.] Amer Coll Med Informat, College Pk, MD USA. [Baggett, Kelvin A.] HCA, Clin Serv Grp, Nashville, TN USA. [Baggett, Kelvin A.] Duke Univ, Sch Med, Durham, NC 27706 USA. RP Perlin, JB (reprint author), HCA, Clin Serv, Nashville, TN 37203 USA. EM jonathan.perlin@hcahealthcare.com NR 41 TC 0 Z9 0 U1 1 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0926-9630 BN 978-1-60750-533-4; 978-1-60750-532-7 J9 STUD HEALTH TECHNOL PY 2010 VL 153 BP 415 EP 434 DI 10.3233/978-1-60750-533-4-415 PG 20 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA BC2MQ UT WOS:000351085000023 PM 20543256 ER PT S AU Strachan, LR Ghadially, R AF Strachan, Lauren R. Ghadially, Ruby BE Turksen, K TI Limiting Dilution Analysis of Murine Epidermal Stem Cells Using an In Vivo Regeneration Assay SO EPIDERMAL CELLS: METHODS AND PROTOCOLS, SECOND EDITION SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Stem cell; Transit amplifying cell; Epidermis; Limiting dilution; Skin; Regeneration ID TERM REPOPULATING CELLS; SIDE POPULATION; 5-FLUOROURACIL; KERATINOCYTES; EXPRESSION; PROGENITORS; VITRO AB Epidermal stem cells are of major importance for tissue homeostasis, wound repair, tumor initiation, and gene therapy. Here we describe an in vivo regeneration assay to test for the ability of keratinocyte progenitors to maintain an epidermis over the long-term in vivo. Limiting dilution analysis of epidermal repopulating units in this in vivo regeneration assay at sequential time points allows the frequency of short-term (transit amplifying cell) and long-term (stem cell) repopulating cells to be quantified. C1 [Strachan, Lauren R.; Ghadially, Ruby] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Strachan, LR (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. FU NIAMS NIH HHS [R01 AR053765-04, R01 AR053765] NR 24 TC 2 Z9 3 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-60761-379-4 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2010 VL 585 BP 421 EP 432 DI 10.1007/978-1-60761-380-0_29 D2 10.1007/978-1-60761-380-0 PG 12 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA BMP85 UT WOS:000273301700029 PM 19908020 ER PT J AU Lopez-Meraz, ML Niquet, J Wasterlain, CG AF Lopez-Meraz, Maria-Leonor Niquet, Jerome Wasterlain, Claude G. TI Distinct caspase pathways mediate necrosis and apoptosis in subpopulations of hippocampal neurons after status epilepticus SO EPILEPSIA LA English DT Article DE Pilocarpine; Hippocampus; Development; Injury ID PILOCARPINE STATUS EPILEPTICUS; RAT-BRAIN; DIFFERENTIAL EXPRESSION; IMMATURE; DEATH; ACTIVATION; INJURY AB P>Status epilepticus in the immature brain induces neuronal injury in the hippocampal formation, but the mode and mechanism of death are poorly understood. Our laboratory has recently investigated the role of caspase-3, -8, and -9 in neuronal injury, using a lithium-pilocarpine model of status epilepticus in 2-week-old rat pups. Our results showed that dying neurons in the dentate gyrus and CA1-subiculum area do not share the same mechanism of death. In CA1-subiculum, caspase-8 upregulation preceded caspase-3 activation in morphologically necrotic neurons. The pan-caspase inhibitor Q-VD-OPH reduced CA1 damage, showing that caspases contribute to status epilepticus-induced necrosis. In the dentate gyrus, dying neurons were caspase-9 and -3 immunoreactive and morphologically apoptotic. It is not clear why the same seizures cause different types of cell death in neurons that are connected in series along the same hippocampal circuit, but the apoptotic dentate neurons express doublecortin, and do not express calbindin-D28k, suggesting that their immaturity may be a factor in producing an apoptotic mode of death. C1 [Lopez-Meraz, Maria-Leonor; Niquet, Jerome; Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Lopez-Meraz, Maria-Leonor] Univ Veracruzana, Programa Neurobiol, Cordoba, Veracruz, Mexico. [Niquet, Jerome; Wasterlain, Claude G.] Vet Affairs Greater Los Angeles Healthcare Syst, Epilepsy Res Lab 151, Los Angeles, CA USA. [Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. RP Niquet, J (reprint author), VA Greater Los Angeles Healthcare Syst, Epilepsy Res Lab, 11301 Wilshire Blvd,Bldg 114,Room 139, Los Angeles, CA 90073 USA. EM jniquet@ucla.edu FU Epilepsy Foundation of America; VHA Research Service, NINDS [RO1 NS13515]; UC MEXUS-CONACyT FX Supported by research grants from the Epilepsy Foundation of America (JN), VHA Research Service, NINDS (grant RO1 NS13515), and by a UC MEXUS-CONACyT postdoctoral fellowship to MLLM. NR 14 TC 14 Z9 19 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2010 VL 51 SU 3 BP 56 EP 60 DI 10.1111/j.1528-1167.2010.02611.x PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 619PP UT WOS:000279442400011 PM 20618402 ER PT J AU Karr, L Pan, YZ Rutecki, PA AF Karr, Linda Pan, Yu-Zhen Rutecki, Paul A. TI CB1 receptor antagonism impairs the induction of epileptiform activity by group I metabotropic glutamate receptor activation SO EPILEPSIA LA English DT Article DE Long-term depression (LTD); Dihydroxy phenylglycine (DHPG); Endocannabinoid; CA3; SR 141716; AM 251 ID HIPPOCAMPAL-NEURONS; PROTEIN-SYNTHESIS; PLASTICITY; HYPEREXCITABILITY AB P>Exposure to the group I metabotropic glutamate receptor (mGluR) agonist dihydroxy phenylglycine (DHPG) induces epileptiform activity in the CA3 region of the hippocampus that persists following washout of DHPG. DHPG also can cause long-term depression of synaptic transmission, and at some synapses this may be mediated by endocannabinoids. We evaluated whether the selective cannabinoid type 1 (CB1) receptor antagonists SR 141716 or AM 251 could modify induction of epileptiform activity produced by DHPG exposure. The induction of epileptiform activity by DHPG exposure was significantly reduced by CB1 receptor antagonists, SR 141716 or AM 251. Minimal effects on epileptiform activity were noted once the activity had been induced. In control slices, exposure to DHPG for 30 min produced long-term depression (LTD) of synaptic transmission, on average about a 70% reduction in slope of the field excitatory postsynaptic potential (EPSP). When slices were exposed to both DHPG and SR 141716 (3 mu m), LTD did not occur and the population EPSP remained at control values or greater. These results suggest that CB1 receptors mediate some of DHPG effects that result in persistent epileptiform activity, and antagonism of CB1 receptors has antiepileptogenic properties. Paradoxically DHPG also caused LTD of excitatory synaptic transmission in the CA3 region and CB1 receptor antagonism prevents the depression. We hypothesize that the ictal activity induced by DHPG requires depression of synaptic strength and CB1 receptor antagonism prevents this depression and the induction of ictal activity. C1 Univ Wisconsin, Neurol Serv, William S Middleton Mem Vet Hosp, Madison, WI 53705 USA. Univ Wisconsin, Dept Neurol, Madison, WI 53705 USA. RP Rutecki, PA (reprint author), Univ Wisconsin, Dept Neurol, William Middleton VA Hosp, Madison, WI 53705 USA. EM rutecki@neurology.wisc.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Service FX This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Service (grant to PAR). The contents do not represent the views of the Dept. of Veterans Affairs or the United States Government. NR 15 TC 5 Z9 6 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PY 2010 VL 51 SU 3 BP 121 EP 125 DI 10.1111/j.1528-1167.2010.02625.x PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 619PP UT WOS:000279442400025 PM 20618416 ER PT B AU Van Cott, AC Brenner, RP AF Van Cott, Anne C. Brenner, Richard P. BE Fisch, BJ TI ENCEPHALOPATHY AND PROGNOSIS IN COMA SO EPILEPSY AND INTENSIVE CARE MONITORING: PRINCIPLES AND PRACTICE LA English DT Article; Book Chapter ID NONCONVULSIVE STATUS EPILEPTICUS; INDUCED HYPERAMMONEMIC ENCEPHALOPATHY; EPILEPSIA PARTIALIS CONTINUA; CRITICALLY-ILL PATIENTS; LOCKED-IN-SYNDROME; STEROID-RESPONSIVE ENCEPHALOPATHY; REFRACTORY STATUS EPILEPTICUS; MYOCLONIC STATUS EPILEPTICUS; SENSORY EVOKED-POTENTIALS; EPISODIC LOW-AMPLITUDE C1 [Van Cott, Anne C.] Univ Pittsburgh, Dept Neurol, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. [Brenner, Richard P.] Univ Pittsburgh, Dept Neurol, Med Ctr, Pittsburgh, PA 15260 USA. RP Van Cott, AC (reprint author), Univ Pittsburgh, Dept Neurol, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. NR 140 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-13-6 PY 2010 BP 309 EP 329 PG 21 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA BLW95 UT WOS:000271242500021 ER PT J AU Ettinger, AB Copeland, LA Zeber, JE Van Cott, AC Pugh, MJV AF Ettinger, Alan B. Copeland, Laurel A. Zeber, John E. Van Cott, Anne C. Pugh, Mary Jo V. TI Are psychiatric disorders independent risk factors for new-onset epilepsy in older individuals? SO EPILEPSY & BEHAVIOR LA English DT Article DE Epilepsy; Comorbidity; Elderly; Mental disorders; Veterans ID TEMPORAL-LOBE EPILEPSY; ADMINISTRATIVE DATA; MAJOR DEPRESSION; UNPROVOKED SEIZURES; SYMPTOMS; COMORBIDITY; PREVALENCE; DISEASE; VETERANS; SURGERY AB This retrospective study examined whether psychiatric conditions are directly related to epilepsy or, rather, are associated with underlying central nervous system (CNS) disorders linked to subsequent epilepsy. We examined data from a sample of older veterans (>65 years) receiving care from the Veterans Health Administration during fiscal year 2000. We compared individuals with new-onset epilepsy and individuals without epilepsy to examine the extent to which psychiatric disorders were associated with new-onset epilepsy; this analysis controlled for demographic and premorbid neurological risk factors previously associated with new-onset epilepsy. Premorbid psychiatric conditions occurred at higher rates in the epilepsy versus nonepilepsy groups, foremost including depression (17% vs 12%), anxiety (12% vs 8%), psychosis (12% vs 5%), and substance abuse (8% vs 4%). However, in the final model, only psychosis (OR = 1.4, CI 1.2-1.6) was significantly associated with epilepsy when controlling for neurological disorders and psychiatric conditions (e.g., stroke, dementia, brain tumor, head injury). Published by Elsevier Inc. C1 [Ettinger, Alan B.] Neurol Surg PC, Lake Success, NY 11042 USA. [Copeland, Laurel A.; Zeber, John E.; Pugh, Mary Jo V.] S Texas Vet Hlth Care Syst VERDICT, San Antonio, TX USA. [Copeland, Laurel A.; Zeber, John E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Van Cott, Anne C.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Van Cott, Anne C.] Univ Pittsburgh, Pittsburgh, PA USA. [Pugh, Mary Jo V.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. RP Ettinger, AB (reprint author), Neurol Surg PC, 1991 Marcus Ave,Suite 108, Lake Success, NY 11042 USA. EM aettinge@gmail.com OI Pugh, Mary Jo/0000-0003-4196-7763; Copeland, Laurel/0000-0002-9478-0209 FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [IIR 02-274]; VERDICT Research Program at the South Texas Veterans Health Care System, San Antonio, TX; University of Texas Health Science Center at San Antonio; VA Health Services Research and Development program [IIR-06-062] FX The authors thank Dale Hesdorffer, Ph.D., for her helpful suggestions in the preparation of this article and Jeffrey Tabares for his invaluable assistance in preparation of this article.; This research was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (IIR 02-274, PI: Pugh). This work was completed with the additional support of the VERDICT Research Program at the South Texas Veterans Health Care System, San Antonio, TX, and the University of Texas Health Science Center at San Antonio. M.J. Pugh, J.E. Zeber, and L.A. Copeland were partially supported by VA HRSD IIR-06-062 from the VA Health Services Research and Development program. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 35 TC 20 Z9 20 U1 1 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1525-5050 J9 EPILEPSY BEHAV JI Epilepsy Behav. PD JAN PY 2010 VL 17 IS 1 BP 70 EP 74 DI 10.1016/j.yebeh.2009.10.010 PG 5 WC Behavioral Sciences; Clinical Neurology; Psychiatry SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry GA 546UF UT WOS:000273837700010 PM 19913462 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Temporal changes in the age distribution of inflammatory bowel disease hospitalization: data from England and Scotland SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY LA English DT Article DE age effects; birth cohort; environmental risk factors; epidemiology of inflammatory bowel disease; hospital statistics; time trends ID ULCERATIVE-COLITIS; CROHNS-DISEASE; TIME TRENDS; UNITED-STATES; MORTALITY; EPIDEMIOLOGY; PREVALENCE; COUNTY AB Objective The ages of patients with Crohn's disease and ulcerative colitis are characterized by a bimodal distribution. This study used separate hospital statistics from England and Scotland to follow the changes in the age distribution of inflammatory bowel disease. The objective of the analysis was to check whether the time trends of hospitalization would show different patterns among different age groups. Methods Hospital statistics from England (1989-2006) and Scotland (1981-2007) were obtained through special requests to the national statistical offices. Hospitalizations (with Crohn's disease or ulcerative colitis listed as primary or primary plus secondary discharge diagnosis) were expressed as age-specific and sex-specific rates per 10000 living population. The separate age-specific rates of Crohn's disease and ulcerative colitis of consecutive 6-year or 7-year time intervals were plotted against their respective age group. Results The hospital data reveal a bimodal age distribution, with a more prominent first peak occurring in younger patients with Crohn's disease and a more prominent second peak occurring in older patients with ulcerative colitis. During the past two decades, the hospitalization rates for both diseases increased in all age groups. However, the increase was relatively more pronounced in the elderly, especially with ulcerative colitis. The age-shift towards older patients was also more evident for Crohn's disease or ulcerative colitis listed as secondary than primary discharge diagnosis. Conclusion The age-related shift in the occurrence of inflammatory bowel disease could reflect the impact of a birth-cohort pattern that underlies the long-term time trends of ulcerative colitis and Crohn's disease. Eur J Gastroenterol Hepatol 22:95-101 (C) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins. C1 [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR 97239 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 21 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0954-691X J9 EUR J GASTROEN HEPAT JI Eur. J. Gastroenterol. Hepatol. PD JAN PY 2010 VL 22 IS 1 BP 95 EP 101 DI 10.1097/MEG.0b013e32832e9d54 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 534XD UT WOS:000272929900014 PM 19738478 ER PT J AU Zhang, GH Chen, WL Lao, LJ Marvizon, JCG AF Zhang, Guohua Chen, Wenling Lao, Lijun Marvizon, Juan Carlos G. TI Cannabinoid CB1 receptor facilitation of substance P release in the rat spinal cord, measured as neurokinin 1 receptor internalization SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE mu-opioid receptor; C-fiber; dorsal horn; GABA(B) receptor; primary afferent ID CAPSAICIN-EVOKED RELEASE; IN-SITU HYBRIDIZATION; ROOT GANGLION NEURONS; DORSAL-HORN NEURONS; SUBARACHNOID SPACE; INFLAMMATORY PAIN; GABA(B) RECEPTORS; NEUROPATHIC PAIN; OPIOID AGONISTS; SENSORY NEURONS AB The contribution of CB1 receptors in the spinal cord to cannabinoid analgesia is still unclear. The objective of this study was to investigate the effect of CB1 receptors on substance P release from primary afferent terminals in the spinal cord. Substance P release was measured as neurokinin 1 (NK1) receptor internalization in lamina I neurons. It was induced in spinal cord slices by dorsal root stimulation and in live rats by a noxious stimulus. In spinal cord slices, the CB1 receptor antagonists AM251, AM281 and rimonabant partially but potently inhibited NK1 receptor internalization induced by electrical stimulation of the dorsal root. This was due to an inhibition of substance P release and not of NK1 receptor internalization itself, because AM251 and AM281 did not inhibit NK1 receptor internalization induced by exogenous substance P. The CB1 receptor agonist ACEA increased NK1 receptor internalization evoked by dorsal root stimulation. The effects of AM251 and ACEA cancelled each other. In vivo, AM251 injected intrathecally decreased NK1 receptor internalization in spinal segments L5 and L6 induced by noxious hind paw clamp. Intrathecal AM251 also produced analgesia to radiant heat stimulation of the paw. The inhibition by AM251 of NK1 receptor internalization was reversed by antagonists of mu-opioid and GABA(B) receptors. This indicates that CB1 receptors facilitate substance P release by inhibiting the release of GABA and opioids next to primary afferent terminals, producing disinhibition. This results in a pronociceptive effect of CB1 receptors in the spinal cord. C1 [Zhang, Guohua; Chen, Wenling; Marvizon, Juan Carlos G.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Zhang, Guohua; Chen, Wenling; Lao, Lijun; Marvizon, Juan Carlos G.] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Ctr Neurobiol Stress,Dept Med,Div Digest Dis, Los Angeles, CA 90095 USA. RP Marvizon, JCG (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Bldg 115,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM marvizon@ucla.edu FU Rehabilitation Research & Development Service, Department of Veteran Affair [B4766I]; National Institutes of Health [R01 DA012609] FX Supported by grant B4766I from the Rehabilitation Research & Development Service, Department of Veteran Affairs to J.C.M., who is also a recipient of grant R01 DA012609 from the National Institutes of Health. NR 94 TC 16 Z9 16 U1 0 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0953-816X J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD JAN PY 2010 VL 31 IS 2 BP 225 EP 237 DI 10.1111/j.1460-9568.2009.07075.x PG 13 WC Neurosciences SC Neurosciences & Neurology GA 545IX UT WOS:000273726800005 PM 20074214 ER PT J AU Lanius, RA Frewen, PA Vermetten, E Yehuda, R AF Lanius, Ruth A. Frewen, Paul A. Vermetten, Eric Yehuda, Rachel TI Fear conditioning and early life vulnerabilities: two distinct pathways of emotional dysregulation and brain dysfunction in PTSD SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Review DE Anterior cingulate cortex; medial prefrontal cortex; amygdale; DSM-V; emotion; attachment; HPA-axis; infant development AB The newly proposed criteria for posttraumatic stress disorder (PTSD) in the Diagnostic and Statistical Manual (DSM-V) include dysregulation of a variety of emotional states including fear, anger, guilt, and shame, in addition to dissociation and numbing. Consistent with these revisions, we postulate two models of emotion dysregulation in PTSD in which fear is not the prevailing emotion but is only one of several components implicated in a dysregulated emotional system that also mediates problems regulating anger, guilt, shame, dissociation, and numbing. We discuss whether there is a relationship between fear and other emotion regulation systems that may help further our understanding of PTSD and its underlying neurocircuitry. Two pathways describing the relationship between fear and other emotion regulation systems in PTSD are proposed. The first pathway describes emotion dysregulation as an outcome of fear conditioning through stress sensitization and kindling. The second pathway views emotion dysregulation as a distal vulnerability factor and hypothesizes a further exacerbation of fear and other emotion regulatory problems, including the development of PTSD after exposure to one or several traumatic event(s) later in life. Future research and treatment implications are discussed. C1 [Lanius, Ruth A.] Univ Western Ontario, Dept Psychiat, London, ON N6A 5A5, Canada. [Frewen, Paul A.] Univ Western Ontario, Dept Psychol, London, ON N6A 5A5, Canada. [Vermetten, Eric] Univ Med Ctr, Utrecht, Netherlands. [Yehuda, Rachel] Mt Sinai Sch Med, New York, NY 10029 USA. [Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA. RP Lanius, RA (reprint author), Univ Western Ontario, Dept Psychiat, 339 Windermere Rd, London, ON N6A 5A5, Canada. EM ruth.lanius@lhsc.on.ca RI Lanius, Ruth/J-6961-2015 OI Lanius, Ruth/0000-0002-3758-1393 NR 127 TC 34 Z9 34 U1 8 U2 17 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2010 VL 1 AR 5467 DI 10.3402/ejpt.v1i0.5467 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA V31EV UT WOS:000208867800001 ER PT J AU Yehuda, R Bierer, LM Pratchett, L Malowney, M AF Yehuda, Rachel Bierer, Linda M. Pratchett, Laura Malowney, Monica TI Glucocorticoid augmentation of prolonged exposure therapy: rationale and case report SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Article DE Glucocorticoids; PTSD; cortisol; treatment; prolonged exposure; learning; memory AB Rationale: Prolonged exposure (PE) therapy has been found to reduce symptoms of posttraumatic stress disorder (PTSD); however, it is difficult for many patients to engage fully in the obligatory retelling of their traumatic experiences. This problem is compounded by the fact that habituation and cognitive restructuring - the main mechanisms through which PE is hypothesized to work - are not instantaneous processes, and often require several weeks before the distress associated with imaginal exposure abates. Case reports: Two cases are described that respectively illustrate the use of hydrocortisone and placebo, in combination with PE, for the treatment of combat-related PTSD. Based on known effects of glucocorticoids on learning and memory performance, we hypothesized that augmentation with hydrocortisone would improve the therapeutic effects of PE by hastening "new'' learning and facilitating decreases in the emotional impact of fear memories during the course of treatment. The veteran receiving hydrocortisone augmentation of PE displayed an accelerated and ultimately greater decline in PTSD symptoms than the veteran receiving placebo. Conclusions: While no general conclusion can be derived from comparison of two patients, the findings are consistent with the rationale for augmentation. These case reports support the potential for an appropriately designed and powered clinical trial to examine the efficacy of glucocorticoids in augmenting the effects of psychotherapy for PTSD. C1 [Yehuda, Rachel; Bierer, Linda M.; Pratchett, Laura] James J Peters Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY 10468 USA. [Yehuda, Rachel; Bierer, Linda M.; Malowney, Monica] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Yehuda, R (reprint author), James J Peters Vet Affairs Med Ctr, Dept Psychiat, 116-1 526 OOMH,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM Rachel.Yehuda@va.gov RI Malowney, Monica/F-8009-2014 OI Malowney, Monica/0000-0002-6521-9754 NR 41 TC 10 Z9 10 U1 2 U2 3 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2010 VL 1 DI 10.3402/ejpt.v1i0.5643 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA V31EV UT WOS:000208867800008 ER PT J AU Ho, L Fivecoat, H Wang, J Pasinetti, GM AF Ho, Lap Fivecoat, Hayley Wang, Jun Pasinetti, Giulio Maria TI Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: Experimental approaches and future clinical applications SO EXPERIMENTAL GERONTOLOGY LA English DT Article DE Alzheimer's disease (AD); Cognitive impairment; Dementia; Genetic risk factors; Biomarkers; Complementary DNA (cDNA) microarray analysis; Protein array analysis; Proteomics; MicroRNA (miRNA) ID SERVICES-TASK-FORCE; CEREBROSPINAL-FLUID; BREAST-CANCER; NEUROFIBRILLARY TANGLES; ALTERED EXPRESSION; SECRETASE ACTIVITY; NEURITIC PLAQUES; GENE-EXPRESSION; GAMMA-SECRETASE; RISK AB Alzheimer's disease (AD) is the most common form of dementia in the elderly. Current treatments for AD are not as effective as needed, nor is there any definitive antemortem diagnostic. Understanding the biological processes that occur during AD onset and/or progression will improve disease diagnosis and treatment. Recent applications of microarray technologies for analysis of messenger (m) RNA expression profiles have elucidated distinct changes in the brain as a function of AD dementia initiation and progression. However, mRNA analysis underestimates post-transcriptional modifications and therefore provides only a partial view of the molecular changes in the AD brain. Combining mRNA studies with protein expression analysis may provide a more global picture of the biological processes associated with AD dementia. Information gathered could lead to the development of select biological indices (biomarkers) for guiding AD diagnosis and therapy. We will provide a brief background on AD, followed by a review on the applications of microarray, proteomics, as well as microRNA expression profile analysis to develop novel diagnostic strategies that may be useful for the diagnosis AD and for monitoring disease progression. The availability of biomarkers that promote early disease diagnosis, particularly among asymptomatic patients, will lead to the application of personalized medicine in AD. Published by Elsevier Inc. C1 [Ho, Lap; Fivecoat, Hayley; Wang, Jun; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, Ctr Excellence Novel Approaches Neurodiagnost & N, Inst Brain, New York, NY 10029 USA. [Ho, Lap; Fivecoat, Hayley; Wang, Jun; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, Ctr Excellence Complementary & Alternat Med Alzei, New York, NY 10029 USA. [Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, GRECC, Biomed Res & Training Program, Bronx, NY 10468 USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, Ctr Excellence Novel Approaches Neurodiagnost & N, Inst Brain, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU NIA [UO1-AG0293310]; Veteran's Affairs Medical Center (Bronx, NY) Geriatrics Research, Education and Clinical Center (GRECC) FX Supported by UO1-AG0293310 by the NIA, and the Veteran's Affairs Medical Center (Bronx, NY) Geriatrics Research, Education and Clinical Center (GRECC) to G.M.P. NR 68 TC 23 Z9 23 U1 1 U2 14 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0531-5565 J9 EXP GERONTOL JI Exp. Gerontol. PD JAN PY 2010 VL 45 IS 1 SI SI BP 15 EP 22 DI 10.1016/j.exger.2009.09.007 PG 8 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 547DQ UT WOS:000273866300004 PM 19796674 ER PT J AU Jonker, SS Giraud, MK Giraud, GD Chattergoon, NN Louey, S Davis, LE Faber, JJ Thornburg, KL AF Jonker, Sonnet S. Giraud, M. Kathryn Giraud, George D. Chattergoon, Natasha N. Louey, Samantha Davis, Lowell E. Faber, J. Job Thornburg, Kent L. TI Cardiomyocyte enlargement, proliferation and maturation during chronic fetal anaemia in sheep SO EXPERIMENTAL PHYSIOLOGY LA English DT Article ID CELL-CYCLE ACTIVITY; ADULT SHEEP; BLOOD-FLOW; HYPERTROPHY; ADAPTATIONS; GROWTH; HEART AB Chronic anaemia increases the workload of the growing fetal heart, leading to cardiac enlargement. To determine which cellular process increases cardiac mass, we measured cardiomyocyte sizes, binucleation as an index of terminal differentiation, and tissue volume fractions in hearts from control and anaemic fetal sheep. Fourteen chronically catheterized fetal sheep at 129 days gestation had blood withdrawn for 9 days to cause severe anaemia; 14 control fetuses were of similar age. At postmortem examination, hearts were either enzymatically dissociated or fixed for morphometric analysis. Daily isovolumetric haemorrhage reduced fetal haematocrit from a baseline value of 35% to 15% on the final day (P < 0.001). At the study conclusion, anaemic fetuses had lower arterial pressures than control fetuses (P < 0.05). Heart weights were increased by 39% in anaemic fetuses compared with control hearts (P < 0.0001), although the groups had similar body weights; the heart weight difference was not due to increased ventricular wall water content or disproportionate non-myocyte tissue expansion. Cardiomyocytes from anaemic fetuses tended to be larger than those of control fetuses. There were no statistically significant differences between groups in the cardiomyocyte cell cycle activity. The degree of terminal differentiation was greater in the right ventricle of anaemic compared with control fetuses by similar to 8% (P < 0.05). Anaemia substantially increased heart weight in fetal sheep. The volume proportions of connective and vascular tissue were unchanged. Cardiomyocyte mass expanded by a balanced combination of cellular enlargement, increased terminal differentiation and accelerated proliferation. C1 [Jonker, Sonnet S.; Giraud, M. Kathryn; Giraud, George D.; Chattergoon, Natasha N.; Louey, Samantha; Davis, Lowell E.; Faber, J. Job; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97239 USA. [Jonker, Sonnet S.; Giraud, George D.; Thornburg, Kent L.] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. [Giraud, George D.] Portland VA Med Ctr, Portland, OR USA. RP Jonker, SS (reprint author), Oregon Hlth & Sci Univ, Heart Res Ctr, 3303 SW Bond Ave,CH14T, Portland, OR 97239 USA. EM jonkers@ohsu.edu OI Thornburg, Kent/0000-0002-5561-4785; Jonker, Sonnet/0000-0002-1097-2562 FU NICHD [P01HD34430]; M. Lowell Edwards Endowment; American Heart Association FX The authors would like to acknowledge the technical assistance of Robert Webber, Loni Socha and Kevin Hearn. This study was supported by the NICHD grant P01HD34430 and the M. Lowell Edwards Endowment. Sonnet Jonker was supported by an American Heart Association Fellowship. NR 20 TC 16 Z9 16 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0958-0670 J9 EXP PHYSIOL JI Exp. Physiol. PD JAN 1 PY 2010 VL 95 IS 1 BP 131 EP 139 DI 10.1113/expphysiol.2009.049379 PG 9 WC Physiology SC Physiology GA 533PI UT WOS:000272836300017 PM 19700519 ER PT J AU McClung, JM DeRuisseau, KC Whidden, MA Van Remmen, H Richardson, A Song, W Vrabas, IS Powers, SK AF McClung, Joseph M. DeRuisseau, Keith C. Whidden, Melissa A. Van Remmen, Holly Richardson, Arlan Song, Wook Vrabas, Ioannis S. Powers, Scott K. TI Overexpression of antioxidant enzymes in diaphragm muscle does not alter contraction-induced fatigue or recovery SO EXPERIMENTAL PHYSIOLOGY LA English DT Article ID RAT SOLEUS MUSCLE; SKELETAL-MUSCLE; OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; FORCE PRODUCTION; REACTIVE OXYGEN; TRANSGENIC MICE; VITAMIN-E; DYSFUNCTION; ATROPHY AB Low levels of reactive oxygen species (ROS) production are necessary to optimize muscle force production in unfatigued muscle. In contrast, sustained high levels of ROS production have been linked to impaired muscle force production and contraction-induced skeletal muscle fatigue. Using genetically engineered mice, we tested the hypothesis that the independent transgenic overexpression of catalase (CAT), copper/zinc superoxide dismutase (CuZnSOD; SOD1) or manganese superoxide dismutase (MnSOD; SOD2) antioxidant enzymes would negatively affect force production in unfatigued diaphragm muscle but would delay the development of muscle fatigue and enhance force recovery after fatiguing contractions. Diaphragm muscle from wild-type littermates (WT) and from CAT, SOD1 and SOD2 overexpressing mice were subjected to an in vitro contractile protocol to investigate the force-frequency characteristics, the fatigue properties and the time course of recovery from fatigue. The CAT, SOD1 and SOD2 overexpressors produced less specific force (in N cm-2) at stimulation frequencies of 20-300 Hz and produced lower maximal tetanic force than WT littermates. The relative development of muscle fatigue and recovery from fatigue were not influenced by transgenic overexpression of any antioxidant enzyme. Morphologically, the mean cross-sectional area (in mu m2) of diaphragm myofibres expressing myosin heavy chain type IIA was decreased in both CAT and SOD2 transgenic animals, and the percentage of non-contractile tissue increased in diaphragms from all transgenic mice. In conclusion, our results do not support the hypothesis that overexpression of independent antioxidant enzymes protects diaphragm muscle from contraction-induced fatigue or improves recovery from fatigue. Moreover, our data are consistent with the concept that a basal level of ROS is important to optimize muscle force production, since transgenic overexpression of major cellular antioxidants is associated with contractile dysfunction. Finally, the transgenic overexpression of independent endogenous antioxidants alters diaphragm skeletal muscle morphology, and these changes may also contribute to the diminished specific force production observed in these animals. C1 [McClung, Joseph M.; Whidden, Melissa A.; Powers, Scott K.] Univ Florida, Ctr Exercise Sci, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA. [DeRuisseau, Keith C.] Syracuse Univ, Dept Exercise Sci, Syracuse, NY 13244 USA. [Van Remmen, Holly; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Van Remmen, Holly; Richardson, Arlan] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA. [Song, Wook] Seoul Natl Univ, Inst Sports Sci, Seoul 151742, South Korea. [Vrabas, Ioannis S.] Aristotle Univ Thessaloniki, Lab Exercise Physiol & Biochem, Dept Phys Educ & Sport Sci Serres, Thessaloniki, Greece. RP Powers, SK (reprint author), Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL 32608 USA. EM spowers@hhp.ufl.edu FU National Institutes of Health [RO1 HL072789] FX This work was supported by the National Institutes of Health (RO1 HL072789 to S.K.P.). NR 27 TC 14 Z9 15 U1 1 U2 4 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0958-0670 J9 EXP PHYSIOL JI Exp. Physiol. PD JAN 1 PY 2010 VL 95 IS 1 BP 222 EP 231 DI 10.1113/expphysiol.2009.049650 PG 10 WC Physiology SC Physiology GA 533PI UT WOS:000272836300026 PM 19783618 ER PT J AU Thompson, GR Lewis, JS AF Thompson, George R., III Lewis, James S., II TI Pharmacology and clinical use of voriconazole SO EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY LA English DT Review DE serum drug levels; therapeutic drug monitoring; voriconazole ID INFECTIOUS-DISEASES-SOCIETY; ACUTE MYELOID-LEUKEMIA; INVASIVE FUNGAL-INFECTIONS; AZOLE ANTIFUNGAL DRUGS; HEALTHY MALE-SUBJECTS; IN-VITRO ACTIVITIES; PRACTICE GUIDELINES; AMPHOTERICIN-B; ASPERGILLUS-FUMIGATUS; PHARMACOKINETIC INTERACTION AB Importance of the field. Voriconazole is an extended-spectrum triazole developed specifically to target Aspergillus spp. and is now indicated as primary therapy in this circumstance. However, it has a broad spectrum of activity against both yeasts and molds and is also a viable treatment option in the treatment of other mycoses. Areas covered in this review. This review discusses the mechanism of action, the pharmacodynamics and pharmacokinetics and the most common mechanisms of resistance to this agent. An overview of therapeutic drug monitoring, drug-drug interactions and pivotal trials are also reviewed. What the reader will gain: The reader will gain further knowledge of the unique aspects of voriconazole compared to other currently available antifungal agents. Take home message: Voriconazole offers distinct advantages over several other antifungals. The side effect profile of voriconazole is unique compared to other triazole agents. Concern for drug-drug interactions due to a frequently shared common metabolic pathway has prompted heightened interest in the use of therapeutic drug monitoring for concerns of toxicity, drug-drug interactions and in attempts to ensure efficacy. These aspects as well as a review of important clinical information pertaining to voriconazole are discussed here. C1 [Thompson, George R., III; Lewis, James S., II] Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, Dept Med, San Antonio, TX 78229 USA. [Lewis, James S., II] Univ Hlth Syst, Dept Pharm, San Antonio, TX USA. [Thompson, George R., III] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Thompson, GR (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Infect Dis, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM thompsong2@uthscsa.edu NR 101 TC 15 Z9 15 U1 1 U2 8 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1742-5255 J9 EXPERT OPIN DRUG MET JI Expert Opin. Drug Metab. Toxicol. PD JAN PY 2010 VL 6 IS 1 BP 83 EP 94 DI 10.1517/17425250903463878 PG 12 WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy GA 546EB UT WOS:000273791600008 PM 19947892 ER PT J AU McGoldrick, T AF McGoldrick, Tom BE Harris, A Botticelli, S TI Where is the "post" in posttraumatic stress disorder? First impressions working with Iraq and Afghanistan soldiers SO FIRST DO NO HARM: PARADOXICAL ENCOUNTERS OF PSYCHOANALYSIS, WARMAKING, AND RESISTANCE SE Relational Perspectives Book Series LA English DT Article; Book Chapter C1 [McGoldrick, Tom] NYU, Postdoctoral Program Psychotherapy & Psychoanal, New York, NY 10003 USA. [McGoldrick, Tom] US Dept Vet Affairs, Readjustment Counseling Serv Ctr, Staten Isl, NY USA. RP McGoldrick, T (reprint author), NYU, Postdoctoral Program Psychotherapy & Psychoanal, New York, NY 10003 USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-1-13584-296-3 J9 RELAT PERSPECT BOOK PY 2010 VL 45 BP 3 EP 14 PG 12 WC Psychology, Psychoanalysis SC Psychology GA BVZ64 UT WOS:000293214200003 ER PT J AU McNeil, MR Katz, WF Fossett, TRD Garst, DM Szuminsky, NJ Carter, G Lim, KY AF McNeil, M. R. Katz, W. F. Fossett, T. R. D. Garst, D. M. Szuminsky, N. J. Carter, G. Lim, K. Y. TI Effects of Online Augmented Kinematic and Perceptual Feedback on Treatment of Speech Movements in Apraxia of Speech SO FOLIA PHONIATRICA ET LOGOPAEDICA LA English DT Article DE Apraxia of speech; Augmented feedback; Kinematic feedback; Perceptual feedback ID CONCURRENT; APHASIA AB Apraxia of speech (AOS) is a motor speech disorder characterized by disturbed spatial and temporal parameters of movement. Research on motor learning suggests that augmented feedback may provide a beneficial effect for training movement. This study examined the effects of the presence and frequency of online augmented visual kinematic feedback (AVKF) and clinician-provided perceptual feedback on speech accuracy in 2 adults with acquired AOS. Within a single-subject multiple-baseline design, AVKF was provided using electromagnetic midsagittal articulography (EMA) in 2 feedback conditions (50 or 100%). Articulator placement was specified for speech motor targets (SMTs). Treated and base-lined SMTs were in the initial or final position of single-syllable words, in varying consonant-vowel or vowel-con sonant contexts. SMTs were selected based on each participant's pre-assessed erred productions. Productions were digitally recorded and online perceptual judgments of accuracy (including segment and intersegment distortions) were made. Inter-and intra-judge reliability for perceptual accuracy was high. Results measured by visual inspection and effect size revealed positive acquisition and generalization effects for both participants. Generalization occurred across vowel contexts and to untreated probes. Results of the frequency manipulation were confounded by presentation order. Maintenance of learned and generalized effects were demonstrated for 1 participant. These data provide support for the role of augmented feedback in treating speech movements that result in perceptually accurate speech production. Future investigations will explore the independent contributions of each feedback type (i.e. kinematic and perceptual) in producing efficient and effective training of SMTs in persons with AOS. Copyright (C) 2010 S. Karger AG, Basel C1 [McNeil, M. R.] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA. [McNeil, M. R.; Fossett, T. R. D.; Szuminsky, N. J.; Lim, K. Y.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Katz, W. F.; Garst, D. M.] Univ Texas Dallas, Callier Ctr Commun Disorders, Dallas, TX 75235 USA. [Katz, W. F.; Garst, D. M.; Carter, G.] Dallas Vet Adm Med Ctr, Dallas, TX USA. RP McNeil, MR (reprint author), Univ Pittsburgh, Dept Commun Sci & Disorders, 4033 Forbes Tower, Pittsburgh, PA 15260 USA. EM mcneil@pitt.edu RI Mansourzadeh, Mohammad Javad/H-5779-2011 FU Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service [B3670R] FX This research was supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service: Award #B3670R to Malcolm R. McNeil. NR 14 TC 8 Z9 9 U1 1 U2 10 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1021-7762 J9 FOLIA PHONIATR LOGO JI Folia Phoniatr. Logop. PY 2010 VL 62 IS 3 BP 127 EP 133 DI 10.1159/000287211 PG 7 WC Audiology & Speech-Language Pathology; Otorhinolaryngology; Rehabilitation SC Audiology & Speech-Language Pathology; Otorhinolaryngology; Rehabilitation GA 633QM UT WOS:000280519000007 PM 20424468 ER PT J AU Bhattacharya, A Jernigan, AL Sabia, M Li, Y Qi, WB Van Remmen, H AF Bhattacharya, Arunabh Jernigan, Amanda Leigh Sabia, Marian Li, Yan Qi, Wenbo Van Remmen, Holly TI Role of 12/15-lipoxygenase Pathway in Muscle Atrophy SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 17th Annual Meeting of the Society-for-Free-Radical-Biology-Medicine /15th Biennial Meeting of the Society-for-Free-Radical-Research-International CY NOV 17-21, 2010 CL Orlando, FL SP Soc Free Radi Biol Med, Soc Free Radi Res Int C1 [Bhattacharya, Arunabh; Jernigan, Amanda Leigh; Li, Yan; Qi, Wenbo; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst, San Antonio, TX 78229 USA. [Sabia, Marian; Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 2010 VL 49 SU 1 BP S77 EP S77 DI 10.1016/j.freeradbiomed.2010.10.189 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 681VD UT WOS:000284348000206 ER PT J AU Chaiswing, L Zhong, WX Oberley, T AF Chaiswing, Luksana Zhong, Weixiong Oberley, Terry TI Regulation of Prostate Cancer Cell Invasion via Modulation of Extracellular CyS/CySS Redox Couple SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 17th Annual Meeting of the Society-for-Free-Radical-Biology-Medicine /15th Biennial Meeting of the Society-for-Free-Radical-Research-International CY NOV 17-21, 2010 CL Orlando, FL SP Soc Free Radi Biol Med, Soc Free Radi Res Int C1 [Chaiswing, Luksana; Zhong, Weixiong; Oberley, Terry] Univ Wisconsin, Madison, WI 53706 USA. [Zhong, Weixiong; Oberley, Terry] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 2010 VL 49 SU 1 BP S57 EP S57 DI 10.1016/j.freeradbiomed.2010.10.129 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 681VD UT WOS:000284348000147 ER PT J AU Mashmoushi, AK Hofbauer, AF Gilkeson, GS Oates, JC AF Mashmoushi, Ahmad K. Hofbauer, Ann F. Gilkeson, Gary S. Oates, Jim C. TI Podocytes: A Potential Source of Nitric Oxide Production in Murine Lupus Nephritis SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 17th Annual Meeting of the Society-for-Free-Radical-Biology-Medicine /15th Biennial Meeting of the Society-for-Free-Radical-Research-International CY NOV 17-21, 2010 CL Orlando, FL SP Soc Free Radi Biol Med, Soc Free Radi Res Int C1 [Mashmoushi, Ahmad K.; Hofbauer, Ann F.; Gilkeson, Gary S.; Oates, Jim C.] Med Univ S Carolina, Charleston, SC USA. [Gilkeson, Gary S.; Oates, Jim C.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 2010 VL 49 SU 1 BP S145 EP S145 DI 10.1016/j.freeradbiomed.2010.10.406 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 681VD UT WOS:000284348000418 ER PT J AU Salmon, A Styskal, J Musi, N Levine, R Richardson, A AF Salmon, Adam Styskal, JennaLynn Musi, Nicolas Levine, Rodney Richardson, Arlan TI Obesity-induced Insulin Resistance is Regulated by Methionine Sulfoxide Reductase SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Meeting Abstract CT 17th Annual Meeting of the Society-for-Free-Radical-Biology-Medicine /15th Biennial Meeting of the Society-for-Free-Radical-Research-International CY NOV 17-21, 2010 CL Orlando, FL SP Soc Free Radi Biol Med, Soc Free Radi Res Int C1 [Salmon, Adam; Styskal, JennaLynn; Musi, Nicolas; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Musi, Nicolas; Richardson, Arlan] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Levine, Rodney] NHLBI, NIH, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PY 2010 VL 49 SU 1 BP S41 EP S41 DI 10.1016/j.freeradbiomed.2010.10.085 PG 1 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 681VD UT WOS:000284348000105 ER PT S AU Blevins, JE Baskin, DG AF Blevins, James E. Baskin, Denis G. BE Langhans, W Geary, N TI Hypothalamic-Brainstem Circuits Controlling Eating SO FRONTIERS IN EATING AND WEIGHT REGULATION SE Forum of Nutrition LA English DT Article; Book Chapter ID C-FOS EXPRESSION; CORTICOTROPIN-RELEASING HORMONE; CONDITIONED TASTE-AVERSION; NERVOUS-SYSTEM CONTROL; PARAVENTRICULAR NUCLEUS; FOOD-INTAKE; PARABRACHIAL NUCLEUS; LEPTIN RECEPTOR; CATECHOLAMINERGIC NEURONS; LATERAL HYPOTHALAMUS AB It is now axiomatic that neurons in the hypothalamic arcuate nucleus have a primary role in responding to changes in circulating levels of leptin and transmitting signals to downstream circuits that influence eating and energy expenditure. Signals generated from the gastrointestinal tract during meals reach the brainstem, via the vagus nerve and other routes, and impinge on neural circuits that influence the timing and size of meals and amount of food consumed. One of the mechanisms by which leptin exerts its anorexic effects is by increasing the effectiveness of intestinal signals that cause satiation during a meal. It is clear that the effects of gut satiation signals such as CCK can be amplified by leptin acting in the CNS, and in the arcuate nucleus in particular. The present article describes the state of our knowledge about specific neural circuits between the hypothalamus and brainstem that play a role in the interaction of leptin and meal-control signals to control food intake. Copyright (C) 2010 S. Karger AG, Basel C1 Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Blevins, James E.; Baskin, Denis G.] Univ Washington, Dept Vet Affairs, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Baskin, Denis G.] Dept Vet Affairs Puget Sound Hlth Care Syst, Res & Dev Serv, Seattle, WA 98108 USA. RP Baskin, DG (reprint author), Dept Vet Affairs Puget Sound Hlth Care Syst, Res & Dev Serv, Mail Stop S-151,1660 S Columbian Way, Seattle, WA 98108 USA. EM baskindg@uw.edu FU NIDDK NIH HHS [P30 DK-17047] NR 54 TC 45 Z9 45 U1 0 U2 3 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1660-0347 BN 978-3-8055-9300-7 J9 FORUM NUTR JI Forum Nutr. PY 2010 VL 63 BP 133 EP 140 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA BMQ74 UT WOS:000273355700011 PM 19955781 ER PT J AU Mathalon, DH Hoffman, RE Watson, TD Miller, RM Roach, BJ Ford, JM AF Mathalon, Daniel H. Hoffman, Ralph E. Watson, Todd D. Miller, Ryan M. Roach, Brian J. Ford, Judith M. TI Neurophysiological distinction between schizophrenia and schizoaffective disorder SO FRONTIERS IN HUMAN NEUROSCIENCE LA English DT Article DE schizophrenia; schizoaffective disorder; event-related potential; P300; EEG ID CYCLOID PSYCHOSES; P300 AMPLITUDE; DUAL-TASK; CLASSIFICATION; PERFORMANCE; TOPOGRAPHY; REDUCTION; DIAGNOSIS; VALIDITY; FEATURES AB Schizoaffective disorder (SA) is distinguished from schizophrenia (SZ) based on the presence of prominent mood symptoms over the illness course. Despite this clinical distinction, SA and SZ patients are often combined in research studies, in part because data supporting a distinct pathophysiological boundary between the disorders are lacking. Indeed, few studies have addressed whether neurobiological abnormalities associated with SZ, such as the widely replicated reduction and delay of the P300 event-related potential (ERP), are also present in SA. Scalp EEG was acquired from patients with DSM-IV SA (n = 15) or SZ (n = 22), as well as healthy controls (HC; n = 22) to assess the P300 elicited by infrequent target (15%) and task-irrelevant distractor (15%) stimuli in separate auditory and visual "oddball" tasks. P300 amplitude was reduced and delayed in SZ, relative to HC, consistent with prior studies. These SZ abnormalities did not interact with stimulus type (target vs. task-irrelevant distractor) or modality (auditory vs. visual). Across sensory modality and stimulus type, SA patients exhibited normal P300 amplitudes (significantly larger than SZ patients and indistinguishable from HC). However, P300 latency and reaction time were both equivalently delayed in SZ and SA patients, relative to HC. P300 differences between SA and SZ patients could not be accounted for by variation in symptom severity, socio-economic status, education, or illness duration. Although both groups show similar deficits in processing speed, SA patients do not exhibit the P300 amplitude deficits evident in SZ, consistent with an underlying pathophysiological boundary between these disorders. C1 [Mathalon, Daniel H.; Miller, Ryan M.; Roach, Brian J.; Ford, Judith M.] San Francisco VA Med Ctr, Psychiat Serv, San Francisco, CA 94121 USA. [Mathalon, Daniel H.; Miller, Ryan M.; Roach, Brian J.; Ford, Judith M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Mathalon, Daniel H.; Hoffman, Ralph E.; Ford, Judith M.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Watson, Todd D.] Lewis & Clark Coll, Dept Psychol, Portland, OR 97219 USA. RP Mathalon, DH (reprint author), San Francisco VA Med Ctr, Mental Hlth Serv 116D, 4150 Clement St, San Francisco, CA 94121 USA. EM daniel.mathalon@ucsf.edu OI Roach, Brian/0000-0002-3264-1465 FU VA Schizophrenia Biological Research Center; VA Merit Review and Research Career Development Award; National Institute of Mental Health [MH 40052, MH 58262, MH 67967]; National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD) FX This work was supported by the VA Schizophrenia Biological Research Center and VA Merit Review and Research Career Development Award, and grants from National Institute of Mental Health (MH 40052, MH 58262, MH 67967), and the National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD). NR 45 TC 26 Z9 26 U1 3 U2 10 PU FRONTIERS RES FOUND PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1662-5161 J9 FRONT HUM NEUROSCI JI Front. Hum. Neurosci. PD JAN PY 2010 VL 3 AR 70 DI 10.3389/neuro.09.070.2009 PG 10 WC Neurosciences; Psychology SC Neurosciences & Neurology; Psychology GA 556UW UT WOS:000274619800007 PM 20140266 ER PT J AU Payami, H Kay, DM Zabetian, CP Schellenberg, GD Factor, SA McCulloch, CC AF Payami, Haydeh Kay, Denise M. Zabetian, Cyrus P. Schellenberg, Gerard D. Factor, Stewart A. McCulloch, Colin C. TI Visualizing Disease Associations: Graphic Analysis of Frequency Distributions as a Function of Age Using Moving Average Plots (MAP) with Application to Alzheimer's and Parkinson's Disease SO GENETIC EPIDEMIOLOGY LA English DT Article DE GWAS; MAPT; SNCA; APOE; coffee ID GENETIC ASSOCIATION; ALPHA-SYNUCLEIN; ONSET; RISK; METAANALYSIS; SMOKING; COFFEE AB Age-related variation in marker frequency can be a confounder in association studies, leading to both false-positive and false-negative findings and subsequently to inconsistent reproducibility. We have developed a simple method, based on a novel extension of moving average plots (MAP), which allows investigators to inspect the frequency data for hidden age-related variations. MAP uses the standard case-control association data and generates a birds-eye view of the frequency distributions across the age spectrum; a picture in which one can see if, how, and when the marker frequencies in cases differ from that in controls. The marker can be specified as an allele, genotype, haplotype, or environmental factor; and age can be age-at-onset, age when subject was last known to be unaffected, or duration of exposure. Signature patterns that emerge can help distinguish true disease associations from spurious associations due to age effects, age-varying associations from associations that are uniform across all ages, and associations with risk from associations with age-at-onset. Utility of MAP is illustrated by application to genetic and epidemiological association data for Alzheimer's and Parkinson's disease. MAP is intended as a descriptive method, to complement standard statistical techniques. Although originally developed for age patterns, MAP is equally useful for visualizing any quantitative trait. Genet. Epidemiol. 34:92-99, 2010. (c) 2009 Wiley-Liss, Inc. C1 [Payami, Haydeh; Kay, Denise M.] Wadsworth Ctr, New York State Dept Hlth, Genom Inst, Albany, NY 12201 USA. [Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Schellenberg, Gerard D.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Factor, Stewart A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [McCulloch, Colin C.] Gen Elect Global Res Ctr, Appl Stat Lab, Niskayuna, NY USA. RP Payami, H (reprint author), Wadsworth Ctr, New York State Dept Hlth, Genom Inst, POB 22002, Albany, NY 12201 USA. EM hpayami@wadsworth.org OI Zabetian, Cyrus/0000-0002-7739-4306; Kay, Denise/0000-0002-9928-2698 FU National Institute for Neurological Disorders and Stroke [R01NS36960, K08-NS044138]; Michael J. Fox Foundation Edmond J. Safra Global Genetics Consortia; VA MeritAwardNational Institute of Aging [P30AG 08017, U24AG021886, P50AG05136] FX Authors thank Drs. Tatiana Foroud, Donald Higgins, Jeffrey Kaye, Patricia Kramer, Eric Molho, John Nutt, and colleagues at NeuroGenetics Research Consortium, Layton Aging & Alzheimer's Disease Center, University of Washington Alzheimer's Disease Research Center, and the National Cell Repository for Alzheimer's Disease for contributing data for analysis. This study was funded by a grant from National Institute for Neurological Disorders and Stroke (R01NS36960 Payami). Data collection was funded by Michael J. Fox Foundation Edmond J. Safra Global Genetics Consortia grant (Payami); National Institute for Neurological Disorders and Stroke (R01NS36960 Payami, K08-NS044138 Zabetian); VA MeritAward (Zabetian); and National Institute of Aging (P30AG 08017 Kaye, U24AG021886 Foroud, P50AG05136 Schellenberg). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. NR 20 TC 3 Z9 3 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0741-0395 J9 GENET EPIDEMIOL JI Genet. Epidemiol. PD JAN PY 2010 VL 34 IS 1 BP 92 EP 99 DI 10.1002/gepi.20439 PG 8 WC Genetics & Heredity; Mathematical & Computational Biology SC Genetics & Heredity; Mathematical & Computational Biology GA 542RP UT WOS:000273513000012 PM 19582778 ER PT J AU Pierre, JM AF Pierre, Joseph M. TI Hallucinations in Nonpsychotic Disorders: Toward a Differential Diagnosis of "Hearing Voices" SO HARVARD REVIEW OF PSYCHIATRY LA English DT Article DE auditory hallucinations; conversion disorder; culture; diagnosis; DSM-V; pseudohallucination; psychosis; PTSD ID POSTTRAUMATIC-STRESS-DISORDER; AUDITORY VERBAL HALLUCINATIONS; CHILDHOOD SEXUAL-ABUSE; MUSICAL HALLUCINATIONS; PSYCHOTIC SYMPTOMS; GENERAL-POPULATION; CONVERSIVE HALLUCINATIONS; ACQUIRED DEAFNESS; PSEUDO-HALLUCINATIONS; TRUE HALLUCINATIONS AB While auditory hallucinations (AH) are prototypic psychotic symptoms whose clinical presence is often equated with a psychotic disorder, they are commonly found among those without mental illness as well as those with nonpsychotic disorders not typically associated with hallucinations in DSM-IV. This incongruity presents a significant challenge for clinical work and efforts to revise the next iteration of the DSM. Auditory hallucinations found among "normal" people suggest that either AH are not as pathologic as they are typically taken to be, or that less-than-hallucinatory experiences are routinely mischaracterized as AH. Such hallucinations in the context of conversion disorder, trauma, sensory deprivation, and certain cultural settings strengthen an association between AH and psychopathology but suggest limited diagnostic specificity and relevance. It may be useful to think of AH like coughs-common experiences that are often, but not always, symptoms of pathology associated with a larger illness. Although these issues have been known for many years, they are rarely discussed In American psychiatry and need to be addressed in future research and clinical work. (HARV REV PSYCHIATRY 2010;18:22-35.) C1 [Pierre, Joseph M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA. [Pierre, Joseph M.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. RP Pierre, JM (reprint author), VA Greater Los Angeles Healthcare Syst Psychiat, 11301 Wilshire Blvd,Bldg 210,Room 15, Los Angeles, CA 90073 USA. EM joseph.pierre2@va.gov NR 154 TC 33 Z9 33 U1 11 U2 26 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1067-3229 J9 HARVARD REV PSYCHIAT JI Harv. Rev. Psychiatr. PD JAN-FEB PY 2010 VL 18 IS 1 BP 22 EP 35 DI 10.3109/10673220903523706 PG 14 WC Psychiatry SC Psychiatry GA 562NF UT WOS:000275057900002 PM 20047459 ER PT J AU Konetzka, RT Werner, RM AF Konetzka, R. Tamara Werner, Rachel M. TI Applying Market-Based Reforms To Long-Term Care SO HEALTH AFFAIRS LA English DT Article ID PAY-FOR-PERFORMANCE; QUALITY-OF-CARE; NEW-YORK-STATE; NURSING-HOME RESIDENTS; ARTERY-BYPASS-SURGERY; HEALTH-CARE; CARDIAC-SURGERY; PUBLICATION; INFORMATION; OUTCOMES AB Recent trends in U. S. long-term care policy reflect three broad goals Americans have for the quality of long-term care: improving quality of life, reducing fragmentation of delivery and financing, and increasing use of home and community-based care. At the same time, market-based reforms-namely, public reporting and pay-for-performance-have taken on their own momentum, aimed at improving the clinical quality of care among nursing home and home health care providers. The focus of reporting systems should be broadened to include quality of life in addition to clinical quality and to make measures less dependent on the setting in which care is delivered. C1 [Konetzka, R. Tamara] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. [Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Werner, Rachel M.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. RP Konetzka, RT (reprint author), Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. EM konetzka@uchicago.edu NR 44 TC 11 Z9 11 U1 1 U2 10 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JAN-FEB PY 2010 VL 29 IS 1 BP 74 EP 80 DI 10.1377/hlthaff.2009.0559 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 539JZ UT WOS:000273251500011 PM 20048363 ER PT J AU Werner, RM Konetzka, RT AF Werner, Rachel M. Konetzka, R. Tamara TI Advancing Nursing Home Quality Through Quality Improvement Itself SO HEALTH AFFAIRS LA English DT Article ID RESIDENT ASSESSMENT INSTRUMENT; PAY-FOR-PERFORMANCE; HEALTH-CARE; OF-LIFE; IMPACT AB The traditional approaches to improving the quality of care at U. S. nursing homes-regulation, inspection, and accountability through public reporting-have produced modest results. Greater progress could be made by focusing incentives on broader processes related to improving quality. This could foster a culture of upstream identification and solving of problems that would supplement existing downstream requirements to meet specific safety and care standards. C1 [Werner, Rachel M.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Werner, Rachel M.] Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Konetzka, R. Tamara] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. RP Werner, RM (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. EM rwerner@mail.med.upenn.edu FU AHRQ HHS [R01HS016478-01] NR 37 TC 15 Z9 15 U1 1 U2 6 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JAN-FEB PY 2010 VL 29 IS 1 BP 81 EP 86 DI 10.1377/hlthaff.2009.0555 PG 6 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 539JZ UT WOS:000273251500012 PM 20048364 ER PT J AU Malaty, HM AF Malaty, H. M. BE Sutton, P Mitchell, HM TI Epidemiology of Helicobacter pylori Infection SO HELICOBACTER PYLORI IN THE 21ST CENTURY SE Advances in Molecular and Cellular Microbiology LA English DT Article; Book Chapter ID PEPTIC-ULCER MORTALITY; RISK-FACTORS; GASTRIC-CANCER; BIRTH-COHORT; DUODENAL-ULCER; SOCIOECONOMIC-STATUS; PERUVIAN CHILDREN; EARLY-CHILDHOOD; UNITED-STATES; ETHNIC-GROUPS C1 Vet Affairs Med Ctr 111D, Houston, TX 77030 USA. RP Malaty, HM (reprint author), Vet Affairs Med Ctr 111D, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM Hmalaty@bcm.tmc.edu NR 75 TC 3 Z9 3 U1 3 U2 3 PU CABI PUBLISHING-C A B INT PI WALLINGFORD PA CABI PUBLISHING, WALLINGFORD 0X10 8DE, OXON, ENGLAND BN 978-1-84593-594-8 J9 ADV M C M PY 2010 IS 17 BP 1 EP 12 DI 10.1079/9781845935948.0001 D2 10.1079/9781845935948.0000 PG 12 WC Biochemistry & Molecular Biology; Gastroenterology & Hepatology; Infectious Diseases; Microbiology SC Biochemistry & Molecular Biology; Gastroenterology & Hepatology; Infectious Diseases; Microbiology GA BVZ78 UT WOS:000293218300002 ER PT J AU Seethala, S Hess, R Bossola, M Unruh, ML Weisbord, SD AF Seethala, Srikanth Hess, Rachel Bossola, Maurizio Unruh, Mark L. Weisbord, Steven D. TI Sexual function in women receiving maintenance dialysis SO HEMODIALYSIS INTERNATIONAL LA English DT Article DE Women; sexual dysfunction; dialysis ID BUPROPION-SUSTAINED-RELEASE; QUALITY-OF-LIFE; ERECTILE DYSFUNCTION; HEMODIALYSIS-PATIENTS; SILDENAFIL TREATMENT; KIDNEY-DISEASE; FUNCTION INDEX; RENAL-DISEASE; MINI-COG; VALIDATION AB While substantial attention has been paid to the issue of sexual dysfunction in men on chronic dialysis, less is known about this problem in women with end-stage renal disease. We sought to assess sexual dysfunction in women on chronic dialysis and determine whether patients discuss this problem with their providers and receive treatment. We prospectively enrolled women receiving chronic hemodialysis or peritoneal dialysis in Pittsburgh, PA. We asked patients to complete the 19-item Female Sexual Function Index (FSFI) to assess sexual function and a 5-item survey that assessed whether patients had discussed sexual dysfunction with their providers and/or received treatment for this problem in the past. We enrolled 66 patients; 59 (89%) on hemodialysis and 7 (11%) on peritoneal dialysis. All patients completed the FSFI, of whom 53 (80%) had FSFI scores < 26.55, consistent with the presence of sexual dysfunction. Of 37 patients who were married or residing with a significant other, 27 (73%) had sexual dysfunction. Among 24 participants who reported having been sexually active over the previous 4 weeks, 11 (46%) had sexual dysfunction. Only 21% of patients with sexual dysfunction had discussed this problem with their gynecologist, renal or primary provider, and 3 (6%) reported having received treatment. Sexual dysfunction is common in women on dialysis, even among patients who are married or residing with a significant other and those who are sexually active. However, few women discuss this issue with their providers or receive treatment. C1 [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Unruh, Mark L.; Weisbord, Steven D.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Bossola, Maurizio] Catholic Univ, Dept Surg, Dialysis Unit, Rome, Italy. [Hess, Rachel] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Seethala, Srikanth] Univ Pittsburgh, Med Ctr, Mercy Hosp, Dept Med, Pittsburgh, PA USA. RP Weisbord, SD (reprint author), VA Pittsburgh Healthcare Syst, Renal Sect, Mailstop 111F-U,7E Room 120, Pittsburgh, PA 15240 USA. EM weisbordsd@upmc.edu OI Seethala, Srikanth/0000-0002-2672-6884 NR 25 TC 13 Z9 13 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1492-7535 J9 HEMODIAL INT JI Hemodial. Int. PD JAN PY 2010 VL 14 IS 1 BP 55 EP 60 DI 10.1111/j.1542-4758.2009.00404.x PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 554RR UT WOS:000274452600008 PM 19758295 ER PT J AU Chatterjee, N Mishra, A Soni, R Kulkarni, H Mamtani, M Shrivasatava, M AF Chatterjee, Nirupama Mishra, Amit Soni, Ravindra Kulkarni, Hemant Mamtani, Manju Shrivasatava, Manisha TI BAYESIAN ESTIMATES OF THE PREVALENCE OF beta-THALASSEMIA TRAIT IN VOLUNTARY BLOOD DONORS OF CENTRAL INDIA: A SURVEY SO HEMOGLOBIN LA English DT Article DE beta-Thalassemia (beta-thal) trait; Voluntary blood donors; Bayesian methods; Madhya Pradesh; India ID TRANSFUSION-DEPENDENT THALASSEMIA; PRENATAL-DIAGNOSIS; DISEASE PREVALENCE; CHELATION-THERAPY; EXPERIENCE; HETEROGENEITY; POPULATIONS; MAHARASHTRA; ORIGIN; CLINES AB Early detection of beta-thalassemia (beta-thal) trait is important. Voluntary blood donors represent an important group who are accessible and cooperative for this purpose. However, the usefulness of this population in beta-thal trait detection programs has not been studied in India. We conducted a hematological survey of 5,045 blood donors who visited the Bhopal Memorial Hospital & Research Centre, Bhopal in central India. Using robust Bayesian methods, we estimated the prevalence of beta-thal trait. The overall prevalence of beta-thal trait in the study population was 9.59% [95% confidence interval (95% CI) 8.78-10.4%]. The prevalence of beta-thal trait varied across the states of origin and within the state of Madhya Pradesh. We observed a cline effect for beta-thal trait prevalence in relation to the latitude (p = 0.024). We conclude that blood donors offer an attractive adjunct to beta-thal trait detection in national programs. Our study also offers insights into the beta-thal trait gene flow and migration in India. C1 [Chatterjee, Nirupama; Mishra, Amit; Soni, Ravindra; Shrivasatava, Manisha] Bhopal Mem Hosp & Res Ctr, Dept Transfus Med, Thalassaemia Unit, Bhopal, India. [Kulkarni, Hemant; Mamtani, Manju] Lata Med Res Fdn, Nagpur, Maharashtra, India. [Kulkarni, Hemant; Mamtani, Manju] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Kulkarni, Hemant; Mamtani, Manju] S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV Infect 1, San Antonio, TX USA. RP Mamtani, M (reprint author), 12023 Waterway Rdg, San Antonio, TX 78249 USA. EM manjuhemant@gmail.com NR 44 TC 2 Z9 2 U1 0 U2 7 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0363-0269 J9 HEMOGLOBIN JI Hemoglobin PY 2010 VL 34 IS 6 BP 548 EP 560 DI 10.3109/03630269.2010.526488 PG 13 WC Biochemistry & Molecular Biology; Hematology SC Biochemistry & Molecular Biology; Hematology GA 680GS UT WOS:000284221000005 PM 21077762 ER PT B AU White, DL Firozi, A El-Serag, HB AF White, Donna L. Firozi, Amir El-Serag, Hashem B. BE Carr, BI TI Epidemiology of Hepatocellular Carcinoma SO HEPATOCELLULAR CARCINOMA: DIAGNOSIS AND TREATMENT, SECOND EDITION SE Current Clinical Oncology Series LA English DT Article; Book Chapter DE Hepatitis C; hepatitis B; cirrhosis; incidence; prevalence; risk; genetic association; coffee; insulin resistance; liver cancer; epidemiology; determinants; risk factors ID CHRONIC HEPATITIS-C; VIRUS-RELATED CIRRHOSIS; CHRONIC LIVER-DISEASE; S-TRANSFERASE M1; GENETIC POLYMORPHISMS; UNITED-STATES; RISK-FACTORS; CANCER-RISK; COFFEE CONSUMPTION; INTERFERON THERAPY AB Hepatocellular carcinoma (HCC) affects more than half a million individuals per year worldwide. It is a largely preventable disease. Most cases are related to hepatitis B virus infection in sub-Saharan Africa and Eastern Asia (except Japan). Hepatitis C virus has emerged as an important cause of HCC particularly in North America and some parts of Europe, where a recent sharp increase in HCC has been reported. There is growing evidence of an association between obesity and diabetes and increased risk of HCC; however, the causal link is still unclear. The striking geographic and racial variations in the occurrence of HCC are partly explained by the distribution of HBV and HCV infections. Additional established risk factors for HCC include older age, male sex, heavy alcohol intake, aflatoxin exposure, iron overload related to hemochromatosis, and possibly tobacco smoking. The role of diet except for alcohol drinking and aflatoxin contamination in the etiology of HCC in human Populations is largely unknown. Host genetic factors are being examined but definitive data are lacking. Most of these risk factors operate by promoting the development of cirrhosis which is present in most HCC cases. The annual risk of HCC in cirrhosis ranges between I and 7%. This review discusses in detail the epidemiology of HCC from a global perspective. C1 [White, Donna L.; Firozi, Amir; El-Serag, Hashem B.] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. [White, Donna L.; Firozi, Amir; El-Serag, Hashem B.] Baylor Coll Med, Gastroenterol Sect, Houston, TX 77030 USA. [White, Donna L.; Firozi, Amir; El-Serag, Hashem B.] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [White, Donna L.; Firozi, Amir; El-Serag, Hashem B.] Houston Ctr Qual Care & Utilizat Studies, Clin Epidemiol & Outcomes Program, Houston, TX USA. RP White, DL (reprint author), Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA. NR 86 TC 4 Z9 4 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60327-373-2 J9 CURR CLIN ONCOL PY 2010 BP 1 EP 25 DI 10.1007/978-1-60327-376-3_1 D2 10.1007/978-1-60327-376-3 PG 25 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BLX28 UT WOS:000271269800001 ER PT J AU Thameem, F Puppala, S Lehman, DM Stern, MP Blangero, J Abboud, HE Duggirala, R Habib, SL AF Thameem, Farook Puppala, Sobha Lehman, Donna M. Stern, Michael P. Blangero, John Abboud, Hanna E. Duggirala, Ravindranath Habib, Samy L. TI The Ser(326)Cys Polymorphism of 8-Oxoguanine Glycosylase 1 (OGG1) Is Associated with Type 2 Diabetes in Mexican Americans SO HUMAN HEREDITY LA English DT Article DE Mexican Americans; OGG1; Type 2 diabetes; Ser326Cys polymorphism; Association; Tagging SNPs; rs1052133 ID OXIDATIVE DNA-DAMAGE; MEASURED GENOTYPE; MELLITUS; EXPRESSION; ISLETS; ENZYME; HOGG1; GENE; RATS AB Objective: Human 8-oxoguanine glycosylase 1 (OGG1) excises oxidatively damaged promutagenic base 8-oxoguanine, a lesion previously observed in a rat model of type 2 diabetes (T2DM). The objective of the present study is to determine whether genetic variation in OGG1 is associated with type 2 diabetes (T2DM) in a Mexican American cohort. Methods: Ten SNPs including two tagging SNPs (rs1052133, rs2072668) across the OGG1 gene region were selected from the Hapmap database and genotyped in the entire cohort (n = 670; 29% diabetes; 39 families) by TaqMan assay. Association analyses between the SNPs and T2DM were performed using the measured genotype approach as implemented in the program SOLAR. Results: Of the ten SNPs genotyped, only five were polymorphic. The minor allele frequencies of these 5 SNPs ranged from 1-38%. Of the SNPs examined for association, the Ser(326)Cys (rs1052133) exhibited significant association with T2DM (p = 0.016) after accounting for age and sex effects. Another intronic variant (rs2072668), which was in strong linkage disequilibrium (r(2) = 0.96) with Ser(326)Cys also exhibited significant association with T2DM (p = 0.031). Conclusions: These results suggest for the first time that the variants in OGG1 could influence diabetes risk in these Mexican American families and support a role for alterations of OGG1 in the pathogenesis of T2DM. Copyright (C) 2010 S. Karger AG, Basel C1 [Thameem, Farook] Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Dept Med, San Antonio, TX 78229 USA. [Lehman, Donna M.; Stern, Michael P.] Univ Texas Hlth Sci Ctr San Antonio, Div Clin Epidemiol, San Antonio, TX 78229 USA. [Thameem, Farook; Abboud, Hanna E.; Habib, Samy L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, George OBrien Kidney Res Ctr, San Antonio, TX 78229 USA. [Puppala, Sobha; Blangero, John; Duggirala, Ravindranath] SW Fdn Biomed Res, Dept Genet, San Antonio, TX USA. [Abboud, Hanna E.; Habib, Samy L.] S Texas Vet Healthcare Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX USA. RP Thameem, F (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM thameem@uthscsa.edu FU NIDDK NIH HHS [R01 DK053889, DK42273, DK47482, DK53889, R01 DK042273-10, R01 DK047482, R01 DK047482-15, R01 DK053889-10] NR 19 TC 16 Z9 20 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0001-5652 J9 HUM HERED JI Hum. Hered. PY 2010 VL 70 IS 2 BP 97 EP 101 DI 10.1159/000291964 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA 633QJ UT WOS:000280518700003 PM 20606456 ER PT B AU Crilly, J Lewis, J AF Crilly, John Lewis, JoAnn BE Baralt, J Callaos, N Lesso, W Tremante, A Welsch, F TI Internet-Based Psychiatric Interventions: Applications for Rural Veterans at Risk for Suicide SO ICSIT 2010: INTERNATIONAL CONFERENCE ON SOCIETY AND INFORMATION TECHNOLOGIES (POST-CONFERENCE EDITION) LA English DT Proceedings Paper CT International Conference on Society and Information Technologies CY APR 06-09, 2010 CL Orlando, FL SP Int Inst Informat & Syst DE Internet; psychiatric interventions; rural; Veteran and suicide ID RANDOMIZED CONTROLLED-TRIAL; DEPRESSION; COMPUTER; DISORDER; PARTICIPATION; COMMUNICATION; INFORMATION; SUPPORT; ANXIETY; URBAN AB The Internet is increasingly used to host interventions to treat depression, anxiety, post traumatic stress disorder, and substance abuse. It is also used to deliver suicide prevention interventions and has particular potential for reaching groups facing distance barriers to healthcare or who are socially isolated, factors which can increase risk for suicide. Veterans with mental health problems living in rural areas pose particular access challenges for Veterans Health Affairs (VHA), the federal agency charged with providing their healthcare. Rural Veterans can easily become isolated from mental healthcare providers. Telemedicine provides some access but requires knowledge of its operation by the user as well as the proper equipment and venue. VHA recently launched an Internet crisis chat service to help address this issue. In this paper we review the field of Internet-based psychiatric interventions and discuss the potential of online applications to deliver suicide prevention for rural Veterans. C1 [Crilly, John; Lewis, JoAnn] US Dept Vet Affairs, Ctr Excellence Suicide Prevent, Canandaigua, NY 14424 USA. RP Crilly, J (reprint author), US Dept Vet Affairs, Ctr Excellence Suicide Prevent, Canandaigua, NY 14424 USA. NR 37 TC 0 Z9 0 U1 1 U2 1 PU INT INST INFORMATICS & SYSTEMICS PI ORLANDO PA 14269 LORD BARCLAY DR, ORLANDO, FL 32837 USA BN 978-1-934272-90-9 PY 2010 BP 39 EP 44 PG 6 WC Computer Science, Theory & Methods; Engineering, Electrical & Electronic SC Computer Science; Engineering GA BG7KX UT WOS:000391415500008 ER PT S AU Baskin, DG Bastian, LS AF Baskin, Denis G. Bastian, L. Scot BE Oliver, C Jamur, MC TI Immuno-Laser Capture Microdissection of Rat Brain Neurons for Real Time Quantitative PCR SO IMMUNOCYTOCHEMICAL METHODS AND PROTOCOLS, THIRD EDITION SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Laser capture microdissection; Immunocytochemistry; Immunohistochemistry; Fixation; PCR; Brain; Neuron; Gene expression ID MESSENGER-RNA ANALYSIS; ETHANOL FIXATION; GENE-EXPRESSION; CELL PICKING; PRESERVATION; SECTIONS AB Laser capture microdissection (LCM) is a technical approach for obtaining microscopic samples as small as individual cells from tissues for Molecular analysis. While the principles and details of the operation of LCM instruments, the technical requirements for obtaining identified cells for LCM "picking", all share the common feature of using a laser in combination with a microscope to microdissect and remove cells from tissue slices (or cultured cells) mounted oil a glass slide. The use of LCM is becoming widespread in pathology laboratories and is increasingly being used for gene expression Studies in cell biology. The approach is particularly powerful when used in conjunction with immunostaining techniques to obtain enriched RNA samples from cells that have been collected by picking and gathering phenotypically similar cells from anatomically complex organs such as the brain. In the present chapter, we describe all approach for combining immunocytochemistry with LCM to obtain RNA for real time quantitative PCR. C1 [Baskin, Denis G.; Bastian, L. Scot] VA Puget Sound Hlth Care Syst, Div Endocrinol Metab, Seattle, WA USA. RP Baskin, DG (reprint author), VA Puget Sound Hlth Care Syst, Div Endocrinol Metab, Seattle, WA USA. FU NIDDK NIH HHS [DK17046] NR 24 TC 2 Z9 3 U1 1 U2 2 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-58829-463-0 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2010 VL 588 BP 219 EP 230 DI 10.1007/978-1-59745-324-0_23 D2 10.1007/978-1-59745-324-0 PG 12 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BND72 UT WOS:000274239800023 PM 20012834 ER PT J AU Nair, G Shen, Q Duong, TQ AF Nair, Govind Shen, Qiang Duong, Timothy Q. TI Relaxation Time Constants and Apparent Diffusion Coefficients of Rat Retina at 7 Tesla SO INTERNATIONAL JOURNAL OF IMAGING SYSTEMS AND TECHNOLOGY LA English DT Article DE spin-spin relaxation time; spin-lattice relaxation time; BOLD; brain; apparent diffusion coefficient; eye ID BLOOD-FLOW; IN-VIVO; T-2 RELAXATION; RESOLUTION; BRAIN; MRI; COLUMNS; TISSUE; LAYERS; WATER AB MRI has recently been applied to study the retina in vivo. Measurements of relaxation time constants (T(1), T(2), and T(2)*) and the apparent diffusion coefficient (ADC) of the retina would be useful to systemically optimize structural, physiological, and functional MRI contrasts. MRI studies were performed on 12 anesthetized and paralyzed rats. High-resolution T(1), T(2), T(2)* and ADC of the rat eyes were measured at 50 x 50 x 800 mu m at 7 Tesla. Profiles of T(1), T(2), T(2)* and ADC across the retinal thickness were analyzed. Region of interests of three layers across the retinal thickness were tabulated. This study demonstrated that high resolution T(1), T(2), T(2)* and ADC of the rat retina could be imaged. Profile analysis of T(1), T(2), T(2)* and ADC across the retinal thickness were helpful to minimize partial volume effects. T(1), T(2), T(2)* and ADC of the rat retina were overall similar to those of the brain. Quantitative T1, T2, T2* and ADC may change in retinal diseases and their measurements could help to stage retinal disease progression and monitor therapeutic intervention. (C) 2010 Wiley-Periodicals, Inc. Int J Imaging Syst Technol, 20, 126-130, 2010; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/ima.20237 C1 [Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, Res Imaging Inst, San Antonio, TX 78229 USA. [Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, Res Imaging Inst, San Antonio, TX 78229 USA. [Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, Res Imaging Inst, San Antonio, TX 78229 USA. [Nair, Govind] Univ Massachusetts, Sch Med, Grad Sch Biomed Sci, Amherst, MA 01003 USA. [Nair, Govind] Worcester Polytech Inst, Worcester, MA USA. [Duong, Timothy Q.] S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, Res Imaging Inst, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu RI Shen, Qiang/B-8784-2008; Duong, Timothy/B-8525-2008 OI Shen, Qiang/0000-0002-4287-3403; NR 21 TC 19 Z9 19 U1 0 U2 3 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0899-9457 J9 INT J IMAG SYST TECH JI Int. J. Imaging Syst. Technol. PY 2010 VL 20 IS 2 SI SI BP 126 EP 130 DI 10.1002/ima.20237 PG 5 WC Engineering, Electrical & Electronic; Optics; Imaging Science & Photographic Technology SC Engineering; Optics; Imaging Science & Photographic Technology GA 604KP UT WOS:000278278200005 ER PT J AU Wulkersdorfer, B Kao, KK Agopian, VG Ahn, A Dunn, JC Wu, BM Stelzner, M AF Wulkersdorfer, B. Kao, K. K. Agopian, V. G. Ahn, A. Dunn, J. C. Wu, B. M. Stelzner, M. TI Bimodal Porous Scaffolds by Sequential Electrospinning of Poly(glycolic acid) with Sucrose Particles SO INTERNATIONAL JOURNAL OF POLYMER SCIENCE LA English DT Article AB Electrospinning is a method to produce fine, biopolymer mesh with a three-dimensional architecture that mimics native extracellular matrix. Due to the small fiber diameter created in this process, conventional electrospun scaffolds have pore sizes smaller than the diameter of most cells. These scaffolds have limited application in tissue engineering due to poor cell penetration. We developed a hybrid electrospinning/particulate leaching technique to create scaffolds with increased porosity and improved cellular ingrowth. Poly(glycolic acid) (PGA) and a sucrose-ethanol suspension were electrospun in equal, alternating sequences at intervals of one, two, and ten minutes each. The scaffolds revealed fiber mesh with micropores of 10 mu m and uniformly distributed sucrose particles. Particulate leaching of sucrose from the one- or two-minute scaffolds revealed honeycomb structures with interconnected macropores between 50 and 250 mu m. Sucrose leaching from the ten-minute scaffolds resulted in laminated structures with isolated macropores between 200 and 350 mu m. Macropore size was directly proportional to the duration of the sucrose spinning interval. After 24 hours of cell culture, conventionally spun scaffolds demonstrated no cellular penetration. Conversely, the PGA/sucrose scaffolds demonstrated deep cellular penetration. This hybrid technique represents a novel method of generating electrospun scaffolds with interconnected pores suitable for cellular ingrowth. C1 [Wulkersdorfer, B.; Kao, K. K.; Agopian, V. G.; Ahn, A.; Stelzner, M.] VA Greater Los Angeles Hlth Care Syst, Dept Surg, Los Angeles, CA 90073 USA. [Kao, K. K.; Agopian, V. G.; Dunn, J. C.; Wu, B. M.; Stelzner, M.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90095 USA. [Dunn, J. C.; Wu, B. M.] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA 90095 USA. RP Stelzner, M (reprint author), VA Greater Los Angeles Hlth Care Syst, Dept Surg, Los Angeles, CA 90073 USA. EM matthias.stelzner@med.va.gov NR 36 TC 5 Z9 5 U1 0 U2 18 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1687-9422 J9 INT J POLYM SCI JI Int. J. Polym. Sci. PY 2010 AR 436178 DI 10.1155/2010/436178 PG 9 WC Polymer Science SC Polymer Science GA V24QR UT WOS:000208425400015 ER PT J AU Kang, JS Schumacher, HR Pullman-Mooar, S AF Kang, Jane S. Schumacher, H. Ralph Pullman-Mooar, Sally TI Tendon Sheath Gout Diagnosed by Ultrasound SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Article C1 Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Kang, JS (reprint author), Columbia Univ, Div Rheumatol, 630 W 168th St,P&S 10-508, New York, NY 10032 USA. EM jsk2182@columbia.edu NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-1608 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD JAN PY 2010 VL 16 IS 1 BP 52 EP 52 DI 10.1097/RHU.0b013e3181c8877b PG 1 WC Rheumatology SC Rheumatology GA 546BN UT WOS:000273782300019 PM 20051763 ER PT J AU Batki, SL Canfield, KM Smyth, E Ploutz-Snyder, R Levine, RA AF Batki, Steven L. Canfield, Kelly M. Smyth, Emily Ploutz-Snyder, Robert Levine, Robert A. TI Hepatitis C Treatment Eligibility and Comorbid Medical Illness in Methadone Maintenance (MMT) and Non-MMT Patients: A Case-Control Study SO JOURNAL OF ADDICTIVE DISEASES LA English DT Article DE Hepatitis C; treatment; methadone; opioid; substance abuse; comorbidity; psychiatry ID INJECTION-DRUG USERS; QUALITY-OF-LIFE; VIRUS-INFECTION; RATING-SCALE; HUMAN-IMMUNODEFICIENCY; ANTIVIRAL TREATMENT; UNITED-STATES; RISK-FACTORS; RIBAVIRIN; HIV AB Comorbid medical illness is common in patients with chronic hepatitis C (HCV) infection and in methadone treatment (MMT) patients, yet little is known about the impact of medical illness on HCV treatment eligibility. Medical illness and HCV treatment eligibility were compared in a case-control study of 80 MMT patients entering an HCV treatment trial and 80 matched non-MMT patients entering HCV treatment in a gastroenterology clinic. 91% of MMT and 85% of non-MMT patients had chronic medical conditions. Despite similar medical severity ratings, a significantly higher proportion (77%) of non-MMT patients were eligible for HCV treatment than were MMT patients (56%) (p .01). Specific comorbid medical and psychiatric illness led to ineligibility in only 18% of MMT and 16% of non-MMT patients. However, failure to complete the medical evaluation process was significantly (p .001) more likely to cause ineligibility among MMT patients (19%) than non-MMT patients (0%). C1 [Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Canfield, Kelly M.; Smyth, Emily; Levine, Robert A.] SUNY Upstate Med Univ, Syracuse, NY USA. [Ploutz-Snyder, Robert] Univ Space Res Assoc, NASA JSC, Houston, TX USA. [Batki, Steven L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA. [Batki, Steven L.] San Francisco VA Med Ctr, San Francisco, CA USA. [Canfield, Kelly M.; Smyth, Emily; Levine, Robert A.] SUNY Upstate Med Univ, Syracuse, NY USA. [Ploutz-Snyder, Robert] NASA JSC, Univ Space Res Assoc, Houston, TX USA. RP Batki, SL (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St, San Francisco, CA 94121 USA. EM steven.batki@ucsf.edu FU NIDA NIH HHS [R01 DA016764-06, R01 DA016764, R01 DA 016764] NR 52 TC 2 Z9 2 U1 0 U2 3 PU HAWORTH PRESS INC PI BINGHAMTON PA 10 ALICE ST, BINGHAMTON, NY 13904-1580 USA SN 1055-0887 J9 J ADDICT DIS JI J. Addict. Dis. PY 2010 VL 29 IS 3 BP 359 EP 369 AR PII 924377213 DI 10.1080/10550887.2010.489449 PG 11 WC Substance Abuse SC Substance Abuse GA 626JY UT WOS:000279963500011 PM 20635285 ER PT J AU Primack, BA Fertman, CI Rice, KR Adachi-Mejia, AM Fine, MJ AF Primack, Brian A. Fertman, Carl I. Rice, Kristen R. Adachi-Mejia, Anna M. Fine, Michael J. TI Waterpipe and Cigarette Smoking Among College Athletes in the United States SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Athletes; Waterpipe; Hookah; Tobacco; Team sports; Club sports; Intramural sports; Varsity sports; Organized sports; College ID TOBACCO SMOKING; CARBON-MONOXIDE; DRUG-USE; STUDENTS; PREVALENCE; NICOTINE; PIPE; DRINKING; FREQUENCY; PRODUCTS AB Purpose: Tobacco use using a waterpipe is an emerging trend among college students. Although cigarette smoking is low among college athletes, waterpipe tobacco smoking may appeal to this population. The purpose of this study was to compare cigarette and waterpipe tobacco smoking in terms of their associations with organized sport participation. Methods: In the spring of 2008, we conducted an online survey of 8,745 college students at eight institutions as part of the revised National College Health Assessment. We used multivariable regression models to assess the associations between tobacco use (cigarette and waterpipe) and organized sports participation. Results: Participants reported participation in varsity (5.2%), club (11.9%), and intramural (24.9%) athletics. Varsity athletes and individuals who were not varsity athletes had similar rates of waterpipe tobacco smoking (27.6% vs. 29.5%, p = .41). However, other types of athletes were more likely than their counterparts to have smoked waterpipe tobacco (35.1% vs. 28.7%, p < .001 for club sports and 34.8% vs. 27.7%, p < .001 for intramural sports). In fully-adjusted multivariable models, sports participants of any type had lower odds of having smoked cigarettes, whereas participants who played intramural sports (odds ratio = 1.15, 95% confidence interval = 1.03, 1.29) or club sports (odds ratio = 1.15, 95% confidence interval = 1.001, 1.33) had significantly higher odds of having smoked waterpipe tobacco. Conclusions: College athletes are susceptible to waterpipe tobacco use. In fact, compared with their nonathletic counterparts, club sports participants and intramural sports participants generally had higher odds of waterpipe tobacco smoking. Allure for waterpipe tobacco smoking may exist even for individuals who are traditionally considered at low risk for tobacco use. (C) 2010 Society for Adolescent Medicine. All rights reserved. C1 [Primack, Brian A.; Rice, Kristen R.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Pittsburgh, PA 15213 USA. [Primack, Brian A.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Primack, Brian A.] Univ Pittsburgh, Sch Med, Dept Pediat, Div Adolescent Med, Pittsburgh, PA 15213 USA. [Fertman, Carl I.] Univ Pittsburgh, Sch Educ, Dept Hlth & Phys Act, Pittsburgh, PA 15213 USA. [Adachi-Mejia, Anna M.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pediat,Hood Ctr Children & Families, Hanover, NH 03756 USA. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Fine, Michael J.] VA Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Primack, BA (reprint author), Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM bprimack@pitt.edu OI Adachi-Mejia, Anna/0000-0001-5980-3850 FU National Cancer Institute [K07-CA114315]; Maurice Falk Foundation FX Dr. Primack is supported in part by a Physician Faculty Scholar Award from the Robert Wood Johnson Foundation, a career development award from the National Cancer Institute (K07-CA114315), and a grant from the Maurice Falk Foundation. Dr. Primack had full access to all data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The authors thank Drs. Mary Hoban and E. Victor Leino for their assistance with data management. NR 30 TC 54 Z9 55 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD JAN PY 2010 VL 46 IS 1 BP 45 EP 51 DI 10.1016/j.jadohealth.2009.05.004 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 548RE UT WOS:000273983100008 PM 20123257 ER PT J AU Baker, LD Frank, LL Foster-Schubert, K Green, PS Wilkinson, CW McTiernan, A Cholerton, BA Plymate, SR Fishel, MA Watson, GS Duncan, GE Mehta, PD Craft, S AF Baker, Laura D. Frank, Laura L. Foster-Schubert, Karen Green, Pattie S. Wilkinson, Charles W. McTiernan, Anne Cholerton, Brenna A. Plymate, Stephen R. Fishel, Mark A. Watson, G. Stennis Duncan, Glen E. Mehta, Pankaj D. Craft, Suzanne TI Aerobic Exercise Improves Cognition for Older Adults with Glucose Intolerance, A Risk Factor for Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Aerobic exercise; Alzheimer's disease; cognition; dementia; diabetes; executive function; glucose intolerance; prediabetes ID INSULIN-RESISTANCE SYNDROME; EXECUTIVE DYSFUNCTION; ELDERLY INDIVIDUALS; NEUROTROPHIC FACTOR; DIABETES-MELLITUS; PHYSICAL-ACTIVITY; TRANSGENIC MODEL; WORKING-MEMORY; FRONTAL-LOBE; AGING HUMANS AB Impaired glucose regulation is a defining characteristic of type 2 diabetes mellitus (T2DM) pathology and has been linked to increased risk of cognitive impairment and dementia. Although the benefits of aerobic exercise for physical health are well-documented, exercise effects on cognition have not been examined for older adults with poor glucose regulation associated with prediabetes and early T2DM. Using a randomized controlled design, twenty-eight adults (57-83 y old) meeting 2-h tolerance test criteria for glucose intolerance completed 6 months of aerobic exercise or stretching, which served as the control. The primary cognitive outcomes included measures of executive function (Trails B, Task Switching, Stroop, Self-ordered Pointing Test, and Verbal Fluency). Other outcomes included memory performance (Story Recall, List Learning), measures of cardiorespiratory fitness obtained via maximal-graded exercise treadmill test, glucose disposal during hyperinsulinemic-euglycemic clamp, body fat, and fasting plasma levels of insulin, cortisol, brain-derived neurotrophic factor, insulin-like growth factor-1, amyloid-beta (A beta(40) and A beta(42)). Six months of aerobic exercise improved executive function (MANCOVA, p = 0.04), cardiorespiratory fitness (MANOVA, p = 0.03), and insulin sensitivity (p = 0.05). Across all subjects, 6-month changes in cardiorespiratory fitness and insulin sensitivity were positively correlated (p = 0.01). For A beta(42), plasma levels tended to decrease for the aerobic group relative to controls (p = 0.07). The results of our study using rigorous controlled methodology suggest a cognition-enhancing effect of aerobic exercise for older glucose intolerant adults. Although replication in a larger sample is needed, our findings potentially have important therapeutic implications for a growing number of adults at increased risk of cognitive decline. C1 [Baker, Laura D.; Frank, Laura L.; Wilkinson, Charles W.; Cholerton, Brenna A.; Watson, G. Stennis; Craft, Suzanne] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Foster-Schubert, Karen; Green, Pattie S.; McTiernan, Anne; Plymate, Stephen R.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Foster-Schubert, Karen; McTiernan, Anne] Fred Hutchinson Canc Res Ctr, Canc Prevent Res Program, Seattle, WA 98104 USA. [Green, Pattie S.] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA USA. [Fishel, Mark A.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Duncan, Glen E.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Nutr Sci Program, Seattle, WA 98195 USA. [Mehta, Pankaj D.] New York State Inst Basic Res Dev Disabil, Dept Immunol, New York, NY USA. [Baker, Laura D.; Frank, Laura L.; Wilkinson, Charles W.; Cholerton, Brenna A.; Plymate, Stephen R.; Fishel, Mark A.; Watson, G. Stennis; Craft, Suzanne] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA 98108 USA. RP Baker, LD (reprint author), VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, GRECC A-182,1660 S Columbian Way, Seattle, WA 98108 USA. EM ldbaker@uw.edu RI Duncan, Glen/A-3771-2008 OI Duncan, Glen/0000-0001-6909-1869 FU Office of Research and Development Medical Research Service; Geriatric Research, Education and Clinical Center of the Department of Veterans Affairs; American Diabetes Association [7-04-CR-02] FX This work was supported by the Office of Research and Development Medical Research Service and the Geriatric Research, Education and Clinical Center of the Department of Veterans Affairs, and the American Diabetes Association (Clinical Research Award: 7-04-CR-02). Neither funding source provided scientific input to the study. The principal investigator, Dr. Baker, had full access to all of the data and takes responsibility for the integrity of the data and the accuracy of the data analysis which was conducted without input from the funding agencies. The authors have no conflict of interest to disclose. Throughout the study, the YMCA of Greater Seattle, the YMCA of Tacoma-Pierce County, and the South Sound YMCA worked closely with us to provide exercise facilities for participants. We are grateful to the members of our laboratory who contributed many hours to this project including Karen Enstrom, RN, Darla Chapman, RN, Donna Davis, RN, Laura Fisher, Lauren Smith, Jaime Tidwell, Tracia Clark, Amy Morgan, Brenna Renn, and Meg Wojtowicz, and to Elizabeth Colasurdo for her assistance with the cortisol assays. NR 72 TC 58 Z9 59 U1 6 U2 42 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 22 IS 2 BP 569 EP 579 DI 10.3233/JAD-2010-100768 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 681JW UT WOS:000284309200017 PM 20847403 ER PT J AU Subramanian, S Ayala, P Wadsworth, TL Harris, CJ Vandenbark, AA Quinn, JF Offner, H AF Subramanian, Sandhya Ayala, Patricia Wadsworth, Teri L. Harris, Christopher J. Vandenbark, Arthur A. Quinn, Joseph F. Offner, Halina TI CCR6: A Biomarker for Alzheimer's-like Disease in a Triple Transgenic Mouse Model SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE 3xTg-AD Mice; Alzheimer's Disease; CCR6; inflammation ID REGULATORY T-CELLS; A-BETA; CLONAL EXPANSIONS; ELEVATED LEVELS; CD4(+) T; MICE; MEMORY; BRAIN; MICROGLIA; STROKE AB The inflammatory status of the brain in patients as well as animal models of Alzheimer's disease (AD) has been extensively studied. Accumulation of activated microglia producing tumor necrosis factor-alpha and monocyte chemotactic protein-1 contribute to the pathology of the disease. However, little is known about the changes in the spleen and associated peripheral immunity that might contribute to AD pathology. The goal of this study was to characterize phenotypic and functional changes in spleen, blood and brain cell populations that contribute to development of an AD-like disease in a triple transgenic (3xTg-AD) mouse model. The 3xTg-AD mice had increased percentages of brain Gr-1+ granulocytes, dendritic cells and macrophages, spleen and blood derived CD8+Ly6C+ memory T cells and CCR6+ B cells, as well as increased levels of secreted interleukin-6. Brain tissue from older 12 month old symptomatic 3xTg-AD female mice exhibited highly elevated mRNA expression of CCR6 compared to wild-type mice. Importantly, this pronounced increase in expression of CCR6 was also detected in brain and spleen tissue from pre-symptomatic 5-6 month old 3xTg-AD females and males. Our data demonstrate increased expression of CCR6 in the brain and peripheral immune organs of both pre-symptomatic and symptomatic 3xTg-AD mice, strongly suggesting an ongoing inflammatory process that precedes onset of clinical AD-like disease. C1 [Subramanian, Sandhya; Wadsworth, Teri L.; Harris, Christopher J.; Vandenbark, Arthur A.; Quinn, Joseph F.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Ayala, Patricia; Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. [Subramanian, Sandhya; Ayala, Patricia; Vandenbark, Arthur A.; Quinn, Joseph F.; Offner, Halina] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Portland, OR 97201 USA. RP Offner, H (reprint author), Portland VA Med Ctr, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU Department of Veterans' Affairs; National Institutes of Health [NS45445, NS47661]; Biomedical Laboratory R&D Service, Department of Veterans Affairs FX This work was supported in part by a Department of Veterans' Affairs Merit Review Grant (Joseph Quinn); National Institutes of Health Grants NS45445 (Halina Offner) and NS47661 (Arthur A. Vandenbark); and The Biomedical Laboratory R&D Service, Department of Veterans Affairs. The authors wish to thank Ms. Eva K. Niehaus for assistance in manuscript preparation. NR 49 TC 18 Z9 18 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 22 IS 2 BP 619 EP 629 DI 10.3233/JAD-2010-100852 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 681JW UT WOS:000284309200021 PM 20847401 ER PT J AU Wang, J Santa-Maria, I Ho, L Ksiezak-Reding, H Ono, K Teplow, DB Pasinetti, GM AF Wang, Jun Santa-Maria, Ismael Ho, Lap Ksiezak-Reding, Hanna Ono, Kenjiro Teplow, David B. Pasinetti, Giulio Maria TI Grape Derived Polyphenols Attenuate Tau Neuropathology in a Mouse Model of Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Aggregation; Alzheimer's disease; hyperphosphorylation; neurofibrillary tangles; tauopathies ID PAIRED HELICAL FILAMENTS; PROGRESSIVE SUPRANUCLEAR PALSY; BETA-STRUCTURE; IN-VITRO; PROTEIN; KINASE; PHOSPHORYLATION; SEED; BRAIN; ERK2 AB Aggregation of microtubule-associated protein tau into insoluble intracellular neurofibrillary tangles is a characteristic hallmark of Alzheimer's disease (AD) and other neurodegenerative diseases, including progressive supranuclear palsy, argyrophilic grain disease, corticobasal degeneration, frontotemporal dementias with Parkinsonism linked to chromosome 17, and Pick's disease. Tau is abnormally hyperphosphorylated in AD and aberrant tau phosphorylation contributes to the neuropathology of AD and other tauopathies. Anti-aggregation and anti-phosphorylation are main approaches for tau-based therapy. In this study, we report that a select grape-seed polyphenol extract (GSPE) could potently interfere with the assembly of tau peptides into neurotoxic aggregates. Moreover, oral administration of GSPE significantly attenuated the development of AD type tau neuropathology in the brain of TMHT mouse model of AD through mechanisms associated with attenuation of extracellular signal-receptor kinase 1/2 signaling in the brain. C1 [Wang, Jun; Santa-Maria, Ismael; Ho, Lap; Ksiezak-Reding, Hanna; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Wang, Jun; Santa-Maria, Ismael; Ho, Lap; Ksiezak-Reding, Hanna; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Santa-Maria, Ismael] Queen Sofia Fdn, CIEN Fdn, Alzheimer Dis Res Unit, Madrid, Spain. [Ho, Lap; Ksiezak-Reding, Hanna; Pasinetti, Giulio Maria] James J Peters Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Ono, Kenjiro] Kanazawa Univ, Grad Sch Med Sci, Takara Machi, Kanazawa, Japan. [Ono, Kenjiro; Teplow, David B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Ono, Kenjiro; Teplow, David B.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. [Ono, Kenjiro; Teplow, David B.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU Department of Veterans Affairs, Veterans Health Administration; Office of Research and Development and Biomedical Laboratory Research and Development at the James J. Peters Veteran Affairs Medical Center; National Institute of Health [PO1AT004511, AG027818]; CurePSP; Jim Easton Consortium for Alzheimer's Drug Discovery and Biomarkers at UCLA FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration, and Office of Research and Development and Biomedical Laboratory Research and Development at the James J. Peters Veteran Affairs Medical Center to GMP; the National Institute of Health grant PO1AT004511 to GMP; and in part by funding from CurePSP awarded to GMP. This work was further supported by the Jim Easton Consortium for Alzheimer's Drug Discovery and Biomarkers at UCLA to DBT and National Institute of Health grant AG027818 to DBT. NR 37 TC 43 Z9 44 U1 1 U2 10 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 22 IS 2 BP 653 EP 661 DI 10.3233/JAD-2010-101074 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 681JW UT WOS:000284309200024 PM 20858961 ER PT J AU Arrieta-Cruz, I Wang, J Pavlides, C Pasinetti, GM AF Arrieta-Cruz, Isabel Wang, Jun Pavlides, Constantine Pasinetti, Giulio Maria TI Carvedilol Reestablishes Long-Term Potentiation in a Mouse Model of alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; carvedilol; epileptic discharges; hippocampus; LTP; neuronal transmission; synaptic plasticity; TgCRND8 mice ID ADRENERGIC-RECEPTOR ACTIVATION; MICE; STIMULATION; EPILEPSY; LTP AB In this study, we examined acute effects of carvedilol, a nonselective alpha/beta-adrenergic receptor blocker, on neuronal transmission and long-term potentiation (LTP) in six month-old TgCRND8 mice and their wild-type age-matched controls. Field excitatory postsynaptic potentials were recorded in the CA1 region of the hippocampus from carvedilol-or vehicle dimethyl sulfoxide-treated slices, and differences in basal synaptic transmission and LTP were assessed. Carvedilol treatment produced a significant increase in basal synaptic transmission and LTP in TgCRND8 mice, as compared to their vehicle-treated slices, in which basal neuronal transmission and LTP decreased. Interestingly, carvedilol significantly suppressed spontaneous seizure activity in TgCRND8 mice as measured by the number of slices showing epileptic discharges as well as the number of spikes within these and the amplitude of the second spike, measured at baseline and end of recording. In contrast, vehicle-treated slices in TgCRND8 mice did not show a significant decrease in epileptic discharges. These results suggest that carvedilol reestablishes basal synaptic transmission, enhances neuronal plasticity and suppresses neuronal hyperexcitability in TgCRND8 mice. C1 [Arrieta-Cruz, Isabel; Wang, Jun; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Pavlides, Constantine] Rockefeller Univ, New York, NY 10021 USA. [Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU Altschul Foundation; National Institute of Aging [U01 AG02219]; Geriatrics, Research, Education and Clinical Center at the James J. Peters Veteran Affairs Medical Center FX These studies were generously supported by funding from the Altschul Foundation, the National Institute of Aging (U01 AG02219), and the Geriatrics, Research, Education and Clinical Center at the James J. Peters Veteran Affairs Medical Center awarded to GMP. We would like to thank Dr. Bing Gong for his comments and Miss Hayley Fivecoat for her assistance in the preparation of this manuscript. NR 15 TC 15 Z9 16 U1 0 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 21 IS 2 BP 649 EP 654 DI 10.3233/JAD-2010-100225 PG 6 WC Neurosciences SC Neurosciences & Neurology GA 650XM UT WOS:000281887600029 PM 20571219 ER PT J AU Quinn, JF Harris, CJ Cobb, KE Domes, C Ralle, M Brewer, G Wadsworth, TL AF Quinn, Joseph F. Harris, Christopher J. Cobb, Katherine E. Domes, Christopher Ralle, Martina Brewer, George Wadsworth, Teri L. TI A Copper-Lowering Strategy Attenuates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid; copper; tetrathiomolybdate; Tg2576 ID TARGETING A-BETA; AMMONIUM TETRATHIOMOLYBDATE; WILSON-DISEASE; DOUBLE-BLIND; ZINC; MICE; THERAPY; EFFICACY; PEPTIDE; TRIAL AB There is increasing evidence for the crucial role of metals in the pathology of Alzheimer's disease. Both the aggregation and neurotoxicity of amyloid-beta are dependent on the presence of copper. This study investigated the ability of the copper-complexing drug tetrathiomolybdate to reduce amyloid-beta pathology and spatial memory impairment in both a prevention and a treatment paradigm in the Tg2576 mouse model of Alzheimer's disease. Tetrathiomolybdate treatment lowered brain copper and reduced amyloid-beta levels in the prevention paradigm, but not in the treatment paradigm. Our data suggests that controlled lowering of systemic copper may achieve anti-amyloid effects if initiated early in the disease process. C1 [Quinn, Joseph F.] P3 R&D, Portland Vet Affairs Med Ctr, Portland, OR USA. [Quinn, Joseph F.; Harris, Christopher J.; Cobb, Katherine E.; Wadsworth, Teri L.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Domes, Christopher] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Ralle, Martina] Oregon Hlth & Sci Univ, Dept Biochem, Portland, OR 97201 USA. [Brewer, George] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA. RP Quinn, JF (reprint author), Oregon Hlth & Sci Univ, Dept Neurol CR 131, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. EM quinnj@ohsu.edu FU Department of Veteran [R21 AG027445] FX This work was supported by a Department of Veteran's Affairs Merit Review Grant and R21 AG027445 to Joseph F. Quinn. NR 27 TC 11 Z9 11 U1 4 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 21 IS 3 BP 903 EP 914 DI 10.3233/JAD-2010-100408 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 651DA UT WOS:000281903600020 PM 20693639 ER PT J AU Bartzokis, G Lu, PH Tishler, TA Peters, DG Kosenko, A Barrall, KA Finn, JP Villablanca, P Laub, G Altshuler, LL Geschwind, DH Mintz, J Neely, E Connor, JR AF Bartzokis, George Lu, Po H. Tishler, Todd A. Peters, Douglas G. Kosenko, Anastasia Barrall, Katherine A. Finn, J. Paul Villablanca, Pablo Laub, Gerhard Altshuler, Lori L. Geschwind, Daniel H. Mintz, Jim Neely, Elizabeth Connor, James R. TI Prevalent Iron Metabolism Gene Variants Associated with Increased Brain Ferritin Iron in Healthy Older Men SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alpha synuclein; amyloid; basal ganglia; chelation; dementia; diet; free radicals; gene; gray matter; iron; Lewy body; metal; myelin; oligodendrocytes; prevention; risk; tau; treatment ID AMYOTROPHIC-LATERAL-SCLEROSIS; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; HEMOCHROMATOSIS GENE; HEREDITARY HEMOCHROMATOSIS; COGNITIVE IMPAIRMENT; OXIDATIVE STRESS; BASAL GANGLIA; HFE MUTATIONS; MR EVALUATION AB Prevalent gene variants involved in iron metabolism [hemochromatosis (HFE) H63D and transferrin C2 (TfC2)] have been associated with higher risk and earlier age at onset of Alzheimer's disease (AD), especially in men. Brain iron increases with age, is higher in men, and is abnormally elevated in several neurodegenerative diseases, including AD and Parkinson's disease, where it has been reported to contribute to younger age at onset in men. The effects of the common genetic variants (HFE H63D and/or TfC2) on brain iron were studied across eight brain regions (caudate, putamen, globus pallidus, thalamus, hippocampus, white matter of frontal lobe, genu, and splenium of corpus callosum) in 66 healthy adults (35 men, 31 women) aged 55 to 76. The iron content of ferritin molecules ( ferritin iron) in the brain was measured with MRI utilizing the Field Dependent Relaxation Rate Increase (FDRI) method. 47% of the sample carried neither genetic variant (IRON-) and 53% carried one and/or the other (IRON+). IRON+ men had significantly higher FDRI compared to IRON- men (p = 0.013). This genotype effect was not observed in women who, as expected, had lower FDRI than men. This is the first published evidence that these highly prevalent genetic variants in iron metabolism genes can influence brain iron levels in men. Clinical phenomena such as differential gender-associated risks of developing neurodegenerative diseases and age at onset may be associated with interactions between iron genes and brain iron accumulation. Clarifying mechanisms of brain iron accumulation may help identify novel interventions for age-related neurodegenerative diseases. C1 [Bartzokis, George; Tishler, Todd A.; Peters, Douglas G.; Kosenko, Anastasia; Barrall, Katherine A.; Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Bartzokis, George; Tishler, Todd A.; Peters, Douglas G.; Kosenko, Anastasia; Barrall, Katherine A.; Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst, Los Angeles, CA 90095 USA. [Bartzokis, George] Univ Calif Los Angeles, Dept Neurol, Div Brain Mapping, Lab Neuroimaging, Los Angeles, CA 90024 USA. [Bartzokis, George; Tishler, Todd A.; Peters, Douglas G.; Kosenko, Anastasia; Altshuler, Lori L.] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. [Lu, Po H.; Geschwind, Daniel H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Finn, J. Paul; Villablanca, Pablo] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA. [Laub, Gerhard] Siemens Med Solut, Los Angeles, CA USA. [Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Neely, Elizabeth; Connor, James R.] Penn State Hershey Med Ctr, Dept Neurosurg, Hershey, PA USA. RP Bartzokis, G (reprint author), 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA. EM gbar@ucla.edu RI Bartzokis, George/K-2409-2013 FU NIH [MH 0266029, AG027342, MH51928]; Department of Veterans Affairs; RCS Alzheimer's Foundation; George M Leader Family FX This work was supported in part by NIH grants (MH 0266029; AG027342; MH51928), the Department of Veterans Affairs, the RCS Alzheimer's Foundation, and the George M Leader Family. NR 67 TC 32 Z9 32 U1 1 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 20 IS 1 BP 333 EP 341 DI 10.3233/JAD-2010-1368 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 582TS UT WOS:000276622600031 PM 20164577 ER PT J AU Carlsson, CM AF Carlsson, Cynthia M. TI Type 2 Diabetes Mellitus, Dyslipidemia, and Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Review DE Alzheimer's disease; biological markers; cognition; diabetes mellitus; dyslipidemia; prevention ID AMYLOID PRECURSOR PROTEIN; VASCULAR RISK-FACTORS; IMPAIRED GLUCOSE-TOLERANCE; MILD COGNITIVE IMPAIRMENT; TOTAL CHOLESTEROL LEVEL; POPULATION-BASED COHORT; GLYCATION END-PRODUCTS; METABOLIC SYNDROME; LATE-LIFE; ENDOTHELIAL DYSFUNCTION AB The prevalence of Alzheimer's disease (AD) is increasing rapidly, heightening the importance of finding effective preventive therapies for this devastating disease. Midlife vascular risk factors, including type 2 diabetes mellitus (T2DM), have been associated with increased risk of AD decades later and may serve as targets for AD prevention. Studies to date suggest that T2DM and hyperinsulinemia increase risk for AD, possibly through their effects on amyloid-beta metabolism and cerebrovascular dysfunction - two early findings in preclinical AD pathology. This paper reviews the evidence supporting a relationship between T2DM, hyperinsulinemia, and diabetic dyslipidemia on the development of AD, discusses DM treatment trials and their preliminary results on cognitive function, and proposes some strategies for optimizing future AD prevention trial design. C1 [Carlsson, Cynthia M.] Univ Wisconsin, Sect Geriatr & Gerontol, Sch Med & Publ Hlth, Madison VA GRECC D4211,Dept Med, Madison, WI 53705 USA. [Carlsson, Cynthia M.] William S Middleton Mem Vet Adm Med Ctr, Wisconsin Alzheimers Dis Res Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. RP Carlsson, CM (reprint author), Univ Wisconsin, Sect Geriatr & Gerontol, Sch Med & Publ Hlth, Madison VA GRECC D4211,Dept Med, 2500 Overlook Terrace, Madison, WI 53705 USA. EM cmc@medicine.wisc.edu FU National Institute on Aging [K23 AG026752] FX Dr. Carlsson was supported in part through National Institute on Aging grant K23 AG026752. This is Madison VA GRECC manuscript number # 2010-03. NR 108 TC 41 Z9 43 U1 0 U2 17 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 20 IS 3 BP 711 EP 722 DI 10.3233/JAD-2010-100012 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 620YH UT WOS:000279538600004 PM 20413858 ER PT J AU Middleton, LE Yaffe, K AF Middleton, Laura E. Yaffe, Kristine TI Targets for the Prevention of Dementia SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Review DE Cognitive activity; dementia; diet; physical activity; prevention; social engagement; vascular risk ID MILD COGNITIVE IMPAIRMENT; INCIDENT ALZHEIMER-DISEASE; PLACEBO-CONTROLLED TRIAL; MIDLIFE BLOOD-PRESSURE; N-3 FATTY-ACIDS; PHYSICAL-ACTIVITY; METABOLIC SYNDROME; DIABETES-MELLITUS; OLDER-ADULTS; MEDITERRANEAN DIET AB The prevalence of dementia is expected to increase dramatically over the upcoming decades due to the aging population. Since treatment is still short of a cure, preventative strategies are of the utmost importance. Stimulating activity (cognitive, physical, and social), vascular risk factors, and diet may be important in preventative strategies. Dementia risk may be modified by participation in stimulating activities. One study suggested that the cognitive, physical, and social components of activity were of equal importance to cognitive outcomes. However, while exercise interventions appear to benefit global cognition, the benefits from cognitive training appear to be domain specific. People with vascular risk factors (hypertension, diabetes, dyslipidemia, and obesity) appear to be at higher risk for dementia than those without in observational and clinical trials. Controlled trials suggest that vascular risk management via some pharmaceutical interventions may benefit cognition, though results are inconsistent. Finally, people who adhere to a Mediterranean diet or who have high intake of antioxidants and omega-3 fatty acids have reduced likelihood of dementia in observational studies. However, supplementation in controlled trials has not generally proved successful at improving cognitive outcomes. A single supplement may be insufficient to prevent dementia; it may be that the overall diet is more important. Future large randomized controlled studies should examine whether interventions can reduce the risk of dementia and whether combining cognitive, physical, and social activity, vascular risk reduction, and dietary interventions might have additive or multiplicative effects. C1 [Middleton, Laura E.] Sunnybrook Hlth Sci Ctr, Heart & Stroke Fdn Ctr Stroke Recovery, Toronto, ON M4N 3M5, Canada. [Yaffe, Kristine] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Middleton, LE (reprint author), 2075 BayviewAve, Toronto, ON M4N 3M5, Canada. EM Middleton_1@hotmail.com RI Middleton, Laura/C-6024-2009 OI Middleton, Laura/0000-0001-8624-3123 FU Canadian Institute of Health Research (CIHR); NIA [AG031155] FX Dr. Middleton is supported by a Canadian Institute of Health Research (CIHR) fellowship. Dr. Yaffe is supported in part by NIA grant AG031155. NR 122 TC 39 Z9 39 U1 3 U2 36 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 20 IS 3 BP 915 EP 924 DI 10.3233/JAD-2010-091657 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 620YH UT WOS:000279538600023 PM 20413867 ER PT J AU Hernandez, S McClendon, MJ Zhou, XHA Sachs, M Lerner, AJ AF Hernandez, Santiago McClendon, McKee J. Zhou, Xiao-Hua Andrew Sachs, Michael Lerner, Alan J. TI Pharmacological Treatment of Alzheimer's Disease: Effect of Race and Demographic Variables SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Acetylcholinesterase inhibitor; Alzheimer's disease; disparity; ethnicity; memantine; race ID PRESCRIPTION DRUG-USE; 600,000 OLDER-PEOPLE; RACIAL DISPARITIES; ETHNIC DISPARITIES; DEMENTIA DRUGS; POPULATION; SCHIZOPHRENIA; MEDICATIONS; SERVICES; WHITES AB Existing research shows differences in medication use for Alzheimer's disease (AD) based on demographics such as race, ethnicity, and geographical location. To determine individual and community characteristics associated with differences in acetylcholinesterase inhibitor (AChEI) and memantine use in AD, 3,049 AD subjects were drawn from 30 centers and evaluated using the Uniform data set (UDS). Cases were evaluated at the individual level within the context of 31 communities (one center encompassed two separate geographical regions). Multivariate analysis was used to determine the significance of individual variables on medication use. Compared to non-Hispanic Whites, Blacks were less likely to use AChEI and memantine with odds ratios (OR) of 0.59 (95% CI 0.46-0.76) and 0.43 (95% CI 0.32-0.57), respectively. Compared to non-Hispanic Whites, non-Black Hispanics were less likely to use memantine (OR = 0.69 (95% CI 0.49-0.98)). No association was found between the proportion of Blacks or non-Black Hispanics versus non-Hispanic Whites at an Alzheimer Disease Center and individual use of AChEI or memantine. Other significant variables include gender, age, marital status, dementia severity, source of referral, AChEI use, and education. Education and age somewhat mitigated disparity. Significant racial and ethnic differences in AChEI and memantine use exist at the individual level regardless of the racial and ethnic composition of the individual's community. Research and initiatives at the societal level may be an important consideration toward addressing these differences. C1 [Hernandez, Santiago] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. [McClendon, McKee J.; Lerner, Alan J.] Case Western Reserve Univ, Univ Memory & Cognit Ctr, Cleveland, OH 44106 USA. [Zhou, Xiao-Hua Andrew] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Sch Publ Hlth & Community Med,Dept Biostat, Seattle, WA 98195 USA. [Zhou, Xiao-Hua Andrew; Sachs, Michael] Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, US Dept Vet Affairs, Seattle, WA USA. [Lerner, Alan J.] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA. [Lerner, Alan J.] Univ Hosp, Case Med Ctr, Cleveland, OH USA. RP Lerner, AJ (reprint author), Memory & Cognit Ctr, 3619 Pk E Dr 211, Beachwood, OH 44122 USA. EM alan.lerner@case.edu FU NIA [P50 AG08012] FX The authors wish to acknowledge Nathaniel Mercaldo, MS and the staff of the National Alzheimer's Coordinating Center (U01 AG016976) for assistance in providing access to the database and preparation of datasets. This work was supported in part by NIA grant P50 AG08012. NR 27 TC 9 Z9 9 U1 2 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 19 IS 2 BP 665 EP 672 DI 10.3233/JAD-2010-1269 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 582RL UT WOS:000276616000024 PM 20110610 ER PT J AU DeMichele-Sweet, MA Sweet, RA AF DeMichele-Sweet, Mary Ann Sweet, Robert A. TI Genetics of Psychosis in Alzheimer's Disease: A Review SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Review DE APOE; association analysis; COMT; dopamine; heritability; linkage analysis; NRG1; serotonin ID SEROTONIN TRANSPORTER GENE; APOLIPOPROTEIN-E GENOTYPE; O-METHYLTRANSFERASE GENE; CARDIO-FACIAL SYNDROME; CEREBRAL AMYLOID ANGIOPATHY; INCREASED FAMILIAL RISK; D3 RECEPTOR GENE; LATE-ONSET; PSYCHOLOGICAL SYMPTOMS; NEUROPSYCHIATRIC SYMPTOMS AB In and of itself, late-onset Alzheimer's disease (AD) can be a devastating illness. However, a sub-group of AD patients develop psychosis as the disease progresses. These patients have an added burden of greater cognitive impairment, higher rates of institutionalization, and higher mortality than AD patients without psychosis. While the etiopathogenesis of psychosis in AD (AD+P) is not known, mounting evidence accrued over the past ten years indicates that AD+P represents a distinct phenotype with a genetic basis. Elucidating the genetic mechanism of AD+P is crucial if better pharmaceutical treatments are to be developed for these patients. The goal of this review is to summarize what is currently known regarding the genetic basis of psychosis in AD. Specific attention is given to familial aggregation and heritability, linkage to chromosomal loci, and associations of candidate genes such as APOE and the monoamine neurotransmitter system. C1 [DeMichele-Sweet, Mary Ann; Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA. RP Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu FU USPHS [AG027224, AG05133] FX This work was supported by USPHS grant AG027224 and AG05133. NR 120 TC 29 Z9 29 U1 1 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 19 IS 3 BP 761 EP 780 DI 10.3233/JAD-2010-1274 PG 20 WC Neurosciences SC Neurosciences & Neurology GA 582RU UT WOS:000276617100001 PM 20157235 ER PT J AU Canu, E McLaren, DG Fitzgerald, ME Bendlin, BB Zoccatelli, G Alessandrini, F Pizzini, FB Ricciardi, GK Beltramello, A Johnson, SC Frisoni, GB AF Canu, Elisa McLaren, Donald G. Fitzgerald, Michele E. Bendlin, Barbara B. Zoccatelli, Giada Alessandrini, Franco Pizzini, Francesca B. Ricciardi, Giuseppe K. Beltramello, Alberto Johnson, Sterling C. Frisoni, Giovanni B. TI Microstructural Diffusion Changes are Independent of Macrostructural Volume Loss in Moderate to Severe Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; diffusion weighted imaging; fractional anisotropy; mean diffusivity; microstructure ID MILD COGNITIVE IMPAIRMENT; WHITE-MATTER CHANGES; MOTOR CORTEX INVOLVEMENT; AGE-RELATED-CHANGES; IN-VIVO; CORPUS-CALLOSUM; HUMAN BRAIN; NEURODEGENERATIVE DISORDERS; AMYLOID DEPOSITS; TRACT INTEGRITY AB Although it is established that Alzheimer's disease (AD) leads to cerebral macrostructural atrophy, microstructural diffusion changes have also been observed, but it is not yet known whether these changes offer unique information about the disease pathology. Thus, a multi-modal imaging study was conducted to determine the independent contribution of each modality in moderate to severe AD. Seventeen patients with moderate-severe AD and 13 healthy volunteers underwent diffusion-weighted and T1-weighted MR scanning. Images were processed to obtain measures of macrostructural atrophy (gray and white matter volumes) and microstructural damage (fractional anisotropy and mean diffusivity). Microstructural diffusion changes independent of macrostructural loss were investigated using an ANCOVA where macrostructural maps were used as voxel-wise covariates. The reverse ANCOVA model was also assessed, where macrostructural loss was the dependent variable and microstructural diffusion tensor imaging maps were the imaging covariates. Diffusion differences between patients and controls were observed after controlling for volumetric differences in medial temporal, retrosplenial regions, anterior commissure, corona radiata, internal capsule, thalamus, corticopontine tracts, cerebral peduncle, striatum, and precentral gyrus. Independent volumetric differences were observed in the entorhinal cortex, inferior temporal lobe, posterior cingulate cortex, splenium and cerebellum. While it is well known that AD is associated with pronounced volumetric change, this study suggests that measures of microstructure provide unique information not obtainable with volumetric mapping in regions known to be pivotal in AD and in those thought to be spared. As such this work provides great understanding of the topography of pathological changes in AD that can be captured with imaging. C1 [Canu, Elisa; Frisoni, Giovanni B.] Natl Ctr Res & Care Alzheimers & Mental Dis, IRCCS Ctr San Giovanni di Dio FBF, LENITEM, Brescia, Italy. [McLaren, Donald G.; Fitzgerald, Michele E.; Bendlin, Barbara B.; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. [McLaren, Donald G.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA. [McLaren, Donald G.; Fitzgerald, Michele E.; Bendlin, Barbara B.; Johnson, Sterling C.] Univ Wisconsin, Dept Med, Wisconsin Alzheimers Dis Res Ctr, Madison, WI 53706 USA. [Zoccatelli, Giada; Alessandrini, Franco; Pizzini, Francesca B.; Ricciardi, Giuseppe K.; Beltramello, Alberto] Osped Maggiore, Serv Neuroradiol, Verona, Italy. [Frisoni, Giovanni B.] Natl Ctr Res & Care Alzheimers & Mental Dis, IRCCS Ctr San Giovanni di Dio FBF, Psychogeriatr Ward, Brescia, Italy. [Frisoni, Giovanni B.] AFaR, Rome, Italy. RP Frisoni, GB (reprint author), IRCCS San Giovanni di Dio FBF, LENITEM, Via Pilastroni 4, I-25125 Brescia, Italy. EM gfrisoni@fatebenefratelli.it RI McLaren, Donald/G-9906-2011; Frisoni, Giovanni B/K-1360-2016; Pizzini, Francesca Bendetta/O-5291-2016; Canu, Elisa/K-1423-2016 OI Frisoni, Giovanni B/0000-0002-6419-1753; Pizzini, Francesca Bendetta/0000-0002-6285-0989; Ricciardi, Giuseppe Kenneth/0000-0001-8536-5794; Canu, Elisa/0000-0001-5804-3378; Bendlin, Barbara/0000-0002-0580-9875 FU Italian Ministry of Health [125/2004]; Lundbeck Italia SpA; National Institutes of Health [AG021155, AG000213] FX This work has been supported by research grant 125/2004 of the Italian Ministry of Health, Ricerca Finalizzata "Malattie neurodegenerative legate all'invecchiamento: dalla patogenesi alle prospettive terapeutiche per un progetto traslazionale" and by Lundbeck Italia SpA. This study was also supported by National Institutes of Health grants AG021155 and AG000213, and by the facilities and resources at the William S. Middleton Memorial Veterans Hospital. NR 69 TC 47 Z9 49 U1 0 U2 8 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 19 IS 3 BP 963 EP 976 DI 10.3233/JAD-2010-1295 PG 14 WC Neurosciences SC Neurosciences & Neurology GA 582RU UT WOS:000276617100018 PM 20157252 ER PT J AU VanFossen, BT Watson, GS Baker, LD Rhoads, KW Cholerton, BA Reger, MA Plymate, SR Schellenberg, G Craft, S AF VanFossen, Brian T. Watson, G. Stennis Baker, Laura D. Rhoads, Kristoffer W. Cholerton, Brenna A. Reger, Mark A. Plymate, Stephen R. Schellenberg, Gerald Craft, Suzanne TI Statin Users Without an APOE-epsilon 4 Allele have Increased Insulin Resistance SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; dementia; diabetes; insulin; statin ID APOLIPOPROTEIN-E GENOTYPE; INCIDENT ALZHEIMER-DISEASE; CEREBROSPINAL-FLUID; RISK; DEMENTIA; POPULATION; PATHOLOGY; GENDER; HEALTH; MODEL AB The present study examined the relationships among statin use, APOE genotype, and insulin resistance as measured by the homeostasis model assessment of insulin resistance (HOMA-IR) in healthy older adults. APOE epsilon 4- (i.e., not having an epsilon 4 allele) statin users had higher HOMA-IR values compared with epsilon 4+/statin users (p = 0.0169), and with non-users who were epsilon 4( p = 0.0003) or epsilon 4+ (p = 0.0006). These results suggest that statin use may modulate insulin levels for individuals without an APOE epsilon 4 allele. C1 [VanFossen, Brian T.; Watson, G. Stennis; Baker, Laura D.; Rhoads, Kristoffer W.; Cholerton, Brenna A.; Reger, Mark A.; Plymate, Stephen R.; Schellenberg, Gerald; Craft, Suzanne] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA 98108 USA. [VanFossen, Brian T.; Watson, G. Stennis; Baker, Laura D.; Rhoads, Kristoffer W.; Cholerton, Brenna A.; Reger, Mark A.; Schellenberg, Gerald; Craft, Suzanne] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Plymate, Stephen R.] Univ Washington, Dept Med, Seattle, WA USA. RP Watson, GS (reprint author), VA Puget Sound Hlth Care Syst, GRECC, S-182-GRECC,1660 S Columbian Way, Seattle, WA 98108 USA. EM gswatson@u.washington.edu FU Department of Veterans Affairs, NIH/NIA [T32 AG000258, R37AG010880, K01AG23640] FX This paper was supported by the Department of Veterans Affairs, NIH/NIA grants T32 AG000258 (BVF), R37AG010880 (SC), and K01AG23640 (GSW). NR 27 TC 4 Z9 4 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2010 VL 19 IS 4 BP 1149 EP 1153 DI 10.3233/JAD-2009-1319 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 582SS UT WOS:000276619700005 PM 20308781 ER PT J AU Nguyen, HM Graber, CJ AF Nguyen, Hien M. Graber, Christopher J. TI Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer? SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Review DE MRSA; combination treatment; bactericidal agents; community-acquired infections ID BLOOD-STREAM INFECTIONS; VITRO PHARMACODYNAMIC MODEL; PANTON-VALENTINE LEUKOCIDIN; SKIN-STRUCTURE INFECTIONS; SIMULATED ENDOCARDIAL VEGETATIONS; VANCOMYCIN PLUS RIFAMPIN; FOREIGN-BODY INFECTION; SMALL-COLONY VARIANT; IN-VITRO; QUINUPRISTIN-DALFOPRISTIN AB Invasive infections caused by methicillin-resistant Staphylococcus aureus (MRSA), particularly those involving persistent bacteraemia, necrotizing pneumonia, osteomyelitis and other deep-seated sites of infections, are associated with high mortality and are often difficult to treat. The response to treatment of severe MRSA infection with currently available antibiotics active against MRSA is often unsatisfactory, leading some physicians to resort to combination antibiotic therapy. Now, with the emergence of community-associated MRSA (CA-MRSA) clones that display enhanced virulence potentially related to up-regulated toxin production, the use of adjuvant protein synthesis-inhibiting antibiotics to reduce toxin production also has been advocated by some experts. In this review, we discuss the limitations of antibiotics currently available for the treatment of serious invasive MRSA infections and review the existing literature that examines the potential role of combination therapy in these infections. C1 [Nguyen, Hien M.; Graber, Christopher J.] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA 90073 USA. [Graber, Christopher J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Graber, CJ (reprint author), VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, 11301 Wilshire Blvd,111-F, Los Angeles, CA 90073 USA. EM cgraber@ucla.edu FU Merck; Ortho-McNeil-Janssen FX H. M. N. has no conflict of interest to report. C. J. G. has received research support from Merck and an educational grant from Ortho-McNeil-Janssen. NR 161 TC 40 Z9 42 U1 0 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD JAN PY 2010 VL 65 IS 1 BP 24 EP 36 DI 10.1093/jac/dkp377 PG 13 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 534XT UT WOS:000272931500005 PM 19861337 ER PT J AU Ge, L Sotiropoulos, F AF Ge, Liang Sotiropoulos, Fotis TI Direction and Magnitude of Blood Flow Shear Stresses on the Leaflets of Aortic Valves: Is There a Link With Valve Calcification? SO JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME LA English DT Article ID ARTERIAL WALL SHEAR; ATHEROSCLEROSIS; ATHEROMA; PATTERNS; STENOSIS AB Aortic stenosis caused by valve calcification is a major cause of death around the world. Hemodynamic factors have been suggested to be major players in the development of valve calcification, yet a detailed knowledge of the blood flow dynamics as experienced by endothelial cells on valve surfaces is still lacking. In this study we carry out high-resolution numerical simulations of the blood flow through a polymeric trileaflet valve in order to elucidate the differential flow dynamics on the aortic and ventricular sides of the valve leaflets. Limiting streamlines and surface shear stress contours are used to probe and quantify the blood flows on its side. Complicated flow patterns were only observed on the aortic side of the valve near the region where focalized distribution of valve calcification is typically observed. [DOI: 10.1115/1.4000162] C1 [Ge, Liang] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. [Ge, Liang] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Sotiropoulos, Fotis] Univ Minnesota, Dept Civil Engn, St Anthony Falls Lab, Minneapolis, MN 55414 USA. RP Ge, L (reprint author), Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA. RI Sotiropoulos, Fotis/C-2163-2012 FU NIH [R01-HL-07262]; Minnesota Supercomputing Institute FX We thank Ajit Yoganathan and the members of Cardiovascular Fluid Mechanics Laboratory (Georgia Tech) and Rami Haj-Ali (Georgia Tech) for kindly providing us with the valve geometry and kinematics used in this study. This study has been supported by NIH under Grant No. R01-HL-07262 and Minnesota Supercomputing Institute. NR 20 TC 20 Z9 20 U1 2 U2 7 PU ASME-AMER SOC MECHANICAL ENG PI NEW YORK PA THREE PARK AVE, NEW YORK, NY 10016-5990 USA SN 0148-0731 J9 J BIOMECH ENG-T ASME JI J. Biomech. Eng.-Trans. ASME PD JAN PY 2010 VL 132 IS 1 AR 014505 DI 10.1115/1.4000162 PG 5 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA 550CW UT WOS:000274106900015 PM 20524753 ER PT J AU Ucuzian, AA Gassman, AA East, AT Greisler, HP AF Ucuzian, Areck A. Gassman, Andrew A. East, Andrea T. Greisler, Howard P. TI Molecular Mediators of Angiogenesis SO JOURNAL OF BURN CARE & RESEARCH LA English DT Review ID ENDOTHELIAL-GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; CAPILLARY-TUBE FORMATION; BLOOD-VESSEL FORMATION; PROTEIN-KINASE-C; 3-DIMENSIONAL EXTRACELLULAR MATRICES; UP-REGULATES ANGIOPOIETIN-2; ACTIVATOR INHIBITOR TYPE-1; FOCAL ADHESION KINASE; THICKNESS SKIN-GRAFTS AB Angiogenesis, or the formation of new blood vessels from the preexisting vasculature, is a key component in numerous physiologic and pathologic responses and has broad impact in many medical and surgical specialties. In this review, we discuss the key cellular steps that lead to the neovascularization of tissues and highlight the main molecular mechanisms and mediators in this process. We include discussions on proteolytic enzymes, cell-matrix interactions, and pertinent cell signaling pathways and end with a survey of the mechanisms that lead to the stabilization and maturation of neovasculatures. (J Burn Care Res 2010;31:158-175) C1 [Ucuzian, Areck A.; Gassman, Andrew A.; Greisler, Howard P.] Loyola Univ, Med Ctr, Dept Surg, Maywood, IL 60153 USA. [Ucuzian, Areck A.; Greisler, Howard P.] Loyola Univ, Med Ctr, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA. [East, Andrea T.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA. [Greisler, Howard P.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res & Surg Serv, Hines, IL 60141 USA. RP Greisler, HP (reprint author), Loyola Univ, Med Ctr, Dept Surg, 2160 S 1st Ave, Maywood, IL 60153 USA. FU National Institutes of Health [NIH R01-HL41272]; Department of Veterans' Affairs; American Heart Association [AHA 0815674G]; Falk Medical Research Trust FX Supported by grants from the National Institutes of Health (NIH R01-HL41272), the Department of Veterans' Affairs, the American Heart Association (AHA 0815674G), and the Falk Medical Research Trust. NR 263 TC 26 Z9 29 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1559-047X J9 J BURN CARE RES JI J. Burn Care Res. PD JAN-FEB PY 2010 VL 31 IS 1 BP 158 EP 175 DI 10.1097/BCR.0b013e3181c7ed82 PG 18 WC Emergency Medicine; Dermatology; Surgery SC Emergency Medicine; Dermatology; Surgery GA 544FF UT WOS:000273637900022 PM 20061852 ER PT J AU Evangelista, LS Rasmusson, KD Laramee, AS Barr, J Ammon, SE Dunbar, S Ziesche, S Patterson, JH Yancy, CW AF Evangelista, Lorraine S. Rasmusson, Kismet D. Laramee, Ann S. Barr, Joan Ammon, Susan E. Dunbar, Sandra Ziesche, Susan Patterson, J. Herbert Yancy, Clyde W. TI Health Literacy and the Patient With Heart Failure-Implications for Patient Care and Research: A Consensus Statement of the Heart Failure Society of America SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Heart failure; health literacy; communication; self-care ID HOSPITAL ADMISSION; MEDICARE ENROLLEES; CHRONIC DISEASE; SELF-CARE; KNOWLEDGE; RISK; MANAGEMENT; BARRIER; ADULTS; HYPERTENSION AB Background: Low health literacy compromises patient safety, quality health care, and desired health outcomes. Specifically, low health literacy is associated with decreased knowledge of one's medical condition, poor medication recall, nonadherence to treatment plans, poor self-care behaviors, compromised physical and mental health, greater risk of hospitalization, and increased mortality. Methods: The health literacy literature was reviewed for: definitions, scope, risk factors, assessment, impact on health outcomes (cardiovascular disease and heart failure), and interventions. Implications for future research and for clinical practice to address health literacy in heart failure patients were summarized. Results: General health literacy principles should be applied to patients with heart failure, similar to others with chronic conditions. Clinicians treating, patients with heart failure should address health literacy using five steps: recognize the consequences of low health literacy, screen patients at risk, document literacy levels and learning preferences, and integrate effective strategies to enhance patients' understanding into practice. Conclusion: Although the literature specifically addressing low health literacy in patients with heart failure is limited, it is consistent with the larger body of health literacy evidence. Timely recognition of low health literacy combined with tailored interventions should be integrated into clinical practice. (J Cardiac Fail 2010:16:9-16) C1 [Evangelista, Lorraine S.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90095 USA. [Rasmusson, Kismet D.] Intermt Med Ctr, Salt Lake City, UT USA. [Laramee, Ann S.] Fletcher Allen Hlth Care, Burlington, VT USA. [Barr, Joan] Methodist Hosp, Indianapolis, IN USA. [Ammon, Susan E.] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. [Dunbar, Sandra] Emory Univ, Sch Nursing, Atlanta, GA USA. [Ziesche, Susan] Univ Minnesota, Epidemiol Res Ctr, Minneapolis, MN USA. [Patterson, J. Herbert] Univ N Carolina, Sch Pharm, Chapel Hill, NC USA. [Yancy, Clyde W.] Baylor Univ, Med Ctr, Dallas, TX USA. RP Evangelista, LS (reprint author), Univ Calif Los Angeles, Sch Nursing, 700 Tiverton,Factor Bldg, Los Angeles, CA 90095 USA. EM levangel@ucla.edu FU NHLBI NIH HHS [R01 HL093466-01, R01 HL093466-02, R01 HL093466] NR 60 TC 57 Z9 60 U1 7 U2 18 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD JAN PY 2010 VL 16 IS 1 BP 9 EP 16 DI 10.1016/j.cardfail.2009.10.026 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 594ZU UT WOS:000277581300002 PM 20123313 ER PT J AU Deo, R Katz, R Kestenbaum, B Fried, L Sarnak, MJ Psaty, BM Siscovick, DS Shlipak, MG AF Deo, Rajat Katz, Ronit Kestenbaum, Bryan Fried, Linda Sarnak, Mark J. Psaty, Bruce M. Siscovick, David S. Shlipak, Michael G. TI Impaired Kidney Function and Atrial Fibrillation in Elderly Subjects SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Kidney function; cystatin C; arrhythmias; elderly; epidemiology ID LEFT-VENTRICULAR DYSFUNCTION; CYSTATIN-C; RISK-FACTORS; CARDIOVASCULAR-DISEASE; HEART-FAILURE; SINUS RHYTHM; HEALTH; ALDOSTERONE; MORTALITY; ENALAPRIL AB Background: Impaired kidney function is associated with increased risk for cardiovascular events. We evaluated whether kidney function is associated with atrial fibrillation (AF) risk in elderly persons. Methods and Results: Subjects were participants in the Cardiovascular Health Study (CHS), a population-based cohort of ambulatory elderly. Measures of kidney function were cystatin C and creatinine-based estimated glomerular filtration rate (eGFR). Among the 4663 participants, 342 (7%) had AF at baseline and 579 (13%) developed incident AF during follow-up (mean 7.4 years). In unadjusted analyses, cystatin C quartiles were strongly associated with prevalent AF with a nearly 3-fold odds in the highest quartile compared with the lowest (HR = 1.19, 95% CI [0.80-1.76] in quartile 2; FIR = 2.00, 95% Cl [1.38-2.88] in quartile 3; and FIR = 2.87, 95% Cl [2.03-4.07] in quartile 4). This increased risk for prevalent AF remained significant after multivariate adjustment. The risk for incident AF increased across cystatin C quartiles in the unadjusted analysis (HR = 1.37, 95% Cl [1.07-1.75] in quartile 2; HR = 1.43, 95% CI [1.11-1.84] in quartile 3; and HR = 1.88, 95% Cl [1.47-2.41] in quartile 4); however, after multivariate adjustment, these findings were no longer significant. An estimated GFR <60 mL . min . 1.73 m(2) was associated with prevalent and incident AF in unadjusted, but not multivariate analyses. Conclusions: Impaired kidney function, as measured by cystatin C, is an independent marker of prevalent AF; however, neither cystatin C nor eGFR are predictors of incident AF. (J Cardiac Fail 2010:16:55-60) C1 [Deo, Rajat] Univ Penn, Div Cardiol, Philadelphia, PA 19104 USA. [Kestenbaum, Bryan] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. [Fried, Linda] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Fried, Linda] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Sarnak, Mark J.] Tufts Univ New England Med Ctr, Dept Internal Med, Div Nephrol, Boston, MA USA. [Psaty, Bruce M.; Siscovick, David S.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA USA. [Shlipak, Michael G.] Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA USA. RP Deo, R (reprint author), Univ Penn, Div Cardiol, 3400 Spruce St,9 Founders Cardiol, Philadelphia, PA 19104 USA. EM Rajat.Deo@uphs.upenn.edu FU National Heart, Lung, and Blood Institute [N01-HC-35129, N01-HC-45133, N01-HC-75150, N01-HC-85079, N01-HC-85086, N01 HC-15103, N01 HC-55222, U01 HL080295] FX Supported by contracts N01-HC-35129, N01-HC-45133, N01-HC-75150, N01-HC-85079 through N01-HC-85086, N01 HC-15103, N01 HC-55222, and U01 HL080295 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. NR 37 TC 21 Z9 26 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD JAN PY 2010 VL 16 IS 1 BP 55 EP 60 DI 10.1016/j.cardfail.2009.07.002 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 594ZU UT WOS:000277581300008 PM 20123319 ER PT J AU Steele, BG Belza, B Cain, K Coppersmith, J Howard, J Lakshminarayan, S Haselkorn, J AF Steele, Bonnie G. Belza, Basia Cain, Kevin Coppersmith, Jeff Howard, JoEllen Lakshminarayan, Sambasiva Haselkorn, Jodi TI The Impact of Chronic Obstructive Pulmonary Disease Exacerbation on Pulmonary Rehabilitation Participation and Functional Outcomes SO JOURNAL OF CARDIOPULMONARY REHABILITATION AND PREVENTION LA English DT Article DE COPD exacerbation; exercise training; pulmonary rehabilitation ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; CHRONIC LUNG-DISEASE; PHYSICAL-ACTIVITY; RESPIRATORY REHABILITATION; ENERGY-EXPENDITURE; COPD EXACERBATIONS; OLDER-ADULTS; EXERCISE; DYSPNEA AB PURPOSE: The purpose of this study was to determine the impact of chronic obstructive Pulmonary disease exacerbation (COPDE) on pulmonary rehabilitation (PR) participation and completion and oil outcomes of daily activity, self-reported daily exercise, and functional capacity. METHODS: Participants in an 8-week outpatient PR program were studied pre- and post-PR. Variables included COPDE Occurrence (computerized patient record system), self-reported exercise (daily activity diary), daily activity (accelerometer), exercise capacity (6-minute walk distance), dyspnea today and over the past 30 days (Lareau's Functional Status and Dyspnea Questionnaire), health status (The Medical Outcomes Study 36-Item Short-Form Health Survey adapted for Veterans), and quality of life (Seattle Obstructive Lung Disease Questionnaire). RESULTS: Outpatients with COPD (N = 146, 140 men) started PR; 112 completed the program and were studied. Of the 30 participants who had at least 1 COPDE during the program, 10 quit the program. Subjects who exacerbated had a lower body mass index than did patients without COPDE (28.4 compared with 30.8, respectively, P < .05), more severe COPD (percent-predicted forced expiratory volume in the first second of expiration, FEV1% predicted, 32%, compared with 40%, respectively, P < .05), and required supplemental oxygen (70% compared with 36%, respectively, P < .05). Exacerbators who completed PR were more likely to be nonsmokers, on oxygen, and have a higher FEV1% predicted than were exacerbators who quit. It was found that postprogram exercise capacity improved overall, with exacerbators performing better than nonexacerbators on the 6-minute walk test (P = .044). There were no significant differences in other outcomes. CONCLUSIONS: Findings suggest that COPD exacerbators who completed PR had similar outcomes as did nonexacerbators and should be encouraged to return to PR after COPDE. C1 [Steele, Bonnie G.; Lakshminarayan, Sambasiva] Dept Vet Affairs Puget Sound Hlth Care Syst, Primary Care & Specialty Med Serv, Seattle, WA USA. [Haselkorn, Jodi] Univ Washington, Sch Med, Dept Vet Affairs Puget Sound Hlth Care Syst & Reh, Rehabil Care Serv, Seattle, WA USA. [Coppersmith, Jeff; Howard, JoEllen] VA Puget Sound Hlth Care Syst, VA Hlth Serv Res & Dev, Seattle, WA USA. RP Steele, BG (reprint author), Dept Vet Affairs Puget Sound Hlth Care Syst S 111, Primary Care & Specialty Med Serv, 1660 S Columbian Way, Seattle, WA 98108 USA. EM bonnie.steele@va.gov FU Offiice of Research and Development Health Service R & D Service, Department of Veterans Affairs, Nursing Research Initiative [NRI 98-194]; School of Nursing, University of Washington FX This material is based upon work supported by the Offiice of Research and Development Health Service R & D Service, Department of Veterans Affairs, Nursing Research Initiative (NRI 98-194), and a Research and Intramural Funding Grant from the School of Nursing, University of Washington. NR 55 TC 11 Z9 12 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-7501 EI 1932-751X J9 J CARDIOPULM REHABIL JI J. Cardiopulm. Rehabil. Prev. PD JAN-FEB PY 2010 VL 30 IS 1 BP 53 EP 60 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 547IK UT WOS:000273880400009 PM 20068424 ER PT J AU Grunfeld, C Scherzer, R Varosy, PD Gopal, A Nasir, K Budoff, M AF Grunfeld, Carl Scherzer, Rebecca Varosy, Paul D. Gopal, Ambarish Nasir, Khurram Budoff, Matthew TI Relation of coronary artery plaque location to extent of coronary artery disease studied by computed tomographic angiography SO JOURNAL OF CARDIOVASCULAR COMPUTED TOMOGRAPHY LA English DT Article DE Computed tomography angiography; CTA; Coronary artery calcium; CAC; Noninvasive angiography; Prevalence AB BACKGROUND: Distal coronary artery disease (CAD) is less amenable to surgery or stenting compared with proximal disease. However, little is known about the epidemiology of distal versus proximal CAD. METHODS: We determined the prevalence and factors associated with proximal, mid, and distally located plaque in the left anterior descending, left circumflex, and right coronary arteries in 418 subjects without prior CAD history who underwent coronary computed tomographic angiography for symptoms or stress test results. Clinical characteristics and coronary artery calcium (CAC) scores were also determined. RESULTS: Most subjects (88%) had plaque, but only 18% of plaques were associated with stenosis >50%. In subjects with single-vessel plaque, only 7% had distal plaque, whereas 75% had proximal plaque. With 3-vessel plaque, 70% had distal and 100% had proximal plaques. Of subjects with a single location of plaque along a vessel, most had proximal plaque (69%); isolated distal-vessel plaque was rare (2%). Distal plaque was dominantly found in association with both proximal and mid plaque (88%). After multivariable adjustment for demographics, traditional, and nontraditional risk factors, both increasing number of vessels with plaque and clinically significant CAC scores were independently associated with higher odds of distal plaque, whereas associations of traditional risk factors were weaker. Distal plaque was independently associated with stenosis > 50%. CONCLUSION: These data support the concept that early lesions are most often proximal and that CAC scoring may be a poor screening tool for detecting proximal disease. Furthermore, distal lesions are more associated with advanced disease than with traditional cardiovascular risk factors. (c) 2010 Society of Cardiovascular Computed Tomography. All rights reserved. C1 [Grunfeld, Carl; Scherzer, Rebecca] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Grunfeld, Carl; Scherzer, Rebecca] Vet Affairs Med Ctr, Metab Sect 111F, San Francisco, CA 94121 USA. [Varosy, Paul D.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Varosy, Paul D.] Univ Colorado, Sch Med, Denver, CO USA. [Gopal, Ambarish; Budoff, Matthew] Los Angeles Biomed Res Inst, Torrance, CA USA. [Nasir, Khurram] Boston Med Ctr, Dept Med, Boston, MA USA. RP Grunfeld, C (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM carl.grunfeld@ucsf.edu FU Veterans Affairs Health Services Research and Development Service Research Career Development Award [RCD 04-115-2]; Albert L. and Janet A. Schulz Supporting Foundation FX Supported in part by a Veterans Affairs Health Services Research and Development Service Research Career Development Award (RCD 04-115-2 to P.D.V.), the Albert L. and Janet A. Schulz Supporting Foundation, and with resources and the use of facilities of the VA Medical Center, San Francisco. CA. NR 34 TC 5 Z9 5 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-5925 J9 J CARDIOVASC COMPUT JI J. Cardiovasc. Comput. Tomogr. PD JAN-FEB PY 2010 VL 4 IS 1 BP 19 EP 26 DI 10.1016/j.jcct.2010.01.009 PG 8 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA V26BE UT WOS:000208520300003 PM 20159623 ER PT J AU Weinstein, JS Varallyay, CG Dosa, E Gahramanov, S Hamilton, B Rooney, WD Muldoon, LL Neuwelt, EA AF Weinstein, Jason S. Varallyay, Csanad G. Dosa, Edit Gahramanov, Seymur Hamilton, Bronwyn Rooney, William D. Muldoon, Leslie L. Neuwelt, Edward A. TI Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Review DE blood-brain barrier; CNS tumors; magnetic resonance imaging; ultrasmall superparamagnetic iron oxide nanoparticles ID CEREBRAL BLOOD-VOLUME; HUMAN BRAIN-TUMORS; IN-VIVO TRACKING; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CAROTID ATHEROSCLEROTIC PLAQUE; WATER SUPPRESSION IRON; SPINAL-CORD-INJURY; MR CONTRAST AGENTS; MULTIPLE-SCLEROSIS; ENHANCED MRI AB Superparamagnetic iron oxide nanoparticles have diverse diagnostic and potential therapeutic applications in the central nervous system (CNS). They are useful as magnetic resonance imaging (MRI) contrast agents to evaluate: areas of blood-brain barrier (BBB) dysfunction related to tumors and other neuroinflammatory pathologies, the cerebrovasculature using perfusion-weighted MRI sequences, and in vivo cellular tracking in CNS disease or injury. Novel, targeted, nanoparticle synthesis strategies will allow for a rapidly expanding range of applications in patients with brain tumors, cerebral ischemia or stroke, carotid atherosclerosis, multiple sclerosis, traumatic brain injury, and epilepsy. These strategies may ultimately improve disease detection, therapeutic monitoring, and treatment efficacy especially in the context of antiangiogenic chemotherapy and antiinflammatory medications. The purpose of this review is to outline the current status of superparamagnetic iron oxide nanoparticles in the context of biomedical nanotechnology as they apply to diagnostic MRI and potential therapeutic applications in neurooncology and other CNS inflammatory conditions. Journal of Cerebral Blood Flow & Metabolism (2010) 30, 15-35; doi: 10.1038/jcbfm.2009.192; published online 16 September 2009 C1 [Weinstein, Jason S.; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97239 USA. [Varallyay, Csanad G.; Dosa, Edit; Gahramanov, Seymur; Muldoon, Leslie L.; Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Varallyay, Csanad G.] Univ Klinikum Wurzburg, Dept Neuroradiol, Wurzburg, Germany. [Hamilton, Bronwyn] Oregon Hlth & Sci Univ, Dept Radiol, Portland, OR 97239 USA. [Rooney, William D.] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97239 USA. [Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR USA. RP Neuwelt, EA (reprint author), Oregon Hlth & Sci Univ, Dept Neurol Surg, 3181 SW Sam Jackson Pk Rd,L603, Portland, OR 97239 USA. EM neuwelte@ohsu.edu FU National Institute of Neurological Disorders and Stroke, a Department of Defense Center of Excellence [NS33618, NS34608, NS053468, NS44687]; AMAG Pharmaceuticals Inc; Department of Veterans Affairs; Neurosurgery Research and Education Foundation grant sponsored by Codman; Johnson & Johnson Company; NIH [RO1-EB007258]; WM Keck Foundation FX We thank Ms. Audrey Selzer for her assistance with 12T MRI acquisitions, Mr. William Woodward for collecting data for Figure 5b, and Ms. Emily Hochhalter for her administrative assistance. This research was funded in part by the National Institutes of Health grants NS33618, NS34608, NS053468, and NS44687 from the National Institute of Neurological Disorders and Stroke, a Department of Defense Center of Excellence Award, AMAG Pharmaceuticals Inc, and by the Department of Veterans Affairs, all to EAN. This research was also funded in part by a Neurosurgery Research and Education Foundation grant sponsored by Codman, a Johnson & Johnson Company to JSW, NIH RO1-EB007258 to WDR, The Oregon Opportunity and a grant from the WM Keck Foundation. NR 126 TC 208 Z9 211 U1 14 U2 109 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD JAN PY 2010 VL 30 IS 1 BP 15 EP 35 DI 10.1038/jcbfm.2009.192 PG 21 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 539IL UT WOS:000273247500003 PM 19756021 ER PT J AU Wolitzky-Taylor, KB Ruggiero, KJ McCart, MR Smith, DW Hanson, RF Resnick, HS de Arellano, MA Saunders, BE Kilpatrick, DG AF Wolitzky-Taylor, Kate B. Ruggiero, Kenneth J. McCart, Michael R. Smith, Daniel W. Hanson, Rochelle F. Resnick, Heidi S. de Arellano, Michael A. Saunders, Benjamin E. Kilpatrick, Dean G. TI Has Adolescent Suicidality Decreased in the United States? Data From Two National Samples of Adolescents Interviewed in 1995 and 2005 SO JOURNAL OF CLINICAL CHILD AND ADOLESCENT PSYCHOLOGY LA English DT Article ID DEPRESSION PREVENTION PROGRAM; RISK-FACTORS; YOUNG-ADULTS; CONTROLLED TRIAL; BEHAVIOR; IDEATION; YOUTH; COMORBIDITY; PREVALENCE; ABUSE AB We compared the prevalence and correlates of adolescent suicidal ideation and attempts in two nationally representative probability samples of adolescents interviewed in 1995 (National Survey of Adolescents; N = 4,023) and 2005 (National Survey of Adolescents-Replication; N = 3,614). Participants in both samples completed a telephone survey that assessed major depressive episode (MDE), post-traumatic stress disorder, suicidal ideation and attempts, violence exposure, and substance use. Results demonstrated that the lifetime prevalence of suicidal ideation among adolescents was lower in 2005 than 1995, whereas the prevalence of suicide attempts remained stable. MDE was the strongest predictor of suicidality in both samples. In addition, several demographic, substance use, and violence exposure variables were significantly associated with increased risk of suicidal ideation and attempts in both samples, with female gender, nonexperimental drug use, and direct violence exposure being consistent risk factors in both samples. C1 [Wolitzky-Taylor, Kate B.] Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Wolitzky-Taylor, KB (reprint author), Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, 67 President St,MSC861, Charleston, SC 29425 USA. EM wolitzky@musc.edu FU NICHD NIH HHS [1R01 HD046830-01, R01 HD046830, R01 HD046830-01] NR 63 TC 22 Z9 22 U1 3 U2 10 PU LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS PI PHILADELPHIA PA 325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA SN 1537-4416 J9 J CLIN CHILD ADOLESC JI J. Clin. Child Adolesc. Psychol. PY 2010 VL 39 IS 1 BP 64 EP 76 DI 10.1080/15374410903401146 PG 13 WC Psychology, Clinical; Psychology, Developmental SC Psychology GA 554BX UT WOS:000274411600006 PM 20390799 ER PT J AU Zinman, B Haffner, SM Herman, WH Holman, RR Lachin, JM Kravitz, BG Paul, G Jones, NP Aftring, RP Viberti, G Kahn, SE AF Zinman, Bernard Haffner, Steven M. Herman, William H. Holman, Rury R. Lachin, John M. Kravitz, Barbara G. Paul, Gitanjali Jones, Nigel P. Aftring, R. Paul Viberti, Giancarlo Kahn, Steven E. CA A Diabet Outcome Progression Trial TI Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID PROGRESSION TRIAL ADOPT; OSTEOBLAST DIFFERENTIATION; MINERAL DENSITY; DECREASES; TROGLITAZONE; GAMMA; WOMEN AB Context: An increase in bone fractures has been observed in women taking thiazolidinediones. Objective: The objective of the study was to examine whether changes in circulating bone biomarkers provide insight into the underlying mechanisms responsible for the increase in bone fractures in female participants randomized to rosiglitazone in A Diabetes Outcome Progression Trial (ADOPT). Research Design and Methods: Paired stored baseline and 12-month serum samples were available from 1605 participants (689 women, 916 men) in ADOPT, a long-term clinical trial comparing the effects of rosiglitazone, glyburide, and metformin on glycemic control in patients with type 2 diabetes. Results: This subset was well matched to the total ADOPT study population. In women a marker of osteoclast activity, C-terminal telopeptide (for type 1 collagen), increased by 6.1% with rosiglitazone compared with reductions of 1.3% (P = 0.03 vs. rosiglitazone) and 3.3% (P = 0.002 vs. rosiglitazone) with metformin and glyburide, respectively. In men, C-terminal telopeptide was unchanged on rosiglitazone (-1.0%) and fell on metformin (-12.7%; P < 0.001) and glyburide (-4.3%, P = NS). Markers of osteoblast activity, procollagen type 1 N-propeptide (P1NP) and bone alkaline phosphatase, were reduced for women and men in almost all treatment groups, with the greatest changes in the metformin group (P1NP in females, -14.4%; P1NP in males, -19.3%), intermediate for rosiglitazone (P1NP in females, -4.4%; P1NP in males, -14.4%), and smallest for glyburide (P1NP in males, +0.2%; bone alkaline phosphatase in females, -11.6%). Conclusions: Commonly measured bone biomarkers suggest that changes in bone resorption may be partly responsible for the increased risk of fracture in women taking thiazolidinediones. (J Clin Endocrinol Metab 95: 134-142, 2010) C1 [Kahn, Steven E.] Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98108 USA. [Zinman, Bernard] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON MT5 3L9, Canada. [Zinman, Bernard] Univ Toronto, Toronto, ON MT5 3L9, Canada. [Haffner, Steven M.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Herman, William H.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Herman, William H.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Holman, Rury R.] Oxford Ctr Diabet Endocrinol & Metab, Diabet Trials Unit, Oxford OX3 7LJ, England. [Lachin, John M.] George Washington Univ, Ctr Biostat, Rockville, MD 20852 USA. [Kravitz, Barbara G.; Paul, Gitanjali; Aftring, R. Paul] GlaxoSmithKline Inc, King Of Prussia, PA 19406 USA. [Jones, Nigel P.] GlaxoSmithKline Inc, Harlow CM19 5AW, Essex, England. [Viberti, Giancarlo] Kings Coll London, Sch Med, London SE5 9RS, England. RP Kahn, SE (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM skahn@u.washington.edu RI Zinman, Bernard/E-7266-2013 OI Lachin, John/0000-0001-9838-2841; Kahn, Steven/0000-0001-7307-9002; Jones, Nigel/0000-0002-1080-8439 FU GlaxoSmithKline FX This work was supported by funds from GlaxoSmithKline from whom the academic members of the ADOPT Steering Committee (B. Z., S. M. H., W. H. H., R. R. H., J. M. L., G. V., and S. E. K.) received honoraria, consulting fees, and/or grant/research support. NR 17 TC 70 Z9 79 U1 0 U2 4 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JAN PY 2010 VL 95 IS 1 BP 134 EP 142 DI 10.1210/jc.2009-0572 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 541CV UT WOS:000273391300020 PM 19875477 ER PT J AU Smyth, JW Hong, TT Gao, DC Vogan, JM Jensen, BC Fong, TS Simpson, PC Stainier, DYR Chi, NC Shaw, RM AF Smyth, James W. Hong, Ting-Ting Gao, Danchen Vogan, Jacob M. Jensen, Brian C. Fong, Tina S. Simpson, Paul C. Stainier, Didier Y. R. Chi, Neil C. Shaw, Robin M. TI Limited forward trafficking of connexin 43 reduces cell-cell coupling in stressed human and mouse myocardium SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID GAP-JUNCTION PROTEIN; RIGHT-VENTRICULAR CARDIOMYOPATHY; EPICARDIAL BORDER ZONE; MICROTUBULE PLUS-END; HEART-FAILURE; OXIDATIVE STRESS; PLASMA-MEMBRANE; FLUORESCENT PROTEIN; ZONULA OCCLUDENS-1; CARDIAC MYOCYTES AB Gap junctions form electrical conduits between adjacent myocardial cells, permitting rapid spatial passage of the excitation current essential to each heartbeat. Arrhythmogenic decreases in gap junction coupling are a characteristic of stressed, failing, and aging myocardium, but the mechanisms of decreased coupling are poorly understood. We previously found that microtubules bearing gap junction hemichannels (connexons) can deliver their cargo directly to adherens junctions. The specificity of this delivery requires the microtubule plus-end tracking protein EB1. We performed this study to investigate the hypothesis that the oxidative stress that accompanies acute and chronic ischemic disease perturbs connexon forward trafficking. We found that EB1 was displaced in ischemic human hearts, stressed mouse hearts, and isolated cells subjected to oxidative stress. As a result, we observed limited microtubule interaction with adherens junctions at intercalated discs and reduced connexon delivery and gap junction coupling. A point mutation within the tubulin-binding domain of EB1 reproduced EB1 displacement and diminished connexon delivery, confirming that EB1 displacement can limit gap junction coupling. In zebrafish hearts, oxidative stress also reduced the membrane localization of connexin and slowed the spatial spread of excitation. We anticipate that protecting the microtubule-based forward delivery apparatus of connexons could improve cell-cell coupling and reduce ischemia-related cardiac arrhythmias. C1 [Smyth, James W.; Hong, Ting-Ting; Gao, Danchen; Vogan, Jacob M.; Fong, Tina S.; Simpson, Paul C.; Stainier, Didier Y. R.; Shaw, Robin M.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA. [Smyth, James W.; Hong, Ting-Ting; Jensen, Brian C.; Simpson, Paul C.; Chi, Neil C.; Shaw, Robin M.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Jensen, Brian C.; Simpson, Paul C.] San Francisco VA Med Ctr, Div Cardiol, San Francisco, CA USA. [Stainier, Didier Y. R.; Chi, Neil C.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA. RP Shaw, RM (reprint author), 505 Parnassus Ave, San Francisco, CA 94143 USA. EM shawrm@medicine.ucsf.edu OI Shaw, Robin/0000-0001-7429-6092; Smyth, James/0000-0003-4246-7904 FU American Federation for Aging Research [A112457]; GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease; UCSF Foundation for Cardiac Research; Department of Veterans Affairs Research Service; NIH [HL31113, HL54737, HL094414, HL07S449] FX The authors are grateful to Kevin Chu, Jose Sanchez, Lily Jan, and Samy Lamouille (UCSF) for critical review of this manuscript, Farah Sheikh for technical advice on tissue Fractionation, Ivy Hsieh and Margaret Mayes for tissue cryosectioning, and Sean Van Slyck (California Transplant Donor Network) for human tissue. This work was supported in part by the American Federation for Aging Research grant A112457 (to J.W. Smyth), the Young Investigators Award from the GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease (to B.C. Jensen and R.M. Shaw), the UCSF Foundation for Cardiac Research (to B.C. Jensen), the Department of Veterans Affairs Research Service (to P.C. Simpson), and NIH grants HL31113 (to P.C. Simpson), HL54737 (to D.Y.R. Stainier), and HL094414 and HL07S449 (to R.M. Shaw). NR 66 TC 106 Z9 110 U1 0 U2 9 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2010 VL 120 IS 1 BP 266 EP 279 DI 10.1172/JCI39740 PG 14 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 542LU UT WOS:000273495700030 PM 20038810 ER PT J AU Friedlander, AH AF Friedlander, Arthur H. TI To Do It Right, Dental Residency Education Is Expensive: Get Over It SO JOURNAL OF DENTAL EDUCATION LA English DT Letter C1 [Friedlander, Arthur H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. [Friedlander, Arthur H.] Univ Calif Los Angeles, Hosp Dent Serv, Med Ctr, Los Angeles, CA 90024 USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER DENTAL EDUCATION ASSOC PI WASHINGTON PA 1400 K STREET, NW, STE 1100, WASHINGTON, DC 20005 USA SN 0022-0337 J9 J DENT EDUC JI J. Dent. Educ. PD JAN PY 2010 VL 74 IS 1 BP 3 EP 4 PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 566SY UT WOS:000275394600001 PM 20061522 ER PT J AU Prisciandaro, JJ Myrick, DH AF Prisciandaro, James J. Myrick, D. Hugh TI Co-morbid Bipolar and Alcohol Use Disorders: A Treatment-Focused Review SO JOURNAL OF DUAL DIAGNOSIS LA English DT Article DE Bipolar disorders; alcohol use disorders; alcohol dependence; treatment; pharmacological; psychosocial; therapy ID SUBSTANCE USE DISORDERS; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; I-DISORDER; KINDLING HYPOTHESIS; RELAPSE PREVENTION; CLINICAL-TRIAL; GROUP-THERAPY; SUICIDE RISK; ACUTE MANIA AB Co-morbid bipolar and alcohol use disorders are common, difficult to properly diagnose, and associated with poor outcome. The present article concisely reviews the diagnosis, epidemiology, consequences, and neurobiological similarities among individuals with dual diagnoses and reviews the pharmacological and psychosocial treatment of bipolar and alcohol use disorders both alone and in combination. Evidence for the efficacy of treatments for individuals with dual diagnoses (i.e., divalproex, atypical antipsychotics, naltrexone, cognitive-behavioral therapy, and integrated group therapy) is discussed, and areas for future treatment development and evaluation are identified. C1 [Prisciandaro, James J.; Myrick, D. Hugh] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Myrick, D. Hugh] Ralph H Johnson Vet Affairs Ctr, Mental Hlth Serv Line, Charleston, SC USA. RP Prisciandaro, JJ (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St,POB 250861, Charleston, SC 29425 USA. EM priscian@musc.edu NR 79 TC 0 Z9 0 U1 5 U2 9 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1550-4263 EI 1550-4271 J9 J DUAL DIAGN JI J. Dual Diagn. PY 2010 VL 6 IS 2 BP 171 EP 188 DI 10.1080/15504261003701858 PG 18 WC Psychology, Clinical; Substance Abuse; Psychiatry SC Psychology; Substance Abuse; Psychiatry GA 668XR UT WOS:000283309300008 ER PT J AU Graham, DY Asaka, M AF Graham, David Y. Asaka, Masahiro TI Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod SO JOURNAL OF GASTROENTEROLOGY LA English DT Review DE Gastric cancer; Surveillance; Pepsinogen; Helicobacter pylori; Natural history ID HELICOBACTER-PYLORI INFECTION; ATROPHIC GASTRITIS; ENDOSCOPIC RESECTION; IRON-DEFICIENCY; EPIDEMIOLOGY; POPULATION; ANTIBODIES; CARCINOMA; ANEMIA; ULCER AB We provide a historical review and update on current thinking regarding the possibility of elimination of gastric cancer from Japan. Because Helicobacter pylori infection is the cause gastric cancer, its elimination forms the cornerstone of eradication of gastric cancer. However, simply eradicating H. pylori from the entire population will not immediately solve the problem because many patients with H. pylori infections have already developed the precursor lesion, atrophic gastritis. Cure of H. pylori in these high risk patients will only reduce the risk of subsequent cancer. In contrast, treatment of low risk patients will prevent cancer. Thus, to eliminate gastric cancer it is necessary to identify and treat all infected individuals. In addition, those at increased risk for gastric cancer (i.e., atrophic gastritis irrespective of age) should be considered for endoscopic surveillance to identify those cancers that develop at an early stage. We propose that severity and extent of atrophy be used to separate those expected to benefit from endoscopy and annual surveillance from those with little or no potential benefit. We suggest an algorithm for eradicating gastric cancer that incorporates H. pylori and atrophic gastritis testing, H. pylori therapy, and surveillance to institute a program of surveillance restricted to those who could benefit most (i.e., those with moderate or severe atrophy). This will also allow a much closer matching of surveillance capacity and surveillance need making surveillance more clinically- and cost-effective. C1 [Graham, David Y.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Asaka, Masahiro] Hokkaido Univ, Sch Med, Sapporo, Hokkaido 060, Japan. RP Graham, DY (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, RM 3A-320 111D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu RI Asaka, Masahiro/A-5948-2012 FU Office of Research and Development Medical Research Service Department of Veterans Affairs; Public Health Service [DK56338] FX This material is based upon work supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs and by Public Health Service grant DK56338 which funds the Texas Gulf Coast Digestive Diseases Center. NR 41 TC 44 Z9 50 U1 0 U2 0 PU SPRINGER TOKYO PI TOKYO PA 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, 102-0073, JAPAN SN 0944-1174 J9 J GASTROENTEROL JI J. Gastroenterol. PD JAN PY 2010 VL 45 IS 1 BP 1 EP 8 DI 10.1007/s00535-009-0117-8 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 546LA UT WOS:000273811100001 PM 19714291 ER PT J AU Shokrzadeh, L Baghaei, K Yamaoka, Y Dabiri, H Jafari, F Sahebekhtiari, N Tahami, A Sugimoto, M Zojaji, H Zali, MR AF Shokrzadeh, Leila Baghaei, Kaveh Yamaoka, Yoshio Dabiri, Hossein Jafari, Fereshteh Sahebekhtiari, Navid Tahami, Ali Sugimoto, Mitsushige Zojaji, Homayon Zali, Mohammad Reza TI Analysis of 3'-end variable region of the cagA gene in Helicobacter pylori isolated from Iranian population SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE cagA; Helicobacter pylori; pathogenesis; repeat region; virulence factors ID GASTRIC EPITHELIAL-CELLS; VIRULENCE FACTOR CAGA; TYROSINE PHOSPHORYLATION; PATHOGENICITY ISLAND; CYTOTOXIN PRODUCTION; BIOLOGICAL-ACTIVITY; ULCER-DISEASE; IV SECRETION; PROTEIN; TRANSLOCATION AB Background and Aims: The 3' region of the cagA gene, the most well-known virulence factor of Helicobacter pylori, contains Glu-Pro-Ile-Tyr-Ala (EPIYA) motifs. Four segments flanking the EPIYA motifs, EPIYA-A, -B, -C, or -D, were reported to play important roles in H. pylori-related gastroduodenal pathogenesis. The aim was to determine the roles of EPIYA segments in gastroduodenal pathogenesis in an Iranian population. Methods: A total of 92 cagA-positive Iranian strains isolated from dyspepsia patients with non-ulcer dyspepsia (n = 77), peptic ulcer (n = 11) and gastric cancer (n = 4) were studied. The EPIYA motif genotyping was determined by polymerase chain reaction and sequencing. Results: A total of 86 (93.5%) strains had three copies of EPIYA (ABC type), three (3.3%) had four copies (ABCC type) and three (3.3%) had two copies (AB type). The alignment of the deduced protein sequences confirmed that there were no East Asian type EPIYA-D sequences (EPIYATIDFDEANQAG) in Iranian strains. When the prevalence of strains with multiple EPIYA-C segments in Iran was compared with previously published data, it was much lower than that in Colombia and Italy, but was higher than that of Iraq, and the patterns were parallel to the incidence of gastric cancer in these countries. Conclusion: The structure of the 3' region of the cagA gene in Iranian strains was Western type. Although we could not find differences between EPIYA types and clinical outcomes, low prevalence of strains with multiple EPIYA-C segments might be reasons for low incidence of gastric cancer in Iran. C1 [Yamaoka, Yoshio] Oita Univ, Dept Environm & Prevent Med, Fac Med, Oita 8795593, Japan. [Shokrzadeh, Leila; Baghaei, Kaveh; Dabiri, Hossein; Jafari, Fereshteh; Sahebekhtiari, Navid; Tahami, Ali; Zojaji, Homayon; Zali, Mohammad Reza] Shaheed Beheshti Univ, Res Ctr Gastroenterol & Liver Dis, MC, Tehran, Iran. [Yamaoka, Yoshio; Sugimoto, Mitsushige] Michael E DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX USA. [Yamaoka, Yoshio; Sugimoto, Mitsushige] Baylor Coll Med, Houston, TX 77030 USA. RP Yamaoka, Y (reprint author), Oita Univ, Dept Environm & Prevent Med, Fac Med, Oita 8795593, Japan. EM yyamaoka@med.oita-u.ac.jp OI Dabiri, Hossein/0000-0002-2782-8970 FU RCGLD; Taleghani Hospital; Shahid Beheshti University, M.C., Tehran, Iran; National Institutes of Health (NIH) [R01 DK62813] FX This study was supported by a grant from RCGLD, Taleghani Hospital, Shahid Beheshti University, M.C., Tehran, Iran. The project described was also supported by grant number R01 DK62813 from the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. NR 40 TC 23 Z9 26 U1 0 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0815-9319 J9 J GASTROEN HEPATOL JI J. Gastroenterol. Hepatol. PD JAN PY 2010 VL 25 IS 1 BP 172 EP 177 DI 10.1111/j.1440-1746.2009.05979.x PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 536CU UT WOS:000273020600030 PM 19793167 ER PT J AU Hauer, KE Papadakis, MA AF Hauer, Karen E. Papadakis, Maxine A. TI Assessment of the Contributions of Clinician Educators SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID PROMOTION; COMPONENTS; MEDICINE; EMPATHY C1 [Hauer, Karen E.; Papadakis, Maxine A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Papadakis, Maxine A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Hauer, KE (reprint author), Univ Calif San Francisco, Dept Med, 533 Parnassus Ave,U113A,Box 0131, San Francisco, CA 94143 USA. EM Karen.hauer@ucsf.edu NR 16 TC 7 Z9 7 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 IS 1 BP 5 EP 6 DI 10.1007/s11606-009-1186-3 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 546DG UT WOS:000273788000003 PM 20016952 ER PT J AU Henderson, M Keenan, C Kohlwes, J Dhaliwal, G AF Henderson, Mark Keenan, Craig Kohlwes, Jeff Dhaliwal, Gupreet TI Introducing Exercises in Clinical Reasoning SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 [Henderson, Mark; Keenan, Craig] Univ Calif Davis, Med Ctr, Dept Internal Med, Sacramento, CA 95817 USA. [Kohlwes, Jeff; Dhaliwal, Gupreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Kohlwes, Jeff; Dhaliwal, Gupreet] San Francisco VA Med Ctr, San Francisco, CA USA. RP Henderson, M (reprint author), Univ Calif Davis, Med Ctr, Dept Internal Med, Sacramento, CA 95817 USA. EM mark.henderson@ucdmc.ucdavis.edu NR 0 TC 1 Z9 1 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 IS 1 BP 9 EP 9 DI 10.1007/s11606-009-1185-4 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 546DG UT WOS:000273788000005 PM 20016953 ER PT J AU Williams, EC Lapham, G Achtmeyer, CE Volpp, B Kivlahan, DR Bradley, KA AF Williams, Emily C. Lapham, Gwen Achtmeyer, Carol E. Volpp, Bryan Kivlahan, Daniel R. Bradley, Katharine A. TI Use of an Electronic Clinical Reminder for Brief Alcohol Counseling is Associated with Resolution of Unhealthy Alcohol Use at Follow-Up Screening SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE alcohol drinking; brief alcohol counseling; brief intervention; clinical reminder; implementation ID HEALTH-CARE-SYSTEM; DECISION-SUPPORT-SYSTEMS; AT-RISK DRINKING; PROBLEM DRINKERS; BRIEF PHYSICIAN; PATIENT; INTERVENTIONS; PERFORMANCE; ADVICE; IMPACT AB Brief alcohol counseling is a foremost US prevention priority, but no health-care system has implemented it into routine care. This study evaluated the effectiveness of an electronic clinical reminder for brief alcohol counseling ("reminder"). The specific aims were to (1) determine the prevalence of use of the reminder and (2) evaluate whether use of the reminder was associated with resolution of unhealthy alcohol use at follow-up screening. The reminder was implemented in February 2004 in eight VA clinics where providers routinely used clinical reminders. Patients eligible for this retrospective cohort study screened positive on the AUDIT-C alcohol screening questionnaire (February 2004-April 2006) and had a repeat AUDIT-C during the 1-36 months of follow-up (mean 14.5). Use of the alcohol counseling clinical reminder was measured from secondary electronic data. Resolution of unhealthy alcohol use was defined as screening negative at follow-up with a a parts per thousand yen2-point reduction in AUDIT-C scores. Logistic regression was used to identify adjusted proportions of patients who resolved unhealthy alcohol use among those with and without reminder use. Among 4,198 participants who screened positive for unhealthy alcohol use, 71% had use of the alcohol counseling clinical reminder documented in their medical records. Adjusted proportions of patients who resolved unhealthy alcohol use were 31% (95% CI 30-33%) and 28% (95% CI 25-30%), respectively, for patients with and without reminder use (p-value = 0.031). The brief alcohol counseling clinical reminder was used for a majority of patients with unhealthy alcohol use and associated with a moderate decrease in drinking at follow-up. C1 [Williams, Emily C.; Lapham, Gwen; Achtmeyer, Carol E.; Kivlahan, Daniel R.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, NW Ctr Excellence Hlth Serv Res & Dev, Seattle, WA USA. [Achtmeyer, Carol E.; Bradley, Katharine A.] VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA USA. [Bradley, Katharine A.] Univ Washington, Dept Med, Seattle, WA USA. [Kivlahan, Daniel R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Williams, Emily C.; Lapham, Gwen] Univ Washington, Hlth Serv, Seattle, WA 98195 USA. [Volpp, Bryan] VA No Calif Healthcare Syst, Martinez, CA USA. RP Williams, EC (reprint author), VA Puget Sound Hlth Care Syst, NW Ctr Excellence Hlth Serv Res Dev, Seattle, WA USA. EM emily.williams3@va.gov FU Robert Wood Johnson Foundation; Veteran's Affairs (VA); VA's Northwest Center of Excellence for Health Services Research and Development FX The clinical reminder evaluated in this study was developed with funding from The Robert Wood Johnson Foundation's Generalist Physicians Faculty Scholars Program. This study was supported by the Veteran's Affairs (VA) Substance Use Disorders Quality Enhancement Research Initiative (SUD QuERI) and the VA's Northwest Center of Excellence for Health Services Research and Development. Views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the University of Washington. Preliminary versions of this work were presented at the 2008 Addiction Health Services Research annual meeting and included in the dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy from the University of Washington ( completed by ECW June 2009). NR 50 TC 19 Z9 19 U1 3 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 SU 1 BP 11 EP 17 DI 10.1007/s11606-009-1100-z PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 544OH UT WOS:000273667000003 PM 20077146 ER PT J AU Cohen, BE Gima, K Bertenthal, D Kim, S Marmar, CR Seal, KH AF Cohen, Beth E. Gima, Kris Bertenthal, Daniel Kim, Sue Marmar, Charles R. Seal, Karen H. TI Mental Health Diagnoses and Utilization of VA Non-Mental Health Medical Services Among Returning Iraq and Afghanistan Veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE veterans; post-traumatic stress disorder; psychiatry; health services research; utilization ID POSTTRAUMATIC-STRESS-DISORDER; VIETNAM VETERANS; MILITARY SERVICE; 1ST ONSET; CARE; WAR; SYMPTOMS; SOLDIERS; RISK; PTSD AB Over 35% of returned Iraq and Afghanistan veterans in VA care have received mental health diagnoses; the most prevalent is post-traumatic stress disorder (PTSD). Little is known about these patients' use of non-mental health medical services and the impact of mental disorders on utilization. To compare utilization across three groups of Iraq and Afghanistan veterans: those without mental disorders, those with mental disorders other than PTSD, and those with PTSD. National, descriptive study of 249,440 veterans newly utilizing VA healthcare between October 7, 2001 and March 31, 2007, followed until March 31, 2008. We used ICD9-CM diagnostic codes to classify mental health status. We compared utilization of outpatient non-mental health services, primary care, medical subspecialty, ancillary services, laboratory tests/diagnostic procedures, emergency services, and hospitalizations during veterans' first year in VA care. Results were adjusted for demographics and military service and VA facility characteristics. Veterans with mental disorders had 42-146% greater utilization than those without mental disorders, depending on the service category (all P < 0.001). Those with PTSD had the highest utilization in all categories: 71-170% greater utilization than those without mental disorders (all P < 0.001). In adjusted analyses, compared with veterans without mental disorders, those with mental disorders other than PTSD had 55% higher utilization of all non-mental health outpatient services; those with PTSD had 91% higher utilization. Female sex and lower rank were also independently associated with greater utilization. Veterans with mental health diagnoses, particularly PTSD, utilize significantly more VA non-mental health medical services. As more veterans return home, we must ensure resources are allocated to meet their outpatient, inpatient, and emergency needs. C1 [Cohen, Beth E.; Gima, Kris; Bertenthal, Daniel; Kim, Sue; Marmar, Charles R.; Seal, Karen H.] San Francisco VA Med Ctr, Dept Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Cohen, Beth E.; Bertenthal, Daniel; Kim, Sue; Marmar, Charles R.; Seal, Karen H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Bertenthal, Daniel; Marmar, Charles R.; Seal, Karen H.] San Francisco VA Med Ctr, Hlth Serv Res & Dev Res Enhancement Award Program, San Francisco, CA 94121 USA. RP Cohen, BE (reprint author), San Francisco VA Med Ctr, Dept Vet Affairs Med Ctr, Box 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM Beth.Cohen@ucsf.edu FU VA Health Services Research and Development (HSRD); VA Seattle Epidemiological Research and Information Center; NIH/NCRR/OD UCSF-CTSI [KL2 RR024130]; San Francisco VA Medical Center HSR&D Research Enhancement [REA 01-097] FX We acknowledge and thank veterans of the wars in Iraq and Afghanistan for their service. This study was funded by a VA Health Services Research and Development (HSR&D) Career Development Transition Award and a grant from the VA Seattle Epidemiological Research and Information Center. Dr. Cohen was supported by NIH/NCRR/OD UCSF-CTSI grant no. KL2 RR024130. We are grateful for the support of the San Francisco VA Medical Center HSR&D Research Enhancement Award Program (REA 01-097). The manuscript contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or other funding agencies. Preliminary data for this paper were presented as an abstract at the Society of General Internal Medicine 2008 National Meeting. The authors have no conflicts of interest. NR 38 TC 93 Z9 93 U1 2 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 IS 1 BP 18 EP 24 DI 10.1007/s11606-009-1117-3 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 546DG UT WOS:000273788000007 PM 19787409 ER PT J AU Hynes, DM Weddle, T Smith, N Whittier, E Atkins, D Francis, J AF Hynes, Denise M. Weddle, Timothy Smith, Nina Whittier, Erika Atkins, David Francis, Joseph TI Use of Health Information Technology to Advance Evidence-Based Care: Lessons from the VA QUERI Program SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE data; health information technology; quality enhancement research initiative; implementation research; veterans health administration ID QUALITY IMPROVEMENT; DECISION-SUPPORT; IMPLEMENTATION; SCHIZOPHRENIA; PHYSICIANS; RECORDS; COSTS AB As the Department of Veterans Affairs (VA) Health Services Research and Development Service's Quality Enhancement Research Initiative (QUERI) has progressed, health information technology (HIT) has occupied a crucial role in implementation research projects. We evaluated the role of HIT in VA QUERI implementation research, including HIT use and development, the contributions implementation research has made to HIT development, and HIT-related barriers and facilitators to implementation research. Key informants from nine disease-specific QUERI Centers. Documentation analysis of 86 implementation project abstracts followed up by semi-structured interviews with key informants from each of the nine QUERI centers. We used qualitative and descriptive analyses. We found: (1) HIT provided data and information to facilitate implementation research, (2) implementation research helped to further HIT development in a variety of uses including the development of clinical decision support systems (23 of 86 implementation research projects), and (3) common HIT barriers to implementation research existed but could be overcome by collaborations with clinical and administrative leadership. Our review of the implementation research progress in the VA revealed interdependency on an HIT infrastructure and research-based development. Collaboration with multiple stakeholders is a key factor in successful use and development of HIT in implementation research efforts and in advancing evidence-based practice. C1 [Hynes, Denise M.; Weddle, Timothy; Whittier, Erika] Edward Hines Jr VA Hosp, VA Informat Resource Ctr, Hines, IL USA. [Hynes, Denise M.] Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA. [Hynes, Denise M.] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Hynes, Denise M.] Univ Illinois, Coll Med, Chicago, IL USA. [Smith, Nina] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Atkins, David] Dept Vet Affairs, Hlth Serv Res & Dev, Washington, DC USA. [Francis, Joseph] Dept Vet Affairs, Off Qual & Performance, Washington, DC USA. RP Hynes, DM (reprint author), Hines VA Hosp 578, VA Informat Resource Ctr 151V, 5000 S 5th Ave,Bldg 1,C302B, Hines, IL 60141 USA. EM Denise.Hynes@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development Service [TRA 01-001]; VA Information Resource Center [SDR-98-004]; VA Research Career Scientist Award FX This research was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development Service, Translation Data Initiative for QUERI Groups, Project Number TRA 01-001, and the VA Information Resource Center, project no. SDR-98-004. Dr. Hynes also received support for a VA Research Career Scientist Award. NR 32 TC 9 Z9 10 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 SU 1 BP 44 EP 49 DI 10.1007/s11606-009-1144-0 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 544OH UT WOS:000273667000008 PM 20077151 ER PT J AU Huang, AJ Luft, J Grady, D Kuppermann, M AF Huang, Alison J. Luft, Janis Grady, Deborah Kuppermann, Miriam TI The Day-to-Day Impact of Urogenital Aging: Perspectives from Racially/Ethnically Diverse Women SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 32nd Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 13-16, 2009 CL Miami, FL SP Soc Gen Internal Med DE urogenital atrophy; vaginal dryness; dyspareunia; menopause; quality of life ID QUALITY-OF-LIFE; POSTMENOPAUSAL WOMEN; SYMPTOMS; HEALTH; ATROPHY AB Urogenital symptoms affect up to half of women after menopause, but their impact on women's day-to-day functioning and wellbeing is poorly understood. Postmenopausal women aged 45 to 80 years reporting urogenital dryness, soreness, itching, or pain during sex were recruited to participate in in-depth focus groups to discuss the impact of their symptoms. Focus groups were homogenous with respect to race/ethnicity and stratified by age (for White or Black women) or language (for Latina women). Transcripts of sessions were analyzed according to grounded theory. Six focus groups were conducted, involving 44 women (16 White, 14 Black, 14 Latina). Five domains of functioning and wellbeing affected by symptoms were identified: sexual functioning, everyday activities, emotional wellbeing, body image, and interpersonal relations. For some participants, symptoms primarily affected their ability to have and enjoy sex, as well as be responsive to their partners. For others, symptoms interfered with everyday activities, such as exercising, toileting, or sleeping. Participants regarded their symptoms as a sign that they were getting old or their body was deteriorating; women also associated symptoms with a loss of womanhood or sexuality. Additionally, participants reported feeling depressed, embarrassed, and frustrated about their symptoms, and expressed reluctance to discuss them with friends, family, or health care providers. Urogenital symptoms can have a marked impact on sexual functioning, everyday activities, emotional wellbeing, body image, and interpersonal relations after menopause. Clinicians may need to question women actively about these symptoms, as many are reluctant to seek help for this problem. C1 [Huang, Alison J.; Grady, Deborah] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Huang, Alison J.; Luft, Janis; Grady, Deborah] Univ Calif San Francisco, Womens Hlth Clin Res Ctr, San Francisco, CA 94143 USA. [Huang, Alison J.; Kuppermann, Miriam] Univ Calif San Francisco, Med Effectiveness Res Ctr Diverse Populat, San Francisco, CA 94143 USA. [Luft, Janis; Kuppermann, Miriam] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. [Grady, Deborah] San Francisco VA Med Ctr, San Francisco, CA USA. RP Huang, AJ (reprint author), 1635 Divisadero St,Suite 600, San Francisco, CA 94115 USA. EM ahuang@ucsfmed.org FU NCRR NIH HHS [KL2RR024130, KL2 RR024130]; NIA NIH HHS [P30 AG015272, R03 AG035207, P30AG15272] NR 19 TC 6 Z9 7 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 IS 1 BP 45 EP 51 DI 10.1007/s11606-009-1135-1 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 546DG UT WOS:000273788000011 PM 19908103 ER PT J AU Holt, DT Helfrich, CD Hall, CG Weiner, BJ AF Holt, Daniel T. Helfrich, Christian D. Hall, Carmen G. Weiner, Bryan J. TI Are You Ready? How Health Professionals Can Comprehensively Conceptualize Readiness for Change SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE organizational change; change readiness; measuring readiness for change; implementation ID ORGANIZATIONAL-CHANGE; PRACTICE GUIDELINES; MODEL; CARE; QUALITY; IMPLEMENTATION; MANAGEMENT; FRAMEWORK; OUTCOMES; SMOKING AB One important factor influencing the successful implementation of system-wide change is initial readiness. Readiness is defined as the degree to which those involved are individually and collectively primed, motivated, and technically capable of executing the change. We present a conceptual framework that highlights three broad areas to be considered if health-care professionals are to comprehensively evaluate readiness that includes psychological factors (i.e., characteristics of those being asked to change), structural factors (i.e., circumstances under which the change is occurring) as well as the level of analysis (i.e., individual and organizational levels). We also describe more specific dimensions within each of these broad categories that have both empirical and theoretical support, presenting several valid and reliable survey instruments that measure key dimensions of readiness quantitatively. C1 [Holt, Daniel T.] USAF, Inst Technol, Dept Syst & Engn Management, AFTT ENV, Wright Patterson AFB, OH 45433 USA. [Helfrich, Christian D.] VA Puget Sound Hlth Care Syst, Ischem Heart Dis QUERI, Seattle, WA USA. [Hall, Carmen G.] VA Minneapolis Hlth Care Syst, Polytrauma & Blast Related Injuries QUERI, Minneapolis, MN USA. [Weiner, Bryan J.] Univ N Carolina, Chapel Hill, NC USA. RP Holt, DT (reprint author), USAF, Inst Technol, Dept Syst & Engn Management, AFTT ENV, 2950 Hobson Way, Wright Patterson AFB, OH 45433 USA. EM daniel.holt@afit.edu RI Helfrich, Christian/D-2382-2016 OI Helfrich, Christian/0000-0002-9827-4768 NR 40 TC 33 Z9 35 U1 2 U2 22 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 SU 1 BP 50 EP 55 DI 10.1007/s11606-009-1112-8 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 544OH UT WOS:000273667000009 PM 20077152 ER PT J AU Yano, EM Hayes, P Wright, S Schnurr, P Lipson, L Bean-Mayberry, B Washington, DL AF Yano, Elizabeth M. Hayes, Patricia Wright, Steven Schnurr, Paula P. Lipson, Linda Bean-Mayberry, Bevanne Washington, Donna L. TI Integration of Women Veterans into VA Quality Improvement Research Efforts: What Researchers Need to Know SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE quality improvement; disparities; implementation research; women's health; veterans ID AFFAIRS HEALTH-CARE; CARDIOVASCULAR-DISEASE; OF-CARE; GENDER; MILITARY; TRANSFORMATION; RECRUITMENT; PERFORMANCE; DISPARITIES; SYSTEM AB The Department of Veterans Affairs (VA) and other federal agencies require funded researchers to include women in their studies. Historically, many researchers have indicated they will include women in proportion to their VA representation or pointed to their numerical minority as justification for exclusion. However, women's participation in the military-currently 14% of active military-is rapidly changing veteran demographics, with women among the fastest growing segments of new VA users. These changes will require researchers to meet the challenge of finding ways to adequately represent women veterans for meaningful analysis. We describe women veterans' health and health-care use, note how VA care is organized to meet their needs, report gender differences in quality, highlight national plans for women veterans' quality improvement, and discuss VA women's health research. We then discuss challenges and potential solutions for increasing representation of women veterans in VA research, including steps for implementation research. C1 [Yano, Elizabeth M.; Bean-Mayberry, Bevanne; Washington, Donna L.] VA Greater Angeles HSR&D Ctr Excellence, Sepulveda, CA 91343 USA. [Bean-Mayberry, Bevanne; Washington, Donna L.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. [Hayes, Patricia] US Dept Vet Affairs, Women Vet Hlth Strateg Hlth Care Grp, Off Publ Hlth & Environm Hazards, Washington, DC USA. [Wright, Steven] Vet Hlth Adm, Off Qual & Performance, Providence, RI USA. [Schnurr, Paula P.] Natl Ctr PTSD, White River Junct VA Med Ctr, White River Jct, VT USA. [Schnurr, Paula P.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA. [Lipson, Linda] Vet Hlth Adm, Off Res & Dev, VA HSR&D Serv, Washington, DC USA. RP Yano, EM (reprint author), VA Greater Angeles HSR&D Ctr Excellence, Mailcode 152,16111 Plummer St, Sepulveda, CA 91343 USA. EM Elizabeth.yano@va.gov FU VA Health Services Research and Development (HSRD) Service [IIR-04-036, IAE-07-170, 05-195, RCD 02-039]; Women Veterans Ambulatory Care [IAE-06-083] FX Several VA Health Services Research and Development (HSR&D) Service funded studies provided source information for this paper, including Impact of Practice Structure on the Quality of Care for Women Veterans (phase 1 project no. IIR-04-036 and phase 2 project no. IAE-07-170), and the Women Veterans Ambulatory Care Use project phase II (project no. IAE-06-083). Dr. Yano's effort was funded by a VA HSR&D Research Career Scientist Award (project no. 05-195), while Dr. Bean-Mayberry's effort was funded by a VA HSR&D Career Development Transition Award (project no. RCD 02-039). We acknowledge the VA Office of Quality and Performance for direct contribution of results from internal reports on gender disparities in VA quality of care. The issues summarized in this paper were presented at the National VA Quality Enhancement Research Initiative (QUERI) Meeting, Phoenix, AZ, December 12, 2008, and the VA HSR&D Meeting, Baltimore, MD, February 12, 2009. NR 39 TC 49 Z9 49 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 SU 1 BP 56 EP 61 DI 10.1007/s11606-009-1116-4 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 544OH UT WOS:000273667000010 PM 20077153 ER PT J AU Egede, LE Ellis, C AF Egede, Leonard E. Ellis, Charles TI Development and Psychometric Properties of the 12-Item Diabetes Fatalism Scale SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE Diabetese Fatalism Scale; type 2 diabetes; DFS ID AFRICAN-AMERICANS; CANCER; EXPECTANCIES; RELIABILITY; VALIDATION; VALIDITY; LOCUS; WOMEN AB This study describes the development and validation of the Diabetes Fatalism Scale (DFS) in adults with type 2 diabetes. Thirty-five items were derived from focus groups, literature review, and expert opinion. The items were pilot tested on 20 adults with diabetes and then administered to 216 primary care patients with type 2 diabetes to assess the validity and reliability of the scale. Exploratory factor analysis (Principal Component Analysis with Varimax rotation) yielded a 12-item scale with three subscales. Pearson's correlation was used to test the DFS's association with diabetes self-care, HbA1c and quality of life. Multiple linear regression was used to assess association between the DFS and HbA1c controlling for demographics, comorbidity and insulin use. Cronbach's alpha for the 12-item DFS scale was 0.804 indicating internal consistency. The DFS is scored in such a way that higher scores represent greater diabetes fatalism. The DFS scores were not significantly correlated with age, years of education, or diabetes duration. Whites, men, those with government or no insurance, and those with 3+ comorbid conditions had significantly higher DFS scores. DFS was significantly correlated with self management understanding (r = -0.35, p < 0.001), control problems (r = 0.22, p = 0.002), self-care ability (r = -0.30, p < 0.001), and self-care adherence (r = -0.23, p < 0.001). The DFS was significantly correlated with HbA1c (r = 0.20, p = 0.004) and mental health component of SF-12 (r = -0.24, p = 0.001). In multivariate models, adjusting for demographics, comorbidity and insulin use, the DFS was independently associated with increased HbA1c (beta 0.21, p = 0.005). The DFS is a valid and reliable measure of diabetes fatalism. Diabetes fatalism is associated with self-care problems, poor glycemic control, and decreased quality of life. C1 [Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Ellis, Charles] Med Univ S Carolina, Dept Hlth Profess, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, Dept Med, 135 Rutledge Ave,Room 280H, Charleston, SC 29425 USA. EM egedel@musc.edu FU NIDDK NIH HHS [R01 DK081121, R01 DK081121-01A1, R01 DK081121-02, R01 DK081121-03] NR 24 TC 17 Z9 17 U1 2 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 IS 1 BP 61 EP 66 DI 10.1007/s11606-009-1168-5 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 546DG UT WOS:000273788000014 PM 19908102 ER PT J AU Nazi, KM Hogan, TP Wagner, TH McInnes, DK Smith, BM Haggstrom, D Chumbler, NR Gifford, AL Charters, KG Saleem, JJ Weingardt, KR Fischetti, LF Weaver, FM AF Nazi, Kim M. Hogan, Timothy P. Wagner, Todd H. McInnes, D. Keith Smith, Bridget M. Haggstrom, David Chumbler, Neale R. Gifford, Allen L. Charters, Kathleen G. Saleem, Jason J. Weingardt, Kenneth R. Fischetti, Linda F. Weaver, Frances M. TI Embracing a Health Services Research Perspective on Personal Health Records: Lessons Learned from the VA My HealtheVet System SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE personal health records; health information; health services research; PHR ID INFORMATION; CARE AB Personal health records (PHRs) are designed to help people manage information about their health. Over the past decade, there has been a proliferation of PHRs, but research regarding their effects on clinical, behavioral, and financial outcomes remains limited. The potential for PHRs to facilitate patient-centered care and health system transformation underscores the importance of embracing a broader perspective on PHR research. Drawing from the experiences of VA staff to evaluate the My HealtheVet (MHV) PHR, this article advocates for a health services research perspective on the study of PHR systems. We describe an organizing framework and research agenda, and offer insights that have emerged from our ongoing efforts regarding the design of PHR-related studies, the need to address PHR data ownership and consent, and the promotion of effective PHR research collaborations. These lessons are applicable to other PHR systems and the conduct of PHR research across different organizational contexts. C1 [Nazi, Kim M.] US Dept Vet Affairs, Vet & Consumers Hlth Informat Off, Off Hlth Informat, Vet Hlth Adm, Washington, DC USA. [Hogan, Timothy P.; Smith, Bridget M.; Weaver, Frances M.] US Dept Vet Affairs, Hlth Serv Res & Dev Ctr Management Complex Chron, Hines, IL USA. [Hogan, Timothy P.; Smith, Bridget M.; Weaver, Frances M.] US Dept Vet Affairs, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL USA. [Hogan, Timothy P.; Smith, Bridget M.; Weaver, Frances M.] US Dept Vet Affairs, Edward J Hines Jr Vet Affairs Hosp, Vet Hlth Adm, Hines, IL 60141 USA. [Wagner, Todd H.; Weingardt, Kenneth R.] US Dept Vet Affairs, Vet Hlth Adm, Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA USA. [Wagner, Todd H.; Weingardt, Kenneth R.] Stanford Univ, Stanford, CA 94305 USA. [McInnes, D. Keith; Gifford, Allen L.] US Dept Vet Affairs, HIV Hepatitis Qual Enhancement Res Initiat QUERI, Bedford, MA USA. [McInnes, D. Keith; Gifford, Allen L.] US Dept Vet Affairs, Hlth Serv Res & Dev Ctr Hlth Qual Outcomes & Econ, Bedford, MA USA. [McInnes, D. Keith; Gifford, Allen L.] US Dept Vet Affairs, Vet Hlth Adm, Edith Nourse Rogers Mem Vet Hosp, Bedford, MA USA. [Smith, Bridget M.; Weaver, Frances M.] Northwestern Univ, Inst Healthcare Studies, Chicago, IL 60611 USA. [Haggstrom, David; Saleem, Jason J.] US Dept Vet Affairs, Hlth Serv Res & Dev Ctr Implementing Evidence Bas, Indianapolis, IN USA. [Haggstrom, David; Chumbler, Neale R.; Saleem, Jason J.] Vet Hlth Adm, Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN USA. [Haggstrom, David; Saleem, Jason J.] Regenstrief Inst Hlth Care, Univ Ctr Hlth Serv & Outcomes Res, Indianapolis, IN USA. [Haggstrom, David] Indiana Univ, Dept Med, Div Gen Internal Med & Geriatr, Indianapolis, IN USA. [Chumbler, Neale R.] US Dept Vet Affairs, Stroke Qual Enhancement Res Initiat QUERI, Indianapolis, IN USA. [Chumbler, Neale R.] Indiana Univ Purdue Univ, Dept Sociol, Indiana Univ Sch Liberal Arts, Indianapolis, IN 46202 USA. [Gifford, Allen L.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Charters, Kathleen G.] Creat Comp Solut Inc, Rockville, MD USA. [Saleem, Jason J.] Indiana Univ Purdue Univ, Dept Elect & Comp Engn, Indianapolis, IN 46202 USA. [Weingardt, Kenneth R.] US Dept Vet Affairs, Subst Use Disorders Qual Enhancement Res Initiat, Houston, TX USA. [Weingardt, Kenneth R.] Vet Hlth Adm, Michael E DeBakey VA Med Ctr, Houston, TX USA. [Fischetti, Linda F.] US Dept Vet Affairs, Vet Hlth Adm, Off Hlth Informat, Washington, DC USA. [Weaver, Frances M.] Northwestern Univ, Sch Med, Dept Neurol, Chicago, IL 60611 USA. RP Nazi, KM (reprint author), US Dept Vet Affairs, Vet & Consumers Hlth Informat Off, Off Hlth Informat, Vet Hlth Adm, Washington, DC USA. EM kim.nazi@va.gov NR 46 TC 30 Z9 30 U1 3 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 SU 1 BP 62 EP 67 DI 10.1007/s11606-009-1114-6 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 544OH UT WOS:000273667000011 PM 20077154 ER PT J AU Damush, TM Jackson, GL Powers, BJ Bosworth, HB Cheng, E Anderson, J Gulhan, M LaVela, S Rajan, S Plue, L AF Damush, T. M. Jackson, G. L. Powers, B. J. Bosworth, H. B. Cheng, E. Anderson, J. Gulhan, M. LaVela, S. Rajan, S. Plue, L. TI Implementing Evidence-Based Patient Self-Management Programs in the Veterans Health Administration: Perspectives on Delivery System Design Considerations SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE self-management; implementation; veterans health administration ID PRIMARY-CARE PATIENTS; LOW-BACK-PAIN; CHRONIC DISEASE; RANDOMIZED-TRIAL; CHRONIC ILLNESS; HYPERTENSION; INTERVENTION; METHODOLOGY; EDUCATION; IMPROVE AB While many patient self-management (PSM) programs have been developed and evaluated for effectiveness, less effort has been devoted to translating and systematically delivering PSM in primary and specialty care. Therefore, the purpose of this paper is to review delivery system design considerations for implementing self-management programs in practice. As lessons are learned about implementing PSM programs in Veterans Health Administration (VHA), resource allocation by healthcare organization for formatting PSM programs, providing patient access, facilitating PSM, and incorporating support tools to foster PSM among its consumers can be refined and tailored. Redesigning the system to deliver and support PSM will be important as implementation researchers translate evidence based PSM practices into routine care and evaluate its impact on the health-related quality of life of veterans living with chronic disease. C1 [Damush, T. M.; Plue, L.] Indiana Univ, Dept Gen Internal Med & Geriatr, Ctr Aging Res, Regenstrief Inc,HSRD COE, Indianapolis, IN 46204 USA. [Damush, T. M.; Plue, L.] VA Stroke QUERI Ctr, Richard L Roudebush VAMC, Indianapolis, IN USA. [Jackson, G. L.; Powers, B. J.; Bosworth, H. B.] Durham VAMC, HSRD COE, Durham, NC USA. [Cheng, E.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Anderson, J.] Michael E DeBakey VAMC, Houston, TX USA. [Gulhan, M.; LaVela, S.] Spinal Cord Injury QUERI Ctr, Edward Hines Jr VAMC, Chicago, IL USA. [Rajan, S.] Spinal Cord Injury QUERI Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Damush, T. M.] Roudebush VAMC, Indianapolis, IN USA. RP Damush, TM (reprint author), Roudebush VAMC, 1481 W 10th St,HSRD 11H, Indianapolis, IN 46202 USA. EM Teresa.Damush@va.gov FU VA HSRD [STR-03-168]; HSRD [IMV 04-096]; NINDS/NIH [5K23NS058571-03]; NCRR/NIH [KL2 RR024127]; National HSRD VA QUERI Program FX The project was supported in part by the following funding: VA HSRD STR-03-168 (Stroke QUERI Center); HSRD IMV#04-096 (Dr. Damush/Ms. Plue); NINDS/NIH Career Development Award (5K23NS058571-03) to Dr. Eric Cheng; VA senior career award to Dr. Bosworth; and a NCRR/NIH career development award KL2 RR024127 to Dr. Ben Powers and the National HSRD VA QUERI Program (Workshop sponsor). NR 46 TC 7 Z9 7 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 SU 1 BP 68 EP 71 DI 10.1007/s11606-009-1123-5 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 544OH UT WOS:000273667000012 PM 20077155 ER PT J AU Box, TL McDonell, M Helfrich, CD Jesse, RL Fihn, SD Rumsfeld, JS AF Box, Tamara L. McDonell, Mary Helfrich, Christian D. Jesse, Robert L. Fihn, Stephan D. Rumsfeld, John S. TI Strategies from a Nationwide Health Information Technology Implementation: The VA CART STORY SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE health information technology; implementation; barriers; facilitators; EMR; organizational culture ID RECORDS; SYSTEM; PHYSICIANS; BARRIERS; ADOPTION; LESSONS AB The VA Cardiovascular Assessment, Reporting, and Tracking (CART) system is a customized electronic medical record system which provides standardized report generation for cardiac catheterization procedures, serves as a national data repository, and is the centerpiece of a national quality improvement program. Like many health information technology projects, CART implementation did not proceed without some barriers and resistance. We describe the nationwide implementation of CART at the 77 VA hospitals which perform cardiac catheterizations in three phases: (1) strategic collaborations; (2) installation; and (3) adoption. Throughout implementation, success required a careful balance of technical, clinical, and organizational factors. We offer strategies developed through CART implementation which are broadly applicable to technology projects aimed at improving the quality, reliability, and efficiency of health care. C1 [Box, Tamara L.; Rumsfeld, John S.] VA Eastern Colorado Hlth Care Syst, Denver, CO 80220 USA. [McDonell, Mary; Helfrich, Christian D.; Fihn, Stephan D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Jesse, Robert L.] VA Cent Off, Washington, DC USA. [Jesse, Robert L.] Richmond VA Med Ctr, Richmond, VA USA. RP Box, TL (reprint author), VA Eastern Colorado Hlth Care Syst, 1055 Clermont St 111B, Denver, CO 80220 USA. EM tamara.box@va.gov RI Helfrich, Christian/D-2382-2016 OI Helfrich, Christian/0000-0002-9827-4768 FU Veterans Health Administration Office of Patient Care Services, Washington, DC FX This material is based upon a workshop led during the 2008 National Meeting of the Quality Enhancement Research Initiative (QUERI) of the Health Services R&D Service, Department of Veterans Affairs. The views expressed here are those of the authors, who are responsible for its contents, and do not necessarily represent the views of the U.S. Department of Veterans Affairs. Funding for this work was provided by the Veterans Health Administration Office of Patient Care Services, Washington, DC. NR 28 TC 30 Z9 30 U1 1 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 SU 1 BP 72 EP 76 DI 10.1007/s11606-009-1130-6 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 544OH UT WOS:000273667000013 PM 20077156 ER PT J AU Henderson, MC Dhaliwal, G Jones, SR Culbertson, C Bowen, JL AF Henderson, Mark C. Dhaliwal, Gurpreet Jones, Stephen R. Culbertson, Charles Bowen, Judith L. TI Doing What Comes Naturally SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material DE diagnostic reasoning; secondary hypertension; problem representation; illness scripts; clinical problem solving C1 [Henderson, Mark C.; Bowen, Judith L.] UC Davis Med Ctr, Dept Internal Med, Sacramento, CA 95718 USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, San Francisco, CA USA. [Jones, Stephen R.; Culbertson, Charles] Legacy Hlth Syst, Dept Internal Med, Portland, OR USA. [Jones, Stephen R.; Culbertson, Charles] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Henderson, MC (reprint author), UC Davis Med Ctr, Dept Internal Med, 4150 V St,Suite 3100, Sacramento, CA 95718 USA. EM MCHenderson@ucdavis.edu NR 6 TC 9 Z9 9 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JAN PY 2010 VL 25 IS 1 BP 84 EP 87 DI 10.1007/s11606-009-1187-2 PG 4 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 546DG UT WOS:000273788000018 PM 20087787 ER PT J AU Miller, MJ Allison, JJ Schmitt, MR Ray, MN Funkhouser, EM Cobaugh, DJ Saag, KG LaCivita, C AF Miller, Michael J. Allison, Jeroan J. Schmitt, Michael R. Ray, Midge N. Funkhouser, Ellen M. Cobaugh, Daniel J. Saag, Kenneth G. LaCivita, Cynthia TI Using Single-Item Health Literacy Screening Questions to Identify Patients Who Read Written Nonsteroidal Anti-Inflammatory Medicine Information Provided at Pharmacies SO JOURNAL OF HEALTH COMMUNICATION LA English DT Article ID CHRONIC DISEASE; MEDICATION; KNOWLEDGE; CARE; EDUCATION; ABILITY; SKILLS; SHAME; RISK AB Our goal was to assess the relationships between single-item health literacy screening questions and reading prescription nonsteroidal anti-inflammatory drug (NSAID) written medicine information (WMI) provided at pharmacies. The health literacy of 382 patients from primary care physician practices in Alabama was estimated using validated health literacy screening questions related to understanding written medical information (SQ1); confidence in completing medical forms alone (SQ2); and need for assistance in reading hospital materials (SQ3). Reading WMI was measured by a oYeso response to the question, oOften the drug store gives you written information such as pamphlets or handouts along with your prescription. Have you read about the risks of NSAIDs in this written material provided by the drug store?o Relationships were assessed using generalized linear latent and mixed models. Two-thirds (67.6%) of patients read WMI. Higher estimated health literacy was associated with increased odds of reading WMI. Adjusted odds ratios (95% CI) were 2.08 (1.08-4.03); 2.09 (1.12-3.91); and 1.98 (1.04-3.77) using SQ1-SQ3. Current WMI may be unable to meet the needs of those with inadequate health literacy. Health literacy screening questions can be used to triage patients at risk for not reading WMI so they can be assisted with supplemental educational strategies. C1 [Miller, Michael J.; Schmitt, Michael R.] Univ Oklahoma, Coll Pharm, Dept Pharm Clin & Adm Sci, Tulsa, OK 74135 USA. [Allison, Jeroan J.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA. [Ray, Midge N.] Univ Alabama Birmingham, Deep S Musculoskeletal Ctr Educ & Res Therapeut, Ctr Outcomes & Effectiveness Res & Educ, Birmingham, AL USA. [Ray, Midge N.] Univ Alabama Birmingham, Sch Hlth Profess, Dept Hlth Serv Adm, Birmingham, AL USA. [Funkhouser, Ellen M.] Univ Alabama Birmingham, VA Res Enhancement Award Program REAP, Birmingham VA Med Ctr, Dept Med,Sch Med, Birmingham, AL USA. [Cobaugh, Daniel J.; LaCivita, Cynthia] Amer Soc Hlth Syst Pharmacists Res & Educ Fdn, Bethesda, MD USA. [Saag, Kenneth G.] Univ Alabama Birmingham, Ctr Educ & Res Therapeut CERTs, Birmingham, AL USA. [Saag, Kenneth G.] Univ Alabama Birmingham, Sch Med, COERE, Birmingham, AL USA. RP Miller, MJ (reprint author), Univ Oklahoma, Coll Pharm, Dept Pharm Clin & Adm Sci, 4502 E 41st St, Tulsa, OK 74135 USA. EM michael-miller@ouhsc.edu OI Allison, Jeroan/0000-0003-4472-2112 FU AHRQ HHS [U18 HS016956] NR 39 TC 5 Z9 5 U1 4 U2 7 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1081-0730 EI 1087-0415 J9 J HEALTH COMMUN JI J. Health Commun. PY 2010 VL 15 IS 4 BP 413 EP 427 AR PII 923240176 DI 10.1080/10810731003753091 PG 15 WC Communication; Information Science & Library Science SC Communication; Information Science & Library Science GA 615FW UT WOS:000279120500006 PM 20574879 ER PT J AU Brau, N Kikuchi, L Nunez, M Barreiro, P Nelson, M Bini, EJ Kristen, M Fox, R Sherman, M Puoti, M AF Braeu, N. Kikuchi, L. Nunez, M. Barreiro, P. Nelson, M. Bini, E. J. Kristen, M. Fox, R. Sherman, M. Puoti, M. CA Liver Canc HIV Study Grp TI IMPROVED SURVIVAL OF HEPATOCELLULAR CARCINOMA (HCC) IN HIV-INFECTED PATIENTS WITH UNDETECTABLE HIV RNA SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 14-18, 2010 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [Braeu, N.] Mt Sinai Sch Med, Div Infect Dis, New York, NY USA. [Braeu, N.] Mt Sinai Sch Med, Div Liver Dis, New York, NY USA. [Braeu, N.] Bronx Vet Affairs Med Ctr, Bronx, NY USA. [Kikuchi, L.] Univ Sao Paulo, Sao Paulo, Brazil. [Nunez, M.] Wake Forest Univ, Winston Salem, NC 27109 USA. [Barreiro, P.] Hosp Carlos III, Madrid, Spain. [Nelson, M.] Chelsea & Westminster Hosp, London, England. [Bini, E. J.] NYU, New York, NY USA. [Bini, E. J.] Vet Affairs New York Harbor Hlth Care Ctr, New York, NY USA. [Kristen, M.] Cornell Univ, New York, NY 10021 USA. [Fox, R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Sherman, M.] Univ Toronto, Toronto, ON, Canada. [Puoti, M.] Univ Brescia, Brescia, Italy. EM norbert.brau@va.gov NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2010 VL 52 SU 1 BP S219 EP S219 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 587UE UT WOS:000277018001174 ER PT J AU Kikuchi, L Nunez, M Barreiro, P Nelson, M Vispo, ME Page, E Puoti, M Fox, R Sherman, M Carrilho, F Brau, N AF Kikuchi, L. Nunez, M. Barreiro, P. Nelson, M. Vispo, M. E. Page, E. Puoti, M. Fox, R. Sherman, M. Carrilho, F. Braeu, N. TI IMPACT OF SCREENING FOR HEPATOCELLULAR CARCINOMA (HCC) IN HIV/HCV-COINFECTED PATIENTS ON STAGING, THERAPY AND SURVIVAL SO JOURNAL OF HEPATOLOGY LA English DT Meeting Abstract CT 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver CY APR 14-18, 2010 CL Vienna, AUSTRIA SP European Assoc Study Liver C1 [Kikuchi, L.; Carrilho, F.] Univ Sao Paulo, Liver Canc HIV Study Grp, Sao Paulo, Brazil. [Nunez, M.] Wake Forest Univ, Winston Salem, NC 27109 USA. [Barreiro, P.; Vispo, M. E.] Hosp Carlos III, Madrid, Spain. [Nelson, M.; Page, E.] Chelsea & Westminster Hosp, London, England. [Puoti, M.] Univ Brescia, Brescia, Italy. [Fox, R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Sherman, M.] Univ Toronto, Toronto, ON, Canada. [Braeu, N.] Bronx Vet Affairs Med Ctr, Bronx, NY USA. [Braeu, N.] Mt Sinai Sch Med, Div Infect Dis & Liver Dis, New York, NY USA. EM lu1912@gmail.com RI Carrilho, Flair/I-3046-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PY 2010 VL 52 SU 1 BP S412 EP S412 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 587UE UT WOS:000277018002265 ER PT J AU Paige, NM Vazirani, SS Graber, CJ AF Paige, Neil M. Vazirani, Sondra S. Graber, Christophe J. TI The Top 10 Infectious Disease Pitfalls That Hospitalists Can Avoid SO JOURNAL OF HOSPITAL MEDICINE LA English DT Review DE antimicrobials bacteremia; candida; clostridium difficile infection; penicillin allergy ID CLOSTRIDIUM-DIFFICILE INFECTION; ASYMPTOMATIC BACTERIURIA; BODY-TEMPERATURE; OCCAMS RAZOR; LEUKOCYTOSIS; MANAGEMENT; ALLERGY; GUIDELINES; CANDIDEMIA; DIAGNOSIS AB Infectious diseases are commonly encountered by hospitalists in their day-to-day care of patients. Challenges involved in caring for patients with infectious diseases include choosing the correct antibiotic, treating patients with a penicillin allergy, interpreting blood cultures, and caring for patients with human immunodeficiency virus (HIV). The evidence-based pearls in this article will help hospitalists avoid common pitfalls in the recognition and treatment of such disorders and guide their decision about when to consult an infectious diseases specialist. Journal of Hospital Medicine 2010;5:42-45. (c) 2010 Society of Hospital Medicine. C1 [Paige, Neil M.] Univ Calif Los Angeles, Dept Med, VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med,David Geffen Sch Med, Los Angeles, CA 90073 USA. [Vazirani, Sondra S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hosp Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. [Graber, Christophe J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. RP Paige, NM (reprint author), Univ Calif Los Angeles, Dept Med, VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med,David Geffen Sch Med, 11301 Wilshire Blvd 111A, Los Angeles, CA 90073 USA. EM neil.paige@va.gov NR 26 TC 3 Z9 3 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1553-5592 J9 J HOSP MED JI J. Hosp. Med. PD JAN PY 2010 VL 5 IS 1 BP 42 EP 45 DI 10.1002/jhm.515 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 545QI UT WOS:000273751000007 PM 20063396 ER PT J AU Rosendorff, C AF Rosendorff, Clive TI Spironolactone for all hypertensive patients? SO JOURNAL OF HYPERTENSION LA English DT Editorial Material ID SELECTIVE ALDOSTERONE BLOCKER; RESISTANT HYPERTENSION; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; EPLERENONE; AMLODIPINE C1 [Rosendorff, Clive] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Rosendorff, Clive] Mt Sinai Sch Med, Dept Med, New York, NY USA. RP Rosendorff, C (reprint author), James J Peters VA Med Ctr, Med 111,134 W Kingsbridge Rd, Bronx, NY 10468 USA. EM clive.rosendorff@va.gov NR 11 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0263-6352 J9 J HYPERTENS JI J. Hypertens. PD JAN PY 2010 VL 28 IS 1 BP 13 EP 14 DI 10.1097/HJH.0b013e328334262f PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 541HM UT WOS:000273405900003 PM 20016304 ER PT J AU Wang, JH Li, J Wu, Q Yang, PA Pawar, RD Xie, ST Timares, L Raman, C Chaplin, DD Lu, L Mountz, JD Hsu, HC AF Wang, John H. Li, Jun Wu, Qi Yang, PingAr Pawar, Rahul D. Xie, Shutao Timares, Laura Raman, Chander Chaplin, David D. Lu, Lu Mountz, John D. Hsu, Hui-Chen TI Marginal Zone Precursor B Cells as Cellular Agents for Type I IFN-Promoted Antigen Transport in Autoimmunity SO JOURNAL OF IMMUNOLOGY LA English DT Article ID PLASMACYTOID DENDRITIC CELLS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; T-CELLS; PATHOGENIC AUTOANTIBODIES; FOLLICULAR EXCLUSION; RHEUMATOID-ARTHRITIS; THERAPEUTIC TARGET; BXD2 MICE; NZB MICE; INTERFERON AB The pathogenic connection of type I IFN and its role in regulating the migration response of Ag delivery by B cells into lymphoid follicles in an autoimmune condition has not been well-identified. Here, we show that there was a significantly larger population of marginal zone precursor (MZ-P) B cells, defined as being IgM(hi)CD1d(hi)CD21(hi)CD23(hi) in the spleens of autoimmune BXD2 mice compared with B6 mice. MZ-P B cells were highly proliferative compared with marginal zone (MZ) and follicular (FO) B cells. The intrafollicular accumulation of MZ-P B cells in proximity to germinal centers (GCs) in BXD2 mice facilitated rapid Ag delivery to the GC area, whereas Ag-carrying MZ B cells, residing predominantly in the periphery, had a lower ability to carry Ag into the GCs. IFN-alpha, generated by plasmacytoid dendritic cells, induced the expression of CD69 and suppressed the sphingosine-1-phosphate-induced chemotactic response, promoting FO-oriented Ag transport by MZ-P B cells. Knockout of type I IFN receptor in BXD2 (MID2-Ifn alpha r(-/-)) mice substantially diffused the intrafollicular MZ-P B cell conglomeration and shifted their location to the FO-MZ border near the marginal sinus, making Ag delivery to the FO interior less efficient. The development of spontaneous GCs was decreased in BXD2-Ifn alpha r(-/-) mice. Together, our results suggest that the MZ-P B cells are major Ag-delivery B cells and that the FO entry of these B cells is highly regulated by type I IFN-producing plasmacytoid dendritic cells in the marginal sinus in the spleens of autoimmune BXD2 mice. The Journal of Immunology, 2010, 184: 442-451. C1 [Wang, John H.; Li, Jun; Wu, Qi; Yang, PingAr; Pawar, Rahul D.; Xie, Shutao; Raman, Chander; Mountz, John D.; Hsu, Hui-Chen] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Timares, Laura] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Chaplin, David D.] Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA. [Lu, Lu] Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. RP Hsu, HC (reprint author), Univ Alabama, Dept Med, 1825 Univ Blvd,SHELB 311, Birmingham, AL 35294 USA. EM rheu078@uab.edu OI Chaplin, David/0000-0002-1354-3069 FU American College of Rheumatology Research and Education Foundation; Department of Veterans Affairs Merit Review [1101BX000600-01]; Daiichi-Sankyo; National Institutes of Health [IA1 071110-01A1, ARRA 3RO1A171110-02S1]; The University of Alabama at Birmingham Skin Diseases Research Center; Arthritis Foundation FX This work was supported by a grant from the American College of Rheumatology Research and Education Foundation Within Our Reach: Finding a Cure for Rheumatoid Arthritis campaign, the Alliance for lupus Research - Target Identification in Lupus program, a Department of Veterans Affairs Merit Review Grant (1101BX000600-01). Daiichi-Sankyo, and National Institutes of Health Grants (IA1 071110-01A1 and ARRA 3RO1A171110-02S1) (all to J.D.M.), The University of Alabama at Birmingham Skin Diseases Research Center (to L.T.), and the Arthritis Investigator Award supported by the Arthritis Foundation (to H.-C.H). NR 55 TC 18 Z9 19 U1 0 U2 3 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD JAN 1 PY 2010 VL 184 IS 1 BP 442 EP 451 DI 10.4049/jimmunol.0900870 PG 10 WC Immunology SC Immunology GA 535QL UT WOS:000272985300050 PM 19949066 ER PT J AU Aqel, R Hage, FG AlJaroudi, W Lawson, D Sweeney, A Hansalia, S Pothineni, K Heo, J Pajaro, O McGiffin, D Dell'Italia, L Iskandrian, AE AF Aqel, Raed Hage, Fadi G. AlJaroudi, Wael Lawson, David Sweeney, Aaron Hansalia, Sachin Pothineni, Koteswara Heo, Jaekyeong Pajaro, Octavio McGiffin, David Dell'Italia, Louis Iskandrian, Ami E. TI How Much Alcohol Should We Infuse in the Coronary Artery of Hypertrophic Cardiomyopathy Patients? SO JOURNAL OF INVASIVE CARDIOLOGY LA English DT Article DE alcohol septal ablation; left ventricular outflow gradient; infarct mass ID OUTFLOW TRACT OBSTRUCTION; PERCUTANEOUS SEPTAL ABLATION; INFARCT SIZE; SUDDEN-DEATH; FOLLOW-UP; EXPERIENCE; THERAPY AB Background. Although alcohol septal ablation (ASA) is increasingly used in hypertrophic cardiomyopathy (HC) patients who are refractory to medical therapy, the amount of alcohol that is required has not been well studied. This study sought to determine the amount of alcohol that is necessary to achieve clinical benefits of ASA. Methods. Myocardial perfusion imaging was used to determine the size of the myocardial infarction produced by ASA in 54 HC patients. Left ventricular outflow gradients (LVOTg) were determined invasively before and after ASA and by Doppler echocardiography before and at a median of 3 months after ASA. Results. LVOTg decreased at rest and after provocation in response to ASA and this was maintained on follow-up at 3 months. There was no relationship between the amount of alcohol infused and the infarct mass as determined by myocardial perfusion imaging. While the infarct mass was not correlated with the drop in the LVOTg at rest or with provocation, the quantity of alcohol infused was correlated with the drop in LVOTg at rest (r = 0.27, p = 0.05) and with provocation (r = 0.34, p = 0.02). Furthermore, infusing more than 2ml of absolute alcohol was associated with a drop in the LVOTg by more than 60 mmHg at rest (p = 0.02) and by more than 130 mmHg with provocation (p = 0.05). Conclusions. Although lower amounts of alcohol infusion are desirable to avoid side-effects, it might be prudent to infuse around 2ml of absolute alcohol in order to achieve the desirable degree of LVOTg reduction in ASA. C1 [AlJaroudi, Wael; Lawson, David; Sweeney, Aaron; Hansalia, Sachin; Pothineni, Koteswara; Heo, Jaekyeong; Pajaro, Octavio; McGiffin, David; Dell'Italia, Louis; Iskandrian, Ami E.] Univ Alabama, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Aqel, Raed; Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Div Cardiol, Birmingham, AL USA. RP Aqel, R (reprint author), BDB 383,1530 3rd Ave S, Birmingham, AL 35294 USA. EM raed.aqel@yahoo.com OI Hage, Fadi/0000-0002-1397-4942 NR 25 TC 2 Z9 4 U1 0 U2 0 PU H M P COMMUNICATIONS PI MALVERN PA 83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA SN 1042-3931 J9 J INVASIVE CARDIOL JI J. Invasive Cardiol. PD JAN PY 2010 VL 22 IS 1 BP 22 EP 26 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 687VX UT WOS:000284807400008 PM 20048395 ER PT J AU Page, ST Lin, DW Mostaghel, E Marck, B Wright, J Amory, JK Matsumoto, AM AF Page, S. T. Lin, D. W. Mostaghel, E. Marck, B. Wright, J. Amory, J. K. Matsumoto, A. M. TI EXOGENOUS DIHYDROTESTOSTERONE DOES NOT INCREASE INTRAPROSTATIC DIHYDROTESTOSTERONE CONCENTRATIONS IN HEALTHY MEN: IMPLICATIONS FOR MALE HORMONAL THERAPIES SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CT Western Region Annual Meeting of the Society-of-Investigative-Medicine CY JAN 27-30, 2010 CY JAN 27-30, 2010 CL Carmel, CA CL Carmel, CA SP Amer Federat Med Res SP Soc Investgat Med, Western Reg C1 [Page, S. T.; Lin, D. W.; Mostaghel, E.; Wright, J.; Amory, J. K.; Matsumoto, A. M.] Univ Washington, Seattle, WA 98195 USA. [Marck, B.; Matsumoto, A. M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2010 VL 58 IS 1 MA 4 BP 103 EP 103 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 544FK UT WOS:000273638400018 ER PT J AU Richter, LL Kogai, T Brent, G AF Richter, L. L. Kogai, T. Brent, G. TI THE REGULATION OF THE SODIUM IODIDE SYMPORTER IN BREAST CANCER BY RETINOIC ACID SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CT Western Region Annual Meeting of the Society-of-Investigative-Medicine CY JAN 27-30, 2010 CY JAN 27-30, 2010 CL Carmel, CA CL Carmel, CA SP Amer Federat Med Res SP Soc Investgat Med, Western Reg C1 [Richter, L. L.; Kogai, T.; Brent, G.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Kogai, T.; Brent, G.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2010 VL 58 IS 1 MA 63 BP 119 EP 120 PG 2 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 544FK UT WOS:000273638400077 ER PT J AU Hirano, LA Page, ST Matsumoto, AM AF Hirano, L. A. Page, S. T. Matsumoto, A. M. TI DUTASTERIDE REDUCES PROSTATE SPECIFIC ANTIGEN (PSA) IN HYPOGONADAL MEN WITH BENIGN PROSTATIC HYPERPLASIA UNDERGOING TESTOSTERONE (T) REPLACEMENT THERAPY SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CT Western Region Annual Meeting of the Society-of-Investigative-Medicine CY JAN 27-30, 2010 CY JAN 27-30, 2010 CL Carmel, CA CL Carmel, CA SP Amer Federat Med Res SP Soc Investgat Med, Western Reg C1 [Hirano, L. A.; Page, S. T.; Matsumoto, A. M.] Univ Washington, Seattle, WA 98195 USA. [Hirano, L. A.; Page, S. T.; Matsumoto, A. M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2010 VL 58 IS 1 MA 67 BP 121 EP 121 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 544FK UT WOS:000273638400081 ER PT J AU Page, ST Lin, DW Mostaghel, E Marck, B Wright, J Amory, JK Matsumoto, AM AF Page, S. T. Lin, D. W. Mostaghel, E. Marck, B. Wright, J. Amory, J. K. Matsumoto, A. M. TI EXOGENOUS DIHYDROTESTOSTERONE DOES NOT INCREASE INTRAPROSTATIC DIHYDROTESTOSTERONE CONCENTRATIONS IN HEALTHY MEN: IMPLICATIONS FOR MALE HORMONAL THERAPIES SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CT Western Region Annual Meeting of the Society-of-Investigative-Medicine CY JAN 27-30, 2010 CY JAN 27-30, 2010 CL Carmel, CA CL Carmel, CA SP Amer Federat Med Res SP Soc Investgat Med, Western Reg C1 [Page, S. T.; Lin, D. W.; Mostaghel, E.; Wright, J.; Amory, J. K.; Matsumoto, A. M.] Univ Washington, Seattle, WA 98195 USA. [Marck, B.; Matsumoto, A. M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2010 VL 58 IS 1 MA 68 BP 121 EP 121 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 544FK UT WOS:000273638400082 ER PT J AU Toukatly, MN Jurgens, C Kahn, SE Hull, RL AF Toukatly, M. N. Jurgens, C. Kahn, S. E. Hull, R. L. TI HUMAN TYPE 2 DIABETES IS ASSOCIATED WITH ISLET AMYLOID DEPOSITION, DECREASED beta-CELL AREA, AND INCREASED beta-CELL APOPTOSIS SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CT Western Region Annual Meeting of the Society-of-Investigative-Medicine CY JAN 27-30, 2010 CY JAN 27-30, 2010 CL Carmel, CA CL Carmel, CA SP Amer Federat Med Res SP Soc Investgat Med, Western Reg C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2010 VL 58 IS 1 MA 109 BP 133 EP 133 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 544FK UT WOS:000273638400123 ER PT J AU Bartholomew, E Hull, RL AF Bartholomew, E. Hull, R. L. TI ALTERED EXPRESSION OF ENZYMES INVOLVED IN NITRIC OXIDE PRODUCTION IN ISLETS FROM DIABETIC MICE SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Western Regional Meeting of the American-Federation-for-Medical-Research CT Western Region Annual Meeting of the Society-of-Investigative-Medicine CY JAN 27-30, 2010 CY JAN 27-30, 2010 CL Carmel, CA CL Carmel, CA SP Amer Federat Med Res SP Soc Investgat Med, Western Reg C1 [Bartholomew, E.; Hull, R. L.] Univ Washington, Sch Med, Seattle, WA USA. [Bartholomew, E.; Hull, R. L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1081-5589 EI 1708-8267 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2010 VL 58 IS 1 MA 493 BP 244 EP 244 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 544FK UT WOS:000273638400505 ER PT J AU Ganguly, K Carmena, JM AF Ganguly, Karunesh Carmena, Jose M. TI Neural Correlates of Skill Acquisition with a Cortical Brain-Machine Interface SO JOURNAL OF MOTOR BEHAVIOR LA English DT Article DE brain-machine interface; learning; electrophysiology; motor control; skill acquisition ID PRIMARY MOTOR CORTEX; COMPUTER INTERFACES; NEURONAL-ACTIVITY; MOVEMENT SIGNAL; CONSOLIDATION; MONKEYS; MEMORY; REPRESENTATIONS; PROSTHETICS; TETRAPLEGIA AB Research into the development of brain-machine interfaces (BMIs) has led to demonstrations of rodents, nonhuman primates, and humans controlling prosthetic devices in real time through modulation of neural signals. In particular, cortical BMI studies have shown that improvements in performance require learning and are associated with changes in neuronal tuning properties. These studies have further shown evidence of long-term improvements in performance with practice. The authors conducted experiments to understand long-term skill acquisition with BMIs and to characterize the neural correlates of improvements in task performance. They specifically assessed long-term acquisition of neuroprosthetic skill (i.e., accurate task performance readily recalled across days). In 2 monkeys performing a center-out task using a brain-controlled (BC) computer cursor, they closely monitored daily performance trends and the neural correlates under different conditions. Importantly, they assessed BC performance using a continuous-control multistep task. The authors first conducted experiments that mimicked experimental conditions commonly used. Specifically, a large set of neurons was incorporated with daily recalibration of the transform of neural activity to BC. Under such conditions, they found evidence of variable daily performance. In contrast, when a fixed transform was applied to stable recordings from an ensemble of neurons across days, there was consistent evidence of long-term skill acquisition. Such skill acquisition was associated with the crystallization of a cortical map for prosthetic control. Taken together, the results suggest that the primate motor cortex can achieve skilled control of a neuroprosthetic device through consolidation of a cortical representation. C1 [Carmena, Jose M.] Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Helen Wills Neurosci Inst, Program Congat Sci, Berkeley, CA 94720 USA. [Ganguly, Karunesh] San Francisco VA Med Ctr, Neurol & Rehabil Serv, San Francisco, CA USA. [Ganguly, Karunesh] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Carmena, Jose M.] Univ Calif Berkeley, Program Cognit Sci, Berkeley, CA 94720 USA. RP Carmena, JM (reprint author), Univ Calif Berkeley, Dept Elect Engn & Comp Sci, Helen Wills Neurosci Inst, Program Congat Sci, Berkeley, CA 94720 USA. EM carmena@eecs.berkeley.edu NR 35 TC 22 Z9 22 U1 1 U2 7 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0022-2895 J9 J MOTOR BEHAV JI J. Mot. Behav. PY 2010 VL 42 IS 6 SI SI BP 355 EP 360 AR PII 929867255 DI 10.1080/00222895.2010.526457 PG 6 WC Neurosciences; Psychology; Psychology, Experimental; Sport Sciences SC Neurosciences & Neurology; Psychology; Sport Sciences GA 683KW UT WOS:000284475700005 PM 21184353 ER PT J AU Seo, Y Aparici, CM Cooperberg, MR Konety, BR Hawkins, RA AF Seo, Youngho Aparici, Carina Mari Cooperberg, Matthew R. Konety, Badrinath R. Hawkins, Randall A. TI In Vivo Tumor Grading of Prostate Cancer Using Quantitative In-111-Capromab Pendetide SPECT/CT SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE prostate cancer; capromab pendetide; SPECT; SPECT/CT; quantification; tracer quantification; quantitative SPECT; prostate-specific membrane antigen (PSMA) ID MEMBRANE ANTIGEN; ATTENUATION CORRECTION; RADICAL PROSTATECTOMY; FOLLOW-UP; PET; VALIDATION; SIMULATION AB We have developed an in vivo method to quantify antibody uptake using In-111-capromab pendetide SPECT combined with CT (SPECT/CT). Our goal was to evaluate this method for potential grading of prostate tumors. Methods: Our phantom experiments focused on the robustness of an advanced iterative reconstruction algorithm that involves corrections for photon attenuation, scatter, and geometric blurring caused by radionuclide collimators. The conversion factors between image values and tracer concentrations (in Bq/mL) were calculated from a uniform phantom filled with an aqueous solution of (InCl3)-In-111 using the same acquisition protocol and reconstruction parameters as for patient studies. In addition, the spatial resolution of the reconstructed images was measured from a point source phantom. The measured spatial resolution was modeled into a point-spread function, and the point-spread function was implemented in a deconvolution-based partial-volume-error correction algorithm. The recovery capability to correctly estimate true tracer concentrations was tested using prostatelike and bladderlike lesion phantoms fitted in the modified National Electrical Manufacturers Association/International Electrotechnical Commission body phantom. Patients with biopsy-proven prostate cancer (n = 10) who underwent prostatectomy were prospectively enrolled in the preoperative SPECT/CT studies at the San Francisco Veterans Affairs Medical Center. The CT portion of SPECT/CT was used to generate CT-based attenuation maps and as an anatomic localization tool for clinical interpretation. Pathologic Gleason grades were compared with in vivo antibody uptake value (AUV) normalized by injected dose, effective half-life, and injection-scan time difference. AUVs were calculated in each lobe of the prostate gland with cylindric volumes of interest having dimensions of 1.5 cm in both diameter and height. Results: Reconstructed SPECT images further corrected by the deconvolution-based partial-volume-error correction could recover tracer concentrations up to 90% of true values in measurements of phantom volumes as small as 7.77 mL. From patient studies, there was a statistically significant correlation (rho = 0.71, P = 0.033) between higher AUVs (from either left or right lobe) and higher components of pathologic Gleason scores. Conclusion: Our results strongly indicate potential for noninvasive prostate tumor grading using quantitative In-111-capromab pendetide SPECT/CT. C1 [Seo, Youngho; Aparici, Carina Mari; Hawkins, Randall A.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Seo, Youngho; Hawkins, Randall A.] Univ Calif San Francisco, Joint Grad Grp Bioengn, San Francisco, CA 94143 USA. [Seo, Youngho; Hawkins, Randall A.] Univ Calif Berkeley, Joint Grad Grp Bioengn, Berkeley, CA 94720 USA. [Seo, Youngho] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Radiat Oncol, San Francisco, CA 94143 USA. [Aparici, Carina Mari; Cooperberg, Matthew R.; Konety, Badrinath R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cooperberg, Matthew R.; Konety, Badrinath R.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. RP Seo, Y (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. EM youngho.seo@radiology.ucsf.edu RI Cooperberg, Matthew/G-6249-2017 OI Cooperberg, Matthew/0000-0003-4339-6685 FU National Cancer Institute [5 K25 CA114254]; University of California Industry-University Cooperative Research Program [0610210] FX We thank Marilyn Morrissey and Charisa Thomas at the San Francisco Veterans Affairs Medical Center for technical assistance with the imaging studies. This work was funded in part by National Cancer Institute grant 5 K25 CA114254 and by the University of California Industry-University Cooperative Research Program grant dig 0610210 with Philips Healthcare. NR 25 TC 14 Z9 14 U1 0 U2 2 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD JAN PY 2010 VL 51 IS 1 BP 31 EP 36 DI 10.2967/jnumed.109.067108 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 539OG UT WOS:000273263800010 PM 20008977 ER PT J AU Cheng, C Wang, XW Weakley, SM Kougias, P Lin, PH Yao, QZ Chen, CY AF Cheng, Charlie Wang, Xinwen Weakley, Sarah M. Kougias, Panagiotis Lin, Peter H. Yao, Qizhi Chen, Changyi TI The Soybean Isoflavonoid Equol Blocks Ritonavir-Induced Endothelial Dysfunction in Porcine Pulmonary Arteries and Human Pulmonary Artery Endothelial Cells SO JOURNAL OF NUTRITION LA English DT Article ID PROTEASE INHIBITOR RITONAVIR; INDUCED VASCULAR DYSFUNCTION; CORONARY-ARTERIES; MEDROXYPROGESTERONE ACETATE; ANTIOXIDANT ACTIVITY; METABOLITE EQUOL; SOY ISOFLAVONES; HIV-INFECTION; RECEPTOR-BETA; JAPANESE MEN AB HIV protease inhibitor (PI) ritonavir(RTV) may cause vascular injury through oxidative stress. Our purpose in this study was to determine whether equol, a soy isoflavone, could prevent RTV-induced endothelial dysfunction in porcine pulmonary arteries and in human pulmonary artery endothelial cells (HPAEC). Fresh porcine pulmonary artery rings were treated with 15 mu mol/L of RTV and/or equol in concentrations of 0.1, 1, and 10 mu mol/L for 24 In. A control was set with no amount of equol or RTV administered. Based on myograph tension analysis, RTV significantly reduced endothelium-dependent relaxation in response to bradykinin in the artery rings compared with untreated vessels, whereas the antioxidant equol effectively reversed the RTV effect in a concentration-dependent manner. RTV also reduced the contraction of artery rings in response to thromboxane A(2) analogue U46619 and this reduction was blocked by equol. In addition, RTV treatment significantly reduced endothelial nitric oxide synthase (eNOS) expression in both porcine pulmonary arteries and HPAEC, whereas equol effectively blocked RTV-induced eNOS downregulation. Furthermore, RTV significantly increased superoxide anion production, whereas equol reversed this effect of RTV in porcine pulmonary arteries. Thus, the antioxidant equol effectively protects vascular function from the detrimental effects of HIV PI RTV in both porcine pulmonary arteries and HPAEC via a reduction in the vasomotor dysfunction, eNOS downregulation, and oxidative stress induced by RTV. These novel data suggest that equol may have a clinical application in preventing HIV-associated cardiovascular complications. J. Nutr. 140: 12-17, 2010. C1 [Cheng, Charlie; Wang, Xinwen; Weakley, Sarah M.; Kougias, Panagiotis; Lin, Peter H.; Yao, Qizhi; Chen, Changyi] Baylor Coll Med, Mol Surg Res Ctr, Div Vasc Surg & Endovasc Therapy, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. [Kougias, Panagiotis; Lin, Peter H.; Yao, Qizhi; Chen, Changyi] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Chen, CY (reprint author), Baylor Coll Med, Mol Surg Res Ctr, Div Vasc Surg & Endovasc Therapy, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. EM jchen@bcm.tmc.edu FU NIH [HL076345, HL65916, HL72716]; Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX FX Supported by research grants from the NIH (no. HL076345 to P. H. Lin and nos. HL65916 and HL72716 to C. Chen) and by the Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX. NR 36 TC 13 Z9 15 U1 0 U2 0 PU AMER SOC NUTRITIONAL SCIENCE PI BETHESDA PA 9650 ROCKVILLE PIKE, RM L-2407A, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD JAN PY 2010 VL 140 IS 1 BP 12 EP 17 DI 10.3945/jn.109.110981 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 535EH UT WOS:000272949100003 PM 19923382 ER PT J AU Osman, A Gutierrez, PM Smith, K Fang, QJ Lozano, G Devine, A AF Osman, Augustine Gutierrez, Peter M. Smith, Kimberly Fang, Qijuan Lozano, Gregorio Devine, Aimee TI The Anxiety Sensitivity Index-3: Analyses of Dimensions, Reliability Estimates, and Correlates in Nonclinical Samples SO JOURNAL OF PERSONALITY ASSESSMENT LA English DT Article ID NEGATIVE AFFECT; PSYCHOMETRIC PROPERTIES; CONSTRUCT-VALIDITY; VALIDATION; BIFACTOR; PANAS; DISORDERS; MODELS; SCALES; ISSUES AB We investigated the factor structure, reliability estimates, and correlates of the Anxiety Sensitivity Index-3 (ASI-3; Taylor et al., 2007) in 2 studies. We established a bifactor model in Study 1 as an alternative representation of the structure of the ASI-3. Analyses of gender differences on the total ASI-3 and subscale scores were not statistically significant (Study 1, N = 462). In Study 2 (N = 293), results of a series of confirmatory factor analyses provided stronger support for the fit of the bifactor model compared with 2 alternative models. Estimates of scale reliability were adequate (all values epsilon .80) and not opo (as in italic p for significance). in the 2 studies. In addition, using simultaneous regression analyses, we found anxiety-specific correlates for the total ASI-3 and subscale scores to include responses on self-report measures of interpersonal sensitivity, obsessive-compulsive anxiety, paranoid ideation, and phobic anxiety. C1 [Osman, Augustine; Smith, Kimberly; Lozano, Gregorio; Devine, Aimee] Univ Texas San Antonio, Dept Psychol, San Antonio, TX 78249 USA. [Gutierrez, Peter M.] Mental Illness Res Educ & Clin Ctr, Denver VA Med Ctr, Denver, CO USA. [Fang, Qijuan] Univ Hawaii Manoa, Dept Psychol, Honolulu, HI 96822 USA. RP Osman, A (reprint author), Univ Texas San Antonio, Dept Psychol, 1 UTSA Circle, San Antonio, TX 78249 USA. EM augustine.osman@utsa.edu OI Gutierrez, Peter/0000-0001-8981-8404 NR 48 TC 31 Z9 33 U1 6 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0022-3891 J9 J PERS ASSESS JI J. Pers. Assess. PY 2010 VL 92 IS 1 BP 45 EP 52 AR PII 917722372 DI 10.1080/00223890903379332 PG 8 WC Psychology, Clinical; Psychology, Social SC Psychology GA 531PM UT WOS:000272680300005 PM 20013455 ER PT J AU Breshears, RE Brenner, LA Harwood, JEF Gutierrez, PM AF Breshears, Ryan E. Brenner, Lisa A. Harwood, Jeri E. F. Gutierrez, Peter M. TI Predicting Suicidal Behavior in Veterans With Traumatic Brain Injury: The Utility of the Personality Assessment Inventory SO JOURNAL OF PERSONALITY ASSESSMENT LA English DT Article ID PSYCHIATRIC-PATIENTS; MMPI-2 PROFILES; HEAD-INJURY; POPULATION; IRAQ; TBI; AFGHANISTAN; DEPRESSION; RISK AB In this study, we investigated the Personality Assessment Inventory's (PAI; Morey, 1991, 2007) Suicide Potential Index (SPI) and Suicide Ideation scale (SUI) as predictors of suicidal behavior (SB) in military Veterans with traumatic brain injury (TBI; N = 154). We analyzed electronic medical records were searched for SB in the 2 years post-PAI administration and data via logistic regressions. We obtained statistical support for the SPI and SUI as predictors of SB. Analyses we performed using receiver operating characteristics suggested an optimal SPI cutoff of epsilon 15 for this sample. Findings suggest that SPI and SUI scores may assist in assessing suicide risk in those with TBI, particularly when population-based cutoffs are considered. C1 [Breshears, Ryan E.; Brenner, Lisa A.; Harwood, Jeri E. F.; Gutierrez, Peter M.] Denver VA Med Ctr, VA VISN MIRECC 19, Denver, CO USA. [Brenner, Lisa A.; Gutierrez, Peter M.] Univ Colorado, Denver Sch Med, Dept Psychiat, Boulder, CO 80309 USA. [Brenner, Lisa A.] Univ Colorado, Denver Sch Med, Dept Phys Med & Rehabil, Boulder, CO 80309 USA. [Brenner, Lisa A.] Univ Colorado, Denver Sch Med, Dept Neurol, Boulder, CO 80309 USA. [Harwood, Jeri E. F.] Univ Colorado, Denver Sch Med, Dept Pediat, Boulder, CO 80309 USA. RP Breshears, RE (reprint author), WellStar Hlth Syst, 2000 S Pk Pl, Atlanta, GA 30339 USA. EM ryan.breshears@wellstar.org OI Gutierrez, Peter/0000-0001-8981-8404 NR 43 TC 5 Z9 5 U1 3 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0022-3891 J9 J PERS ASSESS JI J. Pers. Assess. PY 2010 VL 92 IS 4 BP 349 EP 355 AR PII 923051207 DI 10.1080/00223891.2010.482011 PG 7 WC Psychology, Clinical; Psychology, Social SC Psychology GA 611EL UT WOS:000278794000007 PM 20552509 ER PT J AU Inslicht, SS McCaslin, SE Metzler, TJ Henn-Haase, C Hart, SL Maguen, S Neylan, TC Marmar, CR AF Inslicht, Sabra S. McCaslin, Shannon E. Metzler, Thomas J. Henn-Haase, Clare Hart, Stacey L. Maguen, Shira Neylan, Thomas C. Marmar, Charles R. TI Family psychiatric history, peritraumatic reactivity, and posttraumatic stress symptoms: A prospective study of police SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Family history; Police stress; Peritraumatic distress; Posttraumatic stress disorder; Substance use ID DISORDER SYMPTOMS; CHILDHOOD TRAUMA; ENVIRONMENTAL-INFLUENCES; ANXIETY DISORDERS; MENTAL-DISORDERS; SUBSTANCE-ABUSE; ALCOHOL-ABUSE; RISK-FACTORS; PTSD; TWIN AB Background: Family history of psychiatric and substance use disorders has been associated with posttraumatic stress disorder (PTSD) in cross-sectional studies. Method: Using a prospective design, we examined the relationships of family history of psychiatric and substance use disorders to posttraumatic stress symptoms in 278 healthy police recruits. During academy training, recruits were interviewed on family and personal psychopathology, prior cumulative civilian trauma exposure, and completed self-report questionnaires on nonspecific symptoms of distress and alcohol use. Twelve months after commencement of active duty, participants completed questionnaires on critical incident exposure over the previous year, peritraumatic distress to the worst critical incident during this time, and posttraumatic stress symptoms. Results: A path model indicated: (1) family loading for mood and anxiety disorders had an indirect effect on posttraumatic stress symptoms at 12 months that was mediated through peritraumatic distress to the officer's self-identified worst critical incident, (2) family loading for substance use disorders also predicted posttraumatic stress symptoms at 12 months and this relationship was mediated through peritraumatic distress. Conclusion: These findings support a model in which family histories of psychopathology and substance abuse are pre-existing vulnerability factors for experiencing greater peritraumatic distress to critical incident exposure which, in turn, increases the risk for development of symptoms of posttraumatic stress disorder. Replication in other first responders, military and civilians will be important to determine generalizability of these findings. Published by Elsevier Ltd. C1 [Inslicht, Sabra S.; McCaslin, Shannon E.; Metzler, Thomas J.; Henn-Haase, Clare; Maguen, Shira; Neylan, Thomas C.; Marmar, Charles R.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Inslicht, Sabra S.; McCaslin, Shannon E.; Metzler, Thomas J.; Henn-Haase, Clare; Maguen, Shira; Neylan, Thomas C.; Marmar, Charles R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hart, Stacey L.] Ryerson Univ, Toronto, ON, Canada. RP Inslicht, SS (reprint author), Vet Affairs Med Ctr, PTSD Res Program, 4150 Clement St 116P, San Francisco, CA 94121 USA. EM Sabra.Inslicht@ucsf.edu RI Hart, Stacey/E-4819-2011 FU National Institute of Mental Health [R01 - MH056350-06] FX Funding for this study was provided by National Institute of Mental Health Grant (R01 - MH056350-06) to Dr. Marmar; the NIMH had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 59 TC 15 Z9 16 U1 4 U2 14 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD JAN PY 2010 VL 44 IS 1 BP 22 EP 31 DI 10.1016/j.jpsychires.2009.05.011 PG 10 WC Psychiatry SC Psychiatry GA 555HG UT WOS:000274499100004 PM 19683259 ER PT J AU Tarlov, E Stroupe, KT AF Tarlov, Elizabeth Stroupe, Kevin T. TI Advancing veterans' healthcare using electronic data: Lessons learned from researchers in the field SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Editorial Material ID POSTTRAUMATIC-STRESS-DISORDER; ADMINISTRATIVE DATABASES; QUALITY; REHABILITATION; AMPUTATION; EVALUATE; PROGRAM C1 [Tarlov, Elizabeth; Stroupe, Kevin T.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, VA Informat Resource Ctr, Hines, IL 60141 USA. RP Tarlov, E (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, VA Informat Resource Ctr, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. NR 31 TC 1 Z9 1 U1 0 U2 2 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 8 BP VII EP XI DI 10.1682/JRRD.2010.08.0148 PG 5 WC Rehabilitation SC Rehabilitation GA 691IU UT WOS:000285074300001 PM 21110241 ER PT J AU Chumney, D Nollinger, K Shesko, K Skop, K Spencer, M Newton, RA AF Chumney, Douglas Nollinger, Kristen Shesko, Kristina Skop, Karen Spencer, Madeleine Newton, Roberta A. TI Ability of Functional Independence Measure to accurately predict functional outcome of stroke-specific population: Systematic review SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE civilian; CVA; discharge disposition; FM; length of stay; outcomes; predictability; rehabilitation; stroke; veterans ID REHABILITATION PATIENTS; BARTHEL INDEX; RECOVERY; VETERANS; MODEL AB Stroke is a leading cause of functional impairments. The ability to quantify the functional ability of poststroke patients engaged in a rehabilitation program may assist in prediction of their functional outcome. The Functional Independence Measure (FIM) is widely used and accepted as a functional-level assessment tool that evaluates the functional status of patients throughout the rehabilitation process. From February to March 2009, we searched MEDLINE, Ovid, CINAHL, and EBSCO for full-text articles written in English. Article inclusion criteria consisted of civilian and veteran patients posthemorrhagic and ischemic stroke with an average age of 50 years or older who participated in an inpatient rehabilitation program. Articles rated 5 or higher on the PEDro (Physiotherapy Evidence Database) scale were analyzed, including one cluster randomized trial and five cohort studies. Descriptive and psychometric data were outlined for each study. Key findings, clinical usefulness of the FIM, potential biases, and suggestions for further research were summarized. Although limited, evidence exists that FIM scores can be used as an accurate predictor of outcomes in poststroke patients. C1 [Chumney, Douglas] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Murfreesboro, TN 37129 USA. [Shesko, Kristina] Henry M Jackson Fdn Advancement Mil Med Inc, Phys Therapy, Johnstown, PA USA. [Skop, Karen] James A Haley Vet Hosp, Phys Med & Rehabil Serv, Tampa, FL 33612 USA. [Spencer, Madeleine] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Newton, Roberta A.] Temple Univ, Philadelphia, PA 19122 USA. RP Chumney, D (reprint author), Tennessee Valley Healthcare Syst, Dept Vet Affairs, Alvin C York Campus,3400 Lebanon Pike, Murfreesboro, TN 37129 USA. EM douglas.chumney@va.gov NR 26 TC 37 Z9 38 U1 0 U2 10 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 1 BP 17 EP 29 DI 10.1682/JRRD.2009.08.0140 PG 13 WC Rehabilitation SC Rehabilitation GA 577HH UT WOS:000276212700004 PM 20437324 ER PT J AU Arredondo, J Foote, N Pruden, JD McFarland, MJ McFarland, LV AF Arredondo, Juan Foote, Ned Pruden, Jonathan D. McFarland, Marc J. McFarland, Lynne V. TI Wounded warriors' perspectives: Helping others to heal SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Editorial Material C1 [Arredondo, Juan; Pruden, Jonathan D.] Wounded Warrior Project, Universal City, TX USA. [Foote, Ned] New York State Council, Vietnam Vet Amer, Queensbury, NY USA. [Pruden, Jonathan D.] Gainesville VA Med Ctr, Gainesville, FL USA. [McFarland, Lynne V.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. RP Arredondo, J (reprint author), Wounded Warrior Project, Universal City, TX USA. EM Lynne.McFarland@va.gov NR 2 TC 1 Z9 1 U1 0 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 4 BP XXI EP XXVIII DI 10.1682/JRRD.2009.02.0021 PG 8 WC Rehabilitation SC Rehabilitation GA 623ZK UT WOS:000279785700004 PM 20803397 ER PT J AU Russell, JA Connor, NP Hartig, GK AF Russell, John A. Connor, Nadine P. Hartig, Gregory K. TI Iontophoretic delivery of nitric oxide donor improves local skin flap viability SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE iontophoretic; necrosis; nitric oxide; NO; NO donor; rehabilitation; skin flaps; tissue; vascular supply; wound healing ID ENDOTHELIAL GROWTH-FACTOR; MUSCLE FLAP; MYOCUTANEOUS FLAPS; SURVIVAL; TISSUE; ANGIOGENESIS; REPERFUSION; ISCHEMIA; INJURY; MODEL AB The dimensions of local flaps are often limited by the vascular supply to the distal aspect of the flap. Distal flap necrosis occurs if the vascular supply is inadequate. The purpose of this study was to investigate the use of iontophoretic delivery of nitric oxide (NO) donors to a local skin flap model to improve the survival area of the flap. Thirty-two male Sprague-Dawley rats (300 g) were divided into seven experimental groups to determine the effect of iontophoretic delivery of NO on surface perfusion and flap survival area. A caudally based 3 x 11 cm dorsal skin flap was used to measure the effect of iontophoretic delivery of NO donors to a local skin flap to improve survival area of the flap. Iontophoretic delivery of the NO donors sodium nitroprusside (SNP) and diethylenetriamine NONOate (DETA-NO) resulted in a significant increase in survival area and surface perfusion when compared with sham controls. Iontophoretic delivery of saline was associated with a 13% improvement in flap survival when compared with non-treated controls. Iontophoretic delivery and subcutaneous injection of NO donors (SNP and DETA-NO) increased skin flap viability by demonstrating improved flap survival areas. The results of this study suggest that NO may serve as a postoperative treatment of skin flaps to encourage skin flap survival and prevent distal necrosis. C1 [Connor, Nadine P.] Univ Wisconsin, Ctr Clin Sci, Dept Surg, Div Otolaryngol Head & Neck Surg, Madison, WI 53792 USA. [Connor, Nadine P.] Univ Wisconsin, Dept Communicat Disorders, Madison, WI 53792 USA. [Hartig, Gregory K.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Connor, NP (reprint author), Univ Wisconsin, Ctr Clin Sci, Dept Surg, Div Otolaryngol Head & Neck Surg, Room K4-711,600 Highland Ave, Madison, WI 53792 USA. EM connor@surgery.wisc.edu FU Department of Veterans Affairs, Rehabilitation Research and Development Service FX This material was based on work supported by the Department of Veterans Affairs, Rehabilitation Research and Development Service. NR 27 TC 0 Z9 3 U1 0 U2 1 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 1 BP 61 EP 66 DI 10.1682/JRRD.2008.10.0144 PG 6 WC Rehabilitation SC Rehabilitation GA 577HH UT WOS:000276212700007 PM 20437327 ER PT J AU McFarland, LV Winkler, SLH Heinemann, AW Jones, M Esquenazi, A AF McFarland, Lynne V. Winkler, Sandra L. Hubbard Heinemann, Allen W. Jones, Melissa Esquenazi, Alberto TI Unilateral upper-limb loss: Satisfaction and prosthetic-device use in veterans and servicemembers from Vietnam and OIF/OEF conflicts SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE abandonment; activity measure; limb loss; OIF/OEF; prosthetic device; rehabilitation; satisfaction; upper-limb loss; veterans; Vietnam conflict ID EXTREMITY VASCULAR INJURY; ARMY-MEDICAL-CENTER; TERM-FOLLOW-UP; RISK-FACTORS; COMBAT AMPUTEES; WARTIME REPORT; AMPUTATION; CARE; DEFICIENCY; WAR AB Prosthetic use and satisfaction in wounded servicemembers and veterans with unilateral upper-limb loss has not been thoroughly explored. Through a national survey, we enrolled 47 participants from the Vietnam conflict and 50 from Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) with combat-associated major unilateral upper-limb loss. Upper-limb prosthetic devices were used by 70% of the Vietnam group and 76% of the OIF/OEF group. Mechanical/body-powered upper-limb devices were favored by the Vietnam group, while a combination of myoelectric/hybrid and mechanical/body-powered devices were favored by the OIF/OEF group. Upper-limb devices were completely abandoned in 30% of the Vietnam and 22% of the OIF/OEF groups. Abandonment was more frequent for transhumeral and more proximal levels (42% of Vietnam and 40% of OIF/OEF) than more distal limb-loss levels. Upper-limb prostheses were rejected because of dissatisfaction with the device by significantly fewer (23%) members of the Vietnam group than the OIF/OEF group (45%) (p < 0.001). Most common reasons for rejection included pain, poor comfort, and lack of functionality. A significant paradigm shift has been noted in the OIF/OEF group, who use a greater number and diversity of upper-limb prostheses than the Vietnam group. C1 [McFarland, Lynne V.] Univ Washington, Seattle, WA 98195 USA. [Winkler, Sandra L. Hubbard] N Florida S Georgia Vet Hlth Syst, Rehabil Outcomes Res Ctr, Res Enhancement Award Program, Gainesville, FL USA. [Winkler, Sandra L. Hubbard] Univ Florida, Gainesville, FL USA. [Heinemann, Allen W.] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA. [Heinemann, Allen W.] Rehabil Inst Chicago, Ctr Rehabil Outcomes Res, Chicago, IL 60611 USA. [Jones, Melissa] USA, Manhattan, KS USA. [Esquenazi, Alberto] MossRehab & Albert Einstein Med Ctr, Dept Phys Med & Rehabil, Elkins Pk, PA USA. [McFarland, Lynne V.] Dept Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP McFarland, LV (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM Lynne.McFarland@va.gov RI Heinemann, Allen /K-6283-2012 OI Heinemann, Allen /0000-0003-2782-7326 FU VA Health Services Research and Development Service [IIR 05-244]; Career Scientist Award [RCS 98-353] FX This material was based on work supported by VA Health Services Research and Development Service (grant IIR 05-244) and a Career Scientist Award to Dr. Reiber (grant RCS 98-353). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the VA or DOD. NR 57 TC 52 Z9 52 U1 2 U2 16 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 4 BP 299 EP 316 DI 10.1682/JRRD.2009.03.0027 PG 18 WC Rehabilitation SC Rehabilitation GA 623ZK UT WOS:000279785700007 PM 20803400 ER PT J AU Gailey, R McFarland, LV Cooper, RA Czerniecki, J Gambel, JM Hubbard, S Maynard, C Smith, DG Raya, M Reiber, GE AF Gailey, Robert McFarland, Lynne V. Cooper, Rory A. Czerniecki, Joseph Gambel, Jeffrey M. Hubbard, Sharon Maynard, Charles Smith, Douglas G. Raya, Michele Reiber, Gayle E. TI Unilateral lower-limb loss: Prosthetic device use and functional outcomes in servicemembers from Vietnam war and OIF/OEF conflicts SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE abandonment; amputation; limb loss; lower-limb loss; OIF/OEF; prostheses; prosthetic device; rehabilitation; satisfaction; Vietnam ID PERIPHERAL ARTERIAL-DISEASE; TRAUMA-RELATED AMPUTATIONS; ARMY-MEDICAL-CENTER; LONG-TERM; VASCULAR INJURY; CARE; REHABILITATION; SATISFACTION; AMPUTEES; POPULATION AB Rehabilitation goals following major combat-associated limb loss in World War 11 and the Vietnam war focused on treatment of the injury and a return to civilian life. The goal for Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) servicemembers is to restore function to the greatest possible degree and, if they desire, return them to Active Duty, by providing them with extensive rehabilitation services and a variety of prosthetic devices. Our study determines the usefulness of these diverse types of prosthetic devices for restoring functional capability and documents prosthesis use and satisfaction. We compare servicemembers and veterans with major combat-associated unilateral lower-limb loss: 178 from the Vietnam war and 172 from OIF/OEF conflicts. Of survey participants with unilateral lower-limb loss, 84% of the Vietnam group and 94% of the OIF/OEF group currently use at least one prosthetic device. Reasons for rejection varied by type of device, but common reasons were pain, prosthesis too heavy, and poor fit. Abandonment is infrequent (11% Vietnam group, 4% OIF/OEF group). Future efforts should aim to improve prosthetic-device design, decrease pain, and improve quality of life for these veterans and servicemembers. C1 [McFarland, Lynne V.; Reiber, Gayle E.] Hlth Serv Res & Dev Serv, VA Puget Sound Hlth Care Syst, Seattle, WA 98101 USA. [Gailey, Robert] Dept Vet Affairs VA Miami Healthcare Syst, Miami, FL USA. [Gailey, Robert] Univ Miami, Miller Sch Med, Dept Phys Sci, Coral Gables, FL 33124 USA. [Cooper, Rory A.] VA Rehabil Res & Dev Serv, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Gambel, Jeffrey M.] Rehabil Care Serv, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Czerniecki, Joseph] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Gambel, Jeffrey M.] USA, Med Corps, Washington, DC USA. [Gambel, Jeffrey M.] Walter Reed Army Med Ctr, Armed Forces Amputee Patient Care Program, Washington, DC 20307 USA. [Hubbard, Sharon] Prosthet Res Study, Seattle, WA USA. [Smith, Douglas G.] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. [Raya, Michele] Univ Miami, Miller Sch Med, Dept Phys Therapy, Coral Gables, FL 33124 USA. RP McFarland, LV (reprint author), Hlth Serv Res & Dev Serv, VA Puget Sound Hlth Care Syst, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM Lynne.McFarland@va.gov RI Maynard, Charles/N-3906-2015 OI Maynard, Charles/0000-0002-1644-7814 FU VA Health Services Research and Development Service [IIR 05-244]; Career Scientist Award [RCS 98-353] FX This material was based on work supported in part by VA Health Services Research and Development Service (IIR 05-244) and a Career Scientist Award (RCS 98-353) to Dr. Reiber. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the VA or DOD. NR 34 TC 20 Z9 20 U1 1 U2 11 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 4 BP 317 EP 331 DI 10.1682/JRRD.2009.04.0039 PG 15 WC Rehabilitation SC Rehabilitation GA 623ZK UT WOS:000279785700008 PM 20803401 ER PT J AU Laferrier, JZ McFarland, LV Boninger, ML Cooper, RA Reiber, GE AF Laferrier, Justin Z. McFarland, Lynne V. Boninger, Michael L. Cooper, Rory A. Reiber, Gayle E. TI Wheeled mobility: Factors influencing mobility and assistive technology in veterans and servicemembers with major traumatic limb loss from Vietnam war and OIF/OEF conflicts SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE combat operations; mobility; mobility assistive technology; OIF/OEF; prosthetic device; rehabilitation; traumatic amputation; Vietnam; wheelchair; wounded servicemember ID RANDOMIZED CONTROLLED-TRIAL; LOWER-EXTREMITY AMPUTATIONS; OPERATION ENDURING FREEDOM; SKILLS TRAINING-PROGRAM; WHEELCHAIR USERS; ELDERLY VETERANS; PROSTHETIC USE; IRAQI-FREEDOM; PEOPLE; AMPUTEES AB Returning wounded veterans and servicemembers to their highest level of function following traumatic injury is a priority of the Departments of Defense and Veterans Affairs. We surveyed 245 veterans from the Vietnam war and 226 servicemembers and veterans from Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) conflicts with at least one major traumatic lower-limb loss to determine their use of mobility assistive technology (AT) and patterns of limb abandonment. Prosthetic device use without wheelchair use is found in 50.5% of Vietnam and 42.8% of OIF/OEF groups. Prostheses and supplementary wheelchairs are used by Vietnam (32%) and OIF/OIEF (53%) groups (p < 0.01). Exclusive wheelchair use is more frequent in the Vietnam group (18%) than in the OIF/OFF group (4.0%, p < 0.01). In Vietnam participants, multivariate analysis found that multiple-limb loss (adjusted odds ratio [AOR] = 14.5; 95% confidence interval [CI] 5.5-38.5), bilateral lower-limb loss (AOR = 12.7; 95% Cl 6.2-26.1), and number of comorbidities (AOR = 1.3; 95% Cl 1.2-1.5) are associated with increased likelihood of wheelchair use. In OIF/OEF participants, bilateral lower-limb loss (AOR = 29.8; 95% CI 11.0-80.7), multiple-limb loss (AOR = 16.3; 95% Cl 3.1-85.3), cumulative trauma disorder (AOR = 2.4; 95% Cl 1.2-4.9), and number of combat injuries (AOR = 1.4; 95% Cl 1.2-1.7) are associated with wheelchair use. Combined use of different types of mobility ATs promotes improved rehabilitation and ability to function. C1 [Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Laferrier, Justin Z.; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [McFarland, Lynne V.; Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Dept Hlth Serv Res & Dev, Seattle, WA USA. [McFarland, Lynne V.; Reiber, Gayle E.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [McFarland, Lynne V.; Reiber, Gayle E.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [McFarland, Lynne V.] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA. [Boninger, Michael L.; Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Boninger, Michael L.; Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Laferrier, Justin Z.; Boninger, Michael L.; Cooper, Rory A.] Dept Vet Affairs Rehabil Res & Dev Serv, Human Engn Res Labs, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 7108 Highland Dr,Bldg 4, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu OI Boninger, Michael/0000-0001-6966-919X FU VA, Health Services Research and Development Service [IIR 05-244]; Career Scientist Award [RCS 98-353] FX This material was based on work supported by the VA, Health Services Research and Development Service, grant IIR 05-244, and a Career Scientist Award to Dr. Reiber, grant RCS 98-353. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the VA or the DOD. NR 40 TC 10 Z9 10 U1 6 U2 13 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 4 BP 349 EP 360 DI 10.1682/JRRD.2009.03.0022 PG 12 WC Rehabilitation SC Rehabilitation GA 623ZK UT WOS:000279785700010 PM 20803403 ER PT J AU Berke, GM Fergason, J Milani, JR Hattingh, J McDowell, M Nguyen, V Reiber, GE AF Berke, Gary M. Fergason, John Milani, John R. Hattingh, John McDowell, Martin Nguyen, Viet Reiber, Gayle E. TI Comparison of satisfaction with current prosthetic care in veterans and servicemembers from Vietnam and OIF/OEF conflicts with major traumatic limb loss SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE amputation site; OIF/OEF; prosthesis; prosthetic care; prosthetic device; rehabilitation; satisfaction; traumatic limb loss; veteran; Vietnam; wounded servicemember ID AMPUTEES; AMPUTATIONS; PAIN; DEVICES AB Prosthetic care is a vital aspect of healthcare and rehabilitation for veterans and servicemembers with major traumatic limb loss. Our survey queried 581 veterans and servicemembers with limb loss from the Vietnam and Operation Iraqi Freedom (OIF)/Operation Enduring Freedom (OEF) conflicts. Among survey participants, 78.2% from the Vietnam conflict and 90.5% from the OIF/OEF conflict currently use prosthetic devices. In Vietnam respondents, 78% received prosthetic care From private sources, 16% from Department of Veterans Affairs (VA) prosthetic laboratories, 0.9% from Department of Defense (DOD), and 5% from multiple sources. In OIF/OEF respondents, 42% received prosthetic care from private sources, 9% percent from VA, 39% from DOD, and 10% from multiple sources. Participants identified their satisfaction with current prosthetic devices and prosthetic services. Reports of pain, sweating, skin irritation, and problems with socket fit continue to be significant issues for participants from both conflicts regardless of level of amputation or site of service. In those with upper-limb loss who used myoelectric prostheses, minimal effect on prosthesis use and satisfaction was noted. Among lower-limb loss participants from both conflicts, notable differences existed in prosthesis satisfaction by source of care. C1 [Fergason, John] Brooke Army Med Ctr, Prosthet Orthot Clin, Ft Sam Houston, TX 78234 USA. [Milani, John R.] Prosthet & Clin Logist Off, Dept Vet Affairs Cent Off, Washington, DC USA. [Hattingh, John] NW Prosthet & Orthot Clin, Seattle, WA USA. [McDowell, Martin] VA Puget Sound Hlth Care Syst, Prosthet Orthot Lab, Seattle, WA USA. [Nguyen, Viet; Reiber, Gayle E.] Univ Washington, Sch Med, Seattle, WA USA. [Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Serv, Seattle, WA USA. RP Berke, GM (reprint author), 801 Brewster Ave,Suite 270, Redwood City, CA 94063 USA. EM gmberke@gmail.com FU VA Health Services Research and Development Service [IIR 05-244]; Career Scientist Award [RCS 98-353] FX This material was based on work supported by the VA Health Services Research and Development Service (grant IIR 05-244) and a Career Scientist Award to Dr. Reiber (grant RCS 98-353). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of VA or DOD. NR 22 TC 18 Z9 18 U1 3 U2 14 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 4 BP 361 EP 371 DI 10.1682/JRRD.2009.12.0193 PG 11 WC Rehabilitation SC Rehabilitation GA 623ZK UT WOS:000279785700011 PM 20803404 ER PT J AU Liu, HY Pearlman, J Cooper, R Hong, EK Wang, HW Salatin, B Cooper, RA AF Liu, Hsin-yi Pearlman, Jonathan Cooper, Rosemarie Hong, Eun-kyoung Wang, Hongwu Salatin, Benjamin Cooper, Rory A. TI Evaluation of aluminum ultralight rigid wheelchairs versus other ultralight wheelchairs using ANSI/RESNA standards SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE aluminum wheelchair; ANSI/RESNA; durability; fatigue life; fatigue mode; manual wheelchair; titanium wheelchair; ultralight wheelchair; wheelchair; wheelchair standards ID MANUAL WHEELCHAIRS; MAINTENANCE; ACCIDENTS; LIFE AB Previous studies found that select titanium ultralight rigid wheelchairs (TURWs) had fewer equivalent cycles and less value than select aluminum ultralight folding wheelchairs (AUFWs). The causes of premature failure of TURWs were not clear because the TURWs had different frame material and design than the AUFWs. We tested 12 aluminum ultralight rigid wheelchairs (AURWs) with similar frame designs and dimensions as the TURWs using the American National Standards Institute/Rehabilitation Engineering and Assistive Technology Society of North America and International Organization for Standardization wheelchair standards and hypothesized that the AURWs would be more durable than the TURWs. Across wheelchair models, no significant differences were found in the test results between the AURWs and TURWs, except in their overall length. Tire pressure, tube-wall thickness, and tube manufacturing were proposed to be the factors affecting wheelchair durability through comparison of the failure modes, frames, and components. The frame material did not directly affect the performance of AURWs and TURWs, but proper wheelchair manufacture and design based on mechanical properties are important. C1 [Liu, Hsin-yi; Pearlman, Jonathan; Cooper, Rosemarie; Hong, Eun-kyoung; Wang, Hongwu; Salatin, Benjamin; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Dept Vet Affairs VA Rehabil Res & Dev Serv, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Liu, Hsin-yi; Pearlman, Jonathan; Cooper, Rosemarie; Hong, Eun-kyoung; Wang, Hongwu; Salatin, Benjamin; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Cooper, Rosemarie] Univ Pittsburgh, Med Ctr, Ctr Assist Technol, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151R 1H, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu RI Wang, Hongwu/J-6133-2013 OI Wang, Hongwu/0000-0002-6567-9144; Pearlman, Jon/0000-0003-0830-9136 FU VA Rehabilitation Research and Development Service [B3142C] FX This material was based on work supported by VA Rehabilitation Research and Development Service (grant B3142C). NR 25 TC 11 Z9 12 U1 2 U2 4 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 5 BP 441 EP 455 DI 10.1682/JRRD.2009.08.0137 PG 15 WC Rehabilitation SC Rehabilitation GA 636OS UT WOS:000280748000007 PM 20803388 ER PT J AU Harada, ND Dhanani, S Elrod, M Hahn, T Kleinman, L Fang, MK AF Harada, Nancy D. Dhanani, Shawkat Elrod, Michelle Hahn, Theodore Kleinman, Leonard Fang, Meika TI Feasibility study of home telerehabilitation for physically inactive veterans SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE deconditioning; exercise; exercise adherence; exercise monitoring; Health Buddy; older adults; physical activity; telephone; telerehabilitation; text messaging ID OLDER PERSONS; FRAILTY; COORDINATION; ASSOCIATION; TECHNOLOGY; OUTCOMES; ADULTS; CARE AB The aim of this study was to develop a system for and determine the feasibility of monitoring home exercise for physically inactive older adults using a Health Buddy (HB) text messaging device (Robert Bosch Healthcare; Palo Alto, California). Questions and messages related to exercise adherence are displayed on the HB screen and participants choose a response by pressing the corresponding button on the device. Responses are transmitted through a landline connection and high-risk responses are highlighted by the system for follow-up. We developed the questions and messages based on input from patient and clinician focus groups. We evaluated feasibility by administering the intervention to inpatient and outpatient adults aged 60 or older. We gave participants a choice of exercise monitoring by HB (n = 20) or telephone (n = 18). The results showed that home exercise monitoring by HB and telephone is safe, as evidenced by low adverse event rates. We saw a decline in exercise adherence rates to both the HB and telephone after 8 weeks, although adherence was better for HB than telephone. Taken together, the results demonstrate the feasibility of using text messaging to monitor home exercise adherence in physically inactive older adults. C1 [Harada, Nancy D.] VA Greater Los Angeles Healthcare Syst, ACOS Educ, Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, Los Angeles, CA 90073 USA. [Harada, Nancy D.; Dhanani, Shawkat; Hahn, Theodore; Kleinman, Leonard; Fang, Meika] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Kleinman, Leonard] VA Greater Los Angeles Healthcare Syst, Ambulatory Care Home Telehlth Sect, Los Angeles, CA 90073 USA. [Fang, Meika] VA Greater Los Angeles Healthcare Syst, Rheumatol Sect, Los Angeles, CA 90073 USA. RP Harada, ND (reprint author), VA Greater Los Angeles Healthcare Syst, ACOS Educ, Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Nancy.Harada@va.gov FU VA Rehabilitation Research and Development Service [E4204-R] FX This material was based on work supported by the VA Rehabilitation Research and Development Service (grant E4204-R). NR 28 TC 10 Z9 10 U1 1 U2 4 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 EI 1938-1352 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 5 BP 465 EP 475 DI 10.1682/JRRD.2009.09.0149 PG 11 WC Rehabilitation SC Rehabilitation GA 636OS UT WOS:000280748000009 PM 20803390 ER PT J AU Lewis, MS Lilly, DJ Hutter, MM Bourdette, DN McMillan, GP Fitzpatrick, MA Fausti, SA AF Lewis, M. Samantha Lilly, David J. Hutter, Michele M. Bourdette, Dennis N. McMillan, Garnett P. Fitzpatrick, Mary A. Fausti, Stephen A. TI Audiometric hearing status of individuals with and without multiple sclerosis SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE audiometric hearing status; auditory function; hearing; hearing loss multiple sclerosis; pure tone thresholds; relapsing-remitting multiple sclerosis; secondary progressive multiple sclerosis; speech reception threshold word recognition ID IMPAIRMENT; PREVALENCE; NOISE; EPIDEMIOLOGY; DEAFNESS; LESION; ADULTS; HEALTH AB The purpose of the present investigation was to determine whether differences exist in audiometric hearing status between individuals with and without multiple sclerosis (MS) and between individuals with relapsing-remitting MS (RRMS) and individuals with secondary progressive MS (SPMS) Forty-seven subjects with MS (26 with RRMS and 21 with SPMS) and forty-nine control subjects without MS completed both a comprehensive case-history questionnaire and a conventional hearing evaluation Statistical analyses, accounting for the potential confounding factors of age sex, noise exposure, and use of ototoxic medications, revealed significant differences in hearing thresholds between subjects with and without MS at select audiometric test frequencies < 0 05) At these audiometric test frequencies, the subjects with MS had poorer hearing thresholds Additional analyses revealed significant differences in hearing sensitivity at select audiometric frequencies between the subjects with RRMS and the subjects with SPMS, such that those with SPMS had poorer hearing thresholds These findings have significant clinical implications for practitioners working with patients with MS C1 [Lewis, M. Samantha; Lilly, David J.; Hutter, Michele M.; Bourdette, Dennis N.; McMillan, Garnett P.; Fausti, Stephen A.] Portland Dept Vet Affairs Med Ctr VAMC, Natl Ctr Rehabilitat Auditory Res, Portland, OR USA. [Lewis, M. Samantha; Bourdette, Dennis N.; Fausti, Stephen A.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. [Lilly, David J.] Univ Iowa, Dept Otolaryngol Head & Neck Surg, Carver Coll Med, Iowa City, IA 52242 USA. [Bourdette, Dennis N.; Fitzpatrick, Mary A.] Neurol Serv Portland VAMC, Portland, OR USA. [Fausti, Stephen A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. RP Lewis, MS (reprint author), Portland VA Med Ctr, NCRAR, 3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. FU Department of Veterans Affairs (VA); Veterans Health Administration; Office of Research and Development; Rehabilitation Research and Development (RRD) [B2568R, C3758V]; RR&D National Center for Rehabilitative Auditory Research [C2659C] FX This material was based on work supported by the Department of Veterans Affairs (VA) Veterans Health Administration Office of Research and Development Rehabilitation Research and Development (RR&D) Service Merit Review grant (grant B2568R) RR&D Research Career Development Award (grant C3758V), and RR&D National Center for Rehabilitative Auditory Research (grant C2659C) NR 38 TC 3 Z9 5 U1 0 U2 2 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 7 BP 669 EP 678 DI 10.1682/JRRD.2010.01.0010 PG 10 WC Rehabilitation SC Rehabilitation GA 679BF UT WOS:000284133700009 PM 21110263 ER PT J AU Smith, BM Evans, CT Ullrich, P Burns, S Guihan, M Miskevics, S LaVela, SL Rajan, S Weaver, FM AF Smith, Bridget M. Evans, Charlesnika T. Ullrich, Philip Burns, Stephen Guihan, Marylou Miskevics, Scott LaVela, Sherri L. Rajan, Suparna Weaver, Frances M. TI Using VA data for research in persons with spinal cord injuries and disorders: Lessons from SCI QUERI SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE data quality; paraplegia; pressure ulcers; rehabilitation; respiratory; spinal cord injuries and disorders; spinal cord injury; tetraplegia; VA; veterans ID PRESSURE ULCERS; RISK-FACTORS; VETERANS; PREVALENCE; INFECTION; ILLNESS; OBESITY; VISITS; TRENDS; RATES AB The Department of Veterans Affairs (VA) provides integrated services to more than 25,000 veterans with spinal cord injuries and disorders (SCUD) VA data offer great potential for providing insights into healthcare utilization and morbidity, and these capabilities are central to efforts to improve healthcare for veterans with SCI/D The objective of this article is to introduce researchers to the use of VA data to examine questions related to SCI/D using examples from Spinal Cord Injury (SCI) Quality Enhancement Research Initiative studies Sources of VA data available to investigators interested in SCI/D-related research include national-level VA administrative and clinical databases and primary data (medical record review, patient surveys) Methods used to identify veterans with SCUD include the Allocation Resource Center cohort, the Spinal Cord Dysfunction (SCD) Registry, and the VA inpatient SCI flag, only 33% of veterans were included in all three groups (n = 12,306) While neurological level of SCI was unknown for approximately a third of veterans (from SCD Registry data alone), the percent decreased to 13% when augmented with diagnostic codes Primary data can be used to augment other missing SCI data and to provide more detailed information about complications commonly associated with SCI/D C1 [Smith, Bridget M.; Evans, Charlesnika T.; Guihan, Marylou; Miskevics, Scott; LaVela, Sherri L.; Weaver, Frances M.] Edward Hines Jr Dept Vet Affairs VA Hosp, Spinal Cord Injury Qual Enhancement Res Initiat S, Hines, IL USA. [Smith, Bridget M.; Evans, Charlesnika T.; Guihan, Marylou; LaVela, Sherri L.; Weaver, Frances M.] Northwestern Univ, Inst Healthcare Studies, Feinberg Sch Med, Chicago, IL 60611 USA. [Ullrich, Philip; Burns, Stephen; Rajan, Suparna] VA Puget Sound Healthcare Syst, SCI QUERI, Seattle, WA USA. [Ullrich, Philip; Burns, Stephen] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Smith, Bridget M.; Evans, Charlesnika T.; Guihan, Marylou; Miskevics, Scott; LaVela, Sherri L.; Weaver, Frances M.] Edward Hines Jr Dept Vet Affairs VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA. RP Smith, BM (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, SCI QUERI, 5000 S 5th Ave,151-H, Hines, IL 60141 USA. FU SCI QUERI center from the VA HSRD Service [SCI 98-000]; HSR&D Service study, "Characterizing Variability in Respiratory Care in SCI/D" [SCS 03-216] FX This material was based on work supported by the SCI QUERI center from the VA HSR&D Service (grant SCI 98-000) and by the HSR&D Service study, "Characterizing Variability in Respiratory Care in SCI/D" (grant SCS 03-216) NR 35 TC 22 Z9 22 U1 0 U2 1 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 8 BP 679 EP 688 DI 10.1682/JRRD.2009.08.0117 PG 10 WC Rehabilitation SC Rehabilitation GA 691IU UT WOS:000285074300003 PM 21110243 ER PT J AU Carlson, KF Nugent, SM Grill, J Sayer, NA AF Carlson, Kathleen F. Nugent, Sean M. Grill, Joseph Sayer, Nina A. TI Accuracy of external cause-of-injury coding in VA polytrauma patient discharge records SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE administrative data; causes of injury; E-codes; hospital discharge records; ICD codes; injury surveillance; medical records; missing data; rehabilitation; veterans ID BLAST; VETERANS; CODES; CARE; WAR AB Valid and efficient methods of identifying the etiology of treated injuries are critical for characterizing patient populations and developing prevention and rehabilitation strategies We examined the accuracy of external cause-of-injury codes (E-codes) in Veterans Health Administration (VHA) administrative data for a population of injured patients Chart notes and E-codes were extracted for 566 patients treated at any one of four VHA Polytrauma Rehabilitation Center sites between 2001 and 2006 Two expert coders, blinded to VHA E-codes, used chart notes to assign "gold standard" E-codes to injured patients The accuracy of VHA E-coding was examined based on these gold standard E-codes Only 382 of 517 (74%) injured patients were assigned E-codes in VHA records Sensitivity of VHA E-codes varied significantly by site (range 59%-91%, p < 0 001) Sensitivity was highest for combat-related injuries (81%) and lowest for fall-related injuries (60%) Overall specificity of E-codes was high (92%) E-coding accuracy was markedly higher when we restricted analyses to records that had been assigned VHA E-codes E-codes may not be valid for ascertaining source-of-injury data for all injuries among VHA rehabilitation inpatients at this time Enhanced training and policies may ensure more widespread, standardized use and accuracy of E-codes for injured veterans treated in the VHA C1 [Carlson, Kathleen F.; Nugent, Sean M.; Grill, Joseph; Sayer, Nina A.] Dept Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Carlson, Kathleen F.; Sayer, Nina A.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA. RP Carlson, KF (reprint author), Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. RI Sayer, Nina/E-3249-2016 FU VA Health Services Research and Development (HSRD) Service [RRP 06-150, TPP 67-005, CDA 08-025]; VA HSR&D Service Center for Chronic Disease Outcomes Research [LIP 67-032]; HSR&D Service Polytrauma and Blast-Related Injuries Quality Enhancement Research Initiative FX This material was based on work supported by research and training grants from VA Health Services Research and Development (HSR&D) Service (grants RRP 06-150, TPP 67-005, and CDA 08-025), a locally-initiated project grant from the VA HSR&D Service Center for Chronic Disease Outcomes Research (LIP 67-032), and support from the HSR&D Service Polytrauma and Blast-Related Injuries Quality Enhancement Research Initiative NR 35 TC 9 Z9 9 U1 1 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 8 BP 689 EP 697 DI 10.1682/JRRD.2009.08.0118 PG 9 WC Rehabilitation SC Rehabilitation GA 691IU UT WOS:000285074300004 PM 21110244 ER PT J AU Noel, PH Copeland, LA Perrin, RA Lancaster, AE Pugh, MJ Wang, CP Bollinger, MJ Hazuda, HP AF Noel, Polly Hitchcock Copeland, Laurel A. Perrin, Ruth A. Lancaster, A. Elizabeth Pugh, Mary Jo Wang, Chen-Pin Bollinger, Mary J. Hazuda, Helen P. TI VHA Corporate Data Warehouse height and weight data: Opportunities and challenges for health services research SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE anthropometric measurements; body mass index; data error; electronic medical record; height; obesity; rehabilitation; secondary data; veterans; Veterans Health Administration; weight ID PRIMARY-CARE; OBESITY; MANAGEMENT; OVERWEIGHT; VETERANS; ADULTS; RISK AB Within the Veterans Health Administration (VHA), anthropometric measurements entered into the electronic medical record are stored in local information systems, the national Corporate Data Warehouse (CDW), and in some regional data warehouses This article describes efforts to examine the quality of weight and height data within the CDW and to compare CDW data with data from warehouses maintained by several of VHA's regional groupings of healthcare facilities (Veterans Integrated Service Networks [VISNs]) We found significantly fewer recorded heights than weights in both the CDW and VISN data sources In spite of occasional anomalies, the concordance in the number and value of records in the CDW and the VISN warehouses was generally 97% to 99% or greater Implausible variation in same-day and same-year heights and weights was noted, suggesting measurement or data-entry errors Our work suggests that the CDW, over time and through validation, has become a generally reliable source of anthropometric data Researchers should assess the reliability of data contained within any source and apply strategies to minimize the impact of data errors appropriate to their study population C1 [Noel, Polly Hitchcock; Copeland, Laurel A.; Pugh, Mary Jo; Wang, Chen-Pin; Bollinger, Mary J.] S Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. [Noel, Polly Hitchcock; Copeland, Laurel A.; Pugh, Mary Jo; Wang, Chen-Pin; Hazuda, Helen P.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Perrin, Ruth A.] Ctr Management Complex Chron Care, Hines, IL USA. [Perrin, Ruth A.] VA Informat Resource Ctr, Hines, IL USA. [Lancaster, A. Elizabeth] Vet Hlth Adm Support Serv Ctr, Washington, DC USA. RP Noel, PH (reprint author), S Texas Vet Hlth Care Syst, Dept Vet Affairs, 7400 Merton Minter Blvd,11C6, San Antonio, TX 78229 USA. OI Pugh, Mary Jo/0000-0003-4196-7763; Copeland, Laurel/0000-0002-9478-0209 FU HSRD [IIR 05-121]; VA; VHA FX This material was based on work supported by the VA, VHA, and HSR&D, grant IIR 05-121 Dr Noel is a Research Psychologist at the South Texas Veterans Health Care System The views expressed in this article are those of the authors and do not necessarily represent the views of the VA NR 23 TC 19 Z9 19 U1 0 U2 1 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 8 BP 739 EP 750 DI 10.1682/JRRD.2009.08.0110 PG 12 WC Rehabilitation SC Rehabilitation GA 691IU UT WOS:000285074300009 PM 21141302 ER PT J AU Washington, DL Sun, S Canning, M AF Washington, Donna L. Sun, Su Canning, Mark TI Creating a sampling frame for population-based veteran research: Representativeness and overlap of VA and Department of Defense databases SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE administrative databases; ambulatory care/utilization; hospital; VA nonuser; veteran indicator; veteran population; veteran sampling frame; veterans/utilization; women veterans; women's health services ID HEALTH-CARE; REGISTRY; LESSONS AB Most veteran research is conducted in Department of Veterans Affairs (VA) healthcare settings, although most veterans obtain healthcare outside the VA Our objective was to determine the adequacy and relative contributions of Veterans Health Administration (VHA), Veterans Benefits Administration (VBA), and Department of Defense (DOD) administrative databases for representing the U S veteran population, using as an example the creation of a sampling frame for the National Survey of Women Veterans In 2008, we merged the VHA, VBA, and DOD databases We identified the number of unique records both overall and from each database The combined databases yielded 925,946 unique records, representing 51% of the 1,802,000 U S women veteran population The DOD database included 30% of the population (with 8% overlap with other databases) The VHA enrollment database contributed an additional 20% unique women veterans (with 6% overlap with VBA databases) VBA databases contributed an additional 2% unique women veterans (beyond 10% overlap with other databases) Use of VBA and DOD databases substantially expands access to the population of veterans beyond those in VHA databases, regardless of VA use Adoption of these additional databases would enhance the value and generalizability of a wide range of studies of both male and female veterans C1 [Washington, Donna L.; Sun, Su; Canning, Mark] Dept Vet Affairs VA Greater Los Angeles Healthcar, Los Angeles, CA USA. [Washington, Donna L.; Sun, Su; Canning, Mark] VA Sepulveda Ambulatoly Care Ctr & Nursing Home, VA Greater Los Angeles Hlth Serv Res & Dev Ctr Ex, Sepulveda, CA USA. [Washington, Donna L.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Washington, DL (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,111G, Los Angeles, CA 90073 USA. FU VA, Office of Public Health and Environmental Hazards, Women Veterans Health Strategic Healthcare Group (NSWV); VA Health Services Research and Development Service (HSRD) [SDR-08-270] FX This material was based on work supported in part by the VA, Office of Public Health and Environmental Hazards, Women Veterans Health Strategic Healthcare Group (NSWV), with supplemental funding from the VA Health Services Research and Development Service (HSR&D) (SDR-08-270) NR 22 TC 19 Z9 19 U1 1 U2 1 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 8 BP 763 EP 771 DI 10.1682/JRRD.2009.08.0127 PG 9 WC Rehabilitation SC Rehabilitation GA 691IU UT WOS:000285074300011 PM 21110250 ER PT J AU Stroupe, KT Tarlov, E Zhang, QY Haywood, T Owens, A Hynes, DM AF Stroupe, Kevin T. Tarlov, Elizabeth Zhang, Qiuying Haywood, Thomas Owens, Arika Hynes, Denise M. TI Use of Medicare and DOD data for improving VA race data quality SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE African American; data quality; ethnicity; health science; Hispanic; Medicare; minority; race; validity; veterans ID OF-VETERANS-AFFAIRS; ADMINISTRATIVE DATA; RACIAL DISPARITIES; ETHNIC DISPARITIES; AFRICAN-AMERICAN; CARE; SURVIVAL; RACE/ETHNICITY; MORTALITY; ACCURACY AB We evaluated the improvement in Department of Veterans Affairs (VA) race data completeness that could be achieved by linking VA data with data from Medicare and the Department of Defense (DOD) and examined agreement in values across the data sources After linking VA with Medicare and DOD records for a 10% sample of VA patients, we calculated the percentage for which race could be identified in those sources To evaluate race agreement, we calculated sensitivities, specificities, positive predictive values (PPVs), negative predictive values, and kappa statistics Adding Medicare (and DOD) data improved race data completeness from 48% to 76% Among older patients (65 years), adding Medicare data improved data completeness to nearly 100% Among younger patients (<65 years), combining Medicare and DOD data improved completeness to 75%, 18 percentage points beyond that achieved with Medicare data alone PPVs for white and African-American categories were 98 6 and 94 7, respectively, in Medicare and 97 0 and 96 5, respectively, in DOD data using VA self-reported race as the gold standard PPVs for the non African-American minority groups were lower, ranging from 30 5 to 48 2 Kappa statistics reflected these patterns Supplementing VA with Medicare and DOD data improves VA race data completeness substantially More study is needed to understand poor rates of agreement between VA and external sources in identifying non African-American minority individuals C1 [Stroupe, Kevin T.; Tarlov, Elizabeth; Zhang, Qiuying; Hynes, Denise M.] Edward Hines Jr Dept Vet Affairs VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA. [Stroupe, Kevin T.; Tarlov, Elizabeth; Haywood, Thomas; Owens, Arika; Hynes, Denise M.] VA Inormat Resource Ctr, Hines, IL USA. [Stroupe, Kevin T.] Northwestern Univ, Inst Healthcare Studies, Feinberg Sch Med, Chicago, IL 60611 USA. [Hynes, Denise M.] Univ Illinois, Coll Med, Dept Med, Chicago, IL USA. RP Stroupe, KT (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Ctr Management Complex Chron Care, 151H,5000 S 5th Ave,Bldg 1B260, Hines, IL 60141 USA. FU VA Information Resource Center, VA Health Services Research & Development Service [SD4 98-004]; VA/CMS [SDR 02-237]; VA; VA Health Services Research and Development Service [IIR 03-196] FX This material was based on work supported by the VA Information Resource Center, VA Health Services Research & Development Service (grant SD4 98-004) and the VA/CMS Data for Research Project (SDR 02-237) Dr Hynes was also supported by a VA Research Career Scientist Award and the VA Health Services Research and Development Service (grant IIR 03-196) NR 57 TC 26 Z9 26 U1 0 U2 0 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PY 2010 VL 47 IS 8 BP 781 EP 795 DI 10.1682/JRRD.2009.08.0122 PG 15 WC Rehabilitation SC Rehabilitation GA 691IU UT WOS:000285074300013 PM 21110252 ER PT J AU Sun, BC Knapp, H Shamouelian, A Golden, J Goetz, MB Asch, SM AF Sun, Benjamin C. Knapp, Herschel Shamouelian, Albert Golden, Joya Goetz, Matthew Bidwell Asch, Steven M. TI Effect of an education kiosk on patient knowledge about rapid HIV screening SO JOURNAL OF TELEMEDICINE AND TELECARE LA English DT Article ID EMERGENCY-DEPARTMENT; PROGRAM; ADULTS; HEALTH AB Patient education is an important part of routine HIV screening. In a pilot study, we assessed the effect of a computer kiosk education module on patient knowledge about routine HIV screening. A systematic sample of walk-in clinic patients completed a questionnaire before and after using the education module. The primary outcome was a composite nine-point knowledge score. Secondary outcomes included willingness to undergo HIV screening and patient satisfaction. Of 185 patients who were eligible to participate, 100 completed the study. The median duration of kiosk interaction was 3.9 min. The median knowledge score increased from 7 to 8 (P<0.0001) after viewing the module. There was no significant change in the proportion of patients who were interested in HIV screening. The majority of patients expressed excellent (38%) or very good (39%) satisfaction with the kiosk module. The results suggest that a computer kiosk can deliver brief and targeted education to improve knowledge about HIV screening. C1 [Sun, Benjamin C.; Knapp, Herschel; Shamouelian, Albert; Golden, Joya; Goetz, Matthew Bidwell; Asch, Steven M.] VA Greater Los Angeles Hlth Syst, Dept Med, Los Angeles, CA USA. [Sun, Benjamin C.; Goetz, Matthew Bidwell; Asch, Steven M.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Sun, BC (reprint author), W Los Angeles Vet Affairs Med Ctr, Off 3214A,Mail Stop 111,Bldg 500,Wing 3E, Los Angeles, CA 90073 USA. EM bsun@mednet.ucla.edu OI Goetz, Matthew/0000-0003-4542-992X FU VA [RRP 08-255] FX The study was supported by VA grant RRP 08-255. We thank Dr Ralph Gonzales for his donation of a computer kiosk. The authors have no competing financial interests. NR 13 TC 5 Z9 5 U1 1 U2 5 PU ROYAL SOC MEDICINE PRESS LTD PI LONDON PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND SN 1357-633X J9 J TELEMED TELECARE JI J. Telemed. Telecare PY 2010 VL 16 IS 3 BP 158 EP 161 DI 10.1258/jtt.2009.090815 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 596DV UT WOS:000277665600010 PM 20386037 ER PT J AU Mendez, MF AF Mendez, Mario F. TI The Unique Predisposition to Criminal Violations in Frontotemporal Dementia SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW LA English DT Article ID ACQUIRED SOCIOPATHY; MORAL JUDGMENT; LOBAR DEGENERATION; PREFRONTAL CORTEX; FRONTAL DAMAGE; BEHAVIOR; EMPATHY; DISEASE; BRAIN; DISTURBANCES AB Brain disorders can lead to criminal violations. Patients with frontotemporal dementia (FTD) are particularly prone to sociopathic behavior while retaining knowledge of their acts and of moral and conventional rules. This report describes four FTD patients who committed criminal violations in the presence of clear consciousness and sufficiently intact cognition. They understood the nature of their acts and the potential consequences, but did not feel sufficiently concerned to be deterred. FTD involves a unique pathologic combination affecting the ventromedial prefrontal cortex, with altered moral feelings, right anterior temporal loss of emotional empathy, and orbitofrontal changes with disinhibited, compulsive behavior. These case histories and the literature indicate that those with right temporal FTD retain the capacity to tell right from wrong but have the slow and insidious loss of the capacity for moral rationality. Patients with early FTD present a challenge to the criminal justice system to consider alterations in moral cognition before ascribing criminal responsibility. C1 [Mendez, Mario F.] VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit, Los Angeles, CA 90073 USA. [Mendez, Mario F.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. [Mendez, Mario F.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Mendez, MF (reprint author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit, 691-116AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mmendez@UCLA.edu FU NIA NIH HHS [R01 AG034499, R01 AG034499-03] NR 42 TC 18 Z9 19 U1 2 U2 11 PU AMER ACAD PSYCHIATRY & LAW PI BLOOMFIELD PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA SN 1093-6793 J9 J AM ACAD PSYCHIATRY JI J. Am. Acad. Psychiatry Law PY 2010 VL 38 IS 3 BP 318 EP 323 PG 6 WC Law; Psychiatry SC Government & Law; Psychiatry GA 663ZL UT WOS:000282928600004 PM 20852216 ER PT J AU Shiloach, M Frencher, SK Steeger, JE Rowell, KS Bartzokis, K Tomeh, MG Richards, KE Ko, CY Hall, BL AF Shiloach, Mira Frencher, Stanley K., Jr. Steeger, Janet E. Rowell, Katherine S. Bartzokis, Kristine Tomeh, Majed G. Richards, Karen E. Ko, Clifford Y. Hall, Bruce L. TI Toward Robust Information: Data Quality and Inter-Rater Reliability in the American College of Surgeons National Surgical Quality Improvement Program SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID RISK ADJUSTMENT; CARE; VALIDITY; OUTCOMES; REGISTRY; AUDIT AB BACKGROUND: Data used for evaluating quality of medical care need to be of high reliability to ensure valid quality assessment and benchmarking. The American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) has continually emphasized the collection of highly reliable clinical data through its program infrastructure. STUDY DESIGN: We provide a detailed description of the various mechanisms used in ACS NSQIP to assure collection of high quality data, including training of data collectors (surgical clinical reviewers) and ongoing audits of data reliability. For the 2005 through 2008 calendar years, inter-rater reliability was calculated overall and for individual variables using percentages of agreement between the data collector and the auditor. Variables with > 5% disagreement are flagged for educational efforts to improve accurate collection. Cohen's kappa was estimated for selected variables from the 2007 audit year. RESULTS: Inter-rater reliability audits show that overall disagreement rates on variables have fallen from 3.15% in 2005 (the first year of public enrollment in ACS NSQIP) to 1.56% in 2008. In addition, disagreement levels for individual variables have continually improved, with 26 individual variables demonstrating > 5% disagreement in 2005, to only 2 such variables in 2008. Estimated kappa values suggest substantial or almost perfect agreement for most variables. CONCLUSIONS: The ACS NSQIP has implemented training and audit procedures for its hospital participants that are highly effective in collecting robust data. Audit results show that data have been reliable since the program's inception and that reliability has improved every year. (J Am Coll Surg 2010;210:6-16. (C) 2010 by the American College of Surgeons) C1 [Shiloach, Mira; Richards, Karen E.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Frencher, Stanley K., Jr.] UCLA RAND, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA USA. [Steeger, Janet E.; Rowell, Katherine S.; Bartzokis, Kristine; Tomeh, Majed G.] QCMetrix Inc, Waltham, MA USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hall, Bruce L.] Washington Univ, Dept Surg, Ctr Hlth Policy, John Cochran Vet Affairs Med Ctr, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA. [Hall, Bruce L.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA. RP Shiloach, M (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St, Chicago, IL 60611 USA. NR 21 TC 385 Z9 385 U1 2 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD JAN PY 2010 VL 210 IS 1 BP 6 EP 16 DI 10.1016/j.jamcollsurg.2009.09.031 PG 11 WC Surgery SC Surgery GA 617KO UT WOS:000279279800002 PM 20123325 ER PT J AU Buracchio, T Arvanitakis, Z Leurgans, S Bennett, DA AF Buracchio, Teresa Arvanitakis, Zoe Leurgans, Sue Bennett, David A. TI PARKINSONIAN SIGNS AND INCIDENT FALLS IN OLDER PERSONS WITHOUT PARKINSON'S DISEASE SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter ID COMMUNITY POPULATION; ALZHEIMERS-DISEASE; PEOPLE; PREVALENCE C1 [Buracchio, Teresa] Oregon Hlth & Sci Univ, Layton Aging & Alzheimers Dis Ctr, Portland, OR 97201 USA. [Buracchio, Teresa] Portland VA Med Ctr, Portland, OR USA. [Arvanitakis, Zoe; Leurgans, Sue; Bennett, David A.] Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA. [Arvanitakis, Zoe; Leurgans, Sue; Bennett, David A.] Rush Univ, Dept Neurol Sci, Med Ctr, Chicago, IL 60612 USA. RP Buracchio, T (reprint author), Oregon Hlth & Sci Univ, Layton Aging & Alzheimers Dis Ctr, Portland, OR 97201 USA. FU NIA NIH HHS [R01 AG017917, K23 AG23675, R01 AG17917, K23 AG023675] NR 10 TC 4 Z9 4 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD JAN PY 2010 VL 58 IS 1 BP 205 EP 206 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 540DR UT WOS:000273311500049 PM 20122072 ER PT J AU Hysong, SJ Sawhney, MK Wilson, L Sittig, DF Espadas, D Davis, T Singh, H AF Hysong, Sylvia J. Sawhney, Mona K. Wilson, Lindsay Sittig, Dean F. Espadas, Donna Davis, Traber Singh, Hardeep TI Provider management strategies of abnormal test result alerts: a cognitive task analysis SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID DECISION-MAKING; FOLLOW-UP; WORKLOAD; SYSTEMS; DESIGN; STYLE AB Objective Electronic medical records (EMRs) facilitate abnormal test result communication through "alert" notifications. The aim was to evaluate how primary care providers (PCPs) manage alerts related to critical diagnostic test results on their EMR screens, and compare alert-management strategies of providers with high versus low rates of timely follow-up of results. Design 28 PCPs from a large, tertiary care Veterans Affairs Medical Center (VAMC) were purposively sampled according to their rates of timely follow-up of alerts, determined in a previous study. Using techniques from cognitive task analysis, participants were interviewed about how and when they manage alerts, focusing on four alert-management features to filter, sort and reduce unnecessary alerts on their EMIR screens. Results Provider knowledge of alert-management features ranged between 4% and 75%. Almost half (46%) of providers did not use any of these features, and none used more than two. Providers with higher versus lower rates of timely follow-up used the four features similarly, except one (customizing alert notifications). Providers with low rates of timely follow-up tended to manually scan the alert list and process alerts heuristically using their clinical judgment. Additionally, 46% of providers used at least one workaround strategy to manage alerts. Conclusion Considerable heterogeneity exists in provider use of alert-management strategies; specific strategies may be associated with lower rates of timely follow-up. Standardization of alert-management strategies including improving provider knowledge of appropriate tools in the EMR to manage alerts could reduce the lack of timely follow-up of abnormal diagnostic test results. C1 [Hysong, Sylvia J.] Baylor Coll Med, Houston VA Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Hlth Serv Res & Dev,Ctr Excellence 152, Houston, TX 77030 USA. [Hysong, Sylvia J.; Sawhney, Mona K.; Wilson, Lindsay; Espadas, Donna; Davis, Traber; Singh, Hardeep] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA. [Hysong, Sylvia J.; Sawhney, Mona K.; Wilson, Lindsay; Espadas, Donna; Davis, Traber; Singh, Hardeep] Baylor Coll Med, Ctr Inquiry Improve Outpatient Safety Effect Elec, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Sittig, Dean F.] Univ Texas Sch Hlth Informat Sci, Houston, TX USA. [Sittig, Dean F.] Univ Texas Mem Hermann Ctr Healthcare Qual & Safe, Houston, TX USA. RP Hysong, SJ (reprint author), Baylor Coll Med, Houston VA Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Hlth Serv Res & Dev,Ctr Excellence 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hysong@bcm.edu RI Hysong, Sylvia/B-8420-2008 OI Hysong, Sylvia/0000-0002-9063-5207; Davis Giardina, Traber/0000-0002-9184-6524 FU VA Career Development Award [CD2-07-0818]; VA National Center of Patient Safety; Houston VA HSR&D Center of Excellence [HFP90-020]; VA Career Development Award FX The research reported here was supported in part by a VA Career Development Award (CD2-07-0818) to SJH, the VA National Center of Patient Safety, and the Houston VA HSR&D Center of Excellence (HFP90-020). Other funders: VA Career Development Award; VA National Center of Patient Safety; Houston VA HSR&D Center of Excellence. NR 31 TC 18 Z9 18 U1 4 U2 6 PU HANLEY & BELFUS-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD JAN PY 2010 VL 17 IS 1 BP 71 EP 77 DI 10.1197/jamia.M3200 PG 7 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 538GY UT WOS:000273173800013 PM 20064805 ER PT J AU Gradman, AH Basile, JN Carter, BL Bakris, GL AF Gradman, Alan H. Basile, Jan N. Carter, Barry L. Bakris, George L. CA Hypertension Writing Grp TI Combination therapy in hypertension SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION LA English DT Article DE Hypertension; combination therapy; drug therapy; angiotensin converting enzyme inhibitor; angiotensin receptor blocker; beta blockers diuretic; calcium channel blocker ID BLOOD-PRESSURE CONTROL; LOW-DOSE HYDROCHLOROTHIAZIDE; FELODIPINE EXTENDED-RELEASE; CONVERTING-ENZYME-INHIBITOR; HIGH CARDIOVASCULAR RISK; CALCIUM-CHANNEL BLOCKER; DOUBLE-BLIND; RANDOMIZED-TRIAL; ANTIHYPERTENSIVE TREATMENT; SYSTEMIC HYPERTENSION AB The goal of antihypertensive therapy is to abolish the risks associated with blood pressure (BP) elevation without adversely affecting quality of life. Drug selection is based on efficacy in lowering BP and in reducing cardiovascular (CV) end points including stroke, myocardial infarction, and heart failure. Although the choice of initial drug therapy exerts some effect on long-term outcomes, it is evident that BP reduction per se is the primary determinant of CV risk reduction. Available data suggest that at least 75% of patients will require combination therapy to achieve contemporary BP targets, and increasing emphasis is being placed on the practical tasks involved in consistently achieving and maintaining goal BP in clinical practice. It is within this context that the American Society of Hypertension presents this Position Paper on Combination Therapy for Hypertension. It will address the scientific basis of combination therapy, present the pharmacologic rationale for choosing specific drug combinations, and review patient selection criteria for initial and secondary use. The advantages and disadvantages of single pill (fixed) drug combinations, and the implications of recent clinical trials involving specific combination strategies will also be discussed. J Am Soc Hypertens 2010;4(1):42-50. (C) 2010 American Society of Hypertension. All rights reserved. C1 [Gradman, Alan H.] Western Penn Hosp, Dept Med, Pittsburgh, PA 15224 USA. [Gradman, Alan H.] Temple Univ, Sch Med, Philadelphia, PA 19122 USA. [Basile, Jan N.] Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Carter, Barry L.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Iowa City, IA USA. [Bakris, George L.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA. RP Gradman, AH (reprint author), Western Penn Hosp, Dept Med, 4800 Friendship Ave, Pittsburgh, PA 15224 USA. EM gradmanmd@aol.com NR 65 TC 89 Z9 105 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-1711 J9 J AM SOC HYPERTENS JI J. Am. Soc. Hypertens. PD JAN-FEB PY 2010 VL 4 IS 1 BP 42 EP 50 DI 10.1016/j.jash.2010.02.005 PG 9 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 583HM UT WOS:000276664500007 PM 20374950 ER PT J AU Subramanya, AR Ellison, DH AF Subramanya, Arohan R. Ellison, David H. TI Sorting out Lysosomal Trafficking of the Thiazide-Sensitive Na-Cl Co-transporter SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID PROVOKES ACUTE TRAFFICKING; WNK KINASES; BLOOD-PRESSURE; TRANSPORT; TUBULE; POTASSIUM; PATHWAY; SALT; NCC C1 [Ellison, David H.] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA. [Ellison, David H.] Portland VA Med Ctr, Portland, OR USA. [Subramanya, Arohan R.] Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA USA. [Subramanya, Arohan R.] VA Pittsburgh Healthcare Syst, Res Serv, Pittsburgh, PA USA. [Subramanya, Arohan R.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. RP Ellison, DH (reprint author), Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, PP262,3181 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM ellisond@ohsu.edu OI Ellison, David/0000-0003-2915-265X FU NIDDK NIH HHS [DK051496, DK084566, R01 DK051496] NR 17 TC 6 Z9 7 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2010 VL 21 IS 1 BP 7 EP 9 DI 10.1681/ASN.2009111138 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA 546BK UT WOS:000273781900005 PM 19959708 ER PT J AU Bondi, CD Manickam, N Lee, DY Block, K Gorin, Y Abboud, HE Barnes, JL AF Bondi, Corry D. Manickam, Nagaraj Lee, Duck Yoon Block, Karen Gorin, Yves Abboud, Hanna E. Barnes, Jeffrey L. TI NAD(P)H Oxidase Mediates TGF-beta 1-Induced Activation of Kidney Myofibroblasts SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID SMOOTH MUSCLE ACTIN; GROWTH-FACTOR-BETA; UNILATERAL URETERAL OBSTRUCTION; ANGIOTENSIN-II; MESANGIAL CELLS; TGF-BETA; RENAL FIBROSIS; PROLIFERATIVE GLOMERULONEPHRITIS; DIABETIC-NEPHROPATHY; CARDIAC FIBROBLASTS AB TGF-beta 1 expression closely associates with activation and conversion of fibroblasts to a myofibroblast phenotype and synthesis of an alternatively spliced cellular fibronectin variant, Fn-ED-A. Reactive oxygen species (ROS), such as superoxide, which is a product of NAD(P)H oxidase, also promote the transition of fibroblasts to myofibroblasts, but whether these two pathways are interrelated is unknown. Here, we examined a role for NAD(P)H oxidase-derived ROS in TGF-beta 1-induced activation of rat kidney fibroblasts and expression of alpha-smooth muscle actin (alpha-SMA) and Fn-ED-A. In vitro, TGF-beta 1 stimulated formation of abundant stress fibers and increased expression of both alpha-SMA and Fn-ED-A. In addition, TGF-beta 1 increased both the activity of NADPH oxidase and expression of Nox2 and Nox4, homologs of the NAD(P)H oxidase family, indicating that this growth factor induces production of ROS. Small interfering RNA targeted against Nox4 markedly inhibited TGF-beta 1-induced stimulation of NADPH oxidase activity and reduced alpha-SMA and Fn-ED-A expression. Inhibition of TGF-beta 1 receptor 1 blocked Smad3 phosphorylation; reduced TGF-beta 1-enhanced NADPH oxidase activity; and decreased expression of Nox4, alpha-SMA, and Fn-ED-A. Diphenyleneiodonium, an inhibitor of flavin-containing enzymes such as the Nox oxidases, had no effect on TGF-beta 1-induced Smad3 but reduced both alpha-SIMA and Fn-ED-A protein expression. The Smad3 inhibitor SIS3 reduced NADPH oxidase activity, Nox4 expression, and blocked alpha-SIMA and Fn-ED-A, indicating that stimulation of myofibroblast activation by ROS is downstream of Smad3. In addition, TGF-beta 1 stimulated phosphorylation of extracellular signal-regulated kinase (ERK1/2), and this was inhibited by blocking TGF-beta 1 receptor 1, Smad3, or the Nox oxidases; ERK1/2 activation increased alpha-SMA and Fn-ED-A. Taken together, these results suggest that TGF-beta 1-induced conversion of fibroblasts to a myofibroblast phenotype involves a signaling cascade through Smad3, NAD(P)H oxidase, and ERK1/2. C1 [Bondi, Corry D.; Manickam, Nagaraj; Lee, Duck Yoon; Block, Karen; Gorin, Yves; Abboud, Hanna E.; Barnes, Jeffrey L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. [Abboud, Hanna E.; Barnes, Jeffrey L.] S Texas Vet Hlth Care Syst, Med Res Serv, Audie Murphy Mem Vet Adm Hosp, San Antonio, TX USA. RP Barnes, JL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM barnesj@uthscsa.edu OI Gorin, Yves/0000-0003-4048-6925 FU Department of Veterans Affairs [0555006Y]; American Heart Association, Texas Affiliate; George O'Brien Kidney Center, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases [P50DK061597] FX This work was supported by grants from the Merit Review Program, Department of Veterans Affairs; grant 0555006Y from the American Heart Association, Texas Affiliate; and the George O'Brien Kidney Center (P50DK061597), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. NR 69 TC 131 Z9 138 U1 1 U2 5 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2010 VL 21 IS 1 BP 93 EP 102 DI 10.1681/ASN.2009020146 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 546BK UT WOS:000273781900017 PM 19926889 ER PT J AU Gilbert, GE Pope, C AF Gilbert, Gregory E. Pope, Charlene TI A Brief Introduction to Evaluating the Literature SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION LA English DT Editorial Material DE evidence-based measures; quantitative research; decision making C1 [Gilbert, Gregory E.] Ralph H Johnson VAMC, Res Serv 151, Charleston VA REAP, Charleston, SC 29401 USA. [Gilbert, Gregory E.] Natl Med Assoc, Washington, DC USA. [Pope, Charlene] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. RP Gilbert, GE (reprint author), Ralph H Johnson VAMC, Res Serv 151, Charleston VA REAP, 109 Bee St, Charleston, SC 29401 USA. EM gregory.e.gilbert@gmail.com RI Gilbert, Gregory/C-7735-2016 OI Gilbert, Gregory/0000-0003-0879-5496 NR 2 TC 0 Z9 0 U1 0 U2 2 PU NATL MED ASSOC PI WASHINGON PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA SN 0027-9684 J9 J NATL MED ASSOC JI J. Natl. Med. Assoc. PD JAN PY 2010 VL 102 IS 1 BP 65 EP 67 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 547HX UT WOS:000273878800011 PM 20158140 ER PT J AU Burch, JB Svendsen, E Siegel, PD Wagner, SE von Essen, S Keefe, T Mehaffy, J Martinez, AS Bradford, M Baker, L Cranmer, B Saito, R Tessari, J Linda, P Andersen, C Christensen, O Koehncke, N Reynolds, SJ AF Burch, James B. Svendsen, Erik Siegel, Paul D. Wagner, Sara E. von Essen, Susanna Keefe, Thomas Mehaffy, John Martinez, Angelica Serrano Bradford, Mary Baker, Laura Cranmer, Brian Saito, Rena Tessari, John Linda, Prinz Andersen, Colene Christensen, Opal Koehncke, Niels Reynolds, Stephen J. TI Endotoxin Exposure and Inflammation Markers Among Agricultural Workers in Colorado and Nebraska SO JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES LA English DT Article ID DOSE-RESPONSE RELATIONSHIPS; CHROMATOGRAPHY MASS-SPECTROMETRY; UPPER AIRWAY INFLAMMATION; AMEBOCYTE LYSATE ASSAY; 3-HYDROXY FATTY-ACIDS; SETTLED HOUSE-DUST; GAS-CHROMATOGRAPHY; ORGANIC DUST; BACTERIAL-ENDOTOXIN; ENVIRONMENTAL EXPOSURES AB The adverse respiratory effects of agricultural dust inhalation are mediated in part by endotoxin, a constituent of gram-negative bacterial cell walls. This study quantified personal work-shift exposures to inhalable dust, endotoxin, and its reactive 3-hydroxy fatty acid (3-OHFA) constituents among workers in grain elevators, cattle feedlots, dairies, and on corn farms. Exposures were compared with post-work-shift nasal lavage fluid inflammation markers and respiratory symptoms. Breathing-zone personal air monitoring was performed over one work shift to quantify inhalable dust (Institute of Medicine samplers), endotoxin (recombinant factor C [rFC] assay), and 3-OHFA (gas chromatography/mass spectrometry). Post-shift nasal lavage fluids were assayed for polymorphonuclear neutrophils (PMN), myeloperoxidase (MPO), interleukin 8 (IL-8), albumin, and eosinophilic cation protein (ECP) concentrations. The geometric mean (GSD) of endotoxin exposure (rFC assay) among the 125 male participants was 888 +/- (6.5) EU/m3, and 93% exceeded the proposed exposure limit (50 EU/m3). Mean PMN, MPO, albumin, and ECP levels were two- to threefold higher among workers in the upper quartile of 3-OHFA exposure compared to the lowest exposure quartile. Even numbered 3-OHFA were most strongly associated with nasal inflammation. Symptom prevalence was not elevated among exposed workers, possibly due to endotoxin tolerance or a healthy worker effect in this population. This is the first study to evaluate the relationship between endotoxin's 3-OHFA constituents in agricultural dust and nasal airway inflammation. More research is needed to characterize the extent to which these agents contribute to respiratory disease among agricultural workers. C1 [Burch, James B.; Svendsen, Erik; Wagner, Sara E.] Univ S Carolina, Dept Epidemiol & Biostat, Canc Prevent & Control Program, Columbia, SC 29208 USA. [Burch, James B.; Svendsen, Erik; Wagner, Sara E.] Univ S Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA. [Burch, James B.; Svendsen, Erik; Wagner, Sara E.] US Dept Vet Affairs, Med Ctr, Columbia, SC USA. [Svendsen, Erik] S Carolina Dept Hlth & Environm Control, Columbia, SC 29201 USA. [Siegel, Paul D.] NIOSH, Morgantown, WV USA. [von Essen, Susanna; Linda, Prinz; Andersen, Colene; Christensen, Opal] Univ Nebraska, Med Ctr, Omaha, NE USA. [Keefe, Thomas; Mehaffy, John; Martinez, Angelica Serrano; Bradford, Mary; Baker, Laura; Cranmer, Brian; Saito, Rena; Tessari, John; Reynolds, Stephen J.] Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA. [Koehncke, Niels] Univ Saskatchewan, Saskatoon, SK, Canada. RP Burch, JB (reprint author), Univ S Carolina, Dept Epidemiol & Biostat, Canc Prevent & Control Program, 915 Greene St,Room 228, Columbia, SC 29208 USA. EM burch@mailbox.sc.edu RI Svendsen, Erik/J-2671-2015 OI Svendsen, Erik/0000-0003-3941-0907 FU NIOSH CDC HHS [CDC NIOSH 5U50 OH008085, CDC NIOSH R01 OH007841] NR 53 TC 28 Z9 28 U1 0 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1528-7394 J9 J TOXICOL ENV HEAL A JI J. Toxicol. Env. Health Part A PY 2010 VL 73 IS 1 BP 5 EP 22 AR PII 917265269 DI 10.1080/15287390903248604 PG 18 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 525QQ UT WOS:000272231800002 PM 19953416 ER PT J AU Garzotto, M AF Garzotto, Mark TI Men Presenting for Radical Prostatectomy on Preoperative Statin Therapy Have Reduced Serum Prostate Specific Antigen EDITORIAL COMMENT SO JOURNAL OF UROLOGY LA English DT Editorial Material C1 Portland VA Med Ctr, Dept Urol & Radiat Med, Portland, OR USA. RP Garzotto, M (reprint author), Portland VA Med Ctr, Dept Urol & Radiat Med, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD JAN PY 2010 VL 183 IS 1 BP 123 EP 124 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 531FO UT WOS:000272649300042 PM 19913241 ER PT J AU Henderson, WA Shankar, R Gill, JM Kim, KH Ghany, MG Skanderson, M Butt, AA AF Henderson, Wendy A. Shankar, Ravi Gill, Jessica M. Kim, Kevin H. Ghany, Marc G. Skanderson, Melissa Butt, Adeel A. TI Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma SO JOURNAL OF VIRAL HEPATITIS LA English DT Article DE co-morbidity; dialysis; end stage renal disease; hepatitis C; hepatocellular carcinoma ID CHRONIC-HEMODIALYSIS PATIENTS; HIV-INFECTED VETERANS; VIRUS-INFECTION; UNITED-STATES; RISK; COINFECTION; CIRRHOSIS; IMPACT; COMORBIDITIES; SURVIVAL AB Approximately 3.2 million people in the United States have chronic hepatitis C virus (HCV) infection; the primary cause for adult liver transplantation and a significant burden on healthcare resources. The role of HCV and other risk factors in development of HCC in patients with chronic kidney disease is not well defined. We studied predictors of hepatocellular carcinoma (HCC) in dialysis patients with chronic HCV by analyzing factors associated with its development. Data were extracted from the United States Renal Database System (USRDS) using ICD-9 codes. Variables included were gender, race, duration on dialysis and co-morbidities (alcohol abuse, drug abuse, HIV, hepatitis B, diabetes and/or presence of cirrhosis). Among the 32 806 HCV infected subjects, 262 cases had HCC. HCC was 12 times more likely in subjects with cirrhosis (P < 0.001), three times more likely in subjects with alcohol abuse (P < 0.001), and 1.3 times more likely in subjects with diabetes (P = 0.04). Asians were three times more likely (P < 0.001) to have HCC. Females were less likely to have HCC compared to males (P = 0.002). The likelihood of having HCC increased with age (P = 0.001). This population-based study demonstrates that among subjects with HCV on dialysis, those with cirrhosis, Asian race and history of alcohol abuse are at highest risk for development of HCC. Furthermore, these findings indicate links between HCV and HCC which are valuable in case management for identifying; monitoring, and managing dialysis patients with HCC. C1 [Henderson, Wendy A.] NINR, Symptoms Management Branch, Biobehav Unit, NIH, Bethesda, MD 20892 USA. [Kim, Kevin H.] Univ Pittsburgh, Sch Educ, Pittsburgh, PA 15260 USA. [Ghany, Marc G.] NIDDK, NIH, Bethesda, MD USA. [Skanderson, Melissa] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Butt, Adeel A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Henderson, WA (reprint author), NINR, Symptoms Management Branch, Biobehav Unit, NIH, 10 Ctr Dr,2-1339, Bethesda, MD 20892 USA. EM hendersw@mail.nih.gov OI Henderson, Wendy/0000-0003-3924-7118 FU National Institutes of Health [NIH, 1TL1 RR024155-01, NIH/NIDA, DA016175-01A1]; University of Pittsburgh School of Nursing; Educational Innovation Fund; Duquesne University School of Nursing FX Support was provided by the Symptoms Management Branch, Intramural Research Program, National Institute of Nursing Research, National Institutes of Health. Additional support was provided by the following: Clinical & Translational Science Institute Fellowship (Henderson): NIH, 1TL1 RR024155-01(Reis), NIH/NIDA, DA016175-01A1, (Butt); University of Pittsburgh School of Nursing, Educational Innovation Fund; Duquesne University School of Nursing, Dean's Fund (Henderson). Special thanks to Drs. Thelma Patrick and Mary Ann Thurkettle for their assistance with the pilot phase of this study. NR 28 TC 13 Z9 15 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1352-0504 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD JAN PY 2010 VL 17 IS 1 BP 59 EP 64 DI 10.1111/j.1365-2893.2009.01151.x PG 6 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA 545KT UT WOS:000273731700007 PM 19566787 ER PT J AU Ludman, EJ Russo, JE Katon, WJ Simon, GE Williams, LH Lin, EHB Heckbert, SR Ciechanowski, P Young, BA AF Ludman, Evette J. Russo, Joan E. Katon, Wayne J. Simon, Gregory E. Williams, Lisa H. Lin, Elizabeth H. B. Heckbert, Susan R. Ciechanowski, Paul Young, Bessie A. TI How Does Change in Depressive Symptomatology Influence Weight Change in Patients With Diabetes? Observational Results From the Pathways Longitudinal Cohort SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Depression; Obesity; Diabetes ID RANDOMIZED-TRIAL; SELF-REPORT; HEALTH; RISK; CARE; INDIVIDUALS; OBESITY; ADJUDICATION; PREVENTION; MORTALITY AB Little is known about how change in depressive symptoms over time is associated with change in weight. Longitudinal associations between change in depression (Patient Health Questionnaire-9 [PHQ-9]) and weight (self-reported and chart abstracted) were examined in 2,600 patients with type 2 diabetes (mean age 62, SD = 11.6) who were surveyed by telephone in 2001-2002 and 5 years later as part of the Pathways study. Mixed effects regression analyses compared a) patients with persistently low depression symptoms with those whose depression worsened (increased at least 5 points on PHQ-9) over 5 years and b) patients with persistently high depression symptoms with those who improved (decreased at least 5 points on PHQ-9) over 5 years. Those who worsened in comparison to those with persistently low depression symptoms did not differ in their pattern of weight change (z = 1.54, p = .12). Both groups weighed approximately 92 kg at baseline and lost approximately 2 kg. A significantly different pattern of change over time was observed for those with persistently high depression symptoms in comparison to those whose depression improved (z = 1.98, p = .04). Although the groups had almost identical weight at baseline (approximately 100 kg), at the 5-year assessment, those with persistently high depression symptoms had about half the weight loss (M = -1.71, SD = 9.08) in comparison to those whose depression improved (M = -3.62, SD = 19.93). In persons with diabetes who have clinically significant levels of depressive symptoms, improvement in depression is accompanied by significantly greater, clinically significant weight loss. C1 [Ludman, Evette J.; Simon, Gregory E.; Lin, Elizabeth H. B.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA 98101 USA. [Russo, Joan E.; Katon, Wayne J.; Ciechanowski, Paul] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Williams, Lisa H.] Univ Washington, Sch Med, VA Hlth Serv Res & Dev, Ctr Excellence, Seattle, WA USA. [Williams, Lisa H.] Univ Washington, Div Dermatol, Sch Med, Seattle, WA 98195 USA. [Heckbert, Susan R.] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Young, Bessie A.] Univ Washington, Sch Med, Epidemiol Res & Informat Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Young, Bessie A.] Univ Washington, Sch Med, Div Nephrol, Seattle, WA USA. RP Ludman, EJ (reprint author), Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA. EM ludman.e@ghc.org FU National Institute of Mental Health [K24 MH067587, MH 073686] FX This research was supported by grants from the National Institute of Mental Health (K24 MH067587 to W. J. K. and MH 073686 to Michael Von Korff). NR 27 TC 7 Z9 7 U1 0 U2 1 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD JAN PY 2010 VL 65 IS 1 BP 93 EP 98 DI 10.1093/gerona/glp151 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 537LV UT WOS:000273115300013 PM 19822623 ER PT J AU Alley, DE Chang, VW AF Alley, Dawn E. Chang, Virginia W. TI Metabolic Syndrome and Weight Gain in Adulthood SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Metabolic syndrome; Weight history; Body mass index; Lipids ID CORONARY-HEART-DISEASE; MIDDLE-AGED MEN; BODY-MASS INDEX; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS; US ADULTS; CARDIOMETABOLIC RISK; SUBSEQUENT RISK; OBESITY; WOMEN AB The influence of long-term adult weight history on metabolic risk independent of attained body mass index (BMI) is unknown. Using nationally representative data on adults aged 50-64 years from the 1999-2006 National Health and Nutrition Examination Surveys, we examined weight change for two periods of adulthood: prime age (age 25-10 years ago) and midlife (the last 10 years). Weight changes in each period were categorized as stable (gain < 10 kg) or gain (gain >= 10 kg) to create weight history comparison groups: stable-stable, gain-stable (prime age gain), stable-gain (midlife gain), and gain-gain (continuous gain). Persons who lost weight were excluded. Logistic regression predicted odds of metabolic syndrome and its subcomponents based on weight history, adjusting for current BMI and covariates. Participants in the gain-stable group had 89% elevated odds of metabolic syndrome (odds ratio = 1.89, 95% CI: 1.19-3.01) relative to the stable-stable group, even after adjustment for current BMI. All weight gain groups had increased odds of low HDL and high triglycerides relative to participants with continuously stable weights. No significant associations were found between weight history and hypertension or high glucose. Weight history confers information about metabolic risk factors above and beyond attained weight status. In particular, adult weight gain is related to risk of low HDL and high triglycerides. Weight history may contribute to our understanding of why some obese older persons are metabolically healthy but others are not. C1 [Alley, Dawn E.] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA. [Chang, Virginia W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Chang, Virginia W.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Chang, Virginia W.] Univ Penn, Dept Sociol, Philadelphia, PA 19104 USA. RP Alley, DE (reprint author), Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, 660 W Redwood St 221B, Baltimore, MD 21201 USA. EM dalley@epi.umaryland.edu FU Robert Wood Johnson Foundation Health; National Institute of Child Health and Human Development [K12-HD043459] FX Robert Wood Johnson Foundation Health and Society Scholars program and National Institute of Child Health and Human Development (K12-HD043459). NR 35 TC 15 Z9 17 U1 0 U2 0 PU GERONTOLOGICAL SOC AMER PI WASHINGTON PA 1030 15TH ST NW, STE 250, WASHINGTON, DC 20005202-842 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD JAN PY 2010 VL 65 IS 1 BP 111 EP 117 DI 10.1093/gerona/glp177 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 537LV UT WOS:000273115300016 PM 19906821 ER PT J AU Boudreau, E Chen, G Li, X Buck, K Hitzemann, R Hickman, D AF Boudreau, Eilis Chen, Gang Li, Xin Buck, Kari Hitzemann, Robert Hickman, Debra TI Intraperitoneal catheter placement for pharmacological imaging studies in conscious mice SO LAB ANIMAL LA English DT Article ID IN-VIVO; INJECTION; RATS; MRI; RECEPTORS; STRESS AB Imaging studies that use rodents sometimes involve intraperitoneal administration of pharmacological compounds. To facilitate such studies, the authors developed a simple and easily mastered technique for placing an intraperitoneal catheter in a conscious mouse. This technique eliminates the need to remove the animal from the scanner to administer a drug through the intraperitoneal route. C1 [Boudreau, Eilis] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Boudreau, Eilis; Chen, Gang; Buck, Kari; Hitzemann, Robert; Hickman, Debra] Portland VA Med Ctr, Portland, OR USA. [Chen, Gang; Buck, Kari; Hitzemann, Robert] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Chen, Gang; Buck, Kari; Hitzemann, Robert] Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Portland, OR 97201 USA. [Li, Xin] Oregon Hlth & Sci Univ, Adv Imaging Res Ctr, Portland, OR 97201 USA. RP Boudreau, E (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. EM boudreau@ohsu.edu RI Hickman, Debra/D-3289-2009 FU NIAAA NIH HHS [P60 AA010760] NR 14 TC 1 Z9 1 U1 1 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0093-7355 J9 LAB ANIMAL JI Lab Anim. PD JAN PY 2010 VL 39 IS 1 BP 23 EP 25 DI 10.1038/laban0110-23 PG 3 WC Veterinary Sciences SC Veterinary Sciences GA 537ZF UT WOS:000273152500011 PM 20023678 ER PT J AU Saxena, S Gierl, B Eibling, DE AF Saxena, Shashank Gierl, Brian Eibling, David E. TI Supraglottic Swelling May Not Correlate With Tongue Swelling in Angiotensin Converting Enzyme Inhibitor-Induced Angioedema SO LARYNGOSCOPE LA English DT Article DE Angioedema; laryngeal edema; angiotension converting enzyme inhibitors ID PERIOPERATIVE ANGIOEDEMA; ACE-INHIBITORS; MANAGEMENT; THERAPY AB Angioneurotic edema of upper airway tissues due to angiotensin converting enzyme inhibitor (ACEI) usage is a known perioperative complication of this class of medications. Swelling can begin rapidly, and typically involves the tongue and oral cavity. We have recently encountered four cases in which supraglottic edema developed after onset of tongue swelling and progressed despite resolving tongue edema. We present a representative case. This observation. suggests that all patients with ACEI-induced angioedema should undergo laryngeal fiberoptic examination and appropriate airway management. C1 [Saxena, Shashank] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA. [Eibling, David E.] VA Pittsburgh Hlth Care Syst, Dept Otolaryngol, Pittsburgh, PA USA. RP Saxena, S (reprint author), Univ Pittsburgh, Sch Med, Dept Anesthesiol, A 1305 Scaife Hall, Pittsburgh, PA 15261 USA. EM saxenas@anes.upmc.edu NR 21 TC 8 Z9 8 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD JAN PY 2010 VL 120 IS 1 BP 62 EP 64 DI 10.1002/lary.20683 PG 3 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 539HZ UT WOS:000273245900012 PM 19890965 ER PT J AU Konrad-Martin, D Austin, DF Griest, S McMillan, GP McDermott, D Fausti, S AF Konrad-Martin, Dawn Austin, Donald F. Griest, Susan McMillan, Garnett P. McDermott, Daniel Fausti, Stephen TI Diabetes-Related Changes in Auditory Brainstem Responses SO LARYNGOSCOPE LA English DT Article DE Auditory brainstem response; diabetes; hearing loss; Veterans ID HEARING-LOSS; MELLITUS; IMPAIRMENT AB Objectives/Hypothesis: Determine effects on auditory brainstem response (ABR) of diabetes mellitus (DM) severity. Study Design: A cross-sectional study investigating DM severity and ABR in military Veteran subjects with (166) and without (138) DM and with no more than moderate hearing loss. Methods: Subjects were classified by three age tertiles (<50, 50-56, and 57+). DM severity was classified as insulin-dependent (IDDM), non-insulin-dependent (NIDDM), or no DM. Other DM measures included serum glucose, HbA1c, and several DM-related complications. ABR measures included wave I, III, and V latencies; I-III, III-V, and I-V latency intervals; and wave V amplitude; for each ear at three repetition rates (11, 51, and 71 clicks/second), and both polarities. Outcomes were stratified by age tertile and adjusted for pure tone threshold at 3 kHz. Repeated measures multivariate analysis of covariance modeled the ABR response at each repetition rate for DM severity (main effect) and hearing at 3 kHz (covariate). Modeled contrasts between ABR variables in subjects with and without DM were examined. Results: Significant differences existed between no DM and IDDM groups in the younger tertile only. Adjusting for threshold at 3 kHz had minimal effect. Self-reported noise exposure was not related to ABR differences, but HbA1c and poor circulation were. Conclusions: IDDM is associated with an increased wave V latency, wave I-V interval, and reduced wave V amplitude among Veterans under 50 years. Results were related to several DM complications. C1 [Konrad-Martin, Dawn] Portland VA Med Ctr, VA RR&D, Natl Ctr Rehabil Auditory Res, Vet Affairs Rehabil Res & Dev Serv, Portland, OR 97239 USA. [Austin, Donald F.] Oregon Hlth & Sci Univ, Sch Med, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Konrad-Martin, Dawn; Griest, Susan; Fausti, Stephen] Oregon Hlth & Sci Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Portland, OR 97201 USA. RP Konrad-Martin, D (reprint author), Portland VA Med Ctr, VA RR&D, Natl Ctr Rehabil Auditory Res, Vet Affairs Rehabil Res & Dev Serv, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM dawn.martin@va.gov FU United States Department of Veterans Affairs (VA); Veterans Health Administration, Office of Research and Development Rehabilitation Research and Development (RRD) Service [C3446R, C4447K] FX This work was supported by the United States Department of Veterans Affairs (VA), Veterans Health Administration, Office of Research and Development Rehabilitation Research and Development (RR&D) Service grants C3446R and C4447K. NR 15 TC 15 Z9 20 U1 2 U2 4 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD JAN PY 2010 VL 120 IS 1 BP 150 EP 158 DI 10.1002/lary.20636 PG 9 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 539HZ UT WOS:000273245900027 PM 19904812 ER PT J AU Rix, U Rix, LLR Terker, AS Fernbach, NV Hantschel, O Planyavsky, M Breitwieser, FP Herrmann, H Colinge, J Bennett, KL Augustin, M Till, JH Heinrich, MC Valent, P Superti-Furga, G AF Rix, U. Rix, L. L. Remsing Terker, A. S. Fernbach, N. V. Hantschel, O. Planyavsky, M. Breitwieser, F. P. Herrmann, H. Colinge, J. Bennett, K. L. Augustin, M. Till, J. H. Heinrich, M. C. Valent, P. Superti-Furga, G. TI A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells SO LEUKEMIA LA English DT Article DE CML; INNO-406; kinase profiling; chemical proteomics; kinase inhibitor ID TYROSINE KINASE; LYN KINASE; INTERFERING RNA; IMATINIB; DASATINIB; RESISTANT; SENSITIVITY; ACTIVATION; EXPRESSION; NILOTINIB AB Resistance to the BCR-ABL tyrosine kinase inhibitor imatinib poses a pressing challenge in treating chronic myeloid leukemia (CML). This resistance is often caused by point mutations in the ABL kinase domain or by overexpression of LYN. The second-generation BCR-ABL inhibitor INNO-406 is known to inhibit most BCR-ABL mutants and LYN efficiently. Knowledge of its full target spectrum would provide the molecular basis for potential side effects or suggest novel therapeutic applications and possible combination therapies. We have performed an unbiased chemical proteomics native target profile of INNO-406 in CML cells combined with functional assays using 272 recombinant kinases thereby identifying several new INNO-406 targets. These include the kinases ZAK, DDR1/2 and various ephrin receptors. The oxidoreductase NQO2, inhibited by both imatinib and nilotinib, is not a relevant target of INNO-406. Overall, INNO-406 has an improved activity over imatinib but a slightly broader target profile than both imatinib and nilotinib. In contrast to dasatinib and bosutinib, INNO-406 does not inhibit all SRC kinases and most TEC family kinases and is therefore expected to elicit fewer side effects. Altogether, these properties may make INNO-406 a valuable component in the drug arsenal against CML. Leukemia (2010) 24, 44-50; doi:10.1038/leu.2009.228; published online 5 November 2009 C1 [Rix, U.; Rix, L. L. Remsing; Fernbach, N. V.; Hantschel, O.; Planyavsky, M.; Breitwieser, F. P.; Colinge, J.; Bennett, K. L.; Superti-Furga, G.] Austrian Acad Sci, CeMM Ctr Mol Med, A-1090 Vienna, Austria. [Terker, A. S.; Heinrich, M. C.] Portland VA Med Ctr, Div Hematol & Med Oncol, Portland, OR USA. [Terker, A. S.; Heinrich, M. C.] OHSU Knight Canc Inst, Portland, OR USA. [Herrmann, H.; Valent, P.] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria. [Augustin, M.; Till, J. H.] Millipore UK Ltd, Dundee, Scotland. RP Superti-Furga, G (reprint author), Austrian Acad Sci, CeMM Ctr Mol Med, Lazarettgasse 19, A-1090 Vienna, Austria. EM gsuperti@cemm.oeaw.ac.at RI Hantschel, Oliver/H-4705-2013; Superti-Furga, Giulio/F-4755-2015 OI Hantschel, Oliver/0000-0001-8569-8169; Superti-Furga, Giulio/0000-0002-0570-1768; Terker, Andrew/0000-0003-1498-9043 FU Leukemia and Lymphoma Society [5081-05]; Austrian Federal Ministry for Science and Research (BMWF) [GZ200.142/I-VI/I/2006, GZ200.145/I-VI/I/2006]; Austrian Science Fund (FWF) [P18737-B11]; Austrian National Bank (ONB); Austrian Academy of Sciences (OAW) FX This study was supported by the Leukemia and Lymphoma Society (Grant number 5081-05), the Austrian Federal Ministry for Science and Research (BMWF) under the GEN-AU program (GZ200.142/I-VI/I/2006 and GZ200.145/I-VI/I/2006), the Austrian Science Fund (FWF; P18737-B11), the Austrian National Bank (ONB) and the Austrian Academy of Sciences (OAW). We thank Norbert Venturini for preparation of the SDS-PAGE gels and Florian Grebien for helpful discussions. NR 30 TC 38 Z9 42 U1 0 U2 9 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD JAN PY 2010 VL 24 IS 1 BP 44 EP 50 DI 10.1038/leu.2009.228 PG 7 WC Oncology; Hematology SC Oncology; Hematology GA 543KW UT WOS:000273577100006 PM 19890374 ER PT B AU Forrest, GN Kleinberg, M AF Forrest, Graeme N. Kleinberg, Michael BE Kleinberg, M TI Issues in Anti-infective Management SO MANAGING INFECTIONS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES SE Contemporary Hematology LA English DT Article; Book Chapter DE Anti-infective management; Cost-effectiveness; Drug interactions; Drug safety; Computerized support; HIV-related malignancies ID VANCOMYCIN-RESISTANT ENTEROCOCCI; NON-HODGKINS-LYMPHOMA; ANTIMICROBIAL STEWARDSHIP PROGRAMS; ACTIVE ANTIRETROVIRAL THERAPY; CONVENTIONAL AMPHOTERICIN-B; INFECTIOUS-DISEASES-SOCIETY; POSITIVE BLOOD CULTURES; STEM-CELL TRANSPLANT; STAPHYLOCOCCUS-AUREUS; NEUTROPENIC PATIENTS AB Early antimicrobial therapy to patients with hematologic malignancies has been shown to improve their survival and outcomes. Structured properly, an institution-wide anti-infective program can improve the efficient management of infections with minimized toxicities in a cost-effective manner. Program objectives should encompass standardized approaches to antimicrobial prescribing, systems that can predict potentially dangerous therapeutic toxicities, and monitoring to assess outcome successes. This is ever more critical with the emergence of anti microbial resistant organisms, newer expensive antimicrobial agents, and the significant drug interactions between anti-infectives and chemotherapeutic agents. Patients with HIV-associated malignancies represent a special challenge because of the complexities involved in managing two concurrent diseases and the potential for drug interactions potentiating toxicities between highly active antiretroviral therapy (HAART) and many chemotherapy agents. C1 [Forrest, Graeme N.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Div Infect Dis, Portland, OR 97239 USA. [Kleinberg, Michael] Univ Maryland, Sch Med, Infect Dis Sect, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA. RP Forrest, GN (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Div Infect Dis, 3701 SW US Vet Hosp Rd P3ID, Portland, OR 97239 USA. NR 72 TC 0 Z9 0 U1 0 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-58829-986-4 J9 CONTEMP HEMATOL PY 2010 BP 345 EP 364 D2 10.1007/978-1-59745-415-5 PG 20 WC Oncology; Hematology; Infectious Diseases SC Oncology; Hematology; Infectious Diseases GA BMR57 UT WOS:000273399700013 ER PT J AU Chen, J Li, J Lim, FC Wu, Q Douek, DC Scott, DK Ravussin, E Hsu, HC Jazwinski, SM Mountz, JD AF Chen, Jian Li, Jun Lim, Fei Chu Wu, Qi Douek, Daniel C. Scott, Donald K. Ravussin, Eric Hsu, Hui-Chen Jazwinski, S. Michal Mountz, John D. CA Louisiana Healthy Aging Study TI Maintenance of naive CD8 T cells in nonagenarians by leptin, IGFBP3 and T3 SO MECHANISMS OF AGEING AND DEVELOPMENT LA English DT Article DE Nonagenarians; Naive CD8; TREC; IGFBP3; Leptin; T3 ID RECENT THYMIC EMIGRANTS; RECEPTOR EXCISION CIRCLES; FACTOR-BINDING PROTEIN-3; HEMATOPOIETIC STEM-CELL; IMMUNE-SYSTEM; HUMAN LONGEVITY; AGE; EXPRESSION; IMMUNOSENESCENCE; APOPTOSIS AB Research into the age-associated decline in the immune system has focused on the factors that contribute to the accumulation of senescent CD8 T cells. Less attention has been paid to the non-immune factors that may maintain the pool of naive CD8 T cells. Here, we analyzed the status of the naive CD8 T-cell Population in healthy nonagenarians (>= 90-year-old), old (60-79-year-old), and young (20-34-year-old) subjects Naive CD8 T cells were defined as CD28(+)CD95(-) as this phenotype showed a strong co-expression of the CD45RA(+), CD45RO(-), and CD 127(+) phenotypes. Although there was an age-associated decline in the percentage of CD28(+)CD95(-)CD8 T cells, the healthy nonagenarians maintained a pool of naive CD28(+)CD95(-) cells that contained T-cell receptor excision circles (TREC)(+) cells The percentages of naive CD28(+)CD95(-) CD8 T cells in the nonagenarians correlated with the sera levels of insulin-like growth factor binding protein 3 (IGFBP3) and leptin Higher levels of triiodothyronine (T3) negatively correlated with the accumulation of TREC(-)CD28(-)CD95(+) CD8 T cells from nonagenarians These results Suggest a model in which IGFBP3. leptin and T3 act as non-immune factors to maintain a larger pool of naive CD8 T cells in healthy nonagenarians Published by Elsevier Ireland Ltd. C1 [Mountz, John D.] Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. [Douek, Daniel C.] NIH, Vaccine Res Ctr, Bethesda, MD USA. [Scott, Donald K.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA. [Jazwinski, S. Michal] Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA. [Mountz, John D.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Mountz, JD (reprint author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, 1825 Univ Blvd,Room 307 Shelby Bldg, Birmingham, AL 35294 USA. RI Ermolao, Andrea/I-5463-2012 OI Ermolao, Andrea/0000-0002-0546-1514 FU NIH/NIA [PO1 AG022064-01A1]; Millennium Trust [HEF(2001-06)-02] FX This research was supported by NIH/NIA PO1 AG022064-01A1 and by the Louisiana Board of Regents through the Millennium Trust Health Excellence Fund [HEF(2001-06)-02] We thank the Recruitment and Clinical Testing Core at the Pennington Biomedical Research Center for collecting the blood samples and the Sampling and Data Management Core at Louisiana State University Health Sciences Center for storage, quality control, and analyses of the data presented herein We thank Dr. David Allison for providing advice on Statistical Analysis. We also acknowledge Ms. Enid Keyser and at the Rheumatic Diseases Core Center - Analytic and Preparative Flow Cytometry Facility at University of Alabama-Birmingham for operating the FACS instrument, Dr. Fiona Hunter for expert edition of the manuscript, and Ms. Carol Humber for excellent secretarial assistance. NR 59 TC 19 Z9 20 U1 0 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0047-6374 J9 MECH AGEING DEV JI Mech. Ageing Dev. PD JAN PY 2010 VL 131 IS 1 BP 29 EP 37 DI 10.1016/j.mad.2009.11.003 PG 9 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 560ZU UT WOS:000274945300005 PM 19941883 ER PT J AU Xiang, M Fan, J Fan, J AF Xiang, Meng Fan, Janet Fan, Jie TI Association of Toll-Like Receptor Signaling and Reactive Oxygen Species: A Potential Therapeutic Target for Posttrauma Acute Lung Injury SO MEDIATORS OF INFLAMMATION LA English DT Review ID MULTIPLE ORGAN FAILURE; NF-KAPPA-B; RESPIRATORY-DISTRESS SYNDROME; NEUTROPHIL NADPH OXIDASE; MEDIATES HEPATIC-INJURY; GROUP BOX-1 PROTEIN; TLR2 UP-REGULATION; HEMORRHAGIC-SHOCK; INNATE IMMUNITY; NAD(P)H OXIDASE AB Acute lung injury (ALI) frequently occurs in traumatic patients and serves as an important component of systemic inflammatory response syndrome (SIRS). Hemorrhagic shock (HS) that results from major trauma promotes the development of SIRS and ALI by priming the innate immune system for an exaggerated inflammatory response. Recent studies have reported that the mechanism underlying the priming of pulmonary inflammation involves the complicated cross-talk between Toll-like receptors (TLRs) and interactions between neutrophils (PMNs) and alveolar macrophages (AM phi) as well as endothelial cells (ECs), in which reactive oxygen species (ROS) are the key mediator. This paper summarizes some novel mechanisms underlying HS-primed lung inflammation focusing on the role of TLRs and ROS, and therefore suggests a new therapeutic target for posttrauma ALI. C1 [Xiang, Meng; Fan, Jie] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15260 USA. [Xiang, Meng] Fudan Univ, Dept Pathophysiol, Shanghai 200032, Peoples R China. [Fan, Janet] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA. [Fan, Jie] VA Pittsburgh Healthcare Syst, Surg Res, Pittsburgh, PA 15240 USA. RP Fan, J (reprint author), Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15260 USA. EM fanj2@upmc.edu FU National Institutes of Health [R01-HL-079669, P50-GM-53789]; VA Merit Award FX This work was supported by the National Institutes of Health Grant R01-HL-079669, National Institutes of Health Center Grant P50-GM-53789, and a VA Merit Award. NR 81 TC 11 Z9 12 U1 0 U2 6 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 0962-9351 J9 MEDIAT INFLAMM JI Mediat. Inflamm. PY 2010 AR 916425 DI 10.1155/2010/916425 PG 8 WC Cell Biology; Immunology SC Cell Biology; Immunology GA 640ZI UT WOS:000281092500001 ER PT J AU Dickinson, KC Sharma, R Duckart, JP Corson, K Gerrity, MS Dobscha, SK AF Dickinson, Kathryn C. Sharma, Rajiv Duckart, Jonathan P. Corson, Kathryn Gerrity, Martha S. Dobscha, Steven K. TI VA Healthcare Costs of a Collaborative Intervention for Chronic Pain in Primary Care SO MEDICAL CARE LA English DT Article DE chronic pain; collaborative care; pain improvement; cost; primary care ID RANDOMIZED CONTROLLED-TRIAL; IMPROVING PRIMARY-CARE; MORRIS DISABILITY QUESTIONNAIRE; DECISION-SUPPORT-SYSTEM; LOW-BACK-PAIN; CHRONIC ILLNESS; PHYSICAL-THERAPY; PERSISTENT PAIN; OLDER PERSONS; DEPRESSION AB Background: Chronic pain is costly to individuals and the healthcare system, and is often undertreated. Collaborative care models show promise for improving treatment of patients with chronic pain. The objectives of this article are to report the incremental benefit and incremental health services costs of a collaborative intervention for chronic pain from a veterans affairs (VA) healthcare perspective. Methods: Data on VA treatment costs incurred by participants were obtained from the VA's Decision Support System for all utilization except certain intervention activities which were tracked in a separate database. Outcome data were from a cluster-randomized trial of a collaborative intervention for chronic pain among 401 primary care patients at a VA medical center. Intervention group participants received assessments and care management; stepped-care components were offered to patients requiring more specialized care. The main outcome measure was pain disability-free days (PDFDs), calculated from Roland-Morris Disability Questionnaire scores. Results: Participants in the intervention group experienced an average of 16 additional PDFDs over the 12-month follow-up window as compared with usual care participants; this came at an adjusted incremental cost of $364 per PDFD for a typical participant. Important predictors of costs were baseline medical comorbidities, depression severity, and prior year's treatment costs. Conclusions: This collaborative intervention resulted in more pain disability-free days and was more expensive than usual care. Further research is necessary to identify if the intervention is more cost-effective for some patient subgroups and to learn whether pain improvements and higher costs persist after the intervention has ended. C1 [Dickinson, Kathryn C.; Sharma, Rajiv; Duckart, Jonathan P.; Corson, Kathryn; Gerrity, Martha S.; Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR 97207 USA. [Sharma, Rajiv] Portland State Univ, Dept Econ, Portland, OR 97207 USA. [Corson, Kathryn; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Gerrity, Martha S.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Gerrity, Martha S.] Portland VA Med Ctr, Div Hosp & Specialty Med, Portland, OR 97207 USA. RP Dickinson, KC (reprint author), Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, POB 1034 P3DEP-PC, Portland, OR 97207 USA. EM kathryn.dickinson@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service Projects [PMI 03-195, REA 06-174] FX Supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service Projects PMI 03-195 and REA 06-174. NR 49 TC 10 Z9 10 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD JAN PY 2010 VL 48 IS 1 BP 38 EP 44 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 537YD UT WOS:000273149500007 PM 19952802 ER PT J AU Fung, CC Lagha, RR Henderson, P Gomez, AG AF Fung, Cha-Chi Lagha, Regina Richter Henderson, Paula Gomez, Arthur G. TI Working with interpreters: how student behavior affects quality of patient interaction when using interpreters SO MEDICAL EDUCATION ONLINE LA English DT Article DE cross-cultural communication barriers; physician-patient relations; patient-centered care; interpreter use; educational intervention; performance-based assessment AB Background: Despite the prevalence of medical interpreting in the clinical environment, few medical professionals receive training in best practices when using an interpreter. We designed and implemented an educational workshop on using interpreters as part of the cultural competency curriculum for second year medical students (MSIIs) at David Geffen School of Medicine at UCLA. The purpose of this study is twofold: first, to evaluate the effectiveness of the workshop and second, if deficiencies are found, to investigate whether the deficiencies affected the quality of the patient encounter when using an interpreter. Methods: A total of 152 MSIIs completed the 3-hour workshop and a 1-station objective-structured clinical examination, 8 weeks later to assess skills. Descriptive statistics and independent sample t-tests were used to assess workshop effectiveness. Results: Based on a passing score of 70%, 39.4% of the class failed. Two skills seemed particularly problematic: assuring confidentiality (missed by 50%) and positioning the interpreter (missed by 70%). While addressing confidentiality did not have a significant impact on standardized patient satisfaction, interpreter position did. Conclusion: Instructing the interpreter to sit behind the patient helps sustain eye contact between clinician and patient, while assuring confidentiality is a tenet of quality clinical encounters. Teaching students and faculty to emphasize both is warranted to improve cross-language clinical encounters. C1 [Fung, Cha-Chi; Lagha, Regina Richter; Henderson, Paula; Gomez, Arthur G.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Educ Dev & Res, Los Angeles, CA 90095 USA. [Lagha, Regina Richter] Univ Calif Los Angeles, Grad Sch Educ & Informat Studies, Los Angeles, CA 90095 USA. [Gomez, Arthur G.] West Los Angeles Healthcare Ctr, VA Greater Los Angeles, Los Angeles, CA USA. RP Fung, CC (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Educ Dev & Res, Box 957381, Los Angeles, CA 90095 USA. EM ccfung@mednet.ucla.edu NR 18 TC 1 Z9 1 U1 1 U2 2 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1087-2981 J9 MED EDUC ONLINE JI Med. Educ. Online PY 2010 VL 15 AR 5151 DI 10.3402/meo.v15i0.5151 PG 7 WC Education & Educational Research SC Education & Educational Research GA V28SG UT WOS:000208699900011 ER PT J AU Pena, A AF Pena, Adolfo TI The Dreyfus model of clinical problem-solving skills acquisition: a critical perspective SO MEDICAL EDUCATION ONLINE LA English DT Article DE clinical skills; Dreyfus' model; expertise; intuition; learning; medical education; novice to expert AB Context: The Dreyfus model describes how individuals progress through various levels in their acquisition of skills and subsumes ideas with regard to how individuals learn. Such a model is being accepted almost without debate from physicians to explain the 'acquisition' of clinical skills. Objectives: This paper reviews such a model, discusses several controversial points, clarifies what kind of knowledge the model is about, and examines its coherence in terms of problem-solving skills. Dreyfus' main idea that intuition is a major aspect of expertise is also discussed in some detail. Relevant scientific evidence from cognitive science, psychology, and neuroscience is reviewed to accomplish these aims. Conclusions: Although the Dreyfus model may partially explain the 'acquisition' of some skills, it is debatable if it can explain the acquisition of clinical skills. The complex nature of clinical problem-solving skills and the rich interplay between the implicit and explicit forms of knowledge must be taken into consideration when we want to explain 'acquisition' of clinical skills. The idea that experts work from intuition, not from reason, should be evaluated carefully. C1 [Pena, Adolfo] Birmingham VA Med Ctr, Birmingham, AL USA. [Pena, Adolfo] Univ Alabama Birmingham, Birmingham, AL USA. RP Pena, A (reprint author), VA Birmingham Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, 151 REAP,700 South 19th St, Birmingham, AL 35233 USA. EM adolfope@uab.edu NR 80 TC 6 Z9 6 U1 6 U2 15 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 1087-2981 J9 MED EDUC ONLINE JI Med. Educ. Online PY 2010 VL 15 AR 4846 DI 10.3402/meo.v15i0.4846 PG 11 WC Education & Educational Research SC Education & Educational Research GA V28SG UT WOS:000208699900004 ER PT J AU Kougias, P Weakley, SM Yao, QZ Lin, PH Chen, CY AF Kougias, Panagiotis Weakley, Sarah M. Yao, Qizhi Lin, Peter H. Chen, Changyi TI Arterial baroreceptors in the management of systemic hypertension SO MEDICAL SCIENCE MONITOR LA English DT Review DE baroreceptor; barereflex; hypertension; sinoaortic denervation ID SYMPATHETIC-NERVE ACTIVITY; LONG-TERM CONTROL; BLOOD-PRESSURE; BAROREFLEX SENSITIVITY; CAROTID-ENDARTERECTOMY; AORTIC BARORECEPTORS; CONSCIOUS DOGS; HEART-RATE; CARDIOVASCULAR REGULATION; ANGIOTENSIN HYPERTENSION AB Hypertension is a multifactorial disease associated with significant morbidity. Increased sympathetic nervous system activity has been noted as an important etiologic factor and is, in part, regulated by afferent input arising from arterial and cardiopulmonary baroreceptors, activation of which causes inhibition of sympathetic output. It was thought for many years that baroreceptors control only short-term blood pressure changes, a conclusion stemming from observations in sinoaortic denervation (SAD) animal models and the phenomenon of rapid baroreceptor resetting, also seen in animal models. Newer observations, however, indicate that SAD is rather imperfect and resetting is rarely complete. Recent studies reveal that baroreceptors control sympathetic output on a more long-term basis and participate in fluid volume regulation by the kidney, and thus have the potential to adjust blood pressure chronically. Importantly, these findings are consistent with studies and observations in humans. Meanwhile, a model of electrical stimulation of the carotid sinus has been developed and successfully tested in animals. Following these encouraging results human trials to evaluate the clinical application of electrical carotid sinus manipulation in the treatment of systemic hypertension have commenced, and results so far indicate that this represents an exciting potential tool in the clinician's armament against chronic arterial hypertension. C1 [Kougias, Panagiotis; Weakley, Sarah M.; Yao, Qizhi; Lin, Peter H.; Chen, Changyi] Baylor Coll Med, Michael E DeBakey Dept Surg, Mol Surg Res Ctr, Div Vasc Surg & Endovasc Therapy, Houston, TX 77030 USA. [Kougias, Panagiotis; Yao, Qizhi; Lin, Peter H.; Chen, Changyi] Michael E DeBakey Vet Affairs Med Ctr, Dept Surg, Houston, TX 77030 USA. RP Kougias, P (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Surg, 2002 Holcombe Blvd 112, Houston, TX 77030 USA. EM pkougias@bcm.edu FU Michael E. DeBakey Department of Surgery at the Baylor College of Medicine, Houston, TX, U.S.A.; National Institutes of Health, U.S.A. [T32 HL076345] FX This study was partially supported by the Michael E. DeBakey Department of Surgery at the Baylor College of Medicine, Houston, TX, U.S.A. and a grant (T32 HL076345) from the National Institutes of Health, U.S.A. NR 69 TC 14 Z9 15 U1 1 U2 7 PU INT SCIENTIFIC LITERATURE, INC PI ALBERTSON PA 1125 WILLIS AVE, ALBERTSON, NY 11507 USA SN 1234-1010 J9 MED SCI MONITOR JI Med. Sci. Monitor PY 2010 VL 16 IS 1 BP RA1 EP RA8 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 537NT UT WOS:000273120400023 PM 20037502 ER PT J AU Edson, RS Beckman, TJ West, CP Aronowitz, PB Badgett, RG Feldstein, DA Henderson, MC Kolars, JC McDonald, FS AF Edson, Randall S. Beckman, Thomas J. West, Colin P. Aronowitz, Paul B. Badgett, Robert G. Feldstein, David A. Henderson, Mark C. Kolars, Joseph C. McDonald, Furman S. TI A multi-institutional survey of internal medicine residents' learning habits SO MEDICAL TEACHER LA English DT Article ID KNOWLEDGE ACQUISITION; READING HABITS; HOUSE-STAFF AB Background: Resident physicians are expected to demonstrate medical knowledge. However, little is known about the residents' reading habits and learning preferences. Aim: To assess residents' reading habits and preferred educational resources. Methods: Residents at five internal medicine training programs were surveyed regarding their reading and learning habits and preferences. Results: The majority (77.7%) of residents reported reading less than 7 h a week. Most residents (81.4%) read in response to patient care encounters. The preferred educational format was electronic; 94.6% of residents cited UpToDate (R) as the most effective resource for knowledge acquisition, and 88.9% of residents reported that UpToDate (R) was their first choice for answering clinical questions. Conclusions: Residents spent little time reading and sought knowledge primarily from electronic resources. Most residents read in the context of patient care. Future research should focus on strategies for helping resident physicians learn in the electronic age. C1 [Edson, Randall S.; Beckman, Thomas J.; West, Colin P.; McDonald, Furman S.] Mayo Clin, Coll Med, Rochester, MN 55905 USA. [Aronowitz, Paul B.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Aronowitz, Paul B.] Calif Pacific Med Ctr, San Francisco, CA USA. [Badgett, Robert G.] Univ Texas San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Feldstein, David A.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Henderson, Mark C.] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA. [Kolars, Joseph C.] Univ Michigan, Ann Arbor, MI 48109 USA. RP Edson, RS (reprint author), Mayo Clin, Coll Med, 200 1st St SW, Rochester, MN 55905 USA. EM edson.randall@mayo.edu OI Badgett, Robert/0000-0003-2888-3303 NR 10 TC 18 Z9 18 U1 1 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0142-159X J9 MED TEACH JI Med. Teach. PY 2010 VL 32 IS 9 BP 773 EP 775 DI 10.3109/01421591003692698 PG 3 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 663NJ UT WOS:000282894300016 PM 20795809 ER PT J AU Huang, AJ Moore, EE Boyko, EJ Scholes, D Lin, F Vittinghoff, E Fihn, SD AF Huang, Alison J. Moore, Elya E. Boyko, Edward J. Scholes, Delia Lin, Feng Vittinghoff, Eric Fihn, Stephan D. TI Vaginal symptoms in postmenopausal women: self-reported severity, natural history, and risk factors SO MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY LA English DT Article DE Vaginal dryness; Menopause; Vaginal atrophy; Dyspareunia; Sexual dysfunction ID UROGENITAL ATROPHY; ESTROGEN; HEALTH; POPULATION; PREVALENCE; HORMONES; FLORA AB Objective: This study aimed to examine factors other than estrogen deficiency influencing the development and persistence of vaginal dryness, itching, and painful sexual intercourse after menopause. Methods: We analyzed data from a 2-year, population-based cohort of 1,0 17 postmenopausal women aged 5 5 to 75 years. Vaginal symptoms were assessed by interviewer-administered questionnaire, and vaginal swabs were performed to assess vaginal pH and microbial flora at baseline, 12 months, and 24 months. Generalized estimating equations were used to identify characteristics associated with symptoms. Results: Half of the women (n = 47 1) reported problematic vaginal dryness, a third (n = 3 16) reported itching, and 40% of sexually active women (n = 166) reported painful intercourse at baseline. Of women not taking estrogen, half of those reporting baseline symptoms were symptomatic after 24 months. Vaginal dryness was associated with Younger age (odds ratio [OR], 0.81; 95% CI, 0.69-0.94, per 5-y increase), nonwhite race (ie, African American, Hispanic, Asian or Pacific Islander, or American Indian [OR, 1.53; 95% CI, 1.04-2.27]), diabetes (OR, 1.5 1; 95% Cl, 1.07-2.12), lower 36-item Short-Form Health Survey physical functioning scores (OR, 0.90; 95% Cl, 0.85-0.97, per 10-point increase), lower body mass index (OR, 0.81; 95% Cl, 0.71-0.93, per 5 kg/m(2) increase), recent sexual activity (OR, 1.14; 95% CI, 1.08-1.21), and vaginal colonization with enterococci (OR, 1.25; 95% Cl, 1.04-1.51). Vaginal itching was also associated with lower physical functioning scores (OR, 0.86; 95% Cl, 0.80-0.92, per 10-point increase). Risk factors for painful intercourse included younger age (OR, 0.72; 95% CI, 0.56-0.93, per 5-y increase), diabetes (OR, 3.48; 95% Cl, 1.93-6.27), lower body mass index (OR, 0.76; 95% Cl, 0.61-0.95, per 5 kg/m(2) increase), and higher vaginal pH (OR, 1.10; 95% Cl, 1.00-1.21, per 0.5 units). Conclusions: Vaginal symptoms affect a large proportion of postmenopausal women, particularly those with diabetes and those with lower body mass index, but may resolve for up to half of women without estrogen therapy. C1 [Huang, Alison J.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Moore, Elya E.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia. [Boyko, Edward J.] Univ Washington, Dept Med, Seattle, WA USA. [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle ERIC, Seattle, WA USA. [Scholes, Delia] Grp Hlth Cooperat Puget Sound, Grp Hlth Ctr Hlth Studies, Seattle, WA 98121 USA. [Lin, Feng; Vittinghoff, Eric] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Fihn, Stephan D.] Dept Vet Affairs, Washington, DC USA. RP Huang, AJ (reprint author), 1635 Divisadero St,Suite 600, San Francisco, CA 94115 USA. EM ahuang@ucsfmed.org OI Boyko, Edward/0000-0002-3695-192X FU National Institutes of Health (NIH) [T32AI07140, RO1 DK43134]; National Center for Research Resources, a component of the NIH [RR024130] FX The Prospective Evaluation of Postmenopausal Cystitis study was Supported by National Institutes of Health (NIH) grants T32AI07140 and RO1 DK43134 and the resources and facilities at the Veterans Affairs Puget Sound Health Care System, Seattle, WA. Dr. Huang is supported by KL2 Grant RR024130 from the National Center for Research Resources, a component of the NIH and NIH Clinical and Translational Science Award for Medical Research. NR 23 TC 15 Z9 16 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1072-3714 EI 1530-0374 J9 MENOPAUSE JI Menopause-J. N. Am. Menopause Soc. PD JAN-FEB PY 2010 VL 17 IS 1 BP 121 EP 126 DI 10.1097/gme.0b013e3181acb9ed PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 542TC UT WOS:000273517400020 PM 19574936 ER PT B AU Murray, SS Brochmann, EJ Behnam, K Harker, JO AF Murray, Samuel S. Brochmann, Elsa J. Behnam, Keyvan Harker, Judith O. BE Maguire, T Novik, E TI A Statistical Method to Reduce In Vivo Product Testing Using Related In Vitro Tests and ROC Analysis SO METHODS IN BIOENGINEERING: ALTERNATIVE TECHNOLOGIES TO ANIMAL TESTING SE Artech House Methods in Bioengineering Series LA English DT Article; Book Chapter DE alternatives to animal testing; cut-point analysis; ROC analysis AB Many biological materials, therapeutics, and reagents are tested in animals. It seems self-evident that an in vivo test would most reliably replicate the conditions of the relevant clinical or biological situation. However, in many cases precise and reproducible in vitro tests also exist. Quality control personnel and investigators rely excessively on in vivo gold-standard tests because of a sense of uncertainty as to how reliably the secondary test functions as a replacement for the primary in vivo test. In this chapter we present a statistical method in which the results of the secondary test are calibrated against the results of the primary test in such a way as to allow the investigator to employ the secondary test in the context of very precisely defined and controlled levels of uncertainty. This method will allow for a substantial reduction in the use of animal subjects. C1 [Murray, Samuel S.] Univ Calif Los Angeles, Interdept Program Biomed Engn, Los Angeles, CA USA. [Murray, Samuel S.; Brochmann, Elsa J.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Murray, Samuel S.; Brochmann, Elsa J.] Univ Calif Los Angeles, VA Greater Los Angeles, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90024 USA. [Behnam, Keyvan; Harker, Judith O.] VA Greater Los Angeles, Res Serv, Sepulveda, CA 91343 USA. [Behnam, Keyvan] Lanx Inc, Broomfield, CO USA. RP Murray, SS (reprint author), VA Med Ctr, VA Greater Los Angeles, Geriatr Res Educ & Clin Ctr, GRECC 11-E,,16111 Plummer St, Sepulveda, CA 91343 USA. EM Samuel.Murray@va.gov NR 7 TC 0 Z9 0 U1 0 U2 0 PU ARTECH HOUSE PI NORWOOD PA 685 CANTON ST, NORWOOD, MA 02062 USA BN 978-1-60807-011-4 J9 ARTECH HSE METH BIOE JI Art. Hse. Meth. Bioengr. Ser. PY 2010 BP 147 EP 158 PG 12 WC Engineering, Biomedical SC Engineering GA BPH05 UT WOS:000278836700008 ER PT S AU Perez, VI Pierce, A de Waal, EM Ward, WF Bokov, A Chaudhuri, A Richardson, A AF Perez, Viviana I. Pierce, Anson de Waal, Eric M. Ward, Walter F. Bokov, Alex Chaudhuri, Asish Richardson, Arlan BE Cadenas, E Packer, L TI DETECTION AND QUANTIFICATION OF PROTEIN DISULFIDES IN BIOLOGICAL TISSUES: A FLUORESCENCE-BASED PROTEOMIC APPROACH SO METHODS IN ENZYMOLOGY, VOL 473: THIOL REDOX TRANSITIONS IN CELL SIGNALING, PT A: CHEMISTRY AND BIOCHEMISTRY OF LOW MOLECULAR WEIGHT AND PROTEIN THIOLS SE Methods in Enzymology LA English DT Review; Book Chapter ID OXIDATIVE STRESS; METHIONINE OXIDATION; TOXICITY; DISEASE; MUSCLE; DAMAGE AB While most of the amino acids in proteins are potential targets for oxidation, the thiol group in cysteine is one of the most reactive amino acid side chains. The thiol group can be oxidized to several states, including the disulfide bond. Despite the known sensitivity of cysteine to oxidation and the physiological importance of the thiol group to protein structure and function, little information is available on the oxidative modification of cysteine residues in proteins because of the lack of reproducible and sensitive assays to measure cysteine oxidation in the proteome. We have developed a fluorescence-based assay that allows one to quantify both the global level of protein disulfides in the cellular proteome as well as the disulfide content of individual proteins. This fluorescence-based assay is able to detect an increase in global protein disulfide levels after oxidative stress in vitro or in vivo. Using this assay, we show that the global protein disulfide levels increase significantly with age in liver cytosolic proteins, and we identified 11 proteins that show a more than twofold increase in disulfide content with age. Thus, the fluorescence-based assay we have developed allows one to quantify changes in the oxidation of cysteine residues to disulfides in the proteome of a cell or tissue. C1 [Perez, Viviana I.; Pierce, Anson; Bokov, Alex; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Ward, Walter F.; Chaudhuri, Asish] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA. [de Waal, Eric M.] Univ Texas San Antonio, Dept Biol, San Antonio, TX USA. [Perez, Viviana I.; Pierce, Anson; Ward, Walter F.; Chaudhuri, Asish; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA. [Chaudhuri, Asish] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Bokov, Alex] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Pierce, Anson; Chaudhuri, Asish; Richardson, Arlan] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. RP Perez, VI (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. RI Pierce, Anson/D-1079-2012 OI Pierce, Anson/0000-0002-1383-0180 FU NIA NIH HHS [R01 AG025362]; PHS HHS [R37HE26557] NR 30 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0076-6879 BN 978-0-12-381345-9 J9 METHOD ENZYMOL JI Methods Enzymol. PY 2010 VL 473 BP 161 EP 177 DI 10.1016/S0076-6879(10)73008-1 PG 17 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BPK52 UT WOS:000279058700008 PM 20513477 ER PT B AU Percival, SL Cooper, RA Lipsky, BA AF Percival, Steven L. Cooper, Rose A. Lipsky, Benjamin A. BE Percival, S Cutting, K TI Antimicrobial Interventions for Wounds SO MICROBIOLOGY OF WOUNDS LA English DT Article; Book Chapter ID PSEUDOMONAS-AERUGINOSA BIOFILMS; RESISTANT STAPHYLOCOCCUS-AUREUS; RANDOMIZED CONTROLLED-TRIAL; GRAM-NEGATIVE BACTERIA; CATHETER LOCK SOLUTION; DIABETIC FOOT ULCERS; VENOUS LEG ULCERS; IN-VITRO ACTIVITY; HYDROGEN-PEROXIDE; POLYHEXAMETHYLENE BIGUANIDE C1 [Percival, Steven L.] W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr N, Morgantown, WV 26506 USA. [Percival, Steven L.] Adv Med Solut, Winsford, Cheshire, England. [Cooper, Rose A.] Cardiff Inst Higher Educ, Cardiff, S Glam, Wales. [Lipsky, Benjamin A.] Univ Washington, Sch Med, Dept Med, Vet Affairs Puget Sound Hlth Care Syst,Div Gen In, Seattle, WA 98195 USA. RP Percival, SL (reprint author), W Virginia Univ, Sch Med, Robert C Byrd Hlth Sci Ctr N, Morgantown, WV 26506 USA. NR 206 TC 4 Z9 4 U1 0 U2 1 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4200-7994-4; 978-1-4200-7993-7 PY 2010 BP 293 EP 327 DI 10.1201/9781420079944-c11 D2 10.1201/9781420079944 PG 35 WC Medicine, General & Internal; Microbiology SC General & Internal Medicine; Microbiology GA BQR89 UT WOS:000281681000012 ER PT B AU Naseri, A Chang, DF AF Naseri, Ayman Chang, David F. BE Alio, JL Fine, IH TI Endophthalmitis Prevention SO MINIMIZING INCISIONS AND MAXIMIZING OUTCOMES IN CATARACT SURGERY LA English DT Article; Book Chapter ID CORNEAL CATARACT INCISIONS; PROPHYLACTIC INTRACAMERAL CEFUROXIME; 0.5-PERCENT OPHTHALMIC SOLUTION; ACUTE-ONSET ENDOPHTHALMITIS; OCULAR SURFACE FLUID; POSTOPERATIVE ENDOPHTHALMITIS; AQUEOUS-HUMOR; MOXIFLOXACIN 0.5-PERCENT; GATIFLOXACIN 0.3-PERCENT; SURGERY PATIENTS C1 [Naseri, Ayman] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA. [Naseri, Ayman] San Francisco VA Med Ctr, San Francisco, CA USA. RP Naseri, A (reprint author), Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA. EM Ayman.Naseri@va.gov NR 45 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-3-642-02861-8 PY 2010 BP 156 EP 162 DI 10.1007/978-3-642-02862-5_23 PG 7 WC Ophthalmology SC Ophthalmology GA BMW13 UT WOS:000273701300023 ER PT J AU Troxell, ML Levine, J Beadling, C Warrick, A Dunlap, J Presnell, A Patterson, J Shukla, A Olson, NR Heinrich, MC Corless, CL AF Troxell, Megan L. Levine, Judith Beadling, Carol Warrick, Andrea Dunlap, Jennifer Presnell, Ajia Patterson, Janice Shukla, Arielle Olson, Neal R. Heinrich, Michael C. Corless, Christopher L. TI High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast SO MODERN PATHOLOGY LA English DT Article DE phosphoinositol-3-kinase (PIK3CA); AKT1; breast; papilloma; papillary carcinoma ID COMPARATIVE GENOMIC HYBRIDIZATION; INTRADUCTAL PROLIFERATIVE LESIONS; POLYMERASE-CHAIN-REACTION; IN-SITU; DUCTAL HYPERPLASIA; CLONAL ANALYSIS; HIGH-FREQUENCY; HUMAN CANCERS; PTEN LOSS; CARCINOMA AB Papillary lesions of the breast have an uncertain relationship to the histogenesis of breast carcinoma, and are thus diagnostically and managerially challenging. Molecular genetic studies have provided evidence that ductal carcinoma in situ and even atypical ductal hyperplasia are precursors of invasive carcinoma. However, papillary lesions have been seldom studied. We screened papillary breast neoplasms for activating point mutations in PIK3CA, AKT1, and RAS protein-family members, which are common in invasive ductal carcinomas. DNA extracts were prepared from sections of 89 papillary lesions, including 61 benign papillomas ( 28 without significant hyperplasia; 33 with moderate to florid hyperplasia), 11 papillomas with atypical ductal hyperplasia, 7 papillomas with carcinoma in situ, and 10 papillary carcinomas. Extracts were screened for PIK3CA and AKT1 mutations using mass spectrometry; cases that were negative were further screened for mutations in AKT2, BRAF, CDK, EGFR, ERBB2, KRAS, NRAS, and HRAS. Mutations were confirmed by sequencing or HPLC assay. A total of 55 of 89 papillary neoplasms harbored mutations (62%), predominantly in AKT1 (E17K, 27 cases) and PIK3CA (exon 20 > exon 9, 27 cases). Papillomas had more mutations in AKT1 (54%) than in PIK3CA (21%), whereas papillomas with hyperplasia had more PIK3CA (42%) than AKT1 (15%) mutations, as did papillomas with atypical ductal hyperplasia ( PIK3CA 45%, AKT1 27%, and NRAS 9%). Among seven papillomas with carcinoma in situ, three had AKT1 mutations. The 10 papillary carcinomas showed an overall lower frequency of mutations, including 1 with an AKT1 mutation ( in a tumor arising from a papilloma), 1 with an NRAS gene mutation (Q61H), and 2 with PIK3CA mutations ( 1 overlapping with the NRAS Q61H). These findings indicate that approximately two-thirds of papillomas are driven by mutations in the PI3CA/AKT pathway. Some papillary carcinomas may arise from these lesions, but others may have different molecular origins. Modern Pathology ( 2010) 23, 27-37; doi: 10.1038/modpathol.2009.142; published online 6 November 2009 C1 [Troxell, Megan L.] Oregon Hlth & Sci Univ, Dept Pathol, Knight Canc Inst, Portland, OR 97239 USA. [Olson, Neal R.] Kaiser Permanente NW, Dept Pathol, Portland, OR USA. [Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR USA. [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97239 USA. RP Troxell, ML (reprint author), Oregon Hlth & Sci Univ, Dept Pathol, Knight Canc Inst, 3181 SW Sam Jackson Pk Rd,L471, Portland, OR 97239 USA. EM troxellm@ohsu.edu OI Patterson, Janice/0000-0002-8969-2933 FU Department of Veterans Affairs (MCH); Oregon Health & Science University Medical Research Foundation FX We acknowledge expert technical assistance of Carolyn Gendron, Emily Justusson, Dylan Nelson, Cara Poage, Linh Matsumura, Jennifer Podolak, and administrative assistance of Sally Ison and Lynne Rowell. This work was supported in part by a VA Merit Review Grant from the Department of Veterans Affairs (MCH) and by a grant from the Oregon Health & Science University Medical Research Foundation. NR 51 TC 45 Z9 47 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD JAN PY 2010 VL 23 IS 1 BP 27 EP 37 DI 10.1038/modpathol.2009.142 PG 11 WC Pathology SC Pathology GA 539IV UT WOS:000273248500003 PM 19898424 ER PT S AU Qin, WP Bauman, WA Cardozo, C AF Qin, Weiping Bauman, William A. Cardozo, Christopher BE Mechanick, JI Sun, L Zaidi, M TI Bone and muscle loss after spinal cord injury: organ interactions SO MOLECULAR AND INTEGRATIVE PHYSIOLOGY OF THE MUSCULOSKELETAL SYSTEM SE Annals of the New York Academy of Sciences LA English DT Article; Book Chapter DE spinal cord injury; bone loss; muscle atrophy; body composition; testosterone; estrogen; insulin-like growth factor 1; methylprednisolone ID GROWTH-FACTOR-I; RANDOMIZED CONTROLLED-TRIAL; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; QUANTITATIVE COMPUTED-TOMOGRAPHY; VASOACTIVE-INTESTINAL-PEPTIDE; FOXO TRANSCRIPTION FACTORS; SKELETAL-MUSCLE; MINERAL DENSITY; PARAPLEGIC PATIENTS; GENE-EXPRESSION AB Spinal cord injury (SCI) results in paralysis and marked loss of skeletal muscle and bone below the level of injury. Modest muscle activity prevents atrophy, whereas much larger and as yet poorly defined bone loading seems necessary to prevent bone loss. Once established, bone loss may be irreversible. SCI is associated with reductions in growth hormone, IGF-1, and testosterone, deficiencies likely to exacerbate further loss of muscle and bone. Reduced muscle mass and inactivity are assumed to be contributors to the high prevalence of insulin resistance and diabetes in this population. Alterations in muscle gene expression after SCI share common features with other muscle loss states, but even so, show distinct profiles, possibly reflecting influences of neuromuscular activity due to spasticity. Changes in bone cells and markers after SCI have similarities with other conditions of unloading, although after SCI these changes are much more dramatic, perhaps reflecting the much greater magnitude of unloading. Adiposity and marrow fat are increased after SCI with intriguing, though poorly understood, implications for the function of skeletal muscle and bone cells. C1 [Qin, Weiping; Bauman, William A.; Cardozo, Christopher] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA. [Qin, Weiping; Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. RP Qin, WP (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Weiping.qin@mssm.edu NR 211 TC 54 Z9 55 U1 0 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA SN 0077-8923 BN 978-1-57331-831-0 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1211 BP 66 EP 84 DI 10.1111/j.1749-6632.2010.05806.x PG 19 WC Endocrinology & Metabolism; Multidisciplinary Sciences; Physiology SC Endocrinology & Metabolism; Science & Technology - Other Topics; Physiology GA BTO14 UT WOS:000287463400007 PM 21062296 ER PT J AU Borinstein, SC Conerly, M Dzieciatkowski, S Biswas, S Washington, MK Trobridge, P Henikoff, S Grady, WM AF Borinstein, Scott C. Conerly, Melissa Dzieciatkowski, Slavomir Biswas, Swati Washington, M. Kay Trobridge, Patty Henikoff, Steve Grady, William M. TI Aberrant DNA Methylation Occurs in Colon Neoplasms Arising in the Azoxymethane Colon Cancer Model SO MOLECULAR CARCINOGENESIS LA English DT Article DE DNA methylation; azoxymethane; colorectal cancer; epigenetics ID CPG ISLAND METHYLATION; FACTOR-BETA RECEPTOR; DE-NOVO METHYLATION; PROMOTER HYPERMETHYLATION; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; MOUSE MODELS; CELL LINES; INTESTINAL CANCER; PROSTATE-CANCER AB Mouse models of intestinal tumors have advanced our understanding of the role of gene mutations in colorectal malignancy. However, the utility of these systems for studying the role of epigenetic alterations in intestinal neoplasms remains to be defined. Consequently, we assessed the role of aberrant DNA methylation in the azoxymethane (AOM) rodent model of colon cancer. AOM induced tumors display global DNA hypomethylation, which is similar to human colorectal cancer. We next assessed the methylation status of a panel of candidate genes previously shown to be aberrantly methylated in human cancer or in mouse models of malignant neoplasms. This analysis revealed different patterns of DNA methylation that were gene specific. Zik1 and Gja9 demonstrated cancer-specific aberrant DNA methylation, whereas, Cdkn2a/p16, lgfbp3, Mgmt, 04, and Cxcr4 were methylated in both the AOM tumors and normal colon mucosa. No aberrant methylation of Dapk1 or Mlt1 was detected in the neoplasms, but normal colon mucosa samples displayed methylation of these genes. Finally, p19(Arf) Tslc1, Hltf, and Mlh1 were unmethylated in both the AOM tumors and normal colon mucosa. Thus, aberrant DNA methylation does occur in AOM tumors, although the frequency of aberrantly methylated genes appears to be less common than in human colorectal cancer. Additional studies are necessary to further characterize the patterns of aberrantly methylated genes in AOM tumors. (C) 2009 Wiley-Liss, Inc. C1 [Borinstein, Scott C.; Dzieciatkowski, Slavomir; Trobridge, Patty; Grady, William M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Borinstein, Scott C.] Seattle Childrens Hosp, Seattle, WA USA. [Borinstein, Scott C.] Univ Washington, Dept Pediat, Div Pediat Hematol Oncol, Seattle, WA 98195 USA. [Conerly, Melissa; Henikoff, Steve] Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA. [Biswas, Swati; Washington, M. Kay] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Grady, William M.] Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA USA. [Grady, William M.] VA Puget Sound Hlth Care Syst, R&D Serv, Seattle, WA USA. RP Grady, WM (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D4-100,POB 19024, Seattle, WA 98109 USA. FU Fred Hutchinson Cancer Research Center; [2T32CA009351]; [P30 CA015704] FX S.C.B. was supported by pediatric hematology/ oncology training grant 2T32CA009351. These studies were also supported by pilot project funding from P30 CA015704 (WMG). We also wish to acknowledge Support from the Experimental Histopathology Core and Animal Care Core at the Fred Hutchinson Cancer Research Center and the Mouse Pathology Core Facility at Vanderbilt University Medical Center) for their technical assistance for preparing tissue samples for histological analysis. NR 74 TC 31 Z9 34 U1 1 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0899-1987 J9 MOL CARCINOGEN JI Mol. Carcinog. PD JAN PY 2010 VL 49 IS 1 BP 94 EP 103 DI 10.1002/mc.20581 PG 10 WC Biochemistry & Molecular Biology; Oncology SC Biochemistry & Molecular Biology; Oncology GA 540GO UT WOS:000273319600010 PM 19777566 ER PT J AU Xiang, M Fan, J AF Xiang, Meng Fan, Jie TI Pattern Recognition Receptor-Dependent Mechanisms of Acute Lung Injury SO MOLECULAR MEDICINE LA English DT Review ID TOLL-LIKE RECEPTORS; RESPIRATORY-DISTRESS-SYNDROME; NF-KAPPA-B; INNATE IMMUNE-RESPONSES; AIRWAY EPITHELIAL-CELLS; MULTIPLE ORGAN FAILURE; BACTERIAL MURAMYL DIPEPTIDE; AORTIC ENDOTHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; MOBILITY GROUP BOX-1 AB Acute lung injury (ALI) that clinically manifests as acute respiratory distress syndrome is caused by an uncontrolled systemic inflammatory response resulting from clinical events including sepsis, major surgery and trauma. Innate immunity activation plays a central role in the development of ALI. Innate immunity is activated through families of related pattern recognition receptors (PRRs), which recognize conserved microbial motifs or pathogen-associated molecular patterns (PAMPs). Toll-like receptors were the first major family of PRRs discovered in mammals. Recently, NACHT-leucine-rich repeat (LRR) receptors and retinoic acid-inducible gene-like receptors have been added to the list. It is now understood that in addition to recognizing infectious stimuli, both Toll-like receptors and NACHT-LRR receptors can also respond to endogenous molecules released in response to stress, trauma and cell damage. These molecules have been termed damage-associated molecular patterns (DAMPS). It has been clinically observed for a long time that infectious and noninfectious insults initiate inflammation, so confirmation of overlapping receptor-signal pathways of activation between PAMPs and DAMPS is no surprise. This review provides an overview of the PRR-dependent mechanisms of ALI and clinical implication. Modification of PRR pathways is likely to be a logical therapeutic target for ALI/acute respiratory distress syndrome. (C) 2010 The Feinstein Institute for Medical Research, www.feinsteininstitute.org Online address: http://www.molmed.org del: 10.2119/molmed.2009.00097 C1 [Xiang, Meng; Fan, Jie] Univ Pittsburgh & Surg Res, VA Pittsburgh Healthcare Syst, Sch Med, Dept Surg, Pittsburgh, PA 15240 USA. RP Fan, J (reprint author), Univ Pittsburgh & Surg Res, VA Pittsburgh Healthcare Syst, Sch Med, Dept Surg, Pittsburgh, PA 15240 USA. EM jif7@pitt.edu FU National Institutes of Health [R01-HL-079669]; National Institutes of Health Center [P50-GM-53789]; VA Merit Award FX This work was supported by the National Institutes of Health Grant R01-HL-079669, National Institutes of Health Center Grant P50-GM-53789, and a VA Merit Award. NR 173 TC 35 Z9 40 U1 1 U2 4 PU FEINSTEIN INST MED RES PI MANHASSET PA 350 COMMUNITY DR, MANHASSET, NY 11030 USA SN 1076-1551 J9 MOL MED JI Mol. Med. PD JAN-FEB PY 2010 VL 16 IS 1-2 BP 69 EP 82 DI 10.2119/molmed.2009.00097 PG 14 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 575CY UT WOS:000276044100008 PM 19949486 ER PT J AU Neugroschl, J Sano, M AF Neugroschl, Judith Sano, Mary TI Current Treatment and Recent Clinical Research in Alzheimer's Disease SO MOUNT SINAI JOURNAL OF MEDICINE LA English DT Review DE Alzheimer's disease; amyloid; antioxidant; Dimebon; immunotherapy; receptor for advanced glycation end products; research; secretase; tau; treatment ID RANDOMIZED CONTROLLED-TRIAL; NERVE GROWTH-FACTOR; ESTROGEN REPLACEMENT THERAPY; MILD COGNITIVE IMPAIRMENT; PLACEBO-CONTROLLED TRIAL; AMYLOID PRECURSOR PROTEIN; TOTAL HOMOCYSTEINE LEVELS; MRC/BHF HEART PROTECTION; HEALTH INITIATIVE MEMORY; HIGH-RISK INDIVIDUALS AB The transition from either epidemiological observation or the bench to rigorously tested clinical trials in patients with Alzheimer's disease is clinical in understanding which treatments are beneficial to patients. The amyloid hypothesis has undergone scrutiny recently, as many trials aimed at reducing and plaque have been completed or are in the testing phase. Examples include modulation of the secretases involved in beta amyloid formation, anti-aggregation agents, and immunotherapeutic trials. Other therapies targeting hyperphosphorylated tau and novel targets such as enhancement mitochondrial function, serotonin receptors, receptor for advanced glycation end products, and nerve growth factor, as well as other strategies, are discussed. A brief review of the current Food and Drug Administration-approved treatments is included. Mt Sinai J Med 77:3-16, 2010. (C) 2010 Mount Sinai School of Medicine C1 [Neugroschl, Judith; Sano, Mary] Mt Sinai Sch Med, New York, NY 10029 USA. [Sano, Mary] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Neugroschl, J (reprint author), Mt Sinai Sch Med, New York, NY 10029 USA. EM judith.neugroschl@mssm.edu FU [AG005138] FX This work was supported by grant AG005138. NR 127 TC 36 Z9 43 U1 0 U2 7 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0027-2507 J9 MT SINAI J MED JI Mt. Sinai J. Med. PD JAN-FEB PY 2010 VL 77 IS 1 SI SI BP 3 EP 16 DI 10.1002/msj.20165 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA 553LF UT WOS:000274367500002 PM 20101716 ER PT J AU Elder, GA Sosa, MAG De Gasperi, R AF Elder, Gregory A. Sosa, Miguel A. Gama De Gasperi, Rita TI Transgenic Mouse Models of Alzheimer's Disease SO MOUNT SINAI JOURNAL OF MEDICINE LA English DT Review DE Alzheimer's disease; amyloid precursor protein; animal model; presenilins; transgenic mice ID AMYLOID-PRECURSOR-PROTEIN; A-BETA-DEPOSITION; KNOCK-IN MICE; GENE-TARGETED MICE; PLAQUE-FORMATION; NEURONAL LOSS; MUTANT PRESENILIN-1; SYNAPTIC PLASTICITY; HIPPOCAMPAL-NEURONS; COGNITIVE DEFICITS AB Alzheimer's disease is the most common cause of senile dementia in the United States and Europe. At present, there is no effective treatment. Given the disease's prevalence and poor prognosis, the development of animal models has been a high research priority. Transgenic modeling has been pursued oil the basis of the amyloid hypothesis and has taken advantage Of mutations in the amyloid precursor protein and the presenilins that cause familial forms of Alzheimer's disease. Modeling has been most aggressively pursued in mice, for which the techniques of genetic modification are well developed Transgenic mouse models now exist that mimic a range of Alzheimer's disease-related p pathologies. Although none of the models fully replicates the human disease, the models have contributed significant insights into the pathophysiology of beta-amyloid toxicity, particularly with respect to the effects of: different beta-amyloid species and the possible pathogenic role of beta-amyloid oligomers. They have also been widely used in the preclinical testing of potential therapeutic modalities and have played a pivotal role in the development of immunotherapies for Alzheimer's disease that are currently ill clinical trials. These models Will, without a doubt, continue to Play central roles in preclinical testing and be used as tools for developing insights into the biological basis of Alzheimer's disease. Mt Sinai J Med 77:69-81, 2010. (C) 2010 Mount Sinai School of Medicine C1 [Elder, Gregory A.] Vet Affairs Med Ctr, James J Peters Dept, Neurol Serv, Bronx, NY USA. [Sosa, Miguel A. Gama; De Gasperi, Rita] Vet Affairs Med Ctr, James J Peters Dept, Res & Dev Serv, Bronx, NY USA. [Elder, Gregory A.; Sosa, Miguel A. Gama; De Gasperi, Rita] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Elder, Gregory A.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA. RP Elder, GA (reprint author), Vet Affairs Med Ctr, James J Peters Dept, Neurol Serv, Bronx, NY USA. EM gregory.elder@mssm.edu FU National Institute on Aging [AG20139, AG029361, AG02219, AG05138]; Alzheimer's Association [IIRG-07-57318]; Department of Veterans Affairs [1101BX000342] FX Work conducted in the authors' laboratory has been supported by grants from the National Institute on Aging (AG20139, AG029361, AG02219, and AG05138), the Alzheimer's Association (IIRG-07-57318) and a Merit Award from the Department of Veterans Affairs (1101BX000342). NR 103 TC 66 Z9 69 U1 6 U2 40 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0027-2507 J9 MT SINAI J MED JI Mt. Sinai J. Med. PD JAN-FEB PY 2010 VL 77 IS 1 SI SI BP 69 EP 81 DI 10.1002/msj.20159 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 553LF UT WOS:000274367500008 PM 20101721 ER PT B AU Silbermann, R Roodman, GD AF Silbermann, Rebecca Roodman, G. David BE Roodman, GD TI Clinical Presentation of Myeloma Bone Disease SO MYELOMA BONE DISEASE SE Current Clinical Oncology Series LA English DT Article; Book Chapter DE Multiple myeloma; Myeloma bone disease; Pathologic fracture; Hypercalcemia ID MULTIPLE-MYELOMA; STAGING SYSTEM; PATHOGENESIS; SURVIVAL; OSTEOBLASTS; ACTIVATION; BORTEZOMIB; MARKERS AB Bone disease in multiple myeloma is characterized by lytic lesions that are frequently associated with fracture, hypercalcemia, and severe pain. Bone pain is the most frequent presenting symptom for patients with multiple myeloma. It is estimated that approximately 60% of patients have bone pain at the time of myeloma diagnosis and 90% of patients develop bone lesions during their disease course. In addition to lytic lesions, patients frequently develop diffuse osteopenia, pathologic fractures, and compression fractures of the spine. Bone disease significantly impacts patient morbidity, performance status, and survival. While there is an association between the number of lytic bone lesions in an individual and their disease burden, an individual's degree of bone disease does not appear to have significant utility in predicting outcomes. C1 [Roodman, G. David] Univ Pittsburgh, Med Ctr, VA Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Pittsburgh, PA 15240 USA. RP Roodman, GD (reprint author), Univ Pittsburgh, Med Ctr, VA Pittsburgh Healthcare Syst, Dept Med Hematol Oncol, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu; roodmangd@upmc.edu NR 42 TC 4 Z9 4 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-60761-553-8 J9 CURR CLIN ONCOL PY 2010 BP 1 EP 13 DI 10.1007/978-1-60761-554-5_1 D2 10.1007/978-1-60761-554-5 PG 13 WC Oncology SC Oncology GA BOX84 UT WOS:000277978900001 ER PT J AU Ford, JM Roach, BJ Mathalon, DH AF Ford, Judith M. Roach, Brian J. Mathalon, Daniel H. TI Assessing corollary discharge in humans using noninvasive neurophysiological methods SO NATURE PROTOCOLS LA English DT Article ID HUMAN AUDITORY-CORTEX; CORTICAL RESPONSIVENESS; INDUCED SUPPRESSION; SPEECH PRODUCTION; SCHIZOPHRENIA; DYSFUNCTION; RESPONSES; SYMPTOMS; HALLUCINATIONS; STIMULATION AB In this paper, we present a vocal production protocol for studying the neurophysiological action of the corollary discharge, a mechanism that allows animals to ignore sensations resulting from their own actions, and tag them as 'self'. electroencephalograms are recorded while subjects say 'ah' about 100 times with minimal throat, jaw and tongue movements (talk condition). this sequence of sounds is recorded and played back during the listen condition. event-related potentials are synchronized to the onset of speech sounds during the talk and listen conditions. neural responses from the auditory cortex to the spoken sound as it is being spoken during the talk condition are compared with neural responses to the same sounds when played back during the listen condition. the successful action of the corollary discharge is seen when the response of the auditory cortex is suppressed during the talk compared with the listen condition. the protocol takes about 5 min to complete. C1 [Ford, Judith M.; Roach, Brian J.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Ford, JM (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. EM Judith.ford@ucsf.edu OI Roach, Brian/0000-0002-3264-1465; Mathalon, Daniel/0000-0001-6090-4974 FU VA (Merit Review); National Institute of Mental Health [MH40052, MH 58262, MH067967]; National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD); VA Research Service FX We thank S. Guillory for programming the Matlab task. This work was supported by the VA Research Service and grants from the VA (Merit Review), the National Institute of Mental Health (MH40052, MH 58262, MH067967) and the National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD). NR 44 TC 18 Z9 18 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1754-2189 J9 NAT PROTOC JI Nat. Protoc. PY 2010 VL 5 IS 6 BP 1160 EP 1168 DI 10.1038/nprot.2010.67 PG 9 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 605NQ UT WOS:000278354700018 PM 20539291 ER PT J AU Utzschneider, KM Kowdley, KV AF Utzschneider, Kristina M. Kowdley, Kris V. TI Hereditary hemochromatosis and diabetes mellitus: implications for clinical practice SO NATURE REVIEWS ENDOCRINOLOGY LA English DT Review ID INSULIN SECRETORY CAPACITY; HFE GENE-MUTATIONS; LONG-TERM SURVIVAL; IRON-OVERLOAD; JUVENILE HEMOCHROMATOSIS; GLUCOSE-TOLERANCE; THALASSEMIA MAJOR; BETA-THALASSEMIA; HIGH PREVALENCE; POPULATION AB Hereditary hemochromatosis (HH) is a genetic condition that can lead to unregulated absorption of iron from the gut with resultant iron overload. The most common form of HH is caused by mutations in the HFE gene, with most cases of HH presenting in patients who are homozygous for the Cys282Tyr mutation. The prevalence of HFE gene mutations in persons of Northern European ancestry is fairly high (0.3-0.7% homozygous and 9-14% heterozygous for the Cys282Tyr mutation), but the penetrance of the disease is considered fairly low and is quite variable. While routine screening of the general population is not recommended, a targeted approach to screening in symptomatic patients and in those with a family member with iron overload is warranted. Untreated, iron overload can lead to considerable morbidity including liver cirrhosis, arthritis and diabetes mellitus, and increased mortality. The pathophysiology of diabetes mellitus in HH is thought to be due primarily to defects in the early insulin response to glucose. An Hfe(-/-) mouse model of HH has demonstrated defects in beta-cell function and beta-cell apoptosis that may be mediated by increased oxidative stress. Fortunately, these defects seem to be reversible if phlebotomy treatment is initiated before the development of cirrhosis or diabetes mellitus in patients. Further research into the long-term effects of treatment on prevention of diabetes mellitus in HH is needed. C1 [Utzschneider, Kristina M.] VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. [Kowdley, Kris V.] Virginia Mason Med Ctr, Ctr Liver Dis, Seattle, WA 98101 USA. [Kowdley, Kris V.] Benaroya Res Inst, Seattle, WA 98101 USA. RP Utzschneider, KM (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 1600 S Columbian Way 151, Seattle, WA 98108 USA. EM kutzschn@u.washington.edu FU VA Puget Sound Health Care System, Seattle, WA; Department of Veterans Affairs; NIH [DK02957] FX This work is supported in part by the VA Puget Sound Health Care System, Seattle, WA and the Department of Veterans Affairs (to K. M. U.) and NIH Grant DK02957 (to K. V. K.). NR 57 TC 25 Z9 28 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5029 EI 1759-5037 J9 NAT REV ENDOCRINOL JI Nat. Rev. Endocrinol. PD JAN PY 2010 VL 6 IS 1 BP 26 EP 33 DI 10.1038/nrendo.2009.241 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 533AN UT WOS:000272794400008 PM 20010968 ER PT J AU Keller, C Katz, R Sarnak, MJ Fried, LF Kestenbaum, B Cushman, M Shlipak, MG AF Keller, Christopher Katz, Ronit Sarnak, Mark J. Fried, Linda F. Kestenbaum, Bryan Cushman, Mary Shlipak, Michael G. CA CHS Study TI Inflammatory biomarkers and decline in kidney function in the elderly: the Cardiovascular Health Study SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE cystatin C; inflammation; inflammatory biomarkers; kidney ID C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; SERUM CYSTATIN-C; GLOMERULAR-FILTRATION-RATE; RENAL-INSUFFICIENCY; 10-YEAR INCIDENCE; POOLED ANALYSIS; RISK; PROGRESSION; MORTALITY AB Methods. This study included 4128 subjects from the Cardiovascular Health Study. Cystatin C was measured at baseline, 3 years later and 7 years later; eligible subjects had at least two measures. Cystatin C-based estimated glomerular filtration rate (eGFR(cysC)) was estimated, and rapid kidney function decline was defined as an annual loss of eGFR(cysC) > 3 mL/min/1.73 m(2). Predictors included ten inflammatory and procoagulant biomarkers: C-reactive protein, interleukin-6, intercellular adhesion molecule-1, white blood cell count, fibrinogen, factor VII, factor VIII, D-dimer, plasmin-antiplasmin complex and serum albumin. Results. During the study, 1059 subjects (26%) had a rapid decline in kidney function. In contrast to the other nine inflammatory or procoagulant biomarkers, serum albumin had a consistent and inverse association with rapid kidney function decline [final adjusted logistic regression model: 1.14-fold increased odds (95% CI 1.06-1.23) of rapid decline per standard deviation lower albumin]. The lowest quartile of albumin had an odds ratio of 1.55 (95% CI 1.23-1.96) for rapid decline compared with the highest quartile. These associations persisted after adjusting the albumin models for CRP, IL-6 and fibrinogen. Conclusions. In contrast to nine other inflammatory and procoagulant markers, only lower baseline levels of serum albumin were consistently associated with a rapid decline in kidney function, as measured by cystatin C-based eGFR. C1 [Keller, Christopher; Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Keller, Christopher; Shlipak, Michael G.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Katz, Ronit] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA 98195 USA. [Sarnak, Mark J.] Tufts Univ New England Med Ctr, Div Nephrol, Boston, MA USA. [Fried, Linda F.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Kestenbaum, Bryan] VA Puget Sound Healthcare Syst, Div Nephrol, Seattle, WA USA. [Cushman, Mary] Univ Vermont, Dept Med, Burlington, VT USA. [Cushman, Mary] Univ Vermont, Dept Pathol, Burlington, VT 05405 USA. RP Shlipak, MG (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM michael.shlipak@ucsf.edu FU National Heart, Lung, and Blood Institute [N01-HC-85079, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, U01 HL080295]; Dr Sarnak's National Institute of Aging (NIA) [R01AG027002]; National Kidney Foundation; NIA; American Heart Association; [R01 DK066488-01] FX The Cardiovascular Health Study was funded by the National Heart, Lung, and Blood Institute by contract numbers N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, grant number U01 HL080295, with additional contributions from the National Institute of Neurological Disorders and Stroke. Cystatin C measurements were funded by Dr Sarnak's National Institute of Aging (NIA) grant no. R01AG027002. Dr C. K. is funded by a fellowship award from the National Kidney Foundation. Drs R. K., L. F. and M. S. are additionally funded by the NIA. Dr M. S. is also funded by R01 DK066488-01, as well as by the American Heart Association Established Investigator Award. A full list of principal CHS investigators and institutions can be found at http://www.chs-nhlbi.org/pi.htm. NR 25 TC 25 Z9 28 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD JAN PY 2010 VL 25 IS 1 BP 119 EP 124 DI 10.1093/ndt/gfp429 PG 6 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA 537KZ UT WOS:000273113100021 PM 19734138 ER PT J AU Delgado, C Johansen, KL AF Delgado, Cynthia Johansen, Kirsten L. TI Deficient Counseling on Physical Activity among Nephrologists SO NEPHRON CLINICAL PRACTICE LA English DT Article DE Deficient counseling; Exercise counseling practices; KDOQI guidelines; Nephrologists' counseling practices; Physical activity, nephrologists ID HEMODIALYSIS-PATIENTS; CARDIAC REHABILITATION; DIALYSIS PATIENTS; CORONARY-BYPASS; EXERCISE; HEALTH; SURVIVAL AB Background: An evaluation of exercise counseling practices among nephrologists in 2001 demonstrated few clinicians assessing patients' levels of physical activity (PA) and counseling to increase activity. Recent Kidney Disease Outcomes Quality Initiative (KDOQI) cardiovascular guidelines recommended that nephrologists counsel patients to increase PA. Our objective was to ascertain whether nephrologists' counseling practices have changed. Methods: We administered a 30-item survey regarding exercise counseling to nephrologists attending the ASN meeting in 2007. Some questions were adapted from a prior survey administered in 2001 to assess differences in practice patterns compared to 6 years earlier. Results: Participants answered questions regarding opinions and practices relevant to PA (n = 198), KDOQI guidelines, self-reported PA, and demographic information (n = 173). Participants were 44 +/- 11 years of age, 48% practicing in the USA, and 76% male. In multivariate analysis, older nephrologists (OR; 95% CI) (3.3; 1.2-9.0) and those more physically active (5.5; 2.0-14) were more likely to ask and counsel patients about PA. Opinions associated with less counseling behavior included lack of confidence in ability to discuss PA (0.2; 0.05-0.5). Multivariate comparison to previous respondents (n = 503) showed current nephrologists were not asking and counseling more (1.2; 0.81-1.8). Conclusion: Despite new guidelines, counseling behavior has not increased. Published guidelines are insufficient to reach younger nephrologists. Copyright (C) 2010 S. Karger AG, Basel C1 [Delgado, Cynthia; Johansen, Kirsten L.] Univ Calif San Francisco, Nephrol Sect, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Delgado, C (reprint author), Univ Calif San Francisco, Vet Affairs Med Ctr, 4150 Clement St,Box 111J, San Francisco, CA 94121 USA. EM cynthia.delgado@ucsf.edu FU NIDDK NIH HHS [K24 DK085153, T32 DK007219] NR 13 TC 20 Z9 22 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1660-2110 J9 NEPHRON CLIN PRACT JI Nephron. Clin. Pract. PY 2010 VL 116 IS 4 BP C330 EP C336 DI 10.1159/000319593 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 632XL UT WOS:000280462800015 PM 20664289 ER PT J AU Minev, E Unruh, M Shlipak, MG Simsonick, E Yaffe, K Leak, TS Newman, AB Fried, LF AF Minev, Evgueni Unruh, Mark Shlipak, Michael G. Simsonick, Eleanor Yaffe, Kristine Leak, Tennille S. Newman, Anne B. Fried, Linda F. CA Hlth ABC Study TI Association of Cystatin C and Depression in Healthy Elders: The Health, Aging and Body Composition Study SO NEPHRON CLINICAL PRACTICE LA English DT Article DE Depression, elderly; Cystatin C; Chronic kidney disease ID CHRONIC KIDNEY-DISEASE; RENAL-TRANSPLANTATION; HEMODIALYSIS-PATIENTS; PREVALENCE; DIAGNOSIS; OUTCOMES; DEATH AB Background/Aims: Depression is highly prevalent in individuals with advanced kidney disease, but is less well studied in individuals with milder disease. We evaluated the association between kidney function and depression in the Health, Aging and Body Composition (Health ABC) study. Methods: The study enrolled 3,075 community-dwelling black and white adults aged 70-79 years. Kidney function was measured by cystatin C and estimated glomerular filtration rate (eGFR). The main outcome was incident treated depression. Results: 52% of participants had low (<= 1.0), 33% intermediate (> 1-1.25) and 15% high cystatin C (> 1.25). Kidney function and depression were not associated at baseline. Of 2,731 nondepressed participants at baseline, 95 developed incident depression during follow-up. In unadjusted Cox proportional hazard models, hazard ratios (HR) for incident depression were 1.89 (95% confidence interval (CI) 1.21-2.97) for the intermediate and 2.17 (CI 1.24-3.79) for the high cystatin C group. Intermediate (HR = 1.84) and high (HR = 2.1) serum cystatin C remained associated with incident depression in adjusted models. Chronic kidney disease, defined by an eGFR < 60 ml/min/1.73 m(2), was not associated with depression. Conclusion: Participants with higher cystatin C had an increased likelihood of developing treated depression. Future studies should target this high-risk group. Copyright (C) 2010 S. Karger AG, Basel C1 [Minev, Evgueni; Unruh, Mark; Fried, Linda F.] Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA 15216 USA. [Newman, Anne B.] Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA 15216 USA. [Leak, Tennille S.; Newman, Anne B.; Fried, Linda F.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15216 USA. [Fried, Linda F.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Gen Internal Med Sect, Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Shlipak, Michael G.; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Yaffe, Kristine] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Simsonick, Eleanor] NIA, NIH, Baltimore, MD 21224 USA. RP Minev, E (reprint author), Univ Pittsburgh, Sch Med, Renal Electrolyte Div, 3550 Terrace St, Pittsburgh, PA 15216 USA. EM evgueni.minev@gmail.com RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU NIA NIH HHS [P30 AG024827] NR 21 TC 2 Z9 2 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1660-2110 J9 NEPHRON CLIN PRACT JI Nephron. Clin. Pract. PY 2010 VL 116 IS 3 BP C241 EP C246 DI 10.1159/000317205 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 621OI UT WOS:000279588200015 PM 20606485 ER PT J AU Post, JB Jegede, AB Morin, K Spungen, AM Langhoff, E Sano, M AF Post, James B. Jegede, Adejoke B. Morin, Kel Spungen, Ann M. Langhoff, Erik Sano, Mary TI Cognitive Profile of Chronic Kidney Disease and Hemodialysis Patients without Dementia SO NEPHRON CLINICAL PRACTICE LA English DT Article DE Cognition; Mild cognitive impairment; Cerebrovascular disease; Chronic kidney disease; Hemodialysis ID WHITE-MATTER LESIONS; STAGE RENAL-DISEASE; CARDIOVASCULAR-DISEASE; VASCULAR DEMENTIA; IMPAIRMENT; PREVALENCE; PRODUCTS; ADULTS; HEALTH AB Background/Aims: The high risk and prevalence of dementia among patients with chronic kidney disease (CKD) and in those receiving hemodialysis (HD) may be preceded by mild cognitive impairment (MCI). We aimed to assess cognitive function in CKD and HD patients with no history of stroke or dementia, in order to identify and characterize early cognitive deficits. Methods: 24 CKD and 27 HD male outpatients without history of cerebrovascular or neurodegenerative disease underwent comprehensive neuropsychological testing in an observational cross-sectional study. Test results were used to categorize patients into MCI subtypes. Results: All subjects scored >= 28 on the Mini-Mental State Examination. The prevalence of executive function was at least 25% in both groups and memory impairment occurred in 13% of the HD patients and 15% of those with CKD. MCI occurred in 76% of the group and HD patients showed a higher prevalence of MCI compared to CKD patients (89 vs. 63%) with a preponderance (> 70%) of cases across both groups classified as non-amnestic MCI. Conclusion: Predialysis CKD and HD patients have a high prevalence of MCI despite normal global cognitive function. MCI was more prevalent among the HD patients and deficits more frequently resulted in non-amnestic MCI. Copyright (C) 2010 S. Karger AG, Basel C1 [Post, James B.; Langhoff, Erik] James J Peters VA Med Ctr, Div Nephrol, Bronx, NY 10468 USA. [Post, James B.; Jegede, Adejoke B.; Morin, Kel; Spungen, Ann M.] James J Peters VA Med Ctr, VA RR&D, Ctr Excellence Med Consequences, SCI, Bronx, NY USA. [Post, James B.; Langhoff, Erik] Mt Sinai Sch Med, Dept Med, Bronx, NY USA. [Spungen, Ann M.] Mt Sinai Sch Med, Dept Rehabil Med, Bronx, NY USA. [Sano, Mary] Mt Sinai Sch Med, Dept Psychiat, Bronx, NY USA. RP Post, JB (reprint author), James J Peters VA Med Ctr, Div Nephrol, 4C-12 Outpatient Renal Practice,130 W Kingsbridge, Bronx, NY 10468 USA. EM James.Post@va.gov FU VA VISN 3 Seed Grant Program; VARRD CDA 2 [B5050W]; VARR& D Center of Excellence [B4162C]; NIH/NIA [P50AG005138] FX Funding for this project was provided by the VA VISN 3 Seed Grant Program, VARR&D CDA 2 # B5050W, VARR& D Center of Excellence # B4162C and NIH/NIA # P50AG005138. NR 40 TC 18 Z9 22 U1 1 U2 4 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1660-2110 J9 NEPHRON CLIN PRACT JI Nephron. Clin. Pract. PY 2010 VL 116 IS 3 BP C247 EP C255 DI 10.1159/000317206 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 621OI UT WOS:000279588200016 PM 20606486 ER PT J AU Roumelioti, ME Argyropoulos, C Buysse, DJ Nayar, H Weisbord, SD Unruh, ML AF Roumelioti, Maria-Eleni Argyropoulos, Christos Buysse, Daniel J. Nayar, Harry Weisbord, Steven D. Unruh, Mark L. TI Sleep Quality, Mood, Alertness and Their Variability in CKD and ESRD SO NEPHRON CLINICAL PRACTICE LA English DT Article DE Mood; Sleep quality; Alertness; Chronic kidney disease; End-stage renal disease; Pittsburgh Sleep Diary; SF-36 ID CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; OF-LIFE; MAINTENANCE HEMODIALYSIS; HEALTH SURVEY; HEART HEALTH; DIALYSIS; DEPRESSION; SYMPTOMS; OUTCOMES AB Background/Aims: Little is known about the association of chronic kidney disease (CKD) with sleep quality, mood, and alertness. In this report, we assessed these symptoms among patients with advanced CKD (stages 4-5) and those with end-stage renal disease (ESRD) and compared them to healthy controls without known kidney disease. Methods: Patients were recruited from local dialysis units, outpatient nephrology clinics and the Thomas E. Starzl Transplant Institute. Healthy control subjects matched for age, gender and race were drawn from an archival database. Daily symptoms of sleep quality, mood, and alertness were assessed by visual analogue scales of the Pittsburgh Sleep Diary. Health-related quality of life was assessed by the Short Form-36 instrument. Results: Sixty-nine dialysis patients and 23 patients with advanced CKD demonstrated worse scores in sleep quality, mood, and alertness (p < 0.001) than controls. In adjusted analyses, European-American race, dialysis dependency, younger age, and physical performance SF-36 components were significantly associated with poor sleep quality, mood and alertness (p < 0.05). The dialysis population demonstrated higher day-to-day variability in scores than either the advanced CKD patients or the controls. Conclusion: Advanced CKD and dialysis dependency are associated with impaired and highly variable sleep quality, mood, and alertness. Copyright (C) 2010 S. Karger AG, Basel C1 [Roumelioti, Maria-Eleni; Argyropoulos, Christos; Weisbord, Steven D.; Unruh, Mark L.] Univ Pittsburgh, Med Ctr, Renal Electrolyte Div, Pittsburgh, PA 15213 USA. [Buysse, Daniel J.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA. [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Weisbord, Steven D.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Nayar, Harry] Drexel Univ, Sch Med, Pittsburgh, PA USA. RP Unruh, ML (reprint author), Univ Pittsburgh, Med Ctr, Renal Electrolyte Div, 200 Lothrop St,PUH C-1111, Pittsburgh, PA 15213 USA. EM unruh@pitt.edu OI Argyropoulos, Christos/0000-0002-9679-7805 FU Fresenius National Kidney Foundation; Paul Teschan Research Grant; NIH [DK66006, DK77785, MH24652]; NIH/NCRR/CTSA [UL1 RR024153] FX This work was supported by the Fresenius National Kidney Foundation Young Investigator Grant, Paul Teschan Research Grant, NIH DK66006 and DK77785 (M. L. U.) and NIH MH24652 (D. J. B.). This publication was supported by funds received from the NIH/NCRR/CTSA Grant UL1 RR024153. NR 47 TC 11 Z9 11 U1 1 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1660-2110 J9 NEPHRON CLIN PRACT JI Nephron. Clin. Pract. PY 2010 VL 114 IS 4 BP C277 EP C287 DI 10.1159/000276580 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 546IQ UT WOS:000273804900011 PM 20090370 ER PT J AU Khan, AM Li, M Balamuthusamy, S Maderdrut, JL Simon, EE Batuman, V AF Khan, Altaf-M. Li, Min Balamuthusamy, Saravanan Maderdrut, Jerome L. Simon, Eric E. Batuman, Vecihi TI Myeloma Light Chain-Induced Renal Injury in Mice SO NEPHRON EXPERIMENTAL NEPHROLOGY LA English DT Article DE Protein overload; Kidney failure; Proteinuria; Cytokines; Plasma cell dyscrasias ID PROXIMAL TUBULAR CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; PROGRESSIVE NEPHROPATHIES; GLOMERULAR INJURY; URINARY-EXCRETION; KIDNEY-DISEASE; KAPPA-B; ACTIVATION; PROTEIN-1; OVERLOAD AB We investigated the effects of human light chain (LC) protein-overload in mice kidney to gain further insights into the molecular mechanisms involved in the pathogenesis of myeloma kidney. Intact male C57BL/6, 10- to 12-week-old mice were given daily intraperitoneal (i.p.) injections of 1 ml of human kappa-LCs (1.5 mg/ml, low dose), or (100 mg/ml, high dose) to uninephrectomized mice for 2 weeks. Intact, sham-operated or uninephrectomized control animals were given the same volume (1 ml/day) of saline, human serum albumin (10 mg/ml) or bovine serum albumin (100 mg/ml) i.p. for 2 weeks in place of LCs. The low-dose LC-treated mice had human LCs in their urine and a significant increase in monocyte chemoattractant protein-1 (MCP-1) mRNA in the kidneys. Uninephrectomized mice treated with high-dose kappa-LCs showed tubule casts, and foci of intracytoplasmic rhomboid crystals within the proximal tubules, along with cytoskeletal disruptions and alterations in the brush-border membrane, and high concentrations of human kappa-LC were present in their sera. High-dose LC treatment also led to increases in serum creatinine and tumor necrosis factor-alpha levels, and marked increases in interleukin-6 and MCP-1 expression as well as cellular apoptosis in the kidneys. These studies demonstrate that myeloma LC overload over a range of LC concentrations in mice causes significant functional and morphological kidney injury. The model should be helpful in investigating pathophysiologic mechanisms and exploring therapeutic interventions for myeloma kidney and other LC-associated renal disorders. Copyright (C) 2010 S. Karger AG, Basel C1 [Khan, Altaf-M.; Li, Min; Balamuthusamy, Saravanan; Simon, Eric E.; Batuman, Vecihi] Tulane Univ, Sch Med, Dept Med, Sect Nephrol & Hypertens, New Orleans, LA 70112 USA. [Maderdrut, Jerome L.] Tulane Univ, Sch Med, Dept Med, Peptide Res Lab, New Orleans, LA 70112 USA. [Simon, Eric E.; Batuman, Vecihi] Southeast Louisiana Vet Hlth Care Syst, US Dept Vet Affairs, New Orleans, LA USA. RP Batuman, V (reprint author), Tulane Univ, Sch Med, Dept Med, Sect Nephrol & Hypertens, 1430 Tulane Ave,SL 45, New Orleans, LA 70112 USA. EM vbatuma@tulane.edu OI Batuman, Vecihi/0000-0002-1800-9009 FU Louisiana Board of Regents; Rudolph Matas Memorial Fund; DCI; Louisiana Cancer Research Consortium; Arimura Foundation FX This work was supported in part by research grants from the Research Commercialization and Educational Enhancement Program of the Louisiana Board of Regents (M. L., J.L.M. and V. B.), the Rudolph Matas Memorial Fund (V. B. and M. L.), DCI Research Endowment Fund (V. B.), the Louisiana Cancer Research Consortium (J.L.M.), and the Arimura Foundation (M. L.). We are also thankful to Dr. Solange Abdulnour-Nakhoul in the Department of Medicine, Tulane University School of Medicine, for providing histology facility and helpful discussions. NR 37 TC 9 Z9 9 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1660-2129 J9 NEPHRON EXP NEPHROL JI Nephron Exp. Nephrol PY 2010 VL 116 IS 2 BP E32 EP E41 DI 10.1159/000317129 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 618CV UT WOS:000279329900002 PM 20588062 ER PT J AU Faber, R Azad, A Reinsvold, R AF Faber, Raymond Azad, Alvi Reinsvold, Richard TI A case of the corpus callosum and alien hand syndrome from a discrete paracallosal lesion SO NEUROCASE LA English DT Article DE Split-brain syndrome; Syndrome of hemisphere disconnection; Paracallosal lesion; Apraxia; Agraphia ID DISEASE IMAGE; APRAXIA; DISCONNECTION; INFARCTION AB Here we present a patient with an isolated paracallosal brain lesion who exhibited behavioral changes associated with the corpus callosum syndrome (CCS) including features of the alien hand syndrome (AHS). The CCS is also known as the split-brain syndrome, the syndrome of hemisphere disconnection, the syndrome of brain bisection and the syndrome of the cerebral commissures. Because most reported cases of CCS were caused by tumors which extended beyond the corpus callosum (CC) and did not always induce a complete disconnection, there was much controversy about the role of the CC and the existence of a specific CCS. Aside from surgically based cases, the full complement of the CCS is infrequently clinically encountered. The patient described has a classic CCS from natural causes. This case report is unique in exhibiting a complete CCS with AHS secondary to an ischemic event affecting the left pericallosal region. To our knowledge this is the first case report of such a combination. C1 [Faber, Raymond] Laurel Ridge Treatment Ctr, San Antonio, TX USA. [Faber, Raymond] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Faber, Raymond; Azad, Alvi] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Azad, Alvi; Reinsvold, Richard] Wilford Hall USAF Med Ctr, San Antonio, TX USA. RP Faber, R (reprint author), 7400 Merton Minter Blvd 116-A, San Antonio, TX 78229 USA. EM faber@uthscsa.edu NR 21 TC 2 Z9 3 U1 2 U2 7 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1355-4794 J9 NEUROCASE JI Neurocase PY 2010 VL 16 IS 4 BP 281 EP 285 AR PII 918511495 DI 10.1080/13554790903456217 PG 5 WC Clinical Neurology; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 626JZ UT WOS:000279963600001 PM 20069502 ER PT S AU Kern, RS Horan, WP AF Kern, Robert S. Horan, William P. BE Roder, V Medalia, A TI Definition and Measurement of Neurocognition and Social Cognition SO NEUROCOGNITION AND SOCIAL COGNITION IN SCHIZOPHRENIA PATIENTS: BASIC CONCEPTS AND TREATMENTS SE Key Issues in Mental Health LA English DT Article; Book Chapter ID CONTINUOUS PERFORMANCE-TEST; IDENTICAL PAIRS VERSION; CHRONIC-SCHIZOPHRENIA; EMOTION RECOGNITION; NEURAL BASIS; TEST BATTERY; 1ST-EPISODE SCHIZOPHRENIA; COMPUTERIZED ASSESSMENT; ATTRIBUTIONAL STYLE; IMPROVE COGNITION AB Disturbances in neurocognition and social cognition are widely recognized as core features of schizophrenia. In this chapter, we provide a critical review of measurement in these 2 areas. For neurocognition, we compare 3 approaches: (a) hybrid batteries, (b) computer-based batteries and (c) the MATRICS Consensus Cognitive Battery. For social cognition, we compare measures used to assess 5 key domains: (a) emotional processing, (b) social perception, (c) social knowledge, (d) attribution bias and (e) theory of mind. We conclude with a section on the promise of developing new treatments in neurocognition and social cognition that will rely, in part, on the advances in measurement within these areas. Copyright (C) 2010 S. Karger AG, Basel C1 [Kern, Robert S.; Horan, William P.] Educ & Clin Ctr, Dept Vet Affairs VISN Mental Illness Res 22, Los Angeles, CA USA. [Kern, Robert S.; Horan, William P.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Kern, RS (reprint author), VA Greater Los Angeles Healthcare Syst MIRECC 210, Bldg 210,Room 116,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM rkern@ucla.edu NR 145 TC 6 Z9 6 U1 2 U2 5 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1662-4874 BN 978-3-8055-9338-0 J9 KEY ISSUES MENT HEAL JI Key Iss. Ment. Health PY 2010 VL 177 BP 1 EP 22 PG 22 WC Psychiatry SC Psychiatry GA BNP90 UT WOS:000275191300001 ER PT J AU Luks, TL Oliveira, M Possin, KL Bird, A Miller, BL Weiner, MW Kramer, JH AF Luks, Tracy L. Oliveira, Michael Possin, Katherine L. Bird, Anne Miller, Bruce L. Weiner, Michael W. Kramer, Joel H. TI Atrophy in two attention networks is associated with performance on a Flanker task in neurodegenerative disease SO NEUROPSYCHOLOGIA LA English DT Article DE Neurodegenerative disease; Attentional control; Flanker; Voxel-based morphometry ID ANTERIOR CINGULATE CORTEX; EVENT-RELATED FMRI; RESPONSE CHANNEL ACTIVATION; PRIMARY-PROGRESSIVE-APHASIA; INFERIOR FRONTAL-CORTEX; PREFRONTAL CORTEX; FRONTOTEMPORAL DEMENTIA; SEMANTIC DEMENTIA; ALZHEIMER-DISEASE; CONFLICT AB This study investigated the neurobiological basis of attentional control dysfunction in neurodegenerative disease by determining the effect of regional brain atrophy on Flanker task performance of neurodegenerative patients. We hypothesized that atrophy in DLPFC and ACC would be significantly associated with decreased attentional control performance on the Flanker task. We used voxel-based morphometry (VBM) to measure the relationship between MRI measures of regional grey matter atrophy and performance on a version of the Flanker task, measured by accuracy and response time. Sixty-five subjects participated, including patients with frontotemporal dementia, Alzheimer's disease, mild cognitive impairment, non-fluent progressive aphasia, corticobasal degeneration, progressive supranuclear palsy, semantic dementia, and healthy controls. Accuracy measures of attentional control and response time measures of attentional control were associated with two different patterns of regional atrophy across subjects. First, there was an association between left hemisphere DLPFC and ACC atrophy and poorer attentional control accuracy. Second, right hemisphere temporal-parietal junction (TPJ) and ventrolateral prefrontal cortex (VLPFC) and DLPFC atrophy were associated with slower response times during attentional control on accurate trials, which may reflect emergent involvement due to deficits in the DLPFC-ACC network. (C) 2009 Published by Elsevier Ltd. C1 [Luks, Tracy L.; Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Possin, Katherine L.; Bird, Anne; Miller, Bruce L.; Kramer, Joel H.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA. [Weiner, Michael W.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Luks, TL (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, Box 0628, San Francisco, CA 94143 USA. EM Tracy.Luks@radiology.ucsf.edu FU NIA NIH HHS [K01 AG027369-03, K01 AG027369, K01 AG027369-01A1, K01 AG027369-02, K01 AG027369-04, K01 AG027369-05, P01 AG019724] NR 56 TC 18 Z9 20 U1 2 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD JAN PY 2010 VL 48 IS 1 BP 165 EP 170 DI 10.1016/j.neuropsychologia.2009.09.001 PG 6 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 550NU UT WOS:000274135500018 PM 19747928 ER PT J AU George, MS Aston-Jones, G AF George, Mark S. Aston-Jones, Gary TI Noninvasive techniques for probing neurocircuitry and treating illness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) SO NEUROPSYCHOPHARMACOLOGY LA English DT Review DE TMS; VNS; neuromodulation ID TREATMENT-RESISTANT DEPRESSION; HUMAN MOTOR CORTEX; DEEP BRAIN-REGIONS; LOCUS-COERULEUS; MAJOR DEPRESSION; CORTICAL EXCITABILITY; PARKINSONS-DISEASE; PREFRONTAL CORTEX; BLOOD-FLOW; BOLD FMRI AB Although the preceding chapters discuss much of the new knowledge of neurocircuitry of neuropsychiatric diseases, and an invasive approach to treatment, this chapter describes and reviews the noninvasive methods of testing circuit-based theories and treating neuropsychiatric diseases that do not involve implanting electrodes into the brain or on its surface. These techniques are transcranial magnetic stimulation, vagus nerve stimulation, and transcranial direct current stimulation. Two of these approaches have FDA approval as therapies. Neuropsychopharmacology Reviews (2010) 35, 301-316; doi:10.1038/npp.2009.87; published online 19 August 2009 C1 [George, Mark S.] Med Univ S Carolina, Brain Stimulat Lab, Inst Psychiat, Charleston, SC 29425 USA. [George, Mark S.] Med Univ S Carolina, Dept Psychiat, Inst Psychiat, Ctr Adv Imaging Res, Charleston, SC 29425 USA. [George, Mark S.] Med Univ S Carolina, Dept Radiol, Inst Psychiat, Ctr Adv Imaging Res, Charleston, SC 29425 USA. [George, Mark S.] Med Univ S Carolina, Dept Neurosci, Inst Psychiat, Ctr Adv Imaging Res, Charleston, SC 29425 USA. [George, Mark S.] Med Univ S Carolina, SC Brain Imaging Ctr Econ Excellence, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Aston-Jones, Gary] Med Univ S Carolina, Murray Chair Excellence Neurosci, Charleston, SC 29425 USA. RP George, MS (reprint author), Med Univ S Carolina, Brain Stimulat Lab, Inst Psychiat, 67 President St,Rm 502 N, Charleston, SC 29425 USA. EM georgem@musc.edu NR 184 TC 93 Z9 99 U1 2 U2 23 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2010 VL 35 IS 1 BP 301 EP 316 DI 10.1038/npp.2009.87 PG 16 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 532XV UT WOS:000272784600016 PM 19693003 ER PT J AU Anderson, CA Arciniegas, DB AF Anderson, C. Alan Arciniegas, David B. TI Cognitive sequelae of hypoxic-ischemic brain injury: A review SO NEUROREHABILITATION LA English DT Review DE Hypoxic-ischemic; anoxic; brain injury; cognition; attention; memory; executive function ID HOSPITAL CARDIAC-ARREST; PERSISTENT VEGETATIVE STATE; MINIMALLY CONSCIOUS STATES; QUALITY-OF-LIFE; EFNS TASK-FORCE; CEREBRAL ANOXIA; CARDIOPULMONARY-RESUSCITATION; NEUROPSYCHOLOGICAL PROFILE; ADULT SURVIVORS; MEDICAL ASPECTS AB Despite improvements in the pre-hospital and critical care management of persons with hypoxic-ischemic brain injury (HI-BI) and the conditions with which it is associated, acute and chronic cognitive impairments remain problems for many survivors of such injuries. Disorders of consciousness, attention, speed of processing, and memory impairments, and executive dysfunction are among the most prominent and common disturbances of cognition after HI-BI. Acute interventions, including therapeutic hypothermia, may improve global outcomes after HI-BI, but their specific effects on post-hypoxic cognitive impairments remain uncertain. Additionally, treatments for cognitive impairments after HI-BI are underdeveloped and are generally arrived at by analogy to the treatment of such problems arising from other neurological conditions, especially traumatic brain injury. In the service of offering a practical approach to the evaluation and care of persons with cognitive impairments after HI-BI, the most common types of post-hypoxic cognitive impairments are reviewed. Cognitive outcomes after HI-BI are discussed and suggestions for the nonpharmacologic and pharmacologic neurorehabilitation of these problems are offered. C1 [Anderson, C. Alan; Arciniegas, David B.] Univ Colorado, Sch Med, Dept Neurol, Behav Neurol Sect, Denver, CO USA. [Anderson, C. Alan; Arciniegas, David B.] Univ Colorado, Sch Med, Dept Psychiat, Neurobehav Disorders Program, Denver, CO 80262 USA. [Anderson, C. Alan; Arciniegas, David B.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Arciniegas, David B.] HealthONE Spalding Rehabil Hosp, Brain Injury Rehabil Unit, Aurora, CO USA. RP Anderson, CA (reprint author), Univ Colorado Denver, Dept Neurol, Mail Stop B182,12700 E 19th Ave,Room 5C03, Aurora, CO 80045 USA. EM al.anderson@ucdenver.edu NR 106 TC 32 Z9 36 U1 1 U2 25 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8135 J9 NEUROREHABILITATION JI Neurorehabilitation PY 2010 VL 26 IS 1 BP 47 EP 63 DI 10.3233/NRE-2010-0535 PG 17 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 562NQ UT WOS:000275059000006 PM 20130355 ER PT J AU Morrisroe, S Pollard, M Mossanen, M Shekelle, P Anger, J AF Morrisroe, Shelby Pollard, Matthew Mossanen, Matthew Shekelle, Paul Anger, Jennifer TI OUTCOMES OF PREGNANCY FOLLOWING SURGERY FOR STRESS URINARY INCONTINENCE: A SYSTEMATIC REVIEW SO NEUROUROLOGY AND URODYNAMICS LA English DT Meeting Abstract CT 7th Annual Winter Meeting of the Society-for-Urodynamics-and-Female-Urology CY JAN 23-FEB 27, 2010 CL St Petersburg, FL SP Soc Urodynam & Female Urol C1 [Morrisroe, Shelby; Pollard, Matthew; Mossanen, Matthew; Anger, Jennifer] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. [Shekelle, Paul] W Los Angeles VA Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PY 2010 VL 29 IS 2 BP 308 EP 308 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 569JV UT WOS:000275593300145 ER PT J AU Burgio, KL Brubaker, L Richter, HE Wai, CY Litman, HJ France, DB Menefee, SA Sirls, LT Kraus, SR Johnson, HW Tennstedt, SL AF Burgio, Kathryn L. Brubaker, Linda Richter, Holly E. Wai, Clifford Y. Litman, Heather J. France, Diane Borello Menefee, Shawn A. Sirls, Larry T. Kraus, Stephen R. Johnson, Harry W. Tennstedt, Sharon L. TI Patient Satisfaction With Stress Incontinence Surgery SO NEUROUROLOGY AND URODYNAMICS LA English DT Article DE patient outcomes assessment; patient satisfaction; surgery; urinary incontinence ID QUALITY-OF-LIFE; URINARY-INCONTINENCE; SURGICAL-TREATMENT; WOMEN; SEVERITY; IMPROVEMENT; PREDICTORS; PHYSICIAN; OUTCOMES; HEALTH AB Aims: To identify predictors and correlates of patient satisfaction 24 months after Burch colpopexy or autologous fascial sling for treatment of stress urinary incontinence (SUI). Methods: Participants were the 655 randomized subjects in the Stress Incontinence Surgical Treatment Efficacy Trial (SISTEr). Variables potentially associated with satisfaction were tested in bivariate analysis, including demographics, baseline clinical characteristics of incontinence, and outcomes on validated subjective and objective measures. Satisfaction with treatment was defined as a response of "completely satisfied" or "mostly satisfied" on the Patient Satisfaction Questionnaire (PSQ) at 24 months. Variables significantly related to satisfaction were entered into multivariable regression models to test their independent association with satisfaction. Results: At 24 months post-surgery, 480 (73%) participants completed the PSQ. Mean (+/- SD) age of the sample was 52 ( 10) years and 77% were white. Most (82%) were completely or mostly satisfied with their surgery related to urine leakage. In the final multivariable model, patient satisfaction was associated with greater reduction in SUI symptoms (from baseline to 24 months; OR = 1.17, 95% CI: 1.10, 1.24) and greater reductions in symptom distress (OR = 1.16; CI: 1.08, 1.24). Lower odds of satisfaction were associated with greater urge incontinence symptoms at baseline (OR = 0.09, CI: 0.04, 0.22), detrusor overactivity at 24 months (OR = 0.29, CI: 0.12, 0.69), and a positive stress test at 24 months (OR = 0.45, CI: 0.22, 0.91). Conclusions: Stress incontinent women who also have urge incontinence symptoms may benefit from additional preoperative counseling to set realistic expectations about potential surgical outcomes or proactive treatment of urge incontinence symptoms to minimize their post-operative impact. Neurourol. Urodynam. 29:1403-1409, 2010. (C) 2010 Wiley-Liss, Inc. C1 [Burgio, Kathryn L.; Richter, Holly E.] Univ Alabama, Birmingham VA Med Ctr, Birmingham, AL 35233 USA. [Burgio, Kathryn L.] Dept Vet Affairs, Birmingham, AL USA. [Brubaker, Linda] Loyola Univ, Stritch Sch Med, Chicago, IL 60611 USA. [Wai, Clifford Y.] Univ Texas SW, Dallas, TX USA. [Litman, Heather J.; Tennstedt, Sharon L.] New England Res Inst, Watertown, MA 02172 USA. [France, Diane Borello] Duquesne Univ, Pittsburgh, PA 15219 USA. [Menefee, Shawn A.] Kaiser Permanente, San Diego, CA USA. [Sirls, Larry T.] William Beaumont Hosp, Royal Oak, MI 48072 USA. [Kraus, Stephen R.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Johnson, Harry W.] Univ Maryland, Baltimore, MD 21201 USA. RP Burgio, KL (reprint author), Univ Alabama, Birmingham VA Med Ctr, 11G,700 S 19th St, Birmingham, AL 35233 USA. EM kburgio@uab.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [U01 DK 58225, U01 DK58234, U01 DK58229, U01 DK58231, U01 DK60397, U01 DK60401, U01 DK60395, U01 DK60393, U01 DK60380, U01 DK60379]; National Institute of Child Health and Human Development; Office of Research in Women's Health of the National Institutes of Health FX This study was supported by cooperative agreements with the National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK 58225, U01 DK58234, U01 DK58229, U01 DK58231, U01 DK60397, U01 DK60401, U01 DK60395, U01 DK60393, U01 DK60380, U01 DK60379) and by the National Institute of Child Health and Human Development and Office of Research in Women's Health of the National Institutes of Health. NR 25 TC 16 Z9 16 U1 1 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0733-2467 J9 NEUROUROL URODYNAM JI Neurourol. Urodyn. PY 2010 VL 29 IS 8 BP 1403 EP 1409 DI 10.1002/nau.20877 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 677UI UT WOS:000284016900008 PM 20976815 ER PT J AU Gennari, L Klein, R Ferrari, S AF Gennari, Luigi Klein, Robert Ferrari, Serge BE Orwoll, ES Bilezikian, JP Vanderschueren, D TI The Genetics of Peak Bone Mass SO OSTEOPOROSIS IN MEN: THE EFFECTS OF GENDER ON SKELETAL HEALTH, 2ND EDITION LA English DT Article; Book Chapter ID QUANTITATIVE TRAIT LOCI; RECEPTOR-RELATED PROTEIN-5; VITAMIN-D-RECEPTOR; LDL-RECEPTOR-RELATED-PROTEIN-5 LRP5 GENE; GENOME LINKAGE SCAN; MINERAL DENSITY; IDIOPATHIC OSTEOPOROSIS; FRACTURE RISK; ALPHA GENE; LOW BMD C1 [Gennari, Luigi] Univ Siena, Deparment Internal Med Endocrine Metab Sci & Bioc, I-53100 Siena, Italy. [Klein, Robert] Oregon Hlth & Sci Univ, Bone & Mineral Unit, Portland, OR 97201 USA. [Klein, Robert] Portland VA Med Ctr, Portland, OR USA. [Ferrari, Serge] Univ Hosp Geneva, Serv Bone Dis, Dept Rehabil & Geriatr, WHO Collaborating Ctr Osteoporosis Prevent, Geneva, Switzerland. RP Gennari, L (reprint author), Univ Siena, Deparment Internal Med Endocrine Metab Sci & Bioc, I-53100 Siena, Italy. RI Gennari, Luigi/J-7013-2016 OI Gennari, Luigi/0000-0001-6833-4232 NR 92 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-08-092346-8 PY 2010 BP 149 EP 163 DI 10.1016/B978-0-12-374602-3.00012-2 PG 15 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BFC98 UT WOS:000319219700014 ER PT B AU Wiren, KM Orwoll, ES AF Wiren, Kristine M. Orwoll, Eric S. BE Orwoll, ES Bilezikian, JP Vanderschueren, D TI Androgens and Bone: Basic Aspects SO OSTEOPOROSIS IN MEN: THE EFFECTS OF GENDER ON SKELETAL HEALTH, 2ND EDITION LA English DT Article; Book Chapter ID OSTEOBLASTIC CELL-LINE; GROWTH-FACTOR-BETA; RECEPTOR MODULATOR SARM; ADULT MALE-MICE; AGED MALE-RATS; MINERAL DENSITY; OVARIECTOMIZED RATS; CORTICAL BONE; BIOCHEMICAL MARKERS; PARATHYROID-HORMONE C1 [Wiren, Kristine M.; Orwoll, Eric S.] Oregon Hlth & Sci Univ, Bone & Mineral Unit, Portland, OR 97201 USA. [Wiren, Kristine M.] Portland VA Med Ctr, Portland, OR USA. RP Wiren, KM (reprint author), Oregon Hlth & Sci Univ, Bone & Mineral Unit, Portland, OR 97201 USA. OI Wiren, Kristine/0000-0002-6159-4450 NR 173 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-08-092346-8; 978-0-12-374602-3 PY 2010 BP 295 EP 317 DI 10.1016/B978-0-12-374602-3.00025-0 PG 23 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BFC98 UT WOS:000319219700027 ER PT B AU Wiren, KM AF Wiren, Kristine M. BE Adler, RA TI Androgen Action in Bone: Basic Cellular and Molecular Aspects SO OSTEOPOROSIS: PATHOPHYSIOLOGY AND CLINICAL MANAGEMENT, SECOND EDITION SE Contemporary Endocrinology LA English DT Article; Book Chapter DE Androgen; androgen receptor; osteoblast; osteoclast; bone ID OSTEOBLAST-LIKE CELLS; GROWTH-FACTOR-BETA; MESSENGER-RIBONUCLEIC-ACID; THYROID-HORMONE RECEPTOR; MINERAL DENSITY; IN-VITRO; MALE-RATS; POSTMENOPAUSAL WOMEN; PARATHYROID-HORMONE; AROMATASE-ACTIVITY AB The impact of the menopause on skeletal health is obvious, but there remains confusion interpreting the skeletal actions of sex steroids. Thus, the mechanisms by which androgens affect bone homeostasis are becoming the focus of intensified research. As a classic steroid hormone, the biological cellular signaling responses to androgen are mediated through the androgen receptor (AR), a ligand-inducible transcription factor. Androgen effects on bone may also be indirectly modulated and/or mediated by other autocrine and paracrine factors in the bone microenvironment or through steroid metabolic enzymatic activity. ARs have been identified in a variety of cells found in bone, thus clearly identifying bone as a target tissue for androgen action. The direct effects of androgen that influence the complex processes of proliferation, differentiation, mineralization, and gene expression in the osteoblast are being characterized, but much remains controversial. This chapter will review recent progress on characterization of the molecular and cellular mechanisms that underlie androgen action in bone. C1 Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Bone & Mineral Unit, Portland, OR 97201 USA. RP Wiren, KM (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Bone & Mineral Unit, Portland, OR 97201 USA. NR 158 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA BN 978-1-934115-19-0 J9 CONTEMP ENDOCRINOL S PY 2010 SI 2 BP 359 EP 383 DI 10.1007/978-1-59745-459-9_16 D2 10.1007/978-1-59745-459-9 PG 25 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA BMR67 UT WOS:000273414500016 ER PT J AU Tsao, JCI Stein, JA Dobalian, A AF Tsao, Jennie C. I. Stein, Judith A. Dobalian, Aram TI Sex Differences in Pain and Misuse of Prescription Analgesics Among Persons with HIV SO PAIN MEDICINE LA English DT Article DE Pain; Substance Abuse; Opioid Misuse; Women; Gender Differences; AIDS ID AMBULATORY AIDS PATIENTS; QUALITY-OF-LIFE; NATIONAL PROBABILITY SAMPLES; LOW-PREVALENCE DISEASES; DRUG-USE; INFECTED PATIENTS; SERVICES UTILIZATION; UNITED-STATES; HEALTH; UNDERESTIMATION AB Objective. Women represent the largest percentage of new HIV infections globally. Yet, no large-scale studies have examined the experience of pain and its treatment in women living with HIV. Design. This study used structural equation modeling to examine sex differences in pain and the use and misuse of prescription analgesics in a representative sample of HIV+ persons in the United Stated within a prospective, longitudinal design. Outcome Measures. Bodily pain subscale of the Short-Form 36 and Modified Short Form of the World Health Organization's Composite International Diagnostic Interview (opioid misuse). Results. Women reported more pain than men over a roughly 6-month period regardless of mode of HIV transmission or prior drug use history. Men acknowledged more misuse of prescription analgesics over an approximate 1-year period compared with women, after taking into account pain, use of analgesics specifically for pain, and drug use history. Weaker associations between pain and use of analgesics specifically for pain that persisted over time were found among women compared with men. For both men and women, pain was stable over time. Problem drug use history exerted significant direct and indirect effects on pain, opioid misuse, and pain-specific analgesic use across sex. Conclusion. The current findings are consistent with prior evidence indicating female pain predominance as well as the undertreatment of pain among women with HIV. Efforts should be made to improve the assessment and long-term management of pain in HIV+ persons. C1 [Tsao, Jennie C. I.] Univ Calif Los Angeles, David Geffen Sch Med, Pediat Pain Program, Dept Pediat, Los Angeles, CA 90024 USA. [Stein, Judith A.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Dobalian, Aram] Univ Calif Los Angeles, Sch Publ Hlth, VA Greater Los Angeles Healthcare Syst HSR&D, Ctr Excellence Study Healthcare Provider Behav, Los Angeles, CA 90024 USA. [Dobalian, Aram] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. RP Tsao, JCI (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Pediat Pain Program, Dept Pediat, 1072 Gayley Ave, Los Angeles, CA 90024 USA. EM jtsao@mednet.ucla.edu FU National Institute on Drug Abuse [DA017026, DA01070-35]; RAND [U01HS08578]; Agency for Healthcare Research and Quality [U01HS08578]; Health Resources and Services Administration; National Institute of Mental Health; National Institute on Drug Abuse; Office of Research on Minority Health through the National Institute for Dental Research; Robert Wood Johnson Foundation; Merck and Company; Glaxo-Wellcome; National Institute on Aging FX Support for this research was provided by DA017026 awarded to the first author and by DA01070-35 awarded to the second author by the National Institute on Drug Abuse. The HIV Cost and Services Utilization Study (HCSUS) was supported by a cooperative agreement (U01HS08578) between RAND and the Agency for Healthcare Research and Quality. Substantial additional support for this agreement was provided by the Health Resources and Services Administration, the National Institute of Mental Health, the National Institute on Drug Abuse, and the Office of Research on Minority Health through the National Institute for Dental Research. Additional support was provided by the Robert Wood Johnson Foundation, Merck and Company, Glaxo-Wellcome, and the National Institute on Aging. The authors thank Gisele Pham for her secretarial and administrative contributions to this research project, and the participants in this study. NR 36 TC 7 Z9 7 U1 3 U2 6 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PY 2010 VL 11 IS 6 BP 815 EP 824 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 604YK UT WOS:000278314200004 PM 20456074 ER PT J AU Buckalew, N Haut, MW Aizenstein, H Morrow, L Perera, S Kuwabara, H Weiner, DK AF Buckalew, Neilly Haut, Marc W. Aizenstein, Howard Morrow, Lisa Perera, Subashan Kuwabara, Hiroto Weiner, Debra K. TI Differences in Brain Structure and Function in Older Adults with Self-Reported Disabling and Nondisabling Chronic Low Back Pain SO PAIN MEDICINE LA English DT Article DE Chronic Pain; Older Adults; Structural MRI; Functional MRI; Disability ID POSITRON-EMISSION-TOMOGRAPHY; WHITE-MATTER MICROSTRUCTURE; SUPPLEMENTARY MOTOR AREA; HUMAN CEREBRAL-CORTEX; ILLNESS RATING-SCALE; MINI-MENTAL STATE; GRAY-MATTER; PHYSICAL PERFORMANCE; BODY-COMPOSITION; GAIT SPEED AB Objective. The primary aim of this pilot study was to identify structural and functional brain differences in older adults with self-reported disabling chronic low back pain (CLBP) compared with those who reported nondisabling CLBP. Design. Cross-sectional. Participants. Sixteen cognitively intact older adults, eight with disabling CLBP and eight with nondisabling CLBP. Exclusions were psychiatric or neurological disorders, substance abuse, opioid use, or diabetes mellitus. Methods. Participants underwent: structural and functional brain MRI; neuropsychological assessment using the Repeatable Battery for the Assessment of Neuropsychological Status, Trail Making Tests A and B; and physical performance assessment using the Short Physical Performance Battery. Results. In the disabled group, there was significantly lower white matter (WM) integrity (P < 0.05) of the splenium of the corpus callosum. This group also demonstrated activation of the right medial prefrontal cortex at rest whereas the nondisabled demonstrated activation of the left lateral prefrontal cortex. Combined groups analysis revealed a strong positive correlation (r(s) = 0.80, P < 0.0002) between WM integrity of the left centrum semiovale with gait-speed. Secondary analysis revealed a strong negative correlation between total months of CLBP and WM integrity of the SCC (r(s) = -0.59, P < 0.02). Conclusions. Brain structure and function is different in older adults with disabling CLBP compared with those with nondisabling CLBP. Deficits in brain morphology combining groups are associated with pain duration and poor physical function. Our findings suggest brain structure and function may play a key role in chronic pain related disability and may be important treatment targets. C1 [Morrow, Lisa; Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Sch Med, Pittsburgh, PA 15213 USA. [Perera, Subashan] Univ Pittsburgh, Dept Med, Sch Med, Pittsburgh, PA 15213 USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15213 USA. [Aizenstein, Howard] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15213 USA. [Aizenstein, Howard] Univ Pittsburgh, Adv Ctr Intervent & Serv Res Late life Mood Disor, Pittsburgh, PA 15213 USA. [Aizenstein, Howard] Univ Pittsburgh, John Hartford Ctr Excellence Geriatr Psychiat, Pittsburgh, PA 15213 USA. [Haut, Marc W.] Univ Pittsburgh, Dept Behav Med & Psychiat, Pittsburgh, PA 15213 USA. [Haut, Marc W.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Haut, Marc W.] Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15213 USA. [Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Kuwabara, Hiroto] Johns Hopkins, Dept Radiol, Baltimore, MD USA. RP Buckalew, N (reprint author), Univ Pittsburgh, MSEL, Sch Med, Clin Scientist Training Program, Suite 500,Kaufmann Bldg,3471 5th Ave, Pittsburgh, PA 15213 USA. EM neilly.buckalew@gmail.com RI Perera, Subashan/D-7603-2014 OI Haut, Marc/0000-0003-0235-362X FU National Institute on Aging [T32 AG021885]; NIA; University of Pittsburgh's Claude Pepper Older Americans Independence Center [AG024827] FX The authors would like to generously thank the following people for their assistance and hard work in completing this study: Denise Davis at the University of Pittsburgh Medical Center, Presbyterian MR Research Center; Kate Dunfee and Meg Nable research assistants to Dr. Howard Aizenstein; and Dr. R. P. Detwiler. We would also like to thank Dr. Stephanie Studenski for sponsoring Neilly Buckalew under a National Institute on Aging grant (T32 AG021885) and thank you to Dr. Amber Barnato of the CSTP and Dr. Michael Boninger of the Department of Physical Medicne and Rehabilitation for their added mentorship. We also extend our gratitude to the NIA for funding Ms. Buckalew's training as well as to Dr. Arthur Levine, Senior Vice Chancellor for the Health Sciences and Dean of the School of Medicine at the University of Pittsburgh. This work was also supported by a grant from the University of Pittsburgh's Claude Pepper Older Americans Independence Center AG024827. NR 127 TC 17 Z9 17 U1 2 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PY 2010 VL 11 IS 8 BP 1183 EP 1197 PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA 632WL UT WOS:000280459900008 PM 20609128 ER PT J AU Shugarman, LR Asch, SM Meredith, LS Sherbourne, CD Hagenmeier, E Wen, L Cohen, A Rubenstein, LV Goebel, J Lanto, A Lorenz, KA AF Shugarman, Lisa R. Asch, Steven M. Meredith, Lisa S. Sherbourne, Cathy D. Hagenmeier, Emily Wen, Li Cohen, Angela Rubenstein, Lisa V. Goebel, Joy Lanto, Andy Lorenz, Karl A. TI Factors Associated with Clinician Intention to Address Diverse Aspects of Pain in Seriously III Outpatients SO PAIN MEDICINE LA English DT Article DE Pain; Depression; Mental Health; Opioids; Antidepressants; Existential Pain; Spiritual Pain ID 5TH VITAL SIGN; PRIMARY-CARE; PERSISTENT PAIN; MEDICAL VISITS; CANCER PAIN; QUALITY; DEPRESSION; COMMUNICATION; VIGNETTES; BEHAVIOR AB Background. Pain is a common, often undertreated problem among patients with palliative needs. Objectives. To evaluate clinician factors associated with intention to address diverse aspects of pain. Design. Clinicians reviewed a clinical vignette describing a frail elderly patient with advanced hormone-refractory metastatic prostate cancer, depression, and pain not on analgesic therapy. Clinicians were surveyed about their intentions for treatment. Participants. All 280 primary care and specialist clinicians working in 19 hospital and community-based primary care, oncology, and cardiology clinics at eight geographically dispersed sites in two large VA hospital systems. Main Measures. Endpoints were clinician intention to deliver guideline-concordant care: prescribe opioids/antidepressants, assess existential wellbeing, and offer mental health referral. Demographic and behavioral measures were evaluated in association with endpoints. Key Results. Of 208 (74%) responding practitioners, 189 were responsible for prescribing decisions. Of those, 86, 77, 75, and 69 were "very"/"somewhat likely" to prescribe opioids, antidepressants, refer to a mental health specialist, or assess existential wellbeing, respectively. Factors associated with greater intent to prescribe an opioid or antidepressant included female gender, being an attending physician, being a primary care clinician, and greater confidence in pain management skills. Greater trust in the validity of pain ratings was associated with intent to prescribe an antidepressant and assess existential wellbeing. Prescribing opioids was less likely if perceived as an administrative burden. Assessing existential wellbeing was less likely if time constraints were perceived a barrier to evaluating pain. Female gender was the only factor associated with intent to refer to a mental health specialist. Conclusions. Our findings suggest useful targets for improving pain management include bolstering clinician confidence in pain management and their trust in pain ratings. C1 [Asch, Steven M.; Rubenstein, Lisa V.; Lorenz, Karl A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Wen, Li] Vet Adm Long Beach Healthcare Syst, Long Beach, CA USA. [Goebel, Joy] Calif State Univ Long Beach, Sch Nursing, Long Beach, CA 90840 USA. [Asch, Steven M.; Hagenmeier, Emily; Cohen, Angela; Rubenstein, Lisa V.; Lanto, Andy; Lorenz, Karl A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Asch, Steven M.; Meredith, Lisa S.; Sherbourne, Cathy D.; Rubenstein, Lisa V.; Lorenz, Karl A.] RAND Corp, Santa Monica, CA USA. [Shugarman, Lisa R.] SCAN Fdn, Long Beach, CA USA. RP Lorenz, KA (reprint author), VA Greater Los Angeles Healthcare Syst, 113101 Wilshire Blvd, Los Angeles, CA 90073 USA. EM karl.lorenz@va.gov FU The Veterans Administration [IIR-030150]; VA HSRD FX Dr Karl Lorenz was supported by a VA HSR&D, Career Development Award. This study was funded by The Veterans Administration (IIR-030150). NR 29 TC 6 Z9 6 U1 1 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1526-2375 J9 PAIN MED JI Pain Med. PY 2010 VL 11 IS 9 BP 1365 EP 1372 DI 10.1111/j.1526-4637.2010.00931.x PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 647SA UT WOS:000281638100008 PM 20807347 ER PT J AU Trivedi, RB Ayotte, BJ Thorpe, CT Edelman, D Bosworth, HB AF Trivedi, Ranak B. Ayotte, Brian J. Thorpe, Carolyn T. Edelman, David Bosworth, Hayden B. TI Is there a nonadherent subtype of hypertensive patient? A latent class analysis approach SO PATIENT PREFERENCE AND ADHERENCE LA English DT Article DE adherence; hypertension; latent class analysis; self-management AB To determine subtypes of adherence, 636 hypertensive patients (48% White, 34% male) reported adherence to medications, diet, exercise, smoking, and home blood pressure monitoring. A latent class analysis approach was used to identify subgroups that adhere to these five self-management behaviors. Fit statistics suggested two latent classes. The first class (labeled "more adherent") included patients with greater probability of adhering to recommendations compared with the second class (labeled "less adherent") with regard to nonsmoking (97.7% versus 76.3%), medications (75.5% versus 49.5%), diet (70.7% versus 46.9%), exercise (63.4% versus 27.2%), and blood pressure monitoring (32% versus 3.4%). Logistic regression analyses used to characterize the two classes showed that "more adherent" participants were more likely to report full-time employment, adequate income, and better emotional and physical well-being. Results suggest the presence of a less adherent subtype of hypertensive patients. Behavioral interventions designed to improve adherence might best target these at-risk patients for greater treatment efficiency. C1 [Trivedi, Ranak B.] VA Puget Sound Hlth Care Syst, NW Hlth Serv Res & Dev Serv Ctr Excellence, Seattle, WA USA. [Ayotte, Brian J.] Boston VA Hlth Care Syst, Boston, MA USA. [Thorpe, Carolyn T.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA. [Edelman, David; Bosworth, Hayden B.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. RP Trivedi, RB (reprint author), 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM ranak.trivedi@va.gov FU NHLBI [R01 HL070713]; Pfizer; American Heart Association; VA Puget Sound Health Care System FX This study was supported by NHLBI Grant R01 HL070713, a Pfizer Health Communication Initiative Award, and an American Heart Association Established Investigator Award, awarded to HBB, the principal investigator, who has full access to all of the data in the study and takes responsibility for the integrity of the data and its analysis. Results were initially presented at the 67th Annual Meeting of the American Psychosomatic Society. This work was supported in part by the facilities provided by the VA Puget Sound Health Care System where RBT is a core investigator. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government. We would like to thank Dr Joshua Thorpe for his suggestions regarding presentation of the analytic approach and results. NR 41 TC 3 Z9 3 U1 2 U2 4 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1177-889X J9 PATIENT PREFER ADHER JI Patient Prefer. Adherence PY 2010 VL 4 BP 255 EP 262 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA V21NV UT WOS:000208215200031 PM 20694185 ER PT J AU Hausmann, LRM Ren, DX Sevick, MA AF Hausmann, Leslie R. M. Ren, Dianxu Sevick, Mary Ann TI Racial differences in diabetes-related psychosocial factors and glycemic control in patients with type 2 diabetes SO PATIENT PREFERENCE AND ADHERENCE LA English DT Article DE diabetes mellitus; type 2; minority health; health status disparities; psychosocial factors; disease management AB Background: We examined whether diabetes-related psychosocial factors differ between African American and white patients with type 2 diabetes. We also tested whether racial differences in glycemic control are independent of such factors. Methods: Baseline glycosylated hemoglobin (HbA(1c)) and survey measures from 79 African American and 203 white adult participants in a diabetes self-management clinical trial were analyzed. Results: Several psychosocial characteristics varied by race. Perceived interference of diabetes with daily life, perceived diabetes severity, and diabetes-related emotional distress were higher for African Americans than for whites, as were access to illness-management resources and social support. Mean HbA(1c) levels were higher among African Americans than whites (8.14 vs 7.40, beta = 0.17). This difference persisted after adjusting for demographic, clinical, and diabetes-related psychosocial characteristics that differed by race (beta = 0.18). Less access to illness-management resources (beta = -0.25) and greater perceived severity of diabetes (beta = 0.21) also predicted higher HbA(1c). Discussion: Although racial differences in diabetes-related psychosocial factors were observed, African Americans continued to have poorer glycemic control than whites even after such differences were taken into account. Interventions that target psychosocial factors related to diabetes management, particularly illness-management resources, may be a promising way to improve glycemic control for all patients. C1 [Hausmann, Leslie R. M.; Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15206 USA. [Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15206 USA. [Ren, Dianxu] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. [Sevick, Mary Ann] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15261 USA. [Sevick, Mary Ann] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA. RP Hausmann, LRM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr,151C-H, Pittsburgh, PA 15206 USA. EM leslie.hausmann@va.gov FU Veterans Affairs Pittsburgh Healthcare System in Pittsburgh, PA; VA Health Services Research and Development Career Development Awards [RCD 06-287, ER 0280-1]; [NIH/NINR/NR-R01008792]; [NIH/NCRR/CTSA-UL1-RR024153]; [NIH/NCRR/GCRC-M01-RR000056] FX The work of this paper was supported by the following grants: NIH/NINR/NR-R01008792, NIH/NCRR/CTSA-UL1-RR024153, and NIH/NCRR/GCRC-M01-RR000056. This material is also the result of work supported by resources and the use of facilities at the Veterans Affairs Pittsburgh Healthcare System in Pittsburgh, PA. Dr Hausmann was supported by VA Health Services Research and Development Career Development Awards (RCD 06-287 and ER 0280-1). The authors take full responsibility for the contents of this paper, which do not represent the views of the Department of Veterans Affairs or the United States Government. The authors would like to acknowledge the individual contributions of: Rita Marsh, RN, MSN; Deborah Klinvex, BA; Tienna Luster; Beth Hall, RD; and Kathleen O'Malley, BA, BPhil. NR 66 TC 10 Z9 10 U1 0 U2 6 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1177-889X J9 PATIENT PREFER ADHER JI Patient Prefer. Adherence PY 2010 VL 4 BP 291 EP 299 DI 10.2147/PPA.S12353 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA V21NV UT WOS:000208215200035 PM 20859456 ER PT B AU Wenk, JF Zhang, ZH Cheng, GM Sun, K Walker, JC Saloner, DA Ratcliffe, MB Guccione, JM AF Wenk, Jonathan F. Zhang, Zhihong Cheng, Guangming Sun, Kay Walker, Joseph C. Saloner, David A. Ratcliffe, Mark B. Guccione, Julius M. BE Kerckhoffs, RCP TI In Vivo Myocardial Material Properties and Stress Distributions in Normal and Failing Human Hearts SO PATIENT -SPECIFIC MODELING OF THE CARDIOVASCULAR SYSTEM: TECHNOLOGY-DRIVEN PERSONALIZED MEDICINE LA English DT Article; Book Chapter ID LEFT-VENTRICULAR ANEURYSM; FINITE-ELEMENT-ANALYSIS; TAGGED MR-IMAGES; CANINE LEFT-VENTRICLE; WALL STRESS; DOPPLER-ECHOCARDIOGRAPHY; DILATED CARDIOMYOPATHY; 3-DIMENSIONAL STRAIN; DIASTOLIC FUNCTION; MODEL C1 [Wenk, Jonathan F.; Guccione, Julius M.] Univ Calif San Francisco, Dept Vet Affairs Med Ctr, Div Surg Serv 112D, San Francisco, CA 94121 USA. [Cheng, Guangming] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94121 USA. [Ratcliffe, Mark B.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Wenk, JF (reprint author), Univ Calif San Francisco, Dept Vet Affairs Med Ctr, Div Surg Serv 112D, Bldg 2,Room 106,4150 Clement St, San Francisco, CA 94121 USA. EM jonathan.wenk@va.gov NR 49 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-6690-2 PY 2010 BP 131 EP 144 DI 10.1007/978-1-4419-6691-9_8 D2 10.1007/978-1-4419-6691-9 PG 14 WC Cardiac & Cardiovascular Systems; Engineering, Biomedical SC Cardiovascular System & Cardiology; Engineering GA BQY34 UT WOS:000282103700008 ER PT J AU Shah, SS Ten Have, TR Metlay, JP AF Shah, Samir S. Ten Have, Thomas R. Metlay, Joshua P. TI Costs of Treating Children With Complicated Pneumonia: A Comparison of Primary Video-Assisted Thoracoscopic Surgery and Chest Tube Placement SO PEDIATRIC PULMONOLOGY LA English DT Article DE pleural effusion; empyema; thoracoscopy; resource utilization ID PEDIATRIC PARAPNEUMONIC EMPYEMA; COMMUNITY-ACQUIRED PNEUMONIA; PROPENSITY SCORES; MANAGEMENT; EFFUSIONS; DRAINAGE; OUTCOMES; THERAPY; CARE; DECORTICATION AB Objectives: To describe charges associated with primary video-assisted thoracoscopic surgery (VATS) and primary chest tube placement in a multicenter cohort of children with empyema and to determine whether pleural fluid drainage by primary VATS was associated with cost-savings compared with primary chest tube placement. Study Design: Retrospective cohort study Setting and Participants Administrative database containing inpatient resource utilization data from 27 tertiary care children's hospitals. Patients between 12 months and 18 years of age diagnosed with complicated pneumonia were eligible if they were discharged between 2001 and 2005 and underwent early (within 2 days of index hospitalization) pleural fluid drainage. Main Exposure: Method of pleural fluid drainage, categorized as VATS or chest tube placement. Results: Pleural drainage in the 764 patients was performed by VATS (n = 50) or chest tube placement (n = 714). There were 521 (54%) males. Median hospital charges were $36,320 [interquartile range (IQR), $24,814-$62,269]. The median pharmacy and radiologic imaging charges were $5,884 (IQR, $3,142-$11,357) and $2,875 (IQR, $1,703-$4,950), respectively Adjusting for propensity score matching, patients undergoing primary VATS did not have higher charges than patients undergoing primary chest tube placement. Conclusions: In this multicenter study, we found that the charges incurred in caring for children with empyema were substantial. However, primary VATS was not associated with higher total or pharmacy charges than primary chest tube placement, suggesting that the additional costs of performing VATS are offset by reductions in length of stay (LOS) and requirement for additional procedures. Pediatr Pulmonol. 2010; 45:71-77. (C) 2009 Wiley-Liss, Inc. C1 [Shah, Samir S.] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA. [Shah, Samir S.] Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA. [Shah, Samir S.; Ten Have, Thomas R.; Metlay, Joshua P.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Shah, Samir S.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Metlay, Joshua P.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Shah, Samir S.; Ten Have, Thomas R.; Metlay, Joshua P.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Metlay, Joshua P.] Vet Affairs Med Ctr, Philadelphia, PA USA. RP Shah, SS (reprint author), Childrens Hosp Philadelphia, Div Infect Dis, Room 1526,North Campus,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM shahs@email.chop.edu FU National Institute of Allergy and Infectious Diseases [K01 AI73729, K24 AI073957]; Robert Wood Johnson Foundation FX Grant sponsor: National Institute of Allergy and Infectious Diseases; Grant number: K01 AI73729; Grant number: K24 AI073957. Grant sponsor: Robert Wood Johnson Foundation. NR 33 TC 13 Z9 13 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 8755-6863 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD JAN PY 2010 VL 45 IS 1 BP 71 EP 77 DI 10.1002/ppul.21143 PG 7 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA 544BA UT WOS:000273625000010 PM 19953659 ER PT J AU Melhorn, SJ Krause, EG Scott, KA Mooney, MR Johnson, JD Woods, SC Sakai, RR AF Melhorn, Susan J. Krause, Eric G. Scott, Karen A. Mooney, Marie R. Johnson, Jeffrey D. Woods, Stephen C. Sakai, Randall R. TI Acute exposure to a high-fat diet alters meal patterns and body composition SO PHYSIOLOGY & BEHAVIOR LA English DT Article DE Meal patterns; High-fat diet; Body weight; Body composition ID OBESE ZUCKER RAT; FOOD-INTAKE; POSTPRANDIAL SATIETY; MACRONUTRIENT INTAKE; FEEDING PATTERNS; RESISTANT RATS; ENERGY-BALANCE; FEMALE RATS; OLETF RATS; SIZE AB Weight gain and adiposity are often attributed to the overconsumption of unbalanced, high-fat diets however, the pattern of consumption can also contribute to associated body weight and compositional changes. The present Study explored the rapid alterations in meal patterns of normal-weight rats given continuous access to high-fat diet and examined body weight and composition changes compared to chow fed controls. Ten Long-Evans rats were implanted with Subcutaneous microchips for meal pattern analysis. Animals were body weight matched and separated into two groups: high-fat or chow fed. Each group was maintained on their assigned diet for nine days and monitored for 22 h each day for meal pattern behavior. Body weight was evaluated every other day, and body composition measures were taken prior and following diet exposure. High-fat fed animals gained more weight and adipose tissue than chow fed controls and displayed a reduced meal frequency and increased meal size. Furthermore, meal size was significantly correlated with the gain of adipose tissue. Together, these results Suggest that consumption of a high-fat diet can rapidly alter meal patterns, which in turn contribute to the development of adiposity. Published by Elsevier Inc. C1 [Melhorn, Susan J.; Krause, Eric G.; Scott, Karen A.; Woods, Stephen C.; Sakai, Randall R.] Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH 45237 USA. [Melhorn, Susan J.; Scott, Karen A.] Univ Cincinnati, Coll Med, Program Neurosci, Cincinnati, OH 45237 USA. [Mooney, Marie R.; Johnson, Jeffrey D.] Univ Cincinnati, Dept Biomed Engn, Cincinnati, OH 45221 USA. RP Melhorn, SJ (reprint author), VA Puget Sound Hlth Care Syst, Lattemann Lab 151S, 1660 So Columbian Way, Seattle, WA 98108 USA. EM smelhorn@u.washington.edu FU NIDDK NIH HHS [R01 DK066596-06, R01 DK066596] NR 60 TC 25 Z9 25 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0031-9384 J9 PHYSIOL BEHAV JI Physiol. Behav. PD JAN PY 2010 VL 99 IS 1 BP 33 EP 39 DI 10.1016/j.physbeh.2009.10.004 PG 7 WC Psychology, Biological; Behavioral Sciences SC Psychology; Behavioral Sciences GA 553NL UT WOS:000274374000005 PM 19835896 ER PT J AU Claypool, BM Yoder, SC Citron, DM Finegold, SM Goldstein, EJC Haake, SK AF Claypool, Brianna M. Yoder, Sean C. Citron, Diane M. Finegold, Sydney M. Goldstein, Ellie J. C. Haake, Susan Kinder TI Mobilization and prevalence of a fusobacterial plasmid SO PLASMID LA English DT Article DE Fusobacterium nucleatum; Mobilization; Conjugation; Plasmid; pFN1 ID ENDODONTIC INFECTIONS; NUCLEATUM; PROTEIN; BACTERIA; GENE; IDENTIFICATION; MUTAGENESIS; RELAXOSOME; ABSCESSES; SEQUENCE AB Fusobacterium nucleatum is a Gram-negative anaerobic rod found in dental plaque biofilms, and is an opportunistic pathogen implicated in periodontitis as well as a wide range of systemic abscesses and infections. Genomic analyses of F. nucleatum indicate considerable genetic diversity and a prominent role for horizontal gene transfer in the evolution of the species. Several plasmids isolated from F nucleatum, including pFN1, harbor relaxase gene homologs that may function in plasmid mobilization. In this investigation we examined the RP4-mediated mobilization properties of pFN1 and the prevalence of pFN1-related sequences in a panel of F. nucleatum clinical isolates. The fusobacterial plasmid pFN1 was mobilized by RP4 at a high frequency. Deletion analyses were used to delineate the core mobilon of pFN1, which consisted of the relaxase gene (rlx), an upstream open reading frame ORF4 and a region of DNA upstream of ORF4 with potential nic sites. To examine the prevalence of pFN1 in a panel of clinical isolates, total DNA isolated from the strains was hybridized with pFN1 replication (repA) and rlx gene probes. DNA from strains harboring plasmids known to be homologous to pFN1 hybridized with both the repA and rlx probes. Five additional strains were rlx-positive but repA-negative, indicating a greater prevalence of rlx-related genes in comparison with repA-related genes. Plasmid or plasmid-related sequences were identified in 11.5% of the strains examined. These findings demonstrate mobilization properties of a fusobacterial plasmid that may be important in horizontal gene transfer. (C) 2009 Elsevier Inc. All rights reserved. C1 [Claypool, Brianna M.; Yoder, Sean C.; Haake, Susan Kinder] Univ Calif Los Angeles, Sch Dent, Sect Periodont, Los Angeles, CA 90095 USA. [Haake, Susan Kinder] Univ Calif Los Angeles, Sch Dent, Dent Res Inst, Los Angeles, CA 90095 USA. [Citron, Diane M.; Goldstein, Ellie J. C.] RM Alden Lab, Culver City, CA USA. [Finegold, Sydney M.] W Los Angeles Vet Adm, Wadsworth Anaerobe Lab, Los Angeles, CA USA. RP Haake, SK (reprint author), Univ Calif Los Angeles, Sch Dent, Sect Periodont, 10833 Conte Ave, Los Angeles, CA 90095 USA. EM shaake@ucla.edu FU NIH/NIDCR PHS [DE015348] FX We thank Dr. David Haake for his review of this manuscript. We additional acknowledge Dr. Sharon Hunt Gerardo and Ms. Anna Kreymer for suggestions and technical assistance, respectively. This investigation was supported by NIH/NIDCR PHS Grant No. DE015348 (S.K.H.). NR 36 TC 3 Z9 3 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0147-619X J9 PLASMID JI Plasmid PD JAN PY 2010 VL 63 IS 1 BP 11 EP 19 DI 10.1016/j.plasmid.2009.09.001 PG 9 WC Genetics & Heredity; Microbiology SC Genetics & Heredity; Microbiology GA 544YA UT WOS:000273695400002 PM 19761790 ER PT J AU Qin, ZQ Freitas, E Sullivan, R Mohan, S Bacelieri, R Branch, D Romano, M Kearney, P Oates, J Plaisance, K Renne, R Kaleeba, J Parsons, C AF Qin, Zhiqiang Freitas, Eduardo Sullivan, Roger Mohan, Sarumathi Bacelieri, Rocky Branch, Drake Romano, Margaret Kearney, Patricia Oates, Jim Plaisance, Karlie Renne, Rolf Kaleeba, Johnan Parsons, Chris TI Upregulation of xCT by KSHV-Encoded microRNAs Facilitates KSHV Dissemination and Persistence in an Environment of Oxidative Stress SO PLOS PATHOGENS LA English DT Article ID SARCOMA-ASSOCIATED HERPESVIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; MULTICENTRIC CASTLEMANS-DISEASE; PRIMARY EFFUSION LYMPHOMA; LATENTLY INFECTED-CELLS; KAPOSIS-SARCOMA; ENDOTHELIAL-CELLS; REACTIVE OXYGEN; PERIPHERAL-BLOOD; GENE-EXPRESSION AB Upregulation of xCT, the inducible subunit of a membrane-bound amino acid transporter, replenishes intracellular glutathione stores to maintain cell viability in an environment of oxidative stress. xCT also serves as a fusion-entry receptor for the Kaposi's sarcoma-associated herpesvirus (KSHV), the causative agent of Kaposi's sarcoma (KS). Ongoing KSHV replication and infection of new cell targets is important for KS progression, but whether xCT regulation within the tumor microenvironment plays a role in KS pathogenesis has not been determined. Using gene transfer and whole virus infection experiments, we found that KSHV-encoded microRNAs (KSHV miRNAs) upregulate xCT expression by macrophages and endothelial cells, largely through miR-K12-11 suppression of BACH-1-a negative regulator of transcription recognizing antioxidant response elements within gene promoters. Correlative functional studies reveal that upregulation of xCT by KSHV miRNAs increases cell permissiveness for KSHV infection and protects infected cells from death induced by reactive nitrogen species (RNS). Interestingly, KSHV miRNAs simultaneously upregulate macrophage secretion of RNS, and biochemical inhibition of RNS secretion by macrophages significantly reduces their permissiveness for KSHV infection. The clinical relevance of these findings is supported by our demonstration of increased xCT expression within more advanced human KS tumors containing a larger number of KSHV-infected cells. Collectively, these data support a role for KSHV itself in promoting de novo KSHV infection and the survival of KSHV-infected, RNS-secreting cells in the tumor microenvironment through the induction of xCT. C1 [Qin, Zhiqiang; Freitas, Eduardo; Sullivan, Roger; Mohan, Sarumathi; Kearney, Patricia; Oates, Jim; Parsons, Chris] Med Univ S Carolina, Dept Med, Hollings Canc Ctr, Charleston, SC 29425 USA. [Qin, Zhiqiang; Parsons, Chris] Med Univ S Carolina, Hollings Canc Ctr, Dept Craniofacial Biol, Charleston, SC 29425 USA. [Bacelieri, Rocky; Branch, Drake] Med Univ S Carolina, Hollings Canc Ctr, Dept Dermatol, Charleston, SC 29425 USA. [Romano, Margaret] Med Univ S Carolina, Hollings Canc Ctr, Dept Pathol, Charleston, SC 29425 USA. [Oates, Jim] Ralph H Johnson VA Med Ctr, Med Serv, Charleston, SC USA. [Plaisance, Karlie; Renne, Rolf] Univ Florida, Dept Mol Genet & Microbiol, Shands Canc Ctr, Gainesville, FL USA. [Kaleeba, Johnan] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Microbiol & Immunol, Bethesda, MD 20814 USA. [Kaleeba, Johnan] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Mol Cell Biol, Bethesda, MD 20814 USA. RP Qin, ZQ (reprint author), Med Univ S Carolina, Dept Med, Hollings Canc Ctr, Charleston, SC 29425 USA. EM jkaleeba@usuhs.mil; parsonch@musc.edu FU National Institutes of Health [K08-1CA103858]; South Carolina COBRE for Oral Health [P20-RR017696]; MUSC Hollings Cancer Center Translational Pilot Award; USUHS [R073NS]; MUSC Hollings Cancer Center [P30-CA-138313] FX This work was supported by grants from the National Institutes of Health (K08-1CA103858 to CP), the South Carolina COBRE for Oral Health (P20-RR017696; CP is subproject investigator), an MUSC Hollings Cancer Center Translational Pilot Award (CP), a USUHS grant (R073NS to JK), and the MUSC Hollings Cancer Center (core grant P30-CA-138313 to the HCC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 71 TC 53 Z9 55 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7366 J9 PLOS PATHOG JI PLoS Pathog. PD JAN PY 2010 VL 6 IS 1 AR e1000742 DI 10.1371/journal.ppat.1000742 PG 14 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 551RQ UT WOS:000274227100032 PM 20126446 ER PT B AU Sano, M Jacobs, D Gaynor, K AF Sano, Mary Jacobs, Diane Gaynor, Katya BE Legato, MJ TI Hormone Replacement Therapy and Cognitive Function SO PRINCIPLES OF GENDER-SPECIFIC MEDICINE, 2ND EDITION LA English DT Article; Book Chapter ID HEALTH INITIATIVE MEMORY; RANDOMIZED CONTROLLED-TRIAL; CONJUGATED EQUINE ESTROGENS; SURGICALLY MENOPAUSAL WOMEN; QUALITY-OF-LIFE; RADIAL-ARM MAZE; POSTMENOPAUSAL WOMEN; ALZHEIMERS-DISEASE; BREAST-CANCER; DOUBLE-BLIND C1 [Sano, Mary] Alzheimer Dis Res Ctr, New York, NY USA. [Sano, Mary; Gaynor, Katya] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Sano, Mary] James J Peters VAMC, New York, NY USA. RP Sano, M (reprint author), Alzheimer Dis Res Ctr, New York, NY USA. NR 57 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND BN 978-0-08-092150-1; 978-0-12-374271-1 PY 2010 BP 142 EP 148 DI 10.1016/B978-0-12-374271-1.00013-7 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA BEO92 UT WOS:000317610700017 ER PT B AU Pearlman, J Cooper, R Chhabra, HS Jefferds, A Anbarasan, I AF Pearlman, Jon Cooper, Rory Chhabra, H. S. Jefferds, Alexandra Anbarasan, Ilanagai GP ASME TI A LOW-COST TOOL FOR GATHERING AND INTERPRETING THE MOBILITY NEEDS OF WHEELCHAIR USERS IN INDIA SO PROCEEDINGS OF THE ASME INTERNATIONAL DESIGN ENGINEERING TECHNICAL CONFERENCES AND COMPUTERS AND INFORMATION IN ENGINEERING CONFERENCE, VOL 8, PTS A AND B LA English DT Proceedings Paper CT ASME International Design Engineering Technical Conferences/Computers and Information in Engineering Conference CY AUG 30-SEP 02, 2009 CL San Diego, CA SP ASME, Design Engn Div, ASME, Computers & Info Engn Div ID REHABILITATION; DISABILITIES; WOMEN; DEVICE AB Collecting and interpreting customer needs using traditional product development tools can be difficult or impossible when there is a large geographic, cultural, or social gap between the customer and product designer. As part of a project to design an electric powered wheelchair (EPW) for Indians with disabilities, we piloted a new approach to gather and interpret customer needs. First, we distributed cameras to manual wheelchair users at the Indian Spinal Injury Center in New Delhi, India, and asked subjects take photos and write descriptions of accessibility barriers in and around their homes. The film was then processed; photos were de-identified and integrated into an internet-based questionnaire. Individuals with expertise in wheelchair use and design, and home modifications were recruited to participate in the questionnaire where they identified and ranked the accessibility barriers in each of 50 images which were randomly selected from the full database. Thirty cameras were received, yielding approximately 500 photos which were integrated into the questionnaire. A total of 72 subjects from 8 countries participated in the questionnaire. Using cluster analysis, we developed unique groupings for accessibility barriers based on their severity and prevalence. These groupings provided valuable and relevant information to develop and prioritize the design specifications of the EPW. C1 [Pearlman, Jon; Cooper, Rory] VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Pearlman, J (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. NR 45 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC MECHANICAL ENGINEERS PI NEW YORK PA THREE PARK AVENUE, NEW YORK, NY 10016-5990 USA BN 978-0-7918-4905-7 PY 2010 BP 531 EP 540 PG 10 WC Computer Science, Interdisciplinary Applications; Engineering, Manufacturing; Engineering, Mechanical SC Computer Science; Engineering GA BUU86 UT WOS:000290416800052 ER PT S AU Yehuda, R Bierer, LM Pratchett, LC Pelcovitz, M AF Yehuda, Rachel Bierer, Linda M. Pratchett, Laura C. Pelcovitz, Michelle BE Barchas, JD Difede, J TI Using biological markers to inform a clinically meaningful treatment response SO PSYCHIATRIC AND NEUROLOGIC ASPECTS OF WAR SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT 89th Annual Conference of the Association for Research in Nervous and Mental Disease CY DEC 16, 2009 CL Rockefeller Univ, New York, NY HO Rockefeller Univ DE PTSD; treatment response; combat trauma; neuroendocrinology ID POSTTRAUMATIC-STRESS-DISORDER; EXPOSURE THERAPY; VETERANS; CORTISOL; PTSD; PSYCHOTHERAPY; SERTRALINE; VICTIMS; PLACEBO; TRAUMA AB Combat veterans with posttraumatic stress disorder (PTSD) demonstrate less robust improvement following treatments than do civilians with PTSD. This paper discusses a theoretical model for evaluating treatment response based on the extent of change in biological markers of symptom severity or resilience between treatment initiation and termination. Such analysis permits a determination of biological change associated with the liberal criteria commonly used to determine treatment response in combat PTSD, and a comparison of this to the biological change associated with clinical response determined according to the conservative definition more appropriate to civilian PTSD. Interim data supporting the utility of this approach is presented based on preliminary analyses from our work in progress. We propose that future studies consider the unique consequences of combat trauma and develop treatments that incorporate the complex nature of the exposure and response characteristic of a veteran population. C1 [Yehuda, Rachel; Bierer, Linda M.; Pratchett, Laura C.] James J Peters VAMC, Dept Psychiat, Bronx, NY USA. [Yehuda, Rachel; Bierer, Linda M.; Pelcovitz, Michelle] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Yehuda, R (reprint author), James J Peters VAMC, Dept Psychiat, 526 OOMH,130 W Kingsbridge Rd, Bronx, NY USA. EM rachel.yehuda@va.gov FU NIMH [MH088101]; DOD [PT073577, 10164894]; VA Merit Review FX This work was supported by the following funding: NIMH MH088101, DOD PT073577 and 10164894, and VA Merit Review to R.Y. NR 36 TC 13 Z9 13 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-804-4 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1208 BP 158 EP 163 DI 10.1111/j.1749-6632.2010.05698.x PG 6 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA BSK28 UT WOS:000284742000020 PM 20955338 ER PT J AU Salzer, MS Kundra, LB AF Salzer, Mark S. Kundra, Loran B. TI Liability Issues Associated With Referrals to Self-Help Groups SO PSYCHIATRIC SERVICES LA English DT Article AB Self-help groups, which are also referred to as mutual aid groups, are widely recognized as an important component of a comprehensive public mental health system that promotes recovery. Nonetheless, some psychiatrists and other providers have expressed concerns about these consumer-run groups and fear potential liability if they make referrals and something harmful occurs. This column reviews potential liability claims that could be made pertaining to referrals to self-help groups. The authors conclude that the likelihood of success of a plaintiff's claim is small. Recommendations are given for further lowering the likelihood of a successful suit. (Psychiatric Services 61: 6-8, 2010) C1 [Salzer, Mark S.] Univ Penn, Sch Med, Dept Psychiat, Ctr Mental Hlth Policy & Serv Res, Philadelphia, PA 19104 USA. [Salzer, Mark S.] Philadelphia Dept Veter Affairs Med Ctr, Vet Integrated Serv Network 4, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. [Kundra, Loran B.] UPenn Collaborat Community Integrat, Wayne, PA USA. RP Salzer, MS (reprint author), Univ Penn, Sch Med, Dept Psychiat, Ctr Mental Hlth Policy & Serv Res, 3535 Market St,3rd Floor, Philadelphia, PA 19104 USA. EM mark.salzer@uphs.upenn.edu FU Federal Department of Education, National Institute on Disability and Rehabilitation Research [H133B031109] FX The contents of this legal summary were developed under a grant to the University of Pennsylvania from the Federal Department of Education, National Institute on Disability and Rehabilitation Research grant H133B031109 (Dr. Salzer, principal investigator). However, the contents do not necessarily represent the policy of the Department of Education and do not imply endorsement by the federal government. NR 9 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JAN PY 2010 VL 61 IS 1 BP 6 EP 8 PG 3 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 539DX UT WOS:000273234800002 PM 20044410 ER PT J AU McInnes, DK Hyun, JK Trafton, JA Asch, SM Gifford, AL AF McInnes, D. Keith Hyun, Jenny K. Trafton, Jodie A. Asch, Steven M. Gifford, Allen L. TI Program Characteristics Associated With Testing for HIV and Hepatitis C in Veterans Substance Use Disorder Clinics SO PSYCHIATRIC SERVICES LA English DT Article ID VA PATIENTS; DRUG-USERS; INFECTION; RISK; CARE AB Objective: This study examined whether organizational characteristics and quality improvement initiatives were related to HIV and hepatitis C (HCV) testing rates in veterans' substance use disorders programs. Methods: Data were collected by surveying 232 program directors at all U. S. Department of Veterans Affairs (VA) substance use disorder programs. Results: Program directors (N = 223) reported that, on average, 35% of their patients were tested for HIV (median = 10%) and 57% were tested for HCV (median = 80%). Of the quality improvement initiatives examined, computerized reminders to clinicians (p = .02) and a designated clinician for screening (p = .01) were positively associated with HCV testing, and computerized templates that guide clinicians through ordering of testing were positively associated with HIV testing (p = .06). Conclusions: Despite national emphasis on HIV testing, rates of testing were lower for HIV than for HCV in programs serving veterans with substance use disorders and at risk of both illnesses. System-level quality improvement initiatives may be effective at increasing rates of infectious disease screening. (Psychiatric Services 61: 90-94, 2010) C1 [McInnes, D. Keith] Edith Nourse Rogers Mem Vet Adm Hosp, CHQOER, Bedford, MA 01730 USA. [McInnes, D. Keith] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Hyun, Jenny K.] Dept Vet Affairs, Natl Ctr PTSD, Palo Alto, CA USA. [Trafton, Jodie A.] VA Ctr Hlth Care Evaluat, Menlo Pk, CA USA. [Asch, Steven M.] VA Greater Los Angeles Hlth Care Syst, HIV Hepatitis Qual Enhancement Res Initiat, Los Angeles, CA USA. [Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Gifford, Allen L.] VA New England Hlth Care Syst, HIV Hepatitis Qual Enhancement Res Initiat, Bedford, MA USA. [Gifford, Allen L.] Boston Univ, Sch Med, Boston, MA 02118 USA. RP McInnes, DK (reprint author), Edith Nourse Rogers Mem Vet Adm Hosp, CHQOER, 200 Springs Rd 152,Bldg 70, Bedford, MA 01730 USA. EM keith.mcinnes@va.gov NR 12 TC 1 Z9 1 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JAN PY 2010 VL 61 IS 1 BP 90 EP 94 PG 5 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 539DX UT WOS:000273234800018 PM 20044426 ER PT J AU Even, C Weintraub, D AF Even, Christian Weintraub, Daniel TI Case for and against specificity of depression in Alzheimer's disease SO PSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Review DE aged; Alzheimer's disease; dementia; depression; mood disorders ID LATE-ONSET DEPRESSION; PROVISIONAL DIAGNOSTIC-CRITERIA; DEFINED VASCULAR DEPRESSION; MAJOR DEPRESSION; DOUBLE-BLIND; GERIATRIC DEPRESSION; PSYCHIATRIC-SYMPTOMS; GLUCOSE-METABOLISM; PRIMARY DEMENTIA; CACHE COUNTY AB Aims: The aims of this study were to assess the epidemiological, phenomenological, and pathophysiological evidence that suggests the specificity of depression associated with Alzheimer's disease (AD). Methods: We reviewed the English-language literature. Results: Depression occurs significantly more often in patients with AD than in the general elderly population. While development of depression in response to the disability and emotional stress of AD may be a contributory factor in some patients, several studies showed that depression was not, or was only seldom, related to self-awareness of AD and these studies could not explain the high prevalence figures. To overcome the overlapping phenomenology of the two diseases, specific diagnostic criteria have been developed for depression in this context. Mixed findings have come from neuropathological and neuroimaging studies, with some evidence linking the underlying neural substrate of AD and depression, suggesting an overlapping cause of primary depression and depression comorbid with AD. Few randomized controlled trials for depression associated with AD have been conducted, with rather poor results for the use of antidepressants. Conclusions: Currently, depression associated with AD is not considered a separate disorder by regulatory authorities and is unlikely to be considered as such in the near future. Several obstacles remain to support such a specific position, including the heterogenous nature of depression in general and within AD itself, the lack of a distinct set of symptoms, and limited treatment. C1 [Even, Christian] Univ Paris 05, Ctr Hosp St Anne, Clin Malad Mentales & Encephale, INSERM,U675,Ctr Psychiat & Neurosci, F-75674 Paris 14, France. [Weintraub, Daniel] Univ Penn, PADRECC, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, MIRECC, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Even, C (reprint author), Univ Paris 05, Ctr Hosp St Anne, Clin Malad Mentales & Encephale, INSERM,U675,Ctr Psychiat & Neurosci, 100 Rue Sante, F-75674 Paris 14, France. EM c.even@ch-sainte-anne.fr NR 85 TC 9 Z9 10 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-1316 EI 1440-1819 J9 PSYCHIAT CLIN NEUROS JI Psychiatry Clin. Neurosci. PY 2010 VL 64 IS 4 BP 358 EP 366 DI 10.1111/j.1440-1819.2010.02108.x PG 9 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 631OA UT WOS:000280355800002 PM 20573052 ER PT J AU Boeka, AG Prentice-Dunn, S Lokken, KL AF Boeka, Abbe G. Prentice-Dunn, Steven Lokken, Kristine L. TI Psychosocial predictors of intentions to comply with bariatric surgery guidelines SO PSYCHOLOGY HEALTH & MEDICINE LA English DT Article DE protection motivation theory; health behavior model; post-surgical compliance; bariatric surgery outcome ID PROTECTION MOTIVATION THEORY; GASTRIC BYPASS-SURGERY; SKIN-CANCER RISK; EATING DISTURBANCES; WEIGHT-LOSS; BEHAVIOR; OBESITY; INTERVENTION; GASTROPLASTY; METAANALYSIS AB An increasing body of research suggests that many patients have difficulty adopting the eating guidelines after weight-loss surgery, thereby reducing the long-term success of the procedure. Given such difficulties, it is possible that the typical preoperative education regarding post-surgical eating behavior guidelines is ineffective in motivating some individuals to comply. Presently, no accurate predictors of intentions to comply with post-bariatric surgery guidelines have been identified. In the present pilot study, a psychosocial intervention based on protection motivation theory (PMT) was presented to patients undergoing bariatric surgery. PMT is a well-established preventive health model that has been utilized in a variety of health domains. Participants for this study were recruited before undergoing bariatric surgery, and were randomly assigned to one of two groups: PMT group vs. control. In addition to routine messages from the bariatric surgeon, participants in the PMT group received an intervention based in PMT that focused on the importance of adhering to post-surgical eating behavior guidelines and how best to adhere to these guidelines. Participants in the control group received standard of care information from the bariatric surgeon. Results indicated that the PMT intervention did not have a significant impact. However, follow-up analyses revealed that two aspects of PMT, perceived self-efficacy and perceived threat of not following the guidelines, predicted patients' intentions to comply with post-surgical guidelines. Findings are discussed in terms of the methodological compromises that resulted from the applied research setting as well as promising avenues for future investigation. C1 [Boeka, Abbe G.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. [Boeka, Abbe G.; Prentice-Dunn, Steven] Univ Alabama, Dept Psychol, Tuscaloosa, AL 35487 USA. [Lokken, Kristine L.] Univ Alabama, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA. [Lokken, Kristine L.] Birmingham VA Med Ctr, Dept Phys Med & Rehabil, Birmingham, AL USA. RP Boeka, AG (reprint author), Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. EM abbe.boeka@yale.edu OI Brooks, Steven/0000-0002-4592-4974 NR 26 TC 8 Z9 8 U1 0 U2 14 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1354-8506 J9 PSYCHOL HEALTH MED JI Psychol. Health Med. PY 2010 VL 15 IS 2 BP 188 EP 197 DI 10.1080/13548501003615282 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 583ZO UT WOS:000276720000008 PM 20391236 ER PT J AU Cohn, AM Jakupcak, M Seibert, LA Hildebrandt, TB Zeichner, A AF Cohn, Amy M. Jakupcak, Matthew Seibert, L. Alana Hildebrandt, Thomas B. Zeichner, Amos TI The Role of Emotion Dysregulation in the Association Between Men's Restrictive Emotionality and Use of Physical Aggression SO PSYCHOLOGY OF MEN & MASCULINITY LA English DT Article DE aggression; restrictive emotionality; emotion dysregulation; gender role conflict ID POSTTRAUMATIC-STRESS-DISORDER; GENDER-ROLE STRESS; LABORATORY AGGRESSION; EXPERIENTIAL AVOIDANCE; CHILD CONVERSATIONS; SAMPLE-SIZE; BEHAVIOR; EXPRESSION; VIOLENCE; SCALE AB To test the mediating effect of emotional dysregulation on the association between men's restrictive emotionality and the use of aggression toward another, 128 undergraduate men were asked to complete a Response Choice Aggression Paradigm (RCAP), a competitive reaction time task in which participants were given the choice to shock or refrain from shocking an ostensible opponent. Aggression was measured as the average intensity of shocks delivered by the participant throughout the task, restrictive emotionality was measured using a subscale of the Gender Role Conflict Scale (O'Neil, Helms, Gable, David, & Wrightman, 1986), and emotional dysregulation was measured by the Difficulties in Emotion Regulation Scale (Gratz & Roemer, 2004). Findings from a structural equation model showed that emotional dysregulation does mediate the association between restrictive emotionality and aggression. Specifically, this relationship appeared to be largely driven by a lack of acceptance and inability to tolerate emotional experiences, rather than by overall inability to regulate internal experiences. Conceptual and clinical implications for addressing men's aggressive behavior are discussed. C1 [Cohn, Amy M.] Rutgers State Univ, Ctr Alcohol Studies, Piscataway, NJ 08854 USA. [Jakupcak, Matthew] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, VA Puget Sound Hlth Care Syst,MIRECC, Washington, DC USA. [Seibert, L. Alana; Zeichner, Amos] Univ Georgia, Dept Psychol, Athens, GA 30602 USA. [Hildebrandt, Thomas B.] Mt Sinai Sch Med, New York, NY USA. RP Cohn, AM (reprint author), Rutgers State Univ, Ctr Alcohol Studies, 607 Allison Rd, Piscataway, NJ 08854 USA. EM amycohn@rci.rutgers.edu OI Hildebrandt, Thomas/0000-0001-7054-9590 NR 74 TC 28 Z9 28 U1 0 U2 10 PU EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1524-9220 J9 PSYCHOL MEN MASCULIN JI Psychol. Men Masculinity PD JAN PY 2010 VL 11 IS 1 BP 53 EP 64 DI 10.1037/a0018090 PG 12 WC Psychology, Social SC Psychology GA 586HF UT WOS:000276896400005 ER PT B AU Thompson, BL AF Thompson, Brian L. BE Jackson, RG TI WHY NEUROTICISM MAY BE RELEVANT TO UNDERSTANDING RESPONSE TO MEDITATION-BASED INTERVENTIONS: A REVIEW OF SOME FORGOTTEN LITERATURE SO PSYCHOLOGY OF NEUROTICISM AND SHAME SE Psychology of Emotions Motivations and Actions LA English DT Article; Book Chapter ID COGNITIVE THERAPY; MINDFULNESS MEDITATION; DEPRESSED-PATIENTS; ANXIETY DISORDERS; MAJOR DEPRESSION; 5-FACTOR MODEL; SELF-REPORT; PERSONALITY; METAANALYSIS; POPULATION AB Before the explosion of interest in mindfulness-based interventions (e.g. Hayes, Follette, & Linehan, 2004), early meditation researchers explored the impact of personality traits on response to sitting meditation practice, particularly with Transcendental Meditation. The purpose of this chapter is to provide a brief overview of that early research and explore how some of the findings of these often forgotten studies may be incorporated into contemporary research on meditation-based treatments. Given the incidence of depression in individuals high in neuroticism, particular emphasis is placed on understanding how neuroticism might impact and be impacted by Mindfulness-Based Cognitive Therapy for depression (Segal, Williams, & Teasdale, 2002). C1 Portland VA Med Ctr, Portland, OR USA. RP Thompson, BL (reprint author), Portland VA Med Ctr, Portland, OR USA. NR 51 TC 0 Z9 0 U1 2 U2 3 PU NOVA SCIENCE PUBLISHERS, INC PI HAUPPAUGE PA 400 OSER AVE, STE 1600, HAUPPAUGE, NY 11788-3635 USA BN 978-1-60876-870-7 J9 PSYCHOL EMOT MOTIV A PY 2010 BP 225 EP 234 PG 10 WC Psychology, Multidisciplinary SC Psychology GA BPM62 UT WOS:000279304400012 ER PT J AU Lovallo, WR Robinson, JL Glahn, DC Fox, PT AF Lovallo, William R. Robinson, Jennifer L. Glahn, David C. Fox, Peter T. TI Acute effects of hydrocortisone on the human brain: An fMRI study SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Cortisol; Hydrocortisone; Human; Brain; Magnetic resonance imaging; Amygdala; Hippocampus; Thalamus ID HIPPOCAMPAL-FORMATION VOLUME; MEMORY RETRIEVAL; RAT-BRAIN; PREFRONTAL CORTEX; CORTISOL; STRESS; RECEPTOR; GLUCOCORTICOIDS; CORTICOSTERONE; PERFORMANCE AB Cortisol is essential for regulating all cell types in the body, including those in the brain. Most information concerning cortisol's cerebral effects comes from work in nonhumans. This is a first effort to use functional magnetic resonance imaging (fMRI) to study the time course and locus of cortisol's effects on selected brain structures in resting humans. We repeatedly scanned 21 healthy young adults over 45 min to examine changes in the brain's activity 5 min before, and for 40 min after, an IV injection of 10 mg of hydrocortisone (N = 11) or saline placebo (N = 10). At 15-18 min postinjection we observed in the hydrocortisone group reduced activity in the hippocampus and amygdala that reached a peak response minimum at 25-30 min postinjection (-1 Standard Deviation) relative to placebo. No such effect was seen in the thalamus. Functional MRI appears to be a safe, noninvasive method to study the time course and anatomical effects of glucocorticoids in the human brain. Published by Elsevier Ltd. C1 [Lovallo, William R.] Univ Oklahoma, Hlth Sci Ctr, Vet Affairs Med Ctr, Behav Sci Labs, Oklahoma City, OK 73104 USA. [Lovallo, William R.] Univ Oklahoma, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Oklahoma City, OK 73104 USA. [Robinson, Jennifer L.; Glahn, David C.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Robinson, Jennifer L.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Ctr, San Antonio, TX 78229 USA. [Robinson, Jennifer L.; Fox, Peter T.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Lovallo, WR (reprint author), Vet Affairs Med Ctr, Behav Sci Labs 151A, 921 NE 13th St, Oklahoma City, OK 73104 USA. EM bill@mindbody1.org RI Fox, Peter/B-4725-2010; Robinson, Jennifer/B-7893-2010 OI Fox, Peter/0000-0002-0465-2028; FU Medical Research Service of the Department of Veterans Affairs; National Institutes of Health, NIAAA [AA12207]; NARSAD; UTHSCSA GCRC [M01-RR-01346] FX This work was supported by the Medical Research Service of the Department of Veterans Affairs (W.R.L.), the National Institutes of Health, NIAAA (AA12207) (W.R.L.), NARSAD (Esset Young Investigator, D.C.G.), and the UTHSCSA GCRC (M01-RR-01346). NR 39 TC 52 Z9 52 U1 1 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD JAN PY 2010 VL 35 IS 1 SI SI BP 15 EP 20 DI 10.1016/j.psyneuen.2009.09.010 PG 6 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 546WG UT WOS:000273844100003 PM 19836143 ER PT J AU Condray, R Siegle, GJ Steinhauer, SR AF Condray, Ruth Siegle, Greg J. Steinhauer, Stuart R. TI SEMANTIC MEMORY AND WORD FREQUENCY MODULATE N400 IN THE FAMILY MEMBERS OF SCHIZOPHRENIA PATIENTS SO PSYCHOPHYSIOLOGY LA English DT Meeting Abstract CT 15th Annual Meeting Portland Marriott Downtown Waterfront CY SEP 29-OCT 03, 2010 CL Portland, OR SP Soc Psychophysiolog C1 [Condray, Ruth; Siegle, Greg J.; Steinhauer, Stuart R.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Steinhauer, Stuart R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0048-5772 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PY 2010 VL 47 SU 1 BP S10 EP S10 PG 1 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 635NI UT WOS:000280662000056 ER PT J AU Ford, JM Perez, V Roach, BJ Vinogradov, S Loewy, R Stuart, BK Mathalon, DH AF Ford, Judith M. Perez, Veronica Roach, Brian J. Vinogradov, Sophia Loewy, Rachel Stuart, Barbara K. Mathalon, Daniel H. TI SPEECH-INDUCED SUPPRESSION OF AUDITORY CORTEX: COROLLARY DISCHARGE DYSFUNCTION IN THE PRODROMAL STAGE OF SCHIZOPHRENIA SO PSYCHOPHYSIOLOGY LA English DT Meeting Abstract CT 50th Annual Meeting of the Society-for-Psychophysiological-Research CY SEP 29-OCT 03, 2010 CL Portland, OR SP Soc Psychophysiol Res C1 [Ford, Judith M.; Perez, Veronica; Roach, Brian J.; Vinogradov, Sophia; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ford, Judith M.; Perez, Veronica; Roach, Brian J.; Vinogradov, Sophia; Loewy, Rachel; Stuart, Barbara K.; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0048-5772 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PY 2010 VL 47 SU 1 BP S10 EP S10 PG 1 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 635NI UT WOS:000280662000054 ER PT J AU Mathalon, DH AF Mathalon, Daniel H. TI BEYOND THE ODDBALL IN SCHIZOPHRENIA RESEARCH: NEUROPHYSIOLOGIC STUDIES OF MEMORY AND LANGUAGE PROCESSING SO PSYCHOPHYSIOLOGY LA English DT Meeting Abstract CT 50th Annual Meeting of the Society-for-Psychophysiological-Research CY SEP 29-OCT 03, 2010 CL Portland, OR SP Soc Psychophysiol Res C1 [Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0048-5772 J9 PSYCHOPHYSIOLOGY JI Psychophysiology PY 2010 VL 47 SU 1 BP S10 EP S10 PG 1 WC Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental SC Psychology; Neurosciences & Neurology; Physiology GA 635NI UT WOS:000280662000053 ER PT J AU Prowler, ML Weiss, D Caroff, SN AF Prowler, Matthew L. Weiss, David Caroff, Stanley N. TI Treatment of Catatonia With Methylphenidate in an Elderly Patient With Depression SO PSYCHOSOMATICS LA English DT Article AB Background: Catatonia is especially common among patients with mood disorders. Objective: The authors evaluated the effects of methylphenidate as an augmentation strategy in an elderly patient with catatonia and depression. Method: Methylphenidate was administered to a catatonic patient who had not responded to lorazepam. Results: The patient showed an acute and marked response to methylphenidate. Discussion: Methylphenidate may be effective as an adjunct in elderly depression patients with catatonia, as well as in medically ill, apathetic patients. However, there have been few attempts to study the role of psychostimulants in alleviating catatonia in general, or catatonia associated specifically with an underlying depressive disorder, even though catatonia is frequently associated with mood disorders. (Psychosomatics 2010; 51: 74-76) C1 [Prowler, Matthew L.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Prowler, ML (reprint author), Univ Penn, Sch Med, Dept Psychiat, 3535 Market St,2nd Fl, Philadelphia, PA 19104 USA. EM matthew.prowler@uphs.upenn.edu NR 17 TC 6 Z9 6 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD JAN-FEB PY 2010 VL 51 IS 1 BP 74 EP 76 PG 3 WC Psychiatry; Psychology SC Psychiatry; Psychology GA 550SC UT WOS:000274148500011 PM 20118444 ER PT J AU Arar, N Seo, J Lee, S Abboud, HE Copeland, LA Noel, P Parchman, M AF Arar, N. Seo, J. Lee, S. Abboud, H. E. Copeland, L. A. Noel, P. Parchman, M. TI Preferences regarding Genetic Research Results: Comparing Veterans and Nonveterans Responses SO PUBLIC HEALTH GENOMICS LA English DT Article DE Common complex diseases; Ethics; Genetic family studies; Research results ID RESEARCH PARTICIPANTS; CANCER; INFORMATION; ETHICS; POPULATION; DISCLOSURE; ATTITUDES; GENOMICS; RETURN; ADOLESCENTS AB Objective: Communicating genetic research results to participants presents ethical challenges. Our objectives were to examine participants' preferences in receiving future genetic research results and to compare preferences reported by veteran and nonveterans participants. Methods: Secondary analysis was performed on data collected in 2000-2004 from 1,575 consent forms signed by Mexican-American participants enrolled in 2 genetic family studies (GFS) in San Antonio: The Family Investigation of Nephropathy and Diabetes (FIND) and the Extended FIND (EFIND). The consent forms for these studies contained multiple-choice questions to examine participants' preferences about receiving their (1) clinical lab results and (2) future genetic research results. The FIND and EFIND databases had information on subjects' demographic characteristics and some selected clinical variables. We identified veterans using the Veterans Health Administration's (VHA's) centralized data repository. We compared veterans' and nonveterans' preferences using Student's t test for continuous variables and chi(2) test for discrete variables. A logistic regression analyzed subjects' preference for receiving their research results, controlling for other socio-demographic and clinical variables. Results: The sample included 275 (18%) veterans and 1,247 (82%) nonveterans. Our results indicated a strong desire among the majority of participants 1,445 (95%) in getting their clinical lab research results. Likewise, 93% expressed interest in being informed about their future genetic results. There was no significant difference in veterans' and nonveterans' preference to disclosure of the research results (chi(2) test; p > 0.05). Regression analysis showed no significant relationship (p = 0.449) between the outcome (receiving research results) and veterans' responses after controlling for demographics and educational levels. Conclusion: Participants believed they would prefer receiving their genetic research results. Veterans are similar to nonveterans in their preferences. Offering genetic research results to participants should be based on well defined and structured plans to enhance interpretation of genetic data. Copyright (C) 2010 S. Karger AG, Basel C1 [Arar, N.; Seo, J.; Lee, S.; Abboud, H. E.; Copeland, L. A.; Noel, P.; Parchman, M.] Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Dept Med, Audie L Murphy Mem Vet Hosp, San Antonio, TX 78229 USA. RP Arar, N (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med Nephrol, S Texas Hlth Care Syst, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM ararn@uthscsa.edu OI Copeland, Laurel/0000-0002-9478-0209 FU NIH/NIDDK [P50 DK061597]; VHA-HSRD [PPO 09-241, DNA 08-129] FX We wish to thank all participants of the FIND and EFIND Studies for their cooperation and generous participation. This study was supported by funds from NIH/NIDDK (P50 DK061597). This work was also supported by the VHA-HSR&D (PPO 09-241 and DNA 08-129: Nedal Arar PhD). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 40 TC 8 Z9 8 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1662-4246 J9 PUBLIC HEALTH GENOM JI Pub. Health Genomics PY 2010 VL 13 IS 7-8 BP 431 EP 439 DI 10.1159/000317099 PG 9 WC Genetics & Heredity; Public, Environmental & Occupational Health SC Genetics & Heredity; Public, Environmental & Occupational Health GA 690NQ UT WOS:000285011900006 PM 20829581 ER PT J AU Thornton, E Morrin, MM Yee, J AF Thornton, Eavan Morrin, Martina M. Yee, Judy TI Current Status of MR Colonography SO RADIOGRAPHICS LA English DT Article ID MAGNETIC-RESONANCE COLONOGRAPHY; INITIAL CLINICAL-EXPERIENCE; LIMITED BOWEL PREPARATION; CT COLONOGRAPHY; CONVENTIONAL COLONOSCOPY; COLORECTAL-CANCER; COLONIC DISTENSION; DIAGNOSTIC-ACCURACY; PATIENT ACCEPTANCE; CONTRAST MATERIAL AB The search for an acceptable colorectal cancer screening examination has led to the development of virtual colonoscopy, which includes both computed tomographic (CT) colonography and magnetic resonance (MR) colonography. As indicated by the much larger number of published studies on CT colonography than on MR colonography, multidetector CT appears to be more suitable for colorectal screening than does MR colonography, in part reflecting the ease and speed of performing CT, as well as the increased spatial resolution, decreased cost, and wider availability of CT colonography. The main advantage of MR colonography over CT colonography is that it does not use ionizing radiation, which has important implications for colorectal cancer screening. The use of dark-lumen MR colonography to screen patients for colorectal cancer as well as other abdominopelvic disease could make it more attractive than CT. With the integration of 3.0-T MR colonography, fecal tagging, and parallel imaging into research and clinical settings, new MR colonography protocols must be optimized. Future MR colonography research should address issues such as image characteristics, presence of artifacts, management of specific absorption rate, and hardware-related modifications. (c) RSNA, 2010 . radiographics.rsna.org C1 [Thornton, Eavan; Morrin, Martina M.] Beaumont Hosp, Dept Radiol, Dublin 9, Ireland. [Yee, Judy] San Francisco VA Med Ctr, Dept Radiol, San Francisco, CA USA. RP Thornton, E (reprint author), Beaumont Hosp, Dept Radiol, Dublin 9, Ireland. EM eavanthornton@gmail.com RI Morrin, Maureen/F-2010-2011 NR 60 TC 21 Z9 21 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0271-5333 J9 RADIOGRAPHICS JI Radiographics PD JAN PY 2010 VL 30 IS 1 BP 201 EP U229 DI 10.1148/rg.301095519 PG 19 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 544IO UT WOS:000273649000014 PM 20083594 ER PT J AU Lee, CJ Hoo, GWS Barack, BM AF Lee, C. Joyce Hoo, Guy W. Soo Barack, Bruce M. TI The Subpleural Radiolucent Rim: A Sign of Alveolar Filling and Tachypnea SO RESPIRATION LA English DT Editorial Material C1 Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, Pulm & Crit Care Sect, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Angeles Healthcare Syst, Imaging Serv, Los Angeles, CA 90095 USA. RP Hoo, GWS (reprint author), W Angeles VA Healthcare Ctr, Pulm & Crit Care Sect 111Q, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Guy.Soohoo@va.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0025-7931 J9 RESPIRATION JI Respiration PY 2010 VL 80 IS 4 BP 347 EP 347 DI 10.1159/000295922 PG 1 WC Respiratory System SC Respiratory System GA 642OB UT WOS:000281224000012 PM 20224252 ER PT J AU Greyson, CR AF Greyson, Clifford R. TI The Right Ventricle and Pulmonary Circulation: Basic Concepts SO REVISTA ESPANOLA DE CARDIOLOGIA LA Spanish DT Article DE Right ventricle; Hypertension; Pulmonary arterial; Heart failure; Physiology ID CANINE RIGHT VENTRICLE; PRESSURE-VOLUME; ARTERIAL-HYPERTENSION; CONTRACTILE PERFORMANCE; CLINICAL-IMPLICATIONS; VASCULAR IMPEDANCE; SYSTOLIC PRESSURE; CONSCIOUS DOGS; HEART-DISEASE; STROKE WORK AB The primary purpose of the right ventricle and pulmonary circulation is gas exchange. Because gas exchange occurs in thin, highly permeable alveolar membranes, pulmonary pressure must remain low to avoid pulmonary edema; because the right ventricle and the lungs are in series with the left ventricle and the systemic circulation, the entire cardiac output must pass through the lungs. This low pressure, high volume system, makes dramatically different demands on the right ventricle compared with the demands made on the left ventricle by the systemic circulation. Moreover, the right ventricle and pulmonary circulation must buffer dynamic changes in blood volume and flow resulting from respiration, positional changes, and changes in left ventricular cardiac output. The optimizations needed to meet these conflicting demands result in reduced capacity to compensate for increased afterload or pressure. Unfortunately, a large number of pathologic processes can result in acute and or chronic increases in afterload stress. As afterload stress rises, right heart failure may develop, and hemodynamic instability and death can occur abruptly. Several biochemical pathways have been identified that may participate in adaptation or maladaptation to excessive pressure loads. C1 [Greyson, Clifford R.] Dept Vet Affairs Med Ctr, Denver, CO USA. [Greyson, Clifford R.] Univ Colorado, Denver, CO 80202 USA. RP Greyson, CR (reprint author), Denver VAMC, 1055 Clermont St, Denver, CO 80220 USA. EM Clifford.Greyson@UCDenver.edu FU NHLBI NIH HHS [R01-HL068606, R01-HL49444] NR 95 TC 21 Z9 22 U1 0 U2 4 PU EDICIONES DOYMA S A PI BARCELONA PA TRAV DE GRACIA 17-21, 08021 BARCELONA, SPAIN SN 0300-8932 EI 1579-2242 J9 REV ESP CARDIOL JI Rev. Esp. Cardiol. PD JAN PY 2010 VL 63 IS 1 BP 81 EP 95 DI 10.1016/S0300-8932(10)70012-9 PG 15 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 566WN UT WOS:000275404200012 PM 20089229 ER PT J AU Huckans, M Mitchell, A Ruimy, S Loftis, J Hauser, P AF Huckans, Marilyn Mitchell, Alex Ruimy, Samantha Loftis, Jennifer Hauser, Peter TI Antiviral Therapy Completion and Response Rates Among Hepatitis C Patients With and Without Schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Article DE interferon; mental disorders; psychotic disorders; adverse effects ID SEVERE MENTAL-ILLNESS; SUBSTANCE USE DISORDERS; INTERFERON-ALPHA; VIRUS-INFECTION; RIBAVIRIN; VETERANS; PREVALENCE; MANAGEMENT; PEOPLE AB Background: Despite disproportionately high rates of hepatitis C (HCV) among patients with severe mental illness, to date, there is scant empirical data available regarding antiviral therapy outcomes within this population. Objective: To compare antiviral therapy completion and response rates between HCV patients with vs those without schizophrenia (SCHZ). Methods: A regional Veterans Healthcare Administration database was used to identify veterans meeting criteria for this retrospective chart review. All patients confirmed to have SCHZ and to have received antiviral therapy between 1998 and 2006 (n = 30) were compared with a control group of demographically matched (HCV genotype, age, race, gender) patients with no history of SCHZ (n = 30). Results: For HCV patients with genotype 1, antiviral completion, end of treatment response (ETR), and sustained viral response (SVR) rates did not significantly differ between groups. For those with genotypes 2 and 3 combined, antiviral therapy completion rates did not significantly differ between groups; however, the SCHZ group was significantly (P < 0.050) more likely to achieve an ETR and an SVR. For all genotypes combined, the SCHZ patients were no more likely than controls to discontinue therapy early for psychiatric symptoms, medical complications, or other adverse events, and groups did not significantly differ in terms of hospitalization rates during antiviral therapy. Conclusion: Our retrospective chart review suggests that patients with SCHZ complete and respond to antiviral therapy for HCV at rates comparable with those without SCHZ. Based on these data, SCHZ should not be considered a contraindication to antiviral therapy for HCV. C1 [Huckans, Marilyn; Mitchell, Alex; Ruimy, Samantha; Loftis, Jennifer; Hauser, Peter] Oregon Hlth & Sci Univ, NW Hepatitis Resource Ctr C, Portland, OR 97239 USA. [Huckans, Marilyn; Mitchell, Alex; Ruimy, Samantha; Hauser, Peter] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97239 USA. [Huckans, Marilyn; Loftis, Jennifer; Hauser, Peter] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Loftis, Jennifer; Hauser, Peter] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. [Loftis, Jennifer; Hauser, Peter] Oregon Hlth & Sci Univ, Portland VA Med Ctr, JENS Lab, Portland, OR 97239 USA. [Hauser, Peter] Oregon Hlth & Sci Univ, Dept Internal Med, Portland, OR 97239 USA. RP Huckans, M (reprint author), Portland VA Med Ctr P3MHDC, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM marilyn.huckans@va.gov FU Stanley Medical Research Institute [05R-981] FX Stanley Medical Research Institute (05R-981). NR 23 TC 13 Z9 13 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD JAN PY 2010 VL 36 IS 1 BP 165 EP 172 DI 10.1093/schbul/sbn065 PG 8 WC Psychiatry SC Psychiatry GA 539CR UT WOS:000273231500022 PM 18562341 ER PT S AU Gvilia, I AF Gvilia, Irma BE Clow, A Thorn, L TI UNDERLYING BRAIN MECHANISMS THAT REGULATE SLEEP-WAKEFULNESS CYCLES SO SCIENCE OF AWAKENING SE International Review of Neurobiology LA English DT Review; Book Chapter ID VENTROLATERAL PREOPTIC NUCLEUS; BASAL FOREBRAIN NEURONS; DORSAL RAPHE NUCLEUS; PERIFORNICAL LATERAL HYPOTHALAMUS; EYE-MOVEMENT SLEEP; SEROTONIN-CONTAINING NEURONS; WAKING DISCHARGE PATTERNS; MONOAMINERGIC CELL GROUPS; FREELY MOVING CATS; LOCUS-COERULEUS C1 [Gvilia, Irma] Ilia State Univ, GE-0162 Tbilisi, Rep of Georgia. [Gvilia, Irma] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, North Hills, CA 91343 USA. [Gvilia, Irma] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Gvilia, I (reprint author), Ilia State Univ, GE-0162 Tbilisi, Rep of Georgia. RI Sanguansri, Luz/B-6630-2011 OI Sanguansri, Luz/0000-0003-1908-7604 FU NIMH NIH HHS [MH63323] NR 107 TC 12 Z9 13 U1 0 U2 14 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0074-7742 BN 978-0-12-381324-4 J9 INT REV NEUROBIOL JI Int. Rev. Neurobiol. PY 2010 VL 93 BP 1 EP 21 DI 10.1016/S0074-7742(10)93001-8 PG 21 WC Neurosciences SC Neurosciences & Neurology GA BSH98 UT WOS:000284504400001 PM 20969999 ER PT J AU Tambaca, J Kosor, M Canic, S Paniagua, D AF Tambaca, J. Kosor, M. Canic, S. Paniagua, D. TI MATHEMATICAL MODELING OF VASCULAR STENTS SO SIAM JOURNAL ON APPLIED MATHEMATICS LA English DT Article DE stents; mathematical modeling; theory of elasticity; curved rod model ID CURVED ROD MODEL; MECHANICAL-BEHAVIOR; CORONARY STENTS; DESIGN; FLUID; VALVE; FLOW AB We present a mathematical model for a study of the mechanical properties of endovascular stents in their expanded state. The model is based on the theory of slender curved rods. Stent struts are modeled as linearly elastic curved rods that satisfy the kinematic and dynamic contact conditions at the "vertices" where the struts meet. This defines a stent as a mesh of curved rods. A weak formulation for the stent problem is defined and a finite element method for a numerical computation of its solution was developed. Numerical simulations showing the pressure-displacement (axial and radial) relationship for the entire stent are presented. From the numerical data and from the energy of the problem we deduced an "effective" pressure-displacement relationship of the law of Laplace-type for the mechanical behavior of stents, where the proportionality constant in the Laplace law was expressed explicitly in terms of the geometric and mechanic properties of a stent. C1 [Tambaca, J.] Univ Zagreb, Dept Math, Zagreb 10000, Croatia. [Kosor, M.; Canic, S.] Univ Houston, Dept Math, Houston, TX 77204 USA. [Paniagua, D.] Michael E DeBakey Vet Med Ctr, Cardiac Catheterizat Labs, Houston, TX 77030 USA. [Paniagua, D.] St Lukes Episcopal Hosp, Texas Heart Inst, Med Baylor Coll Med, Houston, TX 77030 USA. RP Tambaca, J (reprint author), Univ Zagreb, Dept Math, Bijenicka 30, Zagreb 10000, Croatia. EM tambaca@math.hr; mate.kosor@gmail.com; canic@math.uh.edu RI Kosor, Mate/H-3404-2012 FU MZOS-Croatia [037-0693014-2765]; NSF/NIH [DMS-0443826]; NSF [DMS-0337355]; Texas Higher Education Board [ARP 003652-0051-2006]; UH [GEAR-2007] FX Research supported in part by MZOS-Croatia under grant 037-0693014-2765 and by the NSF/NIH under grant DMS-0443826.; The work of the second author was supported through NSF/NIH under grant DMS-0443826. The work of the third author was partially supported by the NSF under grant DMS-0337355, Texas Higher Education Board ARP 003652-0051-2006, NSF/NIH under grant DMS-0443826, and UH GEAR-2007 grant. NR 21 TC 12 Z9 12 U1 0 U2 9 PU SIAM PUBLICATIONS PI PHILADELPHIA PA 3600 UNIV CITY SCIENCE CENTER, PHILADELPHIA, PA 19104-2688 USA SN 0036-1399 J9 SIAM J APPL MATH JI SIAM J. Appl. Math. PY 2010 VL 70 IS 6 BP 1922 EP 1952 DI 10.1137/080722618 PG 31 WC Mathematics, Applied SC Mathematics GA 595AV UT WOS:000277584000010 ER PT S AU Roodman, GD AF Roodman, G. David BE Zaidi, M TI Insights into the pathogenesis of Paget's disease SO SKELETAL BIOLOGY AND MEDICINE SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT New York Skeletal Biology and Medicine Conference CY APR 29-MAY 02, 2009 CL Mt Sinai Sch Med, New York, NY HO Mt Sinai Sch Med DE Paget's disease; sequestosome-1; measles virus ID KAPPA-B ACTIVATION; INTERACTING PROTEIN P62; CANINE-DISTEMPER VIRUS; MEASLES-VIRUS; BINDING-PROTEIN; SH2 DOMAIN; BONE; KINASE; MUTATION; OSTEOCLASTS AB Paget's disease (PD) affects approximately 1.5 million persons in the United States and is characterized by grossly distorted bone remodeling, with increases in bone resorption and formation. Both environmental and genetic factors may contribute to the pathogenesis of PD. Mutations in sequestosome-1 (p62) occur in 25-30% of patients with familial PD, and in similar to 10% of patients with sporadic PD. Preclinical studies suggest that the p62(P392L) mutation predisposes patients to developing PD rather than causing it. Other studies have suggested that PD results from a chronic paramyxoviral infection. Transgenic mice expressing the measles virus nucleocapsid gene (MVNP) in osteoclasts (OCLs) develop pagetic bone lesions. Further, approximately 70% of patients harboring the p62(P392L). mutation we studied have detectable MVNP transcripts, and inhibiting MVNP expression in bone marrow cultures from those patients blocked pagetic OCL formation. These studies suggest that both genetic and environmental factors contribute to PD. C1 Univ Pittsburgh, Sch Med Hematol Oncol, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Roodman, GD (reprint author), Univ Pittsburgh, Sch Med Hematol Oncol, VA Pittsburgh Healthcare Syst, R&D 151-U,Room 2E-113,Univ Dr C, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu NR 33 TC 17 Z9 17 U1 1 U2 3 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND SN 0077-8923 BN 978-1-57331-785-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1192 BP 176 EP 180 DI 10.1111/j.1749-6632.2009.05214.x PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BOV34 UT WOS:000277762400025 PM 20392234 ER PT S AU Cardozo, CP Qin, WP Peng, YZ Liu, X Wu, Y Pan, JP Bauman, WA Zaidi, M Sun, L AF Cardozo, Christopher P. Qin, Weiping Peng, Yuanzhen Liu, Xuan Wu, Yong Pan, Jiangping Bauman, William A. Zaidi, Mone Sun, Li BE Zaidi, M TI Nandrolone slows hindlimb bone loss in a rat model of bone loss due to denervation SO SKELETAL BIOLOGY AND MEDICINE SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT New York Skeletal Biology and Medicine Conference CY APR 29-MAY 02, 2009 CL Mt Sinai Sch Med, New York, NY HO Mt Sinai Sch Med DE nandrolone; osteoporosis; bone loss ID SPINAL-CORD-INJURY; IMMOBILIZATION; TESTOSTERONE; DENSITY AB Nandrolone is an anabolic steroid that has been demonstrated to reduce the loss of bone and muscle from hindlimb unweighting and to slow muscle atrophy after nerve transection. To determine whether nandrolone has the ability to protect bone against loss due to disuse after denervation, male rats underwent sciatic nerve transaction, followed 28 days later by treatment with nandrolone or vehicle for 28 days. Bone mineral density (BMD) was determined 28 days later or 56 days after nerve transection. Denervation led to reductions in BMD of 7% and 12% for femur and tibia, respectively. Nandrolone preserved 80% and 60% of BMD in femur and tibia, respectively, demonstrating that nandrolone administration significantly reduced loss of BMD from denervation. This study offers a potential novel pharmacological strategy for use of nandrolone to reduce bone loss in severe disuse- and denervation-related bone loss, such as that which occurs after spinal cord injury. C1 [Cardozo, Christopher P.; Qin, Weiping; Wu, Yong; Pan, Jiangping; Bauman, William A.] James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, Bronx, NY 10468 USA. [Cardozo, Christopher P.; Qin, Weiping; Wu, Yong; Pan, Jiangping; Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Peng, Yuanzhen; Liu, Xuan; Zaidi, Mone; Sun, Li] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY USA. RP Qin, WP (reprint author), James J Peters VA Med Ctr, Ctr Excellence Med Consequences Spinal Cord Injur, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM weiping.qin@mssm.edu FU Veterans Health Administration, Rehabilitation Research and Development Service [B4162C, B3347K]; National Institutes of Health [AG2317b, DK70525, DK80459] FX C.C. and W.A.B. wish to acknowledge grant support from the Veterans Health Administration, Rehabilitation Research and Development Service (B4162C, B3347K). M.Z. and S.L. acknowledge the National Institutes of Health for support (AG2317b, DK70525, and DK80459). NR 14 TC 13 Z9 13 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA SN 0077-8923 BN 978-1-57331-785-6 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1192 BP 303 EP 306 DI 10.1111/j.1749-6632.2009.05313.x PG 4 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BOV34 UT WOS:000277762400042 PM 20392251 ER PT J AU Fung, CH Martin, JL Fiorentino, L Josephson, KR Chung, C Jouldjian, S Alessi, CA AF Fung, C. H. Martin, J. L. Fiorentino, L. Josephson, K. R. Chung, C. Jouldjian, S. Alessi, C. A. TI THE RELATIONSHIP BETWEEN SEDATIVE HYPNOTICS USE AND FUNCTIONAL RECOVERY IN OLDER PATIENTS UNDERGOING INPATIENT POST-ACUTE REHABILITATION SO SLEEP LA English DT Meeting Abstract C1 [Fung, C. H.; Chung, C.; Alessi, C. A.] Univ Calif Los Angeles, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA USA. [Martin, J. L.; Fiorentino, L.; Josephson, K. R.; Jouldjian, S.; Alessi, C. A.] VA Greater Los Angeles Healthcare Syst, GRECC, North Hills, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0846 BP A282 EP A283 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208001331 ER PT J AU Grandner, MA Perlis, ML Martin, JL Gehrman, P Patel, NP Xie, D Sha, D Weaver, TE Gooneratne, N AF Grandner, M. A. Perlis, M. L. Martin, J. L. Gehrman, P. Patel, N. P. Xie, D. Sha, D. Weaver, T. E. Gooneratne, N. TI SLEEP COMPLAINTS AND FATIGUE DECLINE ACROSS THE LIFESPAN: GETTING OLDER DOES NOT NECESSARILY MEAN POOR SUBJECTIVE SLEEP AND DAYTIME FATIGUE SO SLEEP LA English DT Meeting Abstract C1 [Xie, D.; Sha, D.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Weaver, T. E.] Univ Penn, Sch Nursing, Biobehav & Hlth Sci Div, Philadelphia, PA 19104 USA. [Gooneratne, N.] Univ Penn, Div Geriatr Med, Philadelphia, PA 19104 USA. [Martin, J. L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Martin, J. L.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Patel, N. P.] Reading Hosp Med Ctr, Reading, PA USA. NR 0 TC 1 Z9 1 U1 0 U2 6 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 1033 BP A345 EP A345 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208001516 ER PT J AU Gvilia, I Angara, B McGinty, DJ Szymusiak, RS AF Gvilia, I Angara, B. McGinty, D. J. Szymusiak, R. S. TI MATURATION OF SLEEP HOMEOSTASIS IN RATS DURING THE FOURTH POSTNATAL WEEK SO SLEEP LA English DT Meeting Abstract C1 [Gvilia, I; Angara, B.; McGinty, D. J.; Szymusiak, R. S.] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, North Hills, CA USA. [Szymusiak, R. S.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [McGinty, D. J.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Gvilia, I] Chavchavadze State Univ, Tbilisi, Rep of Georgia. [Gvilia, I] I Beritashvili Inst Physiol, Tbilisi, Rep of Georgia. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0142 BP A51 EP A51 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000144 ER PT J AU John, J Kodama, T Siegel, J AF John, J. Kodama, T. Siegel, J. TI ROLE OF HISTAMINE IN DISRUPTED SLEEP SO SLEEP LA English DT Meeting Abstract C1 [John, J.; Kodama, T.; Siegel, J.] VA Greater Los Angeles Healthcare Syst, North Hills, CA USA. [John, J.; Siegel, J.] Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0155 BP A55 EP A55 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000157 ER PT J AU Kostin, A Rai, S Kumar, S Szymusiak, RS McGinty, DJ Alam, M AF Kostin, A. Rai, S. Kumar, S. Szymusiak, R. S. McGinty, D. J. Alam, M. TI ROLE OF NITRIC OXIDE IN THE PERIFORNICAL-LATERAL HYPOTHALAMIC AREA IN THE REGULATION OF SLEEP AND WAKEFULNESS SO SLEEP LA English DT Meeting Abstract C1 [Kostin, A.; Rai, S.; Kumar, S.; Szymusiak, R. S.; McGinty, D. J.; Alam, M.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, North Hills, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0247 BP A86 EP A87 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000250 ER PT J AU Kouskov, OS Boudreau, EA O'Hearn, DJ AF Kouskov, O. S. Boudreau, E. A. O'Hearn, D. J. TI EFFECTIVENESS OF ADAPTIVE SERVOVENTILATION IN PATIENTS ON OPIOIDS RESISTANT TO STANDARD POSITIVE AIRWAY PRESSURE THERAPY SO SLEEP LA English DT Meeting Abstract C1 [Kouskov, O. S.; Boudreau, E. A.; O'Hearn, D. J.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 043 BP A145 EP A145 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000426 ER PT J AU Lyamin, O Pryaslova, J Mukhametov, L Siegel, J AF Lyamin, O. Pryaslova, J. Mukhametov, L. Siegel, J. TI CIRCADIAN ACTIVITY OF NORTHERN FUR SEALS UNDER THE CONTROLLED LIGHT-DARK CYCLE SO SLEEP LA English DT Meeting Abstract C1 [Lyamin, O.; Siegel, J.] Univ Calif Los Angeles, North Hills, CA USA. [Lyamin, O.; Siegel, J.] VA GLAHS Sepulveda, North Hills, CA USA. [Lyamin, O.; Pryaslova, J.; Mukhametov, L.] Dolphin & I Ltd, Moscow, Russia. [Lyamin, O.; Mukhametov, L.] Severtsov Inst Ecol & Evolut, Moscow, Russia. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0211 BP A73 EP A73 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000213 ER PT J AU Lyamin, O Kibalnikov, A Kosenko, P Mukhametov, L Siegel, J AF Lyamin, O. Kibalnikov, A. Kosenko, P. Mukhametov, L. Siegel, J. TI CARDIO-RESPIRATORY PATTERN OF NORTHERN FUR SEALS DURING SLEEP AND WAKING SO SLEEP LA English DT Meeting Abstract C1 [Lyamin, O.; Siegel, J.] Univ Calif Los Angeles, North Hills, CA USA. [Lyamin, O.; Siegel, J.] VA GLAHS Sepulveda, North Hills, CA USA. [Lyamin, O.; Kosenko, P.; Mukhametov, L.] Dolphin & I Ltd, Moscow, Russia. [Lyamin, O.; Mukhametov, L.] Severtsov Inst Ecol & Evolut, Moscow, Russia. [Kibalnikov, A.] So Sci Ctr, Rostov Na Donu, Russia. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0058 BP A23 EP A23 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000060 ER PT J AU Martin, JL Fiorentino, L Jouldjian, S Josephson, KR Fung, CH Alessi, CA AF Martin, J. L. Fiorentino, L. Jouldjian, S. Josephson, K. R. Fung, C. H. Alessi, C. A. TI RATES AND RISK FACTORS FOR INSOMNIA AMONG OLDER PATIENTS UNDERGOING REHABILITATION SO SLEEP LA English DT Meeting Abstract C1 [Martin, J. L.; Fung, C. H.; Alessi, C. A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Martin, J. L.; Jouldjian, S.; Josephson, K. R.; Fung, C. H.; Alessi, C. A.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Fiorentino, L.] Univ Calif Los Angeles, Cousins Ctr Psychoneuroimmunol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 1054 BP A352 EP A352 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208001537 ER PT J AU Naeim, D Becker, K Poon, C Hakim, A Santiago, S Zeidler, MR AF Naeim, D. Becker, K. Poon, C. Hakim, A. Santiago, S. Zeidler, M. R. TI GREATER LOS ANGELES VETERANS ASSOCIATION EXPERIENCE WITH MANDIBULAR ADVANCEMENT DEVICES FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNEA SO SLEEP LA English DT Meeting Abstract C1 [Naeim, D.; Becker, K.; Poon, C.; Hakim, A.; Santiago, S.; Zeidler, M. R.] W Los Angeles VA, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0484 BP A164 EP A164 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000487 ER PT J AU Neylan, TC Mon, A Lenoci, M Metzler, T Meyerhoff, DJ AF Neylan, T. C. Mon, A. Lenoci, M. Metzler, T. Meyerhoff, D. J. TI LOW CORTICAL GABA LEVELS IN PTSD ARE MEDIATED BY POOR SLEEP QUALITY SO SLEEP LA English DT Meeting Abstract C1 [Neylan, T. C.; Mon, A.; Metzler, T.; Meyerhoff, D. J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Neylan, T. C.; Mon, A.; Lenoci, M.; Metzler, T.; Meyerhoff, D. J.] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0695 BP A233 EP A234 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208001181 ER PT J AU Ramey, DB Storzbach, D Tun, S Huckans, M O'Hearn, DJ Boudreau, EA AF Ramey, D. B. Storzbach, D. Tun, S. Huckans, M. O'Hearn, D. J. Boudreau, E. A. TI EVALUATION OF SLEEP QUALITY IN OIF/OEF VETERANS WITH A HISTORY OF BLAST EXPOSURE SO SLEEP LA English DT Meeting Abstract C1 [Ramey, D. B.; Storzbach, D.; Tun, S.; Huckans, M.; O'Hearn, D. J.; Boudreau, E. A.] Portland VA Med Ctr, Portland, OR USA. [Ramey, D. B.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0849 BP A283 EP A284 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208001334 ER PT J AU Xi, M Fung, SJ Chase, MH AF Xi, M. Fung, S. J. Chase, M. H. TI PROJECTIONS FROM THE CENTRAL NUCLEUS OF THE AMYGDALA TO NEURONS IN THE NUCLEUS PONTIS ORALIS: AN INTRACELLULAR STUDY SO SLEEP LA English DT Meeting Abstract C1 [Xi, M.; Fung, S. J.; Chase, M. H.] WebSci Int, Los Angeles, CA USA. [Chase, M. H.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Xi, M.; Fung, S. J.; Chase, M. H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0156 BP A55 EP A55 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000158 ER PT J AU Zhang, J Xi, M Fung, SJ Sampogna, S Lim, V Chase, MH AF Zhang, J. Xi, M. Fung, S. J. Sampogna, S. Lim, V Chase, M. H. TI GLUTAMATERGIC NEURONS IN THE CENTRAL NUCLEUS OF THE AMYGDALA PROJECT DIRECTLY TO THE NPO SO SLEEP LA English DT Meeting Abstract C1 [Zhang, J.; Xi, M.; Fung, S. J.; Sampogna, S.; Lim, V; Chase, M. H.] Websci Int, Los Angeles, CA USA. [Zhang, J.; Xi, M.; Fung, S. J.; Lim, V; Chase, M. H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Chase, M. H.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PY 2010 VL 33 SU S MA 0157 BP A55 EP A56 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V21LB UT WOS:000208208000159 ER PT B AU Stiens, SA Singal, AK Korsten, MA AF Stiens, Steven A. Singal, Ashwani K. Korsten, Mark Allen BE Lin, VW TI The Gastrointestinal System after Spinal Cord Injury: Assessment and Intervention SO SPINAL CORD MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION LA English DT Article; Book Chapter ID ANTEGRADE CONTINENCE ENEMA; GASTROESOPHAGEAL-REFLUX DISEASE; NEUROGENIC BOWEL DYSFUNCTION; MESENTERIC-ARTERY SYNDROME; GASTRIC STRESS ULCERATION; COLONIC TRANSIT-TIME; QUALITY-OF-LIFE; ANORECTAL FUNCTION; ELECTRICAL-STIMULATION; QUADRIPLEGIC PATIENTS C1 [Stiens, Steven A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Stiens, Steven A.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Singal, Ashwani K.] Univ Texas Med Branch, Dept Internal Med, Div Gastroenterol, Galveston, TX USA. [Korsten, Mark Allen] Mt Sinai Sch Med, JJP VA Med Ctr, Dept Internal Med & Gastroenterol, Bronx, NY USA. RP Stiens, SA (reprint author), Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. NR 184 TC 1 Z9 1 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-19-8 PY 2010 BP 382 EP 408 PG 27 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA BOJ93 UT WOS:000276871800031 ER PT B AU Svircev, JN Little, JW AF Svircev, Jelena N. Little, James W. BE Lin, VW TI Syringomyelia SO SPINAL CORD MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION LA English DT Article; Book Chapter ID SPINAL-CORD-INJURY; CHIARI-I MALFORMATION; POST-TRAUMATIC SYRINGOMYELIA; OF-THE-LITERATURE; TERM-FOLLOW-UP; POSTTRAUMATIC SYRINGOMYELIA; SYRINGOPERITONEAL SHUNT; CLINICAL PRESENTATION; SURGICAL-TREATMENT; CYSTIC MYELOPATHY C1 [Svircev, Jelena N.; Little, James W.] Univ Washington, Dept Rehabil Med, Spinal Cord Injury Serv, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Svircev, JN (reprint author), Univ Washington, Dept Rehabil Med, Spinal Cord Injury Serv, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 99 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-19-8 PY 2010 BP 569 EP 575 PG 7 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA BOJ93 UT WOS:000276871800042 ER PT B AU Ayyoub, Z Aragaki, DLR AF Ayyoub, Ziyad Aragaki, Dixie Lynne Reiko BE Lin, VW TI Dual Diagnosis: Spinal Cord Injury and Brain Injury SO SPINAL CORD MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION LA English DT Article; Book Chapter ID CLOSED HEAD-INJURY; FATAL TRAFFIC ACCIDENTS; NEUROPSYCHOLOGICAL DEFICITS; INTRACRANIAL-PRESSURE; CERVICAL-SPINE; RISK-FACTORS; TRAUMA; REHABILITATION; COMPLICATIONS; PERSPECTIVE C1 [Ayyoub, Ziyad] Univ Calif Los Angeles, David Geffen Sch Med, Ranchos Los Amigos Natl Rehabil Ctr, Adult Brain Injury Rehabil Program, Los Angeles, CA 90095 USA. [Ayyoub, Ziyad; Aragaki, Dixie Lynne Reiko] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Aragaki, Dixie Lynne Reiko] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Ayyoub, Z (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ranchos Los Amigos Natl Rehabil Ctr, Adult Brain Injury Rehabil Program, Los Angeles, CA 90095 USA. NR 72 TC 0 Z9 0 U1 0 U2 1 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-933864-19-8 PY 2010 BP 580 EP 594 PG 15 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA BOJ93 UT WOS:000276871800044 ER PT J AU Broyles, LM Gordon, AJ AF Broyles, Lauren M. Gordon, Adam J. TI SBIRT Implementation: Moving Beyond the Interdisciplinary Rhetoric SO SUBSTANCE ABUSE LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; EMERGENCY-DEPARTMENT; BRIEF INTERVENTIONS; COST-EFFECTIVENESS; PROBLEM DRINKERS; PRIMARY-CARE; ALCOHOL; NURSES C1 [Broyles, Lauren M.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Broyles, Lauren M.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Broyles, Lauren M.; Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Gordon, Adam J.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA. RP Broyles, LM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. NR 12 TC 13 Z9 13 U1 0 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0889-7077 J9 SUBST ABUS JI Subst. Abus. PY 2010 VL 31 IS 4 BP 221 EP 223 AR PII 928725868 DI 10.1080/08897077.2010.514238 PG 3 WC Substance Abuse SC Substance Abuse GA 674KU UT WOS:000283742600001 PM 21038175 ER PT J AU Tuerk, PW Fortney, J Bosworth, HB Wakefield, B Ruggiero, KJ Acierno, R Frueh, BC AF Tuerk, Peter W. Fortney, John Bosworth, Hayden B. Wakefield, Bonnie Ruggiero, Kenneth J. Acierno, Ron Frueh, B. Christopher TI Toward the Development of National Telehealth Services: The Role of Veterans Health Administration and Future Directions for Research SO TELEMEDICINE JOURNAL AND E-HEALTH LA English DT Editorial Material DE telehealth technology; Veterans Health Administration; National Institutes of Health; national telehealth services ID RANDOMIZED-TRIAL; HOME TELEHEALTH; DEPRESSION; CARE AB The Veterans Health Administration (VHA) in the Department of Veteran Affairs (VA) has emerged as a national and international leader in the delivery and research of telehealth-based treatment. Several unique characteristics of care in VA settings intersect to create an ideal environment for telehealth modalities and research. However, the value of telehealth experience and initiatives in VA settings is limited if telehealth strategies cannot be widely exported to other public or private systems. Whereas a hierarchical organization, such as VA, can innovate and fund change relatively quickly based on provider and patient preferences and a growing knowledge base, other health provider organizations and third-party payers may likely require replicable scientific findings over time before incremental investments will be made to create infrastructure, reform regulatory barriers, and amend laws to accommodate expansion of telehealth modalities. Accordingly, large-scale scientifically rigorous telehealth research in VHA settings is essential not only to investigate the efficacy of existing and future telehealth practices in VHA, but also to hasten the development of telehealth infrastructure in private and other public health settings. We propose an expanded partnership between the VA, NIH, and other funding agencies to investigate creative and pragmatic uses of telehealth technology. To this end, we identify six specific areas of research we believe to be particularly relevant to the efficient development of telehealth modalities in civilian and military contexts outside VHA. C1 [Tuerk, Peter W.; Ruggiero, Kenneth J.; Acierno, Ron] Med Ctr, Ralph H Johnson Vet Adm, Charleston, SC 29401 USA. [Tuerk, Peter W.; Ruggiero, Kenneth J.; Acierno, Ron] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Fortney, John] Cent Arkansas Vet Healthcare Syst, VA S Cent Mental Illness Res Educ & Clin Ctr MIRE, N Little Rock, AR USA. [Fortney, John] Univ Arkansas Med Sci, Div Hlth Serv Res, Dept Psychiat, Coll Med, Little Rock, AR 72205 USA. [Bosworth, Hayden B.] Durham VA Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. [Bosworth, Hayden B.] Duke Univ, Dept Med, Durham, NC USA. [Bosworth, Hayden B.] Duke Univ, Dept Psychiat, Durham, NC 27706 USA. [Bosworth, Hayden B.] Duke Univ, Dept Nursing, Durham, NC 27706 USA. [Wakefield, Bonnie] Iowa City VA Med Ctr, Ctr Implementat Innovat Strategies Practice, Iowa City, IA USA. [Frueh, B. Christopher] Univ Hawaii, Dept Psychol, Hilo, HI 96720 USA. RP Tuerk, PW (reprint author), Med Ctr, Ralph H Johnson Vet Adm, 109 Bee St, Charleston, SC 29401 USA. EM Peter.Tuerk@VA.GOV NR 8 TC 12 Z9 12 U1 1 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 J9 TELEMED J E-HEALTH JI Telemed. J. e-Health PD JAN-FEB PY 2010 VL 16 IS 1 BP 115 EP 117 DI 10.1089/tmj.2009.0144 PG 3 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 551BV UT WOS:000274181600020 PM 20043704 ER PT J AU Lin, RY Davies, TF AF Lin, Reigh-Yi Davies, Terry F. TI Differentiating Thyroid Cells SO THYROID LA English DT Editorial Material ID EMBRYONIC STEM-CELLS; MOUSE EMBRYOS; THYROCYTES C1 [Lin, Reigh-Yi; Davies, Terry F.] Mt Sinai Sch Med, Dept Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA. [Davies, Terry F.] James J Peters VA Med Ctr, Thyroid Res Unit, New York, NY USA. RP Lin, RY (reprint author), Mt Sinai Sch Med, Dept Med, Div Endocrinol Diabet & Bone Dis, Box 1055,1 Gustave L Levy Pl, New York, NY 10029 USA. EM reigh-yi.lin@mssm.edu NR 11 TC 4 Z9 4 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 J9 THYROID JI Thyroid PD JAN PY 2010 VL 20 IS 1 BP 1 EP 2 DI 10.1089/thy.2009.1613 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 543FI UT WOS:000273556500001 PM 20067376 ER PT B AU Uomoto, JM Williams, RM Randa, LA AF Uomoto, Jay M. Williams, Rhonda M. Randa, Leigh Anne BE Ashley, MJ TI Neurobehavioral Consequences of Combat-Related Blast Injury and Polytrauma SO TRAUMATIC BRAIN INJURY: REHABILITATION, TREATMENT, AND CASE MANAGEMENT, 3RD EDITION LA English DT Article; Book Chapter ID TRAUMATIC BRAIN-INJURY; OPERATION-IRAQI-FREEDOM; MENTAL-HEALTH PROBLEMS; POSTTRAUMATIC-STRESS-DISORDER; PEER SUPPORT PROGRAM; QUALITY-OF-LIFE; ENDURING FREEDOM; BREAST-CANCER; MILITARY PERSONNEL; COGNITIVE REHABILITATION C1 [Uomoto, Jay M.] Def Ctr Excellence Psychol Hlth & Traumat Brain I, Silver Spring, MD USA. [Williams, Rhonda M.] Univ Washington, Sch Med, Seattle, WA USA. [Williams, Rhonda M.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Randa, Leigh Anne] Seattle Pacific Univ, Seattle, WA 98119 USA. RP Uomoto, JM (reprint author), Def Ctr Excellence Psychol Hlth & Traumat Brain I, Silver Spring, MD USA. NR 88 TC 0 Z9 0 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4398-4982-8; 978-1-4200-7194-8 PY 2010 BP 63 EP 95 DI 10.1201/9781439849828-c3 D2 10.1201/9781439849828 PG 33 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA BF7QW UT WOS:000384329900004 ER PT J AU Yilmaz, U Ciol, MA Berger, RE Yang, CC AF Yilmaz, Ugur Ciol, Marcia A. Berger, Richard E. Yang, Claire C. TI Sensory Perception Thresholds in Men With Chronic Pelvic Pain Syndrome SO UROLOGY LA English DT Article ID CENTRAL SENSITIZATION; FIBROMYALGIA; NEUROPATHY; SYSTEM AB OBJECTIVES To compare sensory thresholds in different nerve-fiber types in men with chronic pelvic pain syndrome (CPPS) and healthy controls, using thermal sensory testing and measuring current perception thresholds (CPT). METHODS We enrolled 22 men with CPPS and 20 healthy control participants. We determined the thermal sensory perception thresholds of C and A delta nerve fibers on the perineum and left posterior thigh. To test CPT, we used sine wave electrical stimulation at 5, 250, and 2000 Hz, resulting in the selective depolarization of small unmyelinated C fibers, small myelinated A delta, and large myelinated A beta fibers, respectively. We bilaterally tested the hypothenar surface of the palms, medial parts of soles, midshaft of penis, and 1 site in the midperineum, for a total of 7 sites. RESULTS The mean age of men with CPPS was similar to that of controls [42.8 (standard deviation, 9.4) and 40.4 (standard deviation, 13.2) years, respectively, P = .548]. There was no significant difference between the 2 groups for thermal perception thresholds in both the perineum and left thigh (P >.05). There was also no difference between the 2 groups for CPT values of all 3 frequencies of stimuli in each area tested (P >.05 for all comparisons). CONCLUSIONS The absence of sensory threshold differences between men with CPPS and controls, with either thermal stimulation of C and A delta fiber afferents or electrical stimulation of C, A delta, and A beta fiber afferents, discounts the existence of a peripheral neuropathy as a cause for pain in men with CPPS. UROLOGY 75: 34-37, 2010. Published by Elsevier Inc. C1 [Yang, Claire C.] Univ Washington, Dept Urol, Seattle, WA 98195 USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. VA Puget Sound Healthcare Syst, Seattle, WA USA. RP Yang, CC (reprint author), Univ Washington, Dept Urol, Box 356510, Seattle, WA 98195 USA. EM cyang@u.washington.edu FU Paul G. Allen Family Foundation FX Supported by the Paul G. Allen Family Foundation. NR 25 TC 6 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD JAN PY 2010 VL 75 IS 1 BP 34 EP 37 DI 10.1016/j.urology.2009.08.013 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 553UV UT WOS:000274393200011 PM 19854487 ER PT J AU Ge, PS Ng, G Ishaque, BM Gelabert, H de Virgilio, C AF Ge, Phillip S. Ng, Gladys Ishaque, Brandon M. Gelabert, Hugh de Virgilio, Christian TI Iatrogenic Pseudoaneurysm of the Superior Gluteal Artery Presenting as Pelvic Mass With Foot Drop and Sciatica: Case Report and Review of Literature SO VASCULAR AND ENDOVASCULAR SURGERY LA English DT Article DE pseudoaneurysm; gluteal artery; bone marrow biopsy; foot drop; sciatica; iatrogenic; gluteal pain; vascular surgery; coil embolization; aneurysm ID BONE-MARROW BIOPSY; COIL EMBOLIZATION; FALSE ANEURYSM; COMPLICATION; DIAGNOSIS; PAIN AB We report an unusual case of a pseudoaneurysm of the superior gluteal artery as a complication of bone marrow biopsy. A 51-year-old man presented with sciatic pain and foot drop after undergoing bone marrow biopsy and was initially diagnosed as having degenerative disc disease based on his past medical history. Pelvic magnetic resonance imaging (MRI) revealed a large heterogeneous mass suggestive of a neurogenic tumor, but pulsatile blood was instead encountered during computed tomography (CT)-guided needle biopsy. Subsequent workup established the diagnosis of a superior gluteal artery pseudoaneurysm, which was treated with coil embolization, followed by surgical evacuation of the hematoma, which relieved his sciatic pain. However, the patient continues to have a persistent foot drop. Gluteal artery pseudoaneurysms are exceedingly uncommon but should be considered in the workup of a patient with gluteal pain or sciatic nerve palsy following trauma or medical procedures in the gluteal region. C1 [Ge, Phillip S.; Ng, Gladys; Ishaque, Brandon M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Gelabert, Hugh; de Virgilio, Christian] W Los Angeles VA Med Ctr, Dept Surg, Los Angeles, CA USA. RP de Virgilio, C (reprint author), Harbor UCLA Med Ctr, Dept Surg, 1000 W Carson St, Torrance, CA 90309 USA. EM cdevirgilio@labiomed.org NR 21 TC 7 Z9 9 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1538-5744 J9 VASC ENDOVASC SURG JI Vasc. Endovasc. Surg. PD JAN PY 2010 VL 44 IS 1 BP 64 EP 68 DI 10.1177/1538574409351990 PG 5 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 546DY UT WOS:000273791100014 PM 19917559 ER PT S AU Yee, J AF Yee, J. BE Lefere, P Gryspeerdt, S TI Patient Preparation for CT Colonography SO VIRTUAL COLONOSCOPY: A PRACTICAL GUIDE, SECOND EDITION SE Medical Radiology Diagnostic Imaging LA English DT Article; Book Chapter ID ORAL SODIUM-PHOSPHATE; CONTRAST BARIUM ENEMA; GLYCOL ELECTROLYTE LAVAGE; BOWEL CLEANSING METHODS; CARBON-DIOXIDE; COLONOSCOPY PREPARATION; COLONIC DISTENSION; RANDOMIZED TRIAL; ANTISPASMODIC DRUGS; INSUFFLATION AGENTS C1 Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Yee, J (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM Judy.Yee@med.va.gov NR 46 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 0942-5373 BN 978-3-540-79879-8 J9 MED RADIOL DIAGN IMA PY 2010 BP 49 EP 59 DI 10.1007/978-3-540-79886-6_5 D2 10.1007/978-3-540-79886-6 PG 11 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA BMQ91 UT WOS:000273363400005 ER PT B AU Bird, TD AF Bird, Thomas D. BE Speicher, MR Antonarakis, SE Motulsky, AG TI Genetic Factors in Alzheimer Disease and Dementia SO VOGEL AND MOTULSKY'S HUMAN GENETICS, FOURTH EDITION: PROBLEMS AND APPROACHES LA English DT Article; Book Chapter ID FRONTOTEMPORAL LOBAR DEGENERATION; APOLIPOPROTEIN-E GENOTYPE; PLACEBO-CONTROLLED TRIAL; AMYOTROPHIC-LATERAL-SCLEROSIS; BETA-PEPTIDE DEPOSITION; DOWN-SYNDROME; NEUROPATHOLOGIC CHANGES; COGNITIVE IMPAIRMENT; 1ST-DEGREE RELATIVES; PROSPECTIVE COHORT AB Alzheimer disease (AD) is a common and complex disorder affecting several million people world-wide. It is defined clinically as a progressive dementing illness associated with A beta-amyloid neuritic plaques and neurofibrillary tangles in the brain. From a genetic standpoint it is a heterogeneous disorder. Three separate genes (APP, PSEN1, PSEN2) each cause an autosomal dominant, highly penetrant, early-onset, familial form of the disease. The three proteins encoded by these genes all influence the production of the toxic A beta(1-42) form of amyloid. Commercial genetic testing is available for these rare forms of AD. However, mutations in these genes represent less than 2% of all cases of AD. The more common late-onset form of AD is thought to be polygenic and multi factorial. The epsilon 4 allele of apolipoprotein E (ApoE) is a known genetic risk factor for late-onset AD, lowering the average age of onset by unknown mechanisms. Numerous other candidate risk genes are being identified through genome wide association studies, but have been difficult to confirm. Other familial forms of dementia, such as frontotemporal dementia (FTD), prion-associated diseases, and CADASIL, may be caused by autosomal dominant mutations occurring in their respective genes (MAPT, GRN, PRNP, Notch-3). C1 Univ Washington, Geriatr Res Educ & Clin Ctr 182, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Bird, TD (reprint author), Univ Washington, Geriatr Res Educ & Clin Ctr 182, VA Puget Sound Hlth Care Syst, 1600 S Columbian Way, Seattle, WA 98108 USA. EM tomnroz@u.washington.edu NR 136 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-3-540-37653-8 PY 2010 BP 681 EP 697 DI 10.1007/978-3-540-37654-5_23.3 D2 10.1007/978-3-540-37654-5 PG 17 WC Genetics & Heredity SC Genetics & Heredity GA BNM20 UT WOS:000274935100028 ER PT S AU Kong, YCM Wei, WZ Tomer, Y AF Kong, Yi-chi M. Wei, Wei-Zen Tomer, Yaron BE Rose, NR TI Opportunistic autoimmune disorders From immunotherapy to immune dysregulation SO YEAR IN IMMUNOLOGY 2 SE Annals of the New York Academy of Sciences LA English DT Article; Book Chapter DE opportunistic autoimmunity; immunotherapeutic sequelae; immunotherapy; autoimmunity; immune dysregulation ID CHRONIC HEPATITIS-C; STEM-CELL TRANSPLANTATION; LYMPHOCYTE-ASSOCIATED ANTIGEN-4; REGULATORY T-CELLS; INTERFERON-ALPHA THERAPY; CHRONIC VIRAL-HEPATITIS; LEUKOCYTE-DERIVED INTERFERON; MULTIPLE-SCLEROSIS PATIENTS; LONG-TERM THERAPY; THYROID-DISEASE AB Rapid advances in our understanding of the immune network have led to treatment modalities for malignancies and autoimmune diseases based on modulation of the immune response. Yet therapeutic modulation has resulted in immune dysregulation and opportunistic autoimmune sequelae, despite prescreening efforts in clinical trials. This review focuses on recent clinical data on opportunistic autoimmune disorders arising from three immunotherapeutic modalities: (1) systemic immunomodulators, including interferon-alpha (also used to treat hepatitis C patients) and interferon-beta; (2) monoclonal antibodies to CTLA-4 and CD52, and (3) hematopoietic stem cell transplantation. Uncategorized predisposing factors in these patients include major histocompatibility complex and gender genetics, prevalence of different autoimmune diseases, prior chemotherapy, underlying disorder (e.g., hepatitis C), and preconditioning regimens as part of organ and stem cell transplants. Not unexpectedly, the prevalent autoimmune thyroid disease surfaced frequently. Our combination models to study the balance between thyroid autoimmunity and tumor immunity upon regulatory T-cell perturbation are briefly described. C1 [Kong, Yi-chi M.] Wayne State Univ, Sch Med, Dept Immunol & Microbiol, Detroit, MI 48201 USA. [Wei, Wei-Zen] Wayne State Univ, Sch Med, Karmanos Canc Inst, Detroit, MI 48201 USA. [Tomer, Yaron] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Tomer, Yaron] James J Peters VA Med Ctr, New York, NY USA. RP Kong, YCM (reprint author), Wayne State Univ, Sch Med, Dept Immunol & Microbiol, 540 E Canfield Ave, Detroit, MI 48201 USA. EM ykong@med.wayne.edu FU NCI NIH HHS [R01 CA125680, CA125680, P30 CA022453]; NIDDK NIH HHS [DK073681, DK45960, DK61659, R01 DK045960, R01 DK061659, R01 DK073681] NR 116 TC 17 Z9 17 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA SN 0077-8923 BN 978-1-57331-779-5 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1183 BP 222 EP 236 PG 15 WC Immunology SC Immunology GA BNG71 UT WOS:000274519000015 PM 20146718 ER PT J AU Sinha, S Schwartz, MD Qin, AG Ross, JS AF Sinha, Sanjai Schwartz, Mark D. Qin, Angie Ross, Joseph S. TI Self-Reported and Actual Beta-Blocker Prescribing for Heart Failure Patients: Physician Predictors SO PLOS ONE LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; PRIMARY-CARE; MEDICATION UNDERUSE; MANAGEMENT; DIAGNOSIS; OUTCOMES; ASTHMA; PRACTITIONERS; CARVEDILOL; GUIDELINES AB Background: Beta-blockers reduce mortality among patients with systolic heart failure (HF), yet primary care provider prescription rates remain low. Objective: To examine the association between primary care physician characteristics and both self-reported and actual prescription of beta-blockers among patients with systolic HF. Design: Cross-sectional survey with supplementary retrospective chart review. Participants: Primary care providers at three New York City Veterans Affairs medical centers. Measurements: Main outcomes were: 1) self-reported prescribing of beta-blockers, and 2) actual prescribing of beta-blockers among HF patients. Physician HF practice patterns and confidence levels, as well as socio-demographic and clinical characteristics, were also assessed. Results: Sixty-nine of 101 physicians (68%) completed the survey examining self-reported prescribing of beta-blockers. Physicians who served as inpatient ward attendings self-reported significantly higher rates of beta-blocker prescribing among their HF patients when compared with physicians who did not attend (78% vs. 58%; p = 0.002), as did physicians who were very confident in managing HF patients when compared with physicians who were not (82% vs. 68%; p = 0.009). Fifty-one of these 69 surveyed physicians (74%) were successfully matched to 287 HF patients for whom beta-blocker prescribing data was available. Physicians with greater self-reported rates of prescribing beta-blockers were significantly more likely to actually prescribe beta-blockers ( p = 0.02); however, no other physician characteristics were significantly associated with actual prescribing of beta-blockers among HF patients. Conclusions: Physician teaching responsibilities and confidence levels were associated with self-reported beta-blocker prescribing among their HF patients. Educational efforts focused on improving confidence levels in HF care and increasing exposure to teaching may improve beta-blocker presciption in HF patients managed in primary care. C1 [Sinha, Sanjai; Ross, Joseph S.] James J Peters VA Med Ctr, Dept Med, Bronx, NY USA. [Sinha, Sanjai] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Schwartz, Mark D.; Qin, Angie] VA New York Harbor Healthcare Syst, Dept Med, New York, NY USA. [Schwartz, Mark D.; Qin, Angie] NYU, Sch Med, Dept Med, New York, NY USA. [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. RP Sinha, S (reprint author), James J Peters VA Med Ctr, Dept Med, Bronx, NY USA. EM Sanjai.Sinha@med.va.gov OI Schwartz, Mark/0000-0002-7123-0060 FU New Researcher Seed Grant, Dept. of Veterans Affairs, Veterans Integrated Service Network 3 Award FX Funding source: New Researcher Seed Grant, Dept. of Veterans Affairs, Veterans Integrated Service Network 3 Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 4 Z9 4 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 31 PY 2009 VL 4 IS 12 AR e8522 DI 10.1371/journal.pone.0008522 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 538JK UT WOS:000273180200009 PM 20046824 ER PT J AU Nery, FG Stanley, JA Chen, HH Hatch, JP Nicoletti, MA Monkul, ES Matsuo, K Caetano, SC Peluso, MA Najt, P Soares, JC AF Nery, Fabiano G. Stanley, Jeffrey A. Chen, Hua-Hsuan Hatch, John P. Nicoletti, Mark A. Monkul, Emel Serap Matsuo, Koji Caetano, Sheila C. Peluso, Marco A. Najt, Pablo Soares, Jair C. TI Normal metabolite levels in the left dorsolateral prefrontal cortex of unmedicated major depressive disorder patients: A single voxel H-1 spectroscopy study SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE Major depressive disorder; Magnetic resonance spectroscopy; Prefrontal cortex; Pathophysiology; N-acetyl aspartate; Choline-containing compounds; Glutamate; Phosphocreatine/creatine ID MAGNETIC-RESONANCE-SPECTROSCOPY; GAMMA-AMINOBUTYRIC-ACID; N-ACETYL-ASPARTATE; IN-VIVO; MOOD DISORDERS; WHITE-MATTER; HUMAN BRAIN; GLUTAMATERGIC CONCENTRATIONS; UNIPOLAR DEPRESSION; GABA CONCENTRATIONS AB Few proton magnetic resonance spectroscopy (H-1 spectroscopy) studies have investigated the dorsolateral prefrontal cortex (DLPFC), a key region in the pathophysiology of major depressive disorder (MDD). We used H-1 spectroscopy to verify whether MDD patients differ from healthy controls (HQ in metabolite levels in this brain area. Thirty-seven unmedicated DSM-IV MDD patients were compared with 40 HC. Subjects underwent a short echo-time H-1 spectroscopy examination at 1.5 T, with an 8-cm(3) single voxel placed in the left DLPFC. Reliable absolute metabolite levels of N-acetyl aspartate (NAA), phosphocreatine plus creatine (PCr+Cr), choline-containing compounds (GPC+PC), myo-inositol, glutamate plus glutamine (Glu+Gln), and glutamate were obtained using the unsuppressed water signal as an internal reference. Metabolite levels in the left DLPFC did not statistically differ between MDD patients and HC. We found an interaction between gender and diagnosis on PCr+Cr levels. Male MDD patients presented lower levels of PCr+Cr than male HC, and female MDD patients presented higher levels of PCr+Cr than female HC. Moreover, length of illness was inversely correlated with NAA levels. These findings suggest that there is not an effect of diagnosis on the left DLPFC neurochemistry. Possible effects of gender on PCr+Cr levels of MDD patients need to be further investigated. (C) 2009 Elsevier Ireland Ltd. All rights reserved. C1 [Nicoletti, Mark A.; Soares, Jair C.] Univ N Carolina, CERT BD, Dept Psychiat, Sch Med, Chapel Hill, NC 27599 USA. [Nery, Fabiano G.; Hatch, John P.; Monkul, Emel Serap; Matsuo, Koji; Caetano, Sheila C.; Peluso, Marco A.; Najt, Pablo] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Nery, Fabiano G.; Monkul, Emel Serap; Matsuo, Koji; Caetano, Sheila C.; Peluso, Marco A.; Najt, Pablo] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Nery, Fabiano G.; Caetano, Sheila C.; Peluso, Marco A.] Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. [Stanley, Jeffrey A.] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI USA. [Chen, Hua-Hsuan] Univ Cincinnati, Dept Radiol, Cincinnati, OH USA. [Hatch, John P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Orthodont, San Antonio, TX 78229 USA. RP Soares, JC (reprint author), Univ N Carolina, CERT BD, Dept Psychiat, Sch Med, 10616 Neurosci Hosp CB 7160, Chapel Hill, NC 27599 USA. EM jsoares@med.unc.edu RI Caetano, Sheila/H-5010-2012 OI Caetano, Sheila/0000-0001-8403-7078 FU UTHSCSA GCRC [M01-RR-01346]; Krus Endowed Chair in Psychiatry (UTHSCSA); Veterans Administration (VA Merit Review); CAPES Foundation (Brazil); CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil) [200006/04-5]; [MH 01736]; [MH 068662]; [RR 020571] FX This research was partly supported by grants MH 01736, MH 068662, RR 020571, UTHSCSA GCRC (M01-RR-01346), the Krus Endowed Chair in Psychiatry (UTHSCSA), the Veterans Administration (VA Merit Review), the CAPES Foundation (Brazil) and CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil - grant #200006/04-5). NR 63 TC 21 Z9 22 U1 3 U2 10 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD DEC 30 PY 2009 VL 174 IS 3 BP 177 EP 183 DI 10.1016/j.pscychresns.2009.05.003 PG 7 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 534OW UT WOS:000272908000003 PM 19910168 ER PT J AU Genethliou, N Panayiotou, E Panayi, H Orford, M Mean, R Lapathitis, G Gill, H Raoof, S De Gasperi, R Elder, G Kessaris, N Richardson, WD Malas, S AF Genethliou, Nicholas Panayiotou, Elena Panayi, Helen Orford, Michael Mean, Richard Lapathitis, George Gill, Herman Raoof, Sahir De Gasperi, Rita Elder, Gregory Kessaris, Nicoletta Richardson, William D. Malas, Stavros TI SOX1 links the function of neural patterning and Notch signalling in the ventral spinal cord during the neuron-glial fate switch SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Sox1; Pax6; Nkx2.2; Hes1; Oligodendrocytes; Astrocytes; Notch signalling ID HOMEODOMAIN TRANSCRIPTION FACTOR; SONIC HEDGEHOG; OLIGODENDROCYTE DIFFERENTIATION; CELLS; PRECURSORS; MICE; GLIOGENESIS; NKX2.2; SPECIFICATION; NEUROGENESIS AB During neural development the transition from neurogenesis to gliogenesis, known as the neuron-glial (N/G) fate switch, requires the coordinated function of patterning factors, pro-glial factors and Notch signalling. How this process is coordinated in the embryonic spinal cord is poorly understood. Here, we demonstrate that during the N/G fate switch in the ventral spinal cord (vSC) SOX1 links the function of neural patterning and Notch signalling. We show that, SOX1 expression in the vSC is regulated by PAX6, NKX2.2 and Notch signalling in a domain-specific manner. We further show that SOX1 regulates the expression of Hes1 and that loss of Sox1 leads to enhanced production of oligodendrocyte precursors from the pMN. Finally, we show that Notch signalling functions upstream of SOX1 during this fate switch and is independently required for the acquisition of the glial fate per se by regulating Nuclear Factor I A expression in a PAX6/SOX1/HES1/HES5-independent manner. These data integrate functional roles of neural patterning factors, Notch signalling and SOX1 during gliogenesis. (C) 2009 Elsevier Inc. All rights reserved. C1 [Malas, Stavros] Cyprus Inst Neurol & Genet, Dev & Funct Genet Grp, CY-2370 Nicosia, Cyprus. [Genethliou, Nicholas; Panayiotou, Elena] Univ Cyprus, Dept Biol Sci, CY-1678 Nicosia, Cyprus. [De Gasperi, Rita; Elder, Gregory] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Kessaris, Nicoletta; Richardson, William D.] UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England. [Kessaris, Nicoletta; Richardson, William D.] UCL, Res Dept Cell & Dev Biol, London WC1E 6BT, England. RP Malas, S (reprint author), Cyprus Inst Neurol & Genet, Dev & Funct Genet Grp, Airport Ave 6, CY-2370 Nicosia, Cyprus. EM smalas@cing.ac.cy OI Kessaris, Nicoletta/0000-0003-1191-6009 FU European Union; UK Medical Research Council; Wellcome Trust FX We thank Johan Ericson, Anastasia Stoykova and Austin Smith for the mice and Michael Wegner for antibodies and plasmids. This work was supported by the European Union (SM) and the UK Medical Research Council and the Wellcome Trust (WDR and NK). NR 36 TC 9 Z9 10 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X EI 1090-2104 J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD DEC 25 PY 2009 VL 390 IS 4 BP 1114 EP 1120 DI 10.1016/j.bbrc.2009.08.154 PG 7 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 531GB UT WOS:000272650800008 PM 19723505 ER PT J AU Hata, S Fujishige, S Araki, Y Kato, N Araseki, M Nishimura, M Hartmann, D Saftig, P Fahrenholz, F Taniguchi, M Urakami, K Akatsu, H Martins, RN Yamamoto, K Maeda, M Yamamoto, T Nakaya, T Gandy, S Suzuki, T AF Hata, Saori Fujishige, Sayaka Araki, Yoichi Kato, Naoko Araseki, Masahiko Nishimura, Masaki Hartmann, Dieter Saftig, Paul Fahrenholz, Falk Taniguchi, Miyako Urakami, Katsuya Akatsu, Hiroyasu Martins, Ralph N. Yamamoto, Kazuo Maeda, Masahiro Yamamoto, Tohru Nakaya, Tadashi Gandy, Sam Suzuki, Toshiharu TI Alcadein Cleavages by Amyloid beta-Precursor Protein (APP) alpha- and gamma-Secretases Generate Small Peptides, p3-Alcs, Indicating Alzheimer Disease-related gamma-Secretase Dysfunction SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PRESENILIN-1 MUTATIONS; EARLY-ONSET; CONVERTING-ENZYME; METABOLISM; ASSOCIATION; MEMBRANE; FAMILY; PHOSPHORYLATION; DIFFERENTIATION; A-BETA(42) AB Alcadeins (Alcs) constitute a family of neuronal type I membrane proteins, designated Alc(alpha), Alc(beta), and Alc(gamma). The Alcs express in neurons dominantly and largely colocalize with the Alzheimer amyloid precursor protein (APP) in the brain. Alcs and APP show an identical function as a cargo receptor of kinesin-1. Moreover, proteolytic processing of Alc proteins appears highly similar to that of APP. We found that APP alpha-secretases ADAM 10 and ADAM 17 primarily cleave Alc proteins and trigger the subsequent secondary intramembranous cleavage of Alc C-terminal fragments by a presenilin-dependent gamma-secretase complex, thereby generating "APP p3-like" and non-aggregative Alc peptides (p3-Alcs). Wedetermined the complete amino acid sequence of p3-Alc(alpha), p3-Alc(beta), and p3-Alc(gamma), whose major species comprise 35, 37, and 31 amino acids, respectively, in human cerebrospinal fluid. We demonstrate here that variant p3-Alc C termini are modulated by FAD-linked presenilin 1 mutations increasing minor beta-amyloid species A beta 42, and these mutations alter the level of minor p3-Alc species. However, the magnitudes of C-terminal alteration of p3-Alc(alpha), p3-Alc(beta), and p3-Alc(gamma) were not equivalent, suggesting that one type of gamma-secretase dysfunction does not appear in the phenotype equivalently in the cleavage of type I membrane proteins. Because these C-terminal alterations are detectable in human cerebrospinal fluid, the use of a substrate panel, including Alcs and APP, may be effective to detect gamma-secretase dysfunction in the prepathogenic state of Alzheimer disease subjects. C1 [Gandy, Sam] Mt Sinai Sch Med, Alzheimers Dis Res Ctr, Dept Neurol, New York, NY 10029 USA. [Gandy, Sam] Mt Sinai Sch Med, Alzheimers Dis Res Ctr, Dept Psychiat, New York, NY 10029 USA. [Hata, Saori; Fujishige, Sayaka; Araki, Yoichi; Kato, Naoko; Araseki, Masahiko; Yamamoto, Tohru; Nakaya, Tadashi; Suzuki, Toshiharu] Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Neurosci, Sapporo, Hokkaido 0600812, Japan. [Nishimura, Masaki] Shiga Univ Med Sci, Mol Neurosci Res Ctr, Neurol Unit, Otsu, Shiga 5202192, Japan. [Hartmann, Dieter] Univ Bonn, Dept Anat, D-53115 Bonn, Germany. [Saftig, Paul] Univ Kiel, Inst Biochem, D-2300 Kiel, Germany. [Fahrenholz, Falk] Johannes Gutenberg Univ Mainz, Inst Biochem, D-6500 Mainz, Germany. [Taniguchi, Miyako; Urakami, Katsuya] Tottori Univ, Fac Med, Sch Hlth Sci, Dept Regulat Biol, Yonago, Tottori 6838503, Japan. [Akatsu, Hiroyasu] Fukushimura Hosp, Choju Med Inst, Toyohashi, Aichi 4418124, Japan. [Martins, Ralph N.] Edith Cowan Univ, Sch Exercise Biomed & Hlth Sci, Sir James McCusker Alzheimers Dis Res Unit, Joondalup, WA 6027, Australia. [Martins, Ralph N.] Edith Cowan Univ, Sch Exercise Biomed & Hlth Sci, Ctr Excellence Alzheimers Dis Res & Care, Joondalup, WA 6027, Australia. [Yamamoto, Kazuo] Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Kashiwa, Chiba 2778562, Japan. [Maeda, Masahiro] Immunobiol Labs Co Ltd, Fujioka 3750005, Japan. [Gandy, Sam] James J Peters Vet Adm Med Ctr, Bronx, NY 10468 USA. RP Gandy, S (reprint author), Mt Sinai Sch Med, Alzheimers Dis Res Ctr, Dept Neurol, New York, NY 10029 USA. EM samuel.gandy@mssm.edu; tsuzuki@pharm.hokudai.ac.jp RI Saftig, Paul/A-7966-2010; Hata, Saori /A-3829-2012; Yamamoto, Tohru/A-3801-2012; Suzuki, Toshiharu/B-5342-2013 OI Yamamoto, Tohru/0000-0002-1652-0233; FU National Institutes of Health, NIA [R01 AG23611, P01 AG10491, P50 AG005138]; Ministry of Education, Science, Culture, Sports, and Technology, Japan [20023001] FX This work was supported, in whole or in part, by National Institutes of Health, NIA, Grants R01 AG23611, P01 AG10491, and P50 AG005138 (to S. G.). This work was also supported in part by Grants-in-aid for Scientific Research on Priority Areas 20023001 (to T. S.) from the Ministry of Education, Science, Culture, Sports, and Technology, Japan. NR 31 TC 29 Z9 31 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 25 PY 2009 VL 284 IS 52 BP 36024 EP 36033 DI 10.1074/jbc.M109.057497 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 535LT UT WOS:000272970500004 PM 19864413 ER PT J AU Landefeld, CS Winker, MA Chernof, B AF Landefeld, C. Seth Winker, Margaret A. Chernof, Bruce TI Clinical Care in the Aging Century-Announcing "Care of the Aging Patient: From Evidence to Action" SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 [Landefeld, C. Seth] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94118 USA. [Landefeld, C. Seth] San Francisco VA Med Ctr, San Francisco, CA USA. [Chernof, Bruce] SCAN Fdn, Long Beach, CA USA. RP Landefeld, CS (reprint author), Univ Calif San Francisco, Div Geriatr, 3333 Calif St,Ste 380, San Francisco, CA 94118 USA. EM sethl@medicine.ucsf.edu OI Winker, Margaret/0000-0002-4708-5641 NR 15 TC 12 Z9 12 U1 0 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 23 PY 2009 VL 302 IS 24 BP 2703 EP 2704 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 535JU UT WOS:000272965300030 PM 20040562 ER PT J AU Vanderwerf, SM Svahn, J Olson, S Rathbun, RK Harrington, C Yates, J Keeble, W Anderson, DC Anur, P Pereira, NF Pilonetto, DV Pasquini, R Bagby, GC AF Vanderwerf, Scott M. Svahn, Johanna Olson, Susan Rathbun, R. Keaney Harrington, Christina Yates, Jane Keeble, Winifred Anderson, David C. Anur, Praveen Pereira, Noemi F. Pilonetto, Daniela V. Pasquini, Ricardo Bagby, Grover C. TI TLR8-dependent TNF-alpha overexpression in Fanconi anemia group C cells SO BLOOD LA English DT Article ID NECROSIS-FACTOR-ALPHA; DEPENDENT PROTEIN-KINASE; DOUBLE-STRANDED-RNA; TOLL-LIKE RECEPTORS; INTERFERON-GAMMA; HEMATOPOIETIC-CELLS; IFN-GAMMA; IN-VITRO; APOPTOTIC RESPONSES; SIGNALING PATHWAYS AB Tumor necrosis factor alpha (TNF-alpha) production is abnormally high in Fanconi anemia (FA) cells and contributes to the hematopoietic defects seen in FA complementation group C-deficient (Fancc(-/-)) mice. Applying gene expression microarray and proteomic methods to studies on FANCC-deficient cells we found that genes encoding proteins directly involved in ubiquitinylation are overrepresented in the signature of FA bone marrow cells and that ubiquitinylation profiles of FA-C and complemented cells were substantially different. Finding that Toll-like receptor 8 (TLR8) was one of the proteins ubiquitinylated only in mutant cells, we confirmed that TLR8 (or a TLR8-associated protein) is ubiquitinylated in mutant FA-C cells and that TNF-alpha production in mutant cells depended upon TLR8 and the canonical downstream signaling intermediates interleukin 1 receptor-associated kinase (IRAK) and I kappa B kinase-alpha/beta. FANCC-deficient THP-1 cells and macrophages from Fancc(-/-) mice overexpressed TNF-alpha in response to TLR8 agonists but not other TLR agonists. Ectopically expressed FANCC point mutants were capable of fully complementing the mitomycin-C hypersensitivity phenotype of FA-C cells but did not suppress TNF-alpha overproduction. In conclusion, FANCC suppresses TNF-alpha production in mononuclear phagocytes by suppressing TLR8 activity and this particular function of FANCC is independent of its function in protecting the genome from cross-linking agents. (Blood. 2009; 114: 5290-5298) C1 [Vanderwerf, Scott M.] Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA. [Svahn, Johanna] Osped Gaslini, Dept Pediat Hematol Oncol, Genoa, Italy. [Olson, Susan; Bagby, Grover C.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA. [Rathbun, R. Keaney; Yates, Jane; Keeble, Winifred; Bagby, Grover C.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Vanderwerf, Scott M.; Rathbun, R. Keaney; Yates, Jane; Keeble, Winifred; Bagby, Grover C.] Portland VA Med Ctr, NW VA Canc Res Ctr, Portland, OR 97239 USA. [Harrington, Christina] Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA. [Harrington, Christina; Bagby, Grover C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. [Anderson, David C.] Univ Oregon, Dept Mol Biol, Eugene, OR 97403 USA. [Anur, Praveen] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA. [Pereira, Noemi F.; Pilonetto, Daniela V.; Pasquini, Ricardo] Univ Fed Parana, Bone Marrow Transplantat Serv, BR-80060000 Curitiba, Parana, Brazil. RP Vanderwerf, SM (reprint author), Portland VA Med Ctr, NW VA Canc Res Ctr, Mailstop R&D30,Bldg 104,Rm 6206,3710 SW US Vet Ho, Portland, OR 97239 USA. EM vanderws@ohsu.edu OI Pilonetto, Daniela/0000-0002-3045-5028 FU National Heart, Lung and Blood Institute; National Cancer Institute; Department of Veterans Affairs; Fanconi Anemia Research Fund Inc. FX This study was supported in part by the National Heart, Lung and Blood Institute, the National Cancer Institute, the Department of Veterans Affairs, and the Fanconi Anemia Research Fund Inc. NR 47 TC 36 Z9 37 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD DEC 17 PY 2009 VL 114 IS 26 BP 5290 EP 5298 DI 10.1182/blood-2009-05-222414 PG 9 WC Hematology SC Hematology GA 533ZA UT WOS:000272863800009 PM 19850743 ER PT J AU Steele, JW Kim, SH Cirrito, JR Verges, DK Restivo, JL Westaway, D Fraser, P Hyslop, PS Sano, M Bezprozvanny, I Ehrlich, ME Holtzman, DM Gandy, S AF Steele, John W. Kim, Soong H. Cirrito, John R. Verges, Deborah K. Restivo, Jessica L. Westaway, David Fraser, Paul Hyslop, Peter St George Sano, Mary Bezprozvanny, Ilya Ehrlich, Michelle E. Holtzman, David M. Gandy, Sam TI Acute dosing of latrepirdine (Dimebon (TM)), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo SO MOLECULAR NEURODEGENERATION LA English DT Article ID PRECURSOR PROTEIN; SYNAPTIC PLASTICITY; COGNITIVE DEFICITS; TRANSGENIC MICE; HUMAN BRAIN; A-BETA; DISEASE; OLIGOMERS; SYNAPSES; ACCUMULATION AB Background: Recent reports suggest that latrepirdine (Dimebon T, dimebolin), a retired Russian antihistamine, improves cognitive function in aged rodents and in patients with mild to moderate Alzheimer's disease (AD). However, the mechanism(s) underlying this benefit remain elusive. AD is characterized by extracellular accumulation of the amyloid-beta (A beta) peptide in the brain, and A beta-lowering drugs are currently among the most popular anti-amyloid agents under development for the treatment of AD. In the current study, we assessed the effect of acute dosing of latrepirdine on levels of extracellular A beta using in vitro and in vivo experimental systems. Results: We evaluated extracellular levels of A beta in three experimental systems, under basal conditions and after treatment with latrepirdine. Mouse N2a neuroblastoma cells overexpressing Swedish APP were incubated for 6 hr in the presence of either vehicle or vehicle + latrepirdine (500pM-5 mu M). Synaptoneurosomes were isolated from TgCRND8 mutant APP-overexpressing transgenic mice and incubated for 0 to 10 min in the absence or presence of latrepirdine (1 mu M or 10 mu M). Drug-naive Tg2576 Swedish mutant APP overexpressing transgenic mice received a single intraperitoneal injection of either vehicle or vehicle + latrepirdine (3.5 mg/kg). Picomolar to nanomolar concentrations of acutely administered latrepirdine increased the extracellular concentration of A beta in the conditioned media from Swedish mutant APP-overexpressing N2a cells by up to 64% (p = 0.01), while a clinically relevant acute dose of latrepirdine administered i.p. led to an increase in the interstitial fluid of freely moving APP transgenic mice by up to 40% (p = 0.01). Reconstitution of membrane protein trafficking and processing is frequently inefficient, and, consistent with this interpretation, latrepirdine treatment of isolated TgCRND8 synaptoneurosomes involved higher concentrations of drug (1-10 mu M) and led to more modest increases in extracellular A beta(x-42) levels (+ 10%; p = 0.001); of note, however, was the observation that extracellular A beta(x-40) levels did not change. Conclusions: Here, we report the surprising association of acute latrepirdine dosing with elevated levels of extracellular A beta as measured in three independent neuron-related or neuron-derived systems, including the hippocampus of freely moving Tg2576 mice. Given the reported association of chronic latrepirdine treatment with improvement in cognitive function, the effects of chronic latrepirdine treatment on extracellular A beta levels must now be determined. C1 [Cirrito, John R.; Verges, Deborah K.; Restivo, Jessica L.; Holtzman, David M.] Washington Univ, Hope Ctr Neurol Disorders, Dept Neurol, Sch Med, St Louis, MO 63110 USA. [Cirrito, John R.; Verges, Deborah K.; Restivo, Jessica L.; Holtzman, David M.] Washington Univ, Alzheimers Dis Res Ctr, Sch Med, St Louis, MO 63110 USA. [Steele, John W.; Kim, Soong H.; Ehrlich, Michelle E.; Gandy, Sam] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA. [Steele, John W.; Kim, Soong H.; Sano, Mary; Gandy, Sam] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Steele, John W.; Kim, Soong H.; Sano, Mary; Ehrlich, Michelle E.; Gandy, Sam] Mt Sinai Sch Med, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Westaway, David] Univ Alberta, Ctr Pr & Prot Folding Dis, Edmonton, AB T6G 2M8, Canada. [Fraser, Paul; Hyslop, Peter St George] Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada. [Hyslop, Peter St George] Univ Cambridge, Dept Clin Neurosci, Cambridge CB2 0XY, England. [Sano, Mary; Gandy, Sam] James J Peters VA Med Ctr, Dept Neurol, Bronx, NY 10468 USA. [Bezprozvanny, Ilya] Univ Texas SW, Dept Physiol, Dallas, TX 75390 USA. [Ehrlich, Michelle E.] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA. RP Holtzman, DM (reprint author), Washington Univ, Hope Ctr Neurol Disorders, Dept Neurol, Sch Med, St Louis, MO 63110 USA. EM john.steele@mssm.edu; soongho.kim@mssm.edu; cirritoj@neuro.wustl.edu; vergesd@neuro.wustl.edu; restivoj@neuro.wustl.edu; david.westaway@ualberta.ca; paul.fraser@utoronto.ca; p.hyslop@utoronto.ca; mary.sano@mssm.edu; ilya.bezprozvanny@utsouthwestern.edu; michelle.ehrlich@mssm.edu; holtzman@neuro.wustl.edu; samuel.gandy@mssm.edu FU National Institute of General Medical Sciences [T32GM062754]; National Institute on Aging [P01 AG10491, K01 AG29524]; Cure Alzheimer's Fund; Zenith Award; Alzheimer's Association; NINDS [R01 NS056224]; Canadian Institutes for Health Research; Alzheimer's Society of Ontario FX Support: JWS is a trainee in the Integrated Pharmacological Sciences Training Program supported by grant T32GM062754 from the National Institute of General Medical Sciences. JWS, SHK, and SG; and JRC (National Institute on Aging grant P01 AG10491 and K01 AG29524, respectively); JWS, SHK, and SG; and JRC and DMH (Cure Alzheimer's Fund); DMH [Zenith Award] and IB (Alzheimer's Association); IB (NINDS R01 NS056224); PF (Canadian Institutes for Health Research and the Alzheimer's Society of Ontario). Swedish APP N2a cell line was the generous gift of Dr. Gopal Thinakaran (University of Chicago). The authors would like to thank Loren E. Khan-Vaughan and Justine Bonet for their assistance with animal colony management. NR 41 TC 26 Z9 27 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1750-1326 J9 MOL NEURODEGENER JI Mol. Neurodegener. PD DEC 17 PY 2009 VL 4 AR 51 DI 10.1186/1750-1326-4-51 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 545ZR UT WOS:000273777300001 PM 20017949 ER PT J AU Matthews, AM AF Matthews, Annette M. TI Tobacco Control in VA Hospitals SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 Portland VA Med Ctr, Dept Behav Hlth & Neurosci, Portland, OR USA. RP Matthews, AM (reprint author), Portland VA Med Ctr, Dept Behav Hlth & Neurosci, Portland, OR USA. EM annette.matthews@va.gov NR 2 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 16 PY 2009 VL 302 IS 23 BP 2551 EP 2551 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 532HK UT WOS:000272737200017 PM 20009051 ER PT J AU New, AS Hazlett, EA Newmark, RE Zhang, J Triebwasser, J Meyerson, D Lazarus, S Trisdorfer, R Goldstein, KE Goodman, M Koenigsberg, HW Flory, JD Siever, LJ Buchsbaum, MS AF New, Antonia S. Hazlett, Erin A. Newmark, Randall E. Zhang, Jane Triebwasser, Joseph Meyerson, David Lazarus, Sophie Trisdorfer, Roanna Goldstein, Kim E. Goodman, Marianne Koenigsberg, Harold W. Flory, Janine D. Siever, Larry J. Buchsbaum, Monte S. TI Laboratory Induced Aggression: A Positron Emission Tomography Study of Aggressive Individuals with Borderline Personality Disorder SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Brain imaging; emotion; Point Subtraction Aggression Paradigm; PSAP ID NONVIOLENT MALE PAROLEES; ORBITAL FRONTAL-CORTEX; GLUCOSE-METABOLISM; PSYCHOMETRIC MEASUREMENTS; IMPULSIVE AGGRESSION; BRAIN ABNORMALITIES; SPECTRUM DISORDERS; BRODMANN AREAS; RHESUS-MONKEYS; FDG-PET AB Background: Borderline personality disorder (BPD) is often associated with symptoms of impulsive aggression, which poses a threat to patients themselves and to others. Preclinical studies show that orbital frontal cortex (OFC) plays a role in regulating impulsive aggression. Prior work has found OFC dysfunction in BPD. Methods: We employed a task to provoke aggressive behavior, the Point Subtraction Aggression Paradigm (PSAP), which has never previously been used during functional brain imaging. Thirty-eight BPD patients with intermittent explosive disorder (BPD-IED) and 36 age-matched healthy control subjects (HCs) received (18)fluoro-deoxyglucose positron emission tomography ((18)FDG-PET) on two occasions with a provocation and nonprovocation version of the PSAP. Mean relative glucose metabolism was measured throughout the cortex, and difference scores (provoked - nonprovoked) were calculated. A whole brain exploratory analysis for the double difference of BPD-IED - HC for provoked - nonprovoked was also conducted. Results: BPD-IED patients were significantly more aggressive than HCs on the PSAP. BPD-IED patients also increased relative glucose metabolic rate (rGMR) in OFC and amygdala when provoked, while HCs decreased rGMR in these areas, However, HCs increased rGMR in anterior, medial, and dorsolateral prefrontal regions during provocation more than BPD-IED patients. Conclusions: Patients responded aggressively and showed heightened rGMR in emotional brain areas, including amygdala and OFC, in response to provocation but not in more dorsal brain regions associated with cognitive control of aggression. In contrast, HCs increased rGMR in dorsal regions of PFC during aggression provocation, brain regions involved in top-down cognitive control of aggression, and, more broadly, of emotion. C1 [New, Antonia S.; Triebwasser, Joseph; Goodman, Marianne; Koenigsberg, Harold W.; Siever, Larry J.] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [New, Antonia S.; Hazlett, Erin A.; Zhang, Jane; Triebwasser, Joseph; Lazarus, Sophie; Trisdorfer, Roanna; Goldstein, Kim E.; Goodman, Marianne; Koenigsberg, Harold W.; Flory, Janine D.; Siever, Larry J.; Buchsbaum, Monte S.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Newmark, Randall E.] Boston Univ, Dept Neurosci, Boston, MA 02215 USA. [Meyerson, David] Depaul Univ, Dept Psychol, Chicago, IL 60604 USA. [Flory, Janine D.] CUNY, Queens Coll, Dept Psychol, New York, NY 10021 USA. [Buchsbaum, Monte S.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Buchsbaum, Monte S.] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA. RP New, AS (reprint author), James J Peters Vet Affairs Med Ctr, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM antonia.new@mssm.edu FU James J. Peters Veterans Affairs Medical Center; National Institutes of Health (NIH) [1-R01-MH067918-01, 1-R01-MH07911, 5-M01 RR00071]; National Center for Research Resources FX This work was supported by the James J. Peters Veterans Affairs Medical Center and by a grant to ASN from the National Institutes of Health (NIH) (1-R01-MH067918-01) and to EAH (1-R01-MH07911) and by 5-M01 RR00071 for the Mount Sinai General Clinical Research Center from the National Center for Research Resources at the NIH. NR 64 TC 69 Z9 71 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD DEC 15 PY 2009 VL 66 IS 12 BP 1107 EP 1114 DI 10.1016/j.biopsych.2009.07.015 PG 8 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 530NL UT WOS:000272599500006 PM 19748078 ER PT J AU Collins, MP Souza, PE Liu, CF Heagerty, PJ Amtmann, D Yueh, B AF Collins, Margaret P. Souza, Pamela E. Liu, Chuan-Fen Heagerty, Patrick J. Amtmann, Dagmar Yueh, Bevan TI Hearing aid effectiveness after aural rehabilitation - individual versus group (HEARING) trial: RCT design and baseline characteristics SO BMC HEALTH SERVICES RESEARCH LA English DT Article ID HEALTH MAINTENANCE ORGANIZATION; BEHAVIORAL TREATMENT APPROACH; RANDOMIZED CONTROLLED-TRIAL; CHRONIC CARE CLINICS; 2-YEAR FOLLOW-UP; COMMUNICATION PROFILE; HANDICAP INVENTORY; AUDIOLOGICAL REHABILITATION; DIABETES EDUCATION; GROUP VISITS AB Background: Hearing impairment is the most common body system disability in veterans. In 2008, nearly 520,000 veterans had a disability for hearing loss through the Department of Veterans Affairs (VA). Changes in eligibility for hearing aid services, along with the aging population, contributed to a greater than 300% increase in the number of hearing aids dispensed from 1996 to 2006. In 2006, the VA committed to having no wait times for patient visits while providing quality clinically-appropriate care. One approach to achieving this goal is the use of group visits as an alternative to individual visits. We sought to determine: 1) if group hearing aid fitting and follow-up visits were at least as effective as individual visits, and 2) whether group visits lead to cost savings through the six month period after the hearing aid fitting. We describe the rationale, design, and characteristics of the baseline cohort of the first randomized clinical trial to study the impact of group versus individual hearing aid fitting and follow-up visits. Methods: Participants were recruited from the VA Puget Sound Health Care System Audiology Clinic. Eligible patients had no previous hearing aid use and monaural or binaural air-conduction hearing aids were ordered at the evaluation visit. Participants were randomized to receive the hearing aid fitting and the hearing aid follow-up in an individual or group visit. The primary outcomes were hearing-related function, measured with the first module of the Effectiveness of Aural Rehabilitation (Inner EAR), and hearing aid adherence. We tracked the total cost of planned and unplanned audiology visits over the 6-month interval after the hearing aid fitting. Discussion: A cohort of 659 participants was randomized to receive group or individual hearing aid fitting and follow-up visits. Baseline demographic and self-reported health status and hearing-related measures were evenly distributed across the treatment arms. Outcomes after the 6-month follow-up period are needed to determine if group visits were as least as good as those for individual visits and will be reported in subsequent publication. C1 [Collins, Margaret P.; Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, Hlth Serv Res Dev Ctr Excellence, Seattle, WA 98101 USA. [Collins, Margaret P.] VA Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA 98108 USA. [Souza, Pamela E.] Northwestern Univ, Dept Commun Sci & Disorders, Evanston, IL 60208 USA. [Liu, Chuan-Fen] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Heagerty, Patrick J.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Amtmann, Dagmar] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Yueh, Bevan] Univ Minnesota, Dept Otolaryngol Head & Neck Surg, Minneapolis, MN 55455 USA. RP Collins, MP (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res Dev Ctr Excellence, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM margaret.collins@va.gov; p-souza@northwestern.edu; Chuan-Fen.Liu@va.gov; heagerty@u.washington.edu; dagmara@u.washington.edu; byueh@umn.edu OI Yueh, Bevan/0000-0003-1380-1053 FU Health Services Research & Development Service of the Veterans Health Administration [SLI 04-2653] FX This work is supported by a grant from the Health Services Research & Development Service of the Veterans Health Administration (SLI 04-2653). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs, the United States government, or other affiliated institutions. NR 76 TC 5 Z9 5 U1 2 U2 11 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD DEC 15 PY 2009 VL 9 AR 233 DI 10.1186/1472-6963-9-233 PG 14 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 543JR UT WOS:000273573100001 PM 20003515 ER PT J AU Gramza, AW Corless, CL Heinrich, MC AF Gramza, Ann W. Corless, Christopher L. Heinrich, Michael C. TI Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors SO CLINICAL CANCER RESEARCH LA English DT Article ID CHRONIC MYELOID-LEUKEMIA; SOFT-TISSUE SARCOMAS; C-KIT MUTATIONS; IMATINIB MESYLATE; MOUSE MODEL; DIFFERENTIAL-DIAGNOSIS; STRUCTURAL BASIS; DOSE IMATINIB; CARNEY TRIAD; PHASE-III AB Gastrointestinal stromal tumors (GIST) are the most common type of sarcoma in the gastrointestinal tract. Surgery is the primary treatment modality, but many patients suffer disease recurrence or metastasis. Fortunately, the management of advanced GIST has been revolutionized by the use of small molecule kinase inhibitors that target the underlying pathogenetic mutant kinases found in the vast majority of cases. Approximately 85% of GISTs have oncogenic mutations in KIT, allowing for constitutive kinase activation that is responsible for cellular proliferation and survival. About 5 to 7% of GISTs have activating mutations of the homologous platelet-derived growth factor receptor alpha (PDGFRA) kinase. The progression-free and overall survival of patients with advanced disease is greatly improved by treatment with the kinase inhibitors imatinib and sunitinib. However, the emergence of drug-resistant tumor clones limits the long-term benefit of these drugs in most patients. Resistance to these kinase inhibitors is associated with distinctive clinical and molecular features, with the development of secondary mutations of the oncogenic kinase being the most common mechanism. We review the molecular basis of GIST response and/or resistance to TKIs, and discuss strategies to prevent and/or overcome drug resistance. These concepts are directly relevant to the development of targeted molecular therapy for other solid tumors. (Clin Cancer Res 2009;15(24):7510-8) C1 [Gramza, Ann W.; Corless, Christopher L.; Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR USA. [Gramza, Ann W.; Corless, Christopher L.; Heinrich, Michael C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. RP Heinrich, MC (reprint author), R&D-19,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM heinrich@ohsu.edu FU Department of Veterans Affairs; Life Raft Group; GIST Cancer Research Fund FX In part from a Merit Review Grant from the Department of Veterans Affairs (M.C. Heinrich), as well as the Life Raft Group (C.L. Corless, M.C. Heinrich), and GIST Cancer Research Fund (C.L. Corless, M.C. Heinrich). NR 88 TC 89 Z9 95 U1 1 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD DEC 15 PY 2009 VL 15 IS 24 BP 7510 EP 7518 DI 10.1158/1078-0432.CCR-09-0190 PG 9 WC Oncology SC Oncology GA 533VM UT WOS:000272853500010 ER PT J AU Musher, DM AF Musher, Daniel M. TI The Naming of Strep, with Apologies to T. S. Eliot SO CLINICAL INFECTIOUS DISEASES LA English DT Letter C1 [Musher, Daniel M.] Baylor Coll Med, Med Care Line Infect Dis Sect, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. RP Musher, DM (reprint author), Vet Affairs Med Ctr, Infect Dis Sect, 2002 Holcombe Blvd,Rm 4B-370, Houston, TX 77030 USA. EM daniel.musher@med.va.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 15 PY 2009 VL 49 IS 12 BP 1959 EP 1959 DI 10.1086/648499 PG 1 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 523KA UT WOS:000272070800031 PM 19929391 ER PT J AU Pantaleo, MA Astolfi, A Di Battista, M Heinrich, MC Paterini, P Scotlandi, K Santini, D Catena, F Manara, MC Nannini, M Maleddu, A Saponara, M Lolli, C Formica, S Biasco, G AF Pantaleo, Maria A. Astolfi, Annalisa Di Battista, Monica Heinrich, Michael C. Paterini, Paola Scotlandi, Katia Santini, Donatella Catena, Fausto Manara, Maria C. Nannini, Margherita Maleddu, Alessandra Saponara, Maristella Lolli, Cristian Formica, Serena Biasco, Guido TI Insulin-like growth factor 1 receptor expression in wild-type GISTs: A potential novel therapeutic target SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE gastrointestinal stromal tumours; insulin-like growth factor 1 receptor; KIT receptor; PDGFRA ID GASTROINTESTINAL STROMAL TUMORS; MUTATIONS; PATHWAY; DISEASE; CANCER AB Aberrations of the Insulin-like Growth Factor (IGF) system have been found in association with a variety of cancer types. The potential role of IGF1R has been postulated in a small subset of GISTs, but until now the implications of its aberrations have not been defined. The aim of the study was to examine the IGF1R status in patients with gastric GIST in regard to KIT and PDGFRA genotype. Fresh resection specimens were collected from 8 primary tumours [2 wild-type (WT) and 6 mutant cases]. IGF1R was studied as gene expression profiling with Affymetrix GeneChip HG-U133Plus 2.0 arrays and as genomic copy number with SNP array analysis Affymetrix Genome Wide Human SNP 6.0 arrays, and at protein level with western blotting (WB) and immunohistochemistry (IHC). The unsupervised analysis of gene expression profiling of our patients merged with a data set from gastric GISTs identified 2 patients out of 8 with different expression of IGF1R. The data were confirmed by WB and IHC. In particular, IGF1R was upregulated in 2 young patients (<30-years old), who had both WT disease and metastases at diagnosis. The SNP array analysis showed that none of the tumours had IGF1R amplification. GISTs are characterized by abnormalities of the KIT and PDGFRA receptors that affect prognosis and response to tyrosine kinase inhibitors. Both young adult with WT GIST had the overexpression of IGF1R at mRNA and protein level. These results further confirm the hypothesis that IGF1R may be a potential therapeutic target in GISTs lacking KIT and PDGFRA mutations. (C) 2009 UICC C1 [Pantaleo, Maria A.; Di Battista, Monica; Nannini, Margherita; Maleddu, Alessandra; Saponara, Maristella; Lolli, Cristian; Biasco, Guido] Univ Bologna, St Orsola Malpighi Hosp, Dept Hematol & Oncol Sci LA Seragnoli, I-40138 Bologna, Italy. [Pantaleo, Maria A.; Astolfi, Annalisa; Paterini, Paola; Formica, Serena; Biasco, Guido] Univ Bologna, Interdept Ctr Canc Res G Prodi, I-40138 Bologna, Italy. [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Dept Med, Portland VA Med Ctr, Portland, OR 97201 USA. [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. [Scotlandi, Katia; Manara, Maria C.] Ist Ortoped Rizzoli, Lab Ric Oncol, CRS Sviluppo Terapie Biomol, Bologna, Italy. [Santini, Donatella] Univ Bologna, St Orsola Malpighi Hosp, Pathol Unit, I-40138 Bologna, Italy. [Catena, Fausto] Univ Bologna, St Orsola Malpighi Hosp, Emergency Surg & Transplant Dept, I-40138 Bologna, Italy. RP Pantaleo, MA (reprint author), Univ Bologna, St Orsola Malpighi Hosp, Dept Hematol & Oncol Sci LA Seragnoli, Via Massarenti 9, I-40138 Bologna, Italy. EM maria.pantaleo@unibo.it RI Saponara, Maristella/J-9904-2016; nannini, margherita/J-9866-2016 OI Saponara, Maristella/0000-0003-0715-171X; PANTALEO, MARIA ABBONDANZA/0000-0002-0177-6957; NANNINI, MARGHERITA/0000-0002-2103-1960; astolfi, annalisa/0000-0002-2732-0747 FU Fondazione Cassa di Risparmio of Bologna (CARISBO); Vanini-Cavagnino (Interdepartmental Centre for Cancer Research "G. Prodi"); University of Bologna, Italy FX Grant sponsors: Fondazione Cassa di Risparmio of Bologna (CARISBO), Vanini-Cavagnino (Interdepartmental Centre for Cancer Research "G. Prodi"), University of Bologna, Italy. NR 16 TC 51 Z9 53 U1 0 U2 7 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD DEC 15 PY 2009 VL 125 IS 12 BP 2991 EP 2994 DI 10.1002/ijc.24595 PG 4 WC Oncology SC Oncology GA 523CJ UT WOS:000272049000030 PM 19672856 ER PT J AU York, MK Wilde, EA Simpson, R Jankovic, J AF York, Michele K. Wilde, Elisabeth A. Simpson, Richard Jankovic, Joseph TI Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location SO JOURNAL OF THE NEUROLOGICAL SCIENCES LA English DT Article DE Parkinson's disease; Deep brain stimulation; Neuropsychology; Cognition; Neuroimagmg; Magnetic resonance imaging ID DEEP BRAIN-STIMULATION; ADVANCED PARKINSONS-DISEASE; SUBTHALAMIC NUCLEUS; PALLIDAL STIMULATION; POSTEROVENTRAL PALLIDOTOMY; FOLLOW-UP; CIRCUITS; STN; MRI; GPI AB Background: The outcome literature of subthalamic nuclei (STN) deep brain stimulation (DBS) suggests that cognitive declines are commonly reported following surgery. We hypothesized that differences in electrode position and surgical trajectory may lead to a differential neuropsychological outcome. Methods: We conducted a standardized evaluation of the location of the DBS electrode tip and the active electrodes, the surgical trajectory through which they were placed, and their relation to neuropsychological change scores (mental status, verbal memory, verbal fluency, and psychological measures) in 17 bilateral STN DBS patients using 6 month post-surgical magnetic resonance imaging data. Results: Declines in mental status scores were related to electrodes that were more posterior-laterally placed within the frontal quadrant in either hemisphere or those located superiorally in the left hemisphere. Electrodes that were closer to the approximated STN and more superiorally located in the left hemisphere were associated with verbal learning declines at 6 months following surgery. In the right hemisphere, the electrodes that were located more in the lateral direction were related to verbal short-term memory declines; while for verbal long-term memory declines were found for electrodes located more posterior-laterally in the left hemisphere. Declines in verbal fluency scores were more variable with associations found between change scores and electrodes in the lateral and superior directions in the left hemisphere and those electrodes closer to the approximated STN and more superiorally and posteriorally located in the right hemisphere. In contrast, semantic fluency declines were only related to right hemisphere electrodes located more superiorally. Declines in mood were related to those electrodes located further away from the approximated STN, particularly those located more inferiorally and laterally in the left hemisphere. Anxiety change scores were not associated with the location of the electrodes. Conclusions: The results provide preliminary evidence that 6 months following bilateral STN DBS cognitive and emotional changes may be related to the surgical trajectory and electrode placement. Published by Elsevier B.V. C1 [York, Michele K.; Jankovic, Joseph] Baylor Coll Med, Dept Neurol, Parkinsons Dis & Movement Disorders Clin, Michael E Debakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Wilde, Elisabeth A.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [York, Michele K.] Michael E DeBakey Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Houston, TX USA. [Simpson, Richard] Methodist Hosp, Neurol Inst, Houston, TX 77030 USA. RP York, MK (reprint author), 1 Baylor Plaza,NB302, Houston, TX 77030 USA. EM myork@bcm.edu FU Medtronic, Inc.; NIH [NINDS-5K23NS041254]; Department of Veterans Affairs, Office of Research and Development FX Research supported by Medtronic, Inc., NIH / NINDS-5K23NS041254, and the Department of Veterans Affairs, Office of Research and Development. We gratefully acknowledge the assistance of Stephen McCauley, Ph.D. NR 29 TC 38 Z9 39 U1 1 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-510X J9 J NEUROL SCI JI J. Neurol. Sci. PD DEC 15 PY 2009 VL 287 IS 1-2 BP 159 EP 171 DI 10.1016/j.jns.2009.08.003 PG 13 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 529MK UT WOS:000272521200029 PM 19767016 ER PT J AU Kaufer, D Gandy, S AF Kaufer, Dan Gandy, Sam TI APOE epsilon 4 and bapineuzumab Infusing pharmacogenomics into Alzheimer disease therapeutics SO NEUROLOGY LA English DT Editorial Material ID APOLIPOPROTEIN E4; IMMUNIZATION; PATHOLOGY C1 [Kaufer, Dan] Univ N Carolina, Dept Neurol, Chapel Hill, NC 27599 USA. [Gandy, Sam] Mt Sinai Sch Med, Dept Neurol & Psychiat, New York, NY USA. [Gandy, Sam] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. RP Kaufer, D (reprint author), Univ N Carolina, Dept Neurol, CB 7025,3129 POB,170 Manning Dr, Chapel Hill, NC 27599 USA. EM kauferd@neurology.unc.edu FU NCIPC CDC HHS [R49CE001495]; NIA NIH HHS [R21 AG033387, P01 AG010491, P50 AG005138, R01 AG022462, R21AG033387, P01 AG10491]; NIBIB NIH HHS [K01 EB009724] NR 10 TC 14 Z9 15 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD DEC 15 PY 2009 VL 73 IS 24 BP 2052 EP 2053 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 531YM UT WOS:000272709500001 PM 19923549 ER PT J AU DiPaola, CP Conrad, BP Horodyski, M DiPaola, MJ Sawers, A Rechtine, GR AF DiPaola, Christian P. Conrad, Bryan P. Horodyski, MaryBeth DiPaola, Matthew J. Sawers, Andrew Rechtine, Glenn R., II TI Cervical Spine Motion Generated With Manual Versus Jackson Table Turning Methods in a Cadaveric C1-C2 Global Instability Model SO SPINE LA English DT Article DE patient transfer; Jackson table; prone position; neurologic deterioration; patient safety; atlantoaxial instability; spinal cord injury ID CHIARI-I MALFORMATION; NEUROLOGIC DETERIORATION; EVOKED-POTENTIALS; CORD INJURY; IMMOBILIZATION; PATIENT; MYELOPATHY AB Study Design. Cadaveric biomechanical study. Objective. To quantify spinal motion created by transfer methods from supine to prone position in a cadaveric C1-C2 global instability model. Summary of Background Data. Patients who have sustained a spinal cord injury remain at high risk for further secondary injury until their spine is adequately stabilized. To date, no study has evaluated the effect of patient transfer methods from supine to prone position in the operating room, on atlantoaxial cervical spine motion. Methods. A global instability was surgically created at the C1-C2 level in 4 fresh cadavers. Two transfer protocols were tested on each cadaver. The log-roll technique entailed performing a standard 180 log-roll rotation of the supine patient from a stretcher to the prone position onto the operating room Jackson table (OSI, Union City, CA). The "Jackson technique" involved sliding the supine patient to the Jackson table, securing them to the table, and then rotating them into a prone position. An electromagnetic tracking device registered motion between the C1 and C2 vertebral segments. Three different head holding devices (Mayfield, Prone view, and blue foam pillow) were also compared for their ability to restrict C1-C2 motion. Six motion parameters were tracked. Repeated measures statistical analysis was performed to evaluate angular and translational motion. Results. For 6 of 6 measures of angulation and translation, manual log-roll prone positioning generated significantly more C1-C2 motion than the Jackson table turning technique. Out of 6 motion parameters, 5 were statistically significant (P < 0.001-0.005). There was minimal difference in C1-C2 motion generated when comparing all 3 head holding devices. Conclusion. The data demonstrate that manual log-roll technique generated significantly more C1-C2 motion compared to the Jackson table technique. Choice of headrest has a minimal effect on the amount of motion generated during patient transfer, except that the Mayfield device demonstrates a slight trend toward increased C1-C2 motion. C1 [Rechtine, Glenn R., II] Univ Rochester, Med Ctr, Dept Orthopaed Surg, Spine Div, Rochester, NY 14624 USA. [DiPaola, Christian P.] Univ Massachusetts, Med Ctr, Dept Orthopaed, Worcester, MA USA. [Conrad, Bryan P.] Univ Florida, Dept Orthopaed Res, Gainesville, FL USA. [Horodyski, MaryBeth] Univ Florida, Dept Orthopaed & Rehabil, Gainesville, FL USA. [DiPaola, Matthew J.] Wright State Univ, Dept Orthopaed, Dayton, OH 45435 USA. [Sawers, Andrew] Univ Washington, Ctr Excellence Limb Loss Prevent & Prosthet Engn, VA Puget Sound, Seattle, WA 98195 USA. [Sawers, Andrew] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Rechtine, GR (reprint author), Univ Rochester, Med Ctr, Dept Orthopaed Surg, Spine Div, 601 Elmwood Ave, Rochester, NY 14624 USA. EM cpd62@yahoo.com RI conrad, bryan/I-1299-2012 OI conrad, bryan/0000-0002-7304-3648 NR 28 TC 15 Z9 15 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0362-2436 J9 SPINE JI SPINE PD DEC 15 PY 2009 VL 34 IS 26 BP 2912 EP 2918 DI 10.1097/BRS.0b013e3181b7eddb PG 7 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 533AK UT WOS:000272794000016 PM 20010399 ER PT J AU Meeran, SM Singh, T Nagy, TR Katiyar, SK AF Meeran, Syed M. Singh, Tripti Nagy, Tim R. Katiyar, Santosh K. TI High-fat diet exacerbates inflammation and cell survival signals in the skin of ultraviolet B-irradiated C57BL/6 mice SO TOXICOLOGY AND APPLIED PHARMACOLOGY LA English DT Article DE High-fat diet; Inflammation; Cyclooxygenase-2; Ultraviolet radiation; Skin; Interleukin ID NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; CYCLOOXYGENASE-2 OVEREXPRESSION; TUMOR-DEVELOPMENT; OXIDATIVE STRESS; US CHILDREN; MOUSE SKIN; CANCER; OBESITY; ACTIVATION AB Inflammation induced by chronic exposure to ultraviolet (UV) radiation has been implicated in various skin diseases. We formulated the hypothesis that a high-fat diet may influence the UV-induced inflammatory responses in the skin. C57BL/6 mice were fed a high-fat diet or control diet and exposed to UVB radiation (120 mJ/cm(2)) three times/week for 10 weeks. The mice were then sacrificed and skin and plasma samples collected for analysis of biomarkers of inflammatory responses using immunohistochemistry, western blotting, ELISA and real-time PCR. We found that the levels of inflammatory biomarkers were increased in the UVB-exposed skin of the mice fed the high-fat diet than the UVB-exposed skin of the mice fed the control diet. The levels of inflammatory biomarkers of early responses to UVB exposure (e.g., myeloperoxidase, cyclooxygenase-2, prostaglandin-E(2)), proinflammatory cytokines (i.e., tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6), and proliferating cell nuclear antigen and cell survival signals (phosphatidylinositol-3-kinase and p-Akt-Ser(473)) were higher in high-fat-diet-fed mouse skin than control-diet-fed mouse skin. The plasma levels of insulin growth factor-1 were greater in the UVB-irradiated mice fed the high-fat diet than the UVB-irradiated mice fed the control diet, whereas the levels of plasma adiponectin were significantly lower. This pronounced exacerbation of the UVB-induced inflammatory responses in the skin of mice fed a high-fat diet suggests that high-fat diet may increase susceptibility to inflammation-associated skin diseases, including the risk of skin cancer. (C) 2009 Elsevier Inc. All rights reserved. C1 [Meeran, Syed M.; Singh, Tripti; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557,POB 202, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU Veterans Administration Merit Review Award FX This work was financially supported by the Veterans Administration Merit Review Award (S.K.K.). NR 45 TC 16 Z9 17 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0041-008X J9 TOXICOL APPL PHARM JI Toxicol. Appl. Pharmacol. PD DEC 15 PY 2009 VL 241 IS 3 BP 303 EP 310 DI 10.1016/j.taap.2009.09.003 PG 8 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 520JX UT WOS:000271841400007 PM 19747500 ER PT J AU Robinson-Cohen, C Katz, R Mozaffarian, D Dalrymple, LS de Boer, I Sarnak, M Shlipak, M Siscovick, D Kestenbaum, B AF Robinson-Cohen, Cassianne Katz, Ronit Mozaffarian, Dariush Dalrymple, Lorien S. de Boer, Ian Sarnak, Mark Shlipak, Mike Siscovick, David Kestenbaum, Bryan TI Physical Activity and Rapid Decline in Kidney Function Among Older Adults SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED TRIAL; CYSTATIN-C; CARDIOVASCULAR-HEALTH; METABOLIC SYNDROME; LIFE-STYLE; INSULIN SENSITIVITY; DIABETES-MELLITUS; BLOOD-PRESSURE; RENAL-FUNCTION; HEART-DISEASE AB Background: Habitual physical activity (PA) has both physiologic and metabolic effects that may moderate the risk of kidney function decline. We tested the hypothesis that higher levels of PA are associated with a lower risk of kidney function decline using longitudinal data from a large cohort of older adults. Methods: We studied 4011 ambulatory participants aged 65 or older from the Cardiovascular Health Study (CHS) who completed at least 2 measurements of kidney function over 7 years. We calculated a PA score (range, 2-8) by summing kilocalories expended per week (ordinal score of 1-5 from quintiles of kilocalories per week) and walking pace (ordinal score for categories of <2, 2-3, and >3 mph). Rapid decline in kidney function decline (RDKF) was defined by loss of more than 3.0 mL/min/1.73 m(3) per year in glomerular filtration rate, which we estimated by using longitudinal measurements of cystatin C levels. Results: A total of 958 participants had RDKF (23.9%; 4.1 events per 100 person-years). The estimated risk of RDKF was 16% in the highest PA group (score of 8) and 30% in the lowest PA group (score of 2). After multivariate adjustment, we found that the 2 highest PA groups (scores of 7-8) were associated with a 28% lower risk of RDKF (95% confidence interval, 21%-41% lower risk) than the 2 lowest PA groups (score of 2-3). Greater kilocalories of leisure-time PA and walking pace were also each associated with a lower incidence of RDKF. Conclusion: Higher levels of PA are associated with a lower risk of RDKF among older adults. C1 [Robinson-Cohen, Cassianne] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Katz, Ronit] Univ Washington, Collaborat Hlth Studies Coordinating Ctr, Dept Biostat, Seattle, WA 98195 USA. [de Boer, Ian; Kestenbaum, Bryan] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. [Siscovick, David] Univ Washington, Cardiovasc Hlth Res Unit, Dept Med, Seattle, WA 98195 USA. [Siscovick, David] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Mozaffarian, Dariush] Brigham & Womens Hosp, Div Cardiovasc Med, Dept Med, Boston, MA 02115 USA. [Mozaffarian, Dariush] Harvard Univ, Sch Med, Boston, MA USA. [Mozaffarian, Dariush] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Dalrymple, Lorien S.] Univ Calif Davis, Dept Internal Med, Div Nephrol, Sacramento, CA 95817 USA. [Sarnak, Mark] Tufts Univ New England Med Ctr, Dept Med, Boston, MA USA. [Shlipak, Mike] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Mozaffarian, Dariush] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. RP Robinson-Cohen, C (reprint author), Univ Washington, Dept Epidemiol, Box 357236, Seattle, WA 98195 USA. EM cassyrc@u.washington.edu OI Robinson-Cohen, Cassianne/0000-0003-4783-7046 FU National Institutes of Health Research Project [R01 AG 027002]; CHS [N01-HC-35129, N01-HC-45133, N01-HC-751.50, N01-HC-85079]; National Heart, Lung, and Blood Institute [N01-HC-85086, N01-HC-15103, N01-HC-55222, U01 HL080295]; National Institute of Neurological Disorders and Stroke; National Institutes on Aging [R01AG027002] FX This research was supported by National Institutes of Health Research Project Grant R01 AG 027002. The CHS was supported by contracts N01-HC-35129, N01-HC-45133, N01-HC-751.50, N01-HC-85079 through N01-HC-85086, N01-HC-15103, N01-HC-55222, and U01 HL080295 from the National Heart, Lung, and Blood Institute; by the National Institute of Neurological Disorders and Stroke; and by grant R01AG027002 from the National Institutes on Aging. NR 46 TC 43 Z9 43 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD DEC 14 PY 2009 VL 169 IS 22 BP 2116 EP 2123 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 530XJ UT WOS:000272625800013 PM 20008696 ER PT J AU Ayalon, L Covinsky, KE AF Ayalon, Liat Covinsky, Kenneth E. TI Spouse-Rated vs Self-rated Health as Predictors of Mortality SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID QUALITY-OF-LIFE; FUNCTIONAL STATUS; PROXY AGREEMENT; OLDER; PERSPECTIVE; EXPECTANCY; PATIENT; IMPACT AB Background: The Health and Retirement Study is a national sample of Americans older than 50 years and their spouses. The present study evaluated cross-sectional and longitudinal data from January 2000 through December 2006. The objective of the study was to evaluate the roles of spouse-rated vs self-rated health as predictors of all-cause mortality among adults older than 50 years. Methods: A total of 673 dyads of married couples were randomly selected to participate in a Health and Retirement Study module examining spouse-rated health. For each couple, one member was asked to rate his or her overall health status, and his or her spouse was asked to report the partner's overall health status. Mortality data were available through 2006. Results: our findings demonstrate that spouse-rated health (area under the curve, 0.75) is as strong a predictor of mortality as self-rated health (area under the curve, 0.73) (chi(2)(1) = 0.36, P = .54). Combining spouse-rated and self-rated health predicts mortality better than using self-rated health alone (area under the curve, 0.77) (chi(2)(1) = 6.72, P = .009). Conclusions: Spouse ratings of health are at least as strongly predictive of mortality as self-rated health. This suggests that, when self-rated health is elicited as a prognostic indicator, spouse ratings can be used when self-ratings are unavailable. Both measures together may be more informative than either measure alone. C1 [Ayalon, Liat] Bar Ilan Univ, Louis & Gabi Weisfeld Sch Social Work, IL-52900 Ramat Gan, Israel. [Covinsky, Kenneth E.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Covinsky, Kenneth E.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. RP Ayalon, L (reprint author), Bar Ilan Univ, Louis & Gabi Weisfeld Sch Social Work, IL-52900 Ramat Gan, Israel. EM ayalonl@mail.biu.ac.il FU National Institute on Aging [5K24 AG029812, 5R01 AG023626] FX This study was supported by grants 5K24 AG029812 and 5R01 AG023626 from the National Institute on Aging (Dr Covinsky). NR 31 TC 7 Z9 7 U1 2 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD DEC 14 PY 2009 VL 169 IS 22 BP 2156 EP 2161 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 530XJ UT WOS:000272625800019 PM 20008702 ER PT J AU Singh, H Wilson, L Petersen, LA Sawhney, MK Reis, B Espadas, D Sittig, DF AF Singh, Hardeep Wilson, Lindsey Petersen, Laura A. Sawhney, Mona K. Reis, Brian Espadas, Donna Sittig, Dean F. TI Improving follow-up of abnormal cancer screens using electronic health records: trust but verify test result communication SO BMC MEDICAL INFORMATICS AND DECISION MAKING LA English DT Article ID FECAL OCCULT-BLOOD; COMPLETE DIAGNOSTIC EVALUATION; COLORECTAL-CANCER; MALPRACTICE CLAIMS; UNITED-STATES; QUALITY; REASONS; ERRORS; CARE AB Background: Early detection of colorectal cancer through timely follow-up of positive Fecal Occult Blood Tests (FOBTs) remains a challenge. In our previous work, we found 40% of positive FOBT results eligible for colonoscopy had no documented response by a treating clinician at two weeks despite procedures for electronic result notification. We determined if technical and/or workflow-related aspects of automated communication in the electronic health record could lead to the lack of response. Methods: Using both qualitative and quantitative methods, we evaluated positive FOBT communication in the electronic health record of a large, urban facility between May 2008 and March 2009. We identified the source of test result communication breakdown, and developed an intervention to fix the problem. Explicit medical record reviews measured timely follow-up (defined as response within 30 days of positive FOBT) pre- and post-intervention. Results: Data from 11 interviews and tracking information from 490 FOBT alerts revealed that the software intended to alert primary care practitioners (PCPs) of positive FOBT results was not configured correctly and over a third of positive FOBTs were not transmitted to PCPs. Upon correction of the technical problem, lack of timely follow-up decreased immediately from 29.9% to 5.4% (p < 0.01) and was sustained at month 4 following the intervention. Conclusion: Electronic communication of positive FOBT results should be monitored to avoid limiting colorectal cancer screening benefits. Robust quality assurance and oversight systems are needed to achieve this. Our methods may be useful for others seeking to improve follow-up of FOBTs in their systems. C1 [Singh, Hardeep; Wilson, Lindsey; Petersen, Laura A.; Sawhney, Mona K.; Reis, Brian; Espadas, Donna] VA Med Ctr, Ctr Inquiry Improve Outpatient Safety Effect Elec, Houston, TX 77030 USA. [Singh, Hardeep; Wilson, Lindsey; Petersen, Laura A.; Sawhney, Mona K.; Reis, Brian; Espadas, Donna] VA Med Ctr, Houston VA HSR&D Ctr Excellence Michael E DeBakey, Houston, TX 77030 USA. [Singh, Hardeep; Petersen, Laura A.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, MEDVAMC,HSR&D Ctr Excellence, Houston, TX 77030 USA. [Sittig, Dean F.] Univ Texas Houston, Sch Hlth Informat Sci, Ctr Inquiry Improve Outpatient Safety Effect Elec, Houston, TX 77030 USA. [Sittig, Dean F.] UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX 77030 USA. RP Singh, H (reprint author), VA Med Ctr, Ctr Inquiry Improve Outpatient Safety Effect Elec, 152 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.tmc.edu; lawilson@bcm.tmc.edu; laurap@bcm.tmc.edu; sawhney@bcm.tmc.edu; bareis@bcm.tmc.edu; despadas@bcm.tmc.edu; Dean.F.Sittig@uth.tmc.edu FU NCI NIH HHS [K23CA125585] NR 28 TC 24 Z9 24 U1 1 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6947 J9 BMC MED INFORM DECIS JI BMC Med. Inform. Decis. Mak. PD DEC 9 PY 2009 VL 9 AR 49 DI 10.1186/1472-6947-9-49 PG 7 WC Medical Informatics SC Medical Informatics GA 535YJ UT WOS:000273007600001 PM 20003236 ER PT J AU Tsai, TT Maddox, TM Roe, MT Dai, D Alexander, KP Ho, PM Messenger, JC Nallamothu, BK Peterson, ED Rumsfeld, JS AF Tsai, Thomas T. Maddox, Thomas M. Roe, Matthew T. Dai, David Alexander, Karen P. Ho, P. Michael Messenger, John C. Nallamothu, Brahmajee K. Peterson, Eric D. Rumsfeld, John S. CA Natl Cardiovasc Data Registry TI Contraindicated Medication Use in Dialysis Patients Undergoing Percutaneous Coronary Intervention SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID CHRONIC-HEMODIALYSIS PATIENTS; DRUG-RELATED PROBLEMS; RENAL-INSUFFICIENCY; ENOXAPARIN; ANTICOAGULATION; REGISTRY AB Context The US Food and Drug Administration guides clinicians through drug labeling of medications that are contraindicated or not recommended for use in specific patient groups. Little is known about the use of such medications and their effects on outcomes in clinical practice. Objective To investigate the use of the contraindicated/not-recommended agents enoxaparin and eptifibatide among dialysis patients undergoing percutaneous coronary intervention (PCI) and their association with outcomes. Design, Setting, and Participants Data from 829 US hospitals on 22 778 dialysis patients who underwent PCI between January 1, 2004, and August 31, 2008. Main Outcome Measures In-hospital bleeding and death. Results Five thousand eighty-four patients (22.3%) received a contraindicated antithrombotic; of these patients, 2375 (46.7%) received enoxaparin, 3261 (64.1%) received eptifibatide, and 552 (10.9%) received both. Compared with patients who did not receive a contraindicated antithrombotic, patients who did had higher rates of in-hospital bleeding (5.6% vs 2.9%; odds ratio [OR], 1.93; 95% confidence interval [CI], 1.66-2.23) and death (6.5% vs 3.9%; OR, 1.68; 95% CI, 1.46-1.95). After multivariable adjustment, patients receiving contraindicated antithrombotics had significantly higher risks of in-hospital bleeding (OR, 1.66; 95% CI, 1.43-1.92) and death (OR, 1.24; 95% CI, 1.04-1.48). In 10 158 patients matched by propensity scores, receipt of contraindicated antithrombotics remained significantly associated with in-hospital bleeding (OR, 1.63; 95% CI, 1.35-1.98) but not in-hospital death (OR, 1.15; 95% CI, 0.97-1.36). Conclusions In a sample of dialysis patients undergoing PCI, 22.3% received a contraindicated antithrombotic medication. In propensity-matched analysis, receipt of these medications was significantly associated with an increased risk of in-hospital major bleeding. JAMA. 2009; 302(22): 2458-2464 C1 [Tsai, Thomas T.] Denver VA Med Ctr, Cardiol Sect 111B, Denver, CO 80220 USA. [Tsai, Thomas T.; Maddox, Thomas M.; Ho, P. Michael; Messenger, John C.; Rumsfeld, John S.] Univ Colorado, Denver, CO USA. [Tsai, Thomas T.; Maddox, Thomas M.; Ho, P. Michael; Rumsfeld, John S.] Colorado Cardiovasc Outcomes Res Grp, Denver, CO USA. [Roe, Matthew T.; Dai, David; Alexander, Karen P.; Peterson, Eric D.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Nallamothu, Brahmajee K.] Univ Michigan Hosp, Ann Arbor VA Med Ctr, Ann Arbor, MI 48109 USA. RP Tsai, TT (reprint author), Denver VA Med Ctr, Cardiol Sect 111B, 1055 Clermont St, Denver, CO 80220 USA. EM thomas.tsai@va.gov FU NCDR CathPCI Registry; VA Health Services Research and Development Service (HSR&D) Career Development Award FX This analysis was funded by the NCDR CathPCI Registry, which oversees the collection and management of data in the registry. Dr Ho is supported by a VA Health Services Research and Development Service (HSR&D) Career Development Award. NR 18 TC 46 Z9 46 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 9 PY 2009 VL 302 IS 22 BP 2458 EP 2464 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 529MD UT WOS:000272520500025 PM 19996401 ER PT J AU Hammitt, LL Bartlett, JP Li, SB Rahkola, J Lang, N Janoff, EN Levin, MJ Weinberg, A AF Hammitt, Laura L. Bartlett, Julie Patterson Li, Shaobing Rahkola, Jeremy Lang, Nancy Janoff, Edward N. Levin, Myron J. Weinberg, Adriana TI Kinetics of viral shedding and immune responses in adults following administration of cold-adapted influenza vaccine SO VACCINE LA English DT Article DE Cold-adapted influenza vaccine; Immunogenicity; Vaccine virus shedding ID CULTURE-CONFIRMED INFLUENZA; IMMUNIZATION PRACTICES ACIP; CD8(+) T-CELLS; VIRUS-VACCINE; YOUNG-CHILDREN; ADVISORY-COMMITTEE; LIVE; TRIVALENT; INFECTION; PROTECTION AB The optimal type and timing of specimens to study the immune responses to cold-adapted influenza vaccine (CAIV) and shedding of vaccine virus are not well established. Healthy adults were vaccinated with CAIV (n = 10) or trivalent influenza vaccine (TIV) (n = 5). Shedding of vaccine strain influenza B was detected by culture in 6 of 10 CAN recipients; influenza A was also detected in one of these subjects. Viral shedding by quantitative RT-PCR was detected in 9 of 10 subjects. We detected a >= 2-fold increase in influenza-specific IgA in nasal wash in 80-100% of CAIV recipients following vaccination, but specific IgG increased in neither nasal wash nor saliva. Recipients of TIV had significant increases in specific serum IgG antibodies. Recipients of both CAIV and TIV had significant increases in IFN gamma-secreting peripheral blood mononuclear cells (PBMCs). PBMCs from subjects receiving CAN showed a higher proportion of functional, tissue-tropic T-cells (CD4+CD69+CD18+MIP1 alpha+) specific for homotypic and heterosubtypic strains of influenza by flow cytometry. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Rahkola, Jeremy; Janoff, Edward N.] Univ Colorado Denver, Mucosal & Vaccine Res Ctr Colorado, Div Infect Dis, Dept Med,Denver Vet Affairs Med Ctr, Denver, CO USA. [Hammitt, Laura L.; Bartlett, Julie Patterson; Li, Shaobing; Lang, Nancy; Levin, Myron J.; Weinberg, Adriana] Univ Colorado Denver, Dept Pediat, Infect Dis Sect, Denver, CO USA. RP Hammitt, LL (reprint author), KEMRI Wellcome Trust, Ctr Geog Med Res Coast, POB 230, Kilifi 80108, Kenya. EM lhammitt@kilifi.kemri-wellcome.org FU MedImmune; NIH [R21 A1077069]; Veterans Affairs Research Service FX The authors give special thanks to Kelly Richardson and Adriana Tovar Salazar for assistance with specimen processing and T-cell assays; to Karen Helm at the UCHSC Cancer Center Flow Cytometry Core; to Alicia Huber for assistance with viral culture; to Tingting Yi for statistical advice; and George Kemble at Medimmune for providing attenuated influenza virus. Funding for the study was provided by MedImmune. Laura L. Hammitt was supported by a Pediatric Fellowship Program grant from MedImmune. Myron J. Levin and Adriana Weinberg are paid consultants for MedIMMUne. Edward N. Janoff was supported in part by NIH R21 A1077069 and the Veterans Affairs Research Service. Influenza strain-specific PCR primers were provided by CDC under a materials transfer agreement. NR 47 TC 21 Z9 22 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD DEC 9 PY 2009 VL 27 IS 52 BP 7359 EP 7366 DI 10.1016/j.vaccine.2009.09.041 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 541KP UT WOS:000273414900020 PM 19800447 ER PT J AU Tokhtaeva, E Sachs, G Vagin, O AF Tokhtaeva, Elmira Sachs, George Vagin, Olga TI Assembly with the Na,K-ATPase alpha(1) Subunit Is Required for Export of beta(1) and beta(2) Subunits from the Endoplasmic Reticulum SO BIOCHEMISTRY LA English DT Article ID NA+-K+-ATPASE; ACTIVATED ADENOSINE-TRIPHOSPHATASE; SODIUM-POTASSIUM PUMP; INTRACELLULAR-TRANSPORT; PLASMA-MEMBRANE; FUNCTIONAL EXPRESSION; CRYSTAL-STRUCTURE; MOLECULAR-WEIGHT; N-GLYCOSYLATION; XENOPUS OOCYTES AB The level of the heterodimeric Na,K-ATPase is tightly controlled in epithelia to maintain appropriate transport function. The catalytic Na,K-ATPase alpha subunit is not able to exit the ER or catalyze ion transport unless assembled with the beta subunit. However, requirements for the ER exit of the Na,K-ATPase beta subunit that plays an additional, ion-transport-independent, role in Intercellular adhesion are not clear. Exogenous beta(1) or beta(2) subunits expressed in renal MDCK cells replace endogenous beta(1) subunits in the alpha-beta complexes in the ER, resulting in a decrease in the amount of the alpha(1)-bound endogenous beta(1) subunits by 47-61% with no change in the amount of alpha(1) subunits. Disruption of the alpha(1)-beta association by mutations in defined alpha(1)-interacting regions of either beta(1) or beta(2) subunits results in the ER retention and rapid degradation of unassembled mutants. Hence, the ER quality control system allows export only of assembled alpha-beta complexes to the Golgi, thereby maintaining an equimolar ratio of alpha and beta subunits in the plasma membrane, whereas the number of alpha(1) subunits in the ER determines the amount of the alpha-beta complexes. C1 [Vagin, Olga] Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. Vet Adm Greater Los Angeles Hlth Care Syst, VAGLAHS W LA, Los Angeles, CA 90073 USA. RP Vagin, O (reprint author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Bldg 113,Room 324,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM olgav@ucla.edu FU NIH [DK077149, DK058333] FX Supported by NIH Grants DK077149 and DK058333. NR 44 TC 20 Z9 20 U1 0 U2 2 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD DEC 8 PY 2009 VL 48 IS 48 BP 11421 EP 11431 DI 10.1021/bi901438z PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 523OP UT WOS:000272083900011 PM 19764716 ER PT J AU Figlewicz, DP Ioannou, G Jay, JB Kittleson, S Savard, C Roth, CL AF Figlewicz, D. P. Ioannou, G. Jay, J. Bennett Kittleson, S. Savard, C. Roth, C. L. TI Effect of moderate intake of sweeteners on metabolic health in the rat SO PHYSIOLOGY & BEHAVIOR LA English DT Article DE High fructose corn syrup; Agave; Stevia; Hoodia; Liver ID DIETARY FRUCTOSE; APPETITE-SUPPRESSANT; STEVIA-REBAUDIANA; INSULIN; STEVIOSIDE; OBESITY; SUGAR; DYSREGULATION; ACTIVATION; MECHANISM AB The rise in prevalence of obesity, diabetes. metabolic syndrome, and fatty liver disease has been linked to increased consumption of fructose-containing foods or beverages. Our aim was to compare the effects of moderate consumption of fructose-containing and non-caloric sweetened beverages on feeding behavior, metabolic and serum lipid profiles. and hepatic histology and serum liver enzymes, in rats. Behavioral tests determined preferred ( 12.5-15%) concentrations of solutions of agave, fructose, high fructose corn syrup (HFCS), a combination of HFC5 and Hoodia (a putative appetite suppressant), or the non-caloric sweetener Stevia (n = 5/gp). HFCS intake was highest, in preference and self-administration tests. Groups (n = 10/gp) were then assigned to one of the sweetened beverages or water as the sole source of liquid at night (3 nights/wk, 10 wks). Although within the normal range, serum cholesterol was higher in the fructose and HFCS groups, and serum triglycerides were higher in the Agave, HFCS, and HFCS/Hoodia groups (vs. water-controls, p < 0.05). Liver histology was normal in all groups with no evidence of steatosis, inflammation, or fibrosis; however serum alanine aminotransferase was higher in the fructose and HFCS groups (vs. water-controls, p < 0.05). Serum inflammatory marker levels were comparable among Stevia, agave. fructose, HFCS. and water-consuming groups, however levels of IL-6 were significantly lower in association with the ingestion of Hoodia. There were no differences in terminal body weights, or glucose tolerance assessed by 120-min IVGTTs performed at the end of the 10-week regimen. We conclude that even moderate consumption of fructose-containing liquids may lead to the onset of unfavorable changes in the plasma lipid profile and one marker of liver health. independent of significant effects of sweetener consumption on body weight. Published by Elsevier Inc. C1 [Figlewicz, D. P.; Jay, J. Bennett; Kittleson, S.] VA Puget Sound Hlth Care Syst 151, R&D, Seattle, WA 98108 USA. [Figlewicz, D. P.; Jay, J. Bennett] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Ioannou, G.; Savard, C.] VA Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA USA. [Roth, C. L.] Seattle Childrens Res Inst, Seattle, WA 98101 USA. RP Figlewicz, DP (reprint author), VA Puget Sound Hlth Care Syst 151, R&D, 1660 So Columbian Way, Seattle, WA 98108 USA. EM latte@u.washington.edu FU NIH [RO1 DK40963]; Seattle Children's Hospital Research Institute; Seattle Children's Hospital FX This work was carried out at the VA Puget Sound Health Care System, Seattle Division, and was supported by the Merit Review (DFL), Career Scientist (DFL) and Research Enhancement Award Program (REAP) (GI and DFL) Programs of the Dept of Veterans Affairs; NIH RO1 DK40963 (DFL); and by the CUMG Seed Funds of Seattle Children's Hospital Research Institute and Seattle Children's Hospital (CR). George Ioannou is supported by the Jan Albrecht Award from the American Liver Foundation and American Association for the Study of Liver Diseases. Christian Roth is supported by Seattle Children's Hospital. The authors gratefully acknowledge the outstanding support and technical expertise of Connie Holmes West, Guochi Zhang, and Melissa Ralston. The generous and able assistance of Dr. Nicole Sanders, and student aides Marissa Haberlach, Kimberly Brennan, and Nick Shalygin, is acknowledged with grateful appreciation. The drug Hoodia was generously provided by Trade Avail Company, USA. We thank Dr. Tami Wolden-Hanson for the advice on fat pad dissection, and Dr. Alfred J. Sipols for assistance with the statistical analysis. The helpful discussion of Alan Bernstein, Dr. Janis Wignall, and Dr. Cindy Pekow is gratefully acknowledged. NR 38 TC 20 Z9 22 U1 5 U2 39 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0031-9384 J9 PHYSIOL BEHAV JI Physiol. Behav. PD DEC 7 PY 2009 VL 98 IS 5 BP 618 EP 624 DI 10.1016/j.physbeh.2009.09.016 PG 7 WC Psychology, Biological; Behavioral Sciences SC Psychology; Behavioral Sciences GA 529LN UT WOS:000272518200016 PM 19815021 ER PT J AU Alam, MN Kumar, S Rai, S Methippara, M Szymusiak, R McGinty, D AF Alam, Md Noor Kumar, Sunil Rai, Seema Methippara, Melvi Szymusiak, Ronald McGinty, Dennis TI Role of adenosine A(1) receptor in the perifornical-lateral hypothalamic area in sleep-wake regulation in rats SO BRAIN RESEARCH LA English DT Article DE Orexin; Hypocretin; Adenosine; Posterior-lateral hypothalamus; Sleep ID EYE-MOVEMENT SLEEP; BASAL FOREBRAIN; OREXIN NEURONS; HYPOCRETIN OREXIN; A1 RECEPTOR; NERVOUS-SYSTEM; ACTIVE NEURONS; PREOPTIC AREA; WAKEFULNESS; WAKING AB The perifornical-lateral hypothalamic area (PF-LHA) has been implicated in the regulation of arousal. The PF-LHA contains wake-active neurons that are quiescent during non-REM sleep and in the case of neurons expressing the peptide hypocretin (HCRT), quiescent during both non-REM and REM sleep. Adenosine is an endogenous sleep factor and recent evidence suggests that adenosine via A(1) receptors may act on PF-LHA neurons to promote sleep. We examined the effects of bilateral activation as well as blockade of A(1) receptors in the PF-LHA on sleep wakefulness in freely behaving rats. The sleep-wake profiles of male Wistar rats were recorded during reverse microdialysis perfusion of artificial cerebrospinal fluid (aCSF) and two doses of adenosine A(1) receptor antagonist, 1,3-dipropyl-8-phenylxanthine (CPDX; 5 mu M and 50 mu M) or A(1) receptor agonist, N-6-cyclopentyladenosine (CPA; 5 mu M and 50 mu M) into the PF-LHA for 2 h followed by 4 h of aCSF perfusion. CPDX perfused into the PF-LHA during lights-on phase produced arousal (F=7.035, p<0.001) and concomitantly decreased both non-REM (F=7.295, p<0.001) and REM sleep (F=3.456, p<0.004). In contrast, CPA perfused into the PF-LHA during lights-off phase significantly suppressed arousal (F=7.891,p<0.001) and increased non-REM (F = 8.18, p <0.001) and REM sleep (F = 30.036, p < 0.001). These results suggest that PF-LHA is one of the sites where adenosine, acting via A(1) receptors, inhibits PF-LHA neurons to promote sleep. Published by Elsevier B.V. C1 [Alam, Md Noor; Kumar, Sunil; Rai, Seema; Methippara, Melvi; Szymusiak, Ronald; McGinty, Dennis] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Sepulveda, CA 91343 USA. [Alam, Md Noor; Methippara, Melvi; McGinty, Dennis] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Kumar, Sunil; Szymusiak, Ronald] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Szymusiak, Ronald] Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA USA. RP Alam, MN (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St, Sepulveda, CA 91343 USA. EM noor@ucla.edu FU US Department of Veterans Affairs Medical Research Service; US National Institutes of Health [NS-050939, MH47480, HL60296, MH63323] FX This work was supported by the US Department of Veterans Affairs Medical Research Service and US National Institutes of Health grants NS-050939 (Alam), MH47480 and HL60296 (McGinty), and MH63323 (Szymusiak). NR 56 TC 12 Z9 12 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD DEC 4 PY 2009 VL 1304 BP 96 EP 104 DI 10.1016/j.brainres.2009.09.066 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 531HE UT WOS:000272654400010 PM 19781535 ER PT J AU Teh, J Berendt, T Lipsky, BA AF Teh, James Berendt, Tony Lipsky, Benjamin A. TI Rational Imaging Investigating suspected bone infection in the diabetic foot SO BRITISH MEDICAL JOURNAL LA English DT Editorial Material ID DIAGNOSTIC-ACCURACY; COST-EFFECTIVENESS; OSTEOMYELITIS; METAANALYSIS C1 [Teh, James] Nuffield Orthopaed Ctr, Dept Radiol, Oxford OX3 7LD, England. [Berendt, Tony] Nuffield Orthopaed Ctr, Bone Infect Unit, Oxford OX3 7LD, England. [Lipsky, Benjamin A.] VA Puget Sound Hlth Care Syst, Seattle, WA 98416 USA. [Lipsky, Benjamin A.] Univ Washington, Seattle, WA 98416 USA. RP Teh, J (reprint author), Nuffield Orthopaed Ctr, Dept Radiol, Oxford OX3 7LD, England. EM james.teh@tiscali.co.uk OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 17 TC 12 Z9 12 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0959-535X J9 BRIT MED J JI Br. Med. J. PD DEC 4 PY 2009 VL 339 AR b4690 DI 10.1136/bmj.b4690 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 528NU UT WOS:000272453700001 PM 19965936 ER PT J AU Lu, L Wang, SY Zheng, L Li, XL Suswam, EA Zhang, XW Wheeler, CG Nabors, LB Filippova, N King, PH AF Lu, Liang Wang, Shuying Zheng, Lei Li, Xuelin Suswam, Esther A. Zhang, Xiaowen Wheeler, Crystal G. Nabors, L. B. Filippova, Natalia King, Peter H. TI Amyotrophic Lateral Sclerosis-linked Mutant SOD1 Sequesters Hu Antigen R (HuR) and TIA-1-related Protein (TIAR) IMPLICATIONS FOR IMPAIRED POST-TRANSCRIPTIONAL REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; AU-RICH ELEMENTS; GROWTH-FACTOR; OXIDATIVE STRESS; BINDING PROTEINS; STABILIZATION; APOPTOSIS; BCL-2; GENE AB Down-regulation of vascular endothelial growth factor (VEGF) in the mouse leads to progressive and selective degeneration of motor neurons similar to amyotrophic lateral sclerosis (ALS). In mice expressing ALS-associated mutant superoxide dismutase 1 (SOD1), VEGF mRNA expression in the spinal cord declines significantly prior to the onset of clinical manifestations. In vitro models suggest that dysregulation of VEGF mRNA stability contributes to that decline. Here, we show that the major RNA stabilizer, Hu Antigen R (HuR), and TIA-1-related protein (TIAR) colocalize with mutant SOD1 in mouse spinal cord extracts and cultured glioma cells. The colocalization was markedly reduced or abolished by RNase treatment. Immunoanalysis of transfected cells indicated that colocalization occurred in insoluble aggregates and inclusions. RNA immunoprecipitation showed a significant loss of VEGF mRNA binding to HuR and TIAR in mutant SOD1 cells, and there was marked depletion of HuR from polysomes. Ectopic expression of HuR in mutant SOD1 cells more than doubled the mRNA half-life of VEGF and significantly increased expression to that of wild-type SOD1 control. Cellular effects produced by mutant SOD1, including impaired mitochondrial function and oxidative stress-induced apoptosis, were reversed by HuR in a gene dose-dependent pattern. In summary, our findings indicate that mutant SOD1 impairs post-transcriptional regulation by sequestering key regulatory RNA-binding proteins. The rescue effect of HuR suggests that this impairment, whether related to VEGF or other potential mRNA targets, contributes to cytotoxicity in ALS. C1 [Lu, Liang; Wang, Shuying; Zheng, Lei; Li, Xuelin; Suswam, Esther A.; Zhang, Xiaowen; Nabors, L. B.; Filippova, Natalia; King, Peter H.] Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA. [King, Peter H.] Univ Alabama, Dept Genet, Birmingham, AL 35294 USA. [Wheeler, Crystal G.] Univ Alabama, Dept Neurobiol, Birmingham, AL 35294 USA. [King, Peter H.] Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA. [Lu, Liang; Zheng, Lei; Li, Xuelin; King, Peter H.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP King, PH (reprint author), Sparks Ctr, Suite 260,1720-7th Ave S, Birmingham, AL 35233 USA. EM pking@uab.edu FU National Institutes of Health [NS058538, NS064133, NS057664]; NINDS [R01 CA112397]; NCI; Dept. of Veterans Affairs FX This work was supported, in whole or in part, by National Institutes of Health Grants NS058538, NS064133 (to P. H. K.), NS057664 (to L. L.) from the NINDS, R01 CA112397 (to L. B. N.) from the NCI, and a Merit Review award from the Dept. of Veterans Affairs (to P. H. K.). NR 44 TC 24 Z9 24 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 4 PY 2009 VL 284 IS 49 BP 33989 EP 33998 DI 10.1074/jbc.M109.067918 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 524TE UT WOS:000272165200031 PM 19805546 ER PT J AU Sax, PE Tierney, C Collier, AC Fischl, MA Mollan, K Peeples, L Godfrey, C Jahed, NC Myers, L Katzenstein, D Farajallah, A Rooney, JF Ha, B Woodward, WC Koletar, SL Johnson, VA Geiseler, PJ Daar, ES AF Sax, Paul E. Tierney, Camlin Collier, Ann C. Fischl, Margaret A. Mollan, Katie Peeples, Lynne Godfrey, Catherine Jahed, Nasreen C. Myers, Laurie Katzenstein, David Farajallah, Awny Rooney, James F. Ha, Belinda Woodward, William C. Koletar, Susan L. Johnson, Victoria A. Geiseler, P. Jan Daar, Eric S. CA AIDS Clinical Trials Grp Study TI Abacavir-Lamivudine versus Tenofovir-Emtricitabine for Initial HIV-1 Therapy SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID RANDOMIZED-TRIAL; INFECTED ADULTS; NAIVE PATIENTS; LOPINAVIR/RITONAVIR; ZIDOVUDINE; DF; EFAVIRENZ; EFFICACY; SAFETY AB BACKGROUND The use of fixed-dose combination nucleoside reverse-transcriptase inhibitors (NRTIs) with a nonnucleoside reverse-transcriptase inhibitor or a ritonavir-boosted protease inhibitor is recommended as initial therapy in patients with human immunodeficiency virus type 1 (HIV-1) infection, but which NRTI combination has greater efficacy and safety is not known. METHODS In a randomized, blinded equivalence study involving 1858 eligible patients, we compared four once-daily anti-retroviral regimens as initial therapy for HIV-1 infection: abacavir-lamivudine or tenofovir disoproxil fumarate (DF)-emtricitabine plus efavirenz or ritonavir-boosted atazanavir. The primary efficacy end point was the time from randomization to virologic failure (defined as a confirmed HIV-1 RNA level >= 1000 copies per milliliter at or after 16 weeks and before 24 weeks, or = 200 copies per milliliter at or after 24 weeks). RESULTS A scheduled interim review by an independent data and safety monitoring board showed significant differences in virologic efficacy, according to the NRTI combination, among patients with screening HIV-1 RNA levels of 100,000 copies per milliliter or more. At a median follow-up of 60 weeks, among the 797 patients with screening HIV-1 RNA levels of 100,000 copies per milliliter or more, the time to virologic failure was significantly shorter in the abacavir-lamivudine group than in the tenofovir DF-emtricitabine group (hazard ratio, 2.33; 95% confidence interval, 1.46 to 3.72; P<0.001), with 57 virologic failures (14%) in the abacavir-lamivudine group versus 26 (7%) in the tenofovir DF-emtricitabine group. The time to the first adverse event was also shorter in the abacavir-lamivudine group (P<0.001). There was no significant difference between the study groups in the change from the baseline CD4 cell count at week 48. CONCLUSIONS In patients with screening HIV-1 RNA levels of 100,000 copies per milliliter or more, the times to virologic failure and the first adverse event were both significantly shorter in patients randomly assigned to abacavir-lamivudine than in those assigned to tenofovir DF-emtricitabine. (ClinicalTrials.gov number, NCT00118898.) C1 [Sax, Paul E.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Sax, Paul E.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Sax, Paul E.] Harvard Univ, Sch Med, Boston, MA USA. [Tierney, Camlin; Mollan, Katie; Peeples, Lynne] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Collier, Ann C.] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. [Fischl, Margaret A.] Univ Miami, Sch Med, Miami, FL USA. [Godfrey, Catherine] NIAID, Div Aids, Bethesda, MD 20892 USA. [Jahed, Nasreen C.] Social & Sci Syst, Silver Spring, MD USA. [Myers, Laurie] Frontier Sci & Technol Res Fdn Inc, Amherst, NY USA. [Katzenstein, David] Stanford Univ, Palo Alto, CA 94304 USA. [Rooney, James F.] Gilead Sci Inc, Foster City, CA 94404 USA. [Geiseler, P. Jan] Univ So Calif, Los Angeles, CA USA. [Daar, Eric S.] Univ Calif Los Angeles, Los Angeles, CA USA. [Daar, Eric S.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Los Angeles, CA USA. [Farajallah, Awny] Bristol Myers Squibb Co, Plainsboro, NJ USA. [Ha, Belinda] GlaxoSmithKline, Res Triangle Pk, NC USA. [Woodward, William C.] Abbott Labs, Abbott Pk, IL 60064 USA. [Koletar, Susan L.] Ohio State Univ, Columbus, OH 43210 USA. [Johnson, Victoria A.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Johnson, Victoria A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Sax, PE (reprint author), Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA. EM psax@partners.org FU GlaxoSmithKline; Pfizer; Merck Laboratories; Abbott Laboratories; Bristol-Myers Squibb; Gilead Sciences; Tibotec; Johnson Johnson; Koronis; Schering-Plough; Bionor Immuno AS; Cytheris; Siemens Medical Solutions Diagnostics and Roche Diagnostics; Boehringer Ingelheim; Panacos Pharmaceuticals; National Institute of Allergy and Infectious Diseases, National Institutes of Health [AI38858, AI68636, AI68634]; National Center for Research Resources FX Dr. Sax reports receiving grant support from GlaxoSmithKline, Pfizer, and Merck Laboratories and consulting fees from Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Laboratories, and Tibotec and serving as a member of the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents; Dr. Tierney, serving on a data and safety monitoring board for Tibotec; Dr. Collier, receiving grant support from Johnson & Johnson (Tibotec), Koronis, Merck Laboratories, Schering-Plough, and Gilead Sciences and consulting fees from GlaxoSmithKline, Pfizer, Merck Laboratories; Dr. Fischl, receiving grant support from Abbott Laboratories, Bionor Immuno AS, Bristol-Myers Squibb, Cytheris, GlaxoSmithKline, and Tibotec and grant support and lecture and consulting fees from Merck Laboratories; Dr. Katzenstein, receiving grant support from Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, and Gilead Sciences; Dr. Farajallah, being an employee of Bristol-Myers Squibb; Dr. Rooney, being an employee of Gilead Sciences; Dr. Ha, being an employee of GlaxoSmithKline; Dr. Woodward, being an employee of Abbott Laboratories; Dr. Johnson, receiving grant support from Siemens Medical Solutions Diagnostics and Roche Diagnostics; Dr. Geiseler, receiving lecture fees from Cubist Pharmaceuticals; Dr. Daar, receiving grant support from Abbott Laboratories, Merck Laboratories, GlaxoSmithKline, and Gilead Sciences and consulting fees from Abbott Laboratories, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, Pfizer, Merck Laboratories, Tibotec, Boehringer Ingelheim, and Schering-Plough, and serving as a member of the data and safety monitoring board for Ardea Biosciences and of the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents; and Dr. Koletar, receiving grant support from Panacos Pharmaceuticals. No other potential conflict of interest relevant to this article was reported. Supported by grants (AI38858, to the AIDS Clinical Trials Group [ACTG] Central Group; AI68636, to the ACTG Network; and AI68634 and AI38855, to the ACTG Statistical and Data Analysis Center) from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, with additional support from the General Clinical Research Center units funded by the National Center for Research Resources. NR 16 TC 171 Z9 171 U1 0 U2 7 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 3 PY 2009 VL 361 IS 23 BP 2230 EP 2240 DI 10.1056/NEJMoa0906768 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 525ZM UT WOS:000272257100006 PM 19952143 ER PT J AU Oleastro, M Cordeiro, R Menard, A Yamaoka, Y Queiroz, D Megraud, F Monteiro, L AF Oleastro, Monica Cordeiro, Rita Menard, Armelle Yamaoka, Yoshio Queiroz, Dulciene Megraud, Francis Monteiro, Lurdes TI Allelic diversity and phylogeny of homB, a novel co-virulence marker of Helicobacter pylori SO BMC MICROBIOLOGY LA English DT Article ID PEPTIC-ULCER DISEASE; RESTRICTION-MODIFICATION SYSTEM; COMPLETE GENOME SEQUENCE; CONCERTED EVOLUTION; PHASE VARIATION; HOPQ ALLELES; STRAINS; INFECTION; VACA; CAGA AB Background: The homB gene is a Helicobacter pylori disease-marker candidate, strongly associated with peptic ulcer disease, while homA, its paralogue gene with 90% sequence identity, is correlated with non-ulcer dyspepsia. The HomB encoded outer membrane protein was shown to contribute to the proinflammatory properties of H. pylori and also to be involved in bacterial adherence. This study investigated the distribution of homB and homA genes in 455 H. pylori strains from East Asian and Western countries, and carried out sequence comparison and phylogenetic analyses. Results: Both homB and homA genes were heterogeneously distributed worldwide, with a marked difference between East Asian and Western strains. Analysis of homB and homA sequences revealed diversity regarding the number of copies and their genomic localization, with East Asian and Western strains presenting different genotypes. Moreover, homB and homA sequence analysis suggests regulation by phase variation. It also indicates possible recombination events, leading to gene duplication or homB/homA conversion which may as well be implicated in the regulation of these genes. Phylogenetic reconstruction of homB and homA revealed clustering according to the geographic origin of strains. Allelic diversity in the middle region of the genes was observed for both homB and homA, although there was no correlation between any allele and disease. For each gene, a dominant worldwide allele was detected, suggesting that homB/homA allelic variants were independent of the geographical origin of the strain. Moreover, all alleles were demonstrated to be expressed in vivo. Conclusion: Overall, these results suggest that homB and homA genes are good candidates to be part of the pool of H. pylori OMPs implicated in host-bacteria interface and also contributing to the generation of antigenic variability, and thus involved in H. pylori persistence. C1 [Oleastro, Monica; Menard, Armelle; Megraud, Francis] INSERM, U853, F-33076 Bordeaux, France. [Oleastro, Monica; Cordeiro, Rita; Monteiro, Lurdes] Inst Nacl Saude Dr Ricardo Jorge, Dept Doencas Infecc, P-1649016 Lisbon, Portugal. [Menard, Armelle; Megraud, Francis] Univ Bordeaux 2, Bacteriol Lab, F-33076 Bordeaux, France. [Yamaoka, Yoshio] Baylor Coll Med, Houston, TX 77030 USA. [Yamaoka, Yoshio] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. [Queiroz, Dulciene] Univ Fed Minas Gerais, Fac Med, Lab Pesquisa Bacteriol, BR-30130100 Belo Horizonte, MG, Brazil. RP Megraud, F (reprint author), INSERM, U853, F-33076 Bordeaux, France. EM monica.oleastro@insa.min-saude.pt; rita.cordeiro@insa.min-saude.pt; armelle.menard@labhel.u-bordeaux2.fr; yyamaoka@bcm.tmc.edu; dqueiroz@medicina.ufmg.br; francis.megraud@chu-bordeaux.fr; m.lurdes.monteiro@insa.min-saude.pt OI menard, armelle/0000-0002-6130-736X; Oleastro, Monica/0000-0001-6360-2576; Monteiro, Maria de Lurdes/0000-0002-5064-5718 FU Fundacao para a Ciencia e Tecnologia [PPCDT/SAL-IMI/57297/2004] FX The authors thank Markus Gerhard for supplying H. pylori strains from German patients, and Thomas Boren and Lars Engstrand for providing the Swedish strains used in this study. The authors would like to thank also to Sandrine Dupouy and Christina Morate for technical assistance. Finally, we which to thank to the Fundacao para a Ciencia e Tecnologia, project PPCDT/SAL-IMI/57297/2004, for financial support. NR 40 TC 16 Z9 17 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2180 J9 BMC MICROBIOL JI BMC Microbiol. PD DEC 2 PY 2009 VL 9 AR 248 DI 10.1186/1471-2180-9-248 PG 12 WC Microbiology SC Microbiology GA 535YK UT WOS:000273007700001 PM 19954539 ER PT J AU Rastogi, A Bose, T Feldman, MD Patel, D Stavchansky, S AF Rastogi, Ashish Bose, Tanushree Feldman, Marc D. Patel, Devang Stavchansky, Salomon TI Characterization of Nanoporous Surfaces as Templates for Drug Delivery Devices SO AAPS JOURNAL LA English DT Review DE cyanoacrylate; drug delivery; methyl orange; nanopores; volume calculation ID GENE DELIVERY; NANO DEVICE; NANOPARTICLES; SYSTEM C1 [Rastogi, Ashish; Bose, Tanushree; Stavchansky, Salomon] Univ Texas Austin, Coll Pharm, Div Pharmaceut, Austin, TX 78712 USA. [Feldman, Marc D.; Patel, Devang] Univ Texas Hlth Sci Ctr San Antonio, Div Cardiol, San Antonio, TX 78229 USA. [Feldman, Marc D.] S Texas Vet Affairs Hlth Care Syst, San Antonio, TX 78229 USA. RP Stavchansky, S (reprint author), Univ Texas Austin, Coll Pharm, Div Pharmaceut, Austin, TX 78712 USA. EM stavchansky@mail.utexas.edu NR 19 TC 1 Z9 1 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1550-7416 J9 AAPS J JI AAPS J. PD DEC PY 2009 VL 11 IS 4 BP 758 EP 761 DI 10.1208/s12248-009-9152-x PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 544UZ UT WOS:000273686100012 PM 19876743 ER PT J AU Splaine, ME Ogrinc, G Gilman, SC Aron, DC Estrada, CA Rosenthal, GE Lee, S Dittus, RS Batalden, PB AF Splaine, Mark E. Ogrinc, Greg Gilman, Stuart C. Aron, David C. Estrada, Carlos A. Rosenthal, Gary E. Lee, Sei Dittus, Robert S. Batalden, Paul B. TI The Department of Veterans Affairs National Quality Scholars Fellowship Program: Experience From 10 Years of Training Quality Scholars SO ACADEMIC MEDICINE LA English DT Article AB The Department of Veterans Affairs (VA) National Quality Scholars Fellowship Program (VAQS) was established in 1998 as a postgraduate medical education fellowship to train physicians in new methods of improving the quality and safety of health care for veterans and the nation. The VAQS curriculum is based on adult learning theory, with a national core curriculum of face-to-face components, technologically mediated distance learning components, and a unique local curriculum that draws from the strengths of regional resources. VAQS has established strong ties with other VA programs. Fellows' research and quality improvement projects are integrated with local and regional VA leaders' priorities, enhancing the relevance and visibility of the fellows' efforts and promoting recruitment of fellows to VA positions. VAQS has enrolled 98 fellows since 1999; 75 have completed the program and 24 are currently enrolled. Fellowship graduates have pursued a variety of career paths: 17% are continuing training (most in VA), 31% hold a VA faculty/staff position, 66% are academic faculty, and 80% conduct clinical or research work related to health care improvement. Graduates have held leadership positions in VA, Department of Defense, academic medicine, and public health agencies. Combining knowledge about the improvement of health care with adult learning strategies, distance learning technologies, face-to-face meetings, local mentorship, and experiential projects has been successful in improving care in VA and preparing physicians to participate in, study, and lead the improvement of health care quality and safety. C1 [Splaine, Mark E.] Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice, Ctr Leadership & Improvement, VA Natl Qual Scholars Fellowship Program, Lebanon, NH 03756 USA. [Ogrinc, Greg] Dept Vet Affairs Med Ctr, Dept Vet Affairs Natl Qual Scholars Fellowship Pr, White River Jct, VT USA. [Gilman, Stuart C.] VA Off Acad Affiliat, Washington, DC USA. [Aron, David C.] Vet Affairs Med Ctr, Dept Vet Affairs Natl Qual Scholars Fellowship Pr, Cleveland, OH USA. [Aron, David C.] Vet Affairs Med Ctr, Louis Stokes Cleveland Dept, VA HSR&D QUERI Ctr Implementat Practice & Res Sup, Cleveland, OH USA. [Aron, David C.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Estrada, Carlos A.] Birmingham Vet Affairs Med Ctr, Vet Affairs Natl Qual Scholars Fellowship Program, Birmingham, AL USA. [Estrada, Carlos A.] Univ Alabama, Birmingham, AL USA. [Rosenthal, Gary E.] Univ Iowa, Sch Med, Vet Affairs Med Ctr, Dept Vet Affairs Natl Qual Scholars Fellowship Pr, Iowa City, IA 52242 USA. [Rosenthal, Gary E.] Univ Iowa, Sch Med, Vet Affairs Med Ctr, Iowa City Dept,Dept Med,Div Gen Internal Med, Iowa City, IA 52242 USA. [Lee, Sei] Vet Affairs Med Ctr, San Francisco Dept, Dept Vet Affairs Natl Qual Scholars Fellowship Pr, Div Geriatr, La Jolla, CA 92161 USA. [Lee, Sei] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Dittus, Robert S.] Vanderbilt Univ, Sch Med, Dept Vet Affairs Natl Qual Scholars Fellowship Pr, Nashville, TN 37212 USA. [Dittus, Robert S.] Vanderbilt Univ, Sch Med, Nashville Dept, Dept Med,Div Gen Internal Med, Nashville, TN 37212 USA. RP Splaine, ME (reprint author), Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice, Ctr Leadership & Improvement, VA Natl Qual Scholars Fellowship Program, 30 Lafayette St,3rd Floor Novell, Lebanon, NH 03756 USA. EM mark.e.splaine@hitchcock.org FU Department of Veterans Affairs FX The authors are deeply grateful to Leslie K. Walker, Department of Veterans Affairs National Quality Scholars Fellowship (VAQS) national program coordinator, for her assistance in the preparation of this manuscript and her ongoing support of VAQS. Information about the VAQS can be obtained at www.vaqs.org. NR 35 TC 15 Z9 15 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD DEC PY 2009 VL 84 IS 12 BP 1741 EP 1748 DI 10.1097/ACM.0b013e3181bfdcef PG 8 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA V15EW UT WOS:000207786300022 PM 19940583 ER PT J AU Hauer, KE Ciccone, A Henzel, TR Katsufrakis, P Miller, SH Norcross, WA Papadakis, MA Irby, DM AF Hauer, Karen E. Ciccone, Andrea Henzel, Thomas R. Katsufrakis, Peter Miller, Stephen H. Norcross, William A. Papadakis, Maxine A. Irby, David M. TI Remediation of the Deficiencies of Physicians Across the Continuum From Medical School to Practice: A Thematic Review of the Literature SO ACADEMIC MEDICINE LA English DT Review AB Despite widespread endorsement of competency-based assessment of medical trainees and practicing physicians, methods for identifying those who are not competent and strategies for remediation of their deficits are not standardized. This literature review describes the published studies of deficit remediation at the undergraduate, graduate, and continuing medical education levels. Thirteen studies primarily describe small, single-institution efforts to remediate deficient knowledge or clinical skills of trainees or below-standard-practice performance of practicing physicians. Working from these studies and research from the learning sciences, the authors propose a model that includes multiple assessment tools for identifying deficiencies, individualized instruction, deliberate practice followed by feedback and reflection, and reassessment. The findings of the study reveal a paucity of evidence to guide best practices of remediation in medical education at all levels. There is an urgent need for multiinstitutional, outcomes-based research on strategies for remediation of less than fully competent trainees and physicians with the use of long-term follow-up to determine the impact on future performance. C1 [Hauer, Karen E.] Univ Calif San Francisco, Dept Med, Sch Med, San Francisco, CA 94143 USA. [Ciccone, Andrea; Henzel, Thomas R.] Natl Board Med Examiners, Post Licensure Assessment Serv, Philadelphia, PA USA. [Katsufrakis, Peter] Natl Board Med Examiners, Assessment Programs, Philadelphia, PA USA. [Miller, Stephen H.] Univ Calif San Diego, Sch Med, Dept Family Med, San Diego, CA 92103 USA. [Miller, Stephen H.] Univ Calif San Diego, Dept Surg, Sch Med, San Diego, CA 92103 USA. [Norcross, William A.] Univ Calif San Diego, Dept Family & Prevent Med, Sch Med, San Diego, CA 92103 USA. [Papadakis, Maxine A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Papadakis, Maxine A.; Irby, David M.] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA. RP Hauer, KE (reprint author), Univ Calif San Francisco, Dept Med, Sch Med, 533 Parnassus Ave,U137,Box 0131, San Francisco, CA 94143 USA. EM karen.hauer@ucsf.edu OI Irby, David/0000-0001-5753-8918 NR 55 TC 62 Z9 63 U1 0 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD DEC PY 2009 VL 84 IS 12 BP 1822 EP 1832 DI 10.1097/ACM.0b013e3181bf3170 PG 11 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA V15EW UT WOS:000207786300035 PM 19940595 ER PT J AU Palin, FL Armistead, L Clayton, A Ketchen, B Lindner, G Kokot-Louw, P Pauw, A AF Palin, Frances L. Armistead, Lisa Clayton, Alana Ketchen, Bethany Lindner, Gretchen Kokot-Louw, Penny Pauw, Analie TI Disclosure of Maternal HIV-Infection in South Africa: Description and Relationship to Child Functioning SO AIDS AND BEHAVIOR LA English DT Article DE HIV disclosure; South African mothers ID PSYCHOLOGICAL DISTRESS; PSYCHOSOCIAL ADJUSTMENT; ADOLESCENT DYADS; MOTHERS; AIDS; HIV/AIDS; FAMILIES; DIFFICULTIES; CHALLENGES; SEROSTATUS AB South Africa has one of the highest HIV-infection rates in the world, yet few studies have examined disclosure of maternal HIV status and its influence on children. This study provides descriptive information about HIV disclosure among South African mothers and explores whether family context variables interact with maternal HIV disclosure to affect children's functioning. A total of 103 mothers, who self-identified as living with HIV and who were the primary caregivers of a child between the ages of 11 and 16, were interviewed. A total of 44% of mothers had disclosed, and those who had most typically perceived children's reactions to disclosure to be sadness and worry. Widows and married mothers were more likely than single mothers to disclose their HIV status. Disclosure to children significantly predicted externalizing, but not internalizing, behaviors. Family variables had direct but not interactive effects on child functioning. This study highlights the complexity of disclosure-related decisions and the importance of addressing the family context. C1 [Palin, Frances L.] Cherokee Hlth Syst, Ctr City, Knoxville, TN 37921 USA. [Armistead, Lisa; Clayton, Alana] Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA. [Lindner, Gretchen] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Kokot-Louw, Penny; Pauw, Analie] Univ Pretoria, Dept Psychol, ZA-0002 Pretoria, South Africa. [Ketchen, Bethany] San Francisco VA Med Ctr, San Francisco, CA USA. RP Palin, FL (reprint author), Cherokee Hlth Syst, Ctr City, 2018 Western Ave, Knoxville, TN 37921 USA. EM frances.palin@cherokeehealth.com; lparmistead@gsu.edu FU NICHD NIH HHS [R03 HD046371, R03HD046371] NR 59 TC 27 Z9 27 U1 1 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS behav. PD DEC PY 2009 VL 13 IS 6 BP 1241 EP 1252 DI 10.1007/s10461-008-9447-4 PG 12 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 526NX UT WOS:000272298900023 PM 18770026 ER PT J AU Boodram, B Plankey, MW Cox, C Tien, PC Cohen, MH Anastos, K Karim, R Hyman, C Hershow, RC AF Boodram, Basmattee Plankey, Michael W. Cox, Christopher Tien, Phyllis C. Cohen, Mardge H. Anastos, Kathryn Karim, Roksana Hyman, Charles Hershow, Ronald C. TI Prevalence and Correlates of Elevated Body Mass Index among HIV-Positive and HIV-Negative Women in the Women's Interagency HIV Study SO AIDS PATIENT CARE AND STDS LA English DT Article; Proceedings Paper CT 4th International-AIDS-Society Conference on HIV Pathogenesis, Treatment and Prevention CY JUL 22-25, 2007 CL Sydney, AUSTRALIA SP Int AIDS Soc ID UNITED-STATES; ANTIRETROVIRAL THERAPY; SMOKING-CESSATION; NATIONAL-HEALTH; INFECTED WOMEN; DIETARY-INTAKE; DRUG-ABUSERS; RISK-FACTORS; US ADULTS; OBESITY AB Since the introduction of highly active antiretroviral therapy (HAART) and the subsequent increased life expectancy in HIV-infected persons, non-HIV-related diseases have become an important cause of morbidity and mortality. This cross-sectional study reports the prevalence of overweight and obesity, and sociodemographic, psychological, and substance use-related risk factors for elevated body mass index (BMI) among 2157 HIV-seropositive (HIV+) in comparison to 730 HIV-seronegative (HIV-) participants in the Women's Interagency HIV Study (WIHS). Separate univariable and multivariate linear regression analyses were completed for HIV+ and HIV- women. Our study revealed a similar proportion of obesity (body mass index [BMI] >= 30) among HIV+ (33%) and HIV+ women (29%) (p = 0.12), as well as comparable median BMI (HIV+: 26.1 versus HIV-: 26.7, p = 0.16). HIV+ compared to HIV- women, respectively, were significantly (p < 0.01) older (median 35.6 versus. 32.5), but similar (p = 0.97) by race/ethnicity (57% African American, 28% Hispanic, and 15% white for both). In multivariate models for both HIV+ and HIV- women, African American race/ethnicity was significantly (p < 0.05) associated with higher BMI, while higher quality of life score and illicit hard drug use were associated with lower BMI. Additionally, smoking, alcohol use, markers of advanced HIV infection (AIDS diagnosis, elevated HIV viral load, low CD4 count), and a history of antiretroviral therapy use (ART) were also associated with lower BMI among HIV+ women. In conclusion, risk factors for elevated BMI were similar for HIV+ and HIV- women in the WIHS. For HIV+ women, all markers of advanced HIV infection and ART use were additionally associated with lower BMI. C1 [Boodram, Basmattee; Hershow, Ronald C.] Univ Illinois, Div Epidemiol & Biostat, Sch Publ Hlth, Chicago, IL 60612 USA. [Plankey, Michael W.] Georgetown Univ, Med Ctr, Dept Med, Div Infect Dis, Washington, DC 20007 USA. [Cox, Christopher] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cohen, Mardge H.] Rush Univ, Dept Med, Chicago, IL 60612 USA. [Cohen, Mardge H.] Stroger Hosp, Cook Cty Bur Hlth Serv, Chicago, IL USA. [Anastos, Kathryn] Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA. [Anastos, Kathryn] Montefiore Med Ctr, Dept Epidemiol, Bronx, NY 10467 USA. [Anastos, Kathryn] Montefiore Med Ctr, Dept Populat Hlth, Bronx, NY 10467 USA. [Karim, Roksana] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Hyman, Charles] SUNY Hlth Sci Ctr, Dept Med, Brooklyn, NY 11203 USA. RP Boodram, B (reprint author), Univ Illinois, Div Epidemiol & Biostat, Sch Publ Hlth, 1603 W Taylor St,M-C 923, Chicago, IL 60612 USA. EM bboodram@uic.edu FU NCRR NIH HHS [UL1 RR024131]; NIAID NIH HHS [UO1-AI-31834, UO1-AI-34993, UO1-AI-34994, UO1-AI-35004, UO1-AI-42590, UO1-AI-34989]; NICHD NIH HHS [UO1-HD-32632] NR 48 TC 22 Z9 22 U1 0 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD DEC PY 2009 VL 23 IS 12 BP 1009 EP 1016 DI 10.1089/apc.2009.0175 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 535GR UT WOS:000272955800003 PM 19909168 ER PT J AU Ancha, HR Spungen, AM Bauman, WA Rosman, AS Shaw, S Hunt, KK Post, JB Galea, M Korsten, MA AF Ancha, H. R. Spungen, A. M. Bauman, W. A. Rosman, A. S. Shaw, S. Hunt, K. K. Post, J. B. Galea, M. Korsten, M. A. TI Clinical trial: the efficacy and safety of routine bowel cleansing agents for elective colonoscopy in persons with spinal cord injury - a randomized prospective single-blind study SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID ORAL SODIUM-PHOSPHATE; COLORECTAL-CANCER; POLYETHYLENE-GLYCOL; RENAL-FUNCTION; CT COLONOGRAPHY; KIDNEY INJURY; FAILURE; NEPHROPATHY; EVACUATION; GUIDELINES AB P>Background As difficulty with evacuation is a common occurrence in individuals with spinal cord injury, preparation prior to colonoscopy may be suboptimal and, perhaps, more hazardous. Aim To assess the safety and efficacy of bowel cleansing regimens in persons with spinal cord injury. Methods Randomized, prospective, single blind study comparing polyethylene glycol (PEG), oral sodium phosphosoda (OSPS) and combination of both for colonic preparation prior to colonoscopy in subjects with spinal cord injury. Results Thirty six subjects with eGFR >= 60 mL/min/1.73 m2 were randomized to PEG or OSPS or PEG+OSPS. Regardless of bowel preparation employed, > 73% of subjects had unacceptable colonic cleansing. No subject in the OSPS preparation group demonstrated a decrease in eGFR or an increase in serum creatinine concentration from the baseline. OSPS and PEG+OSPS preparations caused a transient change in serum potassium, phosphate and calcium concentrations, but no change in electrolytes was noted in the PEG group. Conclusions Neither OSPS alone, PEG alone nor their combination was sufficient to prepare adequately the bowel for colonoscopy in most patients with spinal cord injury. However, administration of OSPS and/or PEG appears to be safe in the spinal cord injury population, provided adequate hydration is provided. C1 [Ancha, H. R.; Spungen, A. M.; Bauman, W. A.; Rosman, A. S.; Hunt, K. K.; Post, J. B.; Korsten, M. A.] James J Peters VA Med Ctr, RR&D Ctr Excellence Med Consequences Spinal Cord, Bronx, NY 10468 USA. [Spungen, A. M.; Bauman, W. A.; Rosman, A. S.; Shaw, S.; Post, J. B.; Korsten, M. A.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Spungen, A. M.; Bauman, W. A.; Post, J. B.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [Galea, M.] James J Peters VA Med Ctr, SCI Serv, Bronx, NY 10468 USA. RP Korsten, MA (reprint author), James J Peters VA Med Ctr, RR&D Ctr Excellence Med Consequences Spinal Cord, 7A-11,130 Kingsbridge Rd, Bronx, NY 10468 USA. EM mark.korsten@va.gov FU Center of Excellence VA Grant [B4162C]; VA Merit Review [A6428R] FX Center of Excellence VA Grant #B4162C, VA Merit Review A6428R. NR 33 TC 9 Z9 9 U1 0 U2 6 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD DEC 1 PY 2009 VL 30 IS 11-12 BP 1110 EP 1117 DI 10.1111/j.1365-2036.2009.04147.x PG 8 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 515JF UT WOS:000271465300003 PM 19769634 ER PT J AU Spiegel, B Bolus, R Harris, LA Lucak, S Naliboff, B Esrailian, E Chey, WD Lembo, A Karsan, H Tillisch, K Talley, J Mayer, E Chang, L AF Spiegel, B. Bolus, R. Harris, L. A. Lucak, S. Naliboff, B. Esrailian, E. Chey, W. D. Lembo, A. Karsan, H. Tillisch, K. Talley, J. Mayer, E. Chang, L. TI Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID QUALITY-OF-LIFE; VISCERAL SENSITIVITY INDEX; CLINICAL IMPORTANCE; ILLNESS SEVERITY; HEALTH-STATUS; IBS; VALIDATION; DISORDERS; VALIDITY; ANXIETY AB P>Background Controversy exists on how to measure patient-reported outcomes in irritable bowel syndrome (IBS) clinical trials effectively. Pain numeric rating scales (NRS) are widely used in the non-IBS pain literature. The Food and Drug Administration has proposed using the NRS in IBS. Aim To test the psychometrics of an abdominal pain NRS in IBS. Methods We analysed data from a longitudinal cohort of Rome III IBS subjects. At entry, subjects completed a 10-point NRS, bowel symptoms, IBS severity measurements (IBS-SSS, FBDSI), health-related quality of life indices (IBS-QOL, EQ5D), and the Worker Productivity Activity Index (WPAI). We repeated assessments at 3 months along with a response scale to calculate the minimal clinically important difference. Results There were 277 subjects (82% women; age = 42 +/- 15) at baseline and 90 at 3 months. The NRS correlated cross-sectionally with IBS-SSS (r = 0.60; P < 0.0011), FBDSI (r = 0.49; P < 0.0001), IBS-QOL (r = 0.43; P < 0.0001), EQ5D (r = 0.48; P < 0.0001), presenteeism (r = 0.39; P < 0.0001), absenteeism (r = 0.17; P = 0.04) and distension (r = 0.46; P < 0.0001), but not stool frequency or form. The minimal clinically important difference was 2.2 points, correlating with a 29.5% reduction over time. Conclusions An abdominal pain NRS exhibits excellent validity and can be readily interpreted with a minimal clinically important difference in patients with IBS. These data support the use of the NRS in IBS clinical trials. C1 [Spiegel, B.; Naliboff, B.; Talley, J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Spiegel, B.; Bolus, R.; Naliboff, B.; Esrailian, E.; Tillisch, K.; Mayer, E.; Chang, L.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Spiegel, B.; Bolus, R.; Naliboff, B.; Tillisch, K.; Mayer, E.; Chang, L.] Univ Calif Los Angeles, Ctr Neurobiol Stress, Los Angeles, CA 90024 USA. [Spiegel, B.; Bolus, R.; Esrailian, E.; Talley, J.; Chang, L.] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ, Los Angeles, CA 90024 USA. [Harris, L. A.] Mayo Clin Scottsdale, Scottsdale, AZ USA. [Lucak, S.] Columbia Univ, New York, NY 10027 USA. [Chey, W. D.] Univ Michigan, Ann Arbor, MI 48109 USA. [Lembo, A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Cambridge, MA 02138 USA. [Karsan, H.] Atlanta Gastroenterol Associates, Los Angeles, CA USA. RP Spiegel, B (reprint author), 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu FU Takeda; AstraZeneca; Rose Pharmaceuticals; UCLA Center for Neurobiology of Stress [NIH P50 DK64539, 1 R24 AT002681-NCCAM]; Veteran's Affairs Health Services Research and Development (HSRD) [RCD 03-179-2]; CURE Digestive Disease Research Center [NIH 2P30 DK 041301-17]; NIH [1 R24 AT002681-NCCAM, P50 DK64539] FX Dr Spiegel has received grant support from Takeda, AstraZeneca, and Rose Pharmaceuticals. Partial support was provided from the UCLA Center for Neurobiology of Stress (NIH P50 DK64539 and 1 R24 AT002681-NCCAM). Dr Spiegel is supported by a Veteran's Affairs Health Services Research and Development (HSR&D) Career Development Award (RCD 03-179-2), and the CURE Digestive Disease Research Center (NIH 2P30 DK 041301-17). Dr Chang, Naliboff and Mayer are supported by NIH Grant No. P50 DK64539, and Dr Spiegel, Mayer and Naliboff are supported by NIH Center Grant 1 R24 AT002681-NCCAM. Study supported by an investigator-initiated research grant from Takeda Pharmaceuticals. NR 37 TC 39 Z9 39 U1 2 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-2813 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD DEC 1 PY 2009 VL 30 IS 11-12 BP 1159 EP 1170 DI 10.1111/j.1365-2036.2009.04144.x PG 12 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 515JF UT WOS:000271465300008 PM 19751360 ER PT J AU McManus, DD Corteville, DCM Shlipak, MG Whooley, MA Ix, JH AF McManus, David D. Corteville, David C. M. Shlipak, Michael G. Whooley, Mary A. Ix, Joachim H. TI Relation of Kidney Function and Albuminuria With Atrial Fibrillation (from the Heart and Soul Study) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID CYSTATIN-C; RENAL-DISEASE; HEMODIALYSIS; ASSOCIATION; PREVALENCE; SYSTEM AB Atrial fibrillation (AF) is common in end-stage renal disease, but the relation between more modest decrements in kidney function or albuminuria with AF is uncertain. Among 956 outpatients with coronary artery disease, kidney function was assessed using 3 methods (cystatin C-based estimated glomerular filtration rate [eGFR(cys)], creatinine-based eGFR [eGFR(Cr)], and the urinary albumin/creatinine ratio [ACR]) and prevalent AF using surface electrocardiography. Multivariate logistic regression was used to evaluated the association of 2 each measure of kidney function with AF. The mean eGFR(cys) was 71 +/- 23 ml/min/1.73 m(2), and the median ACR was 10 mg/g (interquartile range 6 to 19). Forty subjects (4%) had prevalent AF. Compared to participants with eGFR(cys) in the highest tertile (eGFR(cys) >79), those with eGFRcys in the lowest tertile (eGFR(cys) <62) had more than threefold greater odds of AF (odds ratio [OR] 3.43, 95% confidence interval [CI] 1.18 to 9.97) after multivariate adjustment for traditional cardiovascular disease risk factors. This association remained significant with further adjustment for ACR (OR 3.37, 95% 1.02 to 11.14). Results were similar for eGFR(Cr) but did not reach statistical significance (OR 1.59, 95% CI 0.57 to 4.40). Participants with ACRs in the highest tertile (ACR > 15 mg/g) had more than fourfold greater odds of AF compared to participants in the lowest ACR tertile (ACR <7 mg/g); an association that remained significant after adjustment for eGFR(cys) (OR 4.36, 95% CI 1.45 to 13.05) or eGFRCr (OR 4.61, 95% CI 1.56 to 13.66). In conclusion, among outpatients with coronary artery disease, lower eGFR(cys) and higher ACR were associated with prevalent AF, independent of each other. Published by Elsevier Inc. (Am J Cardiol 2009;104:1551-1555) C1 [Ix, Joachim H.] Univ Calif San Diego, Dept Med, Div Nephrol, San Diego, CA 92103 USA. [McManus, David D.] Univ Massachusetts, Dept Med, Div Cardiol, Sect Cardiac Electrophysiol, Worcester, MA 01605 USA. [Corteville, David C. M.] Univ Michigan, Dept Med, Div Cardiol, Ann Arbor, MI 48109 USA. [Corteville, David C. M.; Shlipak, Michael G.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shlipak, Michael G.; Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Ix, Joachim H.] Univ Calif San Diego, Dept Family & Prevent Med, Div Prevent Med, San Diego, CA 92103 USA. [Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA. [Shlipak, Michael G.; Whooley, Mary A.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. RP Ix, JH (reprint author), Univ Calif San Diego, Dept Med, Div Nephrol, San Diego, CA 92103 USA. EM joeix@ucsd.edu FU United States Department of Veterans Affairs, Washington; Robert Wood Johnson Foundation; American Federation for Aging Research; Ischemia Research and Education Foundation; National Institutes of Health [R01 HL079235]; American Heart Association Fellow to Faculty Transition Award [0575021N] FX This study was supported by grants from the United States Department of Veterans Affairs, Washington. District of Columbia; the Robert Wood Johnson Foundation (Faculty Scholars Program), Princeton, New Jersey; the American Federation for Aging Research (Paul Beeson Scholars Progoram), New York. New York: the Ischemia Research and Education Foundation. South San Francisco, California: and the National Institutes of Health (R01 HL079235). Bethesda, Maryland. Dr. Ix was Supported by American Heart Association Fellow to Faculty Transition Award 0575021N, Dallas, Texas. Dade Behring, Deerfield, Illinois, supported the cystatin C measurements in the Heart and Soul cohort. NR 16 TC 31 Z9 38 U1 0 U2 1 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD DEC 1 PY 2009 VL 104 IS 11 BP 1551 EP 1555 DI 10.1016/j.amjcard.2009.07.026 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 531BK UT WOS:000272637500017 PM 19932791 ER PT J AU Ragland, M Hutter, C Zabetian, C Edwards, K AF Ragland, Margaret Hutter, Carolyn Zabetian, Cyrus Edwards, Karen TI Association Between the Ubiquitin Carboxyl-Terminal Esterase L1 Gene (UCHL1) S18Y Variant and Parkinson's Disease: A HuGE Review and Meta-Analysis SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Review DE case-control studies; epidemiology; genes; genetics; meta-analysis; Parkinson disease; review; UCHL1 ID SINGLE-NUCLEOTIDE POLYMORPHISMS; WHOLE-GENOME ASSOCIATION; HYDROLASE L1; NEURODEGENERATIVE DISEASES; SUSCEPTIBILITY GENE; CLINICAL-DIAGNOSIS; ALPHA-SYNUCLEIN; UCH-L1 GENE; PESTICIDE EXPOSURE; MUTATION ANALYSIS AB The ubiquitin carboxyl-terminal esterase L1 gene, UCHL1, located on chromosome 4p14, has been studied as a potential candidate gene for Parkinson's disease risk. The authors conducted a Human Genome Epidemiology review and meta-analysis of published case-control studies of the UCHL1 S18Y variant and Parkinson's disease in Asian and Caucasian samples. The meta-analysis of studies in populations of Asian ancestry showed a statistically significant association between the Y allele and reduced risk of Parkinson's disease under a recessive model (odds ratio (OR) for YY vs. SY + SS = 0.79, 95% confidence interval (CI): 0.67, 0.94; P = 0.006). For a dominant model, the association was not significant in Asian populations (OR for YY + SY vs. SS = 0.88, 95% CI: 0.68, 1.14; P = 0.33). For populations of European ancestry, the meta-analysis showed a significant association between the Y allele and decreased risk of Parkinson's disease under a dominant model (OR = 0.89, 95% CI: 0.81, 0.98; P = 0.02) but not under a recessive model (OR = 0.92, 95% CI: 0.66, 1.30; P = 0.65). Using the Venice criteria, developed by the Human Genome Epidemiology Network Working Group on the assessment of cumulative evidence, the authors concluded that moderate evidence exists for an association between the S18Y variant and Parkinson's disease. C1 [Edwards, Karen] Univ Washington, Ctr Genom & Publ Hlth, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98115 USA. [Ragland, Margaret; Edwards, Karen] Univ Washington, Inst Publ Hlth Genet, Sch Publ Hlth, Seattle, WA 98115 USA. [Zabetian, Cyrus] Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Zabetian, Cyrus] Univ Washington, Dept Neurol, Sch Med, Seattle, WA 98115 USA. RP Edwards, K (reprint author), Univ Washington, Ctr Genom & Publ Hlth, Dept Epidemiol, Sch Publ Hlth, Box 354921,6200 NE 74th St,Bldg 29,Suite 250, Seattle, WA 98115 USA. EM keddy@u.washington.edu OI Zabetian, Cyrus/0000-0002-7739-4306 FU Centers for Disease Control and Prevention through the Association of Schools of Public Health [U36/CCU300430-23, U10/CCU025038] FX This project was financially supported under a cooperative agreement from the Centers for Disease Control and Prevention through the Association of Schools of Public Health, grant U36/CCU300430-23 and U10/CCU025038 (Karen L. Edwards, Principal Investigator). NR 111 TC 30 Z9 31 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD DEC 1 PY 2009 VL 170 IS 11 BP 1344 EP 1357 DI 10.1093/aje/kwp288 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 523JR UT WOS:000272069900003 PM 19864305 ER PT J AU Rugge, M de Boni, M Pennelli, G Mescoli, C Graham, DY AF Rugge, Massimo de Boni, Michele Pennelli, Gianmaria Mescoli, Claudia Graham, David Y. TI OLGA Can Guard the Barn SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter ID HELICOBACTER-PYLORI ERADICATION; GASTRIC-CANCER; SYSTEM C1 [Rugge, Massimo] Univ Padua, IRCCS, Ist Oncol Veneto,Dept Med Diagnost Sci & Special, Cattedra Anat Patol,Surg Pathol & Cytopathol Unit, I-35121 Padua, Italy. [de Boni, Michele] Feltre Hosp, Dept Gastroenterol, Feltre, Italy. [Graham, David Y.] Vet Adm Hosp, Baylor Coll Med, Div Digest Dis, Houston, TX USA. RP Rugge, M (reprint author), Univ Padua, IRCCS, Ist Oncol Veneto,Dept Med Diagnost Sci & Special, Cattedra Anat Patol,Surg Pathol & Cytopathol Unit, Via Aristide Gabelli 61, I-35121 Padua, Italy. EM massimo.rugge@unipd.it RI Rugge, Massimo/K-7525-2016 OI PENNELLI, GIANMARIA/0000-0003-0210-165X NR 6 TC 3 Z9 3 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD DEC PY 2009 VL 104 IS 12 BP 3099 EP 3099 DI 10.1038/ajg.2009.512 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 529XQ UT WOS:000272553100030 PM 19956125 ER PT J AU Williams, EV Unutzer, J Lee, S Noel, PH AF Williams, Emily Van Leeuwen Unuetzer, Juergen Lee, Shuko Noel, Polly Hitchcock TI Collaborative Depression Care for the Old-Old: Findings From the IMPACT Trial SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Depression; old-old; collaborative care; late life ID RANDOMIZED CONTROLLED-TRIAL; NURSING-HOME RESIDENTS; LATE-LIFE; MAJOR DEPRESSION; CLINICAL-TRIAL; DISORDERS; PREVALENCE; MANAGEMENT; VALIDITY; RISK AB Objectives: To compare the clinical outcomes of young-old patients (aged 60-74 years) and old-old patients (aged 75 years and older) who received collaborative care management for depression. Design: Multisite randomized clinical trial. Setting: Eighteen primary care clinics from eight healthcare organizations. Participants: Nine hundred six patients (N = 606 young-old; N = 300 old-old) with major depression and/or dysthymia who were randomized to receive collaborative care in the Improving Mood: Promoting Access to Collaborative Treatment trial. Intervention: Patients had access for 12 months to a depression clinical specialist who coordinated depression care with their primary care physician. Measurements: Young-old and old-old patients were compared on process of care and outcome variables. Process of care was determined by the type of treatment and level of care received. Clinical outcomes included Symptom Checklist (SCL)-20 depression scores, treatment response (defined as a >= 50% decrease in the SCL-20 score from baseline), and complete remission (defined as a SCL-20 score <0.5) at 3-, 6-, 12-, 18-, and 24-month follow-up. Results: The process of care variables did not significantly differ between the two age groups. Young-old patients had similar treatment responses at initial follow-up (3 months) but were significantly more likely to respond to treatment and meet complete remission criteria than old-old patients at 6-, 12-, 18-, and 24-months. Conclusions: Young-old and old-old patients who receive collaborative depression care have a similar initial clinical response, but old-old patients may have a lower rate of long-term treatment response and complete remission in the long run. (Am J Geriatr Psychiatry 2009;17:1040-1049) C1 [Williams, Emily Van Leeuwen] Duke Univ, Sch Med, Durham, NC USA. [Williams, Emily Van Leeuwen] Univ Texas Hlth Sci Ctr, Houston Sch Publ Hlth, San Antonio, TX USA. [Unuetzer, Juergen] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Lee, Shuko; Noel, Polly Hitchcock] S Texas Vet Hlth Care Syst, Houston, TX USA. [Noel, Polly Hitchcock] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Williams, EV (reprint author), 15 Med Pk Suite 141, Columbia, SC 29203 USA. EM emily.williams@palmettohealth.org FU John A. Hartford Foundation; California HealthCare Foundation; Hogg Foundation for Mental Health; Kirschstein National Research Service Award FX This work was supported by the John A. Hartford Foundation, the California HealthCare Foundation, the Hogg Foundation for Mental Health, and the Kirschstein National Research Service Award ( to E. V. L. W.). NR 38 TC 9 Z9 9 U1 4 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD DEC PY 2009 VL 17 IS 12 BP 1040 EP 1049 DI 10.1097/JGP.0b013e3181b4bf08 PG 10 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 528PV UT WOS:000272459700006 ER PT J AU de Boer, IH Katz, R Fried, LF Ix, JH Luchsinger, J Sarnak, MJ Shlipak, MG Siscovick, DS Kestenbaum, B AF de Boer, Ian H. Katz, Ronit Fried, Linda F. Ix, Joachim H. Luchsinger, Jose Sarnak, Mark J. Shlipak, Michael G. Siscovick, David S. Kestenbaum, Bryan TI Obesity and Change in Estimated GFR Among Older Adults SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Obesity; chronic kidney disease; glomerular filtration rate; cohort study ID BODY-MASS INDEX; GLOMERULAR-FILTRATION-RATE; SERUM CYSTATIN-C; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; FAT-FREE MASS; CARDIOVASCULAR HEALTH; BIOELECTRICAL IMPEDANCE; POOLED ANALYSIS; RISK-FACTOR AB Background: The prevalence of chronic kidney disease is growing most rapidly among older adults; however, determinants of impaired kidney function in this population are not well understood. Obesity assessed in midlife has been associated with chronic kidney disease. Study Design: Cohort study. Setting & Participants: 4,295 participants in the community-based Cardiovascular Health Study, aged >= 65 years. Predictors: Body mass index, waist circumference, and fat mass measured using bioelectrical impedance. Outcome: Change in glomerular filtration rate (GFR) during 7 years of follow-up. Measurements: Longitudinal estimates of GFR calculated using the 4-variable Modification of Diet in Renal Disease (MDRD) Study equation. Results: Estimated GFR decreased by an average of 0.4 +/- 3.6 mL/min/1.73 m(2)/y, and rapid GFR loss (>3 mL/min/1.73 m(2)/y) occurred in 693 participants (16% ). Baseline body mass index, waist circumference, and fat mass were each associated with increased risk of rapid GFR loss: ORs, 1.19 (95% Cl, 1.09-1.30) per5 kg/m(2),1.25 (95% Cl, 1.16-1.36) per 12 cm, and 1.14 (95%CI, 1.05-1.24) per 10 kg after adjustment for age, sex, race, and smoking. The magnitude of increased risk was larger for participants with estimated GFR < 60 mL/min/1.73 m(2) at baseline (P for interaction < 0.05). Associations were substantially attenuated by further adjustment for diabetes, hypertension, and C-reactive protein level. Obesity measurements were not associated with change in GFR estimated using serum cystatin C level. Limitations: Few participants with advanced chronic kidney disease at baseline, no direct GFR measurements. Conclusion: Obesity may be a modifiable risk factor for the development and progression of kidney disease in older adults. Am J Kidney Dis 54:1043-1051. (C) 2009 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. C1 [de Boer, Ian H.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [Fried, Linda F.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Ix, Joachim H.] Univ Calif San Diego, San Diego, CA 92103 USA. [Luchsinger, Jose] Columbia Univ, New York, NY USA. [Sarnak, Mark J.] Tufts Med Ctr, Boston, MA USA. [Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP de Boer, IH (reprint author), Univ Washington, Div Nephrol, Box 356521,1959 NE Pacific St, Seattle, WA 98195 USA. EM deboer@u.washington.edu FU National Heart, Lung, and Blood Institute [N01-HC-85079 to N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133, U01 HL080295]; National Institute of Neurological Disorders and Stroke; National Center for Research Resources [1KL2RR025015-01] FX The research reported in this article was supported by contract numbers N01-HC-85079 to N01-HC-85086, N01-HC-35129, N01-HC-15103, N01-HC-55222, N01-HC-75150, N01-HC-45133, and grant number U01 HL080295 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support came from grant 1KL2RR025015-01 from the National Center for Research Resources. NR 37 TC 39 Z9 40 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD DEC PY 2009 VL 54 IS 6 BP 1043 EP 1051 DI 10.1053/j.ajkd.2009.07.018 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 524LF UT WOS:000272144100012 PM 19782454 ER PT J AU Steinman, MA Yang, KY Byron, SC Maselli, JH Gonzales, R AF Steinman, Michael A. Yang, Katherine Y. Byron, Sepheen C. Maselli, Judith H. Gonzales, Ralph TI Variation in Outpatient Antibiotic Prescribing in the United States SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID ANTIMICROBIAL CONSUMPTION ESAC; UPPER RESPIRATORY-INFECTIONS; EUROPEAN SURVEILLANCE; GEOGRAPHIC-VARIATION; SORE THROAT; CARE; RESISTANCE; TRENDS; PHYSICIANS; DATABASE AB Objective: To evaluate variation in outpatient antibiotic utilization among US commercial health plans and the implications of this variation for cost and quality. Study Design and Methods: We measured antibiotic utilization rates among 229 US commercial health plans that participated in the 2005 Healthcare Effectiveness Data and Information Set. Rates were adjusted to account for health plan age and sex distribution. To estimate antibiotic costs, we multiplied utilization data for each drug class by national estimates of intraclass distribution of drugs, duration of therapy, and median average wholesale price. Results: Antibiotic utilization rates varied markedly among plans, ranging from 0.64 antibiotic fills per member per year (PMPY) at the 5th percentile of plans to 1.08 fills PMPY at the 95th percentile, with a mean of 0.88 (SD +/- 0.15) antibiotic fills PMPY. US census region was the strongest predictor of antibiotic utilization. Antibiotic costs averaged $49 PMPY and ranged from $34 to $63 PMPY among plans at the 5th and 95th percentiles of cost, respectively. If a health plan with 250,000 members at the 90th percentile of antibiotic costs reduced its costs to the 25th percentile, annual drug cost savings would be approximately $4.1 million. Conclusions: Antibiotic utilization varies substantially among commercial health plans and is not accounted for by differences in the age and sex distribution of plan members. Because reducing rates of antibiotic utilization is likely to lower costs and improve quality, high-utilizing plans may reap considerable rewards from investing in programs to reduce the overuse of antibiotics. (Am J Manag Care. 2009; 15(12): 861-868) C1 [Steinman, Michael A.] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA 94121 USA. [Yang, Katherine Y.] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA. [Steinman, Michael A.; Maselli, Judith H.; Gonzales, Ralph] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Byron, Sepheen C.] Natl Comm Qual Assurance, Washington, DC USA. RP Steinman, MA (reprint author), San Francisco VA Med Ctr, Div Geriatr, 4150 Clement St,Box 181-G, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu FU VA Health Services Research and Development Service [01-013]; National Institute on AginG [K23-AG030999]; American Federation for Aging Research; Agency for Healthcare Research and Quality (NCQA) [R01 HS13915]; National Center for Research Resources [KL2 RR024130] FX This work was supported by Career Development Transition Award 01-013 from the VA Health Services Research and Development Service (Dr Steinman), by grant K23-AG030999 from the National Institute on Aging and the American Federation for Aging Research (Dr Steinman), by the Agency for Healthcare Research and Quality (NCQA) Translating Research into Practice Program (R01 HS13915; Dr Gonzales and Ms Maselli) and by grant KL2 RR024130 from the National Center for Research Resources (Dr Yang). We submitted an advance copy of this paper to NCQA for review and comments, but that institution had no control over the analyses and interpretation of data or over the decision to publish this work. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official view of the Department of Veterans Affairs, the National Center for Research Resources, or the National Institutes of Health. NR 30 TC 21 Z9 21 U1 1 U2 5 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD DEC PY 2009 VL 15 IS 12 BP 861 EP 868 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 538AA UT WOS:000273154800003 PM 20001167 ER PT J AU Dicianno, BE Bellin, MH Zabel, AT AF Dicianno, Brad E. Bellin, Melissa H. Zabel, Andrew T. TI Spina Bifida and Mobility in the Transition Years SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Mobility Limitation; Psychological Stress; Quality of Life; Rehabilitation; Self-Care; Spinal Dysraphism ID ASSISTIVE TECHNOLOGY USE; QUALITY-OF-LIFE; YOUNG-ADULTS; ADOLESCENTS; HEALTH; ILLNESS AB Objective: Adolescents with spina bifida experience decreased mobility (Johnson KL, Dudgeon B, Kuehn C, et al: Am J Public Health 2007;9 7:330-6), especially during the time of transition from pediatric to adult care, but little research has been done on the relationships between mobility and self-management skills, psychological health, or quality of life. Design: In this multicenter, interdisciplinary study, a convenience sample of 61 participants with spina bifida from regional spina bifida clinics (mean age = 21.0 +/- 2.1 yrs) participated in a structured clinical interview on self-management and completed standardized self-report measures of psychological distress, quality of life, and mobility status. Participants were divided into three mobility groups: ambulators, part-time wheelchair users, and full-time wheelchair users and were compared with respect to outcome measures. Results: We found that full-time wheelchair use is associated with reduced quality of life but that psychological distress and problems with self-management are prevalent, regardless of mobility status. Conclusion: Research should be aimed at assessing life satisfaction as it relates to assistive technology use to delineate further how technological advancements in wheelchair design and universal design of homes and communities can have the greatest impact on mobility and quality of life. C1 [Dicianno, Brad E.] Univ Pittsburgh, Human Engn Res Labs, Pittsburgh, PA USA. [Dicianno, Brad E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Adult Spina Bifida Clin, Pittsburgh, PA USA. [Dicianno, Brad E.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Dicianno, Brad E.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Dicianno, Brad E.] Ctr Excellence Wheelchairs & Associated Rehabil E, VA Pittsburgh HealthCare Syst, Pittsburgh, PA USA. [Bellin, Melissa H.] Univ Maryland, Sch Social Work, Baltimore, MD 21201 USA. [Zabel, Andrew T.] Kennedy Krieger Inst, Baltimore, MD USA. RP Dicianno, BE (reprint author), Suite 202,Kaufmann Bldg,3471 5th Ave, Pittsburgh, PA 15213 USA. OI Dicianno, Brad/0000-0003-0738-0192 FU Spina Bifida Association Young Investigator Award; University of Maryland FX Financial disclosure statements have been obtained, and no conflicts of interest have been reported by the authors or by any individuals in control of the content of this article. This study was funded, in part, by the Spina Bifida Association Young Investigator Award and the University of Maryland Designated Research Initiative Funds (PI: M. Bellin). Portions of the results were presented at the Spina Bifida World Congress Meeting, 2009. NR 18 TC 9 Z9 9 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD DEC PY 2009 VL 88 IS 12 BP 1002 EP 1006 DI 10.1097/PHM.0b013e3181c1ede3 PG 5 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 527XV UT WOS:000272405400006 PM 19935183 ER PT J AU Yang, J Boninger, ML Leath, JD Fitzgerald, SG Dyson-Hudson, TA Chang, MW AF Yang, Jennifer Boninger, Michael L. Leath, Janet D. Fitzgerald, Shirley G. Dyson-Hudson, Trevor A. Chang, Michael W. TI Carpal Tunnel Syndrome in Manual Wheelchair Users with Spinal Cord Injury A Cross-Sectional Multicenter Study SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Spinal Cord Injuries; Paraplegia; Carpal Tunnel Syndrome; Median Nerve; Neuropathy; Cumulative Trauma Disorders; Wheelchairs ID BEARING UPPER EXTREMITY; ULNAR NERVE-CONDUCTION; NEUROPHYSIOLOGICAL DIAGNOSIS; ELECTRODIAGNOSTIC FINDINGS; PUSHRIM BIOMECHANICS; PARAPLEGIC PATIENTS; GENERAL-POPULATION; SYMPTOMS; MOTOR; TEMPERATURE AB Objective: To investigate relationships between carpal tunnel syndrome, functional status, subject demographics, physical examination findings, and median nerve conduction study findings in manual wheelchair users with paraplegia. Design: Multicenter cross-sectional study. One hundred twenty-six manual wheelchair-using individuals with chronic paraplegia answered self-administered questionnaires on demographics, symptoms, and functional status. They underwent physical examination specific for carpal tunnel syndrome and upper-limb nerve conduction studies. Results: Fifty-seven percent of subjects had symptoms (72.2% bilateral); hand numbness was most common. Sixty percent of subjects had carpal tunnel syndrome physical examination findings (59.2% bilateral). Those with physical examination findings were more likely to have longer duration of injury (P = 0.003). Seventy-eight percent of subjects had electrophysiologic evidence of median mononeuropathy. Symptomatic subjects had significantly greater median-ulnar motor latency difference in the dominant hand (P = 0.02) and smaller compound muscle action potential amplitudes bilaterally (dominant hand, P = 0.01; nondominant hand, P = 0.04). Persons with carpal tunnel syndrome symptoms and physical examination findings had significantly worse functional status (symptoms, P < 0.001; physical examination, P = 0.02) and symptom severity scores (symptoms, P < 0.001; physical examination, P = 0.01), but a similar difference between subjects with and without median mononeuropathy was not seen. Logistic regression analysis revealed that the presence of symptoms was predicted by median-ulnar motor latency difference in the dominant hand (odds ratio, 4.38; 95% confidence interval 1.72-11.14) and sensory nerve action potential amplitude in the nondominant hand (odds ratio, 0.97; 95% confidence interval, 0.94-0.99). Conclusions: The interaction among symptoms, physical examination, and nerve conduction study findings is complex. Carpal tunnel syndrome and median mononeuropathy are highly prevalent and functionally significant. This study highlights the need for primary prevention and patient education for preserving upper-limb function. C1 [Boninger, Michael L.] Univ Pittsburgh, Human Engn Res Labs, VA Pittsburgh Healthcare Syst, Dept Phys Med & Rehabil,Sch Med, Pittsburgh, PA 15206 USA. [Yang, Jennifer; Boninger, Michael L.; Fitzgerald, Shirley G.] Ctr Excellence Wheelchairs & Related Technol, VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Boninger, Michael L.; Fitzgerald, Shirley G.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Rehabil Sci & Technol, Pittsburgh, PA 15206 USA. [Boninger, Michael L.] Univ Pittsburgh, Sch Engn, Dept Bioengn, Pittsburgh, PA 15206 USA. [Dyson-Hudson, Trevor A.] Univ Med & Dent New Jersey, New Jersey Med Sch, Kessler Med Rehabil Res & Educ Corp, W Orange, NJ 07052 USA. [Dyson-Hudson, Trevor A.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, W Orange, NJ 07052 USA. [Chang, Michael W.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Boninger, ML (reprint author), Univ Pittsburgh, Human Engn Res Labs, VA Pittsburgh Healthcare Syst, Dept Phys Med & Rehabil,Sch Med, 7180 Highland Dr,Bldg 4,2nd Floor E,151R-1, Pittsburgh, PA 15206 USA. OI Boninger, Michael/0000-0001-6966-919X NR 55 TC 17 Z9 17 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD DEC PY 2009 VL 88 IS 12 BP 1007 EP 1016 DI 10.1097/PHM.0b013e3181bbddc9 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 527XV UT WOS:000272405400007 PM 19789435 ER PT J AU Li, YH Xiang, M Yuan, YZ Xiao, GZ Zhang, J Jiang, Y Vodovotz, Y Billiar, TR Wilson, MA Fan, J AF Li, Yuehua Xiang, Meng Yuan, Youzhong Xiao, Guozhi Zhang, Jian Jiang, Yong Vodovotz, Yoram Billiar, Timothy R. Wilson, Mark A. Fan, Jie TI Hemorrhagic shock augments lung endothelial cell activation: role of temporal alterations of TLR4 and TLR2 SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE acute lung injury; neutrophil; Toll-like receptors ID TOLL-LIKE RECEPTOR-4; NF-KAPPA-B; INTERCELLULAR-ADHESION MOLECULE-1; MOBILITY GROUP BOX-1; NEUTROPHIL NADPH OXIDASE; MEDIATES HEPATIC-INJURY; TUMOR-NECROSIS-FACTOR; NAD(P)H OXIDASE; UP-REGULATION; TRANSENDOTHELIAL MIGRATION AB Li Y, Xiang M, Yuan Y, Xiao G, Zhang J, Jiang Y, Vodovotz Y, Billiar TR, Wilson MA, Fan J. Hemorrhagic shock augments lung endothelial cell activation: role of temporal alterations of TLR4 and TLR2. Am J Physiol Regul Integr Comp Physiol 297: R1670-R1680, 2009. First published October 14, 2009; doi:10.1152/ajpregu.00445.2009.-Hemorrhagic shock (HS) due to major trauma predisposes the host to the development of acute lung inflammation and injury. The lung vascular endothelium is an active organ that plays a central role in the development of acute lung injury through generating reactive oxygen species and synthesizing and releasing of a number of inflammatory mediators, including leukocyte adhesion molecules that regulate neutrophils emigration. Previous study from our laboratory has demonstrated that in a setting of sepsis, Toll-like receptor-4 (TLR4) signaling can induce TLR2 expression in endothelial cells (ECs), thereby increasing the cells' response to TLR2 ligands. The present study tested the hypothesis that TLR4 activation by HS and the resultant increased TLR2 surface expression in ECs might contribute to the mechanism underlying HS-augmented activation of lung ECs. The results show that high-mobility group box 1 (HMGB1) through TLR4 signaling mediates HS-induced surface expression of TLR2 in the lung and mouse lung vascular endothelial cells (MLVECs). Furthermore, the results demonstrate that HMGB1 induces activation of NAD(P)H oxidase and expression of ICAM-1 in the lung, and MLVECs sequentially depend on TLR4 in the early phase and on TLR2 in the late phase following HS. Finally, the data indicate an important role of the increased TLR2 surface expression in enhancing the activation of MLVECs and augmenting pulmonary neutrophil infiltration in response to TLR2 agonist peptidoglycan. Thus, induction of TLR2 surface expression in lung ECs, induced by HS and mediated by HMGB1/TLR4 signaling, is an important mechanism responsible for endothelial cell-mediated inflammation and organ injury following trauma and hemorrhage. C1 [Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Dept Surg, Res & Dev, Pittsburgh, PA 15240 USA. [Li, Yuehua; Xiang, Meng; Yuan, Youzhong; Vodovotz, Yoram; Billiar, Timothy R.; Wilson, Mark A.; Fan, Jie] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. [Jiang, Yong] So Med Univ, Dept Pathophysiol, Guangzhou, Guangdong, Peoples R China. [Xiao, Guozhi; Zhang, Jian] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA. RP Fan, J (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Dept Surg, Res & Dev, Bldg 1 2W109 151L-U,Univ Dr, Pittsburgh, PA 15240 USA. EM jif7@pitt.edu FU National Heart, Lung, and Blood Institute [R01-HL-079669]; National Institute of General Medical Sciences [P50-GM-53789]; Veterans Affairs Merit Award; National Key Basic Research Program [2010CB529704, PCSIRT-IRT0731]; National Natural Science Foundation of China (NSFC) [30670828]; Joint Fund of NSFC with the Guangdong Province [U0632004] FX This work was supported by the National Heart, Lung, and Blood Institute Grant R01-HL-079669 ( to J. Fan and M. A. Wilson), National Institute of General Medical Sciences Grant P50-GM-53789 ( T. R. Billiar and Y. Vodovotz), a Veterans Affairs Merit Award ( to J. Fan), National Key Basic Research Program Grant 2010CB529704 ( to Y. Jiang, China), Grant PCSIRT-IRT0731 ( to Y. Jiang), National Natural Science Foundation of China (NSFC) Grant 30670828 ( to Y. Jiang), and Joint Fund of NSFC with the Guangdong Province Grant U0632004 ( to Y. Jiang). NR 69 TC 46 Z9 54 U1 1 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD DEC PY 2009 VL 297 IS 6 BP R1670 EP R1680 DI 10.1152/ajpregu.00445.2009 PG 11 WC Physiology SC Physiology GA 523BD UT WOS:000272044900007 PM 19828841 ER PT J AU Eisenman, DP Glik, D Gonzalez, L Maranon, R Zhou, Q Tseng, CH Asch, SM AF Eisenman, David P. Glik, Deborah Gonzalez, Lupe Maranon, Richard Zhou, Qiong Tseng, Chi-Hong Asch, Steven M. TI Improving Latino Disaster Preparedness Using Social Networks SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID PUBLIC-HEALTH EMERGENCIES; HIDDEN POPULATIONS; RISK; INFORMATION AB Background: Culturally targeted, informal social networking approaches to improving disaster preparedness have not been empirically tested. Purpose: In partnership with community health promoters and the Los Angeles County Department of Public Health, this study tested a disaster preparedness program for Latino households. Design: This study had a community-based, randomized, longitudinal cohort design with two groups and was conducted during February-October 2007. Assessments were made at baseline and 3 months. Analyses were carried out January-October 2008. Settings/participants: Community-based study of 231 Latinos living in Los Angeles County. Intervention: Participants were randomly assigned to attending platicas (small-group discussions led by a health promoter/promotora de salud) or receiving "media" (a culturally tailored mailer). A total of 187 (81.0%) completed the 3-month follow-up. Main outcome measure: A self-reported disaster preparedness checklist was used. Results: Among participants who did not have emergency water pre-intervention, 93.3% of those in the platica arm had it at follow-up, compared to 66.7% in the media arm (p=0.003). Among participants who did not have food pre-intervention, 91.7% in the platica arm reported it at follow-up, compared to 60.6% in the media arm (p=0.013). Finally, among participants who did not have a family communication plan pre-intervention, 70.4% in the platica arm reported one at follow-up, compared to 42.3% in the media arm (p=0.002). Conclusions: Although both arms improved in stockpiling water and food and creating a communication plan, the platica arm showed greater improvement than the media group. (Am J Prev Med 2009;37 (6):512-517) (C) 2009 American journal of Preventive Medicine C1 [Eisenman, David P.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Dept Med, Los Angeles, CA 90095 USA. [Glik, Deborah] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90095 USA. [Asch, Steven M.] VA Greater Los Angeles Hlth Syst, Dept Med, Los Angeles, CA USA. [Gonzalez, Lupe] Coalit Community Hlth, Los Angeles, CA USA. RP Eisenman, DP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Dept Med, 911 Broxton Plaza, Los Angeles, CA 90095 USA. EM deisenman@mednet.ucla.edu FU CDC [1 K01 CD000049-01] FX The survey was supported by award No. 1 K01 CD000049-01 by the CDC to DPE. The manuscript's content is solely the responsibility of the authors and does not necessarily represent the views of the granting agency. NR 37 TC 21 Z9 21 U1 1 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD DEC PY 2009 VL 37 IS 6 BP 512 EP 517 DI 10.1016/j.amepre.2009.07.022 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 532SJ UT WOS:000272769700007 PM 19944917 ER PT J AU Pagan, JA Su, DJ Li, LF Armstrong, K Asch, DA AF Pagan, Jose A. Su, Dejun Li, Lifeng Armstrong, Katrina Asch, David A. TI Racial and Ethnic Disparities in Awareness of Genetic Testing for Cancer Risk SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID HEALTH INTERVIEW SURVEY; ACCULTURATION; BREAST; RACE AB Background: Racial and ethnic disparities in awareness of genetic testing for cancer risk are substantial. Purpose: This study assesses the relative importance of contributing factors to gaps in awareness of genetic testing for cancer risk across racial and ethnic groups. Methods: Data from the 2005 National Health Interview Survey (N=25,364) were analyzed in 2009 to evaluate the contribution of demographic factors, SES, health Status, nativity/length of residency in the U.S., personal/family history of cancer, and perceived cancer risk to racial and ethnic disparities in genetic testing awareness for cancer risk. The contribution of each factor was assessed using the Fairlie decomposition technique. Results: About 48% of non-Hispanic whites reported that they had heard about genetic testing, followed by 31% of blacks, 28% of Asians, and 19% of Hispanics. Education and nativity/length of residency in the U.S. explained 26% and 30% of the gap between whites and Hispanics, respectively. Education accounted for 22% of the white-black gap, with residential region explaining another 11%. Nativity/length of residency in the U.S. explained 51% of the white-Asian gap. Conclusions: The relative importance of Factors contributing to racial and ethnic disparities in genetic testing awareness is specific to the particular groups under comparison. Diverse, culturally competent approaches are needed to improve awareness for different racial and ethnic groups. (Am J Prev Med 2009;37(6):524-530) (C) 2009 American Journal of Preventive Medicine C1 [Pagan, Jose A.] Univ N Texas, Hlth Sci Ctr, Dept Hlth Management & Policy, Sch Publ Hlth, Ft Worth, TX 76107 USA. [Li, Lifeng] Univ Texas Pan Amer, Dept Econ & Finance, Coll Business Adm, Edinburg, TX 78541 USA. [Su, Dejun] Univ Texas Pan Amer, Dept Sociol, Edinburg, TX 78541 USA. [Armstrong, Katrina; Asch, David A.] Univ Penn, Div Gen Internal Med, Sch Med, Philadelphia, PA 19104 USA. [Armstrong, Katrina; Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Pagan, JA (reprint author), Univ N Texas, Hlth Sci Ctr, Dept Hlth Management & Policy, Sch Publ Hlth, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA. EM jpagan@hsc.unt.edu OI Asch, David/0000-0002-7970-286X FU Agency for Healthcare Research and Quality [R24HS017003]; CDC [H75DP00181201]; Department of Defense Breast Cancer Research Program [W81XW11-064-0334] FX Supported by the Agency for Healthcare Research and Quality (Grant R24HS017003); the CDC (Grant H75DP00181201); and the Department of Defense Breast Cancer Research Program (Grant W81XW11-064-0334). Views and opinions of, and endorsements by, the authors do not reflect those of the Agency for Healthcare Research and Quality, the CDC, the U.S. Army, or the Department of Defense. NR 22 TC 30 Z9 30 U1 2 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD DEC PY 2009 VL 37 IS 6 BP 524 EP 530 DI 10.1016/j.amepre.2009.07.021 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 532SJ UT WOS:000272769700009 PM 19944919 ER PT J AU Cordasco, KM Asch, SM Bell, DS Guterman, JJ Gross-Schulman, S Ramer, L Elkayam, U Franco, I Leatherwood, CL Mangione, CM AF Cordasco, Kristina M. Asch, Steven M. Bell, Doug S. Guterman, Jeffrey J. Gross-Schulman, Sandra Ramer, Lois Elkayam, Uri Franco, Idalid Leatherwood, Cianna L. Mangione, Carol M. TI A Low-Literacy Medication Education Tool for Safety-Net Hospital Patients SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article; Proceedings Paper CT Annual Meeting of the Robert Wood Johnson Clinical Scholars CY APR 11, 2008 CL Washington, DC ID CONGESTIVE-HEART-FAILURE; HEALTH LITERACY; ELDERLY PATIENTS; ADHERENCE; KNOWLEDGE; INTERVENTION; PREVENTION; DISCHARGE; REGIMENS; OUTCOMES AB Background: To improve medication adherence in cardiac patients, in partnership with a safety-net provider, this research team developed and evaluated a low-literacy medication education tool. Methods: Using principles of community-based participatory research, the team developed a prototype of a low-literacy hospital discharge medication education tool, customizable for each patient, featuring instruction-specific icons and Pictures of pills. In 2007, a randomized controlled clinical trial was performed, testing the tool's effect on posthospitalization self-reported medication adherence and knowledge, 2 weeks postdischarge in English- and Spanish-speaking safety-net inpatients. To validate the self-report measure, 4 weeks postdischarge, investigators collected self-reports of the number of pills remaining for each medication in a subsample of participants. Nurses rated tool acceptability. Results: Among the 166/210 eligible participants (79%) completing the Week-2 interview, self-reported medication adherence was 70% (95% CI=62%, 79%) in intervention participants and 78% (95% CI=72%, 84%) in controls (p=0.13). Among the 85 participants (31%) completing the Week-4 interview, self-reported pill Counts indicated high adherence (greater than 90%) and did not differ between Study arms. Self-reported adherence was correlated with self-reported pill count in intervention participants (R=0.5, p=0.004) but not in controls (R=0.07, p=0.65). There were no differences by study arm in medication knowledge. The nurses rated the tool as highly acceptable. Conclusions: Although the evaluation did not demonstrate the tool to have any effect on self-reported medication adherence, patients who received the schedule self-reported their medication adherence more accurately, perhaps indicating C1 [Cordasco, Kristina M.; Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Cordasco, Kristina M.; Asch, Steven M.; Bell, Doug S.; Guterman, Jeffrey J.; Franco, Idalid; Leatherwood, Cianna L.; Mangione, Carol M.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Mangione, Carol M.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. [Guterman, Jeffrey J.; Gross-Schulman, Sandra] Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA. [Ramer, Lois; Elkayam, Uri] Los Angeles Cty Univ So Calif, Med Ctr, Los Angeles, CA USA. [Elkayam, Uri] Univ So Calif, Dept Med, Los Angeles, CA USA. RP Cordasco, KM (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd 111G, Los Angeles, CA 90073 USA. EM kcordasco@mednet.ucla.edu RI Bell, Douglas/G-6702-2013 OI Bell, Douglas/0000-0002-5063-8294 FU NIA NIH HHS [P30AG021684, P30AG028748] NR 35 TC 26 Z9 27 U1 3 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD DEC PY 2009 VL 37 IS 6 BP S209 EP S216 DI 10.1016/j.amepre.2009.08.018 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 532SM UT WOS:000272770000005 PM 19896021 ER PT J AU Rosenthal, MS Ross, JS Bilodeau, R Richter, RS Palley, JE Bradley, EH AF Rosenthal, Marjorie S. Ross, Joseph S. Bilodeau, RoseAnne Richter, Rosemary S. Palley, Jane E. Bradley, Elizabeth H. TI Economic Evaluation of a Comprehensive Teenage Pregnancy Prevention Program Pilot Program SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID SAFER CHOICES; UNITED-STATES; MATERNAL AGE; OUTCOMES; SCHOOL; ADOLESCENTS; HIV; STD AB Background: Previous research has Suggested that comprehensive teenage pregnancy prevention programs that address sexual education and life skills development and provide academic Support are effective in reducing births among enrolled teenagers. However, there have been limited data on the costs and cost effectiveness Of Such programs. Purpose: The study used a community-based participation, research approach to develop estimates of the cost-benefit of the Pathways/Senderos Center, a comprehensive neighborhood-based program to prevent unintended pregnancies and promote positive development for adolescents. Methods: Using data from 1997-2003, an in-time intervention analysis was conducted to determine program cost-benefit while teenagers were enrolled; an extrapolation analysis was then used to estimate accrued economic benefits and cost-benefit up to age 30 years. Results: The program operating costs totaled $3,228,152.59 and reduced the teenage childbearing rate from 94.10 to 40.00 per 1000 teenage girls, averting $52,297.84 in total societal costs, with an economic benefit to society from program participation of $2,673,153.11. Therefore, total costs to society exceeded economic benefits by $559,677.05, or $1599.08 per adolescent per year. In an extrapolation analysis, benefits to society exceed costs by $10,474.77 per adolescent per year by age 30 years on average, with social benefits outweighing total social costs by age 20.1 years. Conclusions: This comprehensive teenage pregnancy prevention program is estimated to provide societal economic benefits once participants are young adults, suggesting the need to expand beyond pilot demonstrations and evaluate the long-range cost effectiveness of similarly comprehensive programs when they are implemented more widely in high-risk neighborhoods. (Am J Prev Med 2009;37(6S1):S280-S287) (C) 2009 American journal of Preventive Medicine C1 [Rosenthal, Marjorie S.; Bradley, Elizabeth H.] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06520 USA. [Rosenthal, Marjorie S.] Yale Univ, Sch Med, Div Gen Pediat, New Haven, CT 06520 USA. [Bradley, Elizabeth H.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA. [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, Bronx, NY USA. [Ross, Joseph S.] James J Peters Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. [Bilodeau, RoseAnne] New Britain Teen Pregnancy Prevent Inc, New Britain, CT USA. [Richter, Rosemary S.; Palley, Jane E.] Univ Connecticut, Sch Med, Dept Obstet & Gynecol, Farmington, CT USA. RP Rosenthal, MS (reprint author), Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, Room IE-61 SHM,POB 208088, New Haven, CT 06520 USA. EM marjorie.rosenthal@yale.edu FU Patrick and Catherine Weldon Donaghue Medical Research Foundation [02-102]; National Institute on Aging [K08 AG032886]; American Federation of Aging Research FX Dr. Bradley is supported by a Patrick and Catherine Weldon Donaghue Medical Research Foundation Donaghue Investigator Award (Grant #02-102). Dr. Ross is currently) Supported by the National Institute on Aging (K08 AG032886) and by the American Federation of Aging Research through the Paul B. Beeson Career Development Award Program. NR 31 TC 5 Z9 5 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD DEC PY 2009 VL 37 IS 6 BP S280 EP S287 DI 10.1016/j.amepre.2009.08.014 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 532SM UT WOS:000272770000014 PM 19896030 ER PT J AU Reichmuth, KJ Dopp, JM Barczi, SR Skatrud, JB Wojdyla, P Hayes, D Morgan, BJ AF Reichmuth, Kevin J. Dopp, John M. Barczi, Steven R. Skatrud, James B. Wojdyla, Piotr Hayes, Don, Jr. Morgan, Barbara J. TI Impaired Vascular Regulation in Patients with Obstructive Sleep Apnea SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE hypoxia; sleep; vasodilation; cerebral vascular circulation; regional blood flow ID POSITIVE AIRWAY PRESSURE; ENDOTHELIAL FUNCTION; CEREBROVASCULAR RESPONSES; CHEMOREFLEX SENSITIVITY; SELECTIVE POTENTIATION; VASODILATOR RESPONSES; VENTILATORY RESPONSE; CEREBRAL-ARTERIES; HYPOXIC DILATION; BLOOD-PRESSURE AB Rationale Impaired endothelium-dependent vasodilation has been documented in patients with sleep apnea. This impairment may result in blood flow dysregulation during apnea-induced fluctuations in arterial blood gases. Objectives: To test the hypothesis that hypoxic and hypercapnic vasodilation in the forearm and cerebral circulation are impaired in patients with sleep apnea. Methods: We exposed 20 patients with moderate to severe sleep apnea and 20 control subjects, to isocapnic hypoxia and hyperoxic hypercapnia. A subset of 14 patients was restudied after treatment with continuous positive airway pressure. Measurements and Main Results: Cerebral flow velocity (transcranial Doppler), forearm blood flow (venous occlusion plethysmography), arterial pressure (automated sphygmomanometry), oxygen saturation (pulse oximetry), ventilation (pneumotachograph), and endtidal oxygen and carbon dioxide tensions (expired gas analysis) were measured during three levels of hypoxia and two levels of hypercapnia. Cerebral vasodilator responses to hypoxia (-0.65 +/- 0.44 vs. -1.02 +/- 0.72 [mean +/- SD] units/% saturation; P = 0.03) and bypercapnia (2.01 +/- 0.88 vs. 2.57 +/- 0.89 units/mm Hg; P = 0.03) were smaller in patients versus control subjects. Hypoxic vasodilation in the forearm was also attenuated (-0.05 +/- 0.09 vs. -0.10 +/- 0.09 unit/% saturation; P = 0.04). Hypercapnia did not elicit forearm vasodilation in either group. Twelve weeks of continuous positive airway pressure treatment enhanced hypoxic vasodilation in the cerebral circulation (-0.83 +/- 0.32 vs. -0.46 +/- 0.29 units/% saturation; P = 0.01) and forearm (-0.19 +/- 0.15 vs. -0.02 +/- 0.08 units/% saturation; P = 0.003), and hypercapnic vasodilation in the brain showed a trend toward improvement (2.24 +/- 0.78 vs. 1.76 +/- 0.64 units/mm Hg; P 0.06). Conclusions: Vasodilator responses to chemical stimuli in the cerebral circulation and the forearm are impaired in many patients with obstructive sleep apnea. Some of these impairments can be improved with continuous positive airway pressure. C1 [Reichmuth, Kevin J.; Barczi, Steven R.; Skatrud, James B.; Wojdyla, Piotr; Hayes, Don, Jr.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Dopp, John M.; Morgan, Barbara J.] Middleton Vet Adm Hosp, Madison, WI USA. [Morgan, Barbara J.] Univ Wisconsin, Dept Orthoped & Rehabil, Sch Med & Publ Hlth, Madison, WI USA. RP Morgan, BJ (reprint author), 1300 Univ Ave,5173 Med Sci Ctr, Madison, WI 53706 USA. EM morgan@ortho.wisc.edu FU NHLBI [RO1 HL074072, T32 HL07654]; UW-Madison Institutional Clinical and Translational Science [K12 RR025012]; Office of Research and Development, Clinical Science R&D Service, Department of Veterans Affairs FX Supported by NHLBI grant RO1 HL074072. K.J.R. was supported by NHLBI training grant T32 HL07654 and J.M.D. was supported by UW-Madison Institutional Clinical and Translational Science award K12 RR025012. This research was also supported by the Office of Research and Development, Clinical Science R&D Service, Department of Veterans Affairs. NR 44 TC 42 Z9 43 U1 0 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD DEC 1 PY 2009 VL 180 IS 11 BP 1143 EP 1150 DI 10.1164/rccm.200903-0393OC PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 523WA UT WOS:000272104100016 PM 19745203 ER PT J AU Singh, N Husain, S AF Singh, N. Husain, S. CA AST Infect Dis Community Practice TI Invasive Aspergillosis in Solid Organ Transplant Recipients SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Review DE Aspergillosis; prophylaxis; solid organ transplant; treatment ID COLONY-STIMULATING FACTOR; LIPOSOMAL AMPHOTERICIN-B; CHRONIC GRANULOMATOUS-DISEASE; HEMATOPOIETIC STEM-CELL; BRONCHOALVEOLAR LAVAGE FLUID; SYSTEMIC FUNGAL-INFECTIONS; LUNG TRANSPLANTATION; RISK-FACTORS; INTERFERON-GAMMA; ANTIFUNGAL PROPHYLAXIS C1 [Singh, N.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Singh, N.] Univ Pittsburgh, Pittsburgh, PA USA. [Husain, S.] Univ Toronto, Univ Hlth Network, Div Infect Dis & Multiorgan Transplantat, Toronto, ON, Canada. RP Singh, N (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. EM nis5+@pitt.edu FU Pfizer; Schering Plough; Merck Frost; Astellas FX Singh N.: Grant Support, Pfizer. Husain S.: Grant Support, Pfizer, Schering Plough, Merck Frost, Astellas. NR 123 TC 68 Z9 69 U1 0 U2 6 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD DEC PY 2009 VL 9 BP S180 EP S191 DI 10.1111/j.1600-6143.2009.02910.x PG 12 WC Surgery; Transplantation SC Surgery; Transplantation GA 533ZG UT WOS:000272864500025 PM 20070679 ER PT J AU Singh, N Forrest, G AF Singh, N. Forrest, G. CA AST Infect Dis Community Practice TI Cryptococcosis in Solid Organ Transplant Recipients SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE Cryptococcus; immune reconstitution syndrome; organ transplantation ID IMMUNE RECONSTITUTION SYNDROME; CALCINEURIN-INHIBITOR AGENTS; INVASIVE FUNGAL-INFECTIONS; PULMONARY CRYPTOCOCCOSIS; NEOFORMANS INFECTION; AMPHOTERICIN-B; IN-VITRO; LIVER-TRANSPLANTATION; INFLAMMATORY SYNDROME; PRACTICE GUIDELINES C1 [Singh, N.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Singh, N.] Univ Pittsburgh, Pittsburgh, PA USA. [Forrest, G.] Portland VA Med Ctr, Portland, OR USA. [Forrest, G.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Singh, N (reprint author), VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. EM nis5+@pitt.edu NR 74 TC 32 Z9 32 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD DEC PY 2009 VL 9 BP S192 EP S198 DI 10.1111/j.1600-6143.2009.02911.x PG 7 WC Surgery; Transplantation SC Surgery; Transplantation GA 533ZG UT WOS:000272864500026 PM 20070681 ER PT J AU Travi, BL Osorio, EY Saldarriaga, OA Cadena, H Tabares, CJ Peniche, A Lee, S Melby, PC AF Travi, Bruno L. Osorio, Elvia Yaneth Saldarriaga, Omar A. Cadena, Horacio Javier Tabares, Carlos Peniche, Alex Lee, Shuko Melby, Peter C. TI Clinical, Parasitologic, and Immunologic Evolution in Dogs Experimentally Infected with Sand Fly-Derived Leishmania chagasi Promastigotes SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID CANINE VISCERAL LEISHMANIASIS; CELLULAR IMMUNE-RESPONSE; IGG2 ANTIBODY-RESPONSES; INFANTUM PROMASTIGOTES; MEDIATED-IMMUNITY; ASYMPTOMATIC DOGS; BRAZILIAN DOGS; KALA-AZAR; FOLLOW-UP; INFECTIVITY AB Experimental infection of dogs with Leishmania infantum has yielded heterogeneous clinical, parasitologic, and immunologic results. We studied dogs infected with 10(5) or 10(4) sand fly-derived promastigotes delivered by the intradermal (ID) or intravenous (IV) routes. Total mortality over 1 year post-infection reached 23.8%. The mortality and proportion of sustained polysymptomatic dogs was highest in the IV-10(5) group. The early appearance of polysymptoms was associated with ail increased risk of progression to death. Dissemination of the parasite to lymph nodes was faster, and the subsequent infectivity to sand flies higher, in the IV compared with ID-infected dogs. Parasite-specific IgG1 or IgG2 production was similar among the groups, but higher interferon-gamma (IFN-gamma) and interleukin-10 (IL-10) expression was associated with polysymptomatic dogs. On the basis of the data obtained from this study, a sample size analysis using different endpoints for future vaccine trials is described. C1 [Travi, Bruno L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Cadena, Horacio] Univ Antioquia, SIU, Lab 632, Medellin, Colombia. [Javier Tabares, Carlos] Univ Antioquia, Fac Ciencias Agr, Medellin, Colombia. [Lee, Shuko] S Texas Vet Hlth Care Syst, Res Serv 151, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Dept Vet Affairs Med Ctr, Res Serv, San Antonio, TX 78229 USA. Ctr Int Entrenamiento & Invest Med CIDEIM, Cali 5390, Colombia. RP Travi, BL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM travi@uthscsa.edu FU NIH [AI48823]; [2229-04-11723] FX This work was supported by NIH grant AI48823 awarded to P.C. Melby and Colciencias grant 2229-04-11723 awarded to B. L. Travi. NR 50 TC 13 Z9 13 U1 0 U2 1 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD DEC PY 2009 VL 81 IS 6 BP 994 EP 1003 DI 10.4269/ajtmh.2009.09-0229 PG 10 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 531YN UT WOS:000272709600011 PM 19996427 ER PT J AU Citron, DM Babakhani, F Goldstein, EJC Nagaro, K Sambol, S Sears, P Shue, YK Gerding, DN AF Citron, D. M. Babakhani, F. Goldstein, E. J. C. Nagaro, K. Sambol, S. Sears, P. Shue, Y. -K. Gerding, D. N. TI Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection SO ANAEROBE LA English DT Article; Proceedings Paper CT 9th Biennial Congress of the Anaerobe-Society-of-the-Americas CY JUN 24-27, 2008 CL Long Beach, CA SP Anaerobe Soc Amer DE Clostridium; Difficile; OPT-80; Fidaxomicin; PAR-101; CDI ID IN-VITRO ACTIVITIES; CLOSTRIDIUM-DIFFICILE; METRONIDAZOLE; EPIDEMIC; DIARRHEA; DISEASE; AGENTS; STRAIN AB Background: Clostridium difficile infection (CDI) has been increasing in incidence and severity in recent years, coincident with the spread of a "hypervirulent" strain, REA type BI (ribotype 027, PFGE NAP 1). Exacerbating the problem has been the observation that metronidazole may be showing decreased effectiveness, particularly in the more severe cases. Fidaxomicin is an 18-membered macrocycle currently in phase 3 trials for the treatment of C. difficile infection (CDI). An open-label, phase II study in CDI patients has been completed and the clinical results published. C. difficile organisms were isolated from patient stool specimens and typed by restriction endonuclease analysis (REA) in order to determine the frequency and susceptibility of the C. difficile isolates and their response to treatment. Methods: Fecal samples were plated on CCFA agar for isolation of C. difficile. These isolates were tested for susceptibility to fidaxomicin, vancomycin, and metronidazole using CLSI agar dilution methods and were typed by REA. Results: C. difficile was isolated from 38 of 49 subjects and 16 (42%) were the epidemic C. difficile BI group. The BI strain was distributed approximately equally in the three dosing groups. Overall antibiotic susceptibilities were consistent with the previously reported MIC(90) values for the three antibiotics tested, but the MIC(90) of BI strains was two dilutions higher than non-BI strains for metronidazole and vancomycin (for both antibiotics, MIC(90) was 2 mu g/mL vs. 0.5 mu g/ml, P < 0.01 for metronidazole, P = NS for vancomycin). Clinical cure for BI isolates (11/14, 79%) was not significantly different from non-BI isolates (21/22, 95%). Conclusion: These results underscore the high prevalence of the BI epidemic strain and demonstrate that mild to moderate CDI infection as well as severe disease can be caused by these strains. Fidaxomicin cure rates for subjects with BI and with non-BI strains are similar, although the small numbers of subjects preclude a robust statistical comparison. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Babakhani, F.; Sears, P.; Shue, Y. -K.] Optimer Pharmaceut Inc, San Diego, CA 92121 USA. [Citron, D. M.; Goldstein, E. J. C.] RM Alden Res Lab, Culver City, CA USA. [Nagaro, K.; Sambol, S.; Gerding, D. N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Gerding, D. N.] Loyola Univ, Chicago Stritch Sch Med, Maywood, IL 60153 USA. RP Sears, P (reprint author), Optimer Pharmaceut Inc, 10110 Sorrento Valley Rd Ste, San Diego, CA 92121 USA. EM psears@optimerpharma.com FU NIAID NIH HHS [2 R44 AI063692-02A1] NR 21 TC 31 Z9 32 U1 0 U2 12 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1075-9964 J9 ANAEROBE JI Anaerobe PD DEC PY 2009 VL 15 IS 6 SI SI BP 234 EP 236 DI 10.1016/j.anaerobe.2009.09.005 PG 3 WC Microbiology SC Microbiology GA 547XH UT WOS:000273922700004 PM 19755166 ER PT J AU Sun, BC Derose, SF Liang, LJ Gabayan, GZ Moore, AA Mower, WR Mangione, CM Hoffman, JR AF Sun, Benjamin C. Derose, Stephen F. Liang, Li-Jung Gabayan, Gelareh Z. Moore, Alison A. Mower, William R. Mangione, Carol M. Hoffman, Jerome R. TI Predictors of 30-Day Serious Events in Older Patients With Syncope SO ANNALS OF EMERGENCY MEDICINE LA English DT Article ID EMERGENCY-DEPARTMENT; UNEXPLAINED SYNCOPE; RISK STRATIFICATION; SHORT-TERM; PROSPECTIVE VALIDATION; CLINICAL PREDICTORS; DIAGNOSING SYNCOPE; RULE; MANAGEMENT; POPULATION AB Study objective: We identify predictors of 30-day serious events after syncope in older adults. Methods: We reviewed the medical records of older adults (age >= 60 years) who presented with syncope or near syncope to one of 3 emergency departments (EDs) between 2002 and 2005. Our primary outcome was occurrence of a predefined serious event within 30 days after ED evaluation. We used multivariable logistic regression to identify predictors of 30-day serious events. Results: Of 3,727 potentially eligible patients, 2,871 (77%) met all eligibility criteria. We excluded an additional 287 patients who received a diagnosis of a serious clinical condition while in the ED. In the final study cohort (n=2,584), we identified 173 (7%) patients who experienced a 30-day serious event. High-risk predictors included age greater than 90 years, male sex, history of an arrhythmia, triage systolic blood pressure greater than 160 mm Hg, abnormal ECG result, and abnormal troponin I level. A low-risk predictor was a complaint of near syncope rather than syncope. A risk score, generated by summing high-risk predictors and subtracting the low-risk predictor, can stratify patients into low- (event rate 2.5%; 95% confidence interval [CI] 1.4% to 3.6%), intermediate- (event rate 6.3%; 95% CI 5.1% to 7.5%), and high-risk (event rate 20%; 95% CI 15% to 25%) groups. Conclusion: We identified predictors of 30-day serious events after syncope in adults aged 60 years and greater. A simple score was able to stratify these patients into distinct risk groups and, if externally validated, might have the potential to aid ED decisionmaking. [Ann Emerg Med. 2009;54:769-778.] C1 [Sun, Benjamin C.; Liang, Li-Jung; Gabayan, Gelareh Z.; Moore, Alison A.; Mangione, Carol M.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Sun, Benjamin C.; Gabayan, Gelareh Z.] W Los Angeles Vet Affairs Med Ctr, Dept Med, Los Angeles, CA 90073 USA. [Derose, Stephen F.] Kaiser Permanente So Calif, Div Res & Evaluat, Pasadena, CA USA. [Mower, William R.; Hoffman, Jerome R.] Univ Calif Los Angeles, Ctr Emergency Med, Los Angeles, CA 90024 USA. [Mangione, Carol M.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. RP Sun, BC (reprint author), W Los Angeles Vet Affairs Med Ctr, Dept Med, Off 3214A,Mail Stop 111,Bldg 500,Wing 3E,11301 Wi, Los Angeles, CA 90073 USA. EM bsun@mednet.ucla.edu FU UCLA National Institute of Aging K12 [K12AG001004]; American Geriatrics Society Dennis Jahnigen Career Development [20051687]; Resource Centers for Minority Aging Research/Center for Health Improvement of Minority Elderly (RCMAR/CHIME); National Institutes of Health/National Institute on Aging [P30 AG021684]; UCLA/Drew Project EXPORT; National Institutes of Health/National Center for Minority Health and Health Disparities [P20 MD000182]; UCLA Older Americans Independence Center; NIH/NIA [P30-AG028748]; National Institute on Aging or the National Institutes of Health FX Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article that might create any potential conflict of interest. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement. Dr. Sun is supported by a UCLA National Institute of Aging K12 award (K12AG001004) and an American Geriatrics Society Dennis Jahnigen Career Development Award (20051687). Drs. Mangione and Moore received support from the Resource Centers for Minority Aging Research/Center for Health Improvement of Minority Elderly (RCMAR/CHIME), funded by the National Institutes of Health/National Institute on Aging (P30 AG021684), and from the UCLA/Drew Project EXPORT, funded by the National Institutes of Health/National Center for Minority Health and Health Disparities (P20 MD000182). Dr. Sun received support from the UCLA Older Americans Independence Center, NIH/NIA Grant P30-AG028748, and the content does not necessarily represent the official views of the National Institute on Aging or the National Institutes of Health. NR 39 TC 30 Z9 32 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD DEC PY 2009 VL 54 IS 6 BP 769 EP 778 DI 10.1016/j.annemergmed.2009.07.027 PG 10 WC Emergency Medicine SC Emergency Medicine GA 532FA UT WOS:000272729600004 PM 19766355 ER PT J AU Cohen, ME Bilimoria, KY Ko, CY Richards, K Hall, BL AF Cohen, Mark E. Bilimoria, Karl Y. Ko, Clifford Y. Richards, Karen Hall, Bruce L. TI Variability in Length of Stay After Colorectal Surgery Assessment of 182 Hospitals in the National Surgical Quality Improvement Program SO ANNALS OF SURGERY LA English DT Article ID QUALITY IMPROVEMENT PROGRAM; MEDICAL-CARE; OUTCOMES; SATISFACTION; PERFORMANCE; INFECTION AB Background: Length of postoperative stay (LOS) has gained increasing attention as a potential indicator of surgical efficiency. Our objective was to examine the feasibility of assessing LOS at 182 hospitals to identify institutions with outlying performance. Methods: Patients were identified who underwent colorectal surgery at 182 hospitals participating in the American College of Surgeon's National Surgical Quality Improvement Program (ACS NSQIP) from 2006 to 2007. Regression models for extended LOS (greater than the 75th percentile) were developed to identify hospitals whose ratios of observed to expected events (O/E) were significantly better (low outlier) or worse (high outlier) than expected after adjustment for case mix. To evaluate strategies for evaluating LOS that would be minimally influenced by the occurrence of complications, separate models were developed for patients categorized either by (1) the nonoccurrence or occurrence of any postoperative complication or (2) tercile of preoperative morbidity risk. Results: The 23,098 patients selected for this study were partitioned into groups without complications (0% complications), with complications (100%) or into terciles of preoperative morbidity risk (with 22.4%, 38.7%, and 60.0% of patients having complications, respectively). In general, the greater the complication rate the longer the LOS and the fewer the number of statistical outliers that were identified. Conclusions: ACS NSQIP data can provide individual hospitals with risk-adjusted LOS measures that can be used to identify outlying performance and motivate quality improvement efforts. C1 [Cohen, Mark E.; Bilimoria, Karl Y.; Ko, Clifford Y.; Richards, Karen] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Bilimoria, Karl Y.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hall, Bruce L.] John Cochran Vet Affairs Med Ctr, Dept Surg, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA. [Hall, Bruce L.] Barnes Jewish Hosp, St Louis, MO 63110 USA. [Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO USA. RP Cohen, ME (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St, Chicago, IL 60611 USA. EM markcohen@facs.org NR 26 TC 46 Z9 48 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD DEC PY 2009 VL 250 IS 6 BP 901 EP 907 DI 10.1097/SLA.0b013e3181b2a948 PG 7 WC Surgery SC Surgery GA 526SM UT WOS:000272313700008 PM 19953710 ER PT J AU Azadani, AN Jaussaud, N Matthews, PB Ge, L Guy, TS Chuter, TAM Tseng, EE AF Azadani, Ali N. Jaussaud, Nicolas Matthews, Peter B. Ge, Liang Guy, T. Sloane Chuter, Timothy A. M. Tseng, Elaine E. TI Energy Loss Due to Paravalvular Leak With Transcatheter Aortic Valve Implantation SO ANNALS OF THORACIC SURGERY LA English DT Article ID HEART-VALVE; HEMODYNAMIC PERFORMANCE; MITRAL REGURGITATION; STENOSIS; FEASIBILITY; REPLACEMENT; EXPERIENCE; PROSTHESIS AB Background. Mild to moderate paravalvular leaks commonly occur after transcatheter aortic valve (TAV) implantation. Current TAVs match and may exceed hemodynamic performance of surgically implanted bioprostheses based on pressure gradient and effective orifice area. However, these hemodynamic criteria do not account for paravalvular leaks. We recently demonstrated that TAV implantation within 23 mm Perimount bioprostheses (Edwards Lifesciences, Irvine, CA) yields similar hemodynamics to the 23 mm Perimount valve. However, mild paravalvular leakage was seen after TAV implantation. The present study quantifies energy loss during the entire cardiac cycle to assess the impact of TAV paravalvular leaks on the ventricle. Methods. Four TAVs designed to mimic the 23 mm SAPIEN valve (Edwards Lifesciences) were created. Transvalvular energy loss of 19, 21, and 23 mm Carpentier-Edwards bioprostheses were obtained in vitro within a pulse duplicator as a hemodynamic baseline (n = 4). The 23 mm TAVs were subsequently implanted within the 23 mm bioprostheses to assess energy loss due to paravalvular leak. Results. The 23 mm bioprosthesis demonstrated the least energy loss (213.25 +/- 31.35 mJ) compared with the 19 mm (330.00 +/- 36.97 mJ, p = 0.003) and 21 mm bioprostheses (298.00 +/- 37.25 mJ, p = 0.008). The TAV controls had similar energy loss (241.00 +/- 30.55 mJ, p = 0.17) as the 23 mm bioprostheses. However, after TAV implantation, total energy loss increased to 365.33 +/- 8.02 mJ significantly exceeding the energy loss of the 23 mm bioprosthesis (p < 0.001). Due to mild TAV paravalvular leakage, 39% of energy loss occurred during diastole. Conclusions. Substantial energy loss during diastole occurs due to TAV paravalvular leakage. In the presence of mild paravalvular leakage, TAV implantation imposes a significantly higher workload on the left ventricle than an equivalently sized surgically implanted bioprosthesis. C1 [Tseng, Elaine E.] Univ Calif San Francisco, Med Ctr, Div Cardiothorac Surg, Dept Surg, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Tseng, EE (reprint author), Univ Calif San Francisco, Med Ctr, Div Cardiothorac Surg, Dept Surg, 500 Parnassus Ave,Suite 405W,Box 0118, San Francisco, CA 94143 USA. EM elaine.tseng@ucsfmedctr.org FU American Heart Association; Northern California Institute for Research and Education; Federation/Societe Francaise de Cardiologie; Societe Francaise de Chirurugie Thoracique et Cardio-Vasculaire FX This work was supported by the American Heart Association, Northern California Institute for Research and Education, Federation/Societe Francaise de Cardiologie, and Societe Francaise de Chirurugie Thoracique et Cardio-Vasculaire. We thank Christine Frolich for providing us with normal PERIMOUNT bioprostheses and pericardium. NR 31 TC 20 Z9 20 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD DEC PY 2009 VL 88 IS 6 BP 1857 EP 1863 DI 10.1016/j.athoracsur.2009.08.025 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 522VV UT WOS:000272029100020 PM 19932249 ER PT J AU Azadani, AN Jaussaud, N Matthews, PB Ge, L Guy, TS Chuter, TAM Tseng, EE AF Azadani, Ali N. Jaussaud, Nicolas Matthews, Peter B. Ge, Liang Guy, T. Sloane Chuter, Timothy A. M. Tseng, Elaine E. TI Valve-in-Valve Implantation Using a Novel Supravalvular Transcatheter Aortic Valve: Proof of Concept SO ANNALS OF THORACIC SURGERY LA English DT Article ID EDWARDS PERICARDIAL BIOPROSTHESIS; FAILURE MODES; HEART-VALVE; REPLACEMENT; STENOSIS; POSITION; SURGERY AB Background. Transcatheter valve implantation within degenerated bioprostheses is a potentially promising treatment for high-risk surgical patients. Clinical experience is limited; however, we have shown in vitro that currently available transcatheter aortic valve sizes did not provide acceptable hemodynamics in small bioprostheses. The objective of this study was to develop a new transcatheter valve that would provide good hemodynamics within degenerated bioprostheses. Methods. Supravalvular transcatheter valves were created using a Dacron covered stainless steel stent at the base and trileaflet pericardial leaflets in an open stent above the bioprosthesis. The transcatheter valves were implanted within 19-, 21-, and 23-mm Carpentier-Edwards Perimount bioprostheses with simulated degeneration using BioGlue to achieve a mean pressure gradient of 50 mm Hg. Hemodynamics of valve-in-valve implantation were studied in a pulse duplicator. Results. Supravalvular transcatheter valves successfully relieved bioprosthetic stenosis. Acceptable hemodynamics were achieved with a significant reduction in mean pressure gradient of 54.0 +/- 3.5 to 9.2 +/- 6.3 mm Hg in 23-mm bioprostheses (p < 0.001), from 49.3 +/- 3.1 to 14.4 +/- 4.7 mmHg (p < 0.001) in 21 mm, and from 53.9 +/- 3.8 to 28.3 +/- 9.8 mm Hg (p = 0.013) in 19-mm bioprostheses. Effective orifice area after valve-in-valve implantation increased significantly and was comparable to rereplacement with the same size bioprosthesis. Conclusions. Valve-in-valve implantation was performed using a novel supravalvular transcatheter valve, which successfully relieved bioprosthetic stenosis. The hemodynamics were comparable with standard surgical valve replacement. Further studies are required to assess device safety and efficacy in patients. (Ann Thorac Surg 2009; 88: 1864-70) (C) 2009 by The Society of Thoracic Surgeons C1 [Tseng, Elaine E.] Univ Calif San Francisco, Med Ctr, Div Cardiothorac Surg, Dept Surg, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. RP Tseng, EE (reprint author), Univ Calif San Francisco, Med Ctr, Div Cardiothorac Surg, Dept Surg, 500 Parnassus Ave,Ste 405W,Box 0118, San Francisco, CA 94143 USA. EM elaine.tseng@ucsfmedctr.org FU American Heart Association (AHA); AHA [0565148Y]; Northern California Institute for Research and Education; Federation Francaise de Cardiologie/Societe Francaise de Cardiologie; Societe Francaise de Chirurugie Thoracique et Cardio-Vasculaire FX This work was supported by American Heart Association (AHA) postdoctoral fellowship, AHA Beginning Grant-in-Aid 0565148Y, the Northern California Institute for Research and Education, and Federation Francaise de Cardiologie/Societe Francaise de Cardiologie, Societe Francaise de Chirurugie Thoracique et Cardio-Vasculaire. We thank Christine Frolich for providing us with normal Carpentier-Edwards PERIMOUNT bioprostheses and John Hiebert for providing us with BioGlue. NR 21 TC 22 Z9 22 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD DEC PY 2009 VL 88 IS 6 BP 1864 EP 1870 DI 10.1016/j.athoracsur.2009.08.004 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 522VV UT WOS:000272029100021 PM 19932250 ER PT J AU Galaleldeen, A Strange, RW Whitson, LJ Antonyuk, SV Narayana, N Taylor, AB Schuermann, JP Holloway, SP Hasnain, SS Hart, PJ AF Galaleldeen, Ahmad Strange, Richard W. Whitson, Lisa J. Antonyuk, Svetlana V. Narayana, Narendra Taylor, Alexander B. Schuermann, Jonathan P. Holloway, Stephen P. Hasnain, S. Samar Hart, P. John TI Structural and biophysical properties of metal-free pathogenic SOD1 mutants A4V and G93A SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS LA English DT Article DE X-ray crystallography; Protein structure; Amyotrophic lateral sclerosis; Leu Gehrig's disease; A4V and G93A ID AMYOTROPHIC-LATERAL-SCLEROSIS; ZINC SUPEROXIDE-DISMUTASE; MOTOR-NEURON DEGENERATION; CRYSTALLOGRAPHIC STRUCTURE DETERMINATION; CU,ZN-SUPEROXIDE DISMUTASE; WILD-TYPE; COPPER CHAPERONE; REDUCED FORM; FAMILIAL ALS; AGGREGATION AB Amyotrophic lateral sclerosis (ALS) is a fatal, progressive neurodegenerative disease characterized by the destruction of motor neurons in the spinal cord and brain. A subset of ALS cases are linked to dominant mutations in copper-zinc superoxide dismutase (SOD1). The pathogenic SOD1 variants A4V and G93A have been the foci of multiple Studies aimed at understanding the molecular basis for SOD1-linked ALS. The A4V variant is responsible for the majority of familial ALS cases in North America, causing rapidly progressing Paralysis once symptoms begin and the G93A SOD1 variant is overexpressed in often studied murine models of the disease. Here we report the three-dimensional structures of metal-free A4V and of metal-bound and metal-free G93A SOD1. In the metal-free structures, the metal-binding loop elements are observed to be severely disordered, suggesting that these variants may share mechanisms of aggregation proposed previously for other pathogenic SOD1 proteins. Published by Elsevier Inc. C1 [Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Geriatr Res Educ & Clin Ctr, Dept Vet Affairs, San Antonio, TX 78229 USA. [Galaleldeen, Ahmad; Whitson, Lisa J.; Narayana, Narendra; Taylor, Alexander B.; Schuermann, Jonathan P.; Holloway, Stephen P.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Galaleldeen, Ahmad; Whitson, Lisa J.; Narayana, Narendra; Taylor, Alexander B.; Schuermann, Jonathan P.; Holloway, Stephen P.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Xray Crystallog Core Lab, San Antonio, TX 78229 USA. [Strange, Richard W.; Antonyuk, Svetlana V.; Hasnain, S. Samar] Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England. RP Hart, PJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Geriatr Res Educ & Clin Ctr, Dept Vet Affairs, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM pjhart@biochem.uthscsa.edu OI Antonyuk, Svetlana/0000-0002-2779-9946 FU NIH-NINDS [R01-NS39112]; Motor Neuron Disease Association, U.K.; NIH [T32AG021890-03]; American Foundation for Aging Research; William and Ella Owens Medical Research Foundation; Judith and jean Pape Adams Charitable Foundation; BBSRC; MRC; EPSRC; NWDA; STFC FX This work was supported by grants NIH-NINDS R01-NS39112 (P.J.H.), the Motor Neuron Disease Association, U.K. (S.S.H., R.W.S), and in part by NIH T32AG021890-03 (J.P.S.), the American Foundation for Aging Research (L.J.W.), the William and Ella Owens Medical Research Foundation and the Judith and jean Pape Adams Charitable Foundation (A.G.). The U.K. group is grateful to BBSRC, MRC, EPSRC, NWDA and STFC for financial support and to STFC Daresbury Laboratory for provision of facilities and also thanks Peter A. Doucette and Joan S. Valentine for the gift of G93A SOD1. Support for the X-ray Crystallography Core Laboratory and the Center for Analytical Ultracentrifugation of Macromolecular Assemblies by the UTHSCSA Executive Research Committee and the San Antonio Cancer Institute is also gratefully acknowledged. NR 67 TC 28 Z9 28 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-9861 J9 ARCH BIOCHEM BIOPHYS JI Arch. Biochem. Biophys. PD DEC PY 2009 VL 492 IS 1-2 BP 40 EP 47 DI 10.1016/j.abb.2009.09.020 PG 8 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 527XN UT WOS:000272404600005 PM 19800308 ER PT J AU Green, MF Lee, J Cohen, MS Engel, SA Korb, AS Nuechterlein, KH Wynn, JK Glahn, DC AF Green, Michael F. Lee, Junghee Cohen, Mark S. Engel, Steven A. Korb, Alexander S. Nuechterlein, Keith H. Wynn, Jonathan K. Glahn, David C. TI Functional Neuroanatomy of Visual Masking Deficits in Schizophrenia SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Article ID EVENT-RELATED FMRI; MULTIPLE TRIAL TYPES; BACKWARD-MASKING; UNAFFECTED SIBLINGS; OBJECT RECOGNITION; OCCIPITAL CORTEX; PERFORMANCE; CHANNELS; REPRESENTATION; VULNERABILITY AB Context: Visual masking procedures assess the earliest stages of visual processing. Patients with schizophrenia reliably show deficits on visual masking, and these procedures have been used to explore vulnerability to schizophrenia, probe underlying neural circuits, and help explain functional outcome. Objective: To identify and compare regional brain activity associated with one form of visual masking (ie, backward masking) in schizophrenic patients and healthy controls. Design: Subjects received functional magnetic resonance imaging scans. While in the scanner, subjects performed a backward masking task and were given 3 functional localizer activation scans to identify early visual processing regions of interest (ROIs). Setting: University of California, Los Angeles, and the Department of Veterans Affairs Greater Los Angeles Healthcare System. Participants: Nineteen patients with schizophrenia and 19 healthy control subjects. Main Outcome Measure: The magnitude of the functional magnetic resonance imaging signal during backward masking. Results: Two ROIs (lateral occipital complex [LO] and the human motion selective cortex [hMT vertical bar]) showed sensitivity to the effects of masking, meaning that signal in these areas increased as the target became more visible. Patients had lower activation than controls in LO across all levels of visibility but did not differ in other visual processing ROIs. Using whole-brain analyses, we also identified areas outside the ROIs that were sensitive to masking effects (including bilateral inferior parietal lobe and thalamus), but groups did not differ in signal magnitude in these areas. Conclusions: The study results support a key role in LO for visual masking, consistent with previous studies in healthy controls. The current results indicate that patients fail to activate LO to the same extent as controls during visual processing regardless of stimulus visibility, suggesting a neural basis for the visual masking deficit, and possibly other visual integration deficits, in schizophrenia. C1 [Green, Michael F.; Lee, Junghee; Cohen, Mark S.; Korb, Alexander S.; Nuechterlein, Keith H.; Wynn, Jonathan K.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Nuechterlein, Keith H.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Green, Michael F.; Lee, Junghee; Wynn, Jonathan K.] Vet Affairs Greater Los Angeles Healthcare Syst, Minneapolis, MN USA. [Engel, Steven A.] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA. [Glahn, David C.] Yale Univ, Sch Med, Olin Neuropsychiat Res Ctr, Inst Living, New Haven, CT USA. [Glahn, David C.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. RP Green, MF (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 300 Med Plaza, Los Angeles, CA 90095 USA. EM mgreen@ucla.edu RI Lee, Junghee/C-5226-2014; Wynn, Jonathan/H-3749-2014; Cohen, Mark/C-6610-2011 OI Lee, Junghee/0000-0001-9567-8700; Wynn, Jonathan/0000-0002-1763-8540; Cohen, Mark/0000-0001-6731-4053 FU National Institute of Mental Health [MH43292, MH065707] FX Support for this study came from National Institute of Mental Health grants MH43292 and MH065707 (principal investigator, Dr Green). NR 53 TC 25 Z9 27 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD DEC PY 2009 VL 66 IS 12 BP 1295 EP 1303 PG 9 WC Psychiatry SC Psychiatry GA 529CZ UT WOS:000272494700004 PM 19996034 ER PT J AU McClure, LA Boninger, ML Oyster, ML Williams, S Houlihan, B Lieberman, JA Cooper, RA AF McClure, Laura A. Boninger, Michael L. Oyster, Michelle L. Williams, Steve Houlihan, Bethlyn Lieberman, Jesse A. Cooper, Rory A. TI Wheelchair Repairs, Breakdown, and Adverse Consequences for People With Traumatic Spinal Cord Injury SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Equipment failure; Reference standards; Rehabilitation; Spinal cord injuries; Wheelchairs ID ELECTRIC-POWERED WHEELCHAIRS; ANSI/RESNA STANDARDS; MAINTENANCE; DURABILITY; ACCIDENTS; SAFETY; USERS AB McClure LA, Boninger ML, Oyster ML, Williams S, Houlihan B, Lieberman JA, Cooper RA. Wheelchair repairs, breakdown, and adverse consequences for people with traumatic spinal cord injury. Arch Phys Med Rehabil 2009;90:2034-8. Objectives: To investigate the frequency of repairs that occurred in a 6-month period and the consequences of breakdowns on wheelchair users living with spinal cord injuries (SCIs), and to determine whether certain wheelchair and subject characteristics are associated with an increased number of repairs and adverse consequences. Design: Convenience sample survey. Setting: Sixteen Model Spinal Cord Injury Systems Centers that are part of the national database funded through the Department of Education, National Institute on Disability and Rehabilitation Research. Participants: People with SCI who use a wheelchair for more than 40h/wk (N=2213). Intervention: Not applicable. Main Outcome Measures: The frequency of wheelchair repairs and occurrence of adverse consequences caused by a wheelchair breakdown in a 6-month period. Results: Within a 6-month period, 44.8% of full-time wheelchair users completed a repair, and 8.7% had an adverse consequence occur. People who use power wheelchairs required significantly more repairs (P <.001), and adverse consequences occurred more frequently (P<.001) compared with manual wheelchair users. The presence of power seat functions, and a person's occupational status or sex did not influence the number of repairs or adverse consequences. Conclusions: Frequent repairs and breakdown can negatively impact a person's life by decreasing community participation and threatening health and safety. Mandatory compliance with the American National Standards Institute and the Rehabilitation Engineering and Assistive Technology Society of North America standards, changes in insurance reimbursement policy, and patient and clinician education are necessary to reduce the number of repairs and adverse consequences that occur. C1 [McClure, Laura A.; Boninger, Michael L.; Oyster, Michelle L.; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [McClure, Laura A.; Boninger, Michael L.; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Boninger, Michael L.; Oyster, Michelle L.; Lieberman, Jesse A.; Cooper, Rory A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Williams, Steve; Houlihan, Bethlyn] Boston Univ, Dept Phys Med & Rehabil, Boston, MA 02215 USA. RP Boninger, ML (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 7180 Highland Dr 151R1-H,Bldg 4,2nd Fl, Pittsburgh, PA 15206 USA. EM boninger@pitt.edu OI Boninger, Michael/0000-0001-6966-919X FU National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitation Services, United States Department of Education [H133N000019/H133N060019]; Interdisciplinary Research Training in Assistive Technology [DGE0333420] FX Supported by the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitation Services, United States Department of Education (grant nos. H133N000019/H133N060019) and Interdisciplinary Research Training in Assistive Technology (grant no. DGE0333420). The material presented here is solely the responsibility of the authors and does not necessarily reflect the opinions of the funding agency or the United States Department of Education. NR 27 TC 24 Z9 24 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD DEC PY 2009 VL 90 IS 12 BP 2034 EP 2038 DI 10.1016/j.apmr.2009.07.020 PG 5 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 592YF UT WOS:000277417200009 PM 19969165 ER PT J AU Michalek, K Morshed, SA Latif, R Davies, TF AF Michalek, Krzysztof Morshed, Syed A. Latif, Rauf Davies, Terry F. TI TSH receptor autoantibodies SO AUTOIMMUNITY REVIEWS LA English DT Article DE Thyroid autoimmunity; TSH receptor; Graves' disease; TSHR antibodies; Antibody epitopes; Signal transduction ID THYROID-STIMULATING AUTOANTIBODY; NATIVE THYROTROPIN RECEPTOR; REGULATORY T-CELLS; GRAVES-DISEASE; MONOCLONAL-ANTIBODIES; FOXP3; GENE; AUTOIMMUNITY; ASSOCIATION AB Thyrotropin receptor autoantibodies (TSHR-Abs) of the stimulating variety are the hallmark of Graves' disease. The presence of immune defects leading to synthesis of TSHR-Abs causes hyperthyroidism and is associated with other extrathyroidal manifestations. Further characterization of these antibodies has now been made possible by the generation of monoclonal antibodies with this unique stimulating capacity as well as similar TSHR-Abs not associated with hyperthyroidism. Their present classification divides TSHR-Abs into stimulating, blocking (competing with TSH binding) and neutral (no signaling). Recent studies using monoclonal TSHR-Abs has revealed that stimulating and blocking antibodies bind to the receptor using mostly conformational epitopes, whilst neutral antibodies utilize exclusively linear peptides. Subtle differences in epitopes for stimulating and blocking antibodies account for the diversity of their biological actions. Recently non-classical signaling elicited by neutral antibodies has also been described, raising the need for a new classification of TSHR-Abs. Published by Elsevier B.V. C1 [Michalek, Krzysztof; Morshed, Syed A.; Latif, Rauf; Davies, Terry F.] James J Peters VA Med Ctr, Mt Sinai Sch Med, Thyroid Res Unit, Bronx, NY 10468 USA. RP Davies, TF (reprint author), James J Peters VA Med Ctr, Mt Sinai Sch Med, Thyroid Res Unit, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM terry.davies@mssm.edu FU NIH; NIDDK [DK069713]; VA Merit Award [4535-05-074]; David Owen Segal Endowment FX Supported in part by: NIH grant DK069713 from NIDDK, the VA Merit Award program 4535-05-074 (TFD), and the David Owen Segal Endowment. NR 35 TC 33 Z9 33 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1568-9972 J9 AUTOIMMUN REV JI Autoimmun. Rev. PD DEC PY 2009 VL 9 IS 2 BP 113 EP 116 DI 10.1016/j.autrev.2009.03.012 PG 4 WC Immunology SC Immunology GA 526HA UT WOS:000272277100008 PM 19332151 ER PT J AU Bernardi, RE Lewis, JR Lattal, KM Berger, SP AF Bernardi, Rick E. Lewis, Jason R. Lattal, K. Matthew Berger, S. Paul TI Modafinil reinstates a cocaine conditioned place preference following extinction in rats SO BEHAVIOURAL BRAIN RESEARCH LA English DT Article DE Modafinil; Cocaine; Conditioned place preference; Reinstatement ID DOPAMINE TRANSPORTERS; NUCLEUS-ACCUMBENS; IN-VIVO; MICE; EXPRESSION; WAKEFULNESS; INHIBITORS; MECHANISM; RELEASE; BINDING AB The current study examined whether modafinil would reinstate an extinguished cocaine conditioned place preference (CPP). Following extinction of a cocaine CPP, rats were administered modafinil (128 mg/kg), cocaine (5 mg/kg) or vehicle and given a 60-min reinstatement test. While the effect of cocaine was transient, modafinil robustly reinstated a cocaine CPP following extinction, suggesting that modafinil may induce relapse or increase the vulnerability of addicts to the reinforcing effects of environmental triggers. (C) 2009 Elsevier B.V. All rights reserved. C1 [Bernardi, Rick E.; Lattal, K. Matthew; Berger, S. Paul] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. [Berger, S. Paul] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Lewis, Jason R.; Berger, S. Paul] Portland VA Med Ctr, Dept Psychiat, Portland, OR 97239 USA. RP Bernardi, RE (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, Mail Code L470,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM bernardi@ohsu.edu FU Department of Veterans Affairs Merit Review program [07-1003]; National Institute of Mental Health [R01 MH077111]; National Institute on Drug Abuse [R01 DA025922, T32 DA007262, F31 DA022844] FX This research was supported by a grant from the Department of Veterans Affairs Merit Review program (07-1003) to S. Paul Berger, grants from the National Institute of Mental Health (R01 MH077111) and National Institute on Drug Abuse (R01 DA025922) to K. Matthew Lattal, and grants from the National Institute on Drug Abuse (T32 DA007262 and F31 DA022844) to Rick E. Bernardi. NR 27 TC 23 Z9 23 U1 2 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-4328 J9 BEHAV BRAIN RES JI Behav. Brain Res. PD DEC 1 PY 2009 VL 204 IS 1 BP 250 EP 253 DI 10.1016/j.bbr.2009.05.028 PG 4 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 489XN UT WOS:000269459700030 PM 19482046 ER PT J AU Tomer, Y Menconi, F AF Tomer, Yaron Menconi, Francesca TI Interferon induced thyroiditis SO BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article DE interferon; thyroiditis; autoimmunity ID CHRONIC HEPATITIS-C; HUMAN THYROCYTE CULTURES; CHRONIC VIRAL-HEPATITIS; HIV ENVELOPE PROTEINS; HCV CHRONIC HEPATITIS; GRAVES-DISEASE; ALPHA THERAPY; VIRUS-INFECTION; IFN-ALPHA; AUTOIMMUNE-THYROIDITIS AB Interferon-alpha (IFN alpha) IS used for the treatment of various disorders. most notable chronic hepatitis C Virus (HCV) Infection One of the commonest side effects of IFN alpha therapy is thyroditis, with up to 40% of HCV patients on IFN alpha developing clinical or subclinical disease. In some cases interferon induced thyroiditis (IIT) may result in severe symptomatology necessitating discontinuation of therapy. IIT can manifest as clinical autoimmune thyroiditis, presenting with symptoms of classical Hashimoto's thyroiditis or Graves' disease, or as non-autoimmune thyroiditis Non-autoimmune thyroiditis can manifest as destructive thyroiditis, with early thyrotoxicosis and later hypothyroidism. or as non-autoimmune hypothyroidism While the epidemiology and clinical presentation of IIT have been well characterized the mechanisms causing IIT still poorly understood. It is likely that the hepatitis C Virus (HCV) itself plays a role in the disease, as the association between HCV infection and thyroiditis is well established. It is believed that IFN alpha. induces thyroiditis by both immune stimulatory effects and by direct effects on the thyroid. Early detection and therapy of this condition are Important in order to avoid complications of thyroid disease such as cardiac arrhythmias. (C) 2009 Elsevier Ltd All rights reserved. C1 [Tomer, Yaron] Mt Sinai Sch Med, Div Endocrinol, Dept Med, New York, NY 10029 USA. [Tomer, Yaron] James J Peters VA Med Ctr, New York, NY USA. [Menconi, Francesca] Mt Sinai Med Ctr, Div Endocrinol, New York, NY 10029 USA. RP Tomer, Y (reprint author), Mt Sinai Sch Med, Div Endocrinol, Dept Med, Box 1118,1 Gustave L Levy Pl, New York, NY 10029 USA. FU NIDDK [DK61659]; VA Merit Award FX This work Was Supported in part by: DK61659 from NIDDK and a VA Merit Award (to YT) NR 84 TC 37 Z9 40 U1 1 U2 3 PU BAILLIERE TINDALL PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1521-690X J9 BEST PRACT RES CL EN JI Best Pract. Res. Clin. Endoc. Metab. PD DEC PY 2009 VL 23 IS 6 BP 703 EP 712 DI 10.1016/j.beem.2009.07.004 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 534WL UT WOS:000272928100003 PM 19942147 ER PT J AU Liwanpo, L Hershman, JM AF Liwanpo, Llanyee Hershman, Jerome M. TI Conditions and drugs interfering with thyroxine absorption SO BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article DE thyroxine absorption; interfering drugs; levothyroxine; malabsorption; hypothyroidism ID INTESTINAL-ABSORPTION; CALCIUM-CARBONATE; CELIAC-DISEASE; LEVOTHYROXINE ABSORPTION; HYPOTHYROID PATIENTS; JEJUNOILEAL BYPASS; ALUMINUM HYDROXIDE; THYROID-HORMONE; ORAL THYROXINE; MALABSORPTION AB Food, dietary fibre and espresso coffee interfere with the absorption of levothyroxine. Malabsorptive disorders reported to affect the absorption of levothyroxine Include coeliac: disease, inflammatory bowel disease, lactose intolerance as well as Helicobacter pylon (H. pylori) infection and atrophic gastritis Many commonly used drugs, such as bile acid sequestrants, ferrous sulphate, sucralfate, calcium carbonate, aluminium-containing antacids, phosphate binders, raloxifene and proton-pump inhibitors, have also been shown to interfere with the absorption of levothyroxine (C) 2009 Elsevier Ltd All rights reserved C1 [Liwanpo, Llanyee; Hershman, Jerome M.] VA Greater Los Angeles Healthcare Syst, Dept Endocrinol, Los Angeles, CA 90073 USA. RP Liwanpo, L (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Endocrinol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 45 TC 78 Z9 80 U1 2 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1521-690X EI 1532-1908 J9 BEST PRACT RES CL EN JI Best Pract. Res. Clin. Endoc. Metab. PD DEC PY 2009 VL 23 IS 6 BP 781 EP 792 DI 10.1016/j.beem.2009.06.006 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 534WL UT WOS:000272928100009 PM 19942153 ER PT J AU Spassieva, SD Mullen, TD Townsend, DM Obeid, LM AF Spassieva, Stefka D. Mullen, Thomas D. Townsend, Danyelle M. Obeid, Lina M. TI Disruption of ceramide synthesis by CerS2 down-regulation leads to autophagy and the unfolded protein response SO BIOCHEMICAL JOURNAL LA English DT Article DE autophagy; ceramide; ceramide synthase; endoplasmic reticulum (ER) homoeostasis; growth arrest; unfolded protein response (UPR) ID ENDOPLASMIC-RETICULUM STRESS; LONGEVITY ASSURANCE GENE-1; SQUAMOUS-CELL CARCINOMAS; MEMBRANE-STRUCTURE; MAMMALIAN HOMOLOG; FAMILY-MEMBERS; HUMAN HEAD; DEATH; SPHINGOSINE; ACTIVATION AB Ceramide metabolism has come under recent scrutiny because of its role in cellular stress responses. CerS2 (ceramide synthase 2) is one of the six mammalian isoforms of ceramide synthase and is responsible for the synthesis of VLC (very-long-chain) ceramides, e.g. C(24), C(24:1). To study the role of CerS2 in ceramide metabolism and cellular homoeostasis, we down-regulated CerS2 using siRNA (small interfering RNA) and examined several aspects of sphingolipid metabolism and cell stress responses. CerS2 down-regulation had a broad effect on ceramide homoeostasis, not just on VLC ceramides. Surprisingly, CerS2 down-regulation resulted in significantly increased LC (long-chain) ceramides, e.g. C(14), C(16), and our results suggested that the increase was due to a ceramide synthase-independent mechanism. CerS2-down-regulation-induced LC ceramide accumulation resulted in growth arrest which was not accompanied by apoptotic cell death. Instead, cells remained viable, showing induction of autophagy and activation of PERK [PKR (double-stranded-RNA-dependent protein kinase)-like endoplasmic reticulum kinase] and IRE1 (inositol-requiring 1) pathways [the latter indicating activation of the UPR (unfolded protein response)]. C1 [Spassieva, Stefka D.; Mullen, Thomas D.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Townsend, Danyelle M.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA. [Obeid, Lina M.] Ralph H Johnson Vet Affairs Hosp, Div Gen Internal Med, Charleston, SC 29401 USA. [Obeid, Lina M.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. EM obeidl@musc.edu OI obeid, lina/0000-0002-0734-0847 FU National Institutes of Health [AG016583, ES016975-01] FX This work was supported by the National Institutes of Health [grant numbers AG016583 (to L. M. O.), ES016975-01 (to T D. M.)], and in pan by the Office of Research and Development, Department of Veterans Affairs, Ralph H. Johnson VA Medical Center, Charleston, SC, U.S.A. [MERIT Award (to L. M. O.)]. NR 48 TC 56 Z9 57 U1 0 U2 1 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0264-6021 J9 BIOCHEM J JI Biochem. J. PD DEC 1 PY 2009 VL 424 BP 273 EP 283 DI 10.1042/BJ20090699 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 524HT UT WOS:000272135100012 PM 19728861 ER PT J AU Janckila, AJ Yam, LT AF Janckila, Anthony J. Yam, Lung T. TI Biology and Clinical Significance of Tartrate-Resistant Acid Phosphatases: New Perspectives on an Old Enzyme SO CALCIFIED TISSUE INTERNATIONAL LA English DT Review DE Tartrate-resistant acid phosphatase; Osteoclast; Bone resorption; Macrophage; Inflammation ID MICROPHTHALMIA TRANSCRIPTION FACTOR; BONE-RESORPTION MARKER; BREAST-CANCER-PATIENTS; CHRONIC KIDNEY-DISEASE; MONITORING ALENDRONATE TREATMENT; RANKL-INDUCED TRANSCRIPTION; HUMAN OSTEOCLAST CULTURES; ROS-GENERATING ACTIVITY; HAIRY-CELL LEUKEMIA; STAGE RENAL-DISEASE AB Type 5 tartrate-resistant acid phosphatase (TRAP) has been a clinically relevant biomarker for about 50 years. It has always been a reliable and specific cytochemical marker for hairy cell leukemia and for differentiated cells of monocytic lineage. Only recently has the test for serum TRAP activity been accepted as sensitive and specific enough for clinical use as a marker of osteoclasts and bone resorption. This has come about through steady advances in knowledge about TRAP enzymology, structure, function, and molecular regulation and a consequent appreciation that TRAP isoforms 5a and 5b have very different clinical significance. As a measure of osteoclast number and bone resorption, TRAP 5b has diagnostic and prognostic applications in osteoporosis, cancers with bone metastasis, chronic renal failure, and perhaps other metabolic and pathologic bone diseases. Serum TRAP 5a, on the other hand, has no relationship to bone metabolism but seems instead to be a measure of activated macrophages and chronic inflammation. Exploration of the real clinical usefulness of serum TRAP 5a for diagnosis and disease management in a wide variety of chronic inflammatory diseases is only now beginning. This perspective traces the important basic scientific developments that have led up to the refinement of serum TRAP isoform immunoassays and their validation as biomarkers of disease. Many unanswered questions remain, providing a wealth of opportunity for continued research of this multifaceted enzyme. C1 [Janckila, Anthony J.; Yam, Lung T.] US Dept Vet Affairs, Special Hematol Lab, Med Ctr, Louisville, KY 40206 USA. [Janckila, Anthony J.] Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40292 USA. [Yam, Lung T.] Univ Louisville, Dept Med, Louisville, KY 40292 USA. RP Janckila, AJ (reprint author), US Dept Vet Affairs, Special Hematol Lab, Med Ctr, 800 Zorn Ave, Louisville, KY 40206 USA. EM anthony.janckila@va.gov; lung.yam@va.gov FU U.S. Department of Veterans Affairs; Clinical Research Foundation FX The authors fondly acknowledge the long friendship and collaborations of Dr. Chin-Yang Li and Dr. Kwok-Wai `` Bill'' Lam since the initiation of our studies on TRAP. Early success was possible only through their hard work and dedication. The dedication and support of our wives, Barbara and Julia, have been equally important during long hours in the lab. The valuable contributions made in the lab and clinic over the years by colleagues, fellows, residents, students, and associates at the University of Louisville, School of Medicine, are also heartily acknowledged. We also thank Dr. Jussi Halleen and his colleagues and students from the Anatomy Department, University of Turku, who so generously shared their talents, ideas, and data about TRAP and bone metabolism. Dr. Tsu-Yi Chao and members of his Hematology/Oncology Division at the TriService General Hospital in Taipei deserve our many thanks for their tireless efforts to promote clinical research on the application of TRAP in cancer and other diseases. The authors are supported by grants from the Research Service of the U.S. Department of Veterans Affairs and by funds from the Clinical Research Foundation. NR 211 TC 35 Z9 36 U1 1 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0171-967X J9 CALCIFIED TISSUE INT JI Calcif. Tissue Int. PD DEC PY 2009 VL 85 IS 6 BP 465 EP 483 DI 10.1007/s00223-009-9309-8 PG 19 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 527NI UT WOS:000272373400001 PM 19915788 ER PT J AU Echchgadda, I Kota, S DeLa Cruz, I Sabbah, A Chang, T Harnack, R Mgbemena, V Chatterjee, B Bose, S AF Echchgadda, I. Kota, S. DeLa Cruz, I. Sabbah, A. Chang, T. Harnack, R. Mgbemena, V. Chatterjee, B. Bose, S. TI Anticancer oncolytic activity of respiratory syncytial virus SO CANCER GENE THERAPY LA English DT Article DE oncolytic; respiratory syncytial virus; anticancer; prostate cancer; apoptosis ID HUMAN PROSTATE-CANCER; INNATE ANTIVIRAL RESPONSE; NEWCASTLE-DISEASE VIRUS; LUNG EPITHELIAL-CELLS; KAPPA-B ACTIVATION; MEDIATED APOPTOSIS; CASPASE ACTIVATION; TYPE-3 INFECTION; EXPRESSION; REPLICATION AB Oncolytic virotherapy is an emerging biotherapeutic platform for cancer treatment, which is based on selective infection/killing of cancer cells by viruses. Herein we identify the human respiratory syncytial virus (RSV) as an oncolytic virus. Using prostate cancer models, we show dramatic enhancement of RSV infectivity in vitro in the androgen-independent, highly metastatic PC-3 human prostate cancer cells compared to the non-tumorigenic RWPE-1 human prostate cells. The oncolytic efficiency of RSV was established in vivo using human prostate tumor xenografts in nude mice. Intratumoral and intraperitoneal injections of RSV led to a significant regression of prostate tumors. Furthermore, enhanced viral burden in PC-3 cells led to selective destruction of PC-3 cancer cells in vitro and in xenograft tumors in vivo due to apoptosis triggered by the downregulation of nuclear factor-kappa B (NF-kappa B) activity (and the resulting loss of anti-apoptotic function of NF-kappa B) in RSV-infected PC-3 cells. The intrinsic (mitochondrial) pathway constitutes the major apoptotic pathway; however, the death-receptor-dependent extrinsic pathway, mediated by the paracrine/autocrine action of tumor necrosis factor-alpha produced from infected cells, also partly contributed to apoptosis. Thus, the oncolytic property of RSV can potentially be exploited to develop targeted therapeutics for the clinical management of prostate tumors. Cancer Gene Therapy (2009) 16, 923-935; doi: 10.1038/cgt.2009.34; published online 15 May 2009 C1 [Echchgadda, I.; Kota, S.; Sabbah, A.; Chang, T.; Harnack, R.; Mgbemena, V.; Bose, S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Echchgadda, I.; DeLa Cruz, I.; Chatterjee, B.] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78229 USA. [Chatterjee, B.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Bose, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, 7703 Floyd Curl Dr,MC-7758, San Antonio, TX 78229 USA. EM chatterjee@uthscsa.edu; bose@uthscsa.edu FU American Lung Association National Biomedical Research [RG-49629-N]; NIH [AI069062, CA129246, T32-DE14318, P30 CA54174]; University of Texas Health Science Centre-San Antonio Cancer Institute (SACI) [AG10486, AG19660]; VA Merit Review; Institutional SALSI FX This work was supported by American Lung Association National Biomedical Research Grant (RG-49629-N) (S Bose), NIH grants AI069062 (S Bose), CA129246 (S Bose and B Chatterjee), T32-DE14318 (S Bose and A Sabbah), grant from University of Texas Health Science Centre-San Antonio Cancer Institute (SACI) ( S Bose and B Chatterjee), AG10486 (B Chatterjee), AG19660 (B Chatterjee), VA Merit Review Grant (B Chatterjee) and Institutional SALSI Grant (B Chatterjee). BC is a VA Senior Research Career Scientist. FACS analysis at the Core Facility was supported by the San Antonio Cancer Institute grant from NIH-P30 CA54174. We thank Dr Mark E Peeples (Columbus Children's Hospital and Ohio State University) and Dr Peter L Collins (NIAID, NIH) for providing the GFP-expressing RSV. NR 46 TC 12 Z9 14 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0929-1903 J9 CANCER GENE THER JI Cancer Gene Ther. PD DEC PY 2009 VL 16 IS 12 BP 923 EP 935 DI 10.1038/cgt.2009.34 PG 13 WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity; Research & Experimental Medicine GA 518KZ UT WOS:000271691900006 PM 19444304 ER PT J AU Wiederhold, NP Thornton, CR Najvar, LK Kirkpatrick, WR Bocanegra, R Patterson, TF AF Wiederhold, Nathan P. Thornton, Christopher R. Najvar, Laura K. Kirkpatrick, William R. Bocanegra, Rosie Patterson, Thomas F. TI Comparison of Lateral Flow Technology and Galactomannan and (1 -> 3)-beta-D-Glucan Assays for Detection of Invasive Pulmonary Aspergillosis SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID NEUTROPENIC PATIENTS; ENZYME-IMMUNOASSAY; ANTIFUNGAL THERAPY; FUNGAL-INFECTIONS; DIAGNOSIS; LEUKEMIA AB We compared a lateral flow device to galactomannan and (1 -> 3)-beta-D-glucan assays to detect invasive aspergillosis in an established guinea pig model of pulmonary disease. The lateral flow device became positive earlier ( =day 3) than the (1 -> 3)-beta-D-glucan and galactomannan assays ( day 5), with all samples positive by each assay on day 7. C1 [Wiederhold, Nathan P.; Najvar, Laura K.; Kirkpatrick, William R.; Bocanegra, Rosie; Patterson, Thomas F.] UTHSCSA, San Antonio, TX 78229 USA. [Wiederhold, Nathan P.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA. [Thornton, Christopher R.] Univ Exeter, Exeter, Devon, England. [Najvar, Laura K.; Kirkpatrick, William R.; Bocanegra, Rosie; Patterson, Thomas F.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Wiederhold, NP (reprint author), UTHSCSA, PERC MC 6220,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM wiederholdn@uthscsa.edu OI Wiederhold, Nathan/0000-0002-2225-5122 FU National Institute of Allergy and Infectious Diseases, National Institutes of Health [N01-AI-30041]; CyDex Pharmaceuticals; Pfizer; Schering-Plough; Basilea; Merck; Toyoma FX N. P. W. has received research support from CyDex Pharmaceuticals, Pfizer, and Schering-Plough. T. F. P. has received research support from Basilea, Merck, Pfizer, and Schering-Plough, has received speaker fees from Merck and Pfizer, and has been a consultant for Basilea, Merck, Pfizer, and Toyoma. L. K. N., W. R. K., and R. B. have no such disclosures to report. NR 9 TC 27 Z9 29 U1 0 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD DEC PY 2009 VL 16 IS 12 BP 1844 EP 1846 DI 10.1128/CVI.00268-09 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 524QG UT WOS:000272157200020 PM 19793899 ER PT J AU Sun, HY Alexander, BD Lortholary, O Dromer, F Forrest, GN Lyon, GM Somani, J Gupta, KL del Busto, R Pruett, TL Sifri, CD Limaye, AP John, GT Klintmalm, GB Pursell, K Stosor, V Morris, MI Dowdy, LA Munoz, P Kalil, AC Garcia-Diaz, J Orloff, S House, AA Houston, S Wray, D Huprikar, S Johnson, LB Humar, A Razonable, RR Husain, S Singh, N AF Sun, Hsin-Yun Alexander, Barbara D. Lortholary, Olivier Dromer, Francoise Forrest, Graeme N. Lyon, G. Marshall Somani, Jyoti Gupta, Krishan L. del Busto, Ramon Pruett, Timothy L. Sifri, Costi D. Limaye, Ajit P. John, George T. Klintmalm, Goran B. Pursell, Kenneth Stosor, Valentina Morris, Michelle I. Dowdy, Lorraine A. Munoz, Patricia Kalil, Andre C. Garcia-Diaz, Julia Orloff, Susan House, Andrew A. Houston, Sally Wray, Dannah Huprikar, Shirish Johnson, Leonard B. Humar, Atul Razonable, Raymund R. Husain, Shahid Singh, Nina TI Lipid Formulations of Amphotericin B Significantly Improve Outcome in Solid Organ Transplant Recipients with Central Nervous System Cryptococcosis SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID INVASIVE FUNGAL-INFECTIONS; HEMATOPOIETIC STEM-CELL; NEOFORMANS INFECTION; MENINGITIS; COMBINATION; AIDS; PROPHYLAXIS; MANAGEMENT; TOXICITY; AMBISOME AB Background. Whether outcome of central nervous system (CNS) cryptococcosis in solid organ transplant recipients treated with lipid formulations of amphotericin B is different from the outcome of the condition treated with amphotericin B deoxycholate (AmBd) is not known. Methods. We performed a multicenter study involving a cohort comprising consecutive solid organ transplant recipients with CNS cryptococcosis. Results. Of 75 patients treated with polyenes as induction regimens, 55 (73.3%) received lipid formulations of amphotericin B and 20 (26.7%) received AmBd. Similar proportions of patients in both groups had renal failure at baseline (P = .94). Overall, mortality at 90 days was 10.9% in the group that received lipid formulations of amphotericin B and 40.0% in the group that received AmBd. In univariate analysis, nonreceipt of calcineurin inhibitors (P = .034), renal failure at baseline (P = .016), and fungemia (P = .003) were significantly associated with mortality. Compared with AmBd, lipid formulations of amphotericin B were associated with a lower mortality (P = .007). Mortality did not differ between patients receiving lipid formulations of amphotericin B with or without flucytosine (P = .349). In stepwise logistic regression analysis, renal failure at baseline (odds ratio [OR], 4.61; 95% confidence interval [CI], 1.02-20.80; P = .047) and fungemia (OR, 10.66; 95% CI, 2.08-54.55; P = .004) were associated with an increased mortality, whereas lipid formulations of amphotericin B were associated with a lower mortality (OR, 0.11; 95% CI, 0.02-0.57; P = .008). Conclusions. Lipid formulations of amphotericin B were independently associated with better outcome and may be considered as the first-line treatment for CNS cryptococcosis in these patients. C1 [Husain, Shahid; Singh, Nina] Univ Pittsburgh, Pittsburgh, PA USA. [Sun, Hsin-Yun; Singh, Nina] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Alexander, Barbara D.] Duke Univ, Med Ctr, Durham, NC USA. [Forrest, Graeme N.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Lyon, G. Marshall; Somani, Jyoti] Emory Univ, Atlanta, GA 30322 USA. [del Busto, Ramon] Henry Ford Hosp, Detroit, MI 48202 USA. [Johnson, Leonard B.] St Johns Hosp, Detroit, MI USA. [Pruett, Timothy L.; Sifri, Costi D.] Univ Virginia, Charlottesville, VA USA. [Limaye, Ajit P.] Univ Washington, Seattle, WA 98195 USA. [Klintmalm, Goran B.] Baylor Univ, Med Ctr, Dallas, TX USA. [Pursell, Kenneth] Univ Chicago, Chicago, IL 60637 USA. [Stosor, Valentina] Northwestern Univ, Chicago, IL 60611 USA. [Morris, Michelle I.; Dowdy, Lorraine A.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA. [Houston, Sally] Tampa Gen Hosp, Tampa, FL 33606 USA. [Kalil, Andre C.] Univ Nebraska, Omaha, NE 68182 USA. [Garcia-Diaz, Julia] Alton Ochsner Med Fdn & Ochsner Clin, New Orleans, LA 70121 USA. [Orloff, Susan] Oregon Hlth & Sci Univ, Portland, OR USA. [Wray, Dannah] Med Univ S Carolina, Charleston, SC 29425 USA. [Huprikar, Shirish] Mt Sinai Med Ctr, New York, NY 10029 USA. [Razonable, Raymund R.] Mayo Clin, Rochester, MN USA. [Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan. [Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan. [Dromer, Francoise] Inst Pasteur, Paris, France. [Lortholary, Olivier] Hop Necker Enfants Malad, Fac Med Paris Descartes, Paris, France. [Lortholary, Olivier] Hop Necker Enfants Malad, Inst Pasteur, Paris, France. [Gupta, Krishan L.] Postgrad Inst Med Educ & Res, Chandigarh 160012, India. [John, George T.] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India. [Munoz, Patricia] Hosp Gen Univ Gregorio Maranon, Madrid, Spain. [Munoz, Patricia] CIBER Enfermedades Resp, Madrid, Spain. [House, Andrew A.] Univ Western Ontario, London, ON, Canada. [Humar, Atul] Toronto Gen Hosp, Univ Hlth Network, Toronto, ON, Canada. RP Singh, N (reprint author), VA Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM nis5@pitt.edu RI Garcia-Diaz, Julia/D-3555-2011 OI SUN, HSIN-YUN/0000-0003-0074-7721; Munoz Garcia, Patricia Carmen/0000-0001-5706-5583 FU National Institutes of Health, National Institute of Allergy and Infectious Diseases [R01 AI 054719-01] FX National Institutes of Health, National Institute of Allergy and Infectious Diseases (R01 AI 054719-01 to N.S.) NR 36 TC 28 Z9 28 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 1 PY 2009 VL 49 IS 11 BP 1721 EP 1728 DI 10.1086/647948 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 515XC UT WOS:000271505200015 PM 19886800 ER PT J AU Bryant, MS Rintala, DH Lai, EC Protas, EJ AF Bryant, M. S. Rintala, D. H. Lai, E. C. Protas, E. J. TI An evaluation of self-administration of auditory cueing to improve gait in people with Parkinson's disease SO CLINICAL REHABILITATION LA English DT Article ID CUES; INDIVIDUALS; STIMULATION; METRONOME; STATE AB Objective: To evaluate a self-administration of auditory cueing on gait difficulties in people with Parkinson's disease over a one-week period. Design: Single group pre and post test. Setting: Research lab, community. Participants: Twenty-one individuals with Parkinson's disease. Interventions: Self-application of an auditory pacer set at a rate 25% faster than preferred cadence. Main outcome measures: Self-selected gait speed, cadence, stride length, and double support time with and without the pacer at the initial visit and after one week of pacer use. Results: During the initial visit, the auditory pacer improved gait speed (79.57 (18.13) cm/s vs. 94.02 (22.61) cm/s, P<0.0005), cadence (102.88 (11.34) step/min vs. 109.22 (10.23) steps/min, P=0.036) and stride length (94.33 (21.31) cm vs. 103.5 (22.65) cm, P=0.012). After one week, preferred gait speed was faster than the initial preferred speed (79.57 (18.13) vs. 95.20 (22.23) cm/s, P<0.0005). Stride length was significantly increased (94.33 (21.31) vs. 107.67 (20.01) cm, P=0.001). Double support time was decreased from 21.73 (5.23) to 18.94 (3.59)% gait cycle, P=0.016. Conclusion: Gait performance in people with Parkinson's disease improved significantly after walking with the auditory pacer for one week. C1 [Bryant, M. S.; Protas, E. J.] Univ Texas Med Branch, Sch Hlth Profess, Galveston, TX USA. [Bryant, M. S.; Rintala, D. H.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Lai, E. C.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Lai, E. C.] Michael E DeBakey Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Houston, TX USA. RP Bryant, MS (reprint author), 2002 Holcombe Blvd,Rehabil Res 153, Houston, TX 77030 USA. EM mon.bryant@yahoo.com FU National Institute on Disability and Rehabilitation Research (NIDRR) [H133P020003-05, K12HD055929] FX We thank the Michael E DeBakey VA Medical Center Parkinson's Disease Research, Education and Clinical Center and the Houston Area Parkinson Society (HAPS) for their cooperation in the recruitment of the participants. This work was supported partially by the National Institute on Disability and Rehabilitation Research (NIDRR) Grant #H133P020003-05 and the K12HD055929. NR 21 TC 8 Z9 8 U1 0 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0269-2155 J9 CLIN REHABIL JI Clin. Rehabil. PD DEC PY 2009 VL 23 IS 12 BP 1078 EP 1085 DI 10.1177/0269215509337465 PG 8 WC Rehabilitation SC Rehabilitation GA 531AA UT WOS:000272632900003 PM 19786421 ER PT J AU Saft, H Stein, S Golden, J Ryan, G Lorenz, K Wenger, N Asch, S AF Saft, Howard Stein, Susan Golden, Joya Ryan, Gery Lorenz, Karl Wenger, Neil Asch, Steven TI PATIENT AND FAMILY CENTERED COMMUNICATION AND DECISION MAKING IN A COUNTY INTENSIVE CARE UNIT: A MICROSYSTEM MODEL SO CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT 39th Critical Care Congress of the Society-of-Critical-Care-Medicine CY JAN 09-13, 2010 CL Miami, FL SP Soc Critical Care Med, Pfizer Inc, Hospira Inc, Lippincott Williams & Wilkins C1 [Saft, Howard; Golden, Joya; Lorenz, Karl; Asch, Steven] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA. [Stein, Susan] Olive Viw Med Ctr, Sylmar, CA USA. [Ryan, Gery] RAND Corp, Santa Monica, CA 90406 USA. [Wenger, Neil] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0090-3493 J9 CRIT CARE MED JI Crit. Care Med. PD DEC PY 2009 VL 37 IS 12 SU S MA 810 BP A396 EP A396 PG 1 WC Critical Care Medicine SC General & Internal Medicine GA 529IS UT WOS:000272509900774 ER PT J AU Helfand, M Aguilar-Gaxiola, SA Selker, HP AF Helfand, Mark Aguilar-Gaxiola, Sergio A. Selker, Harry P. TI Comparative Effectiveness Research: An Approach to Avoiding "Overgeneralized Medicine" SO CTS-CLINICAL AND TRANSLATIONAL SCIENCE LA English DT Editorial Material C1 [Helfand, Mark] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Helfand, Mark] Portland VA Med Ctr, Portland, OR USA. [Aguilar-Gaxiola, Sergio A.] Univ Calif Davis, Sch Med, Davis, CA 95616 USA. [Selker, Harry P.] Tufts Univ, Sch Med, Medford, MA 02155 USA. [Selker, Harry P.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA. RP Helfand, M (reprint author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA. EM mark.helfand@va.gov FU NCRR NIH HHS [KL2 RR025751, UL1 RR024140, UL1 RR024140-01, UL1 RR024146, UL1 RR025742] NR 7 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1752-8054 J9 CTS-CLIN TRANSL SCI JI CTS-Clin. Transl. Sci. PD DEC PY 2009 VL 2 IS 6 BP 444 EP 445 DI 10.1111/j.1752-8062.2009.00158.x PG 2 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 541DM UT WOS:000273393600017 PM 20443938 ER PT J AU Thase, ME AF Thase, Michael E. TI Does Concomitant Antidepressant Therapy Enhance Response to Electroconvulsive Therapy? SO CURRENT PSYCHIATRY REPORTS LA English DT Editorial Material C1 [Thase, Michael E.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Center, Philadelphia, PA USA. RP Thase, ME (reprint author), 3535 Market St,Suite 670, Philadelphia, PA 19104 USA. EM thase@mail.med.upenn.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD DEC PY 2009 VL 11 IS 6 BP 423 EP 425 PG 3 WC Psychiatry SC Psychiatry GA V16XT UT WOS:000207903000001 PM 19909662 ER PT J AU Rother, KI Spain, LM Wesley, RA Digon, BJ Baron, A Chen, K Nelson, P Dosch, HM Palmer, JP Brooks-Worrell, B Ring, M Harlan, DM AF Rother, Kristina I. Spain, Lisa M. Wesley, Robert A. Digon, Benigno J., III Baron, Alain Chen, Kim Nelson, Patric Dosch, H. -Michael Palmer, Jerry P. Brooks-Worrell, Barbara Ring, Michael Harlan, David M. TI Effects of Exenatide Alone and in Combination With Daclizumab on beta-Cell Function in Long-Standing Type 1 Diabetes SO DIABETES CARE LA English DT Article ID ANTI-CD3 MONOCLONAL-ANTIBODY; NOD MICE; EXENDIN-4; REPLICATION; ONSET; IMMUNOSUPPRESSION; TRANSPLANTATION; REGENERATION; RESPONSES; REVERSAL AB OBJECTIVE - in patients with long-standing type 1 diabetes, we investigated whether improved P-cell function can be achieved by combining intensive insulin therapy with agents that may 1) promote beta-cell growth and/or limit beta-cell apoptosis and 2) weaken the anti-beta-cell autoimmunity. RESEARCH DESIGN AND METHODS - For this Study, 20 individuals (mean age 39.5 +/- 11.1. years) with long-standing type I diabetes (21.3 +/- 10.7 years) were enrolled in this prospective open-label crossover trial. After achieving optimal blood glucose control, 16 subjects were randomized to exenatide with or Without daclizumab. Endogenous insulin production was determined by repeatedly measuring serum C-peptide. RESULTS - In 85% of individuals with long-standing type 1. diabetes who were screened for participation in this trial, C-peptide levels >= 0.05 ng/ml (0.02 nmol/1) were found. Residual P-cells responded to physiological (mixed-meal) and pharmacological (arginine) stimuli. During exenatde treatment, patients lost 4.1 +/- 2.9 kg body wt and insulin requirements declined significantly (total daily close on exenatide 0.48 +/- 0.11 Vs. 0.55 +/- 0.13 units . kg(-1) . day(-1) without exenatide; P = 0.0062). No signs of further activation of the underlying autoimmune disease were observed. Exenatide delayed gastric emptying, suppressed endogenous incretin levels, but did not increase C-peptide secretion. CONCLUSIONS - In long-standing type 1. diabetes, which remains an active autoimmune disease even decades after its onset, surviving beta-cells Secrete insulin in a physiologically regulated manner. However, the combination of intensified insulin therapy, exenatide, and daclizumab did not induce improved function of these remaining beta-cells. C1 [Rother, Kristina I.; Spain, Lisa M.; Wesley, Robert A.; Digon, Benigno J., III; Ring, Michael; Harlan, David M.] NIDDK, NIH, Bethesda, MD 20892 USA. [Baron, Alain; Chen, Kim; Nelson, Patric] Amylin Pharmaceut, San Diego, CA USA. [Dosch, H. -Michael] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Palmer, Jerry P.; Brooks-Worrell, Barbara] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Rother, KI (reprint author), NIDDK, NIH, Bethesda, MD 20892 USA. EM kristina.rother@nih.gov FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Clinical Center/Nadonal Institutes of Health FX We thank Rebecca J. Brown for her help with manuscript preparation; Patricia Swanson and Terri Wakefield for protocol management; Janet Lee, Pam COSLner, and Pamela Brooks for patient care and sample processing; and, most importantly, our patients. NR 25 TC 63 Z9 69 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD DEC PY 2009 VL 32 IS 12 BP 2251 EP 2257 DI 10.2337/dc09-0773 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 532YH UT WOS:000272786600021 PM 19808924 ER PT J AU Taborsky, GJ Mei, Q Hackney, DJ Figlewicz, DP LeBoeuf, R Mundinger, TO AF Taborsky, G. J., Jr. Mei, Q. Hackney, D. J. Figlewicz, D. P. LeBoeuf, R. Mundinger, T. O. TI Loss of islet sympathetic nerves and impairment of glucagon secretion in the NOD mouse: relationship to invasive insulitis SO DIABETOLOGIA LA English DT Article DE Alloxan; Diabetes; 6-Hydroxydopamine; Hypoglycaemia; Lymphocytes; Neuropathy; NOD mice; Tyramine ID STREPTOZOTOCIN-DIABETIC RATS; DEFECTIVE GLUCOSE COUNTERREGULATION; NERVOUS-SYSTEM; PERFUSED PANCREAS; BB RATS; HYPOGLYCEMIA; RESPONSES; STIMULATION; ALPHA; CELLS AB We hypothesised that non-obese diabetic mice (NOD) mice have an autoimmune-mediated loss of islet sympathetic nerves and an impairment of sympathetically mediated glucagon responses. We aimed: (1) to determine whether diabetic NOD mice have an early impairment of the glucagon response to insulin-induced hypoglycaemia (IIH) and a coincident loss of islet sympathetic nerves; (2) to determine whether invasive insulitis is required for this nerve loss; and (3) to determine whether sympathetically mediated glucagon responses are also impaired. We measured glucagon responses to both IIH and tyramine in anaesthetised mice. We used immunohistochemistry to quantify islet sympathetic nerves and invasive insulitis. The glucagon response to IIH was markedly impaired in NOD mice after only 3 weeks of diabetes (change, -70%). Sympathetic nerve area within the islet was also markedly reduced at this time (change, -66%). This islet nerve loss was proportional to the degree of invasive insulitis. More importantly, blocking the infiltration prevented the nerve loss. Mice with autoimmune diabetes had an impaired glucagon response to sympathetic nerve activation, whereas those with non-autoimmune diabetes did not. The invasive insulitis seen in diabetic NOD mice causes early sympathetic islet neuropathy. Further studies are needed to confirm that early sympathetic islet neuropathy is responsible for the impaired glucagon response to tyramine. C1 [Taborsky, G. J., Jr.; Mei, Q.; Hackney, D. J.; Figlewicz, D. P.; Mundinger, T. O.] Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol Metab S151, Seattle, WA 98108 USA. [Taborsky, G. J., Jr.; Mei, Q.; Hackney, D. J.; LeBoeuf, R.; Mundinger, T. O.] Univ Washington, Dept Med, Seattle, WA USA. [Figlewicz, D. P.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Taborsky, GJ (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Endocrinol Metab S151, 1660 S Columbian Way, Seattle, WA 98108 USA. EM taborsky@u.washington.edu FU Medical Research Service of the Department of Veterans Affairs; National Institutes of Health [R01 DK 50, 154, P30 DK 17, 047, R01 DK 40, 963, R01 DK 63, 159] FX We thank E. Kirk for managing the NOD mouse colony; E. Haines for glucagon, catecholamine and glucose measurements; A. Zavosh for glucagon measurements; and H. Chang for glucose measurements. This work was supported by the Medical Research Service of the Department of Veterans Affairs and by National Institutes of Health Grants R01 DK 50,154; P30 DK 17,047; R01 DK 40,963 and R01 DK 63,159. NR 46 TC 13 Z9 13 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD DEC PY 2009 VL 52 IS 12 BP 2602 EP 2611 DI 10.1007/s00125-009-1494-5 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 518VR UT WOS:000271723800019 PM 19798480 ER PT J AU Kohen, R Jarrett, ME Cain, KC Jun, SE Navaja, GP Symonds, S Heitkemper, MM AF Kohen, Ruth Jarrett, Monica E. Cain, Kevin C. Jun, Sang-Eun Navaja, Grace P. Symonds, Sarah Heitkemper, Margaret M. TI The Serotonin Transporter Polymorphism rs25531 Is Associated with Irritable Bowel Syndrome SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Irritable bowel syndrome; Functional gastrointestinal disorders; Serotonin transporter; Serotonin; Genetic polymorphism ID OBSESSIVE-COMPULSIVE DISORDER; FUNCTIONAL POLYMORPHISM; GENE POLYMORPHISM; PREDOMINANT; EXPRESSION; PROTEIN; CONSTIPATION; GENOTYPES; 5-HTTLPR; COCAINE AB Irritable bowel syndrome is a frequent gastrointestinal disorder of unknown etiology. The serotonin transporter regulates the intensity and duration of serotonin signaling in the gut and is, therefore, an attractive candidate gene for irritable bowel syndrome. Previous studies investigating the 5-HTTLPR and Stin2 VNTR polymorphisms of the serotonin transporter have proved inconclusive. In this exploratory study we therefore expanded the search for a possible association of the serotonin transporter with irritable bowel syndrome to include not only the 5-HTTLPR and Stin2 VNTR length polymorphisms, but also the functional single nucleotide polymorphism rs25531. We genotyped 186 patients with irritable bowel syndrome and 50 healthy control subjects raging in age from 18 to 70 years. Carriers of the rare G allele of rs25531 had approximately threefold increased odds of irritable bowel syndrome compared with healthy controls (OR 3.3, 95% CI 1.1-9.6). Our findings suggest that further investigation of the possible role of the serotonin transporter in the etiology of IBS is warranted. C1 [Kohen, Ruth; Navaja, Grace P.; Symonds, Sarah] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Kohen, Ruth] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Jarrett, Monica E.; Jun, Sang-Eun; Heitkemper, Margaret M.] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Cain, Kevin C.] Univ Washington, Dept Biostat, Sch Publ Hlth, Seattle, WA 98195 USA. RP Kohen, R (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA. EM ruko@u.washington.edu FU NIH [NR01094, P30 NR04001] FX This study was supported by National Institute of Nursing Research Grants NIH NR01094, P30 NR04001, the NIH Office of Research in Women's Health, and by resources from the Veterans Affairs Puget Sound Health Care System, Seattle, Washington. NR 39 TC 26 Z9 26 U1 2 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD DEC PY 2009 VL 54 IS 12 BP 2663 EP 2670 DI 10.1007/s10620-008-0666-3 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 521LQ UT WOS:000271923300019 PM 19125330 ER PT J AU Radonovich, LJ Perl, TM Davey, V Cohen, H AF Radonovich, Lewis J., Jr. Perl, Trish M. Davey, Victoria Cohen, Howard TI Preventing the Soldiers of Health Care From Becoming Victims on the Pandemic Battlefield: Respirators or Surgical Masks as the Armor of Choice SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article ID NOSOCOMIAL TRANSMISSION; AEROSOL TRANSMISSION; N95 RESPIRATORS; SARS OUTBREAK; INFLUENZA-A; WORKERS; PERFORMANCE; TUBERCULOSIS; PROTECTION; WORKPLACE AB The respiratory protective equipment necessary to protect health care workers from the novel swine-origin influenza A (H1N1) virus is not known. The knowledge gap created by this unanswered question has caused substantial debate and controversy on a global scale, leading public health organizations to feel pressured into issuing decisive recommendations despite a lack of supportive data Changes in clinical practice caused by public health guidance during such high-profile events can be expected to establish a new standard of care Also possible is an unforeseen gradual transition to widespread N95 respirator use, driven by public health pressures instead of science, for all outbreaks of influenza or influenza-like illness Therefore, public health organizations and other influential institutions should take care to avoid making changes to established practice standards, if possible, unless these changes are bolstered by sound scientific evidence Until definitive comparative effectiveness clinical trials are conducted, the answer to this question will continue to remain elusive In the meantime, relying on ethical principles that have been substantiated over time may help guide public health and clinical decisions (Disaster Med Public Health Preparedness 2009,3(Suppl 2) S203-S210) C1 [Radonovich, Lewis J., Jr.] US Dept Vet Affairs, Off Publ Hlth & Environm Hazards, Natl Ctr Occupat Hlth & Infect Control, Vet Hlth Adm, Gainesville, FL 32608 USA. [Perl, Trish M.] Johns Hopkins Univ Hosp, Hosp Epidemiol & Infect Control, Div Infect Dis, Dept Med, Baltimore, MD 21287 USA. [Cohen, Howard] Univ New Haven, New Haven, CT USA. RP Radonovich, LJ (reprint author), US Dept Vet Affairs, Off Publ Hlth & Environm Hazards, Natl Ctr Occupat Hlth & Infect Control, Vet Hlth Adm, 1601 Sw Archer Rd,151B, Gainesville, FL 32608 USA. NR 68 TC 7 Z9 7 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD DEC PY 2009 VL 3 SU 2 BP S203 EP S210 DI 10.1097/DMP.0b013e3181be830c PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 554NC UT WOS:000274440700019 PM 19794307 ER PT J AU Wasterlain, CG Liu, HT Naylor, DE Thompson, KW Suchomelova, L Niquet, J Mazarati, AM Baldwin, RA AF Wasterlain, Claude G. Liu, Hantao Naylor, David E. Thompson, Kerry W. Suchomelova, Lucy Niquet, Jerome Mazarati, Audrey M. Baldwin, Roger A. TI Molecular basis of self-sustaining seizures and pharmacoresistance during status epilepticus: The receptor trafficking hypothesis revisited SO EPILEPSIA LA English DT Meeting Abstract CT Innsbruck Colloquium on Status Epilepticus CY APR 02-04, 2009 CL Innsbruck, AUSTRIA SP CEA, ILAE, Austrian Chapter, Med Univ Innsbruck, Univ Coll London ID GABA(A) RECEPTORS; PERFORANT-PATH; INHIBITION; STIMULATION; SENSITIVITY C1 [Wasterlain, Claude G.; Liu, Hantao; Naylor, David E.; Thompson, Kerry W.; Suchomelova, Lucy; Niquet, Jerome; Mazarati, Audrey M.; Baldwin, Roger A.] VA Greater Los Angeles Hlth Care Syst, Epilepsy Res Lab, Los Angeles, CA 90073 USA. [Wasterlain, Claude G.; Liu, Hantao; Naylor, David E.; Suchomelova, Lucy; Niquet, Jerome; Mazarati, Audrey M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. [Naylor, David E.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. [Thompson, Kerry W.] Occidental Coll, Dept Biol, Los Angeles, CA 90041 USA. EM wasterla@ucla.edu FU BLRD VA [I01 BX000273]; NINDS NIH HHS [NS13515, NS059704] NR 10 TC 14 Z9 17 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0013-9580 J9 EPILEPSIA JI Epilepsia PD DEC PY 2009 VL 50 BP 16 EP 18 DI 10.1111/j.1528-1167.2009.02375.x PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 522BU UT WOS:000271973500009 PM 19941513 ER PT J AU Mansouri, MD Boone, TB Darouiche, RO AF Mansouri, Mohammad D. Boone, Timothy B. Darouiche, Rabih O. TI Comparative Assessment of Antimicrobial Activities of Antibiotic-Treated Penile Prostheses SO EUROPEAN UROLOGY LA English DT Article DE Infection; Minocycline; Penile implant; Rifampin; Vancomycin ID STAPHYLOCOCCUS-AUREUS INFECTION; CENTRAL VENOUS CATHETERS; IN-VIVO EFFICACY; REVISION SURGERY; COLONIZATION; MULTICENTER; PREVENTION; IMPLANTS; DEVICE; MINOCYCLINE AB Background: Although infections associated with penile implants are relatively infrequent, they result in serious medical consequences. Because treatment of these infections usually requires removal of the infected penile implant, prevention of infection is crucial. Since bacterial colonization of the implant is a prelude to clinical infection, antimicrobial modification of the devices may inhibit device colonization and subsequent infection. Objective: We compared the spectrum and durability, both in vitro and in vivo, of two antibiotic-treated penile prostheses: InhibiZone implants pre-impregnated with minocycline and rifampin (M/R) and Titan implants dipped in vancomycin. Design, setting, and participants: 1 x 1-cm cylinder segments of (1) control untreated, (2) M/R-impregnated, and (3) vancomycin-dipped implants were studied. Baseline zones of inhibition (ZI) were determined against clinical isolates, including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant S. epidermidis (MRSE), vancomycin-resistant Enterococcus (VRE), and Escherichia coli. In addition, ZI against methicillin-susceptible S. aureus were compared both in vitro after being washed in a flow chamber and after subcutaneous implantation in rabbits for 1, 2, 7, and 14 d. Measurements: ZI were measured as the diameter of the clear zone around each test device minus the external diameter of the device. Results and limitations: Implants pre-impregnated with M/R displayed a broader spectrum of antimicrobial activity than vancomycin-dipped implants against both gram-positive and-negative bacteria. The M/R-impregnated devices also yielded significantly larger zones of inhibition against S. aureus than vancomycin-dipped implants, both in vitro (p < 0.003) and in vivo throughout the 14-d period of device implantation in rabbits (p <= 0.03). Conclusions: Penile prostheses impregnated with M/R have a broader spectrum in vitro and a more durable antimicrobial activity in vitro and in an animal model than implants dipped in vancomycin. Therefore, along with being a more practical model for incorporating antimicrobials onto the device, the use of implants pre-impregnated with M/R may help reduce the incidence of penile implant infection. (C) 2009 Published by Elsevier B. V. on behalf of European Association of Urology. C1 [Mansouri, Mohammad D.; Boone, Timothy B.; Darouiche, Rabih O.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Mansouri, Mohammad D.; Darouiche, Rabih O.] Baylor Coll Med, Houston, TX 77030 USA. [Boone, Timothy B.] Methodist Hosp, Houston, TX 77030 USA. RP Mansouri, MD (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Spinal Cord Injury Care Line 128,Bldg 100,Room 1B, Houston, TX 77030 USA. EM mdmansouri@aol.com FU Baylor College of Medicine, Houston, Texas; American Medical Systems (AMS), Minnetonka, Minnesota, USA FX This study was supported in part by funds from Baylor College of Medicine, Houston, Texas, and American Medical Systems (AMS), Minnetonka, Minnesota, USA. Penile implant test segments were provided by AMS. NR 32 TC 12 Z9 15 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0302-2838 J9 EUR UROL JI Eur. Urol. PD DEC PY 2009 VL 56 IS 6 BP 1039 EP 1045 DI 10.1016/j.eururo.2008.12.020 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 513AI UT WOS:000271293600036 PM 19135292 ER PT J AU Quesada, A Micevych, P Handforth, A AF Quesada, Arnulfo Micevych, Paul Handforth, Adrian TI C-terminal mechano growth factor protects dopamine neurons: A novel peptide that induces heme oxygenase-1 SO EXPERIMENTAL NEUROLOGY LA English DT Article DE Mechano growth factor; Heme oxygenase-1; Dopamine; Neuroprotection; SH-SY5Y; 6-Hydroxydopamine ID I SPLICE VARIANTS; CELL-DEATH; PARKINSONS-DISEASE; SKELETAL-MUSCLE; OXIDATIVE STRESS; NIGROSTRIATAL DOPAMINE; NITRIC-OXIDE; RODENT MODEL; IGF-I; RAT AB To assess potential efficacy of mechano growth factor (MCF) for chronic neurodegenerative disorders, we Studied whether MGF protects dopamine (DA) neurons subjected to neurotoxic stress. We show that a short 24-amino acid C-terminal peptide of MGF (MGF24) upregulates heme oxygenase-1 (HO-1) expression and protects SH-SY5Y cells against apoptosis and cell loss induced by three DA cell-specific neurotoxins: 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenylpyridinium (MPP(+)), and rotenone. MGF24 maintains the mitochondrial membrane potential and blocks the release of mitochondrial apoptotic-inducing factor into the cytoplasm induced by 6-OHDA, MPPI, and rotenone. Chemical inhibition of HO-1 with zinc protoporphyrin-IX prevents neuroprotection by MGF24 against the three neurotoxins. MGF24 does not activate Akt signaling nor does Akt inhibition block MGF24 protection of SH-SY5Y cells. In 6-OHDA-lesioned rats, central or peripheral MGF24 administration protects against the development of contralateral forelimb under-utilization, reduces ipsilateral nigral DA cell body loss, and attenuates tyrosine hydroxylase fiber loss in the ipsilateral striatum, independent of IGF-1 receptor activation. Peripheral MGF24 administration upregulates HO-1 expression in striatal and midbrain tissue. This report is the first to demonstrate that a small peptide, MGF24, upregulates HO-1, an important cell defense mediator, and protects DA cells, suggesting new strategies for neuroprotection in Parkinson's disease. Published by Elsevier Inc. C1 [Quesada, Arnulfo; Handforth, Adrian] VA Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA 90073 USA. [Quesada, Arnulfo; Micevych, Paul] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. RP Quesada, A (reprint author), VA Greater Los Angeles Healthcare Syst, Neurol Serv, 11301 Wilshire Blvd 151, Los Angeles, CA 90073 USA. EM aquesada@mednet.ucla.edu FU Veterans Affairs FX Supported by a career development award from Veterans Affairs to A.Q. We thank Julie Ogi for assistance with SH-SY5Y cells, and Sepehr Lalezari for assistance with motor behavior scoring, nigral cell Counts, and striatal immunohistochemical measures. We also thank Marie-Francoise Chesselet and Paul Goldspink for helpful discussions. NR 52 TC 30 Z9 35 U1 2 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD DEC PY 2009 VL 220 IS 2 BP 255 EP 266 DI 10.1016/j.expneurol.2009.08.029 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 528FV UT WOS:000272428700008 PM 19735655 ER PT J AU Spiegel, B Camilleri, M Bolus, R Andresen, V Chey, WD Fehnel, S Mangel, A Talley, NJ Whitehead, WE AF Spiegel, Brennan Camilleri, Michael Bolus, Roger Andresen, Viola Chey, William D. Fehnel, Sheri Mangel, Allen Talley, Nicholas J. Whitehead, William E. TI Psychometric Evaluation of Patient-Reported Outcomes in Irritable Bowel Syndrome Randomized Controlled Trials: A Rome Foundation Report SO GASTROENTEROLOGY LA English DT Article ID QUALITY-OF-LIFE; SYMPTOM SEVERITY; ADEQUATE RELIEF; END-POINT; IBS; IMPROVEMENT; VALIDATION; EFFICACY AB BACKGROUND & AIMS: There is debate about how best to measure patient-reported outcomes (PROs) in irritable bowel syndrome (IBS). We pooled data to measure the psychometric properties of IBS end points, including binary responses (eg, "adequate relief') and 50% improvement in symptom severity. METHODS: We pooled data from 12 IBS drug trials involving 10,066 participants. We tested the properties of binary response and 50% improvement end points, including the impact of baseline severity on performance, and measured construct validity using clinical anchors. RESULTS: There were 9044 evaluable subjects (age, 44 years; 85% female; 58% IBS constipation-prominent [IBS-C]; 31% IBS diarrhea-prominent [IBS-D]). Using the binary end point, the proportion responding in the mild, moderate, and severe groups was 42%, 40%, and 38%, respectively (P = .0008). There was no effect of baseline severity on binary response (odds ratio [OR], 0.99; 95% confidence interval [01, 0.99-1.0; P = .07). The proportions reaching 50% improvement in pain were 45%, 41%, and 41%, respectively; there was a small, yet significant, impact of baseline severity (OR, 1.04; 95% CI, 1.03-1.05; P < .0001) that did not meet clinical relevance criteria. Both end points revealed strong construct validity and detected "minimally clinically important differences" in symptoms. Both provided better discriminant spread in IBS-D than IBS-C. CONCLUSIONS: Both the traditional binary and 50% improvement end points are equivalent in their psychometric properties. Neither is impacted by baseline severity, and both demonstrate excellent construct validity. They are optimized for the IBS-D population but also appear valid in IBS-C. C1 [Spiegel, Brennan] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. [Spiegel, Brennan; Bolus, Roger] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Spiegel, Brennan; Bolus, Roger] Univ Calif Los Angeles, VA Ctr Outcomes Res & Educ CORE, Los Angeles, CA USA. [Camilleri, Michael] Mayo Clin, Rochester, MN USA. [Chey, William D.] Univ Michigan, Ann Arbor, MI 48109 USA. [Fehnel, Sheri; Mangel, Allen] RTI Hlth Solut, Res Triangle Pk, NC USA. [Talley, Nicholas J.] Mayo Clin, Jacksonville, FL 32224 USA. [Whitehead, William E.] Univ N Carolina, Chapel Hill, NC USA. RP Spiegel, B (reprint author), 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ulca.edu RI Talley, nicholas/D-5399-2013 OI Talley, nicholas/0000-0003-2537-3092 FU Rome Foundation; Veteran's Affairs Health Services Research and Development (HSR&D) Career Development Transition Award [RCD 03-179-2]; CURE Digestive Disease Research Center (NIH) [2P30 DK 041301-17]; NIH Center [1 R24 AT002681-NCCAM] FX Supported by the Rome Foundation and by a Veteran's Affairs Health Services Research and Development (HSR&D) Career Development Transition Award (RCD 03-179-2; to B.S.), the CURE Digestive Disease Research Center (NIH 2P30 DK 041301-17; to B.S.), and NIH Center Grant 1 R24 AT002681-NCCAM (to B.S.). NR 20 TC 41 Z9 44 U1 2 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD DEC PY 2009 VL 137 IS 6 BP 1944 EP 1953 DI 10.1053/j.gastro.2009.08.047 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 529TF UT WOS:000272539900018 PM 19706292 ER PT J AU Videlock, EJ Adeyemo, M Licudine, A Hirano, M Ohning, G Mayer, M Mayer, EA Chang, L AF Videlock, Elizabeth J. Adeyemo, Mopelola Licudine, Arlene Hirano, Miyoshi Ohning, Gordon Mayer, Minou Mayer, Emeran A. Chang, Lin TI Childhood Trauma Is Associated With Hypothalamic-Pituitary-Adrenal Axis Responsiveness in Irritable Bowel Syndrome SO GASTROENTEROLOGY LA English DT Article ID FUNCTIONAL GASTROINTESTINAL DISORDERS; POSTTRAUMATIC-STRESS-DISORDER; SALIVARY CORTISOL-LEVELS; EARLY-LIFE; HPA-AXIS; GLUCOCORTICOID-RECEPTOR; PSYCHOSOCIAL STRESS; ADVERSE EXPERIENCES; ABUSE; RESPONSES AB BACKGROUND & AIMS: A history of early adverse life events (EALs) is associated with a poorer outcome and higher levels of distress in adult patients with functional gastrointestinal disorders. An EAL is thought to predispose individuals to develop a range of chronic illnesses by inducing persistent changes in the central stress response systems, including the hypothalamic-pituitary-adrenal (HPA) axis. We sought to determine if EALs affect the HPA axis response to a visceral stressor in irritable bowel syndrome (IBS) patients and healthy controls, and to determine if this is affected by sex or related to symptoms or quality of life. METHODS: Forty-four IBS patients (25 women, 19 men) and 39 healthy controls (21 women, 18 men) were assessed for gastrointestinal and psychological symptoms and EALs by validated questionnaires and interview. All subjects underwent a visceral stressor (sigmoidoscopy). Salivary cortisol was collected at baseline and serially for I hour poststressor. RESULTS: Twenty-one IBS patients and 18 controls had EALs. In subjects with and without IBS, an EAL was associated with higher mean (+/-SD) cortisol levels (0.32 +/- 0.2 vs 0.20 +/- 0.1 mu g/dL, P = .003) and higher area under the curve (28.1 +/- 17 vs 18.6 +/- 13 mu g x min/dL; P = .005) after the stressor compared with subjects without EALs. In IBS, a faster resolution of cortisol to basal values corresponded to lower symptom severity (r = -0.36, P < .05) and better disease-specific quality of life (r = 0.33, P < OS). CONCLUSIONS: HPA axis hyperresponsiveness to a visceral stressor is related more to a history of EALs than to the presence of IBS. However, HPA axis reactivity has a moderating effect on IBS symptoms. C1 [Videlock, Elizabeth J.; Adeyemo, Mopelola; Licudine, Arlene; Hirano, Miyoshi; Ohning, Gordon; Mayer, Minou; Mayer, Emeran A.; Chang, Lin] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, Los Angeles, CA 90095 USA. [Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. [Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Mayer, Emeran A.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. [Mayer, Minou; Chang, Lin] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. RP Chang, L (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurobiol Stress, 10833 Le Conte Ave,CHS 47-122, Los Angeles, CA 90095 USA. EM linchang@ucla.edu FU National Institutes of Health [P50 DK64539, R01 AR46122, R24 AT002681, GCRC M01-RR00865] FX Supported by National Institutes of Health grants P50 DK64539 (E.A.M., L.C.), R01 AR46122 (L.C.), R24 AT002681 (E.A.M.), and GCRC M01-RR00865. NR 63 TC 77 Z9 81 U1 4 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD DEC PY 2009 VL 137 IS 6 BP 1954 EP 1962 DI 10.1053/j.gastro.2009.08.058 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 529TF UT WOS:000272539900019 PM 19737564 ER PT J AU Boardman, CR Sonnenberg, A AF Boardman, Charles R. Sonnenberg, Amnon TI Upping the "ant-e" on endoscopic ant sightings SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material C1 [Boardman, Charles R.; Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Boardman, CR (reprint author), Portland VA Med Ctr, Portland, OR USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD DEC PY 2009 VL 70 IS 6 BP 1245 EP 1246 DI 10.1016/j.gie.2009.07.015 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 537KH UT WOS:000273111300034 PM 19836743 ER PT J AU Carlson, MDA Herrin, J Du, QL Epstein, AJ Cherlin, E Morrison, RS Bradley, EH AF Carlson, Melissa D. A. Herrin, Jeph Du, Qingling Epstein, Andrew J. Cherlin, Emily Morrison, R. Sean Bradley, Elizabeth H. TI Hospice Characteristics and the Disenrollment of Patients with Cancer SO HEALTH SERVICES RESEARCH LA English DT Article DE Health care organization; hospice; Medicare hospice benefit ID MARKET-STRUCTURE; CARE; COMPETITION; PATTERNS AB Objective To characterize the types of hospices with higher rates of patient disenrollment from the Medicare Hospice Benefit and the markets in which these hospices operate. Data Source Secondary analyses of Surveillance, Epidemiology and End Results-Medicare data. Analyses included patients who died of cancer from 1998 to 2002 and who used hospice (n=90,826). Study Design We used generalized estimating equations to estimate the association of patient disenrollment with hospice size, years since Medicare certification, ownership, staff mix, competition, urban/rural status, region, and fiscal intermediary. Other covariates included patient demographic and clinical characteristics. Principal Findings Patients were more likely to disenroll from hospice if they were served by newer hospices (OR=1.14; 95 percent CI 1.03, 1.26), by smaller hospices (OR=1.11; 95 percent CI 1.02, 1.20), or by hospices in more competitive markets (OR=1.17; 95 percent CI 1.03, 1.35). There was an independent effect of the hospice's fiscal intermediary on disenrollment, particularly disenrollment after 6 months with hospice (Wald chi 2=21.2, p=.007). Conclusions The reasons for higher disenrollment rates for newer hospices, for smaller hospices, and for hospices in highly competitive markets are likely complex; however, results suggest that there are organizational-level barriers to keeping patients with cancer enrolled with hospice. Variation across fiscal intermediaries may indicate that regulatory oversight, particularly of long-stay patients, influences hospice disenrollment. C1 [Carlson, Melissa D. A.; Du, Qingling; Morrison, R. Sean] Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA. [Herrin, Jeph] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA. [Epstein, Andrew J.; Cherlin, Emily; Bradley, Elizabeth H.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA. [Morrison, R. Sean] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. RP Carlson, MDA (reprint author), Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. EM Melissa.Carlson@mssm.edu FU National Cancer Institute [1R01CA116398-01A2]; NINR Career Development Award [1K99NR010495-01]; Patrick and Catherine Weldon Donaghue Medical Research Foundation Investigator Award [02-102]; National Institute on Aging [K24 AG022345] FX This work was supported by the National Cancer Institute (1R01CA116398-01A2). Dr. Carlson is a Brookdale Leadership in Aging Fellow and recipient of an NINR Career Development Award (1K99NR010495-01). Dr. Bradley is supported by the Patrick and Catherine Weldon Donaghue Medical Research Foundation Investigator Award (Grant #02-102). Dr. Morrison is the recipient of a Mid-Career Investigator Award in Patient-Oriented Research (K24 AG022345) from the National Institute on Aging. NR 22 TC 27 Z9 27 U1 1 U2 5 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD DEC PY 2009 VL 44 IS 6 BP 2004 EP 2021 DI 10.1111/j.1475-6773.2009.01002.x PG 18 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 519QZ UT WOS:000271783700007 PM 19656230 ER PT J AU Teerlink, JR Metra, M Zaca, V Sabbah, HN Cotter, G Gheorghiade, M Dei Cas, L AF Teerlink, John R. Metra, Marco Zaca, Valerio Sabbah, Hani N. Cotter, Gadi Gheorghiade, Mihai Dei Cas, Livio TI Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond SO HEART FAILURE REVIEWS LA English DT Article DE Acute heart failure; Advanced chronic heart failure; Inotropic agents; Prognosis; Istaroxime; Omecamtiv mecarbil ID NATIONAL REGISTRY ADHERE; RANDOMIZED CONTROLLED-TRIAL; LEFT-VENTRICULAR FUNCTION; EUROPEAN-SOCIETY; CLINICAL-TRIALS; POSITION STATEMENT; LOOKING BACKWARD; MORTALITY; THERAPY; DIGOXIN AB Treatment with inotropic agents is one of the most controversial topics in heart failure. Initial enthusiasm, based on strong pathophysiological rationale and apparent empirical efficacy, has been progressively limited by results of controlled trials and registries showing poorer outcomes of the patients on inotropic therapy. The use of these agents remains, however, potentially indicated in a significant proportion of patients with low cardiac output, peripheral hypoperfusion and end-organ dysfunction caused by heart failure. Limitations of inotropic therapy seem to be mainly related to their mechanisms of action entailing arrhythmogenesis, peripheral vasodilation, myocardial ischemia and damage, and possibly due to their use in patients without a clear indication, rather than to the general principle of inotropic therapy itself. This review will discuss the characteristics of the patients with a potential indication for inotropic therapy, the main data from registries and controlled trials, the mechanism of the untoward effects of these agents on outcomes and, lastly, perspectives with new agents with novel mechanisms of action. C1 [Metra, Marco; Dei Cas, Livio] Univ Brescia, Spedali Civili Brescia, Dept Expt & Appl Med, I-25123 Brescia, Italy. [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Cardiol Sect, San Francisco, CA 94143 USA. [Zaca, Valerio] Santa Maria Scotte Hosp, Div Cardiol, Cardiovasc & Thorac Dept, Siena, Italy. [Sabbah, Hani N.] Henry Ford Hosp, Henry Ford Heart & Vasc Inst, Div Cardiovasc Med, Dept Med, Detroit, MI 48202 USA. [Cotter, Gadi] Momentum Res, Durham, NC USA. [Gheorghiade, Mihai] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. RP Metra, M (reprint author), Univ Brescia, Spedali Civili Brescia, Dept Expt & Appl Med, Piazza Spedali Civili 1, I-25123 Brescia, Italy. EM metramarco@libero.it RI ; Teerlink, John/D-2986-2012 OI Metra, Marco/0000-0001-6691-8568; NR 61 TC 44 Z9 45 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1382-4147 J9 HEART FAIL REV JI Heart Fail. Rev. PD DEC PY 2009 VL 14 IS 4 BP 243 EP 253 DI 10.1007/s10741-009-9153-y PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 515DA UT WOS:000271445600003 PM 19876734 ER PT J AU Teerlink, JR AF Teerlink, John R. TI A novel approach to improve cardiac performance: cardiac myosin activators SO HEART FAILURE REVIEWS LA English DT Article DE Heart failure; Inotrope; Cardiac myosin activator; CK-1827452; Cardiac function; Systolic ejection time ID VENTRICULAR SYSTOLIC FUNCTION; INCREASING EJECTION TIME; CHRONIC HEART-FAILURE; CALCIUM TRANSIENT; MOLECULAR MOTORS; CK-1827452; CK1122534; MILRINONE; MYOCYTES; CONTRACTILITY AB Decreased systolic function is a central factor in the pathogenesis of heart failure, yet there are no safe medical therapies to improve cardiac function in patients. Currently available inotropes, such as dobutamine and milrinone, increase cardiac contractility at the expense of increased intracellular concentrations of calcium and cAMP, contributing to increased heart rate, hypotension, arrhythmias, and mortality. These adverse effects are inextricably linked to their inotropic mechanism of action. A new class of pharmacologic agents, cardiac myosin activators, directly targets the kinetics of the myosin head. In vitro studies have demonstrated that these agents increase the rate of effective myosin cross-bridge formation, increasing the duration and amount of myocyte contraction, and inhibit non-productive consumption of ATP, potentially improving myocyte energy utilization, with no effect on intracellular calcium or cAMP. Animal models have shown that this novel mechanism increases the systolic ejection time, resulting in improved stroke volume, fractional shortening, and hemodynamics with no effect on myocardial oxygen demand, culminating in significant increases in cardiac efficiency. A first-in-human study in healthy volunteers with the lead cardiac myosin activator, CK-1827452, as well as preliminary results from a study in patients with stable chronic heart failure, have extended these findings to humans, demonstrating significant increases in systolic ejection time, fractional shortening, stroke volume, and cardiac output. These studies suggest that cardiac myosin activators offer the promise of a safe and effective treatment for heart failure. A program of clinical studies are being planned to test whether CK-1827452 will fulfill that promise. C1 [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, Cardiol 111C,4150 Clement St, San Francisco, CA 94121 USA. EM john.teerlink@ucsf.edu RI Teerlink, John/D-2986-2012 NR 28 TC 47 Z9 49 U1 1 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1382-4147 J9 HEART FAIL REV JI Heart Fail. Rev. PD DEC PY 2009 VL 14 IS 4 BP 289 EP 298 DI 10.1007/s10741-009-9135-0 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 515DA UT WOS:000271445600007 PM 19234787 ER PT J AU Metra, M Teerlink, JR Voors, AA Felker, GM Milo-Cotter, O Weatherley, B Dittrich, H Cotter, G AF Metra, Marco Teerlink, John R. Voors, Adriaan A. Felker, G. Michael Milo-Cotter, Olga Weatherley, Beth Dittrich, Howard Cotter, Gad TI Vasodilators in the treatment of acute heart failure: what we know, what we don't SO HEART FAILURE REVIEWS LA English DT Article DE Acute heart failure; Vasodilators; Nitrates ID RANDOMIZED INTRAVENOUS TEZOSENTAN; A(1) RECEPTOR ANTAGONIST; SEVERE PULMONARY-EDEMA; NATRIURETIC-PEPTIDE; RENAL-FUNCTION; DOUBLE-BLIND; SODIUM-NITROPRUSSIDE; ISOSORBIDE-DINITRATE; FLUID ACCUMULATION; CONTROLLED-TRIALS AB Although we have recently witnessed substantial progress in management and outcome of patients with chronic heart failure, acute heart failure (AHF) management and outcome have not changed over almost a generation. Vasodilators are one of the cornerstones of AHF management; however, to a large extent, none of those currently used has been examined by large, placebo-controlled, non-hemodynamic monitored, prospective randomized studies powered to assess the effects on outcomes, in addition to symptoms. In this article, we will discuss the role of vasodilators in AHF trying to point out which are the potentially best indications to their administration and which are the pitfalls which may be associated with their use. Unfortunately, most of this discussion is only partially evidence based due to lack of appropriate clinical trials. In general, we believe that vasodilators should be administered early to AHF patients with normal or high blood pressure (BP) at presentation. They should not be administered to patients with low BP since they may cause hypotension and hypoperfusion of vital organs, leading to renal and/or myocardial damage which may further worsen patients' outcome. It is not clear whether vasodilators have a role in either patients with borderline BP at presentation (i.e., low-normal) or beyond the first 1-2 days from presentation. Given the limitations of the currently available clinical trial data, we cannot recommend any specific agent as first line therapy, although nitrates in different formulations are still the most widely used in clinical practice. C1 [Milo-Cotter, Olga; Weatherley, Beth; Cotter, Gad] Momentum Res Inc, Durham, NC 27707 USA. [Metra, Marco] Univ Brescia, Dept Expt & Appl Med, Sect Cardiovasc Dis, Brescia, Italy. [Teerlink, John R.] San Francisco VA Med Ctr, Dept Cardiol, San Francisco, CA USA. [Teerlink, John R.; Dittrich, Howard] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Felker, G. Michael] Duke Clin Res Inst, Div Cardiovasc Med, Durham, NC USA. RP Cotter, G (reprint author), Momentum Res Inc, 3100 Tower Blvd,Suite 802, Durham, NC 27707 USA. EM metramarco@libero.it; gadcotter@momentum-research.com RI Teerlink, John/D-2986-2012 OI Metra, Marco/0000-0001-6691-8568 NR 60 TC 30 Z9 31 U1 1 U2 5 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1382-4147 J9 HEART FAIL REV JI Heart Fail. Rev. PD DEC PY 2009 VL 14 IS 4 BP 299 EP 307 DI 10.1007/s10741-008-9127-5 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 515DA UT WOS:000271445600008 PM 19096932 ER PT J AU Hamilton, LS Altshuler, LL Townsend, J Bookheimer, SY Phillips, OR Fischer, J Woods, RP Mazziotta, JC Toga, AW Nuechterlein, KH Narr, KL AF Hamilton, Liberty S. Altshuler, Lori L. Townsend, Jennifer Bookheimer, Susan Y. Phillips, Owen R. Fischer, Jeffrey Woods, Roger P. Mazziotta, John C. Toga, Arthur W. Nuechterlein, Keith H. Narr, Katherine L. TI Alterations in Functional Activation in Euthymic Bipolar Disorder and Schizophrenia During a Working Memory Task SO HUMAN BRAIN MAPPING LA English DT Article DE bipolar; schizophrenia; working memory; executive function; fMRI; dorsolateral prefrontal cortex ID DORSOLATERAL PREFRONTAL CORTEX; RATING-SCALE; NEUROCOGNITIVE FUNCTION; EXECUTIVE FUNCTION; BRAIN IMAGES; FMRI; PERFORMANCE; MRI; DYSFUNCTION; IMPAIRMENT AB Dysfunctions in prefrontal cortical networks are thought to underlie working memory (WM) impairments consistently observed in both subjects with bipolar disorder and schizophrenia. It remains unclear, however, whether patterns of WM-related hemodynamic responses are similar in bipolar and schizophrenia subjects compared to controls. We used fMRI to investigate differences in blood oxygen level dependent activation during a WM task in 21 patients with euthymic bipolar 1, 20 patients with schizophrenia, and 38 healthy controls. Subjects were presented with four stimuli (abstract designs) followed by a fifth stimulus and required to recall whether the last stimulus was among the four presented previously. Task-related brain activity was compared within and across groups. All groups activated prefrontal cortex (PFC), primary and supplementary motor cortex, and visual cortex during the WM task. There were no significant differences in PFC activation between controls and euthymic bipolar subjects, but controls exhibited significantly increased activation (cluster-corrected P < 0.05) compared to patients with schizophrenia in prefrontal regions including dorsolateral prefrontal cortex (DLPFC). Although the bipolar group exhibited intermediate percent signal change in a functionally defined DLPFC region of interest with respect to the schizophrenia and control groups, effects remained significant only between patients with schizophrenia and controls. Schizophrenia and bipolar disorder may share some behavioral, diagnostic, and genetic features. Differences in the patterns of WM-related brain activity across groups, however, suggest some diagnostic specificity. Both patient groups showed some regional task-related hypoactivation compared to controls across the brain. Within DLPFC specifically, patients with schizophrenia exhibited more severe WM-related dysfunction than bipolar subjects. Hunt Brain Mapp 30:3958-3969, 2009. (C) 2009 Wiley-Liss, Inc. C1 [Hamilton, Liberty S.; Phillips, Owen R.; Toga, Arthur W.; Narr, Katherine L.] Univ Calif Los Angeles, David Geffen Sch Med, Lab Neuro Imaging, Los Angeles, CA 90095 USA. [Woods, Roger P.; Mazziotta, John C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Ahmanson Lovelace Brain Mapping Ctr, Los Angeles, CA 90095 USA. [Altshuler, Lori L.] W Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Altshuler, Lori L.; Townsend, Jennifer; Bookheimer, Susan Y.; Fischer, Jeffrey; Mazziotta, John C.; Nuechterlein, Keith H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Narr, KL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Lab Neuro Imaging, Neurosci Res Bldg 1,Rm 225,635 Charles Young Dr S, Los Angeles, CA 90095 USA. EM narr@loni.ucla.edu OI Hamilton, Liberty/0000-0003-0182-2500 FU National Center for Research Resources [P41 RR13642, RR12169, RR13642, RR00865]; National Institute of Mental Health [KO1MH073990, RO1MH060374, K24MH001848, R21MH075944, RO1MH03305, P50MH066286]; NIH Roadmap Initiative [P20 RR020750]; National Library of Medicine [RO1 LM05639]; Center for Computational Biology (CCB) [U54 RR021813] FX Contract grant sponsor: National Center for Research Resources; Contract grant numbers: P41 RR13642, RR12169, RR13642, RR00865; Contract grant sponsor: National Institute of Mental Health; Contract grant numbers: KO1MH073990, RO1MH060374, K24MH001848, R21MH075944, RO1MH03305, P50MH066286; Contract grant sponsor: NIH Roadmap Initiative; Contract grant number: P20 RR020750; Contract grant sponsor: National Library of Medicine; Contract grant number: RO1 LM05639; Contract grant sponsor: NLH Roadmap for Medical Research, Center for Computational Biology (CCB); Contract grant number: U54 RR021813. NR 60 TC 28 Z9 29 U1 3 U2 5 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1065-9471 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD DEC PY 2009 VL 30 IS 12 BP 3958 EP 3969 DI 10.1002/hbm.20820 PG 12 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 530IW UT WOS:000272584000010 PM 19449330 ER PT J AU Lee, BY Tsui, BY Bailey, RR Smith, KJ Muder, RR Lewis, GJ Harrison, LH AF Lee, Bruce Y. Tsui, Becky Y. Bailey, Rachel R. Smith, Kenneth J. Muder, Robert R. Lewis, G. Jonathan Harrison, Lee H. TI Should Vascular Surgery Patients Be Screened Preoperatively for Methicillin-Resistant Staphylococcus aureus? SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID HOSPITAL-ACQUIRED INFECTION; COST-EFFECTIVENESS; MRSA; ECONOMICS; UTILITY; SURVEILLANCE; AMPUTATION; CARRIAGE; VALUES; AUDIT AB BACKGROUND. Methicillin-resistant Staphylococcus aureus (MRSA) can cause severe infection in patients who are undergoing vascular surgical operations. Testing all vascular surgery patients preoperatively for MRSA and attempting to decolonize those who have positive results may be a strategy to prevent MRSA infection. The economic value of such a strategy has not yet been determined. METHODS. We developed a decision-analytic computer simulation model to determine the economic value of using such a strategy before all vascular surgical procedures from the societal and third-party payer perspectives at different MRSA prevalence and decolonization success rates. RESULTS. The model showed preoperative MRSA testing to be cost-effective (incremental cost-effectiveness ratio, <$50,000 per quality-adjusted life year) when the MRSA prevalence is >= 0.01 and the decolonization success rate is >= 0.25. In fact, this strategy was dominant (ie, less costly and more effective) at the following thresholds: MRSA prevalence >= 0.01 and decolonization success rate >= 0.5, and MRSA prevalence >= 0.025 and decolonization success rate >= 0.25. CONCLUSION. Testing and decolonizing patients for MRSA before vascular surgery may be a cost-effective strategy over a wide range of MRSA prevalence and decolonization success rates. C1 [Lee, Bruce Y.; Tsui, Becky Y.; Bailey, Rachel R.; Smith, Kenneth J.; Lewis, G. Jonathan] Univ Pittsburgh, Sect Decis Sci & Clin Syst Modeling, Pittsburgh, PA 15213 USA. [Lee, Bruce Y.; Tsui, Becky Y.; Bailey, Rachel R.; Lewis, G. Jonathan] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA 15213 USA. [Muder, Robert R.] Univ Pittsburgh, Div Infect Dis, Pittsburgh, PA 15213 USA. [Harrison, Lee H.] Univ Pittsburgh, Infect Dis Epidemiol Res Unit, Pittsburgh, PA 15213 USA. [Lee, Bruce Y.; Tsui, Becky Y.; Bailey, Rachel R.; Lewis, G. Jonathan; Harrison, Lee H.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. [Lee, Bruce Y.; Tsui, Becky Y.; Bailey, Rachel R.; Lewis, G. Jonathan; Harrison, Lee H.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Muder, Robert R.] Vet Affairs Pittsburgh Hlth Care Syst, Div Infect Dis, Pittsburgh, PA USA. RP Lee, BY (reprint author), Univ Pittsburgh, Sect Decis Sci & Clin Syst Modeling, 200 Meyran Ave,Rm 217, Pittsburgh, PA 15213 USA. EM BYL1@pitt.edu OI Slayton, Rachel/0000-0003-4699-8040; Smith, Kenneth J/0000-0001-8088-566X FU National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) [U01-GM070708-05] FX Financial support. National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) (U01-GM070708-05). NR 31 TC 18 Z9 18 U1 2 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD DEC PY 2009 VL 30 IS 12 BP 1158 EP 1165 DI 10.1086/648087 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 515CL UT WOS:000271444100005 PM 19852665 ER PT J AU Zhang, Z Zhong, W Wegmann, K Hinrichs, D AF Zhang, Z. Zhong, W. Wegmann, K. Hinrichs, D. TI Dual effects of OX40 on different T Cell subset activation and consequent DSS-induced Colitis SO INFLAMMATORY BOWEL DISEASES LA English DT Meeting Abstract CT Conference on Advances in Inflammatory Bowel Diseases Crohns and Research Conference CY DEC 03-06, 2009 CL Hollywood, FL SP Crohns & Coitis Fdn Natl Clin & Res C1 [Zhang, Z.; Zhong, W.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Wegmann, K.; Hinrichs, D.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD DEC PY 2009 VL 15 IS 12 SU S BP S48 EP S48 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 530DK UT WOS:000272569000147 ER PT J AU Guerrero-Berroa, E Luo, XD Schmeidler, J Rapp, MA Dahlman, K Grossman, HT Haroutunian, V Beeri, MS AF Guerrero-Berroa, Elizabeth Luo, Xiaodong Schmeidler, James Rapp, Michael A. Dahlman, Karen Grossman, Hillel T. Haroutunian, Vahram Beeri, Michal Schnaider TI The MMSE orientation for time domain is a strong predictor of subsequent cognitive decline in the elderly SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE MMSE; cognitive domains; cognitive decline; prediction; dementia; Alzheimer's disease ID MENTAL-STATE-EXAMINATION; PRECLINICAL ALZHEIMERS-DISEASE; MEMORY; IMPAIRMENT; DEMENTIA; NEUROPATHOLOGY; TASKS AB Background The mini-mental state exam (MMSE) has been used to address questions such as determination of appropriate cutoff scores for differentiation of individuals with intact cognitive function from patients with dementia and rate of cognitive decline. However, little is known about the relationship of performance in specific cognitive domains to subsequent overall decline. Objective To examine the specific and/or combined contribution of four MMSE domains (orientation for time, orientation for place, delayed recall. and attention) to prediction of overall cognitive decline on the MMSE. Methods Linear mixed models were applied to 505 elderly nursing home residents (mean age = 85, > 12 years education = 27%; 79% F, mean follow-up = 3.20 years) to examine the relationship between baseline scores of these domains and total MMSE scores over time. Results Orientation for time was the only domain significantly associated with MMSE decline over time. Combination of poor delayed recall with either attention or orientation for place was associated with significantly increased decline on the MMSE. Conclusions The MMSE orientation for time predicts overall decline on MMSE scores over time. A good functioning domain added to good functioning delayed recall was associated with slower rate of decline. Copyright (C) 2009 John Wiley Sons. Ltd. C1 [Guerrero-Berroa, Elizabeth; Luo, Xiaodong; Haroutunian, Vahram] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Guerrero-Berroa, Elizabeth; Luo, Xiaodong; Schmeidler, James; Rapp, Michael A.; Dahlman, Karen; Grossman, Hillel T.; Haroutunian, Vahram; Beeri, Michal Schnaider] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Guerrero-Berroa, Elizabeth] CUNY, Dept Psychol, Queens Coll, Neuropsychol Subprogram, Flushing, NY USA. [Guerrero-Berroa, Elizabeth] CUNY, Grad Ctr, Flushing, NY USA. [Rapp, Michael A.] Humboldt Univ, Dept Psychiat, Geriatr Psychiat Ctr, Berlin, Germany. RP Guerrero-Berroa, E (reprint author), James J Peters VA Med Ctr, 130 W Kingsbridge Rd,Room 1F-01, Bronx, NY 10468 USA. EM elizabeth.guerrero-berroa@mssm.edu FU NIA [K01 AG023515-01, A2 AG02219, AG05138]; Dextra Baldwin McGonagle FX This study was supported by NIA grants K01 AG023515-01A2 (Dr. Beeri), AG02219 (Dr. Haroutunian), and AG05138 (Dr. Sano); the Dextra Baldwin McGonagle NR 26 TC 16 Z9 21 U1 0 U2 8 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD DEC PY 2009 VL 24 IS 12 BP 1429 EP 1437 DI 10.1002/gps.2282 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 531AV UT WOS:000272636000014 PM 19382130 ER PT J AU Byers, AL Levy, BR Kasl, SV Bruce, ML Allore, HG AF Byers, Amy L. Levy, Becca R. Kasl, Stanislav V. Bruce, Martha L. Allore, Heather G. TI Heritability of depressive symptoms: a case study using a multilevel approach SO INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH LA English DT Article DE depressive symptoms; heritability; genetic variance; family study; multilevel model ID TWIN SAMPLE; ENVIRONMENTAL-CONTRIBUTIONS; GENETIC EPIDEMIOLOGY; FAMILY HISTORY; OLDER PARENTS; RISK; 3-GENERATION; PSYCHOPATHOLOGY; DISORDERS; CHILDREN AB We present a case Study using a multilevel modeling approach to determine whether depressive symptoms are affected by genetic factors. Existing studies examining this question have focused on twins. The present study built on the literature by conducting a preliminary study of the heritability of depressive symptoms within extended families. At the same time, this study assessed the need for adjustment of a heritability measure in a family study using a multi-generational sample. The sample consisted of 230 community-dwelling extended families that included 431 adult offspring, comprising full siblings, half siblings and cousins that participated in the University Of Southern California Longitudinal Study of Generations. All participants filled out the Center for Epidemiologic Studies Depression (CES-D) scale. The multilevel analysis allowed us to model the natural hierarchy of the extended family. Results indicate that the proportion of the phenotypic variance for CES-D that occurs due to genetic differences is not significantly larger than zero among these participants [h(2) = 8.6%, 95% conficlence interval (CI) = 0-57%, p = 0.71]. Our findings Suggest that future Studies examining depressive symptoms in this sample can focus on non-genetic explanatory factors without the necessity to control for genetic variation. However, our study may be limited by measurement of prevalent depressive symptoms, which may not generalize to lifetime depressive symptoms. Copyright (C) 2009 John Wiley & Sons, Ltd. C1 [Byers, Amy L.; Bruce, Martha L.] Weill Cornell Med Coll, Dept Psychiat, White Plains, NY USA. [Byers, Amy L.; Levy, Becca R.; Kasl, Stanislav V.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA. [Allore, Heather G.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA. RP Byers, AL (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, 4150 Clement St 116H, San Francisco, CA 94121 USA. EM Amy.Byers@ucsf.edu OI Allore, Heather/0000-0001-7685-8175 FU National Institute of Mental Health [T32 MH14235, T32 MH19132, T32 MH073553]; National Institute of Aging [AG05727]; Program on Aging at Yale University School of Medicine; Yale Claude D. Pepper Older Americans Independence Center [P30 AG21342] FX This study is based on a doctoral dissertation submitted by Amy L. Byers to the Department of Epidemiology and Public Health at Yale University. The project was supported by a training grant from the National Institute of Mental Health (T32 MH14235, Research Training in Mental Health Epidemiology, PI: S. Kasl) and a grant from the National Institute of Aging (AG05727), as well as work supported by the Program on Aging at Yale University School of Medicine. Heather G. Allore was supported, in part, by the Yale Claude D. Pepper Older Americans Independence Center (P30 AG21342). In addition, Amy L. Byers was funded by T32 postdoctoral training grants from the National Institute of Mental Health (T32 MH19132, PI: G. Alexopoulos; and T32 MH073553, PI: S. Bartels/M. Bruce) for post-doctoral training at the Weill-Cornell Institute of Geriatric Psychiatry, Weill Cornell Medical College. This research used the Longitudinal Study of Generations and Mental Health, 1971 data set (made accessible in 1990, machine-readable data files). These data were collected by V. Bengtson and M. Gatz and are available through the archive of the Henry A. Murray Research Center of the Radcliffe Institute for Advanced Study, Harvard University, Cambridge, Massachusetts (Producer and Distributor). We would like to thank the Longitudinal Study of Generations and Mental Health researchers who participated in collecting the data that made this project possible. NR 49 TC 1 Z9 1 U1 0 U2 3 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1049-8931 J9 INT J METH PSYCH RES JI Int. J. Methods Psychiatr. Res. PD DEC PY 2009 VL 18 IS 4 BP 287 EP 296 DI 10.1002/mpr.292 PG 10 WC Psychiatry SC Psychiatry GA 546QW UT WOS:000273826300009 PM 19757480 ER PT J AU Lawi, W Wiita, C Snyder, ST Wei, F Wong, D Wong, PK Liao, JC Haake, D Gau, V AF Lawi, Walson Wiita, Chris Snyder, Steven T. Wei, Fang Wong, David Wong, Pak Kin Liao, Joseph C. Haake, David Gau, Vincent TI A Microfluidic Cartridge System for Multiplexed Clinical Analysis SO JALA LA English DT Review DE microfluidics; electrochemical sensor; multiplexed assay; quantiative; molecular analysis; point of care; clinical diagnostics ID ELECTROCHEMICAL DETECTION; AMBIENT-TEMPERATURE; IDENTIFICATION; UROPATHOGENS AB Cartridge-based microfluidics is a promising technology for clinical diagnostics. By miniaturizing the fluid-handling processes required for genomic and proteomic analyses, reagent and specimen volume is minimized along with the size of the system. We demonstrate an automated microfluidic system capable of performing six multiplexed genomic and proteomic analyses simultaneously, by means of an integrated electrochemical sensor and embedded controls. (JALA 2009;14:407-12) C1 [Lawi, Walson; Wiita, Chris; Snyder, Steven T.; Gau, Vincent] GeneFluidics Inc, Mol Anal, Monterey Pk, CA 91754 USA. [Haake, David] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Wong, Pak Kin] Univ Arizona, Tucson, AZ USA. [Liao, Joseph C.] Stanford Univ, Palo Alto, CA 94304 USA. [Liao, Joseph C.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Haake, David] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Gau, V (reprint author), GeneFluidics Inc, Mol Anal, 2540 Corp Pl,STE B101, Monterey Pk, CA 91754 USA. EM vgau@genefluidics.com RI Wong, Pak Kin/A-7974-2012; Liao, Joseph/J-5874-2015 OI Wong, Pak Kin/0000-0001-7388-2110; FU National Institute of Biomedical Imaging and Bioengineering [R01 EB00127]; National Institute of Allergy and Infectious Diseases [U01 A1075565-01, U01 A1082457-01]; National Institute of Dental and Craniofacial Research [U01 DE I 7790]; Department of Veterans Affairs Merit Review [B4872R] FX The development presented in this study was partially supported by Bioengineering Research Partnership R01 EB00127 from the National Institute of Biomedical Imaging and Bioengineering, U01 A1075565-01, U01 A1082457-01 from National Institute of Allergy and Infectious Diseases, U01 DE I 7790 from the National Institute of Dental and Craniofacial Research, and Department of Veterans Affairs Merit Review B4872R. NR 10 TC 17 Z9 17 U1 2 U2 14 PU ELSEVIER INC PI SAN DIEGO PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1535-5535 J9 JALA-J LAB AUTOM JI JALA PD DEC PY 2009 VL 14 IS 6 SI SI BP 407 EP 412 DI 10.1016/j.jala.2009.05.002 PG 6 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 692OZ UT WOS:000285163400011 PM 20161584 ER PT J AU Bakst, R Kovarik, C Werth, VP AF Bakst, Richard Kovarik, Carrie Werth, Victoria P. TI A Case of Localized Scleroderma in a Sculptor and His Wife SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Article DE localized scleroderma; morphea; silica ID SILICA-INDUCED SCLERODERMA; SYSTEMIC-SCLEROSIS; DUST AB The etiology of localized scleroderma is unknown, and its pathogenetic relationship to its systemic counterpart is unclear. Environmental exposures, notably to silica dust, have long been suspected in the pathogenesis of the disorder. However, its relationship to the localized variant has not been well described. Here we present 2 cases of localized scleroderma in a sculptor and his wife who have extensive exposure to silica dust. C1 [Bakst, Richard] Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA. [Kovarik, Carrie; Werth, Victoria P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Kovarik, Carrie; Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Werth, VP (reprint author), 2 Rhodes Pavil,3400 Spruce St, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu FU Department of Veterans Affairs Veterans Health Administration; Office of Research and Development; Biomedical Laboratory Research and Development; National Institutes of Health (NIH) [K24-AR 02207] FX Supported, in part, by a Merit Review Grant from the Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development and by the National Institutes of Health (NIH K24-AR 02207) (to V.P.W.) NR 15 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-1608 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD DEC PY 2009 VL 15 IS 8 BP 399 EP 401 DI 10.1097/RHU.0b013e3181c377ea PG 3 WC Rheumatology SC Rheumatology GA 531IU UT WOS:000272659100008 PM 19955998 ER PT J AU Brady, KT Tuerk, P Back, SE Saladin, ME Waldrop, AE Myrick, H AF Brady, Kathleen T. Tuerk, Peter Back, Sudie E. Saladin, Michael. E. Waldrop, Angela E. Myrick, Hugh TI Combat Posttraumatic Stress Disorder, Substance Use Disorders, and Traumatic Brain Injury SO JOURNAL OF ADDICTION MEDICINE LA English DT Review DE posttraumatic stress disorder; PTSD; substance use disorders; combat; TBI ID CORTICOTROPIN-RELEASING HORMONE; COCAINE-DEPENDENT INDIVIDUALS; FACTOR-LIKE IMMUNOREACTIVITY; NATIONAL COMORBIDITY SURVEY; ADMINISTERED PTSD SCALE; ADDICTED HUMAN BRAIN; DOUBLE-BLIND; EXPOSURE THERAPY; ALCOHOL DEPENDENCE; SEEKING SAFETY AB Among both civilian and veteran populations, substance use disorders (SUDs) and anxiety disorders frequently co-occur. One of the most common comorbid anxiety disorder is posttraumatic stress disorder (PTSD), a condition which may develop after exposure to traumatic events, Such as military combat. In comparison with the general population, rates of both SUDs and PTSD are elevated among veterans. Recent data show that soldiers returning from Iraq and Afghanistan demonstrate high rates of co-occurring SUDs, PTSD, and traumatic brain injury. Careful assessment of these conditions is critical and may be complicated by symptom overlap. More research targeting integrated interventions for these conditions is needed to establish optimal treatments. C1 [Brady, Kathleen T.] Med Univ S Carolina, Dept Psychiat, Clin Neurosci Div, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Brady, Kathleen T.; Tuerk, Peter; Myrick, Hugh] Med Univ S Carolina, Mental Hlth Serv Line, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Waldrop, Angela E.] Univ Calif San Francisco, PTSD Clin Team, San Francisco VAMC, San Francisco, CA 94143 USA. RP Brady, KT (reprint author), Med Univ S Carolina, Dept Psychiat, Clin Neurosci Div, Ralph H Johnson VA Med Ctr, 67 President St, Charleston, SC 29425 USA. EM bradyk@musc.edu FU National Institutes of Health/National Institute on Drug Abuse, Bethesda, MA [R25 DA020537]; Specialized Center of Research (SCOR) on Sex and Gender Factors Affecting Women's Health [P50 DA016511] FX Supported by the National Institutes of Health/National Institute on Drug Abuse, Bethesda, MA, Drug Abuse Research Training Program (R25 DA020537), and Specialized Center of Research (SCOR) on Sex and Gender Factors Affecting Women's Health (P50 DA016511). NR 106 TC 5 Z9 5 U1 6 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1932-0620 J9 J ADDICT MED JI J. Addict. Med. PD DEC PY 2009 VL 3 IS 4 BP 179 EP 188 PG 10 WC Substance Abuse SC Substance Abuse GA 528VG UT WOS:000272474500001 PM 21769015 ER PT J AU Tuerk, P Brady, KT Grubaugh, AL AF Tuerk, Peter Brady, Kathleen T. Grubaugh, Anouk L. TI Clinical Case Discussion: Combat PTSD and Substance Use Disorders SO JOURNAL OF ADDICTION MEDICINE LA English DT Editorial Material ID POSTTRAUMATIC-STRESS-DISORDER; ALCOHOL-CONSUMPTION; TELEPSYCHIATRY; DEPENDENCE; SERTRALINE; AUDIT C1 [Brady, Kathleen T.] Med Univ S Carolina, Dept Psychiat, Clin Neurosci Div, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. RP Brady, KT (reprint author), Med Univ S Carolina, Dept Psychiat, Clin Neurosci Div, 67 President St, Charleston, SC 29425 USA. EM bradyk@musc.edu NR 25 TC 7 Z9 7 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1932-0620 J9 J ADDICT MED JI J. Addict. Med. PD DEC PY 2009 VL 3 IS 4 BP 189 EP 193 PG 5 WC Substance Abuse SC Substance Abuse GA 528VG UT WOS:000272474500002 PM 21769016 ER PT J AU Porterfield, JE Kottam, ATG Raghavan, K Escobedo, D Jenkins, JT Larson, ER Trevino, RJ Valvano, JW Pearce, JA Feldman, MD AF Porterfield, John E. Kottam, Anil T. G. Raghavan, Karthik Escobedo, Daniel Jenkins, James T. Larson, Erik R. Trevino, Rodolfo J. Valvano, Jonathan W. Pearce, John A. Feldman, Marc D. TI Dynamic correction for parallel conductance, G(P), and gain factor, alpha, in invasive murine left ventricular volume measurements SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE conductance catheter; parallel conductance; mouse; left ventricular; admittance; alpha; pressure volume relationship ID IN-VIVO; CATHETER; MICE; SYSTEM; MOUSE; HEART; MODULATION; INOTROPY; RATS AB Porterfield JE, Kottam AT, Raghavan K, Escobedo D, Jenkins JT, Larson ER, Trevino RJ, Valvano JW, Pearce JA, Feldman MD. Dynamic correction for parallel conductance, G(P), and gain factor, alpha, in invasive murine left ventricular volume measurements. J Appl Physiol 107: 1693-1703, 2009. First published August 20, 2009; doi:10.1152/japplphysiol.91322.2008.-The conductance catheter technique could be improved by determining instantaneous parallel conductance (G(P)), which is known to be time varying, and by including a time-varying calibration factor in Baan's equation [alpha(t)]. We have recently proposed solutions to the problems of both time-varying G(P) and time-varying alpha, which we term "admittance" and "Wei's equation," respectively. We validate both our solutions in mice, compared with the currently accepted methods of hypertonic saline (HS) to determine G(P) and Baan's equation calibrated with both stroke volume (SV) and cuvette. We performed simultaneous echocardiography in closed-chest mice (n = 8) as a reference for left ventricular (LV) volume and demonstrate that an off-center position for the miniaturized pressure-volume (PV) catheter in the LV generates end-systolic and diastolic volumes calculated by admittance with less error (P < 0.03) (-2.49 +/- 15.33 mu l error) compared with those same parameters calculated by SV calibrated conductance (35.89 +/- 73.22 mu l error) and by cuvette calibrated conductance (-7.53 +/- 16.23 mu l ES and -29.10 +/- 31.53 mu l ED error). To utilize the admittance approach, myocardial permittivity (epsilon(m)) and conductivity (sigma(m)) were calculated in additional mice (n = 7), and those results are used in this calculation. In aortic banded mice (n = 6), increased myocardial permittivity was measured (11,844 +/- 2,700 control, 21,267 +/- 8,005 banded, P < 0.05), demonstrating that muscle properties vary with disease state. Volume error calculated with respect to echo did not significantly change in aortic banded mice (6.74 +/- 13.06 mu l, P = not significant). Increased inotropy in response to intravenous dobutamine was detected with greater sensitivity with the admittance technique compared with traditional conductance [4.9 +/- 1.4 to 12.5 +/- 6.6 mmHg/mu l Wei's equation (P < 0.05), 3.3 +/- 1.2 to 8.8 +/- 5.1 mmHg/mu l using Baan's equation (P = not significant)]. New theory and method for instantaneous G(P) removal, as well as application of Wei's equation, are presented and validated in vivo in mice. We conclude that, for closed-chest mice, admittance (dynamic G(P)) and Wei's equation (dynamic alpha) provide more accurate volumes than traditional conductance, are more sensitive to inotropic changes, eliminate the need for hypertonic saline, and can be accurately extended to aortic banded mice. C1 [Escobedo, Daniel; Jenkins, James T.; Trevino, Rodolfo J.; Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, Div Cardiol, San Antonio, TX 78229 USA. [Porterfield, John E.; Raghavan, Karthik; Larson, Erik R.; Valvano, Jonathan W.; Pearce, John A.] Univ Texas Austin, Dept Elect & Comp Engn, Austin, TX 78712 USA. [Kottam, Anil T. G.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. [Jenkins, James T.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Feldman, MD (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Div Cardiol, Rm 5-642 U,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM feldmanm@uthscsa.edu FU Veterans' Affairs Merit; National Heart, Lung, and Blood Institute [R21 HL-079926] FX This study was supported by grants from the Veterans' Affairs Merit (M. D. Feldman), and National Heart, Lung, and Blood Institute (R21 HL-079926). NR 32 TC 39 Z9 39 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD DEC PY 2009 VL 107 IS 6 BP 1693 EP 1703 DI 10.1152/japplphysiol.91322.2008 PG 11 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 526PO UT WOS:000272304400005 PM 19696357 ER PT J AU Wenk, JF Wall, ST Peterson, RC Helgerson, SL Sabbah, HN Burger, M Stander, N Ratcliffe, MB Guccione, JM AF Wenk, Jonathan F. Wall, Samuel T. Peterson, Robert C. Helgerson, Sam L. Sabbah, Hani N. Burger, Mike Stander, Nielen Ratcliffe, Mark B. Guccione, Julius M. TI A Method for Automatically Optimizing Medical Devices for Treating Heart Failure: Designing Polymeric Injection Patterns SO JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME LA English DT Article DE finite element modeling; numerical optimization; cardiac mechanics ID FINITE-ELEMENT MODEL; LEFT-VENTRICULAR ANEURYSM; VOLUME REDUCTION SURGERY; STRESS-ANALYSIS; MYOCARDIUM; MECHANICS; RESTORATION; CONTRACTION; MUSCLE; WALL AB Heart failure continues to present a significant medical and economic burden throughout the developed world. Novel treatments involving the injection of polymeric materials into the myocardium of the failing left ventricle (LV) are currently being developed, which may reduce elevated myofiber stresses during the cardiac cycle and act to retard the progression of heart failure. A finite element (FE) simulation-based method was developed in this study that can automatically optimize the injection pattern of the polymeric "inclusions" according to a specific objective function, using commercially available software tools The FE prerocessor TRUEGRID (R) was use to create a parametric axisymmetric LV mesh matched to experimentally measured end-diastole and end-systole metrics from dogs with coronary microembolization-induced heart failure. Passive and active myocardial material properties were defined by a pseudo-elastic-strain energy function and a time-varying elastance model of active contraction, respectively, that were implemented in the FE software L5-DYNA. The companion optimization software Ls-OPT was used to communicate directly with TRUEGRID (R) to determine FE model parameters, such as defining the injection pattern and inclusion characteristics. The optimization resulted in an intuitive optimal injection pattern (i.e., the one with the greatest number of inclusions) when the objective function was weighted to minimize mean end-diastolic and end-systolic myofiber stress and ignore LV stroke volume. In contrast, the optimization resulted in a nonintuitive optimal pattern (i.e., 3 inclusions longitudinally x 6 inclusions circumferentially) when both myofiber stress and stroke volume were incorporated into the objective function with different weights. [DOI: 10.1115/1.4000165] C1 [Ratcliffe, Mark B.; Guccione, Julius M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94121 USA. [Ratcliffe, Mark B.; Guccione, Julius M.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Wenk, Jonathan F.; Wall, Samuel T.; Peterson, Robert C.; Helgerson, Sam L.] CardioPolymers Inc, Laguna Hills, CA 92653 USA. [Sabbah, Hani N.] Henry Ford Hlth Syst, Detroit, MI 48202 USA. [Burger, Mike; Stander, Nielen] Livermore Software Technol Corp, Livermore, CA 94550 USA. RP Guccione, JM (reprint author), Univ Calif San Francisco, Dept Surg, San Francisco, CA 94121 USA. EM guccionej@surgery.ucsf.edu FU CardioPolymers, Inc. FX The study was supported entirely by CardioPolymers, Inc. NR 23 TC 37 Z9 37 U1 2 U2 11 PU ASME-AMER SOC MECHANICAL ENG PI NEW YORK PA THREE PARK AVE, NEW YORK, NY 10016-5990 USA SN 0148-0731 J9 J BIOMECH ENG-T ASME JI J. Biomech. Eng.-Trans. ASME PD DEC PY 2009 VL 131 IS 12 AR 121011-1 DI 10.1115/1.4000165 PG 7 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA 543XQ UT WOS:000273614400011 PM 20524734 ER PT J AU Bradshaw, AD AF Bradshaw, Amy D. TI The role of SPARC in extracellular matrix assembly SO JOURNAL OF CELL COMMUNICATION AND SIGNALING LA English DT Article DE BM-40; Collagen; Fibrillogenesis; Osteonectin; Review AB SPARC is a collagen-binding matricellular protein. Expression of SPARC in adult tissues is frequently associated with excessive deposition of collagen and SPARC-null mice fail to generate a robust fibrotic response to a variety of stimuli. This review summarizes recent advancements in the characterization of the binding of SPARC to collagens and describes the results of studies that implicate a function for SPARC in the regulation of the assembly of basal lamina and fibrillar collagen in the ECM. Potential cellular mechanisms that underlie SPARC activity in ECM deposition are also explored. C1 [Bradshaw, Amy D.] Med Univ S Carolina, Div Cardiol, Dept Med, Charleston, SC 29425 USA. [Bradshaw, Amy D.] Ralph H Johnson Vet Adm, Charleston, SC USA. [Bradshaw, Amy D.] Med Univ S Carolina, Gazes Cardiac Res Inst, Charleston, SC 29425 USA. RP Bradshaw, AD (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, 114 Doughty St, Charleston, SC 29425 USA. EM bradshad@musc.edu FU Veteran's Administration; NIDCR, NIH [P20 2P20RR017696-07] FX ADB is supported by a Merit Award from the Veteran's Administration and by P20 2P20RR017696-07 from the NIDCR, NIH. NR 57 TC 77 Z9 77 U1 1 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1873-9601 EI 1873-961X J9 J CELL COMMUN SIGNAL JI J. Cell Commun. Signal PD DEC PY 2009 VL 3 IS 3-4 SI SI BP 239 EP 246 DI 10.1007/s12079-009-0062-6 PG 8 WC Cell Biology SC Cell Biology GA V39OC UT WOS:000209419300008 PM 19798598 ER PT J AU Basile, J AF Basile, Jan TI Clinical Inertia and Blood Pressure Goal Attainment SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Review ID HYPERTENSION; MANAGEMENT; AWARENESS; PREVENTION; GUIDELINES; ADHERENCE; TRIAL; POPULATION; PREVALENCE; BELIEFS AB Optimal blood pressure (BP) control is still not being achieved for the majority of patients with hypertension. Although the topic of patient adherence to health care practitioner recommendations is less than desirable and medication noncompliance adds to the cost of health care, another issue that affects the ability to attain optimal BP control is therapeutic, or clinical, inertia, which is the failure of health care providers to initiate or intensify therapy when indicated. This paper will discuss therapeutic inertia and other issues that prevent BP goal attainment.J Clin Hypertens (Greenwich). 2009;11:S5-S12. (C) 2009 Wiley Periodicals, Inc. C1 [Basile, Jan] Ralph H Johnson VA Med Ctr, Primary Care Serv Line, Charleston, SC 29401 USA. [Basile, Jan] Med Univ S Carolina, Div Gen Internal Med Geriatr, Charleston, SC 29425 USA. RP Basile, J (reprint author), Ralph H Johnson VA Med Ctr, Primary Care Serv Line, 109 Bee St, Charleston, SC 29401 USA. EM jan.basile@med.va.gov FU National Heart, Lung and Blood Institute; Boehringer Ingelheim; Novartis FX Dr Basile receives grant/research support from the National Heart, Lung and Blood Institute, Boehringer Ingelheim, and Novartis. He has served as a consultant for AstraZeneca, Merck, Novartis, and Daiichi Sankyo and on the speakers' bureau of Abbott, AstraZeneca, Boehringer Ingelheim, Forest, Merck, Novartis, Pfizer, and Daiichi Sankyo. The author acknowledges the assistance of Practicum Educational Services in preparing this article and styling the paper for journal submission. Editorial support was provided by Ronald K. Miller, PhD, and funded by Daiichi Sankyo, Inc. The author received an honorarium from Daiichi Sankyo, Inc, for time and effort spent preparing this article. NR 22 TC 2 Z9 2 U1 1 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD DEC PY 2009 VL 11 IS 12 BP S5 EP S12 DI 10.1111/j.1751-7176.2009.00210.x PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 522BZ UT WOS:000271974000002 ER PT J AU Viola, GM Mansouri, MD Nasir, N Darouiche, RO AF Viola, George M. Mansouri, Mohammad D. Nasir, Nadim, Jr. Darouiche, Rabih O. TI Incubation Alone Is Adequate as a Culturing Technique for Cardiac Rhythm Management Devices SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID INFECTIONS; DIAGNOSIS; DEFIBRILLATORS; PACEMAKERS AB There exist no standardized methods for culturing cardiac rhythm management devices. To identify the most optimal culturing method, we compared various techniques that comprise vortex, sonication, and incubation or combinations thereof. Incubation alone yielded bacterial colony counts similar to those of other culturing combinations and is the least labor-intensive. C1 [Viola, George M.; Darouiche, Rabih O.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA. [Mansouri, Mohammad D.; Darouiche, Rabih O.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Nasir, Nadim, Jr.] Methodist Hosp, Dept Cardiol, Houston, TX 77030 USA. [Mansouri, Mohammad D.; Darouiche, Rabih O.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Viola, GM (reprint author), Baylor Coll Med, Dept Med, Infect Dis Sect, 1 Baylor Plaza,BCM 286,Room N1319, Houston, TX 77030 USA. EM viola@bcm.edu FU Baylor College of Medicine, Houston, TX FX This study was supported by funds from Baylor College of Medicine, Houston, TX. NR 10 TC 6 Z9 6 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD DEC PY 2009 VL 47 IS 12 BP 4168 EP 4170 DI 10.1128/JCM.01354-09 PG 3 WC Microbiology SC Microbiology GA 525QD UT WOS:000272230500062 PM 19846629 ER PT J AU Hennessy, S Leonard, CE Freeman, CP Metlay, JP Chu, X Strom, BL Bilker, WB AF Hennessy, Sean Leonard, Charles E. Freeman, Cristin P. Metlay, Joshua P. Chu, Xin Strom, Brian L. Bilker, Warren B. TI CYP2C9, CYP2C19, and ABCB1 Genotype and Hospitalization for Phenytoin Toxicity SO JOURNAL OF CLINICAL PHARMACOLOGY LA English DT Article DE Phenytoin; cytochrome P-450 CYP2C9; cytochrome P-450 CYP2C19; P-glycoprotein; ABCB1 protein, human; pharmacogenetics ID ANTIEPILEPTIC DRUGS; P-GLYCOPROTEIN; GENETIC-POLYMORPHISM; IDENTIFICATION; CARBAMAZEPINE; EPILEPSY; VARIANT; EFFLUX; BRAIN C1 [Hennessy, Sean; Leonard, Charles E.; Freeman, Cristin P.; Metlay, Joshua P.; Strom, Brian L.; Bilker, Warren B.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA USA. [Hennessy, Sean; Leonard, Charles E.; Freeman, Cristin P.; Metlay, Joshua P.; Strom, Brian L.; Bilker, Warren B.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA USA. [Hennessy, Sean; Leonard, Charles E.; Freeman, Cristin P.; Metlay, Joshua P.; Strom, Brian L.; Bilker, Warren B.] Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA. [Metlay, Joshua P.; Strom, Brian L.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Metlay, Joshua P.] Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Chu, Xin] Geisinger Clin Genom Core, Weis Ctr Res, Danville, PA USA. RP Hennessy, S (reprint author), 803 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. RI Leonard, Charles/K-3447-2012 FU US Department of Health & Human Services' (DHHS') National Institutes of Health [K23-AG000987]; US DHHS [P01-HS11530)]; Pfizer Scholars Grant FX This study was supported by the National Institute on Aging (K23-AG000987) of the US Department of Health & Human Services' (DHHS') National Institutes of Health, the Agency for Healthcare Research and Quality (P01-HS11530) of the US DHHS, and a Pfizer Scholars Grant for Faculty Development in Clinical Epidemiology. Except for comments received during the peer-review process for obtaining funding, the funding sources of this study had no role in its design, conduct, or interpretation. Dr Hennessy has served as a consultant to a law firm representing Pfizer and to Sanofi-Synthelabo and Teva Pharmaceuticals (manufacturers of phenytoin) in matters unrelated to phenytoin. Dr Strom has consulted for the following manufacturers of phenytoin in matters unrelated to phenytoin: Abbott Pharmaceuticals, Pfizer, Sanofi-Synthelabo, and Teva Pharmaceuticals. Dr Leonard, Ms Freeman, Dr Metlay, Dr Chu, and Dr Bilker have no conflicts to report. NR 18 TC 12 Z9 14 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0091-2700 J9 J CLIN PHARMACOL JI J. Clin. Pharmacol. PD DEC PY 2009 VL 49 IS 12 BP 1483 EP 1487 DI 10.1177/0091270009343006 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 523TO UT WOS:000272097700011 PM 19617466 ER PT J AU Gladstone, HB Moy, RL AF Gladstone, Hayes B. Moy, Ronald L. TI Suspension suture canthopexy: a minimally invasive procedure for correcting mild to moderate ectropion SO JOURNAL OF COSMETIC DERMATOLOGY LA English DT Article DE canthopexy; ectropion; lateral canthal tendon; blepharoplasty AB Background: Ectropion of the lower eyelid can occur after blepharoplasty as well as reconstructive procedures. Even mild ectropion can cause irritation or epiphora. Patients with preexisting lid laxity are at higher risk for post procedure ectropion. Aims: To describe a method for canthopexy and discuss its indications, benefits and limitations. Methods: We describe a technique that has been used on dozens of patients by both the authors. Results: This suspension suture canthopexy corrects mild to moderate ectropion. Discussion: Suspension suture canthopexy is effective in patients with the appropriate indications. It can be performed under local anesthesia with minimal complications. Unlike other forms of lid tightening, it does not change the shape of the eye. Conclusion: Suspension suture canthopexy which is an ancillary procedure for eyelid rejuvenation is valuable procedure to master by the dermatologic surgeon. C1 [Gladstone, Hayes B.] Stanford Univ, Dept Dermatol, Sch Med, Div Dermatol Surg, Stanford, CA 94305 USA. [Moy, Ronald L.] Univ Calif Los Angeles, Div Dermatol, Los Angeles Sch Med, Los Angeles, CA 90024 USA. [Moy, Ronald L.] Los Angeles Vet Adm Med Ctr, Div Dermatol, Los Angeles, CA USA. RP Gladstone, HB (reprint author), Stanford Univ Pavill B, Dept Dermatol, Div Dermatol Surg, 4th Floor,450 Broadway St, Redwood City, CA 94063 USA. EM hbglad@stanford.edu NR 17 TC 2 Z9 2 U1 0 U2 0 PU WILEY PERIODICALS, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN, MA 02148-529 USA SN 1473-2130 J9 J COSMET DERMATOL-US JI J. Cosmet. Dermatol. PD DEC PY 2009 VL 8 IS 4 BP 289 EP 294 DI 10.1111/j.1473-2165.2009.00463.x PG 6 WC Dermatology SC Dermatology GA V20JU UT WOS:000208137100009 PM 19958433 ER PT J AU Snyder, CW Burton, RC Brown, LE Kakade, MS Finan, KR Hawn, MT AF Snyder, Christopher W. Burton, Ryan C. Brown, Lindsay E. Kakade, Manasi S. Finan, Kelly R. Hawn, Mary T. TI Multiple Preoperative Endoscopic Interventions Are Associated with Worse Outcomes After Laparoscopic Heller Myotomy for Achalasia SO JOURNAL OF GASTROINTESTINAL SURGERY LA English DT Article; Proceedings Paper CT 50th Annual Meeting of the Society-for-Surgery-of-the-Alimentary-Tract CY MAY 30-JUN 04, 2009 CL Chicago, IL SP Soc Surg Alimentary Tract DE Achalasia; Pneumatic dilation; Botulinum toxin; Myotomy; Treatment failure; Outcomes ID BOTULINUM TOXIN INJECTION; RANDOMIZED CONTROLLED-TRIAL; ESOPHAGEAL ACHALASIA; PNEUMATIC DILATATION; DOR FUNDOPLICATION; FOLLOW-UP; OPERATION; DILATION; FAILURES; THERAPY AB The effect of preoperative pneumatic dilation or botulinum toxin injection on outcomes after laparoscopic Heller myotomy (LHM) for achalasia is unclear. We compared outcomes in patients with and without multiple preoperative endoscopic interventions. This cohort study categorized achalasia patients undergoing first-time LHM by the number of preoperative endoscopic interventions: zero or one intervention vs. two or more interventions. Outcomes of interest included surgical failure (defined as the need for re-intervention), gastrointestinal symptoms, and health-related quality of life. Logistic regression modeling was performed to determine the independent effect of multiple preoperative endoscopic interventions on the likelihood of surgical failure. One hundred thirty-four patients were included; 88 (66%) had zero to one preoperative intervention, and 46 (34%) had multiple (more than one) interventions. The incidence of surgical failure was 7% in the zero to one intervention group and 28% in the more than one intervention group (p < 0.01). Greater improvements in gastrointestinal symptoms and health-related quality of life were seen in the zero to one intervention group. On logistic regression modeling, the likelihood of surgical failure was significantly higher in the more than one intervention group (odds ratio = 5.1, 95% confidence interval 1.6-15.8, p = 0.005). Multiple endoscopic treatments are associated with poorer outcomes and should be limited to achalasia patients who fail surgical therapy. C1 [Kakade, Manasi S.; Hawn, Mary T.] Univ Alabama, Dept Surg, Sect Gastrointestinal Surg, Birmingham, AL 35294 USA. [Burton, Ryan C.; Brown, Lindsay E.] Univ Alabama, Sch Med, Birmingham, AL 35294 USA. [Finan, Kelly R.] Barnes Jewish Med Ctr, St Louis, MO USA. [Hawn, Mary T.] Birmingham Vet Affairs Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA. RP Hawn, MT (reprint author), Univ Alabama, Dept Surg, Sect Gastrointestinal Surg, 1922 7th Ave S,KB 428, Birmingham, AL 35294 USA. EM mhawn@uab.edu NR 36 TC 32 Z9 33 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1091-255X J9 J GASTROINTEST SURG JI J. Gastrointest. Surg. PD DEC PY 2009 VL 13 IS 12 BP 2095 EP 2102 DI 10.1007/s11605-009-1049-6 PG 8 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 526PJ UT WOS:000272303000001 PM 19789928 ER PT J AU Goetz, MB Hoang, T Henry, SR Knapp, H Anaya, HD Gifford, AL Asch, SM AF Goetz, Matthew Bidwell Hoang, Tuyen Henry, S. Randal Knapp, Herschel Anaya, Henry D. Gifford, Allen L. Asch, Steven M. CA QUERI-HIV Hepatitis Program TI Evaluation of the Sustainability of an Intervention to Increase HIV Testing SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE HIV testing; provider education; sustainability; VA hospitals ID HUMAN-IMMUNODEFICIENCY-VIRUS; IMPROVING PRIMARY-CARE; UNITED-STATES; CLINICAL REMINDERS; COST-EFFECTIVENESS; CHRONIC ILLNESS; PERSONS AWARE; QUERI SERIES; RISK; PREVENTION AB Sustainability-the routinization and institutionalization of processes that improve the quality of healthcare-is difficult to achieve and not often studied. To evaluate the sustainability of increased rates of HIV testing after implementation of a multi-component intervention in two Veterans Health Administration healthcare systems. Quasi-experimental implementation study in which the effect of transferring responsibility to conduct the provider education component of the intervention from research to operational staff was assessed. Persons receiving healthcare between 2005 and 2006 (intervention year) and 2006 and 2007 (sustainability year). Monthly HIV testing rate, stratified by frequency of clinic visits. The monthly adjusted testing rate increased from 2% at baseline to 6% at the end intervention year and then declined reaching 4% at the end of the sustainability year. However, the stratified, visit-specific testing rate for persons newly exposed to the intervention (i.e., having their first through third visits during the study period) increased throughout the intervention and sustainability years. Increases in the proportion of visits by patients who remained untested despite multiple, prior exposures to the intervention accounted for the aggregate attenuation of testing during the sustainability year. Overall, the percentage of patients who received an HIV test in the sustainability year was 11.6%, in the intervention year 11.1%, and in the pre-intervention year 5.0% Provider education combined with informatics and organizational support had a sustainable effect on HIV testing rates. The effect was most pronounced during patients' early contacts with the healthcare system. C1 [Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect 111F, Los Angeles, CA 90073 USA. [Hoang, Tuyen; Henry, S. Randal; Knapp, Herschel; Anaya, Henry D.; Asch, Steven M.] VA Greater Los Angeles Healthcare Syst, Gen Med 111G, Los Angeles, CA 90073 USA. [Gifford, Allen L.] Edith Nourse Rogers Mem Vet Hosp, VA Bedford Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Gifford, Allen L.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Gifford, Allen L.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Goetz, Matthew Bidwell; Anaya, Henry D.; Asch, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Goetz, MB (reprint author), VA Greater Los Angeles Healthcare Syst, Infect Dis Sect 111F, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM matthew.goetz@va.gov OI Goetz, Matthew/0000-0003-4542-992X FU Health Services Research & Development Service [SDP 06-001] FX Support: This project was supported by a research grant to Drs. Goetz and Asch by the Health Services Research & Development Service (SDP 06-001) NR 48 TC 19 Z9 20 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2009 VL 24 IS 12 BP 1275 EP 1280 DI 10.1007/s11606-009-1120-8 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 527OC UT WOS:000272375400003 PM 19798538 ER PT J AU Hoffman, RM Walter, LC AF Hoffman, Richard M. Walter, Louise C. TI Colorectal Cancer Screening in the Elderly: The Need for Informed Decision Making SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID FECAL OCCULT-BLOOD; UNITED-STATES; VETERANS; COMORBIDITY; MORTALITY; IMPACT; DEATH C1 [Hoffman, Richard M.] Univ New Mexico, New Mexico VA Hlth Care Syst, Albuquerque, NM 87108 USA. [Walter, Louise C.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. RP Hoffman, RM (reprint author), Univ New Mexico, New Mexico VA Hlth Care Syst, 1501 San Pedro Dr SE, Albuquerque, NM 87108 USA. EM rhoffman@unm.edu NR 14 TC 7 Z9 8 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2009 VL 24 IS 12 BP 1336 EP 1337 DI 10.1007/s11606-009-1121-7 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 527OC UT WOS:000272375400014 PM 19798537 ER PT J AU Tierney, WM Gerrity, MS Byrne, C AF Tierney, William M. Gerrity, Martha S. Byrne, Cindy TI Five Years Before the Masthead: Our Journey with the Journal of General Internal Medicine SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID HOSPITAL MEDICINE; POLICY; SOCIETY; CARE C1 [Tierney, William M.] Indiana Univ, Sch Med, Indianapolis, IN USA. [Tierney, William M.; Byrne, Cindy] Regenstrief Inst Inc, Indianapolis, IN USA. [Gerrity, Martha S.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Gerrity, Martha S.] Portland VA Med Ctr, Portland, OR USA. RP Tierney, WM (reprint author), Hlth Informat & Translat Sci Bldg,410 W 10th St,S, Indianapolis, IN 46202 USA. EM wtierney@iupui.edu NR 17 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2009 VL 24 IS 12 BP 1349 EP 1355 DI 10.1007/s11606-009-1188-1 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 527OC UT WOS:000272375400016 PM 19936844 ER PT J AU Wang, LY Leverenz, JB Larson, EB Vavrek, DA Kukull, WA McCormick, W Bowen, JD Teri, L Montine, T Tsuang, DW AF Wang, Lucy Y. Leverenz, James B. Larson, Eric B. Vavrek, Darcy A. Kukull, Walter A. McCormick, Wayne Bowen, James D. Teri, Linda Montine, Thomas Tsuang, Debby W. TI Cognitive Impairment in Older Adults Without Dementia: Clinical and Pathologic Outcomes in a Community-Based Sample SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY LA English DT Article DE autopsy; neuropathology; dementia; mild cognitive impairment ID ALZHEIMER-DISEASE PATHOLOGY; MEMORY COMPLAINTS; CONSORTIUM; DIAGNOSIS; ASSOCIATION; PROGRESSION; ESTABLISH; REGISTRY; HEALTH; CERAD AB This study examines clinical and neuropathologic characteristics of 37 participants in a community-based dementia series who had cognitive complaints at enrollment but did not meet dementia criteria. Participants had neuropsychological testing, were followed until death, and underwent autopsy. Twenty-four participants progressed to dementia, and their baseline characteristics were analyzed. Of the 24, 13 met criteria for neuropathologic Alzheimer disease (AD). The 13 participants who progressed to neuropathologic AD (mean intake age 78.5 +/- 7.7, mean enrollment 6.4 +/- 2.1 years) performed worse than the 11 who progressed to neuropathologic non-AD dementias (mean intake age 79.0 +/- 6.0, mean enrollment 6.0 +/- 3.2 years) on baseline Wechsler Memory Scale (WMS) delayed logical memory (3.4 +/- 2.9 vs 6.3 +/- 3.9, P = .05) and delayed visual reproduction (1.4 +/- 2.1 vs 3.1 +/- 2.7, P = .02). These observations are consistent with the view that nondemented patients with underlying AD may be more likely to present with memory than nonmemory cognitive impairment. C1 [Wang, Lucy Y.; Leverenz, James B.; Tsuang, Debby W.] VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98018 USA. [Leverenz, James B.] VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA 98018 USA. [Wang, Lucy Y.; Leverenz, James B.; Vavrek, Darcy A.; Tsuang, Debby W.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Kukull, Walter A.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Larson, Eric B.; McCormick, Wayne] Univ Washington, Dept Internal Med, Seattle, WA 98195 USA. [Montine, Thomas] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Teri, Linda] Univ Washington, Dept Psychosocial & Community Hlth, Seattle, WA 98195 USA. [Kukull, Walter A.] Natl Alzheimers Coordinating Ctr, Seattle, WA USA. [Larson, Eric B.] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA USA. [Vavrek, Darcy A.] Western States Chiropract Coll, Portland, OR USA. [Bowen, James D.] Evergreen Healthcare Syst, Kirkland, WA USA. RP Wang, LY (reprint author), VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, 1660 S Columbian Way,S-116-6E, Seattle, WA 98018 USA. EM wanglucy@u.washington.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894; Kukull, Walter/0000-0001-8761-9014 FU NIH [AG006781, NS048595]; Department of Veterans Affairs Mental Illness Research, Education, and Clinical Centers Special Fellowship in Advanced Psychiatry FX This research was presented in part as a poster at the 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, Spain, July 2006. The study was supported by research grants from NIH (AG006781, NS048595) and the Department of Veterans Affairs Mental Illness Research, Education, and Clinical Centers Special Fellowship in Advanced Psychiatry. We gratefully acknowledge G. Stennis Watson, PhD, for his assistance in interpreting neuropsychological data and Andrew David for his editorial assistance. NR 36 TC 2 Z9 2 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0891-9887 J9 J GERIATR PSYCH NEUR JI J. Geriatr. Psychiatry Neurol. PD DEC PY 2009 VL 22 IS 4 BP 256 EP 265 DI 10.1177/0891988709335796 PG 10 WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry GA 520SC UT WOS:000271867200006 PM 19433862 ER PT J AU Maloney, JP AF Maloney, James Peter TI Genetic Factors Impacting Therapy in Acute Lung Injury/Acute Respiratory Distress Syndrome SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Article DE acute lung injury; ARDS; genetics; pre-B-cell colony-enhancing factor; mannose-binding lectin 2 ID MANNOSE-BINDING LECTIN; COLONY-ENHANCING FACTOR; TRANSCRIPTION FACTOR NRF2; UNITED-STATES; SEPSIS; LIPOPOLYSACCHARIDE; SUSCEPTIBILITY; POLYMORPHISMS; NEUTROPHIL; DISEASE AB Acute lung injury (ALI) and its most severe form the acute respiratory distress syndrome occur in patients who have a predisposing severe inflammatory insult to the lung. Most often ALI is due to sepsis from bacterial infection, but ALI can occur with any infection and with noninfectious insults such as severe trauma, acute pancreatitis, aspiration, and near-drowning. After any of these insults, the interindividual risk of progression to ALI and the risk of death remain difficult to predict. Our inability to predict an individual's susceptibility to acute lung injury has long suggested that genetic factors influence ALI risk. There is substantial evidence for heritable predispositions to severe infections and an emerging body of literature implicating genetic factors in ALI pathogenesis. A paradigm is emerging that the genetic risk for ALI can be best understood in terms of factors that control 3 overlapping stages of ALI pathogenesis: risk for the acquisition of a predisposing condition (such as a severe pneumonia), risk for progression to lung injury during systemic inflammatory states (such as severe sepsis), and risk for failure of endogenous mechanisms to resolve the lung injury. The evidence supporting this paradigm is herein reviewed, along with potential treatment strategies that could be directed by knowledge of specific genetic factors in an individual patient. C1 [Maloney, James Peter] Univ Colorado, Div Pulm & Crit Care Med, Denver, CO 80262 USA. [Maloney, James Peter] Denver VA Med Ctr, Denver, CO USA. RP Maloney, JP (reprint author), Univ Colorado, Div Pulm & Crit Care Med, 4200 E 9th Ave,C-272, Denver, CO 80262 USA. EM james.maloney@uchsc.edu RI maloney, james/K-9428-2015 OI maloney, james/0000-0001-8348-4650 FU NHLBI [HL071618] FX Supported by NHLBI grant HL071618. NR 26 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD DEC PY 2009 VL 57 IS 8 BP 865 EP 869 PG 5 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 531CW UT WOS:000272641300017 PM 18827716 ER PT J AU Jin, JF Mullen, TD Hou, Q Bielawski, J Bielawska, A Zhang, XM Obeid, LM Hannun, YA Hsu, YT AF Jin, Junfei Mullen, Thomas D. Hou, Qi Bielawski, Jacek Bielawska, Alicja Zhang, Xiaoming Obeid, Lina M. Hannun, Yusuf A. Hsu, Yi-Te TI AMPK inhibitor Compound C stimulates ceramide production and promotes Bax redistribution and apoptosis in MCF7 breast carcinoma cells SO JOURNAL OF LIPID RESEARCH LA English DT Article DE AMP-activated protein kinase signaling pathway; sphingolipid; cell death ID ACTIVATED PROTEIN-KINASE; MITOCHONDRIAL-MEMBRANE; ACID SPHINGOMYELINASE; DEPENDENT PATHWAY; SALVAGE PATHWAY; SYNTHASE; FAMILY; PROLIFERATION; SPHINGOLIPIDS; TRANSLOCATION AB Compound C is commonly used as an inhibitor of AMP-activated protein kinase (AMPK), which serves as a key energy sensor in cells. In this study, we found that Compound C treatment of MCF7 cells led to Bax redistribution from the cytoplasm to mitochondria and cell death. However, this effect does not involve AMPK. In addition, we found that treatment with this compound leads to an enhanced ceramide production. Analyses by quantitative PCR and ceramide synthase activity assay suggest that ceramide synthase 5 (LASS/CerS 5) is involved in Compound C-induced ceramide upregulation. Downregulation of LASS/CerS 5 was found to attenuate Compound C-mediated ceramide production, Bax redistribution, and cell death.-Jin, J., T. D. Mullen, Q. Hou, J. Bielawski, A. Bielawska, X. Zhang, L. M. Obeid, Y. A. Hannun, and Y-T. Hsu. AMPK inhibitor Compound C stimulates ceramide production and promotes Bax redistribution and apoptosis in MCF7 breast carcinoma cells. J. Lipid Res. 2009. 50: 2389-2397. C1 [Jin, Junfei; Hou, Qi; Bielawski, Jacek; Bielawska, Alicja; Zhang, Xiaoming; Hannun, Yusuf A.; Hsu, Yi-Te] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Jin, Junfei] Univ S China, Res Ctr Life Sci, Hengyang 421001, Hunan, Peoples R China. [Mullen, Thomas D.; Obeid, Lina M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Hou, Qi] Peking Union Med Coll, Inst Mat Med, Dept Pharmacol, Beijing 100050, Peoples R China. Chinese Acad Med Sci, Beijing 100050, Peoples R China. [Obeid, Lina M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Hsu, YT (reprint author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. EM hsuy@musc.edu OI obeid, lina/0000-0002-0734-0847 FU National Institutes of Health [NS40932, NCRR-C06RR018823] FX This research was supported in part by National Institutes of Health Grant NS40932 ( to Y-T.H.). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. Special acknowledgment is given for the National Institutes of Health Grant NCRR-C06RR018823 in providing laboratory space for lipidomics shared resource in the Children's Research Institute. NR 45 TC 53 Z9 54 U1 1 U2 7 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0022-2275 J9 J LIPID RES JI J. Lipid Res. PD DEC PY 2009 VL 50 IS 12 BP 2389 EP 2397 DI 10.1194/jlr.M900119-JLR200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 519LV UT WOS:000271769000007 PM 19528633 ER PT J AU Schrock, LE Ostrem, JL Turner, RS Shimamoto, SA Starr, PA AF Schrock, Lauren E. Ostrem, Jill L. Turner, Robert S. Shimamoto, Shoichi A. Starr, Philip A. TI The Subthalamic Nucleus in Primary Dystonia: Single-Unit Discharge Characteristics SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Review ID DEEP BRAIN-STIMULATION; GLOBUS-PALLIDUS INTERNUS; PRIMARY MOTOR CORTEX; IDIOPATHIC CERVICAL DYSTONIA; LOCAL-FIELD POTENTIALS; PARKINSONS-DISEASE; BASAL GANGLIA; NEURONAL-ACTIVITY; GENERALIZED DYSTONIA; TECHNICAL APPROACH AB Schrock LE, Ostrem JL, Turner RS, Shimamoto SA, Starr PA. The subthalamic nucleus in primary dystonia: single-unit discharge characteristics. J Neurophysiol 102: 3740-3752, 2009. First published October 21, 2009; doi:10.1152/jn.00544.2009. Most models of dystonia pathophysiology predict alterations of activity in the basal ganglia thalamocortical motor circuit. The globus pallidus interna (GPi) shows bursting and oscillatory neuronal discharge in both human dystonia and in animal models, but it is not clear which intrinsic basal ganglia pathways are implicated in this abnormal output. The subthalamic nucleus (STN) receives prominent excitatory input directly from cortical areas implicated in dystonia pathogenesis and inhibitory input from the external globus pallidus. The goal of this study was to elucidate the role of the STN in dystonia by analyzing STN neuronal discharge in patients with idiopathic dystonia. Data were collected in awake patients undergoing microelectrode recording for implantation of STN deep brain stimulation electrodes. We recorded 62 STN neurons in 9 patients with primary dystonia. As a comparison group, we recorded 143 STN neurons in 20 patients with Parkinson's disease (PD). Single-unit activity was discriminated off-line by principal component analysis and evaluated with respect to discharge rate, bursting, and oscillatory activity. The mean STN discharge rate in dystonia patients was 26.3 Hz (SD 13.6), which was lower than that in the PD patients (35.6 Hz, SD 15.2), but higher than published values for subjects without basal ganglia dysfunction. Oscillatory activity was found in both disorders, with a higher proportion of units oscillating in the beta range in PD. Bursting discharge was a prominent feature of both dystonia and PD, whereas sensory receptive fields were expanded in PD compared with dystonia. The STN firing characteristics, in conjunction with those previously published for GPi, suggest that bursting and oscillatory discharge in basal ganglia output may be transmitted via pathways involving the STN and provide a pathophysiologic rationale for STN as a surgical target in dystonia. C1 [Shimamoto, Shoichi A.; Starr, Philip A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. [Schrock, Lauren E.; Ostrem, Jill L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Schrock, Lauren E.; Ostrem, Jill L.; Starr, Philip A.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA USA. [Turner, Robert S.] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA USA. [Turner, Robert S.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA USA. RP Starr, PA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, 533 Parnassus Ave,Box 0445, San Francisco, CA 94143 USA. EM starrp@neurosurg.ucsf.edu RI Turner, Robert/A-9695-2008 OI Turner, Robert/0000-0002-6074-4365 FU NINDS NIH HHS [R01 NS044551, R01 NS044551-06, R21 NS055197, R21 NS055197-01A2] NR 102 TC 28 Z9 29 U1 1 U2 8 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD DEC PY 2009 VL 102 IS 6 BP 3740 EP 3752 DI 10.1152/jn.00544.2009 PG 13 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 528RB UT WOS:000272463200054 PM 19846625 ER PT J AU Raphael, KG Janal, MN Ananthan, S Cook, DB Staud, R AF Raphael, Karen G. Janal, Malvin N. Ananthan, Sowmya Cook, Dane B. Staud, Roland TI Temporal Summation of Heat Pain in Temporomandibular Disorder Patients SO JOURNAL OF OROFACIAL PAIN LA English DT Article DE aftersensations; chronic pain; temporal summation; temporomandibular disorders; wind-up ID EXPERIMENTALLY EVOKED PAIN; 2ND PAIN; FIBROMYALGIA SYNDROME; MYOFASCIAL PAIN; WIND-UP; SENSITIVITY; STIMULATION; SKIN; TMD; SENSITIZATION AB Aims: To compare patients with temporomandibular disorders (TMD) to control subjects on two measures of central processing, ie, temporal summation of beat pain and decay of subsequent aftersensations, following thermal stimulation in both a trigeminal and extratrigeminal area. Methods: A "wind-up" protocol was used in which 19 female TMD patients and 17 female controls were exposed to IS beat stimuli at a rate of 0.3 Hz. Numeric pain ratings were elicited after the 1st, 5th, 10th, and 15th stimulus presentation and every 15 seconds after final presentation (aftersensations) for up to 2 minutes. In separate trials, the thermode was placed on the thenar eminence of the hand and the skin overlying the masseter muscle. Results: Groups did not differ with respect to the slope of wind-up when stimulated at either anatomic site, although asymptotic levels occurred sooner for TMD patients than for controls. In analysis of aftersensations, a significant group X site X time interaction was detected, in which TMD patients experienced more prolonged painful aftersensations than controls when stimulated on the skin overlying the masseter muscles. Conclusion: These results are consistent with the presence of enhanced central sensitivity in TMD and suggest that this sensitivity may be largely confined to the region of clinical pain. This contrasts with conditions such as fibromyalgia, where central sensitivity appears to be widespread. J OROFAC PAIN 2009;23:54-64 C1 [Raphael, Karen G.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, Newark, NJ 07101 USA. [Raphael, Karen G.] Univ Med & Dent New Jersey, Dept Diagnost Sci, Newark, NJ USA. [Cook, Dane B.] Univ Wisconsin, William S Middleton Mem Vet Hosp, Madison, WI 53706 USA. [Cook, Dane B.] Univ Wisconsin, Dept Kinesiol, Madison, WI 53706 USA. [Staud, Roland] Univ Florida, Gainesville, FL USA. RP Raphael, KG (reprint author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, 183 S Orange Ave,BHSB F-1555,POB 1709, Newark, NJ 07101 USA. EM raphaekg@umdnj.edu FU NIDCR NIH HHS [R01 DE018569-01, R01 DE018569] NR 46 TC 40 Z9 40 U1 1 U2 4 PU QUINTESSENCE PUBLISHING CO INC PI HANOVER PARK PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA SN 1064-6655 J9 J OROFAC PAIN JI J. Orofac. Pain PD WIN PY 2009 VL 23 IS 1 BP 54 EP 64 PG 11 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 453SU UT WOS:000266633000010 PM 19264036 ER PT J AU Blackman, AJ Blevins, JJ Sangeorzan, BJ Ledoux, WR AF Blackman, Andrew J. Blevins, Joanna J. Sangeorzan, Bruce J. Ledoux, William R. TI Cadaveric Flatfoot Model: Ligament Attenuation and Achilles Tendon Overpull SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE pes planus; flatfoot; Achilles tendon contracture; cadaver model ID POSTERIOR TIBIAL TENDON; ACQUIRED FLATFOOT; BIOMECHANICAL EVALUATION; FOOT; DEFORMITY; JOINT; DYSFUNCTION; KINEMATICS; INSUFFICIENCY; OPERATION AB Flatfoot deformity is characterized by loss of the medial longitudinal arch, forefoot abduction, hindfoot eversion, and often Achilles tendon contracture. Our objectives were to validate a cadaveric flatfoot model that involves selective ligament attenuation and to determine if Achilles tendon overpull is associated with increased pes planes severity. We measured the three-dimensional (3D) orientation of the bones of interest in the unloaded, loaded, and Achilles tendon overpull conditions. A flatfoot model was created by attenuating ligaments involved in the pes planes deformity followed by cyclic axial loading, and bone orientations were acquired in the three conditions. Significant differences seen between normal feet and flat feet were consistent with those seen with the pes planes deformity. The first metatarsal dorsiflexed and abducted relative to the talus. The navicular abducted relative to the talus. The calcaneus everted relative to the tibia. The talus plantar flexed and adducted. Achilles overpull resulted in first metatarsal-to-tales dorsiflexion and navicular-to-tales abduction. Thus, selective ligament attenuation followed by cyclic axial loading can create a cadaveric flatfoot model consistent with the in vivo deformity. Longitudinal arch depression, hindfoot eversion, talonavicular joint abduction, forefoot abduction, and talar plantar flexion were seen. Simulated Achilles tendon contracture increased the severity of the deformity, particularly in arch depression and forefoot abduction. (C) 2009 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 27:1547-1554, 2009 C1 [Blackman, Andrew J.; Blevins, Joanna J.; Sangeorzan, Bruce J.; Ledoux, William R.] VA Puget Sound Hlth Care Syst, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Dept Vet Affairs, Seattle, WA 98108 USA. [Sangeorzan, Bruce J.; Ledoux, William R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. [Ledoux, William R.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. RP Ledoux, WR (reprint author), VA Puget Sound Hlth Care Syst, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Dept Vet Affairs, Seattle, WA 98108 USA. EM wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714; Blackman, Andrew/0000-0003-4159-5242 FU VA Rehabilitation Research and Development Service [A2661C]; University of Washington Medical Student Research and Training Program FX Andrew J. Blackman is now at the Department of Orthopaedic Surgery, Washington University, Saint Louis, MO 63110. This study was sponsored by VA Rehabilitation Research and Development Service grant no. A2661C and the University of Washington Medical Student Research and Training Program. NR 35 TC 27 Z9 27 U1 2 U2 6 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0736-0266 J9 J ORTHOP RES JI J. Orthop. Res. PD DEC PY 2009 VL 27 IS 12 BP 1547 EP 1554 DI 10.1002/jor.20930 PG 8 WC Orthopedics SC Orthopedics GA 523UV UT WOS:000272101000002 PM 19530145 ER PT J AU Seow, H Snyder, CF Mularski, RA Shugarman, LR Kutner, JS Lorenz, KA Wu, AW Dy, SM AF Seow, Hsien Snyder, Claire F. Mularski, Richard A. Shugarman, Lisa R. Kutner, Jean S. Lorenz, Karl A. Wu, Albert W. Dy, Sydney M. TI A Framework for Assessing Quality Indicators for Cancer Care at the End of Life SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Article DE Cancer; quality indicators; framework; end of life; palliative care ID PALLIATIVE CARE; PERFORMANCE AB Patients with advanced cancer often do not receive high-quality pain and symptom management or support with. coordination of care, communication, and decision making. Implementing quality indicators that are reflective of the scope of care, feasible to implement, and supported by evidence might help to identify areas and settings most in need of improvement. However, recent reviews and policy initiatives identified only a few indicators that met these criteria. To help advance quality indicator development and implementation in this area, we developed a conceptual framework based on previous related initiatives, updated reviews of end-of-life cancer quality indicators and relevant data sources, and expert input. The framework describes five steps for developing and assessing a quality indicator for end-of-life care, defining the I) population of focus, 2) broad quality domains, 3) specific target areas, 4) steps of the care process, and 5) evaluation criteria for quality indicators. The defined population includes seriously or terminally ill cancer patients, who are unlikely to recover or stabilize, and their families. Domains include the structure and processes of care; the physical, psychiatric, psychosocial spiritual, and cultural aspects of care; as well as the care of the imminently dying, ethical and legal issues, and the delivery of care. Evaluation criteria include importance; scientific acceptability, including validity, evidence to improve outcomes, reliability, responsiveness, and variability; usability; and feasibility, including ready data sources. By using this conceptual framework, indicator developers, researchers, and policymakers can, refine and implement indicator sets to effectively evaluate and improve care at the end of life. J Pain Symptom Manage 2009;38:903-912. (C) 2009 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved. C1 [Seow, Hsien; Wu, Albert W.; Dy, Sydney M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA. [Snyder, Claire F.] Johns Hopkins Sch Med, Div Gen Internal Med, Baltimore, MD USA. [Mularski, Richard A.] Oregon Hlth & Sci Univ, Ctr Hlth Res, Kaiser Permanente NW, Portland, OR 97201 USA. [Shugarman, Lisa R.] RAND Corp, Santa Monica, CA USA. [Kutner, Jean S.] Univ Colorado, Sch Med, Div Gen Internal Med, Aurora, CO USA. [Lorenz, Karl A.] VA Greater Los Angeles Healthcare Syst, Vet Integrated Palliat Program, Los Angeles, CA USA. RP Dy, SM (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, 624 N Broadway,Room 609, Baltimore, MD 21205 USA. EM sdy@jhsph.edu FU Agency for Healthcare Research and Quality [290-2005-00341]; U.S. Department of Health and Human Services FX This project was funded under Contract No. 290-2005-00341 from the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, as part of the Developing Evidence to Inform Decisions About Effectiveness (DEcIDE) program. The authors of this report are responsible for its content. Statements in the report should not be construed as endorsement by the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services. The authors have no disclosures. NR 22 TC 23 Z9 23 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD DEC PY 2009 VL 38 IS 6 BP 903 EP 912 DI 10.1016/j.jpainsymman.2009.04.024 PG 10 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 617KS UT WOS:000279280200010 PM 19775860 ER PT J AU Larauche, M Kiank, C Tache, Y AF Larauche, M. Kiank, C. Tache, Y. TI CORTICOTROPIN RELEASING FACTOR SIGNALING IN COLON AND ILEUM: REGULATION BY STRESS AND PATHOPHYSIOLOGICAL IMPLICATIONS SO JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY LA English DT Article; Proceedings Paper CT 13th International Conference on Gastrointestinal Research/International Conference on Ulcer Research CY SEP 10-16, 2009 CL Split, CROATIA DE corticotropin releasing factor; corticotropin releasing factor receptor; urocortin; stress; colon; ileum; irritable bowel syndrome; inflammatory bowel disease ID IRRITABLE-BOWEL-SYNDROME; INTESTINAL BARRIER FUNCTION; FUNCTIONAL GASTROINTESTINAL DISORDERS; ENTERIC NERVOUS-SYSTEM; GUINEA-PIG ILEUM; CHRONIC PSYCHOLOGICAL STRESS; INDUCED VISCERAL HYPERSENSITIVITY; FOLLICLE-ASSOCIATED EPITHELIUM; NEONATAL MATERNAL SEPARATION; 5-HT3 RECEPTOR ANTAGONISTS AB It is well established that central corticotropin releasing factor (CRF) signaling mediates the gastrointestinal responses to stress. However, as shown in the brain, both CRF receptors and ligands are also widely expressed in the colon and the ileum of humans and rodents, and stress modulates their expression. Several functional studies documented that peripheral injection of CRF or urocortin stimulates colonic transit, motility, Fos expression in myenteric neurons, and defecation through activation of CRF1 receptors, whereas it decreases ileal contractility via CRF2 receptors. Additionally, intraperitoneal administration of CRF induces colonic mast cells degranulation via both CRF1 and CRF2 receptors and increases ion secretion and mucosal permeability to macromolecules, which can in turn promote intestinal inflammation and alter visceral sensitivity. Most peripheral CRF-induced alterations of colonic and Heal functions mimic effects which are observed after stress exposure, and CRF receptor antagonists given peripherally prevent stress-induced GI dysfunction. Furthermore, CRF peptides can reproduce secretomotor and mucosal alterations in vitro. Therefore, accumulated clinical and preclinical evidence supports in addition to the brain, a role for peripheral CRF signaling in mediating stress-induced effects on gastrointestinal sensorimotor, mucosal and immune functions, that may be components of underlying mechanisms involved in stress-related impact on inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). C1 VA Greater Los Angeles Hlth Care Syst, Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Dept Med, Angeles, CA USA. RP Larauche, M (reprint author), VA Greater Los Angeles Hlth Care Syst, Bldg 115,Room 3,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM mlarauche@mednet.ucla.edu OI Larauche, Muriel/0000-0003-3320-3675 FU NIDDK NIH HHS [P50 DK-64539, P50 DK-57238, P50 DK064539, R01 DK-57238, R01 DK057238, R01 DK057238-10] NR 198 TC 53 Z9 53 U1 0 U2 7 PU POLISH PHYSIOLOGICAL SOC PI GRZEGORZECKA PA JAGIELLONIAN UNIV SCHOOL MED, INST PHYSIOLOGY, 31-531 KRAKOW, 16 GRZEGORZECKA, POLAND SN 0867-5910 J9 J PHYSIOL PHARMACOL JI J. Physiol. Pharmacol. PD DEC PY 2009 VL 60 SU 7 BP 33 EP 46 PG 14 WC Physiology SC Physiology GA 589RR UT WOS:000277171200005 PM 20388944 ER PT J AU Mestecky, J Moldoveanu, Z Smith, PD Hel, Z Alexander, RC AF Mestecky, Jiri Moldoveanu, Zina Smith, Phillip D. Hel, Zdenek Alexander, Rashada C. TI Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection SO JOURNAL OF REPRODUCTIVE IMMUNOLOGY LA English DT Article; Proceedings Paper CT International Congress on Bio-Immunoregulatory Mechanisms Associated with Reproductive Organs CY FEB 09-13, 2009 CL Natl Inst Immunol, New Delhi, INDIA HO Natl Inst Immunol DE HIV-1; Mucosal immunity; Macrophages; IgA ID VIRUS TYPE-1 INFECTION; T-CELL DEPLETION; NEUTRALIZING ANTIBODIES; 1-INFECTED INDIVIDUALS; VAGINAL TRANSMISSION; RHESUS MACAQUES; IGA ANTIBODIES; SECRETIONS; RESPONSES; PROTECTION AB The male and female genital tracts are protected by a local immune system that displays features distinguishing them from other mucosal sites. In contrast to the intestinal tract, where locally produced IgA is the dominant Ig, secretions of the male and female genital tract contain predominantly IgG of both local and systemic origin. Genital tract tissues also lack mucosal lymphoepithelial inductive sites analogous to intestinal Peyer's patches; consequently, local immunization or infections with sexually transmitted pathogens induce low immune responses. Human immunodeficiency virus 1 (HIV-1) infection must be primarily considered as a mucosal disease with extensive involvement of the systemic immune compartment. Although the majority of infections is acquired through the genital mucosa,a high rate of virus replication and profound CD4(+) T cell depletion occurs in the intestinal mucosa and other mucosal tissues shortly after infection. Evaluation of HIV-specific antibodies in sera and external secretions, including vaginal washes and semen, unexpectedly revealed a selective lack of IgA responses. Moreover, specific antibody-secreting cells in peripheral blood were of the IgG isotype, even in mucosally infected individuals. Whether humoral responses to previously or newly encountered antigens are compromised in HIV-1-infected persons is under current investigation. (C) 2009 Elsevier Ireland Ltd. All rights reserved. C1 [Mestecky, Jiri; Moldoveanu, Zina; Smith, Phillip D.; Hel, Zdenek; Alexander, Rashada C.] Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA. [Mestecky, Jiri; Smith, Phillip D.] Univ Alabama, Dept Med, Birmingham, AL 35294 USA. [Hel, Zdenek] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. [Mestecky, Jiri] Charles Univ Prague, Dept Microbiol & Immunol, Prague, Czech Republic. [Smith, Phillip D.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Mestecky, J (reprint author), Univ Alabama, Dept Microbiol, Box 1,845 19th St S, Birmingham, AL 35294 USA. EM mestecky@uab.edu OI Hel, Zdenek/0000-0002-4923-4794 FU NCRR NIH HHS [RR-20136]; NIAID NIH HHS [AI-74438, AI074438, R01 AI074438, P01 AI083027, R01 AI074438-01A1, AI083027, AI-83027, P01 AI083027-01, R21 AI087178]; NIDDK NIH HHS [DK-64400, R01 DK054495-02, R01 DK047322-10, R01 DK047322, DK-54495, DK-47322, R24 DK064400, R01 DK054495] NR 41 TC 30 Z9 30 U1 0 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-0378 J9 J REPROD IMMUNOL JI J. Reprod. Immunol. PD DEC PY 2009 VL 83 IS 1-2 BP 196 EP 200 DI 10.1016/j.jri.2009.07.005 PG 5 WC Immunology; Reproductive Biology SC Immunology; Reproductive Biology GA 536ED UT WOS:000273024800036 PM 19853927 ER PT J AU Walker, HC Phillips, DE Boswell, DB Guthrie, BL Guthrie, SL Nicholas, AP Montgomery, EB Watts, RL AF Walker, Harrison C. Phillips, Daniel E. Boswell, Deborah B. Guthrie, Barton L. Guthrie, Stephanie L. Nicholas, Anthony P. Montgomery, Erwin B. Watts, Ray L. TI Relief of Acquired Stuttering Associated With Parkinson's Disease by Unilateral Left Subthalamic Brain Stimulation SO JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH LA English DT Article DE stuttering; Parkinson's disease; subthalamic nucleus; deep brain stimulation; speech ID TOURETTE-SYNDROME; THALAMIC-STIMULATION; NUCLEUS STIMULATION; ALE METAANALYSIS; FOLLOW-UP; SPEECH; ALLEVIATION; HYPOTHESIS; PATIENT; SYSTEM AB Purpose: In this article, the authors report a case of acquired stuttering associated with Parkinson's disease (PD) that was responsive to unilateral subthalamic nucleus deep-brain stimulation (STN DBS) in the language-dominant hemisphere. Method: A single-subject, masked, multiple baseline design was used to evaluate the effects of unilateral left STN DBS on stuttering associated with PD. The patient underwent 3 formal speech assessments of spontaneous speech and the reading of passages with DBS off and on. Speech samples were videotaped and placed in random order, and 2 independent speech-language pathologists calculated the percentage of stuttered syllables and classified individual stuttering events. Results: Stuttering improved significantly in the DBS-on condition. In total, 10% of syllables were affected by stuttering events with DBS off, and less than 1% of syllables were affected by stuttering events with DBS on (n = 2,281 syllables, p < .00001, in a chi(2) test). The effect of unilateral STN DBS on stuttering was relatively independent of whether the patient was on or off dopaminergic medications. Conclusion: This article emphasizes the important role of the subthalamic region in the motor control of speech and language. C1 [Walker, Harrison C.; Guthrie, Barton L.; Guthrie, Stephanie L.; Nicholas, Anthony P.; Montgomery, Erwin B.; Watts, Ray L.] Univ Alabama, Birmingham, AL USA. [Phillips, Daniel E.] Auburn Univ, Auburn, AL 36849 USA. [Boswell, Deborah B.] Profess Speech Serv, Birmingham, AL USA. [Nicholas, Anthony P.; Montgomery, Erwin B.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Walker, HC (reprint author), Univ Alabama, Dept Neurol, 1720 7th Ave, Birmingham, AL 35212 USA. EM hcwalker@uab.edu NR 38 TC 11 Z9 11 U1 1 U2 5 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA SN 1092-4388 J9 J SPEECH LANG HEAR R JI J. Speech Lang. Hear. Res. PD DEC 1 PY 2009 VL 52 IS 6 BP 1652 EP 1657 DI 10.1044/1092-4388(2009/08-0089) PG 6 WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation GA 528YK UT WOS:000272482700017 PM 19951930 ER PT J AU Turner, TH LaRowe, S Horner, MD Herron, J Malcolm, R AF Turner, Travis H. LaRowe, Steven Horner, Michael David Herron, Janice Malcolm, Robert TI Measures of cognitive functioning as predictors of treatment outcome for cocaine dependence SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article DE Cocaine dependence; Treatment outcome prediction; Neuropsychology; Cognition; Substance dependence; Cognitive-Behavioral therapy; Amlodipine; Executive functioning ID NEUROCOGNITIVE DEFICITS; ALCOHOL DEPENDENCE; DECISION-MAKING; IMPAIRMENT; DRINKING; ABUSE; ACQUISITION; RELAPSE AB Amlodipine is a calcium-channel antagonist with neuropharmacological properties believed to be protective against cerebral hypoperfusion, microinfarcts, and excitoxic cell death. Based on its pharmacological properties, we hypothesized that amlodipine would be associated with improved attention, processing speed, memory, and executive functioning at treatment follow-up in 84 cocaine-dependent individuals enrolled in a 12-week, placebo-controlled, double-blind clinical trial of amlodipine. We also hypothesized that better cognitive functioning at baseline would be associated with reduced cocaine use (negative urine drug screens) and longer treatment retention (last session attended). Results indicated that amlodipine produced no measurable benefit in cognitive functioning. Percent perseverative errors on Wisconsin Card Sorting Test was negatively correlated with treatment retention (n = 84, r = -.350, p <.01). No other findings were significant. Thus, cocaine-dependent individuals who repeated mistakes and benefited less from corrective feedback on a problem-solving task discontinued treatment earlier. Notably, no other cognitive measures predicted treatment outcome. The observed relationship implicates the relevance of executive functioning to treatment outcome for cocaine dependence. (C) 2009 Elsevier Inc. All rights reserved. C1 [Turner, Travis H.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Turner, Travis H.; LaRowe, Steven; Horner, Michael David; Herron, Janice; Malcolm, Robert] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Turner, Travis H.; LaRowe, Steven; Horner, Michael David] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Turner, TH (reprint author), Med Univ S Carolina, Dept Neurosci, 96 Jonathan Lucas St,Suite 307 Clin Sci Bldg,MSC, Charleston, SC 29425 USA. EM turnertr@musc.edu OI LaRowe, Steven/0000-0002-7664-2451 FU NIDA NIH HHS [R01-DA11454] NR 36 TC 43 Z9 43 U1 1 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD DEC PY 2009 VL 37 IS 4 BP 328 EP 334 DI 10.1016/j.jsat.2009.03.009 PG 7 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 518BY UT WOS:000271666300002 PM 19394790 ER PT J AU Gopaldas, RR Huh, J Bakaeen, FG Wang, XL Coselli, JS LeMaire, SA Chu, D AF Gopaldas, Raja R. Huh, Joseph Bakaeen, Faisal G. Wang, Xing Li Coselli, Joseph S. LeMaire, Scott A. Chu, Danny TI The Impact of Resident Work-Hour Restrictions on Outcomes of Cardiac Operations SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE outcomes; residents; ACGME; work-hour; cardiac surgery ID INTERNAL-MEDICINE; CARE; NIGHT; RISK AB Background. The Accreditation Council of Graduate Medical Education mandated an 80-h/wk resident physician work-hour restriction on July 1, 2003. The objective of this study was to evaluate the impact of the resident work-hour restriction on outcomes of cardiac operations. Materials and Method. We reviewed records of 1562 patients who underwent cardiac operations at our institution between 1997 and 2007, and we compared outcomes of operations performed before July 1, 2003 (pre-reform, n = 777) and those performed after July 1, 2003 (post-reform, n = 785). Multivariate analysis with logistic regression was used to test for the independent effects of the resident work-hour reform by controlling for patient-specific confounding factors. Results. Post-reform patients had a significantly lower 30-d mortality rate (1.8% versus 3.9%; P = 0.01) and a slightly lower 6-month mortality rate (4.5% versus 6.3%; P = 0.12) than pre-reform patients. Multivariate analysis revealed that the post-reform patients had significantly lower adjusted 30-d mortality (odds ratio, 0.37; 95% CI, 0.18-0.75; P = 0.006) and 6-mo mortality (odds ratio, 0.56; 95% CI, 0.34-0.91; P = 0.02) than the pre-reform patients. Conclusions. Cardiac operations performed after the resident work-hour restriction went into effect were associated with significantly lower adjusted 30-d and 6-mo mortality rates than were operations performed before the work-hour restriction became effective. Published by Elsevier Inc. C1 [Chu, Danny] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Div Cardiothorac Surg, Houston, TX 77030 USA. [Gopaldas, Raja R.; Huh, Joseph; Wang, Xing Li; Coselli, Joseph S.; LeMaire, Scott A.] St Lukes Episcopal Hosp, Texas Heart Inst, Sect Adult Cardiac Surg, Houston, TX USA. RP Chu, D (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Div Cardiothorac Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA. EM dchumd@gmail.com NR 19 TC 13 Z9 13 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD DEC PY 2009 VL 157 IS 2 BP 268 EP 274 DI 10.1016/j.jss.2009.03.042 PG 7 WC Surgery SC Surgery GA 583CL UT WOS:000276650200020 PM 19555974 ER PT J AU Cohen, ME Dimick, JB Bilimoria, KY Ko, CY Richards, K Hall, BL AF Cohen, Mark E. Dimick, Justin B. Bilimoria, Karl Y. Ko, Clifford Y. Richards, Karen Hall, Bruce Lee TI Risk Adjustment in the American College of Surgeons National Surgical Quality Improvement Program: A Comparison of Logistic Versus Hierarchical Modeling SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID PROFILING HOSPITAL PERFORMANCE; STATISTICAL METHODOLOGY; MORTALITY; OUTCOMES; CARD AB BACKGROUND: Although logistic regression has commonly been used to adjust for risk differences in patient and case mix to permit quality comparisons across hospitals, hierarchical modeling has been advocated as the preferred methodology, because it accounts for clustering of patients within hospitals. It is unclear whether hierarchical models would yield important differences in quality assessments compared with logistic models when applied to American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) data. Our objective was to evaluate differences in logistic versus hierarchical modeling for identifying hospitals with outlying Outcomes in the ACS-NSQIP. STUDY DESIGN: Data from ACS-NSQIP patients who underwent colorectal operations in 2008 at hospitals that reported at least 100 operations were used to generate logistic and hierarchical prediction models for 30-day morbidity and mortality. Differences in risk-adjusted performance (ratio of observed-to-expected events) and outlier detections from the two models were compared. RESULTS: Logistic and hierarchical models identified the same 25 hospitals is morbidity outliers (14 low and 11 high outliers), but the hierarchical model identified 2 additional high outliers. Both models identified the same eight hospitals as mortality Outliers (five low and three high outliers). The values of observed-to-expected events ratios and p values from the two models were highly correlated. Results were similar when data were permitted from hospitals providing < 100 patients. CONCLUSIONS: When applied to ACS-NSQIP data, logistic and hierarchical models provided nearly identical results with respect to identification of hospitals' observed-to-expected events ratio outliers. As hierarchical models are prone to implementation problems, logistic regression will remain ail accurate and efficient method for performing risk adjustment of hospital quality comparisons. (J Am Coll Surg 2009;209:687-693. (C) 2009 by the American College of Surgeons) C1 [Cohen, Mark E.; Bilimoria, Karl Y.; Ko, Clifford Y.; Richards, Karen] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Dimick, Justin B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA. [Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Hall, Bruce Lee] Washington Univ, Sch Med, Dept Surg, John Cochran Vet Affairs Med Ctr, St Louis, MO 63110 USA. [Hall, Bruce Lee] Barnes Jewish Hosp, Ctr Hlth Policy, St Louis, MO 63110 USA. [Hall, Bruce Lee] Washington Univ, John M Olin Sch Business, St Louis, MO 63130 USA. RP Cohen, ME (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Fl, Chicago, IL 60611 USA. EM markcohen@facs.org NR 33 TC 68 Z9 68 U1 2 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD DEC PY 2009 VL 209 IS 6 BP 687 EP 693 DI 10.1016/j.jamcollsurg.2009.08.020 PG 7 WC Surgery SC Surgery GA 534EZ UT WOS:000272880400002 PM 19959035 ER PT J AU Harris, DP Chodosh, J Vassar, SD Vickrey, BG Shapiro, MF AF Harris, Dorothy P. Chodosh, Joshua Vassar, Stefanie D. Vickrey, Barbara G. Shapiro, Martin F. TI Primary Care Providers' Views of Challenges and Rewards of Dementia Care Relative to Other Conditions SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE dementia; disease management; health services research; primary care; healthcare delivery ID MANAGING ALZHEIMERS-DISEASE; RANDOMIZED CONTROLLED-TRIAL; IMPROVING PRIMARY-CARE; MANAGEMENT INTERVENTION; COGNITIVE IMPAIRMENT; INTERNAL-MEDICINE; CHRONIC ILLNESS; PHYSICIANS; GUIDELINES; COMMUNITY AB OBJECTIVES: To compare primary care providers' (PCPs') perceptions about dementia and its care within their healthcare organization with perceptions of other common chronic conditions and to explore factors associated with differences. DESIGN: Cross-sectional survey. SETTING: Three California healthcare organizations. PARTICIPANTS: One hundred sixty-four PCPs. MEASUREMENTS: PCPs' views about primary care for dementia were analyzed and compared with views about care for heart disease, diabetes mellitus, and selected other conditions. Differences in views about conditions according to PCP type (internists, family physicians) were assessed. Multivariate analysis examined relationships between provider and practice characteristics and views about dementia care. RESULTS: More PCPs strongly agreed that older patients with dementia are difficult to manage (23.8%) than for heart disease (5.0%) or diabetes mellitus (6.3%); PCPs can improve quality of life for heart disease (58.9%) and diabetes mellitus (61.6%) than for dementia (30.9%); older patients should be routinely screened for heart disease (63.8%) and diabetes mellitus (67.7%) than dementia (55.5%); and their organizations have expertise/referral resources to manage diabetes inellitus (49.4%) and heart disease (51.8%) than dementia (21.1%). More PCPs reported almost effortless organizational care coordination for heart disease (13.0%) or diabetes mellitus (13.7%) than for dementia (5.6%), and a great deal or many opportunities for improvement in their ability to manage dementia (50.6%) than incontinence, depression, or hypertension (7.4-34.0%; all P<.05). Internists' views regarding dementia care were less optimistic than those of family physicians, but PCP type was unrelated to views on diabetes mellitus or heart disease. CONCLUSION: Improving primary care management of dementia should directly address PCP concerns about expertise and referral resources, difficulty of care provision, and PCP views about prospects for patient improvement. J Am Geriatr Soc 57:2209-2216, 2009. C1 [Harris, Dorothy P.; Vassar, Stefanie D.; Vickrey, Barbara G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Chodosh, Joshua] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Dept Med, Los Angeles, CA 90095 USA. [Shapiro, Martin F.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Dept Med, Los Angeles, CA 90095 USA. [Shapiro, Martin F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Hlth Serv, Los Angeles, CA 90095 USA. [Chodosh, Joshua] Vet Affairs Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Sepulveda, CA USA. [Chodosh, Joshua; Vickrey, Barbara G.] Vet Affairs Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev Serv Ctr Excellence, Sepulveda, CA USA. [Vassar, Stefanie D.; Vickrey, Barbara G.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Neurol, Sepulveda, CA USA. [Vassar, Stefanie D.; Vickrey, Barbara G.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Neurol, Sepulveda, CA USA. RP Harris, DP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, 710 Westwood Plaza,RNRC C-239, Los Angeles, CA 90095 USA. EM dpharris@ucla.edu RI Max, Mad/E-5238-2010 OI Max, Mad/0000-0001-6966-6829; Chodosh, Joshua/0000-0001-7784-4306 FU California Department of Public Health [06-55314]; Alzheimer's Disease Research Center of California; American Heart Association (AHA) through funding for the AHA/Pharmaceutical Roundtable Outcomes Research Center at the University of California at Los Angeles (UCLA); National Institutes of Health; National Center on Minority Health and Health Disparities [2P20MD000182] FX This Study was supported by the California Department of Public Health (Contract 06-55314) for the Alzheimer's Disease Research Center of California and the American Heart Association (AHA) through funding for the AHA/Pharmaceutical Roundtable Outcomes Research Center at the University of California at Los Angeles (UCLA). Dr. Shapiro was supported in part by UCLA/DREW Project EXPORT, National Institutes of Health, National Center on Minority Health and Health Disparities (2P20MD000182). NR 31 TC 20 Z9 20 U1 1 U2 5 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2009 VL 57 IS 12 BP 2209 EP 2216 DI 10.1111/j.1532-5415.2009.02572.x PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 535NN UT WOS:000272976400004 PM 19943831 ER PT J AU Moore, AA Karno, MP Grella, CE Lin, JC Warda, U Liao, DH Hu, PF AF Moore, Alison A. Karno, Mitchell P. Grella, Christine E. Lin, James C. Warda, Umme Liao, Diana H. Hu, Peifeng TI Alcohol, Tobacco, and Nonmedical Drug Use in Older US Adults: Data from the 2001/02 National Epidemiologic Survey of Alcohol and Related Conditions SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE alcohol; tobacco; nonmedical drugs; epidemiology ID UNITED-STATES; COOCCURRING ALCOHOL; SUBSTANCE USE; CONSUMPTION; DISORDERS; COMORBIDITY; PREVALENCE; DEPENDENCE; DRINKING; PATTERNS AB OBJECTIVES: To exam ne the prevalence and sociodemographic and health-related correlates of substance use, including alcohol, tobacco, and nonmedical drug use, in adults aged 65 and older. DESIGN: Cross-sectional, retrospective survey of a population-based sample, the 2001/02 National Epidemiologic Survey on Alcohol and Related Conditions. SETTING: United States. PARTICIPANTS: Eight thousand two hundred five U.S. adults aged 65 and older. MEASUREMENTS: Prevalence of lifetime and previous-12-month alcohol, tobacco, and nonmedical drug use and associations between substance use and sociodemographic and health-related factors. RESULTS: Almost 80% of older adults had used any of the three substances over their lifetimes, and more than 50% reported such use over the previous 12 months. Alcohol was the most commonly used substance over the lifetime (74%) and in the previous 12 months (45%), followed by tobacco (52% lifetime; 14% previous 12 months); far fewer reported nonmedical use of drugs (5% lifetime; 14% previous 12 months). In general, being younger, male, and divorced or separated were factors consistently associated with use of any of the three substances. CONCLUSION: Most older adults had used substances over their lifetimes and in the previous 12 months. Alcohol is the substance of choice for this age group, followed by tobacco; few report nonmedical drug use. J Am Geriatr Soc 57:2275-2281, 2009. C1 [Moore, Alison A.; Warda, Umme; Liao, Diana H.; Hu, Peifeng] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr Med, Los Angeles, CA 90095 USA. [Moore, Alison A.; Karno, Mitchell P.; Grella, Christine E.] Univ Calif Los Angeles, Integrated Substance Abuse Programs, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Lin, James C.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Geriatr Med, Los Angeles, CA USA. RP Moore, AA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, 10945 Le Conte Ave,Suite 2339, Los Angeles, CA 90095 USA. EM aamoore@mednet.ucla.edu FU National Institute on Drug Abuse [R01DA020944]; National Institute on Alcoholism and Alcohol Abuse [K24AA15957]; National Institute on Aging [P30AG028748] FX National Institute on Drug Abuse (R01DA020944), National Institute on Alcoholism and Alcohol Abuse (K24AA15957), National Institute on Aging (P30AG028748), and a Veterans Affairs Special Fellowship in Advanced Geriatrics provided funding support. NR 28 TC 32 Z9 32 U1 1 U2 5 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2009 VL 57 IS 12 BP 2275 EP 2281 DI 10.1111/j.1532-5415.2009.02554.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 535NN UT WOS:000272976400014 PM 19874409 ER PT J AU Ezra, N Alessi, CA AF Ezra, Navid Alessi, Cathy A. TI CLINICAL OBSERVATION: HYPONATREMIA ASSOCIATED WITH DIURETIC USE AND URINARY RETENTION IN AN OLDER MAN SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter C1 [Ezra, Navid] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Alessi, Cathy A.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Ezra, N (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 6 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2009 VL 57 IS 12 BP 2353 EP 2354 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 535NN UT WOS:000272976400029 PM 20169630 ER PT J AU Shlipak, MG Katz, R Kestenbaum, B Siscovick, D Fried, L Newman, A Rifkin, D Sarnak, MJ AF Shlipak, Michael G. Katz, Ronit Kestenbaum, Bryan Siscovick, David Fried, Linda Newman, Anne Rifkin, Dena Sarnak, Mark J. TI Rapid Decline of Kidney Function Increases Cardiovascular Risk in the Elderly SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID PERIPHERAL ARTERIAL-DISEASE; CYSTATIN-C; HEART-FAILURE; OLDER-ADULTS; RENAL-INSUFFICIENCY; MORTALITY RISK; HEALTH; PREDICTORS; CREATININE; EVENTS AB Chronic kidney disease (CKD), defined at a specific time point, is an important risk factor for cardiovascular disease. Whether the rate of kidney function decline contributes additional cardiovascular risk is unknown. In the Cardiovascular Health Study, we compared the associations of changes in kidney function during the first 7 yr with the incidence of heart failure (HF), myocardial infarction (MI), stroke, and peripheral arterial disease (PAD) during the subsequent 8 yr. We defined a rapid decline in cystatin C-based estimated GFR as >3 ml/min per 1.73 m(2)/yr, on the basis of determination at baseline, year 3, and year 7. Among eligible participants, 1083 (24%) had rapid kidney decline. The incidence of each type of cardiovascular event was significantly higher among patients with rapid decline (all P < 0.001). After multivariate adjustment for demographics, cardiovascular disease risk factors, and baseline kidney function, rapid kidney function decline was significantly associated with HF (adjusted hazard ratio [HR] 1.32; 95% confidence interval [CI] 1.13 to 1.53), MI (HR 1.48; 95% Cl 1.21 to 1.83), and PAD (HR 1.67; 95% Cl 1.02 to 2.75) but not with stroke (HR 1.19; 95% Cl 0.97 to 1.45). The association of rapid decline with each outcome did not differ by the presence or absence of CKD. In conclusion, declining kidney function associates with higher risk for HF, MI, and PAD among patients with or without CKD. C1 [Shlipak, Michael G.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Katz, Ronit] Univ Washington, Sch Med, Collaborat Hlth Studies Coordinating Ctr, Seattle, WA USA. [Kestenbaum, Bryan] Univ Washington, Sch Med, Div Nephrol, Seattle, WA USA. [Siscovick, David] Univ Washington, Dept Med, Seattle, WA USA. [Siscovick, David] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Fried, Linda] VA Pittsburgh Healthcare Syst, Renal Sect, Med Serv, Pittsburgh, PA USA. [Newman, Anne] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Newman, Anne] Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA. [Rifkin, Dena; Sarnak, Mark J.] Tufts Univ New England Med Ctr, Dept Med, Div Nephrol, Boston, MA USA. RP Shlipak, MG (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM michael.shlipak@ucsf.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU American Heart Association [R01 DK066488, R01 AG027002] FX This work was supported by M.S.'s American Heart Association Established Investigator Award and R01 DK066488 (principal investigator M.S.). In addition, it was supported by R01 AG027002 (principal investigator M.J.S.). NR 22 TC 131 Z9 138 U1 2 U2 4 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD DEC PY 2009 VL 20 IS 12 BP 2625 EP 2630 DI 10.1681/ASN.2009050546 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 531BJ UT WOS:000272637400020 PM 19892934 ER PT J AU Brink, HE Bernstein, J Nicoll, SB AF Brink, Hallie E. Bernstein, Joseph Nicoll, Steven B. TI Fetal dermal fibroblasts exhibit enhanced growth and collagen production in two- and three-dimensional culture in comparison to adult fibroblasts SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE LA English DT Article DE fetal; dermis; tendon; proliferation; collagen; scaffold; wound healing; tissue engineering ID MESENCHYMAL STEM-CELLS; PATELLAR TENDON FIBROBLASTS; ACHILLES-TENDON; MECHANICAL STIMULATION; SUPRASPINATUS TENDON; ENGINEERED TENDON; SKIN FIBROBLASTS; ANIMAL-MODEL; WOUND REPAIR; TISSUE AB The high morbidity of tendon injuries and the poor outcomes observed following repair or replacement have stimulated interest in regenerative approaches to treatment and, in particular, the use of cell-based analogues as alternatives to autologous and allogeneic graft repair. Given the known regenerative properties of fetal tissues, the objective of this study was to assess the biological and mechanical properties of tissue-engineered three-dimensional (313) composites seeded with fetal skin cells. Dermal fibroblasts were isolated from pregnant rats and their fetuses and characterized in monolayer culture and on 3D resorbable polyester scaffolds. To determine the differences between fetal and adult fibroblasts, DNA, total protein and types I and III collagen production were measured. In addition, morphology and mechanical properties of the 3D constructs were examined. In monolayer culture, fetal fibroblasts produced significantly more types I and III collagen and displayed serum-independent growth, while adult fibroblasts elaborated less collagen and exhibited reduced cell spreading and attachment under low-serum conditions. In 3D culture, fetal constructs appeared more developed based on gross examination, with significantly more total DNA, total protein and normalized type I collagen production compared to adult specimens. Finally, after 35 days, fetal fibroblast-seeded constructs possessed superior mechanical properties compared to adult samples. Taken together, these findings indicate that fetal dermal fibroblasts may be an effective source of cells for fabricating tissue equivalents to regenerate injured tendons. Copyright (C) 2009 John Wiley & Sons, Ltd. C1 [Brink, Hallie E.; Nicoll, Steven B.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. [Bernstein, Joseph; Nicoll, Steven B.] Univ Penn, Dept Orthopaed Surg, Philadelphia, PA 19104 USA. [Bernstein, Joseph] Philadelphia Vet Affairs Med Ctr, Dept Orthopaed Surg, Philadelphia, PA 19104 USA. RP Nicoll, SB (reprint author), Univ Penn, Dept Bioengn, 210 S 33rd St,240 Skirkanich Hall, Philadelphia, PA 19104 USA. EM nicoll@seas.upenn.edu FU National institutes of Health [R21 AR051056, P30 AR050950]; Department of Veterans Affairs [B5071R] FX The authors would like to thank Dr Louis Soslowsky and Mr David Beason for assistance with mechanical testing and Dr Kenneth Liechty for providing tissue samples. This work was supported by grants from the National institutes of Health (R21 AR051056; Pennsylvania Center for Musculoskeletal Disorders, P30 AR050950) and the Department of Veterans Affairs (B5071R). NR 62 TC 9 Z9 9 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1932-6254 J9 J TISSUE ENG REGEN M JI J. Tissue Eng. Regen. Med. PD DEC PY 2009 VL 3 IS 8 BP 623 EP 633 DI 10.1002/term.204 PG 11 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Engineering, Biomedical SC Cell Biology; Biotechnology & Applied Microbiology; Engineering GA 533QU UT WOS:000272840200005 PM 19685484 ER PT J AU Zinzow, HM Ruggiero, KJ Hanson, RF Smith, DW Saunders, BE Kilpatrick, DG AF Zinzow, Heidi M. Ruggiero, Kenneth J. Hanson, Rochelle F. Smith, Daniel W. Saunders, Benjamin E. Kilpatrick, Dean G. TI Witnessed Community and Parental Violence in Relation to Substance Use and Delinquency in a National Sample of Adolescents SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID DOMESTIC VIOLENCE; CHILD MALTREATMENT; RISK-FACTORS; ALCOHOL-USE; EXPOSURE; ABUSE; ASSOCIATION; PREVENTION; PREVALENCE; INITIATION AB This study examined whether witnessed community and parental violence represented risk factors for substance use and delinquency among adolescents, beyond the contribution of direct violence and other risk factors. We also examined the role of violence characteristics. Participants were a national sample of 3,614 adolescents. Structured telephone interviews assessed demographics, trauma history, witnessed violence, delinquency, and substance use. While accounting for trauma history and other risk factors, witnessed community and parental violence were associated with delinquency. Community violence was associated with substance use, Chronic violence, knowing the perpetrator, and violence outside of school were correlated with substance use and delinqueney among adolescents who witnessed community violence. These findings highlight the importance of targeting witnessed violence in prevention and intervention efforts. C1 [Zinzow, Heidi M.] Clemson Univ, Dept Psychol, Clemson, SC 29634 USA. [Zinzow, Heidi M.; Ruggiero, Kenneth J.; Hanson, Rochelle F.; Smith, Daniel W.; Saunders, Benjamin E.; Kilpatrick, Dean G.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Zinzow, HM (reprint author), Clemson Univ, Dept Psychol, 418 Brackett Hall, Clemson, SC 29634 USA. EM hzinzow@clemson.edu FU NICHD NIH HHS [1R01 HD046830-01, R01 HD046830, R01 HD046830-01] NR 30 TC 31 Z9 32 U1 4 U2 13 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0894-9867 J9 J TRAUMA STRESS JI J. Trauma Stress PD DEC PY 2009 VL 22 IS 6 BP 525 EP 533 DI 10.1002/jts.20469 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 538LX UT WOS:000273187100006 PM 19885872 ER PT J AU Mach, KE Du, CB Phull, H Haake, DA Shih, MC Baron, EJ Liao, JC AF Mach, Kathleen E. Du, Christine B. Phull, Hardeep Haake, David A. Shih, Mei-Chiung Baron, Ellen Jo Liao, Joseph C. TI Multiplex Pathogen Identification for Polymicrobial Urinary Tract Infections Using Biosensor Technology: A Prospective Clinical Study SO JOURNAL OF UROLOGY LA English DT Article DE urinary bladder; neurogenic; spinal cord injuries; urinary tract infections; biosensing techniques; RNA, ribosomal, 16S ID SPINAL-CORD-INJURY; BBL CHROMAGAR ORIENTATION; UROLOGIC DISEASES; AMERICA PROJECT; RESOURCE USE; TRENDS AB Purpose: Rapid diagnosis of urinary tract infection would have a significant beneficial impact on clinical management, particularly in patients with structural or functional urinary tract abnormalities who are highly susceptible to recurrent polymicrobial infections. We examined the analytical validity of an electrochemical biosensor array for rapid molecular diagnosis of urinary tract infection in a prospective clinical study in patients with neurogenic bladder. Materials and Methods: The electrochemical biosensor array was functionalized with DNA probes against 16S rRNA of the most common uropathogens. Spinal cord injured patients at a Veterans Affairs hospital were recruited into the study. Urine samples were generally tested on the biosensor within 1 to 2 hours of collection. Biosensor results were compared with those obtained using standard clinical microbiology laboratory methods. Results: We successfully developed a 1-hour biosensor assay for multiplex identification of pathogens. From July 2007 to December 2008 we recruited 116 patients, yielding a total of 109 urine samples suitable for analysis and comparison between biosensor assay and standard urine culture. Of the samples 74% were positive, of which 42% were polymicrobial. We identified 20 organisms, of which Escherichia coli, Pseudomonas aeruginosa and Enterococcus species were the most common. Biosensor assay specificity and positive predictive value were 100%. Pathogen detection sensitivity was 89%, yielding a 76% negative predictive value. Conclusions: To our knowledge we report the first prospective clinical study to successfully identify pathogens within a point of care time frame using an electrochemical biosensor platform. Additional efforts to improve the limit of detection and probe design are needed to further enhance assay sensitivity. C1 [Liao, Joseph C.] Stanford Univ, Dept Urol, Sch Med, Stanford, CA 94305 USA. Stanford Univ, Dept Hlth Res & Policy, Sch Med, Stanford, CA 94305 USA. Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA. Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Liao, JC (reprint author), Stanford Univ, Dept Urol, Sch Med, 300 Pasteur Dr,S-287, Stanford, CA 94305 USA. EM jliao@stanford.edu RI Liao, Joseph/J-5874-2015 FU NIAID NIH HHS [U01 AI082457-02, U01 AI082457-01, U01 AI075565, U01 AI082457, AI075565] NR 14 TC 24 Z9 24 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD DEC PY 2009 VL 182 IS 6 BP 2735 EP 2741 DI 10.1016/j.juro.2009.08.028 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 518CU UT WOS:000271668600072 PM 19837423 ER PT J AU Chen, SL Jackson, SL Boyko, EJ AF Chen, Swaine L. Jackson, Sara L. Boyko, Edward J. TI Diabetes Mellitus and Urinary Tract Infection: Epidemiology, Pathogenesis and Proposed Studies in Animal Models SO JOURNAL OF UROLOGY LA English DT Article; Proceedings Paper CT Symposium on Urologic Complications of Obesity and Diabetes CY MAR 10-11, 2009 CL Baltimore, MD SP Natl Inst Diabet & Digest & Kidney Dis, NIH, Div Kidney, Urol & Hematol Dis DE urinary tract infections; diabetes complications; diabetes mellitus, experimental; adhesins, Escherichia coli; genomic islands ID UROPATHOGENIC ESCHERICHIA-COLI; INTRACELLULAR BACTERIAL COMMUNITIES; BLADDER EPITHELIAL-CELLS; ASYMPTOMATIC BACTERIURIA; POSTMENOPAUSAL WOMEN; FIMH ADHESIN; RISK-FACTORS; TYPE-1; COLONIZATION; PERSISTENCE AB Purpose: We reviewed the current state of knowledge about urinary tract infection in patients with diabetes from the clinical and basic science perspectives. We identified key knowledge gaps and areas for further research. Materials and Methods: We performed a focused literature search on certain topics, including clinical studies related to etiology and pathophysiology of urinary tract infection in patients with diabetes, urinary tract infection studies in animal models of diabetes and basic science studies of the molecular mechanisms of urinary tract infection. Results: Individuals with diabetes are at higher risk for urinary tract infection Increased susceptibility in patients with diabetes is positively associated with increased duration and severity of diabetes. Clinical epidemiological data identifying mechanisms of increased urinary tract infection susceptibility in patients with diabetes are generally lacking and indicate only that urinary tract infections in women with and without diabetes are qualitatively similar in bacterial etiology and morbid sequelae. Existing animal models for diabetes have not been well characterized for urinary tract infection research. The increased incidence, prevalence and severity of urinary tract infection in patients with diabetes argue for aggressive antibacterial chemotherapy but novel therapies resulting from urinary tract infection research in nondiabetic animal models are still not available. Conclusions: Future clinical investigations of urinary tract infection in patients with diabetes should focus on how the disease differs from that in patients without diabetes, notably on the role of glycosuria and urinary tract infection risk. Basic science research priorities for urinary tract infection in patients with diabetes should emphasize further development of diabetic animal models for urinary tract infection research and clinical translation of known important virulence determinants into new therapies. C1 [Boyko, Edward J.] Univ Washington, Dept Med, Seattle, WA 98101 USA. [Jackson, Sara L.; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA. RP Boyko, EJ (reprint author), Univ Washington, Dept Med, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM eboyko@u.washington.edu OI Chen, Swaine/0000-0002-0107-2861; Boyko, Edward/0000-0002-3695-192X FU NIDDK NIH HHS [DK51406, DK081620, DK43134, DK64540, P30-DK17047] NR 49 TC 31 Z9 33 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD DEC PY 2009 VL 182 IS 6 BP S51 EP S56 DI 10.1016/j.juro.2009.07.090 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 518CW UT WOS:000271668800010 PM 19846134 ER PT J AU Zhang, YQ Ikeno, Y Qi, WB Chaudhuri, A Li, Y Bokov, A Thorpe, SR Baynes, JW Epstein, C Richardson, A Van Remmen, H AF Zhang, Yiqiang Ikeno, Yuji Qi, Wenbo Chaudhuri, Asish Li, Yan Bokov, Alex Thorpe, Suzanne R. Baynes, John W. Epstein, Charles Richardson, Arlan Van Remmen, Holly TI Mice Deficient in Both Mn Superoxide Dismutase and Glutathione Peroxidase-1 Have Increased Oxidative Damage and a Greater Incidence of Pathology but No Reduction in Longevity SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Oxidative stress; Longevity ID LIFE-SPAN; KNOCKOUT MICE; CALORIC RESTRICTION; MUTANT MICE; CAENORHABDITIS-ELEGANS; MITOCHONDRIAL-FUNCTION; INCREASED SENSITIVITY; STRESS; GENE; OVEREXPRESSION AB To test the impact of increased mitochondrial oxidative stress as a mechanism underlying aging and age-related pathologies, we generated mice with a combined deficiency in two mitochondrial-localized antioxidant enzymes, Mn superoxide dismutase (MnSOD) and glutathione peroxidase-1 (Gpx-1). We compared life span, pathology, and oxidative damage in Gpx1(-/)-, Sod2(+/)-Gpx1(+/)-, Sod2(+/)-Gpx1(-/)-, and wild-type control mice. Oxidative damage was elevated in Sod2(+/)-Gpx1(-/)-mice, as shown by increased DNA oxidation in liver and skeletal muscle and increased protein oxidation in brain. Surprisingly, Sod2(+/)-Gpx1(-/)- mice showed no reduction in life span, despite increased levels of oxidative damage. Consistent with the important role for oxidative stress in tumorigenesis during aging, the incidence of neoplasms was significantly increased in the older Sod2(+/)-Gpx1(-/)-mice (28-30 months). Thus, these data do not support a significant role for increased oxidative stress as a result of compromised mitochondrial antioxidant defenses in modulating life span in mice and do not support the oxidative stress theory of aging. C1 [Zhang, Yiqiang; Ikeno, Yuji; Qi, Wenbo; Chaudhuri, Asish; Li, Yan; Bokov, Alex; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA. [Zhang, Yiqiang; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78245 USA. [Ikeno, Yuji; Chaudhuri, Asish; Richardson, Arlan; Van Remmen, Holly] S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Ikeno, Yuji] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78245 USA. [Ikeno, Yuji; Bokov, Alex; Richardson, Arlan; Van Remmen, Holly] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78245 USA. [Chaudhuri, Asish] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78245 USA. [Thorpe, Suzanne R.; Baynes, John W.] Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA. [Baynes, John W.] Univ S Carolina, Dept Exercise Sci, Columbia, SC 29208 USA. [Epstein, Charles] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. [Epstein, Charles] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94143 USA. RP Van Remmen, H (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, 15355 Lambda Dr, San Antonio, TX 78245 USA. EM vanremmen@uthscsa.edu FU The Department of Veterans Affair Merit; Glenn Foundation; The National Institute of Health [DK19971] FX The Department of Veterans Affair Merit Grants (H. R. R., A. C., Y.I., and A. R.); Glenn Foundation (Y.I.); The National Institute of Health grant (DK19971 to J.W.B.) NR 57 TC 87 Z9 88 U1 1 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 EI 1758-535X J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD DEC PY 2009 VL 64 IS 12 BP 1212 EP 1220 DI 10.1093/gerona/glp132 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 516WI UT WOS:000271573600002 PM 19776219 ER PT J AU Dickson, DW Braak, H Duda, JE Duyckaerts, C Gasser, T Halliday, GM Hardy, J Leverenz, JB Del Tredici, K Wszolek, ZK Litvan, I AF Dickson, Dennis W. Braak, Heiko Duda, John E. Duyckaerts, Charles Gasser, Thomas Halliday, Glenda M. Hardy, John Leverenz, James B. Del Tredici, Kelly Wszolek, Zbigniew K. Litvan, Irene TI Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria SO LANCET NEUROLOGY LA English DT Review ID LEWY-BODY DISEASE; ALPHA-SYNUCLEIN PATHOLOGY; MULTIPLE-SYSTEM ATROPHY; BRAINNET EUROPE CONSORTIUM; AUTONOMIC NERVOUS-SYSTEM; SUBSTANTIA-NIGRA; ALZHEIMER-DISEASE; AXONAL-TRANSPORT; STRIATAL PATHOLOGY; TAU-SYNUCLEIN AB To date, there have been few systematic attempts to provide a standard operating procedure for the neuropathological diagnosis of Parkinson's disease (PD). Pathological examination cannot classify the clinical syndrome with certainty; therefore, the neuropathological diagnosis is, at best, a probability statement. The neuropathological diagnosis of parkinsonism has become increasingly based on fundamental molecular underpinnings, with recognition that the genetics of parkinsonism is heterogeneous and includes disorders that are associated with and without Lewy bodies. The advent of a-synuclein immunchistochemistry has substantially improved the ability to identify Lewy pathology, particularly cortical Lewy bodies and smaller aggregates within processes and the neuropil. In this Review we discuss the diagnostic criteria for the neuropathological assessment of PD. These criteria are provisional and need to be validated through an iterative process that could help with their refinement. Additionally, we suggest future directions for neuropathology research on PD. C1 [Litvan, Irene] Univ Louisville, Dept Neurol, Louisville, KY 40202 USA. [Dickson, Dennis W.; Wszolek, Zbigniew K.] Mayo Clin, Jacksonville, FL 32224 USA. [Braak, Heiko; Del Tredici, Kelly] Univ Ulm, Ulm, Germany. [Duda, John E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Duyckaerts, Charles] Hop La Pitie Salpetriere, Paris, France. [Gasser, Thomas] Univ Tubingen, Tubingen, Germany. [Halliday, Glenda M.] Prince Wales Med Res Inst, Randwick, NSW, Australia. [Hardy, John] UCL, London, England. [Leverenz, James B.] Univ Washington, Seattle, DC USA. RP Litvan, I (reprint author), Univ Louisville, Dept Neurol, 220 Abraham Flexner Way,Suite 1503, Louisville, KY 40202 USA. EM i.litvan@louisville.edu RI Hardy, John/C-2451-2009; Halliday, Glenda/E-8555-2011 OI Halliday, Glenda/0000-0003-0422-8398; Dickson, Dennis W/0000-0001-7189-7917; Litvan, Irene/0000-0002-3485-3445 FU Medical Research Council [G0901254, G0701075]; NIA NIH HHS [R01 AG024040]; Parkinson's UK [G-0907] NR 93 TC 237 Z9 238 U1 2 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1474-4422 J9 LANCET NEUROL JI Lancet Neurol. PD DEC PY 2009 VL 8 IS 12 BP 1150 EP 1157 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 523WS UT WOS:000272106100019 PM 19909913 ER PT J AU Sharma, N Cunningham, K Porter, RG Marzo, SJ Jones, KJ Foecking, EM AF Sharma, Nijee Cunningham, Kelly Porter, Ryan G. Marzo, Sam J. Jones, Kathryn J. Foecking, Eileen M. TI Comparison of Extratemporal and Intratemporal Facial Nerve Injury Models SO LARYNGOSCOPE LA English DT Article; Proceedings Paper CT 112th Annual Meeting of the Triological-Society/Combined Otolaryngology Spring Meeting CY MAY 28-31, 2009 CL Phoenix, AZ SP Triol Soc DE Facial nerve injury; facial paralysis; nerve regeneration; peripheral nerve injury ID ELECTRICAL-STIMULATION; GONADAL-STEROIDS; CRUSH INJURY; BELLS-PALSY; RAT; RECOVERY; MOTONEURONS AB Objectives/Hypothesis: The purpose of this study was to compare functional recovery and motor nerve conduction following a distal extratemporal crush injury of the facial nerve to a more proximal intratemporal crush injury. Study Design: Prospective, controlled animal study. Methods: Adult male Sprague-Dawley rats were divided into four experimental groups: 1) extratemporal crush, 2) extratemporal sham-operated, 3) intratemporal crush, and 4) intratemporal sham-operated. Each group had an n of 4-9. The facial nerve was crushed near its exit from the stylomastoid foramen for extratemporal facial nerve injuries and within the facial canal in the temporal bone for intratemporal facial nerve injuries. Recovery times for the return of facial nerve functional parameters were compared between the two injury models. Motor nerve conduction studies were also done weekly to quantify the changes in peak amplitude and latency of evoked response. Results: Rats receiving the extratemporal facial nerve injury recovered full facial function by similar to 2 weeks postoperative (wpo) and displayed normal peak amplitude and latency recordings by 4 wpo. In comparison, rats receiving the intratemporal facial nerve injury failed to reach complete functional recovery at the end of 8 wpo. Although latency of evoked response returned to normal by 2 weeks following the intratemporal injury, peak amplitude remained similar to 70% below normal at the end of 8 wpo. Conclusions: An intratemporal crush of the facial nerve leads to significantly delayed functional recovery and decreased motor nerve conduction as compared to an extratemporal crush, indicating that the location of injury strongly influences the recovery outcome. C1 [Sharma, Nijee] Loyola Univ Chicago, Stritch Sch Med, Neurosci Program, Maywood, IL USA. [Cunningham, Kelly; Porter, Ryan G.; Marzo, Sam J.; Jones, Kathryn J.; Foecking, Eileen M.] Loyola Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, Maywood, IL 60153 USA. [Jones, Kathryn J.] Loyola Univ Chicago, Stritch Sch Med, Dept Cell Biol Neurobiol & Anat, Maywood, IL USA. [Jones, Kathryn J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, R & D Serv, Hines, IL 60141 USA. RP Sharma, N (reprint author), Edward Hines Jr VA Hosp, 5000 S 5th Ave,Bldg 1,Room A241A, Hines, IL 60141 USA. EM nijeesharma@gmail.com NR 14 TC 8 Z9 10 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD DEC PY 2009 VL 119 IS 12 BP 2324 EP 2330 DI 10.1002/lary.20627 PG 7 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 527ZA UT WOS:000272408600008 PM 19718755 ER PT J AU Bernardi, RE Ryabinin, AE Berger, SP Lattal, KM AF Bernardi, Rick E. Ryabinin, Andrey E. Berger, S. Paul Lattal, K. Matthew TI Post-retrieval disruption of a cocaine conditioned place preference by systemic and intrabasolateral amygdala beta(2)- and alpha(1)-adrenergic antagonists SO LEARNING & MEMORY LA English DT Article ID BASOLATERAL AMYGDALA; PROTEIN-SYNTHESIS; MEMORY RECONSOLIDATION; NUCLEUS-ACCUMBENS; NORADRENERGIC RECEPTORS; ADRENERGIC-RECEPTORS; SEEKING BEHAVIOR; D-CYCLOSERINE; FEAR MEMORY; EXTINCTION AB Previous work has demonstrated post-retrieval impairment in associative learning paradigms, including those mediated by drugs of abuse, using nonspecific beta-adrenergic receptor (beta-AR) antagonists. Remarkably little is known about the role of the specific beta-AR subtypes, or other adrenergic receptors, in these effects. The current study examined the effects of beta(1) and beta(2), as well as alpha(1)-adrenergic receptor antagonism following retrieval of a cocaine conditioned place preference (CPP). We found that rats administered the beta(2) antagonist ICI 118,551 (8 mg/kg intraperitoneal [IP]) or the alpha(1) antagonist prazosin (1 mg/kg IP) following a drug-free test for CPP showed attenuated preference during a subsequent test, while the beta(1) antagonist betaxolol (5 or 10 mg/kg IP) and a lower dose of prazosin (0.3 mg/kg IP) had no effect. Furthermore, post-test microinfusion of ICI 118,551 (6 nmol/side) or prazosin (0.5 nmol/side) into the basolateral amygdala (BLA) also impaired a subsequent preference. Systemic or intra-BLA ICI 118,551 or prazosin administered to rats in their home cages, in the absence of a preference test, had no effect on CPP 24 h later. ICI 118,551 also attenuated the FOS response in the BLA induced by the CPP test. These results are the first to demonstrate a role for alpha(1)- and beta(2)-specific adrenergic mechanisms in post-retrieval memory processes. These systemic and site-specific injections, as well as the FOS immunohistochemical analyses, implicate the importance of specific noradrenergic signaling mechanisms within the BLA in post-retrieval plasticity. C1 [Bernardi, Rick E.; Ryabinin, Andrey E.; Berger, S. Paul; Lattal, K. Matthew] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. [Berger, S. Paul] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Berger, S. Paul] Portland VA Med Ctr, Dept Psychiat, Portland, OR 97239 USA. RP Bernardi, RE (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. EM rick.bernardi@zi-mannheim.de FU Department of Veterans Affairs Merit Review program [07-1003]; National Institute of Mental Health [R01 MH077111]; National Institute on Drug Abuse [R01 DA025922, R03 DA025854, F31 DA022844] FX We thank Erika Spangler for help with the FOS studies and Chris Cunningham, Greg Mark, and Laura Kozell for helpful discussions. This research was supported by a grant from the Department of Veterans Affairs Merit Review program (07-1003) to S. P. B., a grant from the National Institute of Mental Health (R01 MH077111) to K. M. L., and grants from the National Institute on Drug Abuse to K. M. L. (R01 DA025922), A. E. R. (R03 DA025854), and R. E. B. (F31 DA022844). NR 64 TC 47 Z9 49 U1 0 U2 5 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 1072-0502 EI 1549-5485 J9 LEARN MEMORY JI Learn. Mem. PD DEC PY 2009 VL 16 IS 12 BP 777 EP 789 DI 10.1101/lm.1648509 PG 13 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 525BK UT WOS:000272187900007 PM 19940038 ER PT J AU Spungen, AM Bauman, WA Lesser, M McCool, FD AF Spungen, Ann M. Bauman, William A. Lesser, Marvin McCool, F. Dennis TI Breathing Pattern and Ventilatory Control in Chronic Tetraplegia SO LUNG LA English DT Article DE Resting breathing; Spinal cord injury; Tidal volume; Minute ventilation; Sigh frequency ID SPINAL-CORD INJURY; OCCLUSION PRESSURE; RESPIRATORY APPARATUS; QUADRIPLEGIA; RESPONSES; HYPERCAPNIA AB Blunted ventilatory responses to carbon dioxide indicate that respiratory control is impaired when ventilation is stimulated in individuals with tetraplegia; however, respiratory control during resting breathing has not been extensively studied in this population. Our objective was to evaluate respiratory control and sigh frequency during resting breathing in persons with tetraplegia. A prospective, two-group comparative study was performed. Breathing pattern was assessed in ten outpatients with chronic tetraplegia and eight age- and gender-matched able-bodied controls. Subjects were noninvasively monitored for 1 h, while seated and at rest. Tidal volume (V(T)) was calculated from the sum of the anteroposterior displacements of the rib cage and abdomen and the axial displacement of the chest wall. Inspiratory time (T(I)), V(T), and the ratio of V(T) to inspiratory time (V(T)/T(I)) were calculated breath by breath. A sigh was defined as any breath greater than two or more times an individual's mean V(T). Minute ventilation, V(T)/T(I), and sigh frequency were reduced in tetraplegia compared with controls (5.24 +/- A 1.15 vs. 7.16 +/- A 1.29 L/min, P < 0.005; 208 +/- A 45 vs. 284 +/- A 47 ml/s, P < 0.005; and 11 +/- A 7 vs. 42 +/- A 19 sighs/h, P < 0.0005, respectively). V(T)/T(I) was associated with sigh frequency in both groups (tetraplegia: R = 0.88; P = 0.001 and control: R = 0.70; P < 0.05). We concluded that reductions in minute ventilation, V(T)/T(I), and sigh frequency suggest that respiratory drive is diminished during resting breathing in subjects with tetraplegia. These findings extend prior observations of disordered respiratory control during breathing stimulated by CO(2) in tetraplegia to resting breathing. C1 [Spungen, Ann M.; Bauman, William A.; Lesser, Marvin; McCool, F. Dennis] James J Peters VA Med Ctr, VA RR&D Ctr Excellence Med Consequences SCI, Bronx, NY 10468 USA. [Spungen, Ann M.; Bauman, William A.] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Spungen, Ann M.; Bauman, William A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA. [McCool, F. Dennis] Brown Univ, Alpert Med Sch, Providence, RI 02860 USA. [McCool, F. Dennis] Brown Univ, Mem Hosp Rhode Isl, Dept Med, Providence, RI 02860 USA. RP Spungen, AM (reprint author), James J Peters VA Med Ctr, VA RR&D Ctr Excellence Med Consequences SCI, Room 1E-02,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM ann.spungen@va.gov FU Department of Veterans Affairs Rehabilitation; Research and Development Service; Center of Excellence for the Medical Consequences of Spinal Cord Injury [B4162C]; United Spinal Association (formerly Eastern Paralyzed Veterans Association) FX This work was funded by the Department of Veterans Affairs Rehabilitation, Research and Development Service, Center of Excellence for the Medical Consequences of Spinal Cord Injury # B4162C and the United Spinal Association (formerly Eastern Paralyzed Veterans Association). NR 23 TC 3 Z9 3 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0341-2040 J9 LUNG JI Lung PD DEC PY 2009 VL 187 IS 6 BP 375 EP 381 DI 10.1007/s00408-009-9186-y PG 7 WC Respiratory System SC Respiratory System GA 516LU UT WOS:000271544500003 PM 19820994 ER PT J AU Silber, JH Rosenbaum, PR Rosen, AK Romano, PS Itani, KMF Cen, LY Mi, LY Halenar, MJ Even-Shoshan, O Volpp, KG AF Silber, Jeffrey H. Rosenbaum, Paul R. Rosen, Amy K. Romano, Patrick S. Itani, Kamal M. F. Cen, Liyi Mi, Lanyu Halenar, Michael J. Even-Shoshan, Orit Volpp, Kevin G. TI Prolonged Hospital Stay and the Resident Duty Hour Rules of 2003 SO MEDICAL CARE LA English DT Article DE prolonged length of stay; teaching hospitals; difference-in-differences ID QUALITY-OF-CARE; PATIENT SAFETY; MEDICARE BENEFICIARIES; ADMINISTRATIVE DATA; WORK HOURS; MORTALITY; REGULATIONS; REFORM; PHYSICIAN AB Background: Resident duty hour reforms of 2003 had the potential to create a major impact on the delivery of inpatient care. Objective: We examine whether the reforms influenced the probability of a patient experiencing a prolonged hospital length of stay (PLOS), a measure reflecting either inefficiency of care or the development of complications that may slow the rate of discharge. Research Design: Conditional logistic models to compare PLOS in more versus less teaching-intensive hospitals before and after the reform, adjusting for patient comorbidities, common time trends, and hospital site. Subjects: Medicare (N = 6,059,015) and Veterans Affairs (VA) (N = 210,276) patients admitted for medical conditions (acute myocardial infarction, heart failure, stroke, or gastrointestinal bleeding) or surgical procedures (general, orthopedic, and vascular) from July 2000 to June 2005. Measures: Prolonged length of stay. Results: Modeling all medical conditions together, the odds of prolonged stay in the first year post reform at more versus less teaching intensive hospitals was 1.01 (95% CI: 0.97-1.05) for Medicare and 1.07 (0.94-1.20) for the VA. Results were similarly negative in the second year post reform. For "combined surgery" the post year 1 odds ratios were 1.04 (0.98-1.09) and 0.94 (0.78-1.14) for Medicare and the VA respectively, and similarly unchanged in post year 2. Isolated increases in the probability of prolonged stay did occur for some vascular surgery procedures. Conclusions: Hospitals generally found ways to cope with duty hour reform without increasing the prevalence of prolonged hospital stays, a marker of either inefficient care or complications. C1 [Silber, Jeffrey H.; Mi, Lanyu; Even-Shoshan, Orit] Childrens Hosp Philadelphia, Ctr Outcomes Res, Philadelphia, PA 19104 USA. [Silber, Jeffrey H.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Silber, Jeffrey H.] Univ Penn, Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA. [Silber, Jeffrey H.; Volpp, Kevin G.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, Philadelphia, PA 19104 USA. [Rosenbaum, Paul R.] Univ Penn, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA. [Rosen, Amy K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Rosen, Amy K.] Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Romano, Patrick S.] Univ Calif Davis, Sch Med, Div Gen Med, Sacramento, CA 95817 USA. [Romano, Patrick S.] Univ Calif Davis, Sch Med, Ctr Healthcare Policy & Res, Sacramento, CA 95817 USA. [Itani, Kamal M. F.] Boston Univ, VA Boston Hlth Care Management, W Roxbury, MA USA. [Cen, Liyi; Halenar, Michael J.; Volpp, Kevin G.] Vet Adm Hosp, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Halenar, Michael J.; Volpp, Kevin G.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. RP Silber, JH (reprint author), Childrens Hosp Philadelphia, Ctr Outcomes Res, 3535 Market St,Suite 1029, Philadelphia, PA 19104 USA. EM silberj@wharton.upenn.edu RI Rosenbaum, Paul/H-8687-2012; Romano, Patrick/N-4225-2014 OI Romano, Patrick/0000-0001-6749-3979; Halenar, Michael/0000-0002-8703-3811 FU National Heart, Lung, and Blood Institute [R01 HL082637]; Department of Veterans Affairs [IIR 04-202]; National Science Foundation [SES 0646002] FX Supported by the National Heart, Lung, and Blood Institute grant (R01 HL082637), The Department of Veterans Affairs grant (IIR 04-202), and The National Science Foundation grant (SES 0646002). NR 29 TC 22 Z9 23 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD DEC PY 2009 VL 47 IS 12 BP 1191 EP 1200 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 529AM UT WOS:000272488100002 PM 19786912 ER PT J AU Harris, AHS Kivlahan, DR Bowe, T Finney, JW Humphreys, K AF Harris, Alex H. S. Kivlahan, Daniel R. Bowe, Thomas Finney, John W. Humphreys, Keith TI Developing and Validating Process Measures of Health Care Quality An Application to Alcohol Use Disorder Treatment SO MEDICAL CARE LA English DT Article; Proceedings Paper CT AcademyHealth Annual Research Meeting CY JUN 08-10, 2008 CL Washington, DC SP AcademyHealth DE alcoholism and addictive behavior; quality of care; quality assessment; quality measurement; substance abuse ID PERFORMANCE-MEASURES; CLINICAL-OUTCOMES; CONTINUING CARE; MISSING DATA; SYSTEM; NHS AB Background: Health care process quality measures usually are designed by expert panels attempting to synthesize nuanced clinical evidence and subsequently operationalized using administrative data. Many quality measures are then adopted without directly validating their presumed links with outcomes. Later efforts to validate process measures often yield negative results, leaving policy makers without a defensible means of measuring quality. This article presents an alternative strategy for developing and validating process quality measures. The development of an alcohol use disorder (AUD) treatment quality measure is used as an example. Methods: An expert panel generated a range of candidate process quality measures of AUD treatment derivable from administrative data that were then tested to determine which had the strongest associations with facility- and patient-level outcomes. Outcome and process data were from 2701 US Veterans Health Administration patients starting a new episode of care at 54 VA facilities. Results: Several of the candidate process-of-care quality measures predicted facility- and patient-level outcomes. Having at least 3 visits during the first month of specialty AUD treatment was correlated with improvement on the Addiction Severity Index Alcohol composite at the facility level, r = 0.41 (95% Confidence Interval 0.16-0.61), and at the patient level, r = 0.07 (CI: 0.03-0.11). Conclusions: These "prevalidated" quality measures can now be judged for the extent they map onto the extant clinical literature and other design requirements. The development and validation strategy we describe should aid in efficiently producing quality measures in other areas of health care. C1 [Harris, Alex H. S.; Bowe, Thomas; Finney, John W.; Humphreys, Keith] Stanford Univ, Sch Med, VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA. [Kivlahan, Daniel R.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Harris, AHS (reprint author), Stanford Univ, Sch Med, VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, 795 Willow Rd 152-MPD, Menlo Pk, CA 94025 USA. EM alexander.harris2@va.gov NR 39 TC 13 Z9 14 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD DEC PY 2009 VL 47 IS 12 BP 1244 EP 1250 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 529AM UT WOS:000272488100008 PM 19786908 ER PT J AU Wang, HW Salatin, B Grindle, GG Ding, D Cooper, RA AF Wang, Hongwu Salatin, Benjamin Grindle, Garrett G. Ding, Dan Cooper, Rory A. TI Real-time model based electrical powered wheelchair control SO MEDICAL ENGINEERING & PHYSICS LA English DT Article DE Electric-powered wheelchair; 3D dynamic model; Model based control; PID; Medical rehabilitation AB The purpose of this study was to evaluate the effects of three different control methods on driving speed variation and wheel slip of an electric-powered wheelchair (EPW). A kinematic model as well as 3D dynamic model was developed to control the velocity and traction of the wheelchair. A smart wheelchair platform was designed and built with a computerized controller and encoders to record wheel speeds and to detect the slip. A model based, a proportional-integral-derivative (PID) and an open-loop controller were applied with the EPW driving on four different surfaces at three specified speeds. The speed errors, variation, rise time, settling time and slip coefficient were calculated and compared for a speed step-response input. Experimental results showed that model based control performed best on all surfaces across the speeds. Published by Elsevier Ltd on behalf of IPEM. C1 [Wang, Hongwu; Salatin, Benjamin; Grindle, Garrett G.; Ding, Dan; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA 15206 USA. [Wang, Hongwu; Salatin, Benjamin; Grindle, Garrett G.; Ding, Dan; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15261 USA. [Ding, Dan; Cooper, Rory A.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15261 USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151R 1, 7180 Highland Dr,Bldg 4,Room 243E 151R-1, Pittsburgh, PA 15206 USA. EM rcooper+@pitt.edu RI Wang, Hongwu/J-6133-2013 OI Wang, Hongwu/0000-0002-6567-9144 FU Quality of Life Technology Engineering Research Center; National Science Foundation [EEC-0540865]; National Institutes of Health [1R03HD048465-01A1]; VA Rehabilitation Research and Development Service [B3142C] FX This work was supported in part by Quality of Life Technology Engineering Research Center, National Science Foundation (EEC-0540865), the National Institutes of Health (1R03HD048465-01A1), and the VA Rehabilitation Research and Development Service (B3142C). NR 23 TC 16 Z9 16 U1 2 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1350-4533 J9 MED ENG PHYS JI Med. Eng. Phys. PD DEC PY 2009 VL 31 IS 10 BP 1244 EP 1254 DI 10.1016/j.medengphy.2009.08.002 PG 11 WC Engineering, Biomedical SC Engineering GA 534UG UT WOS:000272922200006 PM 19733494 ER PT J AU Grubaugh, AL Elhai, JD Ruggiero, KJ Egede, LE Naifeh, JA Frueh, C AF Grubaugh, Anouk L. Elhai, Jon D. Ruggiero, Kenneth J. Egede, Leonard E. Naifeh, James A. Frueh, Christopher TI Equity in Veterans Affairs Disability Claims Adjudication in a National Sample of Veterans SO MILITARY MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH-SERVICES; VIETNAM VETERANS; MILITARY SERVICE; CARE SERVICES; HELP-SEEKING; IRAQ; AFGHANISTAN; CONNECTION; PREDICTORS AB Objectives: To address potential equity concerns about the U.S. Department of Veterans Affairs' (VA) process for adjudicating military service-related disability claims. Methods: Participants were a nationally representative sample of 20,048 veterans completing the 2001 National Survey of Veterans. Sociodemographic, access, and illness correlates of both the award and rate of general disability benefits awarded by the VA were examined using an established theoretical framework. Results: Sociodemographic, access, and illness variables were associated with both the award ("yes/no") and rate of benefits (0-100%) awarded, with combat exposure, unemployment, and physical impairment accounting for the strongest model effects. Conclusions: Veterans' needs were not overshadowed by factors related to demographic background or access (e.g., race, gender, insurance), reducing concerns about disparities in general VA disability disbursements. These data are timely as disability claims/payments will likely increase dramatically in the near future because of current conflicts in the Middle East. C1 [Grubaugh, Anouk L.; Ruggiero, Kenneth J.; Egede, Leonard E.] Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29425 USA. [Grubaugh, Anouk L.; Ruggiero, Kenneth J.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Elhai, Jon D.] Univ Toledo, Dept Psychol, Toledo, OH 43606 USA. [Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Naifeh, James A.] Univ Mississippi, Med Ctr, Dept Psychiat & Human Behav, Jackson, MS 39216 USA. [Frueh, Christopher] Univ Hawaii, Hilo, HI 96720 USA. RP Grubaugh, AL (reprint author), Med Univ S Carolina, Ralph H Johnson VAMC, POB 250861, Charleston, SC 29425 USA. FU Veterans Affairs Health Service Research [CD-207015]; National Institute of Mental Health [MH074468] FX This work was partially supported by Grant CD-207015 from Veterans Affairs Health Service Research and Development and Grant MH074468 from the National Institute of Mental Health. NR 28 TC 3 Z9 3 U1 0 U2 2 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 J9 MIL MED JI Milit. Med. PD DEC PY 2009 VL 174 IS 12 BP 1241 EP 1246 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 601LM UT WOS:000278061000018 PM 20055063 ER PT J AU Shin, JM Sachs, G Cho, YM Garst, M AF Shin, Jai Moo Sachs, George Cho, Young-moon Garst, Michael TI 1-Arylsulfonyl-2-(Pyridylmethylsulfinyl) Benzimidazoles as New Proton Pump Inhibitor Prodrugs SO MOLECULES LA English DT Article DE proton pump inhibitor; prodrug; gastric acid secretion ID GASTRIC-ACID-SECRETION; OMEPRAZOLE; SUPPRESSION; DERIVATIVES; EFFICACY AB New arylsulfonyl proton pump inhibitor (PPI) prodrug forms were synthesized. These prodrugs provided longer residence time of an effective PPI plasma concentration, resulting in better gastric acid inhibition. C1 [Shin, Jai Moo; Sachs, George; Cho, Young-moon] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. [Shin, Jai Moo; Sachs, George; Cho, Young-moon] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Garst, Michael] Allergan Pharmaceut Inc, Irvine, CA 92660 USA. RP Shin, JM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. EM jaishin@ucla.edu; gsachs@ucla.edu; ymkscho@yahoo.com; garst_michael@allergan.com FU US VA Merit Grant; NIH/NIDDK [DK053642, DK58333]; Winston Pharmaceuticals; LLC.; Allergan, Inc FX This work was supported by US VA Merit Grant, NIH/NIDDK grant number's DK053642 and DK58333, and Winston Pharmaceuticals, LLC., and Allergan, Inc. NR 23 TC 3 Z9 3 U1 0 U2 1 PU MOLECULAR DIVERSITY PRESERVATION INTERNATIONAL-MDPI PI BASEL PA KANDERERSTRASSE 25, CH-4057 BASEL, SWITZERLAND SN 1420-3049 J9 MOLECULES JI Molecules PD DEC PY 2009 VL 14 IS 12 BP 5247 EP 5280 DI 10.3390/molecules14125247 PG 34 WC Chemistry, Organic SC Chemistry GA 536KL UT WOS:000273043200031 PM 20032890 ER PT J AU Carter, GT Weiss, MD Bird, TD AF Carter, Gregory T. Weiss, Michael D. Bird, Thomas D. TI MYOTONIC DISORDER WITHOUT MYOTONIA? SO MUSCLE & NERVE LA English DT Letter ID DYSTROPHY TYPE-2 C1 [Carter, Gregory T.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA. [Weiss, Michael D.] Univ Washington, Sch Med, Dept Neurol, Div Neuromuscular Disorders, Seattle, WA 98195 USA. [Bird, Thomas D.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ Clin Ctr, Seattle, WA USA. RP Carter, GT (reprint author), Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA. OI Carter, Gregory/0000-0001-7617-4750 NR 7 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0148-639X J9 MUSCLE NERVE JI Muscle Nerve PD DEC PY 2009 VL 40 IS 6 BP 1071 EP 1072 DI 10.1002/mus.21418 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 523JM UT WOS:000272069400025 PM 19722253 ER PT J AU Hakimi, K Kinney, G Kraft, G Micklesen, P Robinson, L AF Hakimi, Kevin Kinney, Greg Kraft, George Micklesen, Paula Robinson, Lawrence TI Reliability in Interpretation of Median Somatosensory Evoked Potentials in the Setting of Coma: Factors and Implications SO NEUROCRITICAL CARE LA English DT Article DE Cerebral anoxia; Coma; Somatosensory evoked potentials; Interobserver variation; Hypoxic ischemic encephalopathy; Median nerve ID ANOXIC-ISCHEMIC COMA AB Median nerve short-latency somatosensory evoked potentials (SSEPs) are useful in determining prognosis for awakening after coma following hypoxic ischemic encephalopathy, but reliability of interpretation is unclear. To measure inter- and intra-observer reliability of determining presence or absence of SSEPs in comatose patients following hypoxic ischemic encephalopathy and to identify factors that enhance reliability. Retrospective review by four readers (experience ranging from 2-27 years) of SSEP recordings in 95 comatose patients. Twenty waveforms were presented twice and five waveforms were presented pre- and post-neuromuscular junction (NMJ) blockade. Academic teaching hospital and level 1 trauma center. Inpatients in coma due to hypoxic ischemic encephalopathy. Kappa values among the four readers, reflecting inter-observer reliability, ranged from 0.39 to 0.79 (mean 0.60, SD 0.16), a level of agreement interpreted as "moderate." Better inter-observer reliability was seen when: cortical amplitudes were a parts per thousand yen0.7 mu V, baseline noise was smaller, and when experience level between reviewers was most similar. In cases examined both pre- and post-NMJ blockade, average kappa values of inter-observer reliability increased significantly from 0.03 pre-NMJ blockade to 0.41 post-NMJ blockade. Intra-observer reliability was higher than that for inter-observer, with a "substantial" average kappa of 0.84 (range 0.79-0.89, SD .06). Inter- and intra-observer reliability of SSEP interpretation in comatose patients varies from moderate to substantial, respectively. In order to reliably interpret the presence of small cortical responses, NMJ blockade should be used when baseline noise is excessive. C1 [Hakimi, Kevin] VA Puget Sound Hlth Care Syst, Rehabil Care Serv 117, Seattle, WA 98108 USA. [Hakimi, Kevin; Kinney, Greg; Kraft, George; Micklesen, Paula; Robinson, Lawrence] Univ Washington, Sch Med, Harborview Med Ctr, Dept Rehabil Med, Seattle, WA 98195 USA. RP Hakimi, K (reprint author), VA Puget Sound Hlth Care Syst, Rehabil Care Serv 117, 1660 S Columbian Way, Seattle, WA 98108 USA. EM khakimi@u.washington.edu; lorenzo@u.washington.edu FU Harborview Medical Center; University of Washington FX This work was supported by the Department of Rehabilitation Medicine, Harborview Medical Center, University of Washington School of Medicine. NR 8 TC 4 Z9 4 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1541-6933 J9 NEUROCRIT CARE JI Neurocrit. Care PD DEC PY 2009 VL 11 IS 3 BP 353 EP 361 DI 10.1007/s12028-009-9251-7 PG 9 WC Critical Care Medicine; Clinical Neurology SC General & Internal Medicine; Neurosciences & Neurology GA 521SH UT WOS:000271943800009 PM 19649750 ER PT J AU Thase, ME AF Thase, Michael E. TI Atypical Depression: Useful Concept, but it's Time to Revise the DSM-IV Criteria SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE DSM-IV; atypical depression; MAOIs; mood reactivity; reverse neurovegetative features ID ANERGIC BIPOLAR DEPRESSION; DOUBLE-BLIND CROSSOVER; STAR-ASTERISK-D; AGE-OF-ONSET; MAJOR DEPRESSION; NEUROVEGETATIVE SYMPTOMS; RECURRENT DEPRESSION; HYSTEROID DYSPHORIA; OXIDASE-INHIBITORS; FEATURES AB Stewart et al (2009) have outlined the evidence in support of the validity of the DSM-IV definition of the 'With Atypical Features' episode specifier. Although recognizing the historical significance and clinical utility of the concept of atypical depression, this article takes issue with the DSM-IV criteria. It is concluded that mood reactivity, the A or obligative criterion, is neither significantly associated with the other symptomatic criteria nor useful to diagnose atypical depression, and thus should be eliminated. Problems with operationalization, specification, and reliability of ratings of the diagnostic criteria further limit validity. Despite these limitations in classification, many of the features associated with atypical depression are linked to an early onset of affective illness, including trait-like interpersonal sensitivity, comorbid social anxiety and agoraphobia, a history of childhood physical or sexual trauma, and indicators of the 'soft' side of the bipolar spectrum. Neurophysiologic studies also suggest that chronic, early-onset atypical depressions differ from both melancholia and normality. Re-analyses of the Columbia group's seminal studies suggest that preferential response to phenelzine vs imipramine-arguably the strongest validator of atypical depression-similarly appears to be limited to patients with chronic, early-onset syndromes. The criteria for atypical depression need to be revised in DSM-V, including sharpening the operational definitions for the specific symptoms. The importance of age of onset and comorbid anxiety warrant further study. Research examining the validity of a subform of atypical depression characterized by trait-like interpersonal sensitivity and a chronic, early-onset course may further enhance the clinical utility of the DSM-V classification. Neuropsychopharmacology (2009) 34, 2633-2641; doi:10.1038/npp.2009.100; published online 9 September 2009 C1 [Thase, Michael E.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 15213 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 15213 USA. RP Thase, ME (reprint author), Univ Penn, Sch Med, Dept Psychiat, 3535 Market St,Suite 670, Philadelphia, PA 15213 USA. EM thase@mail.med.upenn.edu NR 65 TC 29 Z9 30 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2009 VL 34 IS 13 BP 2633 EP 2641 DI 10.1038/npp.2009.100 PG 9 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 517TC UT WOS:000271639700005 PM 19741592 ER PT J AU Jacobs, JV Lou, JS Kraakevik, JA Horak, FB AF Jacobs, J. V. Lou, J. S. Kraakevik, J. A. Horak, F. B. TI THE SUPPLEMENTARY MOTOR AREA CONTRIBUTES TO THE TIMING OF THE ANTICIPATORY POSTURAL ADJUSTMENT DURING STEP INITIATION IN PARTICIPANTS WITH AND WITHOUT PARKINSON'S DISEASE SO NEUROSCIENCE LA English DT Article DE gait; balance; posture; cerebral cortex; transcranial magnetic stimulation ID TRANSCRANIAL MAGNETIC STIMULATION; STRIDE LENGTH REGULATION; LATERAL PREMOTOR CORTEX; LOW-FREQUENCY RTMS; GAIT APRAXIA; SURFACE EMG; LEG AREA; EXCITABILITY; RESPONSES; MOVEMENT AB The supplementary motor area (SMA) is thought to contribute to the generation of anticipatory postural adjustments (APAs, which act to stabilize supporting body segments prior to movement), but its precise role remains unclear. In addition, participants with Parkinson's disease (PD) exhibit impaired function of the SMA as well as decreased amplitudes and altered timing of the APA during step initiation, but the contribution of the SMA to these impairments also remains unclear. To determine how the SMA contributes to generating the APA and to the impaired APAs of participants with PD, we examined the voluntary steps of eight participants with PD and eight participants without PD, before and after disrupting the SMA and dorsolateral premotor cortex (dIPMC), in separate sessions, with 1-Hz repetitive transcranial magnetic stimulation (rTMS). Both groups exhibited decreased durations of their APAs after rTMS over the SMA but not over the dIPMC. Peak amplitudes of the APAs were unaffected by rTMS to either site. The symptom severity of the participants with PD positively correlated with the extent that rTMS over the SMA affected the durations of their APAs. The results suggest that the SMA contributes to the timing of the APA and that participants with PD exhibit impaired timing of their APAs, in part, due to progressive dysfunction of circuits associated with the SMA. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Jacobs, J. V.] Univ Vermont, Dept Rehabil & Movement Sci, Burlington, VT 05405 USA. [Lou, J. S.; Kraakevik, J. A.; Horak, F. B.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Kraakevik, J. A.] Portland VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Portland, OR USA. RP Jacobs, JV (reprint author), Univ Vermont, Dept Rehabil & Movement Sci, Burlington, VT 05405 USA. EM JJacobs@uvm.edu FU National Institute of Neurological Disorders and Stroke [F31NS048800]; National Institute of Aging [AG-06457] FX Acknowledgments-We thank our research participants for their participation, Andrew Owings and Ryan Eaton for hardware assistance, George Knafl for statistical consultation, as well as Dr. John Nutt and the staff of the Parkinson's Center of Oregon for their help with participant recruitment. We also thank Triana Nagel-Nelson and the other members of the Balance Disorders Laboratory for assisting the participants during data collection. This research was supported by the National Institutes of Health grants F31NS048800 (Jacobs) from the National Institute of Neurological Disorders and Stroke and AG-06457 (Horak) from the National Institute of Aging. NR 60 TC 61 Z9 62 U1 3 U2 18 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 J9 NEUROSCIENCE JI Neuroscience PD DEC 1 PY 2009 VL 164 IS 2 BP 877 EP 885 DI 10.1016/j.neuroscience.2009.08.002 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 518YI UT WOS:000271731700052 PM 19665521 ER PT J AU Kim, JH Studer, RK Vo, NV Sowa, GA Kang, JD AF Kim, J. H. Studer, R. K. Vo, N. V. Sowa, G. A. Kang, J. D. TI p38 MAPK inhibition selectively mitigates inflammatory mediators and VEGF production in AF cells co-cultured with activated macrophage-like THP-1 cells SO OSTEOARTHRITIS AND CARTILAGE LA English DT Article DE Low back pain; Macrophages; Annulus fibrosus; p38 MAPK; SB202190 ID ENDOTHELIAL GROWTH-FACTOR; INTERVERTEBRAL DISC DEGENERATION; NUCLEUS PULPOSUS CELLS; NECROSIS-FACTOR-ALPHA; NEUROPATHIC PAIN; GENE-EXPRESSION; KAPPA-B; ANGIOGENESIS; INTERLEUKIN-6; CHONDROCYTES AB Objectives: Recent data have suggested that macrophages are involved in the pathogenesis of discogenic back pain and enhance the secretion of inflammatory mediators in co-cultured annulus fibrosus (AF) cells. The purpose of these studies is to determine the role of p38 mitogen-activated protein kinase (p38 MAPK) signaling in the interactions between macrophage and AF cells. Methods: Human AF cells were co-cultured with phorbol myristate acetate-stimulated macrophage-like THP-1 cells with and without p38 MAPK inhibition. Conditioned media from co-cultured cells were assayed for interleukin (IL)-6, IL-8, prostaglandin E2 (PGE2), PGF2 alpha, and vascular endothelial growth factor (VEGF). Naive and macrophage-exposed AF cell responses to 10 ng/ml tumor necrosis factor-alpha. (TNF-alpha) were compared using the same outcome measures. Results: IL-6, IL-8, PGE2, PGF2 alpha, and VEGF were secreted in greater quantities by cells maintained in co-culture compared to macrophages or AF cells cultured alone. SB202190 blunted IL-6, PGE2, and PGF2 alpha production in a dose-dependent manner in co-culture. However, it did not suppress IL-8 and VEGF production. TNF-alpha-stimulated AF cell inflammatory mediators were up-regulated by macrophage exposure. SB202190 successfully suppressed IL-6, IL-8, PGE2, and PGF2 alpha secretion in macrophage-exposed AF cells in response to TNF-alpha. Conclusions: Annular injury can result in macrophage infiltration, and this can cause enhanced inflammatory mediator and VEGF production by AF cells. The p38 MAPK pathway signals are responsible for much of IL-6 and PG secretion from AF cells with macrophage-like cells, suggesting that blockade of this signal may serve as a therapeutic approach to discogenic pain. (C) 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved. C1 [Kim, J. H.; Vo, N. V.; Kang, J. D.] Univ Pittsburgh, Ferguson Lab Orthopaed Res, Dept Orthopaed Surg, Sch Med, Pittsburgh, PA 15261 USA. [Kim, J. H.] Korea Univ, Coll Med, Dept Neurosurg, Seoul 136705, South Korea. [Studer, R. K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Sowa, G. A.] Univ Pittsburgh, Dept Phys Med & Rehabil, Sch Med, Pittsburgh, PA 15261 USA. RP Kang, JD (reprint author), Univ Pittsburgh, Ferguson Lab Orthopaed Res, Dept Orthopaed Surg, Sch Med, 200 Lothrop St,E1641 BST, Pittsburgh, PA 15261 USA. EM kangjd@upmc.edu FU Pittsburgh Foundation at Department of Orthopaedic Surgery, University of Pittsburgh FX Source of support: This work was supported by the Pittsburgh Foundation at Department of Orthopaedic Surgery, University of Pittsburgh. NR 43 TC 19 Z9 20 U1 0 U2 7 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1063-4584 J9 OSTEOARTHR CARTILAGE JI Osteoarthritis Cartilage PD DEC PY 2009 VL 17 IS 12 BP 1662 EP 1669 DI 10.1016/j.joca.2009.06.004 PG 8 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA 535KI UT WOS:000272966700020 PM 19583958 ER PT J AU Haidet, P Fecile, ML West, HF Teal, CR AF Haidet, Paul Fecile, Mary Lynn West, Heather F. Teal, Cayla R. TI Reconsidering the team concept: Educational implications for patient-centered cancer care SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Physician-patient relations; Patient-centered care; Medical oncology; Radiation oncology; Oncology service ID SKILLS TRAINING-PROGRAM; COMMUNICATION-SKILLS; PALLIATIVE CARE; FAMILY-MEMBERS; PHYSICIANS; ONCOLOGISTS; EFFICACY; INTERDISCIPLINARY; CURRICULUM AB Patient-centered cancer care has become a priority in the oncology field. Increasing efforts to train oncologists in communication skills have led to a growing literature on patient-centered cancer education. In addition, systems approaches have led to an increased emphasis on the concept of teams as an Organizing framework for cancer care. In this essay, we examine issues involved in educating teams to provide patient-centered cancer care. in the process, we question the applicability of a tightly coordinated 'team' concept, and suggest the concept of a 'care community' as a more achievable ideal for the way that cancer care is commonly delivered. We discuss the implications that this has for cancer communication education, and Propose three principles to guide the development of educational interventions aimed at increasing patient-centeredness in cancer care delivery systems. (C) 2009 Elsevier Ireland Ltd. All rights reserved. C1 [Haidet, Paul] Penn State Univ, Coll Med, Off Med Educ, Hershey, PA 17033 USA. [Haidet, Paul] Penn State Univ, Coll Med, Dept Med, Hershey, PA 17033 USA. [Fecile, Mary Lynn] Penn State Univ, Coll Med, Div Pediat Hematol Oncol, Hershey, PA 17033 USA. [West, Heather F.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA. [West, Heather F.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Teal, Cayla R.] Baylor Coll Med, DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. [Teal, Cayla R.] Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP Haidet, P (reprint author), Penn State Univ, Coll Med, Off Med Educ, 500 Univ Dr HU15, Hershey, PA 17033 USA. EM phaidet@hmc.psu.edu FU Office of Research and Development, U.S. Department of Veterans Affairs [HFP 90-020]; National Heart, Lung, and Blood Institute [K07-HL85622] FX The opinions contained herein are those of the authors and do not necessarily represent the views of the US Department of Veterans Affairs, the National Heart, Lung, and Blood Institute, The Pennsylvania State University, or Baylor College of Medicine. NR 45 TC 24 Z9 24 U1 2 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD DEC PY 2009 VL 77 IS 3 BP 450 EP 455 DI 10.1016/j.pec.2009.09.020 PG 6 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 538BI UT WOS:000273158600019 PM 19850437 ER PT J AU Sotir, MJ Ewald, G Kimura, AC Higa, JI Sheth, A Troppy, S Meyer, S Hoekstra, M Austin, J Archer, J Spayne, M Daly, ER Griffin, PM AF Sotir, Mark J. Ewald, Gwen Kimura, Akiko C. Higa, Jeffrey I. Sheth, Anandi Troppy, Scott Meyer, Stephanie Hoekstra, Michael Austin, Jana Archer, John Spayne, Mary Daly, Elizabeth R. Griffin, Patricia M. CA Salmonella Wandsworth Outbreak Inv TI Outbreak of Salmonella Wandsworth and Typhimurium Infections in Infants and Toddlers Traced to a Commercial Vegetable-Coated Snack Food SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article; Proceedings Paper CT 45th Annual Meeting of the Infectious-Diseases-Society-of-America CY OCT, 2007 CL San Diego, CA SP Infect Dis Soc Amer DE Salmonella; toddlers; children; food intake; infection ID EAT SAVOURY SNACK; MULTISTATE OUTBREAK; AGONA INFECTION; UNITED-STATES; ORANIENBURG; PULSENET; CHILDREN AB Objective: Human outbreaks of salmonella infection have been attributed to a variety of food vehicles. Processed snack foods are increasingly consumed by children. In May 2007, state and local health departments and the Centers for Disease Control and Prevention investigated human infections from Salmonella Wandsworth, an extremely rare serotype. Materials and Methods: Serotyping and pulsed-field gel electrophoresis were used to identify outbreak-associated illnesses. Food history questionnaires and open-ended interviews were used to generate exposure hypotheses. A nationwide case-control study was conducted to epidemiologically implicate a source. Public health laboratories cultured implicated product from patient homes and retail stores. Results: Sixty-nine patients from 23 states were identified; 93% were aged 10 months to 3 years. Eighty-one percent of child patients had bloody diarrhea; 6 were hospitalized. No deaths were reported. The case-control study strongly associated illness with a commercial puffed vegetable-coated ready-to-eat snack food (mOR = 23.3, P = 0.0001), leading to a nationwide recall. Parents of 92% of interviewed case-children reported that children consumed the food during the week before their illness began; 43% reported daily consumption. Salmonella Wandsworth, 3 additional Salmonella serotypes and Chronobacter (formerly Enterobacter) sakazaki were all cultured from this product, leading to the identification of 18 human outbreak-related Salmonella Typhimurium illnesses. Conclusions: This report documents a nationwide outbreak associated with a commercial processed ready-to-eat snack food. Cases occurred primarily in infants and toddlers, many of whom frequently consumed the food. Measures are needed to ensure that ingredients added to ready-to-cat foods after the final lethal processing step are free of pathogens. C1 [Sotir, Mark J.] Ctr Dis Control & Prevent, Div Foodborne Bacterial & Mycot Dis, Enter Dis Epidemiol Branch, Atlanta, GA 30306 USA. [Ewald, Gwen] US Dept Vet Affairs, Atlanta Res & Educ Fdn, Atlanta, GA USA. [Kimura, Akiko C.; Higa, Jeffrey I.] Calif Dept Publ Hlth, Gardena, CA USA. [Troppy, Scott] Massachusetts Dept Hlth, Jamaica Plain, MA USA. [Meyer, Stephanie] Minnesota Dept Hlth, St Paul, MN USA. [Archer, John] Wisconsin Dept Hlth & Family Serv, Madison, WI USA. [Spayne, Mary] Vermont Dept Hlth, Burlington, VT 05402 USA. [Daly, Elizabeth R.] New Hampshire Dept Hlth & Human Serv, Concord, NH 03301 USA. RP Sotir, MJ (reprint author), Ctr Dis Control & Prevent, Div Foodborne Bacterial & Mycot Dis, Enter Dis Epidemiol Branch, 1600 Clifton Rd NE,MS A-38, Atlanta, GA 30306 USA. EM msotir@cdc.gov NR 27 TC 11 Z9 14 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD DEC PY 2009 VL 28 IS 12 BP 1041 EP 1046 DI 10.1097/INF.0b013e3181af6218 PG 6 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 525OH UT WOS:000272225200001 PM 19779390 ER PT J AU Gutierrez, PM Brenner, LA Olson-Madden, JH Breshears, RE Homaifar, BY Betthauser, LM Staves, P Adler, LE AF Gutierrez, Peter M. Brenner, Lisa A. Olson-Madden, Jennifer H. Breshears, Ryan E. Homaifar, Beeta Y. Betthauser, Lisa M. Staves, Pamela Adler, Lawrence E. TI Consultation as a Means of Veteran Suicide Prevention SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article DE suicide; veterans; consultation; assessment; collaboration ID SELF-HARM; COUNTERTRANSFERENCE; BEHAVIOR; REASONS; RISK; IMPULSIVITY; VALIDATION; ATTEMPTERS; INVENTORY; WORKING AB The development and implementation of a suicide consultation service being run by an interdisciplinary team in a metropolitan Veteran's Administration (VA) medical center is described. This service is grounded in a collaborative theoretical framework. An overview of the consultation process and theoretical and empirical literature to support the framework used by the service are provided. Some of the interventions commonly recommended to referring clinicians to reduce client suicide risk are reviewed. Although there are many challenges to running a service such as this, the authors conclude that the model presented is flexible enough to be applied in a variety of settings. C1 [Gutierrez, Peter M.] Denver VA Med Ctr, MIRECC, Denver, CO 80220 USA. [Gutierrez, Peter M.] Univ Colorado Denver, Sch Med, Dept Psychiat, Denver, CO USA. RP Gutierrez, PM (reprint author), Denver VA Med Ctr, MIRECC, 1055 Clermont St, Denver, CO 80220 USA. EM peter.gutierrez@va.gov OI Gutierrez, Peter/0000-0001-8981-8404 NR 68 TC 2 Z9 2 U1 0 U2 2 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD DEC PY 2009 VL 40 IS 6 BP 586 EP 592 DI 10.1037/a0016497 PG 7 WC Psychology, Multidisciplinary SC Psychology GA 532RK UT WOS:000272767000007 ER PT J AU Lybrand, J Caroff, S AF Lybrand, Janice Caroff, Stanley TI Management of Schizophrenia with Substance Use Disorders SO PSYCHIATRIC CLINICS OF NORTH AMERICA LA English DT Article DE Schizophrenia; Substance use disorders; Alcohol; Cannabis; Nicotine; Cocaine ID SEVERE MENTAL-ILLNESS; SELF-MEDICATION HYPOTHESIS; DRUG-USE DISORDERS; DUAL DIAGNOSIS; COCAINE DEPENDENCE; ALCOHOL-USE; TARDIVE-DYSKINESIA; SMOKING-CESSATION; CIGARETTE-SMOKING; EXCESS MORTALITY AB Around 50% of patients with schizophrenia develop a co-occurring substance use disorder involving alcohol or illicit substances at some time during their lives. The comorbid substance abuse will markedly affect the course of illness of schizophrenia. In this article, the authors review the epidemiology, theories of causation, effect on the course of illness, and treatment of co-occurring schizophrenia and substance use disorder. C1 [Lybrand, Janice; Caroff, Stanley] Philadelphia VA Med Ctr, Dept Psychiat, Philadelphia, PA 19104 USA. [Caroff, Stanley] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. RP Lybrand, J (reprint author), Philadelphia VA Med Ctr, Dept Psychiat, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM janice.lybrand@va.gov NR 75 TC 10 Z9 10 U1 2 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0193-953X EI 1558-3147 J9 PSYCHIAT CLIN N AM JI Psychiatr. Clin. North Amer. PD DEC PY 2009 VL 32 IS 4 BP 821 EP + DI 10.1016/j.psc.2009.09.002 PG 14 WC Psychiatry SC Psychiatry GA 601KO UT WOS:000278058200007 PM 19944886 ER PT J AU Goldstein, G Luther, JF Haas, GL Gordon, AJ Appelt, C AF Goldstein, Gerald Luther, James F. Haas, Gretchen L. Gordon, Adam J. Appelt, Cathleen TI Comorbidity Between Psychiatric and General Medical Disorders in Homeless Veterans SO PSYCHIATRIC QUARTERLY LA English DT Article DE Homelessness; Comorbidity; Health Status ID MENTALLY-ILL VETERANS; EXPERIENCING HOMELESSNESS; SUBSTANCE-ABUSE; URBAN HOMELESS; HEALTH; PEOPLE; SERVICES; ILLNESS; PROGRAM; DISEASE AB Homeless veterans have numerous co-occurring medical and behavioral health problems. Identification of common patterns of comorbid conditions may help providers to determine severity of medical conditions and triage health care more effectively. In this study we identify such patterns of comorbid medical and psychiatric disorders using cluster analysis and we evaluate relationships between these patterns and sociodemographic factors. We used data from a survey of 3,595 veterans in a regional VA network who were presently or recently homeless assessing nine major medical disorder and six psychiatric disorder categories. Diagnostic ratings of presence or absence of these disorders were placed into the same cluster analysis to determine whether separable clusters emerged reflecting differing diagnostic profiles. There are recognizable patterns of comorbidity involving several psychiatric and general medical disorders, as well as disorders of both types that exist independently. Cluster membership was associated with various sociodemographic indices. Mental and general medical health problems in homeless veterans often occur in association with each other and form identifiable patterns that vary on sociodemographic factors. C1 [Goldstein, Gerald; Luther, James F.; Haas, Gretchen L.; Gordon, Adam J.; Appelt, Cathleen] VA Pittsburgh Healthcare Syst, MIRECC, VISN MIRECC 4, Pittsburgh, PA 15206 USA. [Goldstein, Gerald; Luther, James F.; Haas, Gretchen L.; Gordon, Adam J.; Appelt, Cathleen] Univ Pittsburgh, Pittsburgh, PA USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, MIRECC, VISN MIRECC 4, 7180 Highland Dr 151R, Pittsburgh, PA 15206 USA. EM ggold@nb.net FU NIMH NIH HHS [T32 MH015169-31, T32 MH015169] NR 22 TC 7 Z9 7 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-2720 J9 PSYCHIAT QUART JI Psychiatr. Q. PD DEC PY 2009 VL 80 IS 4 BP 199 EP 212 DI 10.1007/s11126-009-9106-6 PG 14 WC Psychiatry SC Psychiatry GA 523BP UT WOS:000272046500001 PM 19597992 ER PT J AU Chan, D Cheadle, AD Reiber, G Unutzer, J Chaney, EF AF Chan, Domin Cheadle, Allen D. Reiber, Gayle Unutzer, Jurgen Chaney, Edmund F. TI Health Care Utilization and Its Costs for Depressed Veterans With and Without Comorbid PTSD Symptoms SO PSYCHIATRIC SERVICES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; COLLABORATIVE CARE; ANXIETY DISORDERS; VIETNAM VETERANS; MAJOR DEPRESSION; IMPACT; AFGHANISTAN; DIAGNOSES; SERVICES; TRAUMA AB Objective: This study examined health care utilization and costs of care among Veterans Affairs (VA) patients with depression and with or without symptoms of comorbid posttraumatic stress disorder (PTSD). Methods: Cross-sectional comparisons of health care utilization and costs were conducted with VA administrative data for a sample of veterans from a randomized trial of collaborative care depression treatment in ten VA primary care clinics across five states. Patients with depression or dysthymia were included in the study, and those who were acutely suicidal or had probable bipolar disorder were excluded. The sample of 606 patients was mainly male, white, and aged 55 or older. Health care utilization, costs, and medication data from VA administrative databases were analyzed over 12 months. Results: Patients with depression and PTSD (screen score >= 3) were more emotionally distressed, had more frequent mental health specialty visits (6.91 versus 1.68, p<.001), more total outpatient visits (26.16 versus 19.94, p<.001), and correspondingly higher outpatient mental health care costs over the previous 12 months compared with depressed patients without PTSD. Antidepressants were prescribed to a higher proportion of depressed patients with PTSD (61% versus 40%). Conclusions: Patients with PTSD and depression had greater utilization of specialty mental health treatments and antidepressant medications and higher mental health care costs in the previous 12 months than depressed patients without PTSD. As military personnel return from Iraq, both VA and non-VA health care providers need to plan for an increase in outpatient mental health services and costs, particularly among depressed veterans who also have PTSD. (Psychiatric Services 60: 1612-1617, 2009) C1 [Chan, Domin; Unutzer, Jurgen; Chaney, Edmund F.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Cheadle, Allen D.; Reiber, Gayle] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Reiber, Gayle; Chaney, Edmund F.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. RP Chan, D (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Box 356560, Seattle, WA 98195 USA. EM dominc@u.washington.edu FU U. S. Department of Veterans Affairs; Veterans Health Administration; Health Services Research and Development Service [MHI 99375] FX The results reported here were from WAVES. The research reported was supported by the U. S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (MHI 99375). The authors recognize Chuan-Fen Liu, Ph. D., M. P. H., for contributing to the conceptual design, guidance in data preparation and review of this study; Lori Zoellner, Ph. D., for her PTSD content expertise; and Ming-Yu Fan, Ph. D., B. S., for her statistical consultation and guidance. The views expressed here are those of the authors and do not necessarily represent the views of the VA or the University of Washington. NR 33 TC 33 Z9 33 U1 7 U2 11 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD DEC PY 2009 VL 60 IS 12 BP 1612 EP 1617 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 526FO UT WOS:000272273300008 PM 19952151 ER PT J AU Chen, DC Wang, J Wang, B Yang, SC Zhang, CX Zheng, YL Li, YL Wang, N Yang, KB Xiu, MH Kosten, TR Zhang, XY AF Chen, Da Chun Wang, Jing Wang, Bo Yang, Sheng Chang Zhang, Chong Xi Zheng, You Lan Li, Yan Li Wang, Ning Yang, Ke Bing Xiu, Mei Hong Kosten, Thomas R. Zhang, Xiang Yang TI Decreased levels of serum brain-derived neurotrophic factor in drug-naive first-episode schizophrenia: relationship to clinical phenotypes SO PSYCHOPHARMACOLOGY LA English DT Article DE Schizophrenia; Brain-derived neurotrophic factor; First-episode psychosis; Psychopathology; Neurotrophin ID LONG-TERM TREATMENT; BDNF LEVELS; VAL66MET POLYMORPHISM; BIPOLAR DISORDER; RAT-BRAIN; ANTIPSYCHOTICS; EXPRESSION; PSYCHOSES; TRANSPORT; DOPAMINE AB There is accumulating evidence that brain-derived neurotrophic factor (BDNF) may be involved in the pathophysiology of patients with schizophrenia. Clinical studies show reductions in BDNF in schizophrenic patients treated with first generation antipsychotics or second generation antipsychotics. However, there have been few systematic studies to examine the relationship between BDNF levels and psychopathology in first-episode and drug-na < ve patients with schizophrenia. Serum BDNF levels were determined using enzyme-linked-immunosorbent assay (ELISA) in the serum of 88 never-medicated first-episode and 90 healthy controls subjects matched for age and gender. The schizophrenia symptomatology and the depressive symptoms were assessed by the positive and negative syndrome scale (PANSS) and the Hamilton rating (HAMD) scale for depression. The results showed that BDNF levels were significantly lower in first-episode patients with schizophrenia than in healthy control subjects (9.0 +/- 4.2 ng/ml vs 12.1 +/- 2.2 ng/ml; F = 37.6; df = 1, 176; p < 0.0001). A significant positive correlation between BDNF levels and PANSS positive subscore was observed (r = 0.29; df = 88; p = 0.008). Furthermore, higher BDNF levels were observed in patients with paranoid subtype of schizophrenia. However, no significant correlation between BDNF and HAMD total score was found. Low BDNF levels at the onset of psychosis suggest that it may contribute to the pathogenesis of schizophrenia and perhaps, could be a candidate biological marker for positive symptoms. C1 [Kosten, Thomas R.; Zhang, Xiang Yang] Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Chen, Da Chun; Li, Yan Li; Wang, Ning; Yang, Ke Bing; Xiu, Mei Hong] Beijing Huilongguan Hosp, Beijing, Peoples R China. [Wang, Jing; Yang, Sheng Chang] Guangxi Normal Univ, Coll Life Sci, Guilin 541004, Peoples R China. [Wang, Bo; Zheng, You Lan] Jilin Agr Univ, Coll Chinese Med Mat, Changchun 130118, Peoples R China. [Zhang, Chong Xi] Shandong Univ Weihai, Marine Coll, Shandong Weihai 264209, Peoples R China. RP Kosten, TR (reprint author), Baylor Coll Med, VA Med Ctr, Menninger Dept Psychiat & Behav Sci, Res Bldg 110,Room 229,2002 Holcombe Blvd, Houston, TX 77030 USA. EM kosten@bcm.edu; xyzhang@bcm.edu FU Beijing Municipal Natural Science Foundation [7072035]; Stanley Medical Research Institute [03T-459, 05T-726]; Department of Veterans Affairs, VISN 16, Mental Illness Research, Education, and Clinical Center, United States National Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639] FX Supported by grants from the Beijing Municipal Natural Science Foundation (identification 7072035), the Stanley Medical Research Institute (03T-459 and 05T-726), and the Department of Veterans Affairs, VISN 16, Mental Illness Research, Education, and Clinical Center, United States National Institute of Health K05-DA0454, P50-DA18827, and U01-MH79639. NR 30 TC 47 Z9 50 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 EI 1432-2072 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD DEC PY 2009 VL 207 IS 3 BP 375 EP 380 DI 10.1007/s00213-009-1665-6 PG 6 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 519FX UT WOS:000271751500003 PM 19787338 ER PT J AU Niewoehner, DE Lapidus, R Cote, C Sharafkhaneh, A Plautz, M Johnson, P Kesten, S AF Niewoehner, Dennis E. Lapidus, Robert Cote, Claudia Sharafkhaneh, Amir Plautz, Mark Johnson, Philip Kesten, Steven TI Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease SO PULMONARY PHARMACOLOGY & THERAPEUTICS LA English DT Article DE COPD; Tiotropium; Ipratropium/albuterol; Clinical trial ID ONCE-DAILY TIOTROPIUM; HEALTH OUTCOMES; COPD; SALMETEROL; EFFICACY; TRIAL; MULTICENTER; BROMIDE AB Background: Ipratropium and albuterol, combined in a single formulation, is widely used as three to four times daily maintenance therapy in COPD. This trial compared tiotropium, once daily, as a potential alternative to patients already taking the ipratropium/albuterol combination. Methods: 676 patients with moderate to very severe stable COPD (mean FEV(1) = 39% of predicted) maintained on ipratropium/albuterol were randomized to receive over an 84 day period either tiotropium (18 mcg) each morning, or continue with ipratropium (26 mcg)/albuterol (206 mcg), 2 actuations 4 times daily, using a parallel group, double-blind, double-dummy design. Six-hour spirometry was assessed on study days 1, 22, and 84, along with safety assessments and other efficacy measures. Results: In terms of primary outcomes, mean trough FEV(1) at 84 days was larger in the tiotropium arm as, compared with the ipratropium/albuterol arm (difference = 86 ml: 95% CI. 49 to 123 ml, p < 0.0001). The mean FEV(1) AUC(0-6) at 84 days was also larger in the tiotropium arm (difference = 17 ml: 95% CI, -21 to 56 ml), this difference being statistically non-inferior to the ipratropium/albuterol arm (p < 0.001), but not statistically superior (p = 0.37). Other efficacy measures were similar in the two groups. Lower respiratory adverse events were reported in 40 tiotropium patients vs. 52 ipratropium/albuterol patients. Safety reporting was otherwise similar. Conclusion: Patients previously maintained on the ipratropium/albuterol combination taken four times daily can be switched to tiotropium once daily with the reasonable expectation of at least equivalent bronchodilation during daytime hours and superior bronchodilation during early morning hours. Published by Elsevier Ltd. C1 [Niewoehner, Dennis E.] Vet Affairs Med Ctr, Dept Med, Pulm Sect 111N, Minneapolis, MN 55417 USA. [Lapidus, Robert] Rocky Mt Ctr Clin Res, Wheat Ridge, CO 80033 USA. [Cote, Claudia] Vet Affairs Med Ctr, Bay Pines, FL 33744 USA. [Sharafkhaneh, Amir] Michael E DeBakey Vet Affairs Med Ctr, Pulm Sect 111 1, Houston, TX 77030 USA. [Plautz, Mark] Vet Affairs Med Ctr, Med Serv 111, Kansas City, MO 64128 USA. [Johnson, Philip] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA. [Kesten, Steven] Boehringer Ingelheim GmbH & Co KG, Corp Headquarters, D-52216 Ingelheim, Germany. RP Niewoehner, DE (reprint author), Vet Affairs Med Ctr, Dept Med, Pulm Sect 111N, 1 Vet Dr, Minneapolis, MN 55417 USA. EM niewo001@umn.edu; rlapidus@rockymtnpulmonary.com; Claudia.Cote@va.gov; amirs@bcm.tmc.edu; Mark.Plautz@va.gov; pjohnson@rdg.boehringer-ingelheim.com; skesten@rdg.boehringer-ingelheim.com NR 19 TC 9 Z9 11 U1 0 U2 1 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1094-5539 J9 PULM PHARMACOL THER JI Pulm. Pharmacol. Ther. PD DEC PY 2009 VL 22 IS 6 BP 587 EP 592 DI 10.1016/j.pupt.2009.08.006 PG 6 WC Pharmacology & Pharmacy; Respiratory System SC Pharmacology & Pharmacy; Respiratory System GA 523KR UT WOS:000272072600020 PM 19737620 ER PT J AU Bell, PD Komlosi, P Zhang, ZR AF Bell, P. Darwin Komlosi, Peter Zhang, Zhi-Ren TI ATP as a mediator of macula densa cell signalling SO PURINERGIC SIGNALLING LA English DT Review DE ATP; Macula densa; Cell signalling ID NITRIC-OXIDE SYNTHASE; TUBULO-GLOMERULAR FEEDBACK; RENAL VASCULAR-RESISTANCE; THICK ASCENDING LIMB; RAT MESANGIAL CELLS; TUBULOGLOMERULAR FEEDBACK; ANGIOTENSIN-II; JUXTAGLOMERULAR APPARATUS; FILTRATION-RATE; RENIN SECRETION AB Within each nephro-vascular unit, the tubule returns to the vicinity of its own glomerulus. At this site, there are specialised tubular cells, the macula densa cells, which sense changes in tubular fluid composition and transmit information to the glomerular arterioles resulting in alterations in glomerular filtration rate and blood flow. Work over the last few years has characterised the mechanisms that lead to the detection of changes in luminal sodium chloride and osmolality by the macula densa cells. These cells are true "sensor cells" since intracellular ion concentrations and membrane potential reflect the level of luminal sodium chloride concentration. An unresolved question has been the nature of the signalling molecule(s) released by the macula densa cells. Currently, there is evidence that macula densa cells produce nitric oxide via neuronal nitric oxide synthase (nNOS) and prostaglandin E(2) (PGE(2)) through cyclooxygenase 2 (COX 2)-microsomal prostaglandin E synthase (mPGES). However, both of these signalling molecules play a role in modulating or regulating the macula-tubuloglomerular feedback system. Direct macula densa signalling appears to involve the release of ATP across the basolateral membrane through a maxi-anion channel in response to an increase in luminal sodium chloride concentration. ATP that is released by macula densa cells may directly activate P2 receptors on adjacent mesangial cells and afferent arteriolar smooth muscle cells, or the ATP may be converted to adenosine. However, the critical step in signalling would appear to be the regulated release of ATP across the basolateral membrane of macula densa cells. C1 [Bell, P. Darwin] Med Univ S Carolina, Div Nephrol, Charleston, SC 29425 USA. [Bell, P. Darwin; Komlosi, Peter; Zhang, Zhi-Ren] Med Univ S Carolina, Dept Med, Div Nephrol, Childrens Res Inst, Charleston, SC 29425 USA. [Bell, P. Darwin; Komlosi, Peter; Zhang, Zhi-Ren] Ralph H Johnson VA Med Ctr, Dept Vet Affairs, Charleston, SC USA. RP Bell, PD (reprint author), Med Univ S Carolina, Div Nephrol, 173 Ashley Ave,210 CRI, Charleston, SC 29425 USA. EM BellPD@MUSC.EDU OI Komlosi, Peter/0000-0002-5284-8877 FU National Institute of Diabetes and Digestive and Kidney Disease [DK-32032]; American Heart Association; VA Merit Grant FX This work was supported by a grant from the National Institute of Diabetes and Digestive and Kidney Disease (DK-32032) and by a Scientist Development Award from the American Heart Association and a VA Merit Grant. We thank Ms. Barbara Harris for administrative assistance. NR 119 TC 21 Z9 21 U1 1 U2 6 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1573-9538 J9 PURINERG SIGNAL JI Purinergic Signal. PD DEC PY 2009 VL 5 IS 4 BP 461 EP 471 DI 10.1007/s11302-009-9148-0 PG 11 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 519AL UT WOS:000271737300004 PM 19330465 ER PT J AU Sanz, F Restrepo, MI Fernandez, E Briones, ML Blanquer, R Mortensen, EM Chiner, E Blanquer, J AF Sanz, Francisco Restrepo, Marcos I. Fernandez, Estrella Luisa Briones, Maria Blanquer, Rafael Mortensen, Eric M. Chiner, Eusebi Blanquer, Jose CA NAC-CV Study Grp TI Is it possible to predict which patients with mild pneumonias will develop hypoxemia? SO RESPIRATORY MEDICINE LA English DT Article DE Community-acquired pneumonia; Hypoxemia; Risk factors; Severity assessment ID COMMUNITY-ACQUIRED PNEUMONIA; LOW-RISK PATIENTS; RANDOMIZED-TRIAL; MANAGEMENT; OUTCOMES; HOSPITALIZATION; GUIDELINES; MORTALITY; DIAGNOSIS; ADULTS AB Usually, mortality due to mild community-acquired pneumonias (CAP) (Pneumonia severity index (PSI) classes I-III) is tow (<3%), but the appearance of hypoxemia significantly increases mortality. Our aim was to determine the clinical parameters associated with risk factors of developing hypoxemia in subjects with mild CAP (PSI I-III) and the clinical. outcomes of the hypoxemic group. We analyzed clinical characteristics and the outcomes of patients with mild CAP and hypoxemia (PaO(2)/FiO(2) < 300), in a prospective, multicenter cohort study of 1195 patients. Mild pneumonias (PSI I-III) were found in 645 cases (53.9%), of which 217 (33.6%) presented hypoxemia according to a PaO(2)/FiO(2) < 300. Patients with PaO(2)/FiO(2) < 300 required more ICU admissions, mechanical ventilation, and developed septic shock than other PSI I-III patients. The clinical parameters associated with hypoxemia were: COPD, bilateral chest X-ray involvement, and hypoalbuminemia. We conclude that patients with COPD, those with bilateral chest X-ray involvement, or hypoalbuminemia were significantly more Likely to have hypoxemia in mild CAP. Hypoxemic patients with low-risk pneumonia have worse clinical outcomes, including more ICU admission, need for mechanical ventilation and presence of septic shock than non-hypoxemic low-risk patients. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Sanz, Francisco] Univ Valencia, Consorci Hosp Gen, Serv Neumol, Valencia 46014, Spain. [Restrepo, Marcos I.; Mortensen, Eric M.] VERDICT Res Program, San Antonio, TX 78229 USA. [Restrepo, Marcos I.; Mortensen, Eric M.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78284 USA. [Fernandez, Estrella; Blanquer, Rafael] Hosp Univ Dr Peset Valencia, Serv Neumol, Valencia 46017, Spain. [Luisa Briones, Maria] Univ Valencia, Hosp Clin, Serv Neumol, Valencia 46010, Spain. [Chiner, Eusebi] Hosp St Joan, Serv Neumol, Sant Joan dAlacant 03550, Spain. [Blanquer, Jose] Univ Valencia, Hosp Clin, Serv Med Intens, Valencia 46010, Spain. RP Sanz, F (reprint author), Univ Valencia, Consorci Hosp Gen, Serv Neumol, Av Tres Cruces 2, Valencia 46014, Spain. EM sanz_fraher@gva.es RI Restrepo, Marcos/H-4442-2014 OI Mortensen, Eric/0000-0002-3880-5563 NR 27 TC 9 Z9 9 U1 0 U2 1 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 J9 RESP MED JI Respir. Med. PD DEC PY 2009 VL 103 IS 12 BP 1871 EP 1877 DI 10.1016/j.rmed.2009.06.013 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA 526FK UT WOS:000272272900014 PM 19619999 ER PT J AU Ohning, GV Machicado, GA Jensen, DM AF Ohning, Gordon V. Machicado, Gustavo A. Jensen, Dennis M. TI Definitive Therapy for Internal Hemorrhoids-New Opportunities and Options SO REVIEWS IN GASTROENTEROLOGICAL DISORDERS LA English DT Review DE Symptomatic internal hemorrhoids; Anorectal symptoms; Sclerotherapy; Thermocoagulation; Electrocoagulation; Infrared coagulation; Rubber band ligation ID RUBBER BAND LIGATION; FISSURE AB Hemorrhoids are common in Western societies. Appropriate assessment and treatment of symptomatic hemorrhoids can substantially reduce morbidity and improve patient well-being. In this article, the clinical presentation, differential diagnoses, and current treatment options, including the CRH-O'Regan banding device, an emerging technology for the anoscopic treatment of symptomatic internal hemorrhoids, are reviewed. C1 [Ohning, Gordon V.; Machicado, Gustavo A.; Jensen, Dennis M.] Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles VA Healthcare Ctr, CURE,Digest Dis Res Ctr, Los Angeles, CA 90095 USA. RP Ohning, GV (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Greater Los Angeles VA Healthcare Ctr, CURE,Digest Dis Res Ctr, Los Angeles, CA 90095 USA. FU NIDDK NIH HHS [K24 DK02650, DK41301] NR 26 TC 4 Z9 4 U1 1 U2 4 PU MEDREVIEWS PI NEW YORK PA 1333 BROADWAY, STE 400, NEW YORK, NY 10018 USA SN 1533-001X J9 REV GASTROENTEROL DI JI Rev. Gastroenterol. Disord. PD WIN PY 2009 VL 9 IS 1 BP 16 EP 26 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 433IV UT WOS:000265198400003 PM 19367214 ER PT J AU Fung, SJ Xi, MC Zhang, JH Yamuy, J Sampogna, S Tsai, KL Lim, V Morales, FR Chase, MH AF Fung, Simon J. Xi, Ming-Chu Zhang, Jian-Hua Yamuy, Jack Sampogna, Sharon Tsai, Kevin L. Lim, Vincent Morales, Francisco R. Chase, Michael H. TI Eszopiclone Prevents Excitotoxicity and Neurodegeneration in the Hippocampus Induced by Experimental Apnea SO SLEEP LA English DT Article DE Neuroprotection; GABA; OSA; CA1; apoptosis ID OBSTRUCTIVE SLEEP-APNEA; LONG-TERM POTENTIATION; GABA(A) RECEPTOR SUBUNITS; INTERMITTENT HYPOXIA; MONOCLONAL-ANTIBODY; GLUCOSE DEPRIVATION; ALPHA-CHLORALOSE; PYRAMIDAL CELLS; NEURONAL DEATH; A-RECEPTORS AB Study Objective: This study was designed to determine the effects of eszopiclone on apnea-induced excitotoxic synaptic processes and apoptosis in the hippocampus. Design: Recurrent periods of apnea, which consisted of a sequence of apnea (75% SpO(2)), followed by ventilation with recovery to normoxia (>95% SpO(2))' were induced for a period of three hours in anesthetized guinea pigs. The CA3 Schaffer collateral pathway in the hippocampus was stimulated and the field excitatory postsynaptic potential (fEPSP) response was recorded in CA1. Animals in the experimental group received an intravenous injection of eszopiclone (3 mg/kg) 10 min prior to the initiation of the periods of recurrent apnea, and once every 60 min thereafter; control animals received comparable injections of vehicle. At the end of the 3-h period of recurrent apnea, the animals were perfused, and hippocampal sections were immunostained in order to determine the presence of apoptosis, i.e., programmed cell death. Analyses and Results: Apnea resulted in a persistent increase in synaptic responsiveness of CA1 neurons as determined by analyses of the fEPSP. Eszopiclone antagonized the apnea-induced increase in the fEPSP Morphological analyses revealed significant apoptosis of CA1 neurons in control animals; however, there was no significant apoptosis in eszopiclone-treated animals. Conclusions: Eszopiclone was determined to suppress the apnea-induced hyperexcitability of hippocampal CA1 neurons, thereby reducing/eliminating neurotoxicity. These data lend credence to our hypothesis that eszopiclone, exclusive of its hypnotic actions, has the capacity to function as a potent neuroprotective agent. C1 [Fung, Simon J.; Xi, Ming-Chu; Zhang, Jian-Hua; Sampogna, Sharon; Tsai, Kevin L.; Lim, Vincent; Morales, Francisco R.; Chase, Michael H.] WebSci Int, Los Angeles, CA 90024 USA. [Yamuy, Jack] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Morales, Francisco R.; Chase, Michael H.] Univ Republica, Fac Med, Dept Fisiol, Montevideo, Uruguay. [Chase, Michael H.] Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90024 USA. RP Fung, SJ (reprint author), WebSci Int, 1251 Westwood Blvd, Los Angeles, CA 90024 USA. EM sfung@websciences.org FU Sepracor, Inc FX We are grateful to Oscar Ramos, Emi Koda, and Nichole Stevens for their excellent technical assistance. We would also like to thank Nichole Stevens and Daniel Bronson for their constructive input in revising this manuscript. Trent Wenzel provided expert computer support for AxoGraph X Scientific Software. Gerald Chao designed the software for automated control of the ventilator used in combination with the pulse oximeter for the apnea paradigms. This research was supported by Sepracor, Inc. NR 60 TC 8 Z9 8 U1 0 U2 1 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD DEC 1 PY 2009 VL 32 IS 12 BP 1593 EP 1601 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 527OL UT WOS:000272376300011 PM 20041595 ER PT J AU Clegg, LX Hankey, BF Tiwari, R Feuer, EJ Edwards, BK AF Clegg, Limin X. Hankey, Benjamin F. Tiwari, Ram Feuer, Eric J. Edwards, Brenda K. TI Estimating average annual per cent change in trend analysis SO STATISTICS IN MEDICINE LA English DT Article DE confidence interval for trends; geometric means; trend comparisons ID CANCER; NATION; RATES AB Trends in incidence or mortality rates over a specified time interval are usually described by the conventional annual per cent change (cAPC), under the assumption of a constant rate of change. When this assumption does not hold over the entire time interval, the trend may be characterized using the annual per cent changes from segmented analysis (sAPCs). This approach assumes that the change in rates is constant over each time partition defined by the transition points, but varies among different time partitions. Different groups (e.g. racial subgroups), however, may have different transition points and thus different time partitions over which they have constant rates of change, making comparison of sAPCs; problematic across groups over a common time interval of interest (e.g. the past 10 years). We propose a new measure, the average annual per cent change (AAPC), which uses sAPCs to summarize and compare trends for a specific time period. The advantage of the proposed AAPC is that it takes into account the trend transitions, whereas cAPC does not and can lead to erroneous conclusions. In addition, when the trend is constant over the entire time interval of interest, the AAPC has the advantage of reducing to both cAPC and sAPC. Moreover, because the estimated AAPC is based on the segmented analysis over the entire data series, any selected subinterval within a single time partition will yield the same AAPC estimate-that is it will be equal to the estimated sAPC for that time partition. The cAPC, however, is re-estimated using data only from that selected subinterval; thus, its estimate may be sensitive to the subinterval selected. The AAPC estimation has been incorporated into the segmented regression (free) software Joinpoint, which is used by many registries throughout the world for characterizing trends in cancer rates. Copyright (C) 2009 John Wiley & Sons, Ltd. C1 [Clegg, Limin X.] US Dept Vet Affairs, Off Inspector Gen, Washington, DC USA. [Hankey, Benjamin F.] Informat Management Serv Inc, Silver Spring, MD USA. [Tiwari, Ram] US FDA, Off Biostat, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA. [Feuer, Eric J.; Edwards, Brenda K.] NCI, Surveillance Res Program, Bethesda, MD 20892 USA. RP Clegg, LX (reprint author), US Dept Vet Affairs, Off Inspector Gen, 801 1 St NW,Room 1018, Washington, DC USA. EM lin_clegg@nih.gov NR 16 TC 121 Z9 126 U1 0 U2 4 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0277-6715 J9 STAT MED JI Stat. Med. PD DEC PY 2009 VL 28 IS 29 BP 3670 EP 3682 DI 10.1002/sim.3733 PG 13 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 533EU UT WOS:000272807300007 PM 19856324 ER PT J AU Anaya, DA Bulger, EM Kwon, YS Kao, LS Evans, H Nathens, AB AF Anaya, Daniel A. Bulger, Eileen M. Kwon, Yong S. Kao, Lillian S. Evans, Heather Nathens, Avery B. TI Predicting Death in Necrotizing Soft Tissue Infections: A Clinical Score SO SURGICAL INFECTIONS LA English DT Article; Proceedings Paper CT 25th Annual Meeting of the Surgical-Infection-Society CY MAY 06, 2005 CL Miami, FL SP Surg Infect Soc ID EARLY-DIAGNOSIS; RISK-FACTORS; FASCIITIS; MANAGEMENT; MORTALITY; SURVIVAL; DISEASE; MODEL; CARE AB Background: Necrotizing soft tissue infections (NSTIs) are associated with a high mortality rate; however, there is no uniform way to categorize the severity of this disease early in its course. The goal of this study was to develop a clinical score based on data available at the time of initial assessment to aid in stratifying patients according to their risk of death. Methods: A cohort of all 350 patients admitted with NSTI to two institutions over a nine-year period was examined retrospectively. Using random split sampling, two datasets were created: Prediction (PD) and validation (VD). Multivariable stepwise regression analysis of the PD identified independent predictors of death using data available at the time of admission. Model performance was evaluated for accuracy, discrimination, and calibration. A clinical score to predict death was created, and using the Trauma and Injury Severity Score (TRISS) methodology, the score was validated on the VD (z-statistic). Results: Six admission parameters independently predicted death: Age >50 years, heart rate >110 beats/min, temperature <36 degrees C, white blood cell count >40,000/mcL, serum creatinine concentration >1.5 mg/dL, and hematocrit >50%. The accuracy of this model was 86.8%; the area under the receiver-operating characteristic curve was 0.81, and the Hosmer-Lemeshow statistic was 11.8. Additionally, the score had excellent performance in evaluation on the VD (z-score/statistic 0.23 to 0.83). Conclusion: A clinical score that categorizes patients with NSTI according to the risk of death was created. It uses simple variables, all available at the time of first assessment. It stratifies patients according to disease severity and can guide the use of aggressive or novel therapeutic strategies and selection of patients for clinical trials. C1 [Anaya, Daniel A.] Baylor Coll Med, Dept Surg, Michael E DeBakey Vet Affairs Med Ctr, Div Gen Surg, Houston, TX 77030 USA. [Bulger, Eileen M.; Kwon, Yong S.; Evans, Heather] Univ Washington, Harborview Med Ctr, Div Gen & Trauma Surg, Seattle, WA 98104 USA. [Bulger, Eileen M.; Kwon, Yong S.; Evans, Heather] Univ Washington, Dept Surg, Seattle, WA 98195 USA. [Kao, Lillian S.] Lyndon Baines Johnson Gen Hosp, Div Gen Surg, Houston, TX USA. [Kao, Lillian S.] Univ Texas Houston, Dept Surg, Houston, TX USA. [Nathens, Avery B.] Univ Toronto, St Michaels Hosp, Dept Surg, Div Gen Surg, Toronto, ON M5B 1W8, Canada. RP Anaya, DA (reprint author), Michael E DeBakey Houston VA Med Ctr, Dept Surg, 2002 Holcombe Blvd,Operat Care Line 112, Houston, TX 77030 USA. EM danaya@bcm.edu NR 28 TC 25 Z9 26 U1 0 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-2964 J9 SURG INFECT JI Surg. Infect. PD DEC PY 2009 VL 10 IS 6 BP 517 EP 522 DI 10.1089/sur.2008.112 PG 6 WC Infectious Diseases; Surgery SC Infectious Diseases; Surgery GA 613VY UT WOS:000279012800003 PM 20001332 ER PT J AU Virani, SS Nambi, V Lee, VV Elayda, MA Pan, W Petersen, LA Wilson, JM Willerson, JT Ballantyne, CM AF Virani, Salim S. Nambi, Vijay Lee, Vei-Vei Elayda, MacArthur A. Pan, Wei Petersen, Laura A. Wilson, James M. Willerson, James T. Ballantyne, Christie M. TI Obesity An Independent Predictor of In-Hospital Postoperative Renal Insufficiency among Patients Undergoing Cardiac Surgery? SO TEXAS HEART INSTITUTE JOURNAL LA English DT Article DE Body mass index; cardiac surgical procedures/adverse effects; cardiopulmonary bypass/adverse effects; inflammation/complications; kidney failure/etiology; obesity/complications; oxidative stress; postoperative complications; retrospective studies; risk factors; systemic inflammatory response syndrome; treatment outcome ID BODY-MASS INDEX; ARTERY-BYPASS-SURGERY; EXTREME OBESITY; KIDNEY-DISEASE; RISK-FACTOR; OUTCOMES; MORTALITY; CKD; HYPERTENSION; ASSOCIATION AB We sought to determine, retrospectively, whether obesity was associated with adverse renal outcomes in 17,630 patients who underwent cardiac surgery from January 7995 through December 2006. Obesity was defined as a body mass index >= 30 kg/m(2). The primary outcome was any episode of postoperative renal insufficiency (requiring or not requiring dialysis) before hospital discharge. Outcomes were evaluated in the entire cohort and in subgroups undergoing isolated coronary artery bypass grafting (CABG), isolated valve surgery, and combined CABG and valve surgery. The final analysis included 7 6,429 patients, 5,124 (31%) of whom were obese. In the entire cohort, obesity was associated both with increased risk of any postoperative renal insufficiency (odds ratio [OR], 1.37; 95% confidence interval [CI], 1.21-1.55) and with increased risk of renal insufficiency not requiring dialysis (OR, 1.41; 95% CI, 1.23-1.62). Obesity was associated with an increased risk of postoperative renal insufficiency in patients undergoing isolated CABG (OR, 1.38; 95% CI, 1.18-1.61), isolated valve surgeries (OR, 1.39; 95% CI, 1.05-1.85), and combined CABG and valve surgeries (OR, 7.35; 95% CI, 0.99-1.83; statistically nonsignificant). Development of postoperative renal insufficiency was associated with a significantly higher mortality rate (P<0.0001) and with a significantly longer hospital stay (23 vs 10.5 days; P <0.0001). We conclude that obesity is associated with a significant increase in postoperative renal insufficiency in cardiac surgery patients, an effect that we attribute to an increase in postoperative renal failure that does not require dialysis. (Tex Heart Inst J 2009,36(6):540-5) C1 [Virani, Salim S.; Nambi, Vijay; Ballantyne, Christie M.] Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA. [Virani, Salim S.; Nambi, Vijay; Ballantyne, Christie M.] Baylor Coll Med, Dept Med, Sect Atherosclerosis & Vasc Med, Houston, TX 77030 USA. [Petersen, Laura A.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Lee, Vei-Vei; Elayda, MacArthur A.] St Lukes Episcopal Hosp, Texas Heart Inst, Dept Biostat & Epidemiol, Houston, TX 77036 USA. [Virani, Salim S.; Wilson, James M.; Willerson, James T.] St Lukes Episcopal Hosp, Texas Heart Inst, Dept Cardiol, Houston, TX 77036 USA. [Pan, Wei] St Lukes Episcopal Hosp, Texas Heart Inst, Dept Anesthesiol, Houston, TX 77036 USA. [Virani, Salim S.; Nambi, Vijay; Ballantyne, Christie M.] Methodist DeBakey Heart & Vasc Ctr, Ctr Cardiovasc Dis Prevent, Houston, TX 77036 USA. [Petersen, Laura A.] Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77036 USA. RP Ballantyne, CM (reprint author), Baylor Coll Med, Dept Med, Cardiol Sect, 6565 Fannin,MS A-601,Suite A656, Houston, TX 77030 USA. EM cmb@bcm.tmc.edu OI Virani, Salim/0000-0001-9541-6954 FU Texas Heart Institute Muller Fund for Cardiovascular Research; Houston VA Health Services Research & Development Center of Excellence [HFP90-020] FX This is work was supported by the Texas Heart Institute Muller Fund for Cardiovascular Research and the Houston VA Health Services Research & Development Center of Excellence (grant number HFP90-020). NR 29 TC 12 Z9 12 U1 0 U2 2 PU TEXAS HEART INST PI HOUSTON PA PO BOX 20345, HOUSTON, TX 77225-0345 USA SN 0730-2347 J9 TEX HEART I J JI Tex. Heart Inst. J. PD DEC PY 2009 VL 36 IS 6 BP 540 EP 545 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 533EX UT WOS:000272807600006 PM 20069078 ER PT J AU Doolittle, MH Neher, SB Ben-Zeev, O Jo, LL Gallagher, CM Hosseini, M Yin, F Wong, H Walter, P Peterfy, M AF Doolittle, Mark H. Neher, Saskia B. Ben-Zeev, Osnat Jo Ling-liao Gallagher, Ciara M. Hosseini, Maryam Yin, Fen Wong, Howard Walter, Peter Peterfy, Miklos TI Lipase Maturation Factor LMF1, Membrane Topology and Interaction with Lipase Proteins in the Endoplasmic Reticulum SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID FLUORESCENCE PROTEASE PROTECTION; N-TERMINAL DOMAIN; LIPOPROTEIN-LIPASE; HEPATIC LIPASE; SUBCELLULAR-LOCALIZATION; TRANSMEMBRANE ORGANIZATION; DEFICIENCY CLD/CLD; EPITOPE INSERTION; P-GLYCOPROTEIN; MOUSE AB Lipase maturation factor 1 (LMF1) is predicted to be a polytopic protein localized to the endoplasmic reticulum (ER) membrane. It functions in the post-translational attainment of enzyme activity for both lipoprotein lipase and hepatic lipase. By using transmembrane prediction methods in mouse and human orthologs, models of LMF1 topology were constructed and tested experimentally. Employing a tagging strategy that used insertion of ectopic glycan attachment sites and terminal fusions of green fluorescent protein, we established a five-transmembrane model, thus dividing LMF1 into six domains. Three domains were found to face the cytoplasm (the amino-terminal domain and loops B and D), and the other half was oriented to the ER lumen (loops A and C and the carboxyl-terminal domain). This representative model shows the arrangement of an evolutionarily conserved domain within LMF1 (DUF1222) that is essential to lipase maturation. DUF1222 comprises four of the six domains, with the two largest ones facing the ER lumen. We showed for the first time, using several naturally occurring variants featuring DUF1222 truncations, that Lmf1 interacts physically with lipoprotein lipase and hepatic lipase and localizes the lipase interaction site to loop C within DUF1222. We discuss the implication of our results with regard to lipase maturation and DUF1222 domain structure. C1 [Doolittle, Mark H.; Ben-Zeev, Osnat; Jo Ling-liao; Hosseini, Maryam; Yin, Fen; Wong, Howard; Peterfy, Miklos] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Doolittle, Mark H.; Ben-Zeev, Osnat; Hosseini, Maryam; Yin, Fen; Wong, Howard; Peterfy, Miklos] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Neher, Saskia B.; Gallagher, Ciara M.; Walter, Peter] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA. [Walter, Peter] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94158 USA. [Jo Ling-liao; Hosseini, Maryam; Yin, Fen; Peterfy, Miklos] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA. RP Doolittle, MH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 113,Rm 312, Los Angeles, CA 90073 USA. EM markdool@ucla.edu; mpeterfy@ucla.edu FU National Institutes of Health [HL24841]; Cedars-Sinai Medical Center; United States Department of Veterans Affairs FX This work was supported, in whole or in part, by National Institutes of Health Grant HL24841. This work was also supported by the Cedars-Sinai Medical Center and the United States Department of Veterans Affairs. NR 41 TC 14 Z9 16 U1 0 U2 5 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 27 PY 2009 VL 284 IS 48 BP 33623 EP 33633 DI 10.1074/jbc.M109.049395 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 522VS UT WOS:000272028500066 PM 19783858 ER PT J AU Haywood, LJ Ford, CE Crow, RS Davis, BR Massie, BM Einhorn, PT Williard, A AF Haywood, L. Julian Ford, Charles E. Crow, Richard S. Davis, Barry R. Massie, Barry M. Einhorn, Paula T. Williard, Angela CA ALLHAT Collaborative Res Grp TI Atrial Fibrillation at Baseline and During Follow-Up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE hypertension; atrial fibrillation; clinical trial; chlorthalidone; amlodipine; lisinopril; doxazosin; pravastatin ID RANDOMIZED CONTROLLED-TRIALS; II RECEPTOR BLOCKADE; RISK-FACTORS; MAJOR OUTCOMES; BLOOD-PRESSURE; FAILURE; PREVALENCE; THERAPY; STROKE; CHLORTHALIDONE AB Objectives The ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) determined that treatment with amlodipine, lisinopril, or doxazosin was not superior to thiazide-like diuretic (chlorthalidone) in preventing coronary heart disease (CHD) or other cardiovascular events. This subanalysis examines baseline prevalence and in-trial incidence of new-onset atrial fibrillation (AF) or atrial flutter (AFL) and their influence on clinical outcomes. Background Limited information is available on whether atrial fibrillation incidence is affected differentially by different classes of antihypertensive medications or treatment with statins. Methods AF/AFL was identified from baseline and follow-up electrocardiograms performed biannually. Analyses were performed to identify characteristics associated with baseline AF/AFL and its subsequent incidence. Results AF/AFL was present at baseline in 423 participants (1.1%), more frequent in men (odds ratio: 1.72; 95% confidence interval [CI]: 1.37 to 2.17) and nonblacks (odds ratio: 2.09; 95% CI: 1.58 to 2.75). Its prevalence increased with age (p < 0.001) and was associated with CHD, cardiovascular disease, obesity, and high-density lipoprotein cholesterol <35 mg/dl. New-onset AF/AFL was associated with the same baseline risk factors plus electrocardiogram left ventricular hypertrophy. It occurred in 641 participants (2.0%) and, excluding doxazosin, did not differ by antihypertensive treatment group or, in a subset of participants, by pravastatin versus usual care. Baseline AF/AFL was associated with increased mortality (hazard ratio [HR]: 2.82; 95% CI: 2.36 to 3.37; p < 0.001), stroke (HR: 3.63; 95% CI: 2.72 to 4.86; p < 0.001), heart failure (HR: 3.17; 95% CI: 2.38 to 4.25; p < 0.001), and fatal CHD or nonfatal myocardial infarction (HR: 1.64; 95% CI: 1.22 to 2.21; p < 0.01). There was a nearly 2.5-fold increase in mortality risk when AF/AFL was present at baseline or developed during the trial (HR: 2.42; 95% CI: 2.11 to 2.77; p < 0.001). Conclusions In this high-risk hypertensive population, pre-existing and new-onset AF/AFL were associated with increased mortality. Excluding doxazosin, treatment assignment to either antihypertensive drugs or pravastatin versus usual care did not affect AF/AFL incidence. (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]; NCT00000542) (J Am Coll Cardiol 2009; 54:2023-31) (C) 2009 by the American College of Cardiology Foundation C1 [Haywood, L. Julian] Los Angeles Cty Univ So Calif Med Ctr, Los Angeles, CA USA. [Ford, Charles E.; Davis, Barry R.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX USA. [Crow, Richard S.] Univ Minnesota, Minneapolis, MN USA. [Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Einhorn, Paula T.] NHLBI, Div Prevent & Populat Sci, Bethesda, MD 20892 USA. [Williard, Angela] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA USA. RP Ford, CE (reprint author), Univ Texas Sch Publ Hlth, 1200 Herman Pressler Dr,E-827, Houston, TX 77030 USA. EM charles.e.ford@uth.tmc.edu FU Pfizer, Inc FX From the Los Angeles County/University of Southern California Medical Center, Los Angeles, California; dagger University of Texas Health Science Center at Houston, School of Public Health, Houston, Texas; University of Minnesota, Minneapolis, Minnesota; San Francisco Veterans Affairs Medical Center, San Francisco, California; parallel to Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland; and the Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana. This research was supported by Health and Human Services contract number N01-HC-35130 from the National Heart, Lung, and Blood Institute, National Institutes of Health, U. S. Department of Health and Human Services, Bethesda, Maryland. Additional financial support was provided by Pfizer, Inc. Study medications were supplied by Pfizer, Inc. (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and Bristol-Myers Squibb (pravastatin). Dr. Davis is on the Data Safety Monitoring Board of Takeda Pharmaceuticals. NR 35 TC 84 Z9 91 U1 3 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 24 PY 2009 VL 54 IS 22 BP 2023 EP 2031 DI 10.1016/j.jacc.2009.08.020 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 521EH UT WOS:000271902500006 PM 19926008 ER PT J AU Filley, CM AF Filley, Christopher M. TI Exploring white matter microstructure New insights from diffusion tensor imaging SO NEUROLOGY LA English DT Editorial Material ID DISCONNEXION SYNDROMES; ANIMALS; DISEASE C1 [Filley, Christopher M.] Univ Colorado, Denver Sch Med, Denver Vet Affairs Med Ctr, Behav Neurol Sect,Dept Neurol, Aurora, CO 80045 USA. [Filley, Christopher M.] Univ Colorado, Denver Sch Med, Denver Vet Affairs Med Ctr, Behav Neurol Sect,Dept Psychiat, Aurora, CO 80045 USA. RP Filley, CM (reprint author), Univ Colorado, Denver Sch Med, Denver Vet Affairs Med Ctr, Behav Neurol Sect,Dept Neurol, 12631 E 17th Ave,MS B185,POB 6511, Aurora, CO 80045 USA. EM christopher.filley@ucdenver.edu FU NIAMS NIH HHS [1 R01 AR04915-01A2, 3 RO1 AR049152-02S1] NR 12 TC 8 Z9 8 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 24 PY 2009 VL 73 IS 21 BP 1718 EP 1719 DI 10.1212/WNL.0b013e3181c2936b PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 523LY UT WOS:000272076200001 PM 19846831 ER PT J AU Hoops, S Nazem, S Siderowf, AD Duda, JE Xie, SX Stern, MB Weintraub, D AF Hoops, S. Nazem, S. Siderowf, A. D. Duda, J. E. Xie, S. X. Stern, M. B. Weintraub, D. TI Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease SO NEUROLOGY LA English DT Article ID MILD COGNITIVE IMPAIRMENT; MENTAL-STATE-EXAMINATION; COMMUNITY POPULATION; DIAGNOSTIC-CRITERIA; SCREENING TOOL; RATING-SCALE; INCIDENT; ACCURACY; COHORT AB Background: Due to the high prevalence of mild cognitive impairment (MCI) and dementia in Parkinson disease (PD), routine cognitive screening is important for the optimal management of patients with PD. The Montreal Cognitive Assessment (MoCA) is more sensitive than the commonly used Mini-Mental State Examination (MMSE) in detecting MCI and dementia in patients without PD, but its validity in PD has not been established. Methods: A representative sample of 132 patients with PD at 2 movement disorders centers was administered the MoCA, MMSE, and a neuropsychological battery with operationalized criteria for deficits. MCI and PD dementia (PDD) criteria were applied by an investigator blinded to the MoCA and MMSE results. The discriminant validity of the MoCA and MMSE as screening and diagnostic instruments was ascertained. Results: Approximately one third of the sample met diagnostic criteria for a cognitive disorder (12.9% PDD and 17.4% MCI). Mean (SD) MoCA and MMSE scores were 25.0 (3.8) and 28.1 (2.0). The overall discriminant validity for detection of any cognitive disorder was similar for the MoCA and the MMSE (receiver operating characteristic area under the curve [95% confidence interval]): MoCA (0.79 [0.72, 0.87]) and MMSE (0.76 [0.67, 0.85]), but as a screening instrument the MoCA (optimal cutoff point = 26/27, 64% correctly diagnosed, lack of ceiling effect) was superior to the MMSE (optimal cutoff point = 29/30, 54% correctly diagnosed, presence of ceiling effect). Conclusions: The Montreal Cognitive Assessment, but not the Mini-Mental State Examination, has adequate psychometric properties as a screening instrument for the detection of mild cognitive impairment or dementia in Parkinson disease. However, a positive screen using either instrument requires additional assessment due to suboptimal specificity at the recommended screening cutoff point. Neurology (R) 2009; 73: 1738-1745 C1 [Hoops, S.; Nazem, S.; Weintraub, D.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Siderowf, A. D.; Duda, J. E.; Stern, M. B.; Weintraub, D.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Xie, S. X.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Duda, J. E.; Stern, M. B.; Weintraub, D.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Weintraub, D.] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr, Philadelphia, PA USA. RP Weintraub, D (reprint author), 3615 Chestnut St,Room 330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu FU NIH [U10 NS044451, P50 NS053488, R43 NS0636071, RO1 NS41265-01, RO1 NS44266, K23 MH067894]; Department of Veterans Affairs; Michael J. Fox Foundation; Samueli Foundation; NIH/NINDS [NS053488]; Ceregene; Institute of Neurodegeneration, New Haven, CT; Department of Defense [USAMRAA810002]; Boehringer Ingelheim FX S. Hoops and S. Nazem report no disclosures. Dr. Siderowf serves on the editorial advisory board of Neura; serves on a speakers' bureau for Teva Pharmaceutical Industries Ltd.; serves as a consultant to Supernus Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Merck Serono, and Schering-Plough Corp.; and receives research support from the NIH [U10 NS044451 (Principal Investigator), P50 NS053488 (Project Leader), R43 NS0636071(Co-Investigator)]. Dr. Duda serves/has served on a scientific advisory boards for Boehringer Ingelheim, the Lewy Body Dementia Association, and the Lewy Body Society; has received honoraria for lectures or educational activities not funded by industry; and receives research support from the Department of Veterans Affairs [Biomedical Laboratory Research and Development Service Merit Award (PI), Cooperative Studies Program 468 (Site PI)], the NIH [RO1 NS41265-01 (Coinvestigator), RO1 NS44266 (Coinvestigator)], the Michael J. Fox Foundation, and the Samueli Foundation. Dr. Xie receives research support from the NIH/NINDS [NS053488 (Coinvestigator and Core Director)]. Dr. Stern receives royalties for publishing Deep Brain Stimulation for Parkinson's Disease (Taylor and Francis Group, 2007); has received honoraria from Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, and Novartis; serves as a consultant to Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Novartis, Vernalis plc, Ipsen, ScheringPlough Corp., and NuPathe Inc.; and receives research support from Ceregene, and a foundation grant from the Institute of Neurodegeneration, New Haven, CT, and the Department of Defense [USAMRAA810002 (Coinvestigator)]. Dr. Weintraub has served on a scientific advisory board for Boehringer Ingelheim; serves on the editorial board of Movement Disorders; has received honoraria from Boehringer Ingelheim, ACADIA Pharmaceuticals Inc., Novartis, Osmotica Pharmaceutical Corp., BrainCells Inc., Merck Serono, Sanofi-Aventis, and Pfizer Inc.; and receives research support from Boehringer Ingelheim and the NIH [K23 MH067894 (Principal Investigator)]. NR 40 TC 227 Z9 253 U1 8 U2 33 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 24 PY 2009 VL 73 IS 21 BP 1738 EP 1745 DI 10.1212/WNL.0b013e3181c34b47 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 523LY UT WOS:000272076200005 PM 19933974 ER PT J AU Kumar, S Sharafkhaneh, A Edmonds, J Schultz, R Hopkins, B AF Kumar, S. Sharafkhaneh, A. Edmonds, J. Schultz, R. Hopkins, B. TI TREATMENT OF VNS-INDUCED LARYNGOSPASM WITH BOTULINUM TOXIN SO NEUROLOGY LA English DT Editorial Material ID VAGUS NERVE-STIMULATION; REFRACTORY EPILEPSY; SLEEP; CHILDREN C1 [Kumar, S.; Sharafkhaneh, A.] Baylor Coll Med, Dept Pulm Crit Care & Sleep Med, Houston, TX 77030 USA. [Schultz, R.; Hopkins, B.] Baylor Coll Med, Dept Pediat, Sect Child Neurol & Dev Neurosci, Houston, TX 77030 USA. [Sharafkhaneh, A.] Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX USA. [Edmonds, J.] Otolaryngol Sect, Houston, TX USA. [Schultz, R.; Hopkins, B.] Texas Childrens Hosp, Houston, TX 77030 USA. RP Kumar, S (reprint author), 2128 Babcock Rd,Bldg 1,Suite C, San Antonio, TX 78229 USA. EM sumeetk55@gmail.com NR 7 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD NOV 24 PY 2009 VL 73 IS 21 BP 1808 EP 1810 DI 10.1212/WNL.0b013e3181c34ae3 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 523LY UT WOS:000272076200017 PM 19933985 ER PT J AU Feng, R Huang, X Coulton, L De Raeve, H DiLiberto, M Ely, S Xiao, G Luo, M Menu, E Croucher, P Roodman, GD Vanderkerken, K Chen-Kiang, S Lentzsch, S AF Feng, Rentian Huang, Xiangao Coulton, Les De Raeve, Hendrik DiLiberto, Maurizio Ely, Scott Xiao, Guozhi Luo, Min Menu, Eline Croucher, Peter Roodman, G. David Vanderkerken, Karin Chen-Kiang, Selina Lentzsch, Suzanne TI Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Feng, Rentian; Xiao, Guozhi; Luo, Min; Roodman, G. David; Lentzsch, Suzanne] Univ Pittsburgh, Inst Canc, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA. [Huang, Xiangao; DiLiberto, Maurizio; Ely, Scott] Weill Cornell Med Coll, Dept Pathol, New York, NY USA. [Coulton, Les] Univ Sheffield, Sch Med, Dept Musculoskeletal Sci, Sheffield, S Yorkshire, England. [De Raeve, Hendrik] UZ Brussel, Dept Pathol, Brussels, Belgium. [Menu, Eline; Vanderkerken, Karin] Vrije Univ Brussel, Myeloma Ctr Brussels, Dept Hematol & Immunol, Brussels, Belgium. [Croucher, Peter] Univ Sheffield, Sch Med, Dept Human Metab, Sheffield, S Yorkshire, England. [Roodman, G. David] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RI Vanderkerken, Karin/I-3513-2013; Menu, Eline/K-2856-2015 OI Menu, Eline/0000-0002-0805-6581 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 125 EP 126 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725800299 ER PT J AU Sandmaier, BM Maris, M Storer, B Vindelov, L Langston, A Wade, JC Bethge, WA Pulsipher, M Lange, T Chauncey, T Petersen, F Hubel, K Woolfrey, A Flowers, MED Maloney, DG Storb, RF AF Sandmaier, Brenda M. Maris, Michael Storer, Barry Vindelov, Lars Langston, Amelia Wade, James C. Bethge, Wolfgang A. Pulsipher, Michael Lange, Thoralf Chauncey, Thomas Petersen, Finn Huebel, Kai Woolfrey, Ann Flowers, Mary E. D. Maloney, David G. Storb, Rainer F. TI A Randomized 3-Arm Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Sandmaier, Brenda M.; Storer, Barry; Chauncey, Thomas; Woolfrey, Ann; Flowers, Mary E. D.; Maloney, David G.; Storb, Rainer F.] Univ Washington, Fred Hutchinson Canc Res Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Maris, Michael] Rocky Mt Canc Ctr, Denver, CO USA. [Vindelov, Lars] Univ Copenhagen, Rigshosp, DK-2100 Copenhagen, Denmark. [Langston, Amelia] Emory Univ, Atlanta, GA 30322 USA. [Wade, James C.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Bethge, Wolfgang A.] Univ Tubingen, Med Ctr, Tubingen, Germany. [Pulsipher, Michael] Univ Utah, Med Ctr, Salt Lake City, UT USA. [Lange, Thoralf] Univ Leipzig, Leipzig, Germany. [Petersen, Finn] LDS Hosp, Salt Lake City, UT USA. [Huebel, Kai] Univ Cologne, Cologne, Germany. NR 0 TC 4 Z9 4 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 147 EP 147 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725800349 ER PT J AU Ram, R Storb, RF Maloney, DG Sandmaier, BM Maris, M Shizuru, J Chauncey, T Langston, AA Georges, GE AF Ram, Ron Storb, Rainer F. Maloney, David G. Sandmaier, Brenda M. Maris, Michael Shizuru, Judith Chauncey, Thomas Langston, Amelia A. Georges, George E. TI Reduced Intensity Conditioning with Allogeneic Hematopoietic Cell Transplantation for the Treatment of High-Risk Acute Lymphoblastic Leukemia. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ram, Ron; Storb, Rainer F.; Maloney, David G.; Sandmaier, Brenda M.; Georges, George E.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Ram, Ron; Storb, Rainer F.; Maloney, David G.; Sandmaier, Brenda M.; Georges, George E.] Univ Washington, Seattle, WA 98195 USA. [Maris, Michael] Rocky Mt Canc Ctr, Denver, CO USA. [Shizuru, Judith] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Langston, Amelia A.] Emory Univ, Sch Med, Atlanta, GA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 497 EP 498 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725801390 ER PT J AU Konig, H Kiefer, S Robbins, L Rauchman, M Salman, HS AF Konig, Heiko Kiefer, Susan Robbins, Lynn Rauchman, Michael Salman, Huda S. TI The Sal-Like 1 (SALL1) Protein is Highly Expressed in Primary Bone Marrow Cells Derived From Patients with Acute Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Konig, Heiko] St Louis Univ, Med Ctr, Dept Internal Med, St Louis, MO USA. [Kiefer, Susan; Robbins, Lynn; Rauchman, Michael] St Louis Vet Adm Med Ctr, Res & Educ Serv Line, Div Nephrol, US Dept Vet Affairs, St Louis, MO USA. [Salman, Huda S.] Case Western Reserve Univ, Div Hematol & Med Oncol, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 527 EP 527 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801465 ER PT J AU Howard, TE Cole, SA Kasper, CK Ameri, A Natarajan, K Watts, RG Manard, VA Nakaya, SM Kempton, CL Kennedy, M Kim, B Iyer, RV Almasy, L AF Howard, Tom E. Cole, Shelley A. Kasper, Carol K. Ameri, Afshin Natarajan, Kavita Watts, Raymond G. Manard, Valrie A. Nakaya, Shelley M. Kempton, Christine L. Kennedy, Martina Kim, Benjamin Iyer, Rathi V. Almasy, Laura TI The Role of Immune-Response Gene Variants in Inhibitor Development in Black Patients with Hemophilia SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Howard, Tom E.; Manard, Valrie A.; Kennedy, Martina] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Cole, Shelley A.; Almasy, Laura] SW Fdn Biomed Res, San Antonio, TX USA. [Kasper, Carol K.] Orthoped Hosp, Pasadena, CA USA. [Ameri, Afshin] Med Coll Georgia, Childrens Med Ctr, Augusta, GA 30912 USA. [Natarajan, Kavita] Med Coll Georgia, MCG Canc Ctr, Augusta, GA 30912 USA. [Watts, Raymond G.] Univ Alabama, Birmingham, AL USA. [Nakaya, Shelley M.] Puget Sound Blood Ctr, Seattle, WA 98104 USA. [Kempton, Christine L.] Emory Univ, Aflac Canc Ctr, Atlanta, GA 30322 USA. [Kempton, Christine L.] Emory Univ, Blood Disorders Serv, Atlanta, GA 30322 USA. [Kempton, Christine L.] Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA. [Kim, Benjamin] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Iyer, Rathi V.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 533 EP 533 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725801481 ER PT J AU Kampa, KM Mueller, S Rasp, KH Kanz, L Heinrich, MC Schittenhelm, MM AF Kampa, Kerstin M. Mueller, Sandra Rasp, Katharina-Henriette Kanz, Lothar Heinrich, Michael C. Schittenhelm, Marcus M. TI FLT3 and KIT Isoforms Activate PI3K/AKT Signaling Which Is Potently Blocked by the Novel Dual PI3K/Mtor Inhibitors NVP-BEZ235 and NVP-BGT226. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Kampa, Kerstin M.; Mueller, Sandra; Rasp, Katharina-Henriette] Univ Hosp Tuebingen, Tubingen, Germany. [Kanz, Lothar] Univ Tubingen, Dept Hematol Oncol Immunol Rheumatol & Pneumol, Med Ctr 2, Tubingen, Germany. [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97201 USA. [Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR USA. [Schittenhelm, Marcus M.] Univ Tubingen, Dept Hematol Oncol Rheumatol Immunol & Pulmol, Tubingen, Germany. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 692 EP 692 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802108 ER PT J AU Maes, K Huston, A Roodman, D Rivera, S Nemeth, E Lichtenstein, A Vanderkerken, K Ganz, T AF Maes, Ken Huston, Alissa Roodman, David Rivera, Seth Nemeth, Elizabeta Lichtenstein, Alan Vanderkerken, Karin Ganz, Tomas TI Characterization of Hepcidin-Inducing Cytokines in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Maes, Ken; Vanderkerken, Karin] Vrije Univ Brussel, Brussels, Belgium. [Lichtenstein, Alan] Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Huston, Alissa] Univ Rochester, Sch Med, Rochester, NY USA. [Roodman, David] Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA. [Roodman, David] Inst Canc Res, Pittsburgh, PA USA. [Ganz, Tomas] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RI Vanderkerken, Karin/I-3513-2013 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 790 EP 790 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725802369 ER PT J AU Kampa, KM Grandl, T Mueller, S Normant, E Walter, M Schuetz, W Kanz, L Heinrich, MC Schittenhelm, MM AF Kampa, Kerstin M. Grandl, Tanja Mueller, Sandra Normant, Emmanuel Walter, Michael Schuetz, Wolfgang Kanz, Lothar Heinrich, Michael C. Schittenhelm, Marcus M. TI KIT Inhibition Affects Heat Shock Protein (HSP) Activity: A Potential Rescue Mechanism towards KIT Tyrosine Kinase Inhibition and a Rationale for Dual KIT/HSP Inhibition. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Kampa, Kerstin M.; Grandl, Tanja; Mueller, Sandra; Schittenhelm, Marcus M.] Univ Hosp Tuebingen, Dept Hematol Oncol Rheumatol Immunol & Pulmol, Tubingen, Germany. [Normant, Emmanuel] Infin Pharmaceut Inc, Cambridge, MA USA. [Walter, Michael] Univ Tubingen, Microarray Facil, Tubingen, Germany. [Schuetz, Wolfgang] Univ Tubingen, Proteome Ctr Tuebingen, Tubingen, Germany. [Kanz, Lothar] Univ Tubingen, Med Ctr 2, Dept Hematol Oncol Immunol Rheumatol & Pneumol, Tubingen, Germany. [Heinrich, Michael C.] Oregon Hlth & Sci Univ, Inst Canc, Portland, OR 97201 USA. [Heinrich, Michael C.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1076 EP 1077 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725803308 ER PT J AU Feng, RT Kurihara, N Ma, HH Roodman, GD Lentzsch, S AF Feng, Rentian Kurihara, Noriyoshi Ma, Huihui Roodman, G. David Lentzsch, Suzanne TI Matrix Metalloproteinses-13 (Collagenase-3) Secreted by Multiple Myeloma Cells Enhances the Bone Resorptive Activity of Osteoclasts. SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Feng, Rentian; Kurihara, Noriyoshi; Ma, Huihui; Roodman, G. David; Lentzsch, Suzanne] Univ Pittsburgh, Dept Med, Div Hematol Oncol, Inst Canc, Pittsburgh, PA USA. [Roodman, G. David] VA Pittsburgh Healthcare Syst, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1114 EP 1114 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803408 ER PT J AU Ishizuka, F Windle, J Roodman, D Kurihara, N AF Ishizuka, Fumito Windle, Jolene Roodman, David Kurihara, Noriyoshi TI p62 as a Therapeutic Target for Myeloma Cell Growth and Osteoclast Formation SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Ishizuka, Fumito; Roodman, David; Kurihara, Noriyoshi] Univ Pittsburgh, Ctr Bone Biol, UPMC, Pittsburgh, PA USA. [Roodman, David] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Windle, Jolene] Virginia Commonwealth Univ, Richmond, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1115 EP 1115 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725803412 ER PT J AU Budde, LE Guthrie, KA Till, BG Chauncey, T Press, OW Pagel, JM Petersdorf, S Bensinger, W Holmberg, L Shustov, AR Maloney, DG Gopal, AK AF Budde, Lihua E. Guthrie, Katherine A. Till, Brian G. Chauncey, Thomas Press, Oliver W. Pagel, John M. Petersdorf, Stephen Bensinger, William Holmberg, Leona Shustov, Andrei R. Maloney, David G. Gopal, Ajay K. TI Prognostic Factors On Outcome of Mantle Cell Lymphoma Patients Relapsing After Autologous Hematopoietic Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Budde, Lihua E.; Guthrie, Katherine A.; Till, Brian G.; Press, Oliver W.; Pagel, John M.; Petersdorf, Stephen; Bensinger, William; Holmberg, Leona; Maloney, David G.; Gopal, Ajay K.] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98195 USA. [Chauncey, Thomas] Univ Washington, Fred Hutchinson Canc Res Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Shustov, Andrei R.] Univ Washington, Dept Hematol, Seattle, WA 98195 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1290 EP 1291 PG 2 WC Hematology SC Hematology GA 532DS UT WOS:000272725803882 ER PT J AU Rotta, M Storer, BE Lange, T Pulsipher, M Shizuru, J Bruno, B McSweeney, PA Agura, E Chauncey, T Appelbaum, FR Bensinger, W Sandmaier, BM Storb, RF Georges, GE Maloney, DG AF Rotta, Marcello Storer, Barry E. Lange, Thoralf Pulsipher, Michael Shizuru, Judith Bruno, Benedetto McSweeney, Peter A. Agura, Edward Chauncey, Thomas Appelbaum, Frederick R. Bensinger, William Sandmaier, Brenda M. Storb, Rainer F. Georges, George E. Maloney, David G. TI Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM) SO BLOOD LA English DT Meeting Abstract CT 51st Annual Meeting of the American-Society-of-Hematology CY DEC 05-08, 2009 CL New Orleans, LA SP Amer Soc Hematol C1 [Rotta, Marcello] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Storer, Barry E.; Appelbaum, Frederick R.; Bensinger, William; Sandmaier, Brenda M.; Storb, Rainer F.; Georges, George E.; Maloney, David G.] Univ Washington, Seattle, WA 98195 USA. [Lange, Thoralf] Univ Leipzig, Dept Hematol & Oncol, Leipzig, Germany. [Pulsipher, Michael] Univ Utah, Med Ctr, Salt Lake City, UT USA. [Shizuru, Judith] Stanford Univ, Stanford, CA 94305 USA. [Bruno, Benedetto] Univ Turin, Turin, Italy. [McSweeney, Peter A.] Rocky Mt Blood & Marrow Transplant Program, Denver, CO USA. [Agura, Edward] Baylor Sammons Canc Ctr, Dallas, TX USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 20 PY 2009 VL 114 IS 22 BP 1317 EP 1317 PG 1 WC Hematology SC Hematology GA 532DS UT WOS:000272725804056 ER EF